FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Klein, MR
   Fox, A
AF Klein, MR
   Fox, A
TI Mycobacterium-specific human CD8 T cell responses
SO ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
LA English
DT Review
DE mycobacterium; tuberculosis; CD8; epitope; vaccine; diagnosis
ID IMMUNE-RESPONSES; ANTIGEN 85A; TUBERCULOSIS; VACCINATION; GENE; BCG;
   INFECTION; PEPTIDES; DISEASE; PREDICTIONS
AB Tuberculosis (TB) remains a global health problem. There is an intense effort to identify correlates of protective immunity and to design new TB vaccines. CD8 T cells are thought to play a significant role in controlling Mycobacterium tuberculosis infection. Relatively little has been published about the antigens and epitopes targeted by mycobacteria-specific CD8 T cells. Here we present an update of our 1999 overview of human CD8 T cell epitopes in mycobacterial antigens and discuss related issues relevant to TB diagnosis and vaccine development.
C1 MRC Labs, TB Res Programme, Banjul, Gambia.
RP Klein, MR (reprint author), MRC Labs, TB Res Programme, Atlantic Rd,POB 273, Banjul, Gambia.
CR Andersen P, 2001, TRENDS IMMUNOL, V22, P160, DOI 10.1016/S1471-4906(01)01865-8
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520
   BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0
   CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497
   Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000
   De Groot AS, 1999, NAT BIOTECHNOL, V17, P533, DOI 10.1038/9833
   DeGroot AS, 1997, AIDS RES HUM RETROV, V13, P529, DOI 10.1089/aid.1997.13.529
   Denis O, 1998, INFECT IMMUN, V66, P1527
   Dillon DC, 1999, INFECT IMMUN, V67, P2941
   Dockrell HM, 2000, LEPROSY REV, V71, pS55
   FAITH A, 1992, CLIN EXP IMMUNOL, V87, P272
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Flynn JL, 2000, CURR OPIN IMMUNOL, V12, P432, DOI 10.1016/S0952-7915(00)00116-3
   Geluk A, 2000, J IMMUNOL, V165, P6463
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530
   Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631
   Klein Michel R., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P313
   Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267
   KLEIN MR, 2001, UNPUB HLA B ASTERISK
   KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439
   *LOS AL NAT LAB, 1999, HIV MOL IMM DAT
   Marchese A, 2000, MICROB DRUG RESIST, V6, P163, DOI 10.1089/107662900419483
   MEHTADAMANI A, 1994, J IMMUNOL, V153, P996
   Moha-Ouchane M, 1998, INT J THERMOPHYS, V19, P161, DOI 10.1023/A:1021455203728
   Olsen AW, 2000, EUR J IMMUNOL, V30, P1724
   Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8
   PALMER CE, 1966, AM REV RESPIR DIS, V94, P553
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Pathan AA, 2000, EUR J IMMUNOL, V30, P2713, DOI 10.1002/1521-4141(200009)30:9<2713::AID-IMMU2713>3.0.CO;2-4
   Plebanski M, 1999, NAT MED, V5, P565, DOI 10.1038/8444
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   REES A, 1988, EUR J IMMUNOL, V18, P1881, DOI 10.1002/eji.1830181203
   ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6
   ROSSI GA, 1987, AM REV RESPIR DIS, V136, P575
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Skeiky YAW, 2000, J IMMUNOL, V165, P7140
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Smith SM, 2000, IMMUNOL CELL BIOL, V78, P325, DOI 10.1046/j.1440-1711.2000.00936.x
   SMITH SM, 2001, IN PRESS TUBER LUNG
   Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200
   *TIGR, COMPR MICR RES WHOL
   Uebel S, 1999, CURR OPIN IMMUNOL, V11, P203, DOI 10.1016/S0952-7915(99)80034-X
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
   vanderBurg SH, 1996, J IMMUNOL, V156, P3308
   *WHO, 2000, TUB FACT SHEET
   Wilkinson RJ, 1998, IMMUNOLOGY, V95, P585
NR 53
TC 6
Z9 7
U1 0
U2 1
PU INST IMMUNOLOGY & EXPERIMENTAL THERAPY
PI WROCLAW
PA POLISH ACADEMY OF SCIENCES CZERSKA 12, 53-114 WROCLAW, POLAND
SN 0004-069X
J9 ARCH IMMUNOL THER EX
JI Arch. Immunol. Ther. Exp.
PY 2001
VL 49
IS 5
BP 379
EP 389
PG 11
WC Immunology
SC Immunology
GA 500JF
UT WOS:000172622900006
PM 11798136
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
AF Prentice, AM
TI Obesity and its potential mechanistic basis
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
ID INSULIN-RESISTANCE SYNDROME; LOW-BIRTH-WEIGHT; ENERGY-EXPENDITURE;
   ADIPOSE-TISSUE; BODY-WEIGHT; ADULT LIFE; SUBSTRATE OXIDATION;
   RECOMBINANT LEPTIN; SKELETAL-MUSCLE; MORBID-OBESITY
AB Obesity plays a central role in the development of the thrifty phenotype. The metabolic disturbances of the cardiovascular metabolic syndrome, frequently ascribed to the thrifty phenotype, are rare in the absence of obesity and their expression is generally proportional to the size of the excess fat mass. Thus obesity interacts with early-life programming in the establishment of disease. Surprisingly, the evidence that fetal or infant diet leads to programming of obesity itself is rather weak, though this may be explained by the fact that lifestyle influences obscure the linkage between metabolic predisposition and maturity-onset obesity. This paper summarises the possible metabolic basis of obesity with special reference to those processes for which there are plausible mechanisms by which long-term programming may operate. It is concluded that the newly-emerging molecular discoveries in body weight regulatory systems point to the need for detailed studies of gene-environment interactions and life-course influences before we will fully understand the aetiology of complex phenotypes such as the metabolic syndrome.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
CR AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nutr.12.1.207
   Arner P, 2000, BRIT J NUTR, V83, pS9
   Astrup A, 1996, P NUTR SOC, V55, P817, DOI 10.1079/PNS19960081
   ASTRUP A, 1994, AM J PHYSIOL, V266, pE592
   Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35047145
   Bjorntorp P, 1996, INT J OBESITY, V20, P291
   Blundell JE, 1997, J AM DIET ASSOC, V97, pS63, DOI 10.1016/S0002-8223(97)00733-5
   Bouchard Claude, 1997, Human Reproduction (Oxford), V12, P1
   *BRIT NUTR FDN, 1999, OB REP BNF TASKF
   Byberg L, 2000, DIABETOLOGIA, V43, P54, DOI 10.1007/s001250050007
   Chagnon YC, 2000, OBES RES, V8, P89, DOI 10.1038/oby.2000.12
   Clement K, 1996, INT J OBESITY, V20, P1062
   Clement K, 1996, INT J OBESITY, V20, P507
   FALL CHD, 1995, BRIT MED J, V310, P428
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   FLATT JP, 1988, DIABETES METAB REV, V4, P571
   Friedman J M, 1997, Eur J Med Res, V2, P7
   Friedman JM, 2000, NATURE, V404, P632
   Gautier JF, 2000, DIABETES, V49, P838, DOI 10.2337/diabetes.49.5.838
   GEERLING BJ, 1994, INT J OBESITY, V18, P453
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   HEITMANN BL, 1995, AM J CLIN NUTR, V61, P1213
   Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568
   HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271
   Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x
   Jebb SA, 1995, P NUTR SOC, V54, P721, DOI 10.1079/PNS19950071
   Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677
   Keys A, 1950, BIOL HUMAN STARVATIO
   KHOURY MJ, 1988, AM J HUM GENET, V42, P89
   LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5
   LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701
   Lissner L, 1999, OBES RES, V7, P150
   Lowell BB, 2000, NATURE, V404, P652
   Maes HHM, 1997, BEHAV GENET, V27, P325, DOI 10.1023/A:1025635913927
   MCGILL HC, 1996, NUTR REV S, V54, P31
   MINGHELLI G, 1990, AM J CLIN NUTR, V51, P563
   Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757
   Phillips DIW, 1999, INT J OBESITY, V23, P1025, DOI 10.1038/sj.ijo.0801050
   Phillips DIW, 2000, INT J OBESITY, V24, P281, DOI 10.1038/sj.ijo.0801125
   Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7
   POSKITT EME, 1977, BRIT MED J, V1, P7
   Prentice A. M., 2001, BNF Nutrition Bulletin, V26, P13, DOI 10.1046/j.1467-3010.2001.00100.x
   PRENTICE A M, 1989, Journal of Human Nutrition and Dietetics, V2, P95, DOI 10.1111/j.1365-277X.1989.tb00014.x
   Prentice AM, 1996, EUR J CLIN NUTR, V50, P93
   PRENTICE AM, 1986, BRIT MED J, V292, P983
   PRENTICE AM, 1995, BRIT MED J, V311, P437
   Prentice AM, 1997, BRIT MED BULL, V53, P229
   PRENTICE AM, 1999, APPETITE OBESITY DIS, P13
   Prentice AM, 1995, WEIGHT CONTROL CURRE, P8
   Prins JB, 1997, CLIN SCI, V92, P3
   Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811
   Ravussin E, 2000, BRIT J NUTR, V83, pS17
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   ROLLS BJ, 1994, AM J CLIN NUTR, V60, P476
   SCHOELLER DA, 1990, NUTR REV, V48, P373
   Schrauwen P, 1999, OBES RES, V7, P97
   Schwartz MW, 2000, NATURE, V404, P661
   SHETTY PS, 1993, P NUTR SOC, V52, P267, DOI 10.1079/PNS19930063
   Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000
   Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5
   Thompson CH, 1997, CLIN SCI, V92, P291
   Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83
   VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703
   WADE AJ, 1990, LANCET, V335, P805, DOI 10.1016/0140-6736(90)90933-V
   Wareham NJ, 1998, BRIT J NUTR, V80, P235
   WEST DB, 1995, AM J PHYSIOL-REG I, V268, pR658
   *WHO, 1998, OB PREV MAN GLOB EP
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   2000, NATURE, V404, P631
NR 71
TC 44
Z9 48
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-1420
J9 BRIT MED BULL
JI Br. Med. Bull.
PY 2001
VL 60
BP 51
EP 67
DI 10.1093/bmb/60.1.51
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA 518DM
UT WOS:000173651400005
PM 11809618
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Inskip, HM
   Jaiteh, KO
   Maine, NP
   Walraven, GEL
   Hall, AJ
   McAdam, KPWJ
AF van der Sande, MAB
   Inskip, HM
   Jaiteh, KO
   Maine, NP
   Walraven, GEL
   Hall, AJ
   McAdam, KPWJ
TI Changing causes of death in the West African town of Banjul, 1942-97
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE cause of death; mortality, trends; communicable diseases, mortality,
   trends; chronic disease, mortality, trends; Gambia
ID SUB-SAHARAN AFRICA; EPIDEMIOLOGIC TRANSITION; ADULT MORTALITY;
   SOUTH-AFRICA; POPULATION; IMPACT; DISEASE; HEALTH; CHLOROQUINE; CHILDREN
AB Objective To determine trends in the causes of death in a West African town. Mortality caused by infectious diseases is reported to be declining while degenerative and man-made mortality factors a re increasing ly significant. Most mortality analyses for sub-Saharan Africa have involved extrapolation and have not been derived from community-based data.
   Methods Historical data on causes of death coded by physicians were analysed for the urban population of Banjul for the period 1942-97. As the calculation of rates is not possible in the absence of a reliable population denominator, age-standardized proportional mortality ratios (PMRs) for men and women by major groups of causes of death were calculated, using the 1942-49 data for reference purposes.
   Findings Most deaths were attributable to communicable diseases. There was a shift in proportional mortality over the study period: the contribution of communicable diseases declined and that of noncommunicable diseases and injuries increased. These trends were more marked among men than women.
   Conclusion The data illustrate that while noncommunicable diseases and injuries are emerging as important contributors to mortality in sub-Saharan Africa, communicable diseases remain significant causes of mortality and should not be neglected.
C1 MRC Labs, Banjul, Gambia.
   Gambia Hepatitis Intervent Study, Fajara, Gambia.
   Dept State Hlth, Epidemiol & Stat Unit, Banjul, Gambia.
   Eurostat, Luxembourg, Luxembourg.
   MRC, Farafenni, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), MRC Labs, POB 273, Banjul, Gambia.
OI Inskip, Hazel/0000-0001-8897-1749
CR Bah SM, 1995, SOC BIOL, V42, P247
   BARKER DJP, 1989, NATURE, V338, P371, DOI 10.1038/338371a0
   BOFETTA P, 1993, INT J EPIDEMIOL, V22, P377
   BRADSHAW D, 1992, S AFR MED J, V82, P237
   Campbell H, 1980, World Health Stat Q, V33, P152
   *CENTR STAT DEP, 1998, POP HOUS CENS 1993 M
   Cooper RS, 1998, LANCET, V351, P208, DOI 10.1016/S0140-6736(97)06512-4
   Couper I, 1997, Cent Afr J Med, V43, P219
   DECOCK KM, 1991, AIDS, V5, P393, DOI 10.1097/00002030-199104000-00006
   Garenne ML, 1996, AIDS, V10, P1279
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   Gregson S, 1997, AIDS, V11, P1269, DOI 10.1097/00002030-199710000-00011
   Gwatkin DR, 1997, BRIT MED J, V315, P497
   Kahn K, 1999, TROP MED INT HEALTH, V4, P433, DOI 10.1046/j.1365-3156.1999.00415.x
   Kaufman JS, 1997, B WORLD HEALTH ORGAN, V75, P389
   Kitange HM, 1996, BRIT MED J, V312, P216
   MARSHALL M, 1991, SOC SCI MED, V33, P1327, DOI 10.1016/0277-9536(91)90276-I
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Mosley W. H., 1993, DIS CONTROL PRIORITI, P673
   MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   ODONOVAN D, 1996, 9 INT C AIDS
   OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375
   Root G, 1997, SOC SCI MED, V44, P413, DOI 10.1016/S0277-9536(96)00162-1
   SODERLUND N, 1995, B WORLD HEALTH ORGAN, V73, P175
   Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013
   UEMURA K, 1988, World Health Statistics Quarterly, V41, P155
   World Health Organization, 1994, INT STAT CLASS DIS R
   *WHO COLL CTR CLAS, 1996, TEND ICD 10 COMP BAS
   WolleswinkelVandenBosch JH, 1997, INT J EPIDEMIOL, V26, P772, DOI 10.1093/ije/26.4.772
   YACK D, 1996, S AFRICA HLTHR EV 19
   [Anonymous], 1993, WORLD DEV REPORT 199
NR 34
TC 19
Z9 19
U1 1
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2001
VL 79
IS 2
BP 133
EP 141
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 409GY
UT WOS:000167377100008
PM 11242820
OA No
DA 2017-08-15
ER

PT J
AU Bailey, R
   Lietman, T
AF Bailey, R
   Lietman, T
TI The SAFE strategy for the elimination of trachoma by 2020: will it work?
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE trachoma/surgery/drug therapy/prevention and control; meibomian
   glands/surgery; azithromycin/therapeutic use; hygiene; environmental
   health
ID SINGLE-DOSE AZITHROMYCIN; HYPERENDEMIC AREA; CONTROLLED TRIAL;
   TRICHIASIS; SURGERY; RISK; BLINDNESS; TANZANIA; WOMEN
AB WHO has recently launched a programme (GET 2020) for the elimination of trachoma, the leading cause of preventable blindness. GET 2020 has adopted the SAFE strategy, a comprehensive set of control measures (Surgery for entropion/trichiasis; Antibiotics for infectious trachoma; Facial cleanliness to reduce transmission; Environmental improvements such as control of disease-spreading fries and access to clean water).
   The present article reviews the strengths and weaknesses of each component of the strategy. Although significant hurdles remain to be overcome there is every reason to hope that GET 2020 will be successful.
C1 Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Lietman, T (reprint author), Univ Calif San Francisco, Francis I Proctor Fdn, Box 0944, San Francisco, CA 94143 USA.
FU NIAID NIH HHS [K08 AI 01441]
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   Bowman RJC, 2000, TROP MED INT HEALTH, V5, P528, DOI 10.1046/j.1365-3156.2000.00605.x
   Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074
   *COL U, 2000, TRACH TECHN M NEW YO
   COURTRIGHT P, 1994, E AFR MED J, V71, P803
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   Dawson C. Daniel, 2000, COMMUNICATION
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Estes J W, 1989, MED SKILLS ANCIENT E
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   LIETMAN T, 1999, OPHTHALMOL CLIN N AM, V12, P21, DOI 10.1016/S0896-1549(05)70146-2
   Munoz B, 1997, EPIDEMIOL REV, V19, P205
   Munoz B, 1997, TROP MED INT HEALTH, V2, P1030, DOI 10.1046/j.1365-3156.1997.d01-186.x
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   TAYLOR HR, 1985, REV INFECT DIS, V7, P765
   THYLEFORS B, 1990, INT OPHTHALMOL, V14, P211, DOI 10.1007/BF00158321
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855
   *WHO, 2000, UNP 4 M WHO ALL GLOB
   *WHO, 1998, WHOPBLGET993
   WHO, 1997, WHOPBLGET971
   World Health Organization, 1997, WHOPBL9761
NR 28
TC 41
Z9 44
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2001
VL 79
IS 3
BP 233
EP 236
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 411MC
UT WOS:000167503000011
PM 11285668
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Walraven, GEL
   Milligan, PJM
   Banya, WAS
   Ceesay, SM
   Nyan, OA
   McAdam, KPWJ
AF van der Sande, MAB
   Walraven, GEL
   Milligan, PJM
   Banya, WAS
   Ceesay, SM
   Nyan, OA
   McAdam, KPWJ
TI Interventions and improved control or hypertension, obesity and diabetes
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE hypertension/genetics; obesity/genetics; diabetes mellitus/genetics;
   cerebrovascular accident/genetics; genetic predisposicion to disease;
   risk assessment; cross-sectional studies; Ghana (source : MeSH)
ID HIGH BLOOD-PRESSURE; PARENTAL HISTORY; FAMILY HISTORY; RISK-FACTORS;
   CARDIOVASCULAR REACTIVITY; INSULIN-RESISTANCE; MELLITUS; CHILDREN;
   DISEASE; GLUCOSE
AB Objective To examine whether a family history of high-risk groups for major noncommunicable diseases (NCDs) was a significant risk factor for these conditions among family members in a study population in the Gambia, where strong community and family coherence are important determinants that have to be taken into consideration in promoting lifestyle changes.
   Methods We questioned 5389 adults as to any first-degree family history of major noncommunicable diseases (hypertension, obesity, diabetes and stroke), and measured their blood pressure (BP) and body mass index (MI). Total blood cholesterol, triglyceride, uric acid, and creatinine concentrations were measured in a stratified subsample, as well as blood glucose (2 hours after ingesting 75 g glucose) in persons aged greater than or equal to 35 years.
   Findings A significant number of subjects reported a family history of hypertension (8.0%), obesity (5.4%), diabetes (3.3%) and stroke (1.4%), with 14.6% of participants reporting any of these NCDs. Subjects with a family history of hypertension had a higher diastolic BP and BMI, higher cholesterol and uric acid concentrations, and an increased risk of obesity. Those with a family history of obesity had a higher BMI and were at increased risk of obesity. Individuals with a family history of diabetes had a higher BMI and higher concentrations of glucose, cholesterol, triglycerides and uric acid, and their risk of obesity and diabetes was increased. Subjects with a family history of stroke had a higher BMI, as well as higher cholesterol, triglyceride and uric acid concentrations.
   Conclusions A family history of hypertension, obesity, diabetes, or stroke was a significant risk factor for obesity and hyperlipidaemia. With increase of age, more pathological manifestations can develop in this high-risk group. Health professionals should therefore utilize every opportunity to include direct family members in health education.
C1 MRC Labs, Banjul, Gambia.
RP van der Sande, MAB (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mvdsande@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ALLEMANN Y, 1995, J HYPERTENS, V13, P163
   ALLEN MT, 1987, HEALTH PSYCHOL, V6, P113, DOI 10.1037//0278-6133.6.2.113
   Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633
   CORVOL P, 1992, AM J CARDIOL, V70, pD14, DOI 10.1016/0002-9149(92)90267-3
   DITTO B, 1986, PSYCHOPHYSIOLOGY, V23, P62, DOI 10.1111/j.1469-8986.1986.tb00596.x
   Elbagir MN, 1996, DIABETES CARE, V19, P1126, DOI 10.2337/diacare.19.10.1126
   ENDRE T, 1994, J HYPERTENS, V12, P81
   EZENWAKA CE, 1993, DIABETES RES CLIN PR, V20, P175, DOI 10.1016/0168-8227(93)90075-G
   FEACHEM RGA, 1991, HLTH ADULTS DEV WORL
   HANSEN HS, 1992, J HYPERTENS, V10, P677
   HARRIS MI, 1995, CLIN INVEST MED, V18, P231
   LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9
   *MIN FIN EC AFF, 1995, 1993 94 HOUS ED HLTH
   Mosley W. H., 1993, DIS CONTROL PRIORITI, P673
   Mosuwan L, 1996, INT J OBESITY, V20, P697
   MULDOON MF, 1993, AM J HYPERTENS, V6, P76
   Muna Walinjom F. T., 1993, World Health Statistics Quarterly, V46, P125
   Neutel Joel M., 1995, Cardiology Clinics, V13, P539
   OBRIEN E, 1994, J HUM HYPERTENS, V8, P797
   PAPOZ L, 1988, INT J EPIDEMIOL, V17, P419, DOI 10.1093/ije/17.2.419
   PIERCE M, 1995, DIABETIC MED, V12, P6
   Poulter NR, 1985, J Hypertens, V3, P5375
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   VANDERSANDE MAB, IN PRESS AM J PUBLIC
   WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001
   WATT GCM, 1994, J HUM HYPERTENS, V8, P327
   World Health Organization, 1985, WHO TECHN REP SER, V727
   WIDGREN BR, 1991, J INTERN MED, V229, P217
   WILLIAMS RR, 1993, AM J HYPERTENS, V6, pS319
   World Bank, 1993, WORLD DEV REP 1993 I
NR 30
TC 43
Z9 51
U1 0
U2 4
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2001
VL 79
IS 4
BP 321
EP 328
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 421WQ
UT WOS:000168086900008
PM 11357211
OA No
DA 2017-08-15
ER

PT J
AU Fraser-Hurt, N
   Bailey, RL
   Cousens, S
   Mabey, D
   Faal, H
   Mabey, DCW
AF Fraser-Hurt, N
   Bailey, RL
   Cousens, S
   Mabey, D
   Faal, H
   Mabey, DCW
TI Efficacy of oral azithromycin versus topical tetracycline in mass
   treatment of endemic trachoma
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE trachoma/drug therapy; azithromycin/therapeutic use;
   tetracycline/therapeutic use; clinical trials; comparative study; Gambia
   (source : MeSH)
ID SINGLE-DOSE AZITHROMYCIN; CONTROLLED TRIAL; CHILDREN; IMPACT; INFECTION;
   VILLAGE
AB Objective To compare the impact of mass treatment with oral azithromycin and topical tetracycline on the prevalence of active trachoma.
   Methods A total of 1803 inhabitants from 106 households of eight Gambian villages were randomized, in pairs, to receive either three doses of azithromycin at weekly intervals, or daily topical tetracycline over 6 weeks. Ocular examinations were conducted before treatment, and 2, 6 and 12 months after treatment.
   Findings Prior to treatment, 16% of the study participants had active trachoma, Two months after treatment, the prevalence of trachoma was 4.6% and 5.1% in the azithromycin and the tetracycline groups, respectively (adjusted odds ratio (OR) = 1.09; 95% confidence interval (CI)= 0.53, 2.02). Subsequently, the prevalence rose to 16% in the tetracycline group, while remaining at 7.7% in the azithromycin group (adjusted OR at 12 months = 0.52; 95% CI = 0.34, 0.80). At 12 months post-treatment, there were fewer new prevalent cases in the azithromycin group, and trachoma resolution was significantly better for this group (adjusted OR = 2.02; 95% CI = 1.42, 3.50).
   Conclusion Oral azithromycin therefore appears to offer a means for controlling blinding trachoma. II is easy to administer and higher coverages may be possible than have been achieved hitherto.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, LSHTM, London WC1E 7HT, England.
   LSHTM, Dept Infect & Trop Dis, London, England.
   Guys & St Thomas Hosp Trust, Dept Ophthalmol, London, England.
   Natl Eye Care Programme, Banjul, Gambia.
RP Mabey, DCW (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, LSHTM, Keppel St, London WC1E 7HT, England.
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BARENFANGER J, 1975, AM J TROP MED HYG, V24, P509
   Bobo LD, 1997, J INFECT DIS, V176, P1524
   DAROUGAR S, 1980, BRIT J OPHTHALMOL, V64, P291, DOI 10.1136/bjo.64.4.291
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   DAWSON CR, 1969, J INFECT DIS, V119, P581
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   DREW RH, 1992, PHARMACOTHERAPY, V12, P161
   Efron B., 1993, INTRO BOOTSTRAP
   FOSTER SO, 1966, AM J OPHTHALMOL, V61, P451
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HOSHIWARA I, 1973, JAMA-J AM MED ASSOC, V224, P220, DOI 10.1001/jama.224.2.220
   KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865
   Leach AJ, 1997, CLIN INFECT DIS, V24, P356
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   LIETMAN TM, 1998, CHLAMYDIAL INFECT, P359
   LULAT AG, 1993, THESIS U LONDON
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304
   NICHOLS RL, 1971, TRACHOMA RELATED DIS, P337
   Resnikoff S, 1995, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V72, P89
   Resnikoff S, 1995, REV INT TRACHOME PAT, V72, P101
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   SHUKLA, 1966, BRIT J OPHTHALMOLOGY, V50, P218
   TABBARA KF, 1988, INT OPHTHALMOL, V12, P59, DOI 10.1007/BF00133783
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Thylefors B, 1992, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V69, P107
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TREHARNE JD, 1982, CHLAMYDIAL INFECT, P83
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   Whitty CJM, 1999, PEDIATR INFECT DIS J, V18, P955, DOI 10.1097/00006454-199911000-00003
   WHO, 1998, WHOPBLGET982
   *WHO, 1996, WHOPBL9656
NR 39
TC 18
Z9 18
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2001
VL 79
IS 7
BP 632
EP 640
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 454VL
UT WOS:000169992400007
PM 11477966
OA No
DA 2017-08-15
ER

PT J
AU Mahdi, OSM
   Whittle, HC
   Joof, H
   Mabey, DCW
   Bailey, RL
AF Mahdi, OSM
   Whittle, HC
   Joof, H
   Mabey, DCW
   Bailey, RL
TI Failure to detect HLA-A*6802-restricted CD8(+) T cells specific for
   Chlamydia trachomatis antigens in subjects from trachoma-endemic
   communities
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CD8(+) T cells; Chlamydia trachomatis; HLA-A*6802 trachoma
ID OUTER-MEMBRANE PROTEIN; HLA-CLASS-I; LYMPHOCYTES; INFECTION;
   IDENTIFICATION; POPULATION; RESPONSES; PEPTIDES; EPITOPES; SEQUENCE
AB The role of HLA-A*6802-restricted CD8(+) T cells in chlamydial disease was investigated in human ocular infections. Peptides with predicted binding motifs for HLA-A*6802 were synthesized using sequences based on chlamydial antigens, major outer membrane protein (MOMP), macrophage infectivity potentiator (MIP) and heat shock protein (hsp70). Peptides were pooled according to Chlamydia trachomatis protein type and serovar, and were tested in Cr-51-release cytotoxic T lymphocyte (CTL) and enzyme-linked immunospot (ELISPOT) assays, using peripheral blood mononuclear cells (PBMC) isolated from subjects living in trachoma-endemic communities in The Gambia. Significant CTL activity or interferon-gamma release was not detected in any of the subjects, suggesting either that HLA-A*6802 CD8(+) T cells may not be important in ocular infections or that the peptides chosen did not represent epitopes.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Bailey, RL (reprint author), MRC Labs, Banjul, Gambia.
CR BAEHR W, 1988, P NATL ACAD SCI USA, V85, P4000, DOI 10.1073/pnas.85.11.4000
   BEATTY PR, 1994, J IMMUNOL, V153, P4588
   BREWERTON DA, 1973, LANCET, V2, P996
   Conway DJ, 1996, J INFECT DIS, V174, P643
   DANILITION SL, 1990, INFECT IMMUN, V58, P189
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   HAYES LJ, 1992, J INFECT DIS, V166, P1173
   Holland MJ, 1997, CLIN EXP IMMUNOL, V107, P44, DOI 10.1046/j.1365-2249.1997.2511129.x
   Kim SK, 1999, J IMMUNOL, V162, P6855
   Kimani J, 1996, J INFECT DIS, V173, P1437
   KRAUSA P, 1993, TISSUE ANTIGENS, V42, P91, DOI 10.1111/j.1399-0039.1993.tb02173.x
   Krausa P, 1996, TISSUE ANTIGENS, V47, P237, DOI 10.1111/j.1399-0039.1996.tb02547.x
   Kuon W, 1997, ARTHRITIS RHEUM, V40, P945, DOI 10.1002/art.1780400524
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Lampe MF, 1998, INFECT IMMUN, V66, P5457
   LUNDEMOSE AG, 1992, MOL MICROBIOL, V6, P2539
   Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314
   Schachter J, 1978, HUMAN CHLAMYDIAL INF
   SCHACHTER J, 1990, SCAND J EXP MED, V181, P137
   STARNBACH MN, 1995, INFECT IMMUN, V63, P3527
   STARNBACH MN, 1994, J IMMUNOL, V153, P5183
   Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754
   SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222
   ZEMMOUR J, 1992, J IMMUNOL, V148, P1941
NR 25
TC 4
Z9 5
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 2001
VL 123
IS 1
BP 68
EP 72
DI 10.1046/j.1365-2249.2001.01416.x
PG 5
WC Immunology
SC Immunology
GA 396HT
UT WOS:000166630800011
PM 11168000
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
AF Lienhardt, C
TI From exposure to disease: The role of environmental factors in
   susceptibility to and development of tuberculosis
SO EPIDEMIOLOGIC REVIEWS
LA English
DT Review
ID NEW-YORK-CITY; HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS;
   PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES;
   RISK-FACTORS; EXOGENOUS REINFECTION; INCREASING INCIDENCE; ACTIVE
   TUBERCULOSIS
C1 IRD, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
RP Lienhardt, C (reprint author), IRD, Route Peres Maristes,BP 1386, Dakar, Senegal.
EM lienhardt@dakar.ird.sn
CR Ainsworth Martha, 1994, P559
   Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   ANDERSEN S, 1960, Bull World Health Organ, V22, P39
   Aoki M, 1985, B INT UNION TUBERC, V60, P128
   Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   BELLAMY RJ, 1997, NOVARTIS PUBLICATION, V217, P3
   BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228
   BEYERS N, 1994, TUBERCLE, V74, P260
   BHATTI N, 1995, BRIT MED J, V310, P967
   BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1
   BLACKWELL JM, 1995, MOL MED, V1, P194
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745
   BUSKIN SE, 1994, AM J PUBLIC HEALTH, V84, P1750, DOI 10.2105/AJPH.84.11.1750
   Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535
   CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8
   CHAPMAN JS, 1964, AM REV RESPIR DIS, V90, P48
   COETZEE N, 1988, S AFR MED J, V74, P352
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131
   COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404
   Davies PDO, 1994, CLIN TUBERCULOSIS
   de Jong R, 1998, SCIENCE, V280, P1435
   DECOCK KM, 1994, TUBERCULOSIS BACK FU
   DIPERRI G, 1989, LANCET, V2, P1502
   DOHERTY MJ, 1995, BRIT MED J, V311, P187
   DOHERTY T, 2000, CURR OPIN PULM MED, V3, P203
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7
   Dubos R, 1987, WHITE PLAGUE TUBERCU
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U
   ENARSON D, 1979, AM REV RESPIR DIS, V119, P11
   ENARSON DA, 1989, AM J EPIDEMIOL, V129, P1268
   ENARSON DA, 1994, CLIN TUBERCULOSIS
   Roberts J, 1977, VITAL HLTH STAT, V11, P1
   Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8
   FELTON CP, 1990, NEW ENGL J MED, V322, P1670
   FINE PEM, 1981, INT J LEPROSY, V49, P437
   Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609
   Fine PEM, 1994, TUBERCULOSIS BACK FU, P53
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406
   Friedman SR, 1997, AIDS, V11, pS201
   FRIEDMAN SR, 1993, ADV MED SOCIOLOGY, V3, P19
   Frost WH, 1933, AM J PUBLIC HEALTH N, V23, P426, DOI 10.2105/AJPH.23.5.426
   GLYNN JR, 1998, 12 WORLD AIDS C GEN
   Grange JM, 1999, LANCET, V353, P996, DOI 10.1016/S0140-6736(99)01196-4
   GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90
   HAWKES SJ, 1993, AIDS CARE, V5, P207, DOI 10.1080/09540129308258601
   HOGE CW, 1994, AM J EPIDEMIOL, V139, P520
   HOLLAND WW, 1969, BRIT MED J, V2, P205
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0
   HUNTER JM, 1984, SOC SCI MED, V19, P27, DOI 10.1016/0277-9536(84)90134-5
   KASS EH, 1971, J INFECT DIS, V123, P110
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501
   Wood R., 1990, AIDS, V4, P811
   KUEMMERE.JM, 1967, AM REV RESPIR DIS, V96, P885
   KUSHIGEMACHI M, 1984, J CHRON DIS, V37, P853, DOI 10.1016/0021-9681(84)90018-3
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635
   Liefooghe R, 1997, TROP MED INT HEALTH, V2, P809, DOI 10.1046/j.1365-3156.1997.d01-380.x
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233
   Lienhardt C, 1997, INT J TUBERC LUNG D, V1, P196
   Lienhardt C, 1999, LANCET, V353, P145, DOI 10.1016/S0140-6736(05)76180-8
   LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958
   Long ER, 1941, ARCH PATHOL, V32, P122
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109
   MANGTANI P, 1995, BRIT MED J, V310, P963
   MARKOWITZ SB, 1994, OCCUP MED, V9, P589
   MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306
   MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798
   McKenna MT, 1996, AM J RESP CRIT CARE, V154, P587
   McKenna MT, 1998, AM J PUBLIC HEALTH, V88, P1059, DOI 10.2105/AJPH.88.7.1059
   Medical Research Unit Tuberculosis and Chest Diseases Unit, 1980, BMJ-BRIT MED J, V281, P895
   Meredith S, 1996, BRIT MED J, V313, P522
   Mitnick C, 1998, INT J TUBERC LUNG D, V2, pS32
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G
   NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502
   National Tuberculosis Institute, 1974, B WHO, V51, P473
   Needham DM, 1998, INT J TUBERC LUNG D, V2, P811
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NORTH RJ, 1993, J EXP MED, V177, P1723, DOI 10.1084/jem.177.6.1723
   NUNN AJ, 1995, AIDS, V9, P503
   Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X
   Ogden J, 2000, T ROY SOC TROP MED H, V94, P135, DOI 10.1016/S0035-9203(00)90249-9
   ORDWAY DJ, 1995, INFECT IMMUN, V63, P741
   Pirkis JE, 1996, TUBERCLE LUNG DIS, V77, P401, DOI 10.1016/S0962-8479(96)90111-2
   Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1
   Pym AS, 1999, LANCET, V353, P1004, DOI 10.1016/S0140-6736(99)02118-2
   Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   REICHMAN LB, 1978, AM REV RESPIR DIS, V117, P705
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79
   ROELSGAARD E., 1964, BULL WORLD HEALTH ORGAN, V30, P459
   ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32
   ROUILLON A, 1976, TUBERCLE, V57, P275
   Rowland A J, 1966, Public Health, V80, P179, DOI 10.1016/S0033-3506(66)80036-7
   SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843
   SCHOEMAN JH, 1991, INT J EPIDEMIOL, V20, P435, DOI 10.1093/ije/20.2.435
   SHANKS NJ, 1984, J EPIDEMIOL COMMUN H, V38, P66, DOI 10.1136/jech.38.1.66
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724
   SIMMONDS B, 1963, TUBERCULOSIS TWINS
   Smith P., 1994, TUBERCULOSIS PATHOGE
   SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011
   SPENCE DPS, 1993, BRIT MED J, V307, P759
   SPRINGETT V H, 1958, Br J Prev Soc Med, V12, P135
   SPRINGETT VH, 1964, LANCET, V1, P1091
   SPRINGETT VH, 1952, LANCET, V1, P521
   STEAD WW, 1992, ANN INTERN MED, V116, P937
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544
   STEIN L, 1954, Tubercle, V35, P195
   Stein L, 1952, BR J SOC MED, V6, P1
   STRADLIN.P, 1973, TUBERCLE, V54, P249
   Styblo K, 1969, Bull Int Union Tuberc, V42, P1
   STYBLO K, 1989, REV INFECT DIS S2, V2, P339
   STYBLO K, 1991, SELECTED PAPERS ROYA, V24
   Sutherland I, 1976, Adv Tuberc Res, V19, P1
   SUTHERLAND I, 1982, TUBERCLE, V63, P255, DOI 10.1016/S0041-3879(82)80013-5
   Sweat M D, 1995, AIDS, V9 Suppl A, pS251
   TOQUE K, 1998, INT J TUBERC LUNG D, V2, P213
   Tornieporth NG, 1997, INT J TUBERC LUNG D, V1, P528
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247
   WALLGREN A, 1948, Tubercle, V29, P245, DOI 10.1016/S0041-3879(48)80033-4
   WATSON JM, 1993, BRIT MED J, V306, P221
   Weiss KB, 1998, AM J RESP CRIT CARE, V157, P1011
   WHITEHEAD M, 1988, HLTH DIVIDE INEQUALI, P215
   World Health Organization, 1994, WHOTB94177
   World Health Organization, 1994, WHOTB94179
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Yang QH, 1997, EPIDEMIOL REV, V19, P33
NR 144
TC 104
Z9 110
U1 3
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0193-936X
EI 1478-6729
J9 EPIDEMIOL REV
JI Epidemiol. Rev.
PY 2001
VL 23
IS 2
BP 288
EP 301
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 513ZG
UT WOS:000173410700006
PM 12192738
OA No
DA 2017-08-15
ER

PT J
AU MacLennan, J
   Obaro, S
   Deeks, J
   Lake, D
   Elie, C
   Carlone, G
   Moxon, ER
   Greenwood, B
AF MacLennan, J
   Obaro, S
   Deeks, J
   Lake, D
   Elie, C
   Carlone, G
   Moxon, ER
   Greenwood, B
TI Immunologic memory 5 years after meningococcal A/C conjugate vaccination
   in infancy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 11th International Pathogenic Neisseria Conference
CY NOV 01-06, 1998
CL NICE, FRANCE
ID LINKED-IMMUNOSORBENT-ASSAY; A CAPSULAR POLYSACCHARIDE; MENINGITIDIS
   SEROGROUP-A; T-CELL MODULATION; INFLUENZAE TYPE-B;
   NEISSERIA-MENINGITIDIS; ANTIBODY-RESPONSE; GAMBIAN CHILDREN; INDUCTION;
   IMMUNIZATION
AB Infant vaccination with meningococcal conjugates may provide long-term protection against disease. Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy. At 2 years, they were randomized to receive a booster of MenA/C (conjugate group), meningococcal A/C polysaccharide (MPS group), or inactivated polio vaccine (IPV group). All groups were revaccinated with 10 mug MPS at 5 years of age, as were 39 previously unvaccinated age-matched control subjects. Before revaccination, titers were higher in the conjugate and MPS groups than in control subjects (P<.001); titers for the IPV group were similar to those for control subjects. Ten days after revaccination, the conjugate and IPV groups had similar serogroup C serum bactericidal antibody titers (3421 vs. 2790, respectively). These levels were significantly higher than those in the MPS (426) and control (485) groups (P<.001). Thus, immunologic memory was sustained for greater than or equal to5 years; however, MPS challenge at 2 years interfered with a subsequent memory response.
C1 John Radcliffe Hosp, Dept Pediat, Oxford Vaccine Grp, Oxford OX3 9DU, England.
   Ctr Stat Med, Oxford, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Med Res Council Labs, Banjul, Gambia.
   Ctr Dis Control & Prevent, Atlanta, GA USA.
RP MacLennan, J (reprint author), John Radcliffe Hosp, Dept Pediat, Oxford Vaccine Grp, Oxford OX3 9DU, England.
OI Deeks, Jonathan/0000-0002-8850-1971
CR ARTENSTEIN MS, 1975, J IMMUNOL, V115, P5
   BOOY R, 1992, ARCH DIS CHILD, V67, P475
   BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325
   Campagne G, 1999, B WORLD HEALTH ORGAN, V77, P499
   Campagne G, 2000, PEDIATR INFECT DIS J, V19, P144, DOI 10.1097/00006454-200002000-00013
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   EVANSJONES LG, 1977, ARCH DIS CHILD, V52, P320
   Fairley CK, 1996, J INFECT DIS, V174, P1360
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475
   GOLD R, 1979, J INFECT DIS, V140, P690
   Gold R., 1977, J INFECT DIS       S, V136, P31
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   GRANOFF DM, 1993, J INFECT DIS, V168, P663
   Granoff DM, 1998, J INFECT DIS, V178, P870
   GREENWOOD BM, 1979, T ROY SOC TROP MED H, V73, P557, DOI 10.1016/0035-9203(79)90052-X
   Heath PT, 1998, PEDIATR INFECT DIS J, V17, pS117, DOI 10.1097/00006454-199809001-00005
   HOLDER PK, 1995, CLIN DIAGN LAB IMMUN, V2, P132
   JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383
   KAYHTY H, 1980, J INFECT DIS, V142, P861
   Krizova P., 1995, Epidemiologie Mikrobiologie Imunologie, V44, P9
   Leach A, 1997, J INFECT DIS, V175, P200
   LIEBERMAN JM, 1996, 10 INT PATH NEISS C, P231
   MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685
   MacLennan J, 1999, VACCINE, V17, P3086, DOI 10.1016/S0264-410X(99)00139-5
   MacLennan JM, 2000, JAMA-J AM MED ASSOC, V283, P2795, DOI 10.1001/jama.283.21.2795
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156
   Mateo S., 1997, EUROSURVEILLANCE, V2, P71
   MULLER E, 1988, INFECT IMMUN, V56, P259
   Ramsay M, 1997, Commun Dis Rep CDR Rev, V7, pR49
   Ramsay ME, 1997, EUROSURVEILLANCE, V2, P74
   REINGOLD AL, 1985, LANCET, V2, P114
   Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753
   Richmond P, 2000, J INFECT DIS, V181, P761, DOI 10.1086/315284
   SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1282
   *STAT CORP, 1997, STAT STAT SOFTW
   TAYLOR CE, 1989, INFECT IMMUN, V57, P180
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
   WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390
   Zepp F, 1997, EUR J PEDIATR, V156, P18
   1999, COMMUN DIS REP CDR W, V9, P261
   [Anonymous], 1997, WKLY EPIDEMIOL REC, V72, P313
NR 41
TC 67
Z9 69
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2001
VL 183
IS 1
BP 97
EP 104
DI 10.1086/317667
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 385CE
UT WOS:000165983400012
PM 11087205
OA No
DA 2017-08-15
ER

PT J
AU Jonsyn-Ellis, FE
AF Jonsyn-Ellis, FE
TI Seasonal variation in exposure frequency and concentration levels of
   aflatoxins and ochratoxins in urine samples of boys and girls
SO MYCOPATHOLOGIA
LA English
DT Article
DE aflatoxin; children; dry season; ochratoxin; rainy season; Sierra Leone;
   urine
ID B VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; SIERRA-LEONE; MOLECULAR
   DOSIMETRY; DIETARY; CANCER; KWASHIORKOR; EXCRETION; AFRICA; KENYA
AB Urine samples from children in Sierra Leone (134 boys and 110 girls), were collected during the dry season. During the rainy season samples were collected from 97 boys and 93 girls. Analysis of the dry season samples, revealed that, with the exception of one boy, all children had detectable amounts of aflatoxins and/or ochratoxins in their urine. Similarly, with the exception of four children (two from each sex), rainy season urine samples also contained these two mycotoxins. There were significant differences in the frequency of exposure to some mycotoxins: ochratoxin A (OTA), p < 0.01; 4-hydroxyochratoxin A (4R-OTA), p < 0.002; aflatoxin M1 (AFM(1)), p < 0.04; aflatoxicol (AFL), p < 0.03; aflatoxin B-2 (AFB(2)), p < 0.04 . There were also significant differences in the levels of aflatoxin B-1 (AFB(1)), (p < 0.05) and AFB(2), (p < 0.02) detected in dry season samples. Stratification of these results according to season and sex, has indicated significant differences with respect to 4R-OTA (p < 0.04) and AFB(1) (p < 0.02). The results of this study show that in Sierra Leone, children are frequently and constantly exposed to both aflatoxins and ochratoxins.
C1 Univ Sierra Leone, Sch Pharm, Coll Med & Allied Hlth Sci, Freetown, Sierra Leone.
RP Jonsyn-Ellis, FE (reprint author), Univ Gambia, POB 3530, Kanifing, Gambia.
CR ALPERT ME, 1971, CANCER, V28, P253, DOI 10.1002/1097-0142(197107)28:1<253::AID-CNCR2820280151>3.0.CO;2-G
   AUTRUP H, 1987, CANCER RES, V47, P3430
   BACHA H, 1993, HUMAN OCHRATOXICOSIS, V231, P111
   BEAN TA, 1989, J TOXICOL-TOXIN REV, V8, P43
   BULATAOJAYME J, 1982, INT J EPIDEMIOL, V11, P112, DOI 10.1093/ije/11.2.112
   COULTER JBS, 1986, T ROY SOC TROP MED H, V80, P945, DOI 10.1016/0035-9203(86)90266-X
   COURSAGET P, 1980, J NATL CANCER I, V65, P687
   DEVRIES HR, 1987, ANN TROP PAEDIATR, V7, P249
   GROOPMAN JD, 1988, CRIT REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902
   GROOPMAN JD, 1992, CANCER EPIDEM BIOMAR, V1, P221
   GROOPMAN JD, 1992, CANCER RES, V52, P45
   HATCH MC, 1993, INT J CANCER, V54, P931, DOI 10.1002/ijc.2910540611
   Hendrickse R. G., 1981, Paediatrics in the tropics: current review., P185
   JONSYN FE, 1989, MIRCEN J APPL MICROB, V5, P457, DOI 10.1007/BF01741821
   JONSYN FE, 1992, NAHRUNG, V36, P485, DOI 10.1002/food.19920360510
   JONSYN FE, 1990, MYCOPATHOLOGIA, V110, P113, DOI 10.1007/BF00447000
   JONSYN FE, 1988, MYCOPATHOLOGIA, V104, P123
   JONSYN FE, 1993, INT S HUM OCHR ASS P, V31
   JONSYN FE, 1994, THESIS U LIVERPOOL U
   KANE A, 1991, IARC SCI PUBLICATION, V115
   KHALEF A, 1995, C INSERM, V231, P123
   Puhlev A, 1974, ENDEMIC NEPHROPATHY, P266
   NYATHI CB, 1987, INT J EPIDEMIOL, V16, P516, DOI 10.1093/ije/16.4.516
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   STORMER FC, 1985, APPL ENVIRON MICROB, V49, P1108
   *UNICEF, 1989, CHILDR WOM S LEON AN, V1, P1
   VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107
   WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A
   ZHU JQ, 1987, CANCER RES, V47, P1848
NR 29
TC 16
Z9 19
U1 0
U2 6
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0301-486X
J9 MYCOPATHOLOGIA
JI Mycopathologia
PY 2001
VL 152
IS 1
BP 35
EP 40
DI 10.1023/A:1011950512675
PG 6
WC Mycology
SC Mycology
GA 477RD
UT WOS:000171297300006
PM 11694094
OA No
DA 2017-08-15
ER

PT J
AU Smith, SM
   Brookes, R
   Klein, MR
   Malin, AS
   Lukey, PT
   King, AS
   Ogg, GS
   Hill, AVS
   Dockrell, HM
AF Smith, SM
   Brookes, R
   Klein, MR
   Malin, AS
   Lukey, PT
   King, AS
   Ogg, GS
   Hill, AVS
   Dockrell, HM
TI Human CD8(+) CTL specific for the mycobacterial major secreted antigen
   85A
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; BACILLUS-CALMETTE-GUERIN; ACTIVE ANTIRETROVIRAL
   THERAPY; PEPTIDE-MHC TETRAMERS; CLASS-I PRESENTATION; TUBERCULOSIS
   INFECTION; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; CELL RESPONSES;
   GAMMA-INTERFERON
AB The role of CD8(+) CTL in protection against tuberculosis in human disease is unclear. In this study, we stimulated the peripheral blood mononuclear cells of bacillus Calmette-Guerin (BCG)-vaccinated individuals with live Mycobacterium bovis BCG bacilli to establish short-term cell lines and then purified the CD8(+) T cells. A highly sensitive enzyme-linked immunospot (ELISPOT) assay for single cell IFN-gamma release was used to screen CD8(+) T cells with overlapping peptides spanning the mycobacterial major secreted protein, Ag85A, Three peptides consistently induced a high frequency of IFN-gamma responsive CD8(+) T cells, and two HLA-A*0201 binding motifs, P48-56 and P242-250 were revealed within the core sequences, CD8(+) T cells responding to the 9-mer epitopes were visualized within fresh blood by ELISPOT using free peptide or by binding of HLA-A*0201 tetrameric complexes, The class I-restricted CD8(+) T cells were potent CTL effector cells that efficiently lysed an HLA-A2-matched monocyte cell line pulsed with peptide as well as autologous macrophages infected with Mycobacterium tuberculosis or recombinant vaccinia virus er;pressing the whole Ag85A protein. Tetramer assays revealed a 6-fold higher frequency of peptide-specific T cells than IFN-gamma ELISPOT assays, indicating functional heterogeneity within the CD8(+) T cell population. These results demonstrate a previously unrecognized, MHC class I-restricted, CD8(+) CTL response to a major secreted Ag of mycobacteria and supports the use of Ag85A as a candidate vaccine against tuberculosis.
C1 Univ London London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Mol Immunol Grp, Oxford OX3 9DU, England.
   MRC Labs, TB Res Programme, Fajara, Gambia.
   Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England.
RP Smith, SM (reprint author), Univ London London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI HILL, Adrian/C-1306-2008
OI Dockrell, Hazel/0000-0003-1869-9107
CR ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Baldwin S. L., 1999, Tubercle and Lung Disease, V79, P251, DOI 10.1054/tuld.1998.0196
   BARNES PF, 1993, INFECT IMMUN, V61, P197
   BARNES PF, 1993, INFECT IMMUN, V61, P3482
   Bieganowska K, 1999, J IMMUNOL, V162, P1765
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055
   BOOM WH, 1991, INFECT IMMUN, V59, P2737
   CANADAY DH, 1999, J IMMUNOL, V162, P327
   CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257
   Cooper AM, 1997, INFECT IMMUN, V65, P1317
   Denis O, 1999, INT IMMUNOL, V11, P209, DOI 10.1093/intimm/11.2.209
   Denis O, 1997, INFECT IMMUN, V65, P676
   Denis O, 1998, INFECT IMMUN, V66, P1527
   Dunbar PR, 1999, J IMMUNOL, V162, P6959
   Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7
   Esin S, 1996, CLIN EXP IMMUNOL, V104, P419, DOI 10.1046/j.1365-2249.1996.d01-691.x
   Feng CG, 1999, INFECT IMMUN, V67, P3242
   FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   Gray CM, 1999, J IMMUNOL, V162, P1780
   He XS, 1999, P NATL ACAD SCI USA, V96, P5692, DOI 10.1073/pnas.96.10.5692
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893
   HUYGEN K, 1994, INFECT IMMUN, V62, P363
   Kalams SA, 1999, J VIROL, V73, P6721
   KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127
   LAUNOIS P, 1994, INFECT IMMUN, V62, P3679
   Lee PP, 1999, NAT MED, V5, P677
   Lewin D, 1998, ADV IND LAB, V8, P1
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326
   Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786
   Moha-Ouchane M, 1998, INT J THERMOPHYS, V19, P161, DOI 10.1023/A:1021455203728
   Moreira AL, 1997, INFECT IMMUN, V65, P305
   MUNK ME, 1994, INFECT IMMUN, V62, P726
   Ogg GS, 1999, J VIROL, V73, P9153
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203
   ORME IM, 1993, J IMMUNOL, V151, P518
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Ravn P, 1997, J IMMUNOL, V158, P1949
   Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641
   Serbina NV, 1999, INFECT IMMUN, V67, P3980
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146
   Tan JS, 1997, J IMMUNOL, V159, P290
   Tan LC, 1999, J IMMUNOL, V162, P1827
   Tascon RE, 1998, INFECT IMMUN, V66, P830
   Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888
   TIETLEBAUM R, 1999, P NATL ACAD SCI USA, V96, P15190
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x
   Whelan JA, 1999, J IMMUNOL, V163, P4342
   Harboe M, 1992, MICROBIOL, V56, P648
   Wilkinson RJ, 1998, IMMUNOLOGY, V95, P585
   Wren BW, 1998, MICROBIOL-UK, V144, P1205
   Yee C, 1999, J IMMUNOL, V162, P2227
NR 59
TC 91
Z9 96
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2000
VL 165
IS 12
BP 7088
EP 7095
PG 8
WC Immunology
SC Immunology
GA 381XZ
UT WOS:000165790500056
PM 11120838
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Jatta, B
   Faal, H
   Bailey, R
   Foster, A
   Johnson, GJ
AF Bowman, RJC
   Jatta, B
   Faal, H
   Bailey, R
   Foster, A
   Johnson, GJ
TI Long-term follow-up of lid surgery for trichiasis in the Gambia:
   surgical success and patient perceptions
SO EYE
LA English
DT Article
DE eyelid surgery; the Gambia; trachoma; trichiasis
ID TRACHOMA; WOMEN
AB Background Surgery is an important component of the SAFE strategy which has been shown to improve visual acuity. There are limited data on long-term surgical success and patient perceptions and satisfaction. A sample of patients from the Gambia who had undergone previous lid surgery for trichiasis were therefore examined for recurrence of trichiasis and interviewed for patient satisfaction.
   Methods Health centre surgical records and community screening were used to identify patients who had undergone previous lid surgery. Consenting patients were examined and a questionnaire administered. Kaplan-Meier survival plots were constructed for recurrence of trichiasis.
   Results Sixty-five subjects were recruited. Median age at surgery was 50 years. Median time since surgery was 7 years. Fifty-two of 115 (45%) operated eyes were free of trichiasis at follow-up and 23 of 65 (35%) patients had not suffered recurrent trichiasis in an operated eye. Median time from surgery to recurrence of trichiasis was estimated as 10.0 years (95% CI 3.7-16.3). Recurrent trichiasis was not significantly associated with visual impairment or blindness at follow-up. The following patient perceptions were reported: satisfaction with surgery (88%), less discomfort than before surgery (93%), improved vision (83%), work easier (38%), worth the expenditure (94%), would recommend it to others (93%), had recommended it to others (38%), experienced intra-operative pain (26%) and experienced post-operative pain (26%).
   Conclusion Factors affecting surgical success, including surgical technique and re-exposure to infection, are discussed. This study provides important preliminary data for programme planners but larger prospective studies are required.
C1 Int Ctr Eye Hlth, London EC1V 9EL, England.
   Natl Eye Care Programme Gambia, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Bowman, RJC (reprint author), Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
CR BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   BOWMAN RJC, UNPUB LONGITUDINAL S
   BRILLIANT GE, 1991, ARCH OPHTHALMOL-CHIC, V109, P584
   COURTRIGHT P, 1994, E AFR MED J, V71, P803
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   DOLIN PJ, 1998, BR J OPHTHALMOL, V82, P903
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   OLIVA MS, 1998, INT OPHTHALMOL, V21, P235
   Reacher NI, 1993, WHOPBL9329
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249
   World Health Organization, 1997, WHOPBL9761
NR 15
TC 27
Z9 28
U1 0
U2 0
PU ROYAL COLL OPHTHALMOLOGISTS
PI LONDON
PA 17 CORNWALL TERRACE, LONDON NW1 4QW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD DEC
PY 2000
VL 14
BP 864
EP 868
PN 6
PG 5
WC Ophthalmology
SC Ophthalmology
GA 386HG
UT WOS:000166054500010
PM 11584844
OA No
DA 2017-08-15
ER

PT J
AU Smith, SM
   Klein, MR
   Malin, AS
   Sillah, J
   Huygen, K
   Andersen, P
   McAdam, KPWJ
   Dockrell, HM
AF Smith, SM
   Klein, MR
   Malin, AS
   Sillah, J
   Huygen, K
   Andersen, P
   McAdam, KPWJ
   Dockrell, HM
TI Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted
   antigens in tuberculosis patients and healthy BCG-vaccinated controls in
   The Gambia
SO INFECTION AND IMMUNITY
LA English
DT Article
ID ESAT-6 PROTEIN; H-2(B) MICE; BOVIS BCG; INFECTION; RESPONSES;
   RESISTANCE; PERFORIN; CD4(+)
AB Intracellular flow cytometry analysis of perforin production by CD8(+) T cells showed levels were greatly reduced in tuberculosis (TB) patients compared to healthy controls. Reduced cytotoxic-T-lymphocyte activity was also obtained with CD8(+) T cells from TB patients compared to healthy controls in The Gambia. A change in antigen recognition was noted between the two groups of donors: in addition to recognition of Ag85A and Ag85B, as seen in healthy donors, a prominent ESAT-6 response was found in TB patients.
C1 Univ London London Sch Hyg & Trop Med, Immunol Unit, London WC1E 7HT, England.
   MRC Labs, TB Res Programme, Fajara, Gambia.
   Inst Pasteur, Brussels, Belgium.
   Statens Serum Inst, Dept TB Immunol, DK-2300 Copenhagen, Denmark.
RP Smith, SM (reprint author), Univ London London Sch Hyg & Trop Med, Immunol Unit, Keppel St, London WC1E 7HT, England.
OI Dockrell, Hazel/0000-0003-1869-9107
CR ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   CANADAY DH, 1999, J IMMUNOL, V162, P327
   Cooper AM, 1997, INFECT IMMUN, V65, P1317
   Denis O, 1999, INT IMMUNOL, V11, P209, DOI 10.1093/intimm/11.2.209
   Denis O, 1997, INFECT IMMUN, V65, P676
   Denis O, 1998, INFECT IMMUN, V66, P1527
   FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   Gong JH, 1998, J CLIN INVEST, V101, P383, DOI 10.1172/JCI318
   Harboe M, 1998, INFECT IMMUN, V66, P717
   Harboe M, 1996, INFECT IMMUN, V64, P16
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633
   Mohagheghpour N, 1998, J IMMUNOL, V161, P2400
   ORME IM, 1993, J INFECT DIS, V167, P1481
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640
   Rosat JP, 1999, J IMMUNOL, V162, P366
   Smith SM, 1999, INFECT IMMUN, V67, P5223
   Tan JS, 1997, J IMMUNOL, V159, P290
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Zhu X, 1997, IMMUNOLOGY, V92, P6, DOI 10.1046/j.1365-2567.1997.00358.x
   Zhu XJ, 1997, INT IMMUNOL, V9, P1669, DOI 10.1093/intimm/9.11.1669
NR 26
TC 57
Z9 63
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2000
VL 68
IS 12
BP 7144
EP 7148
DI 10.1128/IAI.68.12.7144-7148.2000
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 403AH
UT WOS:000167020000085
PM 11083843
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Sillah, A
   van Dehn, C
   Goode, VM
   Muquit, M
   Johnson, GJ
   Milligan, P
   Rowley, J
   Faal, H
   Bailey, RL
AF Bowman, RJC
   Sillah, A
   van Dehn, C
   Goode, VM
   Muquit, M
   Johnson, GJ
   Milligan, P
   Rowley, J
   Faal, H
   Bailey, RL
TI Operational comparison of single-dose azithromycin and topical
   tetracycline for trachoma
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OCULAR CHLAMYDIAL INFECTION
AB PURPOSE. World Health Organization guidelines for antibiotic treatment of trachoma currently include a 6-week course of tetracycline eye ointment twice daily or a single dose of oral azithromycin. Previous trials have shown similar efficacy of these two alternatives when administration of the ointment was carefully supervised. It is believed, however, that azithromycin may be a more effective treatment in practice, and the purpose of this study was to test that hypothesis.
   METHODS. A masked randomized controlled trial was conducted to compare azithromycin and tetracycline under practical operational conditions-i.e., without supervision of the administration of the ointment. Three hundred fourteen children aged 6 months to 10 years with clinically active trachoma were recruited and individually randomized to receive one of the two treatments. Follow-up visits were conducted at 10 weeks and 6 months. The outcome was resolution of disease (clinical "cure").
   RESULTS. Children allocated to azithromycin were significantly more likely to have resolved disease than those allocated to tetracycline, both at 10 weeks (68% versus 51%; cure rate ratio, 1.31; 95% confidence interval [CI], 1.08-1.59; P = 0.007) and at 6 months (88% versus 73%; cure rate ratio, 1.19; 95% CI, 1.06-1.34; P = 0.004). Azithromycin was particularly effective for intense inflammation (P = 0.023, Fisher's exact test).
   CONCLUSIONS. Single-dose oral azithromycin was a more effective treatment for active trachoma than tetracycline ointment as applied by caregivers. The high cure rate achieved with tetracycline in this study in the absence of supervision and the significantly higher costs of azithromycin, suggest that in the absence of donation programs, switching routine treatment from tetracycline to azithromycin would not be a good use of resources.
C1 Int Ctr Eye Hlth, London EC1V 9EL, England.
   Natl Eye Care Program Gambia, Banjul, Gambia.
   Univ Maastricht, Sch Med, Maastricht, Netherlands.
   Univ Glasgow, Sch Med, Glasgow G12 8QQ, Lanark, Scotland.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
RP Bowman, RJC (reprint author), Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   Dawson CR, 1990, CHLAMYDIAL INFECT, P271
   Francis V, 1995, ACHIEVING COMMUNITY
   GIRARD AE, 1996, J ANTIMICROB CHEMO S, V37, pC9
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   LODE H, 1996, J ANTIMICROB CHEMO S, V37, pC1
   MABEY D, 1998, P 9 INT S HUM CHLAM, P351
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
NR 13
TC 45
Z9 45
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2000
VL 41
IS 13
BP 4074
EP 4079
PG 6
WC Ophthalmology
SC Ophthalmology
GA 378HL
UT WOS:000165578900005
PM 11095598
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
AF Obaro, SK
TI Respiratory diseases in Africa: causes and effects
SO LANCET
LA English
DT Article
C1 MRC Labs, Basse Field Stn, Fajara, Gambia.
RP Obaro, SK (reprint author), MRC Labs, Basse Field Stn, POB 273, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC
PY 2000
VL 356
SU S
BP S55
EP S55
DI 10.1016/S0140-6736(00)92041-5
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 386RG
UT WOS:000166074900057
PM 11191514
OA No
DA 2017-08-15
ER

PT J
AU Quinones, ML
   Drakeley, CJ
   Muller, O
   Lines, JD
   Haywood, M
   Greenwood, BM
AF Quinones, ML
   Drakeley, CJ
   Muller, O
   Lines, JD
   Haywood, M
   Greenwood, BM
TI Diversion of Anopheles gambiae from children to other hosts following
   exposure to permethrin-treated bednets
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE Anopheles gambiae; beta-globin; bednets; bloodmeals; diversion; hosts;
   insecticide-treated nets; malaria vectors; The Gambia
ID BED NETS; IMPREGNATED BEDNETS; TARGETED CHEMOPROPHYLAXIS; MOSQUITO
   BLOODMEALS; WEST-AFRICA; RURAL AREA; MALARIA; TRIAL; IDENTIFICATION;
   AMPLIFICATION
AB Permethrin-treated bednets reduce mortality and morbidity from malaria in Gambian children. However, it is not certain how this effect is achieved, as neither mosquito numbers nor the human blood index of indoor-resting female Anopheles gambiae Giles sensu lato (Diptera: Culicidae) mosquitoes have been reduced when treated bednets were introduced into a community. One possibility is that insecticide-treated bednets divert mosquitoes from children to adults. To investigate this hypothesis, a cross-over trial with insecticide-treated bednets was undertaken in two small Gambian villages. To differentiate mosquitoes that had fed on children from those that had fed on adults, all children in the study villages were immunized with rabies vaccine before the trial. Using the detection of rabies antibody in a bloodmeal as an indicator that a mosquito had bitten a child, it was found that the percentage of blood-fed mosquitoes caught indoors that had bitten a child fell significantly from 30.8% to 9.2% and from 28.0% to 6.9% in each village after insecticide-treated bednets were introduced. To investigate the possibility that some diversion to animals had occurred, a PCR analysis for human beta -globin DNA was undertaken on selected samples. The results of this investigation were confusing, as some rabies-antibody positive bloodmeals were negative for human DNA. This may have been due to cross-reacting antibodies in animal sera and/or DNA degradation by digestion in the mosquito. Although good evidence for diversion of mosquitoes away from children was obtained, it remains uncertain whether diversion was mainly to adult humans, to animals or to both.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Quinones, ML (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P473
   BODKER R, 1995, T ROY SOC TROP MED H, V89, P449, DOI 10.1016/0035-9203(95)90054-3
   BOREHAM PFL, 1978, J TROP MED HYG, V81, P63
   BRYAN JH, 1978, T ROY SOC TROP MED H, V72, P357, DOI 10.1016/0035-9203(78)90127-X
   BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336
   CLEAVELAND S, 1996, THESIS U LONDON
   COULSON RMR, 1990, MED VET ENTOMOL, V4, P357, DOI 10.1111/j.1365-2915.1990.tb00452.x
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DAlessandro U, 1995, T ROY SOC TROP MED H, V89, P596, DOI 10.1016/0035-9203(95)90401-8
   GOKOOL S, 1993, MED VET ENTOMOL, V7, P208, DOI 10.1111/j.1365-2915.1993.tb00678.x
   IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385
   KARCH S, 1993, ANN SOC BELG MED TR, V73, P37
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   Quinones ML, 1997, MED VET ENTOMOL, V11, P71, DOI 10.1111/j.1365-2915.1997.tb00292.x
   Quinones ML, 1998, T ROY SOC TROP MED H, V92, P373, DOI 10.1016/S0035-9203(98)91053-7
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   TAMIHIRSCH A, 1994, USE PCR IDENTIFY IND
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
NR 23
TC 8
Z9 8
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD DEC
PY 2000
VL 14
IS 4
BP 369
EP 375
DI 10.1046/j.1365-2915.2000.00256.x
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 376QT
UT WOS:000165468800004
PM 11129700
OA No
DA 2017-08-15
ER

PT J
AU Naidoo, B
   Stevens, W
   McPherson, K
AF Naidoo, B
   Stevens, W
   McPherson, K
TI Modelling the short term consequences of smoking cessation in England on
   the hospitalisation rates for acute myocardial infarction and stroke
SO TOBACCO CONTROL
LA English
DT Article
DE smoking cessation modelling cost; acute myocardial infarction; stroke
ID COSTS; UNIT
AB Objectives-To estimate the short term event and cost consequences of achieving two smoking cessation targets for England among a cohort of 35-64 year olds, in terms of the number of hospitalised acute myocardial infarctions (AMIs) and strokes avoided.
   Design-A spreadsheet model based on previous work and using data for England was constructed to simulate the effects of achieving the target set out in the government's tobacco white paper (target 1). We also examined the consequence of achieving the intensive smoking reduction witnessed in California (target 2).
   Results-Target 1 would result in 347 AMI and 214 stroke hospitalisations avoided in the year 2000, and by 2010 this would be 6386 AMI and 4969 strokes avoided. Achieving target 2 would result in 739 AMI and 455 stroke hospitalisations avoided in 2000, and 14 554 AMI and 11 304 strokes avoided by 2010. Achieving target 1 would save pound 524 million (pound 423 million discounted at a rate of 2.67% for stroke and 2.31% for AMI) and target 2 would save pound1.14 billion (pound 921 million discounted) in terms of National Health Service costs.
   Conclusion-In the short term (11 years), reductions in the prevalence of smoking will produce sizeable reductions in both events and hospital costs.
C1 Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Promot Res Unit, London WC1E 7HT, England.
   MRC Int, Fajara, Gambia.
   London Sch Hyg & Trop Med, Canc & Publ Hlth Unit, London WC1, England.
RP Naidoo, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Promot Res Unit, Keppel St, London WC1E 7HT, England.
CR *AUD COMM, 1995, DEAR OUR HEARTS COMM
   BATES C, 1999, CIGARETTE ENG NICOTI
   Beech N, 1999, MANAGE LEARN, V30, P7, DOI 10.1177/1350507699301002
   *CHART I PUBL FIN, HLTH DAT 1998
   Department of Health, 1998, SMOK KILLS WHIT PAP
   *DEP HLTH, 1999, NHS WAIT TIM SUMM EN
   DOLL R, 1976, BRIT MED J, V2, P1525
   Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311
   *HM TREAS, 1997, APPR EV CENTR GOV, P25
   ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988
   JOHNSTON M, 1981, P MORRIS US INT 0331
   Jorgensen HS, 1999, STROKE, V30, P930
   Lightwood JM, 1997, CIRCULATION, V96, P1089
   Mamoli A, 1999, NEUROLOGY, V53, P112
   *OFF HLTH EC, 1999, HLTH HLTH CAR STAT
   Persson U, 1990, Int J Technol Assess Health Care, V6, P125
   PETO R, 1999, NHS SMOK CESS C 10 M
   PETO R, 1994, MORTALITY SMOKING DE
   PORSDAL V, 1999, EUR J NEUROL, V6, P44954
   RAW M, 1998, THORAX S5, V53
   *SERV PUBL HTLH SE, 1962, REP ROYAL COLL PHYS
   STEVENS W, 1999, COST CORONARY HEART
   Torp-Pedersen C, 1999, LANCET, V354, P9, DOI 10.1016/S0140-6736(98)09374-X
   *USDHHS, 1990, 908416 DHHS CDC CDCP
   Van Hout BA, 1998, HEALTH ECON, V7, P581, DOI 10.1002/(SICI)1099-1050(1998110)7:7<581::AID-HEC380>3.0.CO;2-U
NR 25
TC 11
Z9 13
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD DEC
PY 2000
VL 9
IS 4
BP 397
EP 400
DI 10.1136/tc.9.4.397
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 384TE
UT WOS:000165960300013
PM 11106709
OA No
DA 2017-08-15
ER

PT J
AU Turner, PC
   Mendy, M
   Whittle, H
   Fortuin, M
   Hall, AJ
   Wild, CP
AF Turner, PC
   Mendy, M
   Whittle, H
   Fortuin, M
   Hall, AJ
   Wild, CP
TI Hepatitis B infection and aflatoxin biomarker levels in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE HBV; aflatoxin; Gambia; children; biomarkers
ID CARCINOGEN METABOLIZING ENZYMES; REPUBLIC-OF-CHINA;
   HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; ALBUMIN ADDUCTS;
   SURFACE-ANTIGEN; B-1-DNA ADDUCTS; LIVER-CANCER; WEST-AFRICA; EXPOSURE
AB OBJECTIVES To examine the relationship between hepatitis B virus (HBV) infection and biomarkers of aflatoxin exposure in West African children.
   METHODS Sera from 444 children aged 3-4 years who were selected to be representative of their communities were analysed for aflatoxin-albumin (AF-alb) adducts and markers of hepatitis B infection.
   RESULTS There was large interindividual variation in adduct levels (range: 2.2 to 459 pg AF-lysine eq./mg albumin). Adduct level was strongly correlated with season, with an approximately twofold higher mean level in the dry season than the wet. Geometric mean adduct levels in uninfected children, chronic carriers and acutely infected children were 31.6 (n = 404), 44.9 (n = 34) and 96.9 (n = 6) pg/mg, respectively. The relationship of AF -alb level to ethnicity, month of sampling and HBV status was examined in a multiple regression model. Month of obtaining the blood sample (P=0.0001) and HBV status (P=0.0023) each made a highly significant contribution to the model; the high AF-alb levels were particularly associated with acute infection. Elevated serum transaminase levels were significantly (P<0.002) associated with HBV status, with acutely infected children having the highest levels. Ethnicity was not significantly associated with AF-alb adduct levels in the model (P=0.09).
   CONCLUSIONS. HBV infection and month of sampling both significantly influence AF-alb adduct levels. The effect of seasonality on adducts was also observed in a previous study of 347 Gambian adults, although there was no correlation between adduct level and HBV status in that population. This difference between children and adults may reflect a more severe effect of HBV infection, particularly acute infection, in childhood on hepatic AF metabolism.
C1 Univ Leeds, Sch Med, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England.
   MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Wild, CP (reprint author), Univ Leeds, Sch Med, Mol Epidemiol Unit, 3rd Floor,Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.
RI Turner, Paul/A-6152-2011; Turner, Paul/B-8131-2013
FU NIEHS NIH HHS [ES06052]
CR ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Barraud L, 1999, HEPATOLOGY, V29, P1317, DOI 10.1002/hep.510290441
   Chemin I, 1996, HEPATOLOGY, V24, P649, DOI 10.1002/hep.510240330
   Chemin I, 1999, LIVER, V19, P81, DOI 10.1111/j.1478-3231.1999.tb00015.x
   Chomarat P, 1997, CARCINOGENESIS, V18, P2179, DOI 10.1093/carcin/18.11.2179
   Chomarat Pascale, 1998, Toxicology Letters (Shannon), V102-103, P595, DOI 10.1016/S0378-4274(98)00254-9
   DEFLORA S, 1985, CANCER RES, V47, P4052
   Diallo Mamadou S., 1995, Natural Toxins, V3, P6, DOI 10.1002/nt.2620030103
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3
   Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208
   KIRBY GM, 1994, MOL CARCINOGEN, V11, P81, DOI 10.1002/mc.2940110205
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0
   Wang JS, 1996, CANCER EPIDEM BIOMAR, V5, P253
   Wild CP, 1996, CANCER EPIDEM BIOMAR, V5, P179
   Wild CP, 1999, CANCER SURV, V33, P35
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K
   Yu MW, 1996, CANCER EPIDEM BIOMAR, V5, P613
   Yu MW, 1997, CARCINOGENESIS, V18, P1189, DOI 10.1093/carcin/18.6.1189
   Zhou TL, 1997, CANCER RES, V57, P2749
NR 29
TC 71
Z9 75
U1 0
U2 9
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD DEC
PY 2000
VL 5
IS 12
BP 837
EP 841
DI 10.1046/j.1365-3156.2000.00664.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 399DW
UT WOS:000166796900002
PM 11169271
OA No
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   Whittle, H
AF Ariyoshi, K
   Whittle, H
TI HIV-1 viral load and scrub typhus
SO LANCET
LA English
DT Letter
ID FALCIPARUM
C1 Natl Inst Infect Dis, Tokyo 2080011, Japan.
   MRC Labs, Banjul, Gambia.
RP Ariyoshi, K (reprint author), Natl Inst Infect Dis, 4-7-1 Gakuen Musashimurayama, Tokyo 2080011, Japan.
CR Ariyoshi K, 1999, AIDS, V13, P1145, DOI 10.1097/00002030-199906180-00023
   Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5
NR 4
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 18
PY 2000
VL 356
IS 9243
BP 1766
EP 1766
DI 10.1016/S0140-6736(05)71954-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 376MX
UT WOS:000165462300045
PM 11095279
OA No
DA 2017-08-15
ER

PT J
AU Cham, F
   Heyndrickx, L
   Janssens, W
   Van der Auwera, G
   Vereecken, K
   De Houwer, K
   Coppens, S
   Whittle, H
   Van der Groen, G
AF Cham, F
   Heyndrickx, L
   Janssens, W
   Van der Auwera, G
   Vereecken, K
   De Houwer, K
   Coppens, S
   Whittle, H
   Van der Groen, G
TI Study of HIV type 1 gag/env variability in The Gambia, using a multiplex
   DNA polymerase chain reaction
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SEQUENCE ALIGNMENT
AB A multiplex DNA PCR assay was developed for the simultaneous first-round amplification of HIV-1 gag and env fragments for the heteroduplex mobility assay (HMA). This assay was compared with the conventional amplification assay, using DNA extracted from PBMC samples from 30 HIV-1-seropositive individuals from The Gambia, who were enrolled between 1992 and 1997. From 27 of 30 (90%) samples both gag and env HMA fragments were amplified simultaneously. In one sample only the gag HMA fragment could be amplified by multiplex DNA PCR, and in two samples amplification was negative for both gag and env HMA in multiplex as well as the mono-DNA PCR. Of the 28 Gambian isolates subtyped by gag/env HMA or by sequencing and phylogenetic analysis, the majority (19 of 28; 68%) were intersubtype recombinant. Fifteen of 28 (53%) samples were circulating recombinant form (CRF) CRF02.AG variants. Two isolates clustering with the previously documented Gambian isolate GM4 (previously described as an env GC recombinant) are classified as gag A/env J recombinants.
C1 Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   MRC Labs, Fajara, Gambia.
   Univ Ghent VIB, B-9052 Ghent, Belgium.
RP Janssens, W (reprint author), Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
CR Bobkov A, 1996, AIDS RES HUM RETROV, V12, P169, DOI 10.1089/aid.1996.12.169
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DERIJK P, 1993, COMPUT APPL BIOSCI, V9, P735
   Heyndrickx L, 2000, J VIROL, V74, P363
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569
NR 7
TC 17
Z9 17
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2000
VL 16
IS 17
BP 1915
EP 1919
DI 10.1089/08892220050195874
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 375AR
UT WOS:000165377800013
PM 11118077
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
   Adegbola, RA
   Tharpe, JA
   Ades, EW
   McAdam, KPWJ
   Carlone, G
   Sampson, JS
AF Obaro, SK
   Adegbola, RA
   Tharpe, JA
   Ades, EW
   McAdam, KPWJ
   Carlone, G
   Sampson, JS
TI Pneumococcal surface adhesin A antibody concentration in serum and
   nasopharyngeal carriage of Streptococcus pneumoniae in young African
   infants
SO VACCINE
LA English
DT Editorial Material
ID PROTEIN PSAA
C1 MRC Labs, Banjul, Gambia.
   CDC, Atlanta, GA 30333 USA.
RP Obaro, SK (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Ades, Edwin/A-9931-2009
CR Briles DE, 2000, INFECT IMMUN, V68, P796, DOI 10.1128/IAI.68.2.796-800.2000
   Crook J, 1998, CLIN DIAGN LAB IMMUN, V5, P205
   Sampson JS, 1997, INFECT IMMUN, V65, P1967
   TALKINGTON DF, 1996, MICROB PATHOGENESIS, V21, P1967
   Tharpe JA, 1998, PATHOBIOLOGY, V66, P77, DOI 10.1159/000028000
NR 5
TC 11
Z9 13
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 15
PY 2000
VL 19
IS 4-5
BP 411
EP 412
DI 10.1016/S0264-410X(00)00201-2
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 365CH
UT WOS:000089930500007
PM 11027802
OA No
DA 2017-08-15
ER

PT J
AU Nurkka, A
   MacLennan, J
   Jantti, V
   Obaro, S
   Greenwood, B
   Kayhty, H
AF Nurkka, A
   MacLennan, J
   Jantti, V
   Obaro, S
   Greenwood, B
   Kayhty, H
TI Salivary antibody response to vaccination with meningococcal A/C
   polysaccharide vaccine in previously vaccinated and unvaccinated Gambian
   children
SO VACCINE
LA English
DT Article
DE meningococcal vaccines; salivary antibodies
ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINATION; SECRETING CELL
   RESPONSE; GROUP-A; NEISSERIA-MENINGITIDIS; INFANT RATS; IMMUNIZATION;
   SERUM; CARRIAGE; COLONIZATION
AB Development of salivary antibodies at the age of 4 or 5 years to group A and C meningococcal polysaccharides (MenA/C PS) was studied among Gambian children, who had received MenA/C conjugate or PS vaccine in infancy. There was also a control group of 64 age matched children, IgG, IgA, and secretory Ig concentrations were measured by enzyme immune assay. MenA/C PS vaccine induced antibodies both in previously vaccinated and unvaccinated children. The previous vaccination had not induced long lasting IgA-mediated memory. IgA antibodies were secretory, and most of IgG was serum derived. The IgG salivary response seen was similar to the serum response. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Natl Publ Hlth Inst, Dept Vaccines, SF-00300 Helsinki, Finland.
   John Radcliffe Hosp, Oxford Vaccine Grp, Oxford OX3 9DU, England.
   Med Res Council Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Nurkka, A (reprint author), Natl Publ Hlth Inst, Dept Vaccines, Mannerheimintie 166, SF-00300 Helsinki, Finland.
CR ARAKERE G, 1994, J BACTERIOL, V176, P691
   Asanuma H, 1998, VACCINE, V16, P1257, DOI 10.1016/S0264-410X(98)00048-6
   BARBOUR ML, 1995, J INFECT DIS, V171, P93
   BEUVERY EC, 1981, J INFECTION, V3, P71, DOI 10.1016/S0163-4453(81)80011-4
   Borrow R, 1999, EPIDEMIOL INFECT, V123, P201, DOI 10.1017/S0950268899002915
   BUTLER JE, 1990, ORAL MICROBIOL IMMUN, V5, P113, DOI 10.1111/j.1399-302X.1990.tb00408.x
   CAMPAGNE G, 1997, 37 INT C ANT AG CHEM
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   CEESAY SJ, 1993, J INFECT DIS, V167, P1212
   Dagan R, 1996, J INFECT DIS, V174, P1271
   Gold R., 1977, J INFECT DIS       S, V136, P31
   GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349
   GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367
   JENNINGS HJ, 1981, J IMMUNOL, V127, P1011
   KAUPPI M, 1993, J INFECT DIS, V167, P365
   KAUPPI M, 1995, PEDIATR INFECT DIS J, V14, P286, DOI 10.1097/00006454-199504000-00008
   Kauppi-Korkeila M, 1998, CLIN EXP IMMUNOL, V111, P237
   KAYHTY H, 1980, J INFECT DIS, V142, P861
   Kilian M, 1996, APMIS, V104, P321
   Korkeila M, 2000, VACCINE, V18, P1218, DOI 10.1016/S0264-410X(99)00393-X
   Leach A, 1997, J INFECT DIS, V175, P200
   LEPOW ML, 1977, PEDIATRICS, V60, P673
   MacLennan J, 1999, VACCINE, V17, P3086, DOI 10.1016/S0264-410X(99)00139-5
   MACLENNAN JM, 1998, 11 INT PATH NEISS C, P151
   MAKELA PH, 1975, LANCET, V2, P883
   Nieminen T, 1998, VACCINE, V16, P313, DOI 10.1016/S0264-410X(97)00162-X
   Nieminen T, 1999, PEDIATR INFECT DIS J, V18, P764, DOI 10.1097/00006454-199909000-00005
   Nieminen T, 1998, VACCINE, V16, P630, DOI 10.1016/S0264-410X(97)00235-1
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   REINGOLD AL, 1985, LANCET, V2, P114
   Stack AM, 1998, J INFECT DIS, V177, P986
   TAI JY, 1996, 7 INT C INF DIS 1996
   TARKOWSKI A, 1990, J IMMUNOL, V144, P3770
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
NR 35
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 15
PY 2000
VL 19
IS 4-5
BP 547
EP 556
DI 10.1016/S0264-410X(00)00180-8
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 365CH
UT WOS:000089930500025
PM 11027820
OA No
DA 2017-08-15
ER

PT J
AU Cham, F
   Heyndrickx, L
   Janssens, W
   Vereecken, K
   De Houwer, K
   Coppens, S
   van der Auwera, G
   Whittle, H
   van der Groen, G
AF Cham, F
   Heyndrickx, L
   Janssens, W
   Vereecken, K
   De Houwer, K
   Coppens, S
   van der Auwera, G
   Whittle, H
   van der Groen, G
TI Development of a one-tube multiplex reverse transcriptase-polymerase
   chain reaction assay for the simultaneous amplification of HIV type 1
   group M gag and env heteroduplex mobility assay fragments
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
AB The emergence of intersubtype recombinant HIV-1 isolates has made it imperative to analyze different regions of HIV-1 genomes. For this purpose a one-tube multiplex RT-PCR, coamplifying first-round amplicons that allow amplification of gag and env heteroduplex mobility assay (HMA) fragments from different HIV-1 group M isolates, was developed, starting with plasma samples. The multiplex RT-PCR assay is sensitive: 115 of 136 (84.5%) samples were positive for both gag and env, positive amplification of the gag fragment was observed in 130 of 136 (95.6%) samples, while for the env fragment 119 of 136 (87.5%) tested positive. The multiplex RT-PCR in combination with gag and env HMA makes large-scale HIV-1 subtyping fast, simple, and more economical.
C1 Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   MRC Labs, Banjul, Gambia.
   Univ Ghent VIB, B-9052 Ghent, Belgium.
RP Janssens, W (reprint author), Inst Trop Med, Dept Microbiol, Natl Str 155, B-2000 Antwerp, Belgium.
EM wjanssens@itg.be
CR BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   CARR JK, 1998, HIV SEQUENCE DATABAS
   CHAM F, 2000, IN PRESS AIDS RES HU, V16
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DELWART EL, 1995, PCR METH APPL, V4, pS202
   Heyndrickx L, 2000, J VIROL, V74, P363
   ROBERTSON DL, 2000, HIV SEQUENCE DATABAS
NR 7
TC 7
Z9 7
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2000
VL 16
IS 15
BP 1503
EP 1505
DI 10.1089/088922200750006029
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 365LA
UT WOS:000089951700005
PM 11054263
OA No
DA 2017-08-15
ER

PT J
AU Marchant, A
AF Marchant, A
TI Serological markers of disease activity in tuberculosis and HIV
   infection
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Editorial Material
ID TUMOR-NECROSIS-FACTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; SOLUBLE ACTIVATION
   MARKERS; IMMUNE ACTIVATION; PULMONARY TUBERCULOSIS; FACTOR RECEPTORS;
   FACTOR-ALPHA; VIRAL LOAD; T-CELLS; CYTOKINES
C1 MRC Labs, Banjul, Gambia.
RP Marchant, A (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Adams JFA, 1999, LANCET, V353, P2030, DOI 10.1016/S0140-6736(98)08510-9
   Aderka D, 1998, J CLIN INVEST, V101, P650, DOI 10.1172/JCI694
   Amiel C, 1999, J INFECT DIS, V179, P83, DOI 10.1086/314550
   Aziz N, 1999, CLIN DIAGN LAB IMMUN, V6, P89
   Aziz N, 1999, J INFECT DIS, V179, P843, DOI 10.1086/314673
   Bekker LG, 1998, J INFECT DIS, V178, P580
   Center DM, 2000, IMMUNOL TODAY, V21, P273, DOI 10.1016/S0167-5699(00)01629-7
   Collazos J, 1999, SCAND J INFECT DIS, V31, P265
   Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117
   Fahey JL, 1998, AIDS, V12, P1581, DOI 10.1097/00002030-199813000-00004
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   Franco JM, 1999, EUR J CLIN MICROBIOL, V18, P733, DOI 10.1007/s100960050388
   GODFRIED MH, 1995, J ACQ IMMUN DEF SYND, V10, P531, DOI 10.1097/00042560-199510050-00006
   GODFRIED MH, 1994, J INFECT DIS, V169, P739
   Herbein G, 1997, J VIROL, V71, P4150
   Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667
   Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007
   Hosp M, 1997, LUNG, V175, P265, DOI 10.1007/PL00007573
   Immanuel C, 1997, INT J TUBERC LUNG D, V1, P175
   Juffermans NP, 1998, J INFECT DIS, V178, P1839, DOI 10.1086/314492
   Juffermans NP, 1998, AM J RESP CRIT CARE, V157, P1328
   Lawn SD, 2000, CLIN EXP IMMUNOL, V120, P483, DOI 10.1046/j.1365-2249.2000.01246.x
   Lederman MM, 2000, AIDS, V14, P951, DOI 10.1097/00002030-200005260-00006
   Mellors JW, 1997, ANN INTERN MED, V126, P946
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Munk ME, 1999, INFECT IMMUN, V67, P423
   N'Gom PT, 1997, BRIT J BIOMED SCI, V54, P251
   Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8
   Salazar-Gonzalez JF, 1998, J INFECT DIS, V178, P423
   Screaton G, 2000, CURR OPIN IMMUNOL, V12, P316, DOI 10.1016/S0952-7915(00)00093-5
   Sulkowski MS, 1998, J INFECT DIS, V178, P1642, DOI 10.1086/314491
   Vanham G, 1997, TUBERCLE LUNG DIS, V78, P145, DOI 10.1016/S0962-8479(97)90021-6
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   ZANGERLE R, 1994, J ACQ IMMUN DEF SYND, V7, P79
NR 35
TC 3
Z9 3
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD OCT
PY 2000
VL 122
IS 1
BP 10
EP 12
DI 10.1046/j.1365-2249.2000.01371.x
PG 3
WC Immunology
SC Immunology
GA 363DE
UT WOS:000089818900002
PM 11012610
OA No
DA 2017-08-15
ER

PT J
AU Bickler, SW
   Sanno-Duanda, B
AF Bickler, SW
   Sanno-Duanda, B
TI Bone setter's gangrene
SO JOURNAL OF PEDIATRIC SURGERY
LA English
DT Article
DE Africa; amputations; complications; extremity; fracture; gangrene;
   injuries; trauma
ID LIMB AMPUTATION; NIGERIA; CHILDREN; ZARIA
AB Background/Purpose: Little published data exist on the morbidity and mortality associated with poor trauma care in developing countries, This report highlights our experience with iatrogenic limb gangrene related to fracture management by traditional bone setters.
   Methods: Children with "bone setter's" gangrene were identified from a prospectively recorded pediatric surgery database at the Royal Victoria Hospital in Banjul, The Gambia-the main government referral hospital.
   Results: Nine children were treated for bone setter's gangrene during a 29-month period. The average age was 8.2 years (range, 5 to 14 years). Bone setter's gangrene was more common in boys (male to female ratio, 2:1) and occurred almost exclusively (89%) in children from rural areas where access to health care was limited, Five children (56%) underwent proximal extremity amputations. Complications included 1 death related to sepsis, a case of chronic osteomyelitis at an amputation site, and a contracted insensate hand in a child whose parents refused amputation.
   Conclusions: Bonesetter's gangrene is a preventable complication that results from a failure of child health planners to recognize the importance of basic trauma ca re. Management of fractures should be considered an essential component of child health programs in developing countries. J Pediatr Surg 35:1431-1433. Copyright (C) 2000 by W.B, Saunders Company.
C1 Univ Calif San Diego, Med Ctr, Dept Surg, Div Pediat Surg, San Diego, CA 92103 USA.
   Royal Victoria Hosp, Dept Surg, Banjul, Gambia.
RP Bickler, SW (reprint author), Univ Calif San Diego, Med Ctr, Dept Surg, Div Pediat Surg, 200 W Arbor Dr, San Diego, CA 92103 USA.
CR BICKLER SW, 1998, 22 INT C PED AMST AU
   BICKLER SW, IN PRESS B WHO
   LORO A, 1994, TROP DOCT, V24, P99
   Musa AA, 1998, TROP DOCT, V28, P249
   OFIAELI RO, 1991, TROP DOCT, V21, P182
   Onuminya JE, 1999, INT ORTHOP, V23, P111, DOI 10.1007/s002640050320
   SWANN M, 1966, BRIT MED J, V1, P1041
   YAKUBU A, 1995, ANN TROP PAEDIATR, V15, P163
   Yakubu A, 1996, J ROY COLL SURG EDIN, V41, P102
NR 9
TC 8
Z9 8
U1 1
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0022-3468
J9 J PEDIATR SURG
JI J. Pediatr. Surg.
PD OCT
PY 2000
VL 35
IS 10
BP 1431
EP 1433
DI 10.1053/jpsu.2000.16406
PG 3
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA 361BE
UT WOS:000089701200005
PM 11051143
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
AF Deen, JL
TI Late presentation and increased mortality in children with dengue
   haemorrhagic fever
SO TROPICAL DOCTOR
LA English
DT Article
C1 So Isl Med Ctr, Dept Pediat, Cebu 6000, Philippines.
RP Deen, JL (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480
   Gubler DJ, 1988, ARBOVIRUSES EPIDEMIO, P223
   Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161
   Shekhar K C, 1992, Asia Pac J Public Health, V6, P15
   Shepard DS, 1993, DIS CONTROL PRIORITI, P303
   *WHO, DENG UPD
   World Health Organization, 1986, DENG HEM FEV DIAGN T
NR 7
TC 3
Z9 4
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2000
VL 30
IS 4
BP 227
EP 228
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 361KY
UT WOS:000089723300015
PM 11075659
OA No
DA 2017-08-15
ER

PT J
AU MacLennan, JM
   Urwin, R
   Obaro, S
   Griffiths, D
   Greenwood, B
   Maiden, MCJ
AF MacLennan, JM
   Urwin, R
   Obaro, S
   Griffiths, D
   Greenwood, B
   Maiden, MCJ
TI Carriage of serogroup W-135, ET-37 meningococci in The Gambia:
   Implications for immunisation policy?
SO LANCET
LA English
DT Article
ID NEISSERIA-MENINGITIDIS
AB We found high levels of symptomless carriage of hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Hai-associated spread of serogroup W-135, FT-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.
C1 Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.
   Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford Vaccine Grp, Oxford OX3 9DU, England.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Maiden, MCJ (reprint author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.
CR *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P129
   *COMM DIS SURV CTR, 2000, COMMON DIS REP CDR W, V10, P133
   Kwara A, 1998, TROP MED INT HEALTH, V3, P742
   Maiden MCJ, 1999, LANCET, V354, P615
   MOORE PS, 1989, LANCET, V2, P260
NR 5
TC 35
Z9 35
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 23
PY 2000
VL 356
IS 9235
BP 1078
EP 1078
DI 10.1016/S0140-6736(00)02734-3
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 356EC
UT WOS:000089430500015
PM 11009146
OA No
DA 2017-08-15
ER

PT J
AU Dorrell, L
   O'Callaghan, CA
   Britton, W
   Hambleton, S
   McMichael, A
   Smith, GL
   Rowland-Jones, S
   Blanchard, TJ
AF Dorrell, L
   O'Callaghan, CA
   Britton, W
   Hambleton, S
   McMichael, A
   Smith, GL
   Rowland-Jones, S
   Blanchard, TJ
TI Recombinant modified vaccinia virus Ankara efficiently restimulates
   human cytotoxic T lymphocytes in vitro
SO VACCINE
LA English
DT Article
DE cytotoxic T lymphocyte; vaccinia virus; MVA strain
ID INFLUENZA-A VIRUS; CELLS; ANTIGEN; RECOGNITION; INDUCTION; STIMULATION;
   REPLICATION; VACCINATION; EXPRESSION; EFFICACY
AB The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity for known NP epitopes. These CTL efficiently lysed NP peptide-pulsed targets and released interferon-gamma (IFN-gamma) on contact with epitope peptide. MVA-NP-stimulated CTL specific for the HLA-B8 epitope, NP380-88, stained with a tetrameric complex of HLA-B8 refolded with the NP380-88 peptide and anti-CD8 antibody on flow cytometry, CTL were also elicited from two HIV-I seropositive donors by restimulation with MVA-HIV-1 gag and showed specificity for immunodominant gag epitopes. These data indicate that restimulation of human CTL with recombinant MVA is effective and suggest that MVA will elicit CTL responses in humans in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DU, England.
   Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   Centenary Inst, Newtown, NSW 2042, Australia.
RP Blanchard, TJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM tblanchard@mrc.gm
OI Smith, Geoffrey L/0000-0002-3730-9955
CR Aidoo M, 1997, INT IMMUNOL, V9, P731, DOI 10.1093/intimm/9.5.731
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   BALKWILL FR, 1989, LANCET, V1, P1060
   Blanchard TJ, 1998, J GEN VIROL, V79, P1159
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403
   CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0
   COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9
   DIFABIO S, 1994, INT IMMUNOL, V6, P11, DOI 10.1093/intimm/6.1.11
   Dorrell L, 1999, J VIROL, V73, P1708
   ENNIS FA, 1981, J EXP MED, V154, P1279, DOI 10.1084/jem.154.5.1279
   Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383
   GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0
   Hanke T, 1999, J VIROL, V73, P7524
   Hirsch VM, 1996, J VIROL, V70, P3741
   HIRSCH VM, 1995, VACCINES, P195
   KRAUSA P, 1993, TISSUE ANTIGENS, V42, P91, DOI 10.1111/j.1399-0039.1993.tb02173.x
   Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Larsson M, 1999, AIDS, V13, P767, DOI 10.1097/00002030-199905070-00005
   MATSUO H, 1995, J IMMUNOL, V155, P3683
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   MORRIS AG, 1982, NATURE, V295, P150, DOI 10.1038/295150a0
   Moss B, 1996, Adv Exp Med Biol, V397, P7
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   Parker CE, 1996, SEMIN VIROL, V7, P61, DOI 10.1006/smvy.1996.0008
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7
   YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785
NR 31
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD SEP 15
PY 2000
VL 19
IS 2-3
BP 327
EP 336
DI 10.1016/S0264-410X(00)00135-3
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 352UV
UT WOS:000089237000023
PM 10930688
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
AF Enwere, GC
TI Severe malaria with impaired cerebral function?
SO LANCET
LA English
DT Letter
ID CHILDREN
C1 MRC Labs, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR DESAI SP, 1996, IND J PATH MICROBIOL, V39, P5477
   Marsh K, 1996, ANN TROP MED PARASIT, V90, P395
   SEIN KK, 1993, AM J TROP MED HYG, V48, P4504
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 5
TC 4
Z9 4
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 2
PY 2000
VL 356
IS 9232
BP 860
EP 860
DI 10.1016/S0140-6736(05)73446-2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 350LF
UT WOS:000089101800061
PM 11022964
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
   Ota, MO
   Obaro, SK
AF Enwere, GC
   Ota, MO
   Obaro, SK
TI Electrolyte derangement in cerebral malaria: a case for a more
   aggressive approach to the management of hyponatraemia
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Review
ID SEVERE HYPONATREMIA; HOSPITAL POPULATION; FALCIPARUM-MALARIA; RAPID
   CORRECTION; CLINICAL-FEATURES; GAMBIAN CHILDREN; BRAIN; MORTALITY
AB Although hyponatraemia has been consistently shown to occur in a large proportion of children with cerebral malaria, no statistical relationship has been established between the incidence of hyponatraemia and that of malaria-attributable mortality. However, hyponatraemia is not a benign state in other conditions (such as meningitis) or in surgical patients, and is likely to add to malarial deaths. The high mortality rate seen among cases of cerebral malaria, despite all efforts to curb it, therefore calls for a more aggressive approach to the management of hyponatraemia. Current methods for the administration of hypotonic saline and isotonic glucose solutions need review. In addition, children admitted with cerebral malaria should have their electrolyte status monitored to identify new or ongoing hyponatraemia. When hyponatraemia is discovered, it should be quickly and actively corrected.
C1 MRC Labs, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ADELMAN RD, 1996, NELSON TXB PEDIAT, P185
   ARIEFF AI, 1992, BRIT MED J, V304, P1218
   AYUS JC, 1985, AM J PHYSIOL, V248, pF711
   AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7
   BARAN D, 1984, CLIN NEPHROL, V22, P72
   Crook MA, 1999, ANN CLIN BIOCHEM, V36, P158
   CURRANS JS, 1982, CORE TXB PEDIAT, P163
   Dunn K, 1997, J PAEDIATR CHILD H, V33, P26, DOI 10.1111/j.1440-1754.1997.tb00986.x
   English MC, 1996, ARCH DIS CHILD, V74, P201
   Enwere GC, 1999, ANN TROP PAEDIATR, V19, P327, DOI 10.1080/02724939992158
   Erasmus R. T., 1998, Central African Journal of Medicine, V44, P154
   FRYATT RJ, 1989, TROP GEOGR MED, V41, P57
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hojer J, 1992, Lakartidningen, V89, P2933
   HOLST FGE, 1994, AM J TROP MED HYG, V50, P602
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   KENNEDY PGE, 1978, BRIT MED J, V2, P1251
   Kiviranta T, 1995, ACTA PAEDIATR, V84, P1372, DOI 10.1111/j.1651-2227.1995.tb13571.x
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   KROLL M, 1992, J INTERN MED, V232, P291
   MILLER LH, 1994, SCIENCE, V264, P1874
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   MULLER MU, 1976, MONATSSCHR KINDERH, V124, P66
   NATKUNAM A, 1991, J MED, V22, P83
   NORENBERG MD, 1984, ANN NEUROL, V15, P544, DOI 10.1002/ana.410150606
   PARKE JT, 1990, PRINCIPLES PRACTICE, P1842
   Singer GG, 1998, HARRISONS PRINCIPLES, P265
   Singhi S, 1994, Indian Pediatr, V31, P19
   Sonnenschein C H, 1991, Ugeskr Laeger, V153, P2065
   Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011
   Sowunmi A, 1996, Afr J Med Med Sci, V25, P47
   Sowunmi A, 1996, ARCH DIS CHILD, V74, P293
   SPITZ S, 1946, Mil Surg, V99, P555
   STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402
   Thuma PE, 1998, T ROY SOC TROP MED H, V92, P214, DOI 10.1016/S0035-9203(98)90753-2
   TIERNEY WM, 1986, J GEN INTERN MED, V1, P380, DOI 10.1007/BF02596422
   vanHensbroek MB, 1996, J INFECT DIS, V174, P1091
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   vanHensbroek MB, 1997, J PEDIATR-US, V131, P125, DOI 10.1016/S0022-3476(97)70135-5
   VANREETH O, 1989, CLIN SCI, V77, P351
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   WATTANAGOON Y, 1994, T ROY SOC TROP MED H, V88, P426, DOI 10.1016/0035-9203(94)90415-4
   White NJ, 1998, LANCET, V352, P594, DOI 10.1016/S0140-6736(05)79572-6
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 44
TC 8
Z9 8
U1 0
U2 1
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD SEP
PY 2000
VL 94
IS 6
BP 541
EP 547
PG 7
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA 363BZ
UT WOS:000089815200001
PM 11064755
OA No
DA 2017-08-15
ER

PT J
AU Faal, H
   Minassian, DC
   Dolin, PJ
   Mohamed, AA
   Ajewole, J
   Johnson, GJ
AF Faal, H
   Minassian, DC
   Dolin, PJ
   Mohamed, AA
   Ajewole, J
   Johnson, GJ
TI Evaluation of a national eye care programme: re-survey after 10 years
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GAMBIA; TRACHOMA
AB Aim-TO re-survey the Gambia after an interval of 10 years to assess the impact of a national eye care programme (NECP) on the prevalence of blindness and low vision.
   Method-Comparison of two multistage cluster random sample surveys taking into account the marked increase in population in the Gambia, west Africa. Samples of the whole population in 1986 and 1996 were taken. The definition of blindness is presenting vision less than 3/60 in the better eye, or visual fields constricted to less than 10 degrees from fixation. Low vision is less than 6/18 but 3/60 or better. Causes of blindness were determined clinically by three ophthalmologists.
   Results-The crude prevalence of blindness fell from 0.70% to 0.42%, a relative reduction of 40%. During the same 10 year period, the population increased by 51% from 775 000 to 1 169 000. When the results were standardised for age, a west to east gradient was found for changes in risk of blindness over the 10 year period. This matched the phased west to east introduction of the NECP interventions. There was a modest but significant increase in the risk of low vision across the whole country.
   Conclusions-The overall reduction in risk of blindness, in those areas where the NECP has been active, appears to justify the programme and the support of donor organisations. The low vision cases due to cataract must now be addressed.
C1 Inst Ophthalmol, Int Ctr Eye Hlth, London EC1V 9EL, England.
   Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
RP Johnson, GJ (reprint author), Inst Ophthalmol, Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
CR Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   *WHO, 1992, INT STAT CLASS DIS R, V1, P456
NR 5
TC 33
Z9 33
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2000
VL 84
IS 9
BP 948
EP 951
DI 10.1136/bjo.84.9.948
PG 4
WC Ophthalmology
SC Ophthalmology
GA 354CK
UT WOS:000089312100004
PM 10966942
OA No
DA 2017-08-15
ER

PT J
AU Drakeley, CJ
   Akim, NIJ
   Sauerwein, RW
   Greenwood, BM
   Targett, GAT
AF Drakeley, CJ
   Akim, NIJ
   Sauerwein, RW
   Greenwood, BM
   Targett, GAT
TI Estimates of the infectious reservoir of Plasmodium falciparum malaria
   in The Gambia and in Tanzania
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; infectious reservoir; The Gambia;
   Tanzania
ID ANOPHELES-GAMBIAE; GAMETOCYTE CARRIERS; BURKINA-FASO; TRANSMISSION;
   AREA; MOSQUITOS; PARASITES; VACCINE; EFFICACY; SURVIVAL
AB Separate studies carried out in Farafenni, The Gambia and Ifakara, Tanzania in 1990-94 provided comparative data on population age structure, population gametocyte prevalences and gametocyte carrier infectivity. The percentage of the population estimated to be infective to mosquitoes was 5(.)5% and 3(.)8% in The Gambia and Tanzania, respectively. The age groups 1-4 years, 5-9 years, 10-19 years and 20 years or more comprised 17(.)5%, 21(.)7%, 22(.)2% and 37(.)9%, respectively, of the infectious population in The Gambia; the corresponding figures for Tanzania were 30(.)9%, 25(.)2%, 15(.)7% and 28(.)1%. These figures are in broad agreement with those from other published studies which estimated the infectious reservoir directly and suggest that adults contribute significantly to the infectious reservoir of malaria, particularly in areas of intense seasonal transmission. Control measures aimed at reduction of transmission may have only a limited effect in areas of moderate seasonal transmission if directed only at children.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania.
   Univ Nijmegen, Univ Nijmegen Hosp, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands.
RP Drakeley, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Sauerwein, Robert/C-8519-2013
CR AKIM NIJ, IN PRESS AM J TROPIC
   ALONSO PL, 1994, LANCET, V344, P1175
   ALONSO PL, 1993, T ROYAL SOC TROPI S2, V87
   Bonnet S, 2000, T ROY SOC TROP MED H, V94, P103, DOI 10.1016/S0035-9203(00)90456-5
   BOUDIN C, 1991, ANN TROP MED PARASIT, V85, P377
   BOUDIN C, 1993, AM J TROP MED HYG, V48, P700
   Buckling AGJ, 1997, P ROY SOC B-BIOL SCI, V264, P553
   Carter R, 1988, MALARIA PRINCIPLES P, V1, P253
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Drakeley CJ, 1999, TROP MED INT HEALTH, V4, P131, DOI 10.1046/j.1365-3156.1999.00361.x
   GITHEKO AK, 1992, T ROY SOC TROP MED H, V86, P355, DOI 10.1016/0035-9203(92)90216-Y
   GRAVES PM, 1988, PARASITOLOGY, V96, P251
   HaileMariam M, 1996, J ANIM BREED GENET, V113, P43, DOI 10.1111/j.1439-0388.1996.tb00590.x
   Handunnetti SM, 1996, T ROY SOC TROP MED H, V90, P563, DOI 10.1016/S0035-9203(96)90325-9
   LINDSAY SW, 1993, T ROYAL SOC TROPI S2, V87
   LULAT A, 1993, THESIS U LONDON UK
   Molineaux L, 1980, GARKI PROJECT
   MUIRHEADTHOMSON RC, 1957, AM J TROP MED HYG, V6, P971
   MULDER B, 1994, T ROY SOC TROP MED H, V88, P121, DOI 10.1016/0035-9203(94)90534-7
   NAOTUNNE TD, 1991, J EXP MED, V173, P523, DOI 10.1084/jem.173.3.523
   Nedelman J., 1989, Advances in Disease Vector Research, V6, P59
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   QUINONES M, IN PRESS MED VET ENT
   Schellenberg JRMA, 1999, T ROY SOC TROP MED H, V93, P225, DOI 10.1016/S0035-9203(99)90001-9
   SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M
   Tanner M, 1991, DIS MORTALITY SUBSAH, P286
   Targett G.A.T., 1985, Parasitology Today, V1, P155, DOI 10.1016/0169-4758(85)90172-3
   Taylor LH, 1997, PARASITOL TODAY, V13, P135, DOI 10.1016/S0169-4758(97)89810-9
   TCHUINKAM T, 1993, TROP MED PARASITOL, V44, P271
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
   Toure YT, 1998, AM J TROP MED HYG, V59, P481
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
NR 33
TC 64
Z9 65
U1 0
U2 4
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON W1N 1EY, ENGLAND
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 2000
VL 94
IS 5
BP 472
EP 476
DI 10.1016/S0035-9203(00)90056-7
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 379YD
UT WOS:000165670000002
PM 11132369
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Leach, A
   Greenwood, A
   Greenwood, B
AF Jaffar, S
   Leach, A
   Greenwood, A
   Greenwood, B
TI Season of birth is not associated with delayed childhood mortality in
   Upper River Division,The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE season of birth; child mortality; infant mortality; verbal autopsy;
   Africa; The Gambia
ID PATTERN; INFANT
AB There is evidence that season of birth may predict adult mortality from infectious diseases in rural Gambia. Using data collected over a five-year period from the rural, eastern region of the Gambia, we examined whether the season of birth influences mortality in childhood. 26 894 births and 3776 deaths among children under the age of five years were recorded in this region during the period 1989-1993. The estimated 1-4 year population was 95 355. In children aged 1-4 years, the mortality rate per 1000 per year mas 16.1 (95% CI 14.9, 17.2.) for those born in the 'harvest' season (January to June), which was not significantly different from the rate of 17.9 (95% CI 16.7, 19.0) recorded for those born in the 'hungry' season (July to December) (age-stratified Mantel-Haenszel mortality ratio 0.91, 95% CI 0.83, 1.01; p = 0.08). Nearly all deaths of 1-4 year olds were attributed to infectious diseases, with malaria accounting for over 40%. None of the cause-specific child mortality rates differed significantly according to the season of birth. These data suggest that beyond infancy, when It is easier to separate the effect of season on cause of death from that of the season of birth, there is no marked difference in the rate of death between Gambian children born in the harvest season and those born in the hungry season.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, MRC Trop epidemiol Grp, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, MRC Trop epidemiol Grp, Keppel St, London WC1E 7HT, England.
CR Barker DJP, 1994, MOTHERS BABIES DIS L
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   SMITH PG, 1996, FIELD TRIALS HLTH IN
NR 7
TC 13
Z9 13
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2000
VL 5
IS 9
BP 628
EP 632
DI 10.1046/j.1365-3156.2000.00610.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 363CV
UT WOS:000089818000006
PM 11044277
OA No
DA 2017-08-15
ER

PT J
AU Sear, R
   Mace, R
   McGregor, IA
AF Sear, R
   Mace, R
   McGregor, IA
TI Maternal grandmothers improve nutritional status and survival of
   children in rural Gambia
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE kin selection; child mortality; menopause; human social evolution
ID TIME ALLOCATION; EVOLUTION; MENOPAUSE; VILLAGES; FAMILY
AB Hypotheses for the evolution of human female life-history characteristics have often focused on the social nature of human societies, which allows women to share the burden of childcare and provisioning amongst other members of their kin group. We test the hypothesis that child health and survival pm,abilities will Le improved by the presence of kin using a longitudinal database from rural Gambia. We find that the only kill to improve the nutritional status of children significantly (apart from mothers) are maternal grandmothers, and that this is reflected in higher survival probabilities for children with living maternal grandmothers. There is also evidence that the reproductive status of the maternal grandmother influences child nutrition, with young children being taller in the presence of non-reproductive grandmothers than grandmothers who are still reproductively active. Paternal grandmothers and male kin, including fathers, have negligible impacts on the nutritional status and survival of children.
C1 UCL, Dept Anthropol, London WC1E 6BT, England.
   MRC Labs, Keneba, Gambia.
RP Sear, R (reprint author), UCL, Dept Anthropol, Gower St, London WC1E 6BT, England.
EM r.sear@ucl.ac.uk
OI Mace, Ruth/0000-0002-6137-7739
CR ALAWAD AME, 1992, CHILD DEV, V63, P906
   Allison P. D, 1984, EVENT HIST ANAL REGR
   BILLEWICZ WZ, 1982, ANN HUM BIOL, V9, P309, DOI 10.1080/03014468200005811
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092
   Euler HA, 1996, HUM NATURE-INT BIOS, V7, P39, DOI 10.1007/BF02733489
   GALDIKAS BMF, 1990, AM J PHYS ANTHROPOL, V83, P185, DOI 10.1002/ajpa.1330830207
   Goldstein H, 1998, USERS GUIDE MLWIN
   Goldstein H, 1995, MULTILEVEL STAT MODE
   HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6
   HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90038-4
   Hawkes K, 1997, CURR ANTHROPOL, V38, P551, DOI 10.1086/204646
   Hawkes K, 1998, P NATL ACAD SCI USA, V95, P1336, DOI 10.1073/pnas.95.3.1336
   Hewlett B. S., 1992, FATHER CHILD RELATIO, P153
   HILL K, 1985, HUM ECOL, V13, P29, DOI 10.1007/BF01531087
   Hill K., 1996, ACHE LIFE HIST ECOLO
   Hill Kim, 1993, Evolutionary Anthropology, V2, P78, DOI 10.1002/evan.1360020303
   McGregor IA, 1991, DIS MORTALITY SUBSAH, P306
   POPE SK, 1993, JAMA-J AM MED ASSOC, V269, P1396, DOI 10.1001/jama.269.11.1396
   ROGERS AR, 1993, EVOL ECOL, V7, P406, DOI 10.1007/BF01237872
   SEAR R, 2001, UNPUB EFFECTS KIN CH
   THOMPSON EDB, 1965, THESIS U ABERDEEN UK
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.2307/2406060
   WILSON MN, 1986, DEV PSYCHOL, V22, P246, DOI 10.1037//0012-1649.22.2.246
   Wood JW., 1994, DYNAMICS HUMAN REPRO
NR 25
TC 138
Z9 139
U1 6
U2 36
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
J9 P ROY SOC B-BIOL SCI
JI Proc. R. Soc. B-Biol. Sci.
PD AUG 22
PY 2000
VL 267
IS 1453
BP 1641
EP 1647
DI 10.1098/rspb.2000.1190
PG 7
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 348QY
UT WOS:000088998500007
PM 11467427
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Milligan, PJM
   Nyan, OA
   Rowley, JTF
   Banya, WAS
   Ceesay, SM
   Dolmans, WMV
   Thien, T
   McAdam, KPWJ
   Walraven, GEL
AF van der Sande, MAB
   Milligan, PJM
   Nyan, OA
   Rowley, JTF
   Banya, WAS
   Ceesay, SM
   Dolmans, WMV
   Thien, T
   McAdam, KPWJ
   Walraven, GEL
TI Blood pressure patterns and cardiovascular risk factors in rural and
   urban Gambian communities
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article
DE blood pressure; cardiovascular risk factors; sub-Sahara Africa;
   urban-rural
ID CORONARY HEART-DISEASE; NONCOMMUNICABLE DISEASES; AFRICAN ORIGIN;
   SOUTH-AFRICA; HYPERTENSION; PREVALENCE; POPULATIONS; COUNTRIES; NIGERIA
AB Hypertension is emerging as an important public health problem in sub-Saharan Africa. We studied blood pressure (BP) patterns, hypertension and other cardiovascular risk factors in a rural and an urban area of The Gambia. A total of 5389 adults (greater than or equal to 15 years) were selected by cluster sampling in the capital Banjul and a rural area around Farafenni. A questionnaire was completed, BP, pulse rate, height and weight were recorded. Glucose was measured 2 h after a 75 g glucose load among participants greater than or equal to 35 years (n = 2301); total cholesterol, triglycerides, creatinine and uric acid were measured among a stratified subsample (n = 1075). A total of 7.1% of the study participants had a BP greater than or equal to 160/95 mm Hg; 18.4% of them had a BP greater than or equal to 140/90 mm Hg. BP was significantly higher in the urban area. BP increased with age in both sexes in both areas. Increasing age was the major independent risk factor for hypertension. Related cardiovascular risk factors (obesity, diabetes and hyperlipidaemia) were significantly more prevalent in the urban area and among hypertensives; 17% of measured hypertensives were aware of this, 73% of people who reported to have been diagnosed as hypertensive before had discontinued treatment; 56% of those who reported being on treatment were normotensive. We conclude that hypertension is no longer rare in either urban or rural Gambians. In the urban site hypertension and related cardiovascular risk factors were more prevalent. Compliance with treatment was low. Interventions aimed at modifying risk factors at the population level, and at improving control of diagnosed hypertension are essential to prevent future increases of cardiovascular morbidity and mortality. In view of limited resources and feasibility of intervention in rural Gambia, these could initially be directed towards urbanised populations.
C1 Med Res Council Labs, Fajara, Senegal.
   Dunn Nutr Unit, Cambridge, England.
   Dept Gen Internal Med, Nijmegen, Netherlands.
RP van der Sande, MAB (reprint author), MRC, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR BEEVERS DG, 1991, T ROY SOC TROP MED H, V85, P324, DOI 10.1016/0035-9203(91)90276-5
   *CENTR STAT DEP, 1998, POP HOUS CENS 1993 M
   Chalmers J, 1999, J HYPERTENS, V17, P151
   Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Cooper RS, 1998, BRIT MED J, V316, P614
   Dagli E, 1999, INT J TUBERC LUNG D, V3, P113
   DOWSE GK, 1995, BRIT MED J, V311, P1255
   Grim Clarence E., 1995, P171
   KAPLAN NM, 1994, LANCET, V344, P450, DOI 10.1016/S0140-6736(94)91774-4
   Kaufman JS, 1996, EPIDEMIOLOGY, V7, P398, DOI 10.1097/00001648-199607000-00010
   Kaufman JS, 1999, HUM BIOL, V71, P641
   Kaufman JS, 1996, J HUM HYPERTENS, V10, P461
   LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9
   LEWIS B, 1987, EUR HEART J, V8, P77
   MBUYAMBAKABANGU JR, 1987, J HYPERTENS, V5, P371, DOI 10.1097/00004872-198706000-00018
   MENSAH GA, 1994, J HUM HYPERTENS, V8, P799
   *MIN FIN EC AFF, 1995, 1993 4 HOUS ED HLTH
   Mosley W. H., 1993, DIS CONTROL PRIORITI, P673
   Muna Walinjom F. T., 1993, World Health Statistics Quarterly, V46, P125
   Nair P., 1994, Central African Journal of Medicine, V40, P278
   O'Brien E, 1996, BLOOD PRESS MONIT, V1, P55
   Pobee Joseph O. M., 1993, Ethnicity and Disease, V3, pS38
   POULTER NR, 1990, BRIT MED J, V300, P967
   ROSE G, 1981, BRIT MED J, V282, P1847
   SEEDAT YK, 1982, J EPIDEMIOL COMMUN H, V36, P256, DOI 10.1136/jech.36.4.256
   SEVER PS, 1980, LANCET, V2, P60
   Shaper A G, 1969, East Afr Med J, V46, P273
   Steyn K, 1996, E AFR MED J, V73, P758
   SWAI ABM, 1993, INT J EPIDEMIOL, V22, P651, DOI 10.1093/ije/22.4.651
   TRUSWELL AS, 1972, AM HEART J, V84, P5, DOI 10.1016/0002-8703(72)90299-2
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   VAUGHAN JP, 1979, B WORLD HEALTH ORGAN, V57, P281
   WILKINS HA, 1977, ANN TROP MED PARASIT, V71, P179
   World Bank, 1993, WORLD DEV REP 1993 I
NR 35
TC 54
Z9 55
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0950-9240
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD AUG
PY 2000
VL 14
IS 8
BP 489
EP 496
DI 10.1038/sj.jhh.1001050
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 348ET
UT WOS:000088973100004
PM 10962516
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Cairncross, S
   Bailey, RL
   Mabey, DCW
AF Emerson, PM
   Cairncross, S
   Bailey, RL
   Mabey, DCW
TI Review of the evidence base for the 'F' and 'E' components of the SAFE
   strategy for trachoma control
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Review
ID OCULAR CHLAMYDIAL INFECTION; GAMBIAN VILLAGE; CENTRAL TANZANIA;
   WATER-USE; HYPERENDEMIC AREA; RISK-FACTORS; EPIDEMIOLOGY; PREVALENCE;
   BLINDNESS; IMPACT
AB Community control of trachoma as a blinding disease is based on the SAFE strategy of Surgery, Antibiotic therapy, Facial cleanliness and Environmental improvement. Surgery and antibiotic therapy currently dominate most programmes. Blindness from trachoma results from frequent infections repeated over many years, so ultimate success requires the reduction of transmission. This is only likely to be sustainable through the F and E components of SAFE. Environmental improvement with access to water, enhanced hygiene and better sanitation reduces trachoma transmission and the blinding sequelae eventually disappear. Transmission routes and factors that cause this are not known and consequently no single specific tool for F and E is in place. Evidence from intervention studies shows that the promotion of face-washing gave modest gains for intense effort and a pilot study showed that trachoma transmission was reduced in the absence of eye-seeking flies. Other studies have shown that latrines and improved access to water are associated with a lower prevalence of active trachoma. There is likely to be a long-term beneficial effect of a combination of improved water supplies, provision of latrines, facial hygiene promotion through established infrastructure and control of eye-seeking flies. Each of these interventions offers additional public health and other benefits in its own right. Further research on the routes of transmission, the role of hygiene and means of sustainable fly control should be a priority.
C1 Med Res Council Labs, Fajara, Gambia.
   Univ Durham, Dept Biol Sci, Durham DH1 3HP, England.
   London Sch Hyg & Trop Med, London, England.
RP Emerson, PM (reprint author), Med Res Council Labs Fajara, POB 273, Banjul, Gambia.
CR ASSAAD FA, 1969, B WORLD HEALTH ORGAN, V41, P181
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BARENFANGER J, 1975, AM J TROP MED HYG, V24, P509
   BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357
   BOBB AA, 1969, AM J OPHTHALMOL, V67, P235
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   BRECHNER RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P687
   BRUNHAM RC, 1990, AM J EPIDEMIOL, V132, P946
   CAIRNCROSS S, 1987, T ROY SOC TROP MED H, V81, P51, DOI 10.1016/0035-9203(87)90280-X
   Cairncross S, 1993, ENV HLTH ENG TROPICS
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   DAWSON CR, 1976, BRIT J OPHTHALMOL, V60, P245, DOI 10.1136/bjo.60.4.245
   DESOLE G, 1987, BRIT J OPHTHALMOL, V71, P873, DOI 10.1136/bjo.71.11.873
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   DUKEELDER S, 1965, CONJUNCTIVAL DIS D 1, P260
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   EMERSON PM, 2000, T ROY SOC TROP MED H, V94, P1
   FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147
   Graz B, 1999, TROP MED INT HEALTH, V4, P222, DOI 10.1046/j.1365-3156.1999.43375.x
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275
   JONES BR, 1980, T OPHTHAL SOC UK, V100, P25
   JONES BR, 1975, T OPHTHAL SOC UK, V95, P16
   KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865
   KUPKA K, 1968, B WORLD HEALTH ORGAN, V39, P547
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   LUNA EJA, 1992, INT J EPIDEMIOL, V21, P169, DOI 10.1093/ije/21.1.169
   LYNCH M, 1994, T ROY SOC TROP MED H, V88, P513, DOI 10.1016/0035-9203(94)90141-4
   LYONS FM, 1952, B OPHTHALMOLOGY SOC, V45, P81
   MABEY DCW, 1991, J CLIN PATHOL, V44, P285, DOI 10.1136/jcp.44.4.285
   MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295
   MABEY DCW, 1992, EPIDEMIOL INFECT, V108, P343
   MAJCUK JF, 1966, B WORLD HEALTH ORGAN, V35, P262
   MANN I, 1967, AM J OPHTHALMOL, V63, P1303
   MARSHALL CL, 1968, ARCH ENVIRON HEALTH, V17, P215
   MARX R, 1989, SOC SCI MED, V29, P23, DOI 10.1016/0277-9536(89)90124-X
   MATHUR G M, 1970, Indian Journal of Medical Sciences, V24, P325
   MCCAULEY AP, 1990, SOC SCI MED, V31, P1233, DOI 10.1016/0277-9536(90)90129-G
   MECASKEY J, 1998, 3 M WHO GLOB ALL EL
   Munoz B, 1997, EPIDEMIOL REV, V19, P205
   NICHOLS RL, 1967, AM J OPHTHALMOL, V63, P1372
   PATERSON H E, 1970, Australian Journal of Zoology, V18, P231, DOI 10.1071/ZO9700231
   Pont A.C., 1991, Fauna of Saudi Arabia, V12, P312
   PORTNEY GL, 1970, AM J OPHTHALMOL, V70, P843
   PROST A, 1989, B WORLD HEALTH ORGAN, V67, P9
   REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   Royal Australian College of Ophthalmologists, 1980, NAT TRACH EYE HLTH P
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   SUKWA TY, 1992, E AFR MED J, V69, P34
   SUTTER EE, 1978, S AFR MED J, V53, P622
   SUTTER EE, 1983, SOC SCI MED, V17, P1813, DOI 10.1016/0277-9536(83)90397-0
   TABBARA KF, 1986, JAMA-J AM MED ASSOC, V255, P3378, DOI 10.1001/jama.255.24.3378
   TAYLOR CE, 1958, AM J TROP MED HYG, V7, P42
   TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559
   TAYLOR HR, 1988, AM J TROP MED HYG, V38, P623
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   TEDESCO LR, 1980, SOC SCI MED-MED GEOG, V14, P111, DOI 10.1016/0160-8002(80)90051-9
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393
   TRAORE E, 1994, J EPIDEMIOL COMMUN H, V48, P270, DOI 10.1136/jech.48.3.270
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1989, B WORLD HEALTH ORGAN, V67, P71
   WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST S K, 1988, Investigative Ophthalmology and Visual Science, V29, P359
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   WEST SK, 1991, J INFECT DIS, V163, P752
   WILSON JM, 1991, T ROY SOC TROP MED H, V85, P819, DOI 10.1016/0035-9203(91)90468-E
   Zerihun N, 1997, TROP MED INT HEALTH, V2, P1115, DOI 10.1046/j.1365-3156.1997.d01-211.x
NR 77
TC 90
Z9 92
U1 0
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2000
VL 5
IS 8
BP 515
EP 527
DI 10.1046/j.1365-3156.2000.00603.x
PG 13
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 351KG
UT WOS:000089155900002
PM 10995092
OA No
DA 2017-08-15
ER

PT J
AU Bowman, RJC
   Soma, OS
   Alexander, N
   Milligan, P
   Rowley, J
   Faal, H
   Foster, A
   Bailey, RL
   Johnson, GJ
AF Bowman, RJC
   Soma, OS
   Alexander, N
   Milligan, P
   Rowley, J
   Faal, H
   Foster, A
   Bailey, RL
   Johnson, GJ
TI Should trichiasis surgery be offered in the village? A community
   randomised trial of village vs. health centre-based surgery
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE trichiasis; trachoma; surgery; community; village; compliance
ID TRACHOMA; GAMBIA; WOMEN
AB INTRODUCTION Surgery for trachomatous trichiasis prevents blindness and is advocated by the WHO as part of the SAFE strategy for the global elimination of trachoma. We conducted a randomised community trial to investigate the effect of providing surgery in villages on surgical uptake in The Gambia.
   METHODS 56 villages from two divisions were assigned to eight pairs of clusters matched by geographical division and proximity. One cluster from each pair was randomly assigned to receive village-based surgery and the other cluster health centre-based surgery. Outcome measures were uptake rates and surgical results after 1 week and 3 months. The paired t-test was used to analyse the results.
   RESULTS Overall uptake was 66% in the village-based clusters and 44% in the health centre-based clusters. Subjects in the village-based surgery arm had significantly shorter journey times (P = 0.01) and lower costs (P = 0.002). The mean difference in absolute acceptance rates of surgery was 20% better in village-based clusters (95% CI -9 to +49%, P = 0.15), which would equate to an improvement of 45% (95% CI -20% to 120%) on the average acceptance rates of 44% in the health centre-based group.
   CONCLUSION These results strongly suggest better surgical uptake when surgery is provided in patients' villages due to lower cost to the patient, time saved and less fear of the operation.
C1 Int Ctr Eye Hlth, London EC1V 9EL, England.
   Natl Eye Care Programme Gambia, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Med, London, England.
   Med Res Council Labs, Banjul, Gambia.
RP Bowman, RJC (reprint author), Int Ctr Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   COURTRIGHT P, 1994, E AFR MED J, V71, P803
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   HOLLOWS FC, 1985, REV INFECT DIS, V7, P777
   OLIVA MS, 1998, INT OPHTHALMOL, V21, P235
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249
   WHO, 1996, FUT APPR TRACH CONTR
   World_Health_Organization, 1998, GLOB EL BLIND TRACH
   World Health Organization, 1997, WHOPBL9761
NR 12
TC 48
Z9 48
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2000
VL 5
IS 8
BP 528
EP 533
DI 10.1046/j.1365-3156.2000.00605.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 351KG
UT WOS:000089155900003
PM 10995093
OA No
DA 2017-08-15
ER

PT J
AU Bellamy, R
   Beyers, N
   McAdam, KPWJ
   Ruwende, C
   Gie, R
   Samaai, P
   Bester, D
   Meyer, M
   Corrah, T
   Collin, M
   Camidge, DR
   Wilkinson, D
   Hoal-van Helden, E
   Whittle, HC
   Amos, W
   van Helden, P
   Hill, AVS
AF Bellamy, R
   Beyers, N
   McAdam, KPWJ
   Ruwende, C
   Gie, R
   Samaai, P
   Bester, D
   Meyer, M
   Corrah, T
   Collin, M
   Camidge, DR
   Wilkinson, D
   Hoal-van Helden, E
   Whittle, HC
   Amos, W
   van Helden, P
   Hill, AVS
TI Genetic susceptibility to tuberculosis in Africans: A genome-wide scan
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID AFFECTED RELATIVE PAIRS; MYCOBACTERIUM-TUBERCULOSIS;
   SCHISTOSOMA-MANSONI; CHROMOSOME 5Q31-Q33; MULTIPLE-SCLEROSIS; LINKAGE
   STRATEGIES; COMPLEX TRAITS; RECEPTOR GENE; SEARCH; INFECTION
AB Human genetic variation is an important determinant of the outcome of infection with Mycobacterium tuberculosis. We have conducted a two-stage genome-wide linkage study to search for regions of the human genome containing tuberculosis-susceptibility genes. This approach uses sibpair families that contain two full siblings who have both been affected by clinical tuberculosis. For any chromosomal region containing a major tuberculosis-susceptibility gene, affected sibpairs inherit the same parental alleles more often than expected by chance. In the first round of the screen, 299 highly informative genetic markers, spanning the entire human genome, were typed in 92 sibpairs from The Gambia and South Africa. Seven chromosomal regions that showed provisional evidence of coinheritance with clinical tuberculosis were identified. To identify whether any of these regions contained a potential tuberculosis-susceptibility gene, 22 markers from these regions were genotyped in a second set of 81 sibpairs from the same countries, Markers on chromosomes 15q and Xq showed suggestive evidence of linkage (lod = 2.00 and 1.77, respectively) to tuberculosis, The potential identification of susceptibility loci on both chromosomes 15q and Xq was supported by an independent analysis designated common ancestry using microsatellite mapping. These results indicate that genome-wide linkage analysis can contribute to the mapping and identification of major genes for multifactorial infectious diseases of humans. An X chromosome susceptibility gene may contribute to the excess of males with tuberculosis observed in many different populations.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Stellenbosch, Dept Biochem Med, MRC, Ctr Cellular & Mol Biol, ZA-7600 Stellenbosch, South Africa.
   Univ Stellenbosch, Fac Med, ZA-7600 Stellenbosch, South Africa.
   MRC Labs, Banjul, Gambia.
   Hiabisa Hosp, KwaZulu Natal, South Africa.
   Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
RI HILL, Adrian/C-1306-2008; Wilkinson, David/A-6207-2008
OI Wilkinson, David/0000-0002-7265-9846; Hoal, Eileen/0000-0002-6444-5688
CR Aktogu S, 1996, EUR RESPIR J, V9, P2031, DOI 10.1183/09031936.96.09102031
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   BELLAMY R, 1998, THESIS U OXFORD
   Beyers N, 1996, S AFR MED J, V86, P40
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0
   DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472
   GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121
   Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469
   Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161
   Heng B H, 1991, Bull Int Union Tuberc Lung Dis, V66, P125
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HOLMANS P, 1993, AM J HUM GENET, V52, P362
   Ji YG, 1999, HUM MOL GENET, V8, P533, DOI 10.1093/hmg/8.3.533
   Reisner D, 1942, AM REV TUBERC, V47, P549
   KRUGLYAK L, 1995, AM J HUM GENET, V57, P439
   KUSTNER HGV, 1979, S AFR MED J, V55, P460
   Marquet S, 1999, EUR J HUM GENET, V7, P88, DOI 10.1038/sj.ejhg.5200243
   Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181
   Marsh DG, 1997, NAT GENET, V15, P389
   MCGUFFIN P, 1990, AM J HUM GENET, V46, P994
   MEREDITH SK, 1992, THORAX, V47, P770
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390
   RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678
   RISCH N, 1990, AM J HUM GENET, V46, P229
   RISCH N, 1990, AM J HUM GENET, V46, P242
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   ROUILLON A, 1976, TUBERCLE, V57, P275
   Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199
   Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464
   Shaw MA, 1997, TUBERCLE LUNG DIS, V78, P35, DOI 10.1016/S0962-8479(97)90014-9
   SINGH SPN, 1983, J INFECT DIS, V148, P676
   STEAD WW, 1992, ANN INTERN MED, V116, P937
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813
   WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5
   Zhong F, 1996, NAT GENET, V14, P329, DOI 10.1038/ng1196-329
NR 44
TC 212
Z9 228
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 5
PY 2000
VL 97
IS 14
BP 8005
EP 8009
DI 10.1073/pnas.140201897
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 331ZK
UT WOS:000088048400063
PM 10859364
OA No
DA 2017-08-15
ER

PT J
AU Smith, OB
   Akinbamijo, OO
AF Smith, OB
   Akinbamijo, OO
TI Micronutrients and reproduction in farm animals
SO ANIMAL REPRODUCTION SCIENCE
LA English
DT Article; Proceedings Paper
CT 14th International Congress on Animal Reproduction - Research and
   Practice II
CY JUL 02-06, 2000
CL STOCKHOLM, SWEDEN
DE reproduction; vitamins; microminerals
ID VITAMIN-E; DAIRY-COWS; RETAINED PLACENTA; SELENIUM; PERFORMANCE;
   HEIFERS; CATTLE; GILTS; SUPPLEMENTATION; DEFICIENCY
AB Reproductive well-being and performance of farm animals is largely dependent on their nutritional status, which is often less than optimum in developing tropical countries. More often than not, they are malnourished, particularly with regards to micronutrients. Evidence was presented to show that because these micronutrients are involved in such functions as intracellular detoxification of free radials, synthesis of reproductive steroids and other hormones, carbohydrate and protein and nucleic acid metabolism, their deficiencies and/or excesses may impair spermatogenesis and libido in the male, fertility, embryonic development and survival, post-partum recovery activities, milk production and offspring development and survival. A plea was made for intensified research efforts, farmer education and quality control of vitamin-mineral pre-mixes, in order to improve micronutrient nutrition, and, consequently, the reproductive performance and overall productivity of farm animals in developing tropical countries. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Int Dev Res Ctr, Ottawa, ON K1P 6M1, Canada.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP Smith, OB (reprint author), Int Dev Res Ctr, 250 Albert St, Ottawa, ON K1P 6M1, Canada.
CR Ali H. A., 1998, Veterinary Medical Journal Giza, V46, P77
   ALVAREZ JG, 1989, GAMETE RES, V23, P77, DOI 10.1002/mrd.1120230108
   ANKE M, 1989, ARCH TIERERNAHR, V39, P483
   ANNENKOV BN, 1981, MINERAL NUTR ANIMALS, P285
   ARECHIGA CF, 1994, THERIOGENOLOGY, V41, P1251, DOI 10.1016/0093-691X(94)90482-X
   BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nutr.13.1.65
   Campbell MH, 1998, J DAIRY SCI, V81, P2693
   COFFEY MT, 1993, J ANIM SCI, V71, P1198
   Corah L.R., 1991, Vet Clin North Am Food Anim Pract., V7, P40
   DENHARTOG LA, 1980, NETH J AGR SCI, V28, P211
   EGER S, 1985, J DAIRY SCI, V68, P2119, DOI 10.3168/jds.S0022-0302(85)81077-8
   FRIEDRICHSEN JV, 1980, NUTR REP INT, V22, P41
   GOTO Y, 1992, FREE RADICAL BIO MED, V13, P47, DOI 10.1016/0891-5849(92)90165-D
   Gutteridge J. M. C., 1994, ANTIOXIDANTS NUTR HL
   HAMRA AM, 1982, ANIM PROD, V34, P41
   HARRISON JH, 1984, J DAIRY SCI, V67, P123
   HEMLER ME, 1980, J BIOL CHEM, V255, P6253
   HIDIROGLOU M, 1987, J DAIRY SCI, V70, P1281
   HURLEY WL, 1989, J DAIRY SCI, V72, P784
   Jindal R, 1996, J ANIM SCI, V74, P620
   JULIEN WE, 1976, J DAIRY SCI, V59, P1954
   KIRKWOOD RN, 1987, CAN J ANIM SCI, V67, P405
   Liu C. H., 1982, Acta Veterinaria et Zootechnica Sinica, V13, P73
   MANSPEAKER JE, 1989, BOVINE PRACTITIONER, V24, P154
   MarinGuzman J, 1997, J ANIM SCI, V75, P2994
   MASTERS DG, 1983, BRIT J NUTR, V49, P365, DOI 10.1079/BJN19830045
   MASTERS DG, 1980, BIOL TRACE ELEM RES, V2, P228
   McKenzie RC, 1998, IMMUNOL TODAY, V19, P342, DOI 10.1016/S0167-5699(98)01294-8
   NOGUCHI T, 1973, J NUTR, V103, P444
   OLSON JD, 1995, CATTLE PRACT, V3, P47
   PHILLIPO M, 1987, J AGR SCI, V109, P326
   PITTS WJ, 1966, J DAIRY SCI, V49, P995
   SEGERSON EC, 1982, THERIOGENOLOGY, V17, P333, DOI 10.1016/0093-691X(82)90093-0
   SHORT RE, 1988, CAN J ANIM SCI, V68, P29
   SMART ME, 1981, CAN VET J, V22, P372
   SMITH OB, 1994, P REG SEM AN REPR JA
   STAATS DA, 1988, ENDOCRINOLOGY, V123, P975
   Surai PF, 1999, POULT AVIAN BIOL REV, V10, P1
   SUTTLE NF, 1986, VET REC, V119, P519
   THOMAS JW, 1951, J DAIRY SCI, V34, P929
   TRINDER N, 1969, VET REC, V85, P550
   Underwood EJ, 1981, MINERAL NUTR LIVESTO
   WARD GM, 1978, J ANIM SCI, V46, P1078
   Whaley SL, 1997, J ANIM SCI, V75, P1071
   Wichtel JJ, 1996, THERIOGENOLOGY, V46, P491, DOI 10.1016/0093-691X(96)00171-9
   WISE T, 1984, P SOC EXP BIOL MED, V176, P243
NR 46
TC 55
Z9 69
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4320
J9 ANIM REPROD SCI
JI Anim. Reprod. Sci.
PD JUL 2
PY 2000
VL 60
SI SI
BP 549
EP 560
DI 10.1016/S0378-4320(00)00114-7
PG 12
WC Agriculture, Dairy & Animal Science; Reproductive Biology
SC Agriculture; Reproductive Biology
GA 327HJ
UT WOS:000087788200044
PM 10844223
OA No
DA 2017-08-15
ER

PT J
AU Duraisingh, MT
   Von Seidlein, L
   Jepson, A
   Jones, P
   Sambou, I
   Pinder, M
   Warhurst, DC
AF Duraisingh, MT
   Von Seidlein, L
   Jepson, A
   Jones, P
   Sambou, I
   Pinder, M
   Warhurst, DC
TI Linkage disequilibrium between two chromosomally distinct loci
   associated with increased resistance to chloroquine in Plasmodium
   falciparum
SO PARASITOLOGY
LA English
DT Article
DE chloroquine; pfmdr1; cg2; dhfr; msp2; linkage disequilibrium; Plasmodium
   falciparum
ID SUB-SAHARAN AFRICA; PFMDR1 GENE; MALARIA PARASITES; IN-VITRO;
   DRUG-RESISTANCE; POINT MUTATIONS; GAMBIA; SUSCEPTIBILITY; PYRIMETHAMINE;
   POPULATIONS
AB Chloroquine-resistance in Plasmodium falciparum is associated with polymorphisms in a locus on or near the cg2 gene on chromosome 7, and in the pfmdr1 gene on chromosome 5. In this study we typed P. falciparum DNA from uncomplicated malaria cases in The Gambia in 1990, 1995 and 1996 for size polymorphism in the omega repeat of cg2, for sequence polymorphisms in pfmdr1 at codons 86 and 184, in dhfr at codon 108 and in the msp2 gene. Chloroquine sensitivity tests were conducted in vitro. A significant but incomplete association was found between the presence of the cg2 Dd2-like omega repeat size polymorphism and in vitro resistance, and between the tyr-86 allele of pfmdr1 and in vitro resistance. Furthermore there was strong linkage disequilibrium between the pfmdr1 asn-86 allele and the cg2 not Dd2-like omega repeat allele located on different chromosomes. In contrast, no linkage disequilibrium was found between these alleles and either the dhfr ser-108 allele or the msp2 IC sequence polymorphism. No significant linkage was measured between pfmdr1 asn-86 and phe-184 although these loci are separated only by 296 base pairs. Our results suggest that genetic elements linked to the cg2 and the pfmdr1 genes are important determinants of chloroquine resistance. It can be concluded that the observed linkage disequilibrium is maintained epistatically through selection by chloroquine.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
RP Warhurst, DC (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR ADAGU IS, 1995, T ROY SOC TROP MED H, V89, P422, DOI 10.1016/0035-9203(95)90037-3
   Adagu IS, 1996, T ROY SOC TROP MED H, V90, P90, DOI 10.1016/S0035-9203(96)90491-5
   ADAGU IS, 1995, T ROY SOC TROP MED H, V89, P132
   AWADELKARIEM FM, 1992, T ROY SOC TROP MED H, V86, P587, DOI 10.1016/0035-9203(92)90140-8
   BABIKER HA, 1994, PARASITOLOGY, V109, P413
   Basco LK, 1996, EXP PARASITOL, V82, P97, DOI 10.1006/expr.1996.0013
   Basco LK, 1998, AM J TROP MED HYG, V59, P577
   Basco LK, 1995, MOL BIOCHEM PARASIT, V74, P157, DOI 10.1016/0166-6851(95)02492-1
   Bray PG, 1998, MOL PHARMACOL, V54, P170
   CARTER R, 1975, T ROY SOC TROP MED H, V69, P371, DOI 10.1016/0035-9203(75)90191-1
   CARTER R, 1973, T ROY SOC TROP MED H, V67, P830, DOI 10.1016/0035-9203(73)90011-4
   CASSOL S, 1992, J CLIN MICROBIOL, V30, P3039
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   CONWAY DJ, 1991, PARASITOLOGY, V103, P7
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Duraisingh MT, 1999, PARASITOLOGY, V119, P435, DOI 10.1017/S0031182099004953
   Duraisingh MT, 1997, PARASITOLOGY, V114, P205, DOI 10.1017/S0031182096008487
   Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274
   Durand R, 1999, MOL BIOCHEM PARASIT, V101, P185, DOI 10.1016/S0166-6851(99)00073-0
   Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61
   Garnham PCC, 1966, MALARIA PARASITES OT
   Goldberg DE, 1997, J BIOL CHEM, V272, P6567
   Hastings IM, 1998, PARASITOLOGY, V117, P411, DOI 10.1017/S0031182098003291
   HELLGREN U, 1994, TROP MED PARASITOL, V45, P293
   HILL WG, 1968, GENETICS, V60, P615
   Mackinnon MJ, 1997, P ROY SOC B-BIOL SCI, V264, P53, DOI 10.1098/rspb.1997.0008
   MARTI J, 1990, ANTARCT SCI, V2, P345
   Maxwell CA, 1999, T ROY SOC TROP MED H, V93, P4, DOI 10.1016/S0035-9203(99)90158-X
   Maynard-Smith J, 1989, EVOLUTIONARY GENETIC
   MENON A, 1987, LANCET, V1, P1029
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Oduola AMJ, 1998, AM J TROP MED HYG, V58, P625
   ONEILL MJ, 1985, PLANTA MED, V51, P394
   PANTON LJ, 1985, T ROY SOC TROP MED H, V79, P484, DOI 10.1016/0035-9203(85)90072-0
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018
   PONNUDURAI T, 1981, TROP GEOGR MED, V33, P50
   Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Van Nierop WH, 1999, S AFR J SCI, V95, P133
   VANES HHG, 1994, MOL BIOCHEM PARASIT, V68, P209, DOI 10.1016/0166-6851(94)90166-X
   VANES HHG, 1994, MOL CELL BIOL, V14, P2419
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   VOLKMAN SK, 1995, P NATL ACAD SCI USA, V92, P8921, DOI 10.1073/pnas.92.19.8921
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0
   WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S
   Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335
NR 50
TC 40
Z9 41
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD JUL
PY 2000
VL 121
BP 1
EP 7
DI 10.1017/S0031182099006022
PN 1
PG 7
WC Parasitology
SC Parasitology
GA 345YQ
UT WOS:000088843200001
PM 11085219
OA No
DA 2017-08-15
ER

PT J
AU Aitman, TJ
   Cooper, LD
   Norsworthy, PJ
   Wahid, FN
   Gray, JK
   Curtis, BR
   McKeigue, PM
   Kwiatkowski, D
   Greenwood, BM
   Snow, RW
   Hill, AV
   Scott, J
AF Aitman, TJ
   Cooper, LD
   Norsworthy, PJ
   Wahid, FN
   Gray, JK
   Curtis, BR
   McKeigue, PM
   Kwiatkowski, D
   Greenwood, BM
   Snow, RW
   Hill, AV
   Scott, J
TI Population genetics - Malaria susceptibility and CD36 mutation
SO NATURE
LA English
DT Article
ID FALCIPARUM-INFECTED ERYTHROCYTES; GLYCOPROTEIN; ANTIGENS; ASIANS
C1 MRC, Ctr Clin Sci, Mol Med Grp, London W12 0NN, England.
   Hammersmith Hosp, Imperial Coll Genet, London W12 0NN, England.
   Hammersmith Hosp, Genom Res Inst, London W12 0NN, England.
   Med Coll Wisconsin, Blood Ctr SE Wisconsin, Milwaukee, WI 53201 USA.
   Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   KEMRI, Coastal Res Unit, Kilifi, Kenya.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RP Aitman, TJ (reprint author), MRC, Ctr Clin Sci, Mol Med Grp, London W12 0NN, England.
RI HILL, Adrian/C-1306-2008
CR ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985
   Baruch DI, 1999, BLOOD, V94, P2121
   Curtis BR, 1996, TRANSFUSION, V36, P331, DOI 10.1046/j.1537-2995.1996.36496226147.x
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749
   LIPSKY RH, 1994, HUM MOL GENET, V3, P217, DOI 10.1093/hmg/3.1.217
   MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P
   OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377
   SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   URWIJITAROON Y, 1995, TRANSFUSION, V35, P868, DOI 10.1046/j.1537-2995.1995.351096026370.x
NR 11
TC 133
Z9 139
U1 3
U2 9
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 29
PY 2000
VL 405
IS 6790
BP 1015
EP 1016
DI 10.1038/35016636
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 328VN
UT WOS:000087871700033
PM 10890433
OA No
DA 2017-08-15
ER

PT J
AU Dorrell, L
   Hessell, AJ
   Wang, M
   Whittle, H
   Sabally, S
   Rowland-Jones, S
   Burton, DR
   Parren, PWHI
AF Dorrell, L
   Hessell, AJ
   Wang, M
   Whittle, H
   Sabally, S
   Rowland-Jones, S
   Burton, DR
   Parren, PWHI
TI Absence of specific mucosal antibody responses in HIV-exposed uninfected
   sex workers from the Gambia
SO AIDS
LA English
DT Article
DE exposed-uninfected; HIV-1; HIV-2; IgA; mucosal antibody
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED INFECTIONS; CYTOTOXIC
   T-LYMPHOCYTES; NEUTRALIZATION SEROTYPES; IMMUNE-RESPONSE; SERONEGATIVE
   PARTNERS; TYPE-1 NEUTRALIZATION; VAGINAL SECRETIONS; GENETIC SUBTYPES;
   GP120
AB Objectives: Specific antibodies to HIV envelope that inactivate virus at the mucosal surfaces involved in sexual contact are of interest for the design of a vaccine against HIV-1. It has been suggested that, in frequently HIV-exposed but uninfected individuals, HIV-specific mucosal antibody responses may exist and play a role in resistance against HIV. This study investigated HIV-1 envelope specific mucosal antibody responses in HIV-resistant sex workers in west Africa.
   Methods: A group of 26 exposed uninfected female commercial sex workers from the Gambia, who have had repeated exposures to HIV-1 and HIV-2 were studied. We assessed the presence of vaginal IgA and Ige in vaginal swabs against a range of HIV-1 and HIV-2 envelope presentations and performed HIV-1 neutralization assays.
   Results: No significant vaginal IgA or Ige responses against HIV-1 or HIV-2 were detected, and none of the vaginal secretions tested displayed any HIV-1 neutralizing activity.
   Conclusion: Vaginal antibody responses against HIV were not found in Gambian sex workers who resist HIV infection. Resistance against HIV infection can therefore occur in the absence of specific antibodies against HIV at the genital mucosa. A protective role for HIV-envelope specific IgA in resistance against HIV-1 infection in exposed uninfected individuals as reported in the literature is uncertain. (C) 2000 Lippincott Williams & Wilkins.
C1 Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DU, England.
   Med Res Council Unit, Fajara, Gambia.
RP Parren, PWHI (reprint author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,IMM2, La Jolla, CA 92037 USA.
OI Parren, Paul/0000-0002-4365-3859
FU NIAID NIH HHS [AI33292, AI40377]
CR Becquart P, 1999, AIDS, V13, P1323, DOI 10.1097/00002030-199907300-00008
   BELEC L, 1989, J INFECT DIS, V159, P324
   BELEC L, 1989, J INFECT DIS, V160, P385
   BEYER C, 1999, J INFECT DIS, V179, P59
   Blankhart D, 1999, INT J STD AIDS, V10, P609, DOI 10.1258/0956462991914753
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Burton DR, 2000, VIROLOGY, V270, P1, DOI 10.1006/viro.2000.0239
   Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018
   CLAVEL F, 1994, J VIROL, V68, P1179
   Clerici M, 1999, IMMUNOL LETT, V66, P21, DOI 10.1016/S0165-2478(98)00181-3
   CLERICI M, 1992, J INFECT DIS, V165, P1012
   Ditzel HJ, 1997, J MOL BIOL, V267, P684, DOI 10.1006/jmbi.1997.0912
   Haimovici F, 1997, J ACQ IMMUN DEF SYND, V15, P185
   Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004
   Kostrikis LG, 1996, J VIROL, V70, P445
   Kozlowski PA, 1999, J INFECT DIS, V179, pS493, DOI 10.1086/314810
   LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085
   MABEY DCW, 1988, BRIT MED J, V296, P83
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0
   Moore JP, 1996, J VIROL, V70, P427
   MOORE JP, 1995, AIDS, V9, P117
   MUSTER T, 1993, J VIROL, V67, P6642
   Nyambi PN, 1996, J VIROL, V70, P6235
   Parr EL, 1997, J VIROL, V71, P8109
   Parren PWHI, 1998, J VIROL, V72, P10270
   Parren PWHI, 1999, AIDS, V13, pS137
   Parren PWHI, 1998, J VIROL, V72, P3512
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   PICKERING H, 1993, AIDS, V7, P271, DOI 10.1097/00002030-199302000-00017
   Ramjee G, 1998, SEX TRANSM DIS, V25, P346, DOI 10.1097/00007435-199808000-00004
   Renegar KB, 1998, J IMMUNOL, V160, P1219
   ROBEN P, 1994, J VIROL, V68, P4821
   Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314
   Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185
   Weber J, 1996, J VIROL, V70, P7827
   *WHO, 1998, WKLY EPIDEMIOL REC, V73, P373
   *WHO, 1998, WEEKLY EPIDEMIOL REC, V73, P381
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
NR 42
TC 79
Z9 80
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 16
PY 2000
VL 14
IS 9
BP 1117
EP 1122
DI 10.1097/00002030-200006160-00008
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 326KY
UT WOS:000087735700008
PM 10894275
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Corrah, T
   Whittle, HC
AF van der Loeff, MFS
   Corrah, T
   Whittle, HC
TI Low and stable HIV infection rates in Senegal?
SO AIDS
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP van der Loeff, MFS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   MARLINK R, 1998, 12 WORLD AIDS C GEN
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   van der Loeff MFS, 1999, AIDS, V13, pS69
NR 5
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 16
PY 2000
VL 14
IS 9
BP 1276
EP 1277
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 326KY
UT WOS:000087735700027
OA No
DA 2017-08-15
ER

PT J
AU Obaro, S
AF Obaro, S
TI Pneumocystis carinii pneumonia in Malawian children
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Obaro, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7
   Ruiz-Gonzalez A, 1999, AM J MED, V106, P385, DOI 10.1016/S0002-9343(99)00050-9
NR 2
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 10
PY 2000
VL 355
IS 9220
BP 2074
EP 2074
DI 10.1016/S0140-6736(05)73528-5
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 322QC
UT WOS:000087519400052
PM 10885379
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
   Obu, HA
   Jobarteh, A
AF Enwere, GC
   Obu, HA
   Jobarteh, A
TI Snake bites in children in The Gambia
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
AB This is a retrospective study of the demographic features, treatment and outcome of 28 cases of snake bite admitted to the department of paediatrics of the Royal Victoria Hospital, Banjul, The Gambia over a 3-year period. The age range was 2-14 years and the male:female ratio was 2.1:1. Most bites were on the legs and occurred near home. Most snake bites presented early at hospital and marked swelling of the affected limb was the most common clinical sign. Shock, restlessness and regional adenitis of the affected limb were common in children who died. The case fatality rate was 14.3%. Most children did nor receive specific antivenom therapy.
C1 Royal Victoria Hosp, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Andersson L. G., 1937, Arkiv for Zoologi Stockholm, V29 A, P1
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   HAKANSSON NT, 1981, J HERPETOL, V15, P155, DOI 10.2307/1563375
   HUNG DZ, 1997, CHIN MED J TAIPEI, V60, P326
   LALLOO DG, 1995, T ROY SOC TROP MED H, V89, P178, DOI 10.1016/0035-9203(95)90485-9
   MCALLISTER CT, 1992, J WILDLIFE DIS, V28, P641
   Meyer WP, 1997, AM J TROP MED HYG, V56, P291
   REID HA, 1983, B WORLD HEALTH ORGAN, V61, P885
   Rojnuckarin P, 1998, AM J TROP MED HYG, V58, P22
   SNOW RW, 1994, ANN TROP MED PARASIT, V88, P665
   THEAKSTON RDG, 1991, PAEDIAT TROPICS, P903
   Warrell D.A., 1976, Acta Tropica, V33, P307
   WARRELL DA, 1977, Q J MED, V46, P33
   WARRELL DA, 1976, AM J TROP MED HYG, V25, P517
   WARRELL DA, 1976, Q J MED, V45, P1
   WARRELL DA, 1993, MED J AUSTRALIA, V159, P773
NR 16
TC 5
Z9 5
U1 0
U2 1
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD JUN
PY 2000
VL 20
IS 2
BP 121
EP 124
PG 4
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 332GW
UT WOS:000088066800008
PM 10945062
OA No
DA 2017-08-15
ER

PT J
AU Marchant, A
   Newport, M
AF Marchant, A
   Newport, M
TI Prevention of infectious diseases by neonatal and early infantile
   immunization: prospects for the new millennium
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
ID RESPIRATORY SYNCYTIAL VIRUS; CYTOTOXIC T-LYMPHOCYTES; EARLY-LIFE;
   MATERNAL IMMUNIZATION; CONJUGATE VACCINES; DNA IMMUNIZATION;
   IMMUNE-RESPONSE; MEASLES-VACCINE; ANTIBODY; MICE
AB Newborns and young infants are at increased risk of severe or prolonged infections. Recent advances in our understanding of the host immune response in this age group, coupled with the development of molecular genetic tools, have paved the way for a new generation of preventive vaccines. Curr Opin Infect Dis 13:241-246. (C) 2000 Lippincott Williams & Wilkins.
C1 MRC Labs, Banjul, Gambia.
RP Newport, M (reprint author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust Ctr Study Mol Mechanisms Dis, Hills Rd, Cambridge CB2 2XY, England.
CR Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Arulanandam BP, 1999, EUR J IMMUNOL, V29, P256, DOI 10.1002/(SICI)1521-4141(199901)29:01<256::AID-IMMU256>3.0.CO;2-G
   BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Butts C, 1998, VACCINE, V16, P1444, DOI 10.1016/S0264-410X(98)00106-6
   CHOUGNET C, 2000, IN PRESS J INFECT DI
   Englund J, 1998, VACCINE, V16, P1456, DOI 10.1016/S0264-410X(98)00108-X
   Eskola J, 1998, VACCINE, V16, P1433, DOI 10.1016/S0264-410X(98)00104-2
   Eskola J, 1999, PEDIATR INFECT DIS J, V18, P543, DOI 10.1097/00006454-199906000-00015
   Fennelly GJ, 1999, J IMMUNOL, V162, P1603
   Flamand V, 1998, J IMMUNOL, V160, P4666
   Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728
   Freytag LC, 1999, CURR TOP MICROBIOL, V236, P215
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   Gans HA, 1999, J IMMUNOL, V162, P5569
   Hanke T, 1999, J VIROL, V73, P7524
   Ichino M, 1999, J IMMUNOL, V162, P3814
   Jaye A, 1998, J CLIN INVEST, V102, P1969, DOI 10.1172/JCI3290
   Kovarik J, 1999, J IMMUNOL, V162, P1611
   KURIKKA S, 1995, PEDIATRICS, V95, P815
   Lagranderie M, 1998, AIDS RES HUM RETROV, V14, P1625, DOI 10.1089/aid.1998.14.1625
   Lambert PH, 1997, BRIT MED J, V315, P1595
   Levine MM, 1998, LANCET, V351, P1375, DOI 10.1016/S0140-6736(05)79439-3
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Martinez X, 1999, EUR J IMMUNOL, V29, P3390, DOI 10.1002/(SICI)1521-4141(199910)29:10<3390::AID-IMMU3390>3.0.CO;2-A
   Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726
   MCLENNAN J, 1999, VACICNE, V17, P3086
   Mulholland K, 1998, VACCINE, V16, P1464, DOI 10.1016/S0264-410X(98)00109-1
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   NEWELL KW, 1966, B WORLD HEALTH ORGAN, V35, P863
   Ogra PL, 1999, PEDIATR INFECT DIS J, V18, P10, DOI 10.1097/00006454-199901000-00004
   Osterhaus A, 1998, VACCINE, V16, P1479, DOI 10.1016/S0264-410X(98)00112-1
   Ramsay AJ, 1999, IMMUNOL REV, V171, P27, DOI 10.1111/j.1600-065X.1999.tb01341.x
   Rappuoli R, 1999, IMMUNOL TODAY, V20, P493, DOI 10.1016/S0167-5699(99)01523-6
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505
   Siegrist CA, 1999, J INFECT DIS, V179, P1326, DOI 10.1086/314778
   Siegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.3.CO;2-C
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Watts AM, 1999, NAT MED, V5, P427
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHO, 1999, PEDIATR INFECT DIS J, V18, pS32
   Wright PF, 1998, VACCINE, V16, P1355, DOI 10.1016/S0264-410X(98)00091-7
NR 46
TC 18
Z9 18
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD JUN
PY 2000
VL 13
IS 3
BP 241
EP 246
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 320CF
UT WOS:000087383000007
OA No
DA 2017-08-15
ER

PT J
AU Conway, DJ
   Cavanagh, DR
   Tanabe, K
   Roper, C
   Mikes, ZS
   Sakihama, N
   Bojang, KA
   Oduola, AMJ
   Kremsner, PG
   Arnot, DE
   Greenwood, BM
   McBride, JS
AF Conway, DJ
   Cavanagh, DR
   Tanabe, K
   Roper, C
   Mikes, ZS
   Sakihama, N
   Bojang, KA
   Oduola, AMJ
   Kremsner, PG
   Arnot, DE
   Greenwood, BM
   McBride, JS
TI A principal target of human immunity to malaria identified by molecular
   population genetic and immunological analyses
SO NATURE MEDICINE
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM MEROZOITES;
   CARBOXY-TERMINAL FRAGMENT; NATURAL-SELECTION; SERUM ANTIBODIES; SOUTHERN
   VIETNAM; ANTIGEN GENE; PARASITE; RECOMBINATION; RESPONSES
AB New strategies are required to identify the most important targets of protective immunity in complex eukaryotic pathogens. Natural selection maintains allelic variation in some antigens of the malaria parasite Plasmodium falciparum(1-3). Analysis of allele frequency distributions could identify the loci under most intense selection(4-7). The merozoite surface protein 1 (Msp1) is the most-abundant surface component on the erythrocyte-invading stage of P. falciparum(8-10). Immunization with whole Msp1 has protected monkeys completely against homologous(11) and partially against non-homologous(12) parasite strains. The single-copy msp1 gene, of about 5 kilobases, has highly divergent alleles(13) with stable frequencies in endemic populations(14,15). To identify the region of msp1 under strongest selection to maintain alleles within populations, we studied multiple intragenic sequence loci in populations in different regions of Africa and Southeast Asia. On both continents, the locus with the lowest inter-population variance in allele frequencies was block 2 indicating selection in this part of the gene. To test the hypothesis of immune selection, we undertook a large prospective longitudinal cohort study. This demonstrated that serum IgG antibodies against each of the two most frequent allelic types of block 2 of the protein were strongly associated with protection from P. falciparum malaria.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland.
   Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan.
   Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan.
   MRC Labs, Banjul, Gambia.
   Univ Ibadan, Coll Med, Postgrad Inst Med Res & Training, Ibadan, Nigeria.
   Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Cavanagh, David/A-1828-2008; Roper, Cally/K-2989-2013
OI Roper, Cally/0000-0002-6545-309X; Conway, David/0000-0002-8711-3037
CR AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552
   Beaumont MA, 1996, P ROY SOC B-BIOL SCI, V263, P1619, DOI 10.1098/rspb.1996.0237
   BERRY A, 1993, GENETICS, V134, P869
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Dodoo D, 1999, INFECT IMMUN, V67, P2131
   EGAN AF, 1995, INFECT IMMUN, V63, P456
   Egan AF, 1996, J INFECT DIS, V173, P765
   Escalante AA, 1998, GENETICS, V149, P189
   Ferreira MU, 1998, J EUKARYOT MICROBIOL, V45, P131, DOI 10.1111/j.1550-7408.1998.tb05080.x
   Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689
   Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437
   HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0
   Hastings IM, 1996, PARASITOLOGY, V112, P155
   HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0
   HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2
   Kaneko O, 1997, EXP PARASITOL, V86, P45, DOI 10.1006/expr.1997.4147
   Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091
   MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7
   McDonald John H., 1994, P88
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   Sakihama N, 1999, GENE, V230, P47, DOI 10.1016/S0378-1119(99)00069-4
   SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014
   Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218
   TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
   TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
NR 37
TC 192
Z9 195
U1 0
U2 15
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2000
VL 6
IS 6
BP 689
EP 692
DI 10.1038/76272
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 321CX
UT WOS:000087438300041
PM 10835687
OA No
DA 2017-08-15
ER

PT J
AU Corrah, T
   Byass, P
   Jaffar, S
   Thomas, V
   Bouchier, V
   Stanford, JL
   Whittle, HC
AF Corrah, T
   Byass, P
   Jaffar, S
   Thomas, V
   Bouchier, V
   Stanford, JL
   Whittle, HC
TI Prior BCG vaccination improves survival of Gambian patients treated for
   pulmonary tuberculosis
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE BCG; pulmonary tuberculosis; The Gambia
ID BACILLUS-CALMETTE-GUERIN; IMMUNITY
AB The protection provided by BCG against pulmonary tuberculosis ranges from nil to over 90%. While BCG protects against the more serious forms of tuberculosis, it is not known whether or nor it protects patients with pulmonary tuberculosis from death. In a study designed to look at the effects of immunotherapy with hi. vaccae as an adjunct to chemotherapy in 285 adult Gambian patients treated for proven pulmonary tuberculosis, we examined the association between the presence or absence of a BCG scar and mortality The data showed that subjects who had a BCG scar were significantly younger than those who did not, and were less likely to have nutritional oedema. During the course of treatment, none of the 85 patients who had a BCG scar died compared to 35 of 200 patients (17.5%) who did not (P < 0.001). In these Gambian patients with pulmonary tuberculosis, prior vaccination with BCG may have provided substantial protection against death. However, there is the possibility that this finding is the result of confounding by other factors or has arisen from bias. Researchers with similar data need to investigate this question as this association, if true, could have major implications for BCG vaccination.
C1 MRC Labs, Banjul, Gambia.
   Univ Nottingham, Nottingham Sch Publ Hlth, Nottingham NG7 2RD, England.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Govt Gambia, Minist Hlth, Banjul, Gambia.
   UCL, Dept Bacteriol, London, England.
RP Corrah, T (reprint author), MRC Labs Fajara, POB 273, Banjul, Gambia.
EM tcorrah@mrc.gm
OI Byass, Peter/0000-0001-5474-4361
CR BESKOW R, 1980, B INT UNION TUBERC, V55, P100
   Bloom BR, 1994, TUBERCULOSIS PATHOGE
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   Fine PEM, 1996, LANCET, V348, P17
   FINE PEM, 1988, BRIT MED BULL, V44, P691
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35
   NUNN P, 1992, AM REV RESPIR DIS, V146, P649
   Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8
   PYAKALIA T, 1977, PAPUA NEW GUINEA MED, V20, P141
   Ravn P, 1997, J IMMUNOL, V158, P1949
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Tuberculosis Prevention Trial Madras, 1980, INDIAN J MED RES S, V72, pS1
NR 13
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2000
VL 5
IS 6
BP 413
EP 417
DI 10.1046/j.1365-3156.2000.00571.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 337LP
UT WOS:000088362700005
PM 10929140
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Pandey, VS
   Murray, M
   Fitzpatrick, JL
AF Mattioli, RC
   Pandey, VS
   Murray, M
   Fitzpatrick, JL
TI Immunogenetic influences on tick resistance in African cattle with
   particular reference to trypanotolerant N'Dama (Bos taurus) and
   trypanosusceptible Gobra zebu (Bos indicus) cattle
SO ACTA TROPICA
LA English
DT Review
DE ticks; tick-borne diseases; host resistance; N'Dama; Gobra zebu
ID BROWN EAR-TICK; RHIPICEPHALUS-APPENDICULATUS NEUMANN; AMBLYOMMA-HEBRAEUM
   ACARINA; BOOPHILUS-MICROPLUS; TRYPANOSOMA-CONGOLENSE;
   COWDRIA-RUMINANTIUM; THEILERIA-PARVA; MILK-PRODUCTION; BORAN CATTLE;
   GUINEA-PIGS
AB In sub-Saharan Africa, tick infestation and tick-borne infections together with tsetse-transmitted trypanosomosis arguably constitute the main parasitological disease complex constraining livestock production. Resistance to tick attack and tick-borne micro-organisms (TBMs) varies among different breeds of cattle. The magnitude of losses due to these parasites is related to an extent to the degree of breed resistance. Generally, zebu (Bos indicus) cattle possess a higher resistance to ticks and TBMs than European (Bos taurus) cattle. The host's immune system would appear to be the single most important factor that regulates this resistance. This paper reports on the main effector immune mechanisms governing resistance against ticks and TBMs. The cellular immune response appears mote effective and stable than humoral immunity in modulating resistance to ticks and TBMs. Similarities between the immune mechanisms employed by trypanotolerant N'Dama (B, taurus) cattle, when infected with trypanosomes, and those elicited by tick bites and TBMs seem to exist, particularly at the skin level in the early phases of parasitic invasion. Moreover, then is evidence that in the N'Dama breed, resistance against ticks per se also has a genetic basis. Therefore, the N'Dama appears to be a unique breed in that it exhibits resistance to several parasitic diseases and/or infections, including helminths, when compared to other cattle breeds in West Africa. It is concluded that the multi-parasite resistant traits of the N'Dama breed should be exploited in those areas where trypanosomosis, ticks and tick-borne diseases constrain animal production. This should be of benefit for low-input farming systems where the use of chemicals for prophylaxis and therapy is limited by their relatively high cost. Additionally, the potential contribution of multiple disease resistant N'Dama cattle should be considered in crossbreeding programmes with exotic dairy breeds for increasing milk production in West Africa. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Glasgow, Sch Vet, Glasgow G61 1QH, Lanark, Scotland.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ADACHI K, 1993, J VET MED SCI, V55, P189
   ADAMSON D, 1991, VET PARASITOL, V38, P317, DOI 10.1016/0304-4017(91)90143-J
   AKOL GWO, 1982, VET REC, V110, P295
   ALI M, 1993, TROP ANIM HEALTH PRO, V25, P215, DOI 10.1007/BF02250871
   ALLISON AC, 1980, AM J PATHOL, V101, P114
   ASSELBERGS MJ, 1989, LIVESTOCK PRODUCTION, P358
   AUTHIE E, 1990, VET PARASITOL, V35, P43, DOI 10.1016/0304-4017(90)90115-R
   BARBET AF, 1995, VET PARASITOL, V57, P43, DOI 10.1016/0304-4017(94)03108-9
   BARNARD DR, 1990, EXP APPL ACAROL, V9, P259, DOI 10.1007/BF01193432
   BARON RW, 1987, PARASITOL TODAY, V3, P77, DOI 10.1016/0169-4758(87)90163-3
   Barre N, 1988, Rev Elev Med Vet Pays Trop, V41, P339
   Barre N, 1988, Rev Elev Med Vet Pays Trop, V41, P129
   BARRIGA OO, 1991, J PARASITOL, V77, P703, DOI 10.2307/3282702
   BARRIGA OO, 1994, VET PARASITOL, V55, P29, DOI 10.1016/0304-4017(94)90054-X
   BARRIGA OO, 1993, J PARASITOL, V79, P710, DOI 10.2307/3283609
   BARRIGA OO, 1991, J PARASITOL, V77, P710, DOI 10.2307/3282703
   BENNETT GF, 1968, P ECOL SOC AUST, V3, P150
   Binnington KC, 1980, ADV PARASIT, V8, P315, DOI 10.1016/S0065-308X(08)60403-0
   Bowman AS, 1997, MED VET ENTOMOL, V11, P277, DOI 10.1111/j.1365-2915.1997.tb00407.x
   Brizuela CM, 1996, VET PARASITOL, V63, P95, DOI 10.1016/0304-4017(95)00885-3
   Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x
   Brossard M., 1976, Acta Tropica, V33, P15
   Brown S J, 1985, Parasitol Today, V1, P166, DOI 10.1016/0169-4758(85)90175-9
   BROWN SJ, 1984, J IMMUNOL, V133, P3319
   CLARKE FC, 1989, MED VET ENTOMOL, V3, P35, DOI 10.1111/j.1365-2915.1989.tb00472.x
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DARJI A, 1992, ANN SOC BELG MED TR, V72, P27
   DECASTRO JJ, 1993, PARASITOL TODAY, V9, P13
   deCastro JJ, 1997, VET PARASITOL, V71, P77, DOI 10.1016/S0304-4017(97)00033-2
   DECASTRO JJ, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P244
   DECASTRO JJ, 1987, ACIAR P, V17, P118
   Deem SL, 1996, VET PARASITOL, V61, P133, DOI 10.1016/0304-4017(95)00820-9
   DOENHOFF MJ, 1991, PARASITOL TODAY, V7, P16, DOI 10.1016/0169-4758(91)90079-4
   DOKO SA, 1996, THESIS PRINCE LEOPOL
   Dossa SC, 1996, VET PARASITOL, V62, P317, DOI 10.1016/0304-4017(95)00875-6
   DUPLESSIS JL, 1985, ONDERSTEPOORT J VET, V52, P55
   DWINGER RH, 1986, RES VET SCI, V41, P307
   EMERY DL, 1981, IMMUNOLOGY, V43, P232
   EUGUI EM, 1981, NATURE, V290, P251, DOI 10.1038/290251a0
   FAO, 1984, TICKS TICK BORN DIS, VI
   FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P131, DOI 10.1007/BF02236231
   FIVAZ BH, 1991, VET PARASITOL, V38, P299, DOI 10.1016/0304-4017(91)90142-I
   FIVAZ BH, 1989, TROP ANIM HEALTH PRO, V21, P129, DOI 10.1007/BF02236193
   FIVAZ BH, 1989, J PARASITOL, V75, P946, DOI 10.2307/3282875
   FLYNN JN, 1991, IMMUNOLOGY, V74, P310
   FRANCIS J., 1964, AUSTRALIAN VETERINARY J, V40, P247, DOI 10.1111/j.1751-0813.1964.tb08746.x
   GAIDO AB, 1995, ANN TROP MED PARASIT, V89, P309
   GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A
   GROOTENHUIS JG, 1985, STUDIES EARLY PATHOG, P85
   Gueye A, 1990, Rev Elev Med Vet Pays Trop, V42, P517
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P551
   Guglielmone A. A., 1992, Research and Reviews in Parasitology, V52, P77
   HELLERHAUPT A, 1983, ANN TROP MED PARASIT, V77, P219
   HERNANDEZ RM, 1994, MED VET ENTOMOL, V8, P238, DOI 10.1111/j.1365-2915.1994.tb00505.x
   HOLMES PH, 1987, PARASITOLOGY, V94, pS29
   How S J, 1988, Rev Elev Med Vet Pays Trop, V41, P139
   Hursey B. S., 1995, World Animal Review, P67
   INOKUMA H, 1993, VET PARASITOL, V47, P107, DOI 10.1016/0304-4017(93)90181-L
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201
   JONGEJAN F, 1989, EXP APPL ACAROL, V7, P181, DOI 10.1007/BF01194059
   Jordan A.M., 1986, TRYPANOSOMIASIS CONT, P357
   KAISER MN, 1988, PREV VET MED, V6, P199, DOI 10.1016/0167-5877(88)90031-1
   KAISER MN, 1982, TROP ANIM HEALTH PRO, V14, P63, DOI 10.1007/BF02282583
   KARBE E, 1982, REV ELEV MED VET PAY, V35, P365
   KAUFMAN WR, 1989, PARASITOL TODAY, V5, P47
   KEMP DH, 1980, PARASITOLOGY, V80, P487
   Kemp SJ, 1996, VET IMMUNOL IMMUNOP, V54, P239, DOI 10.1016/S0165-2427(96)05692-9
   Koney E B, 1994, Rev Elev Med Vet Pays Trop, V47, P163
   KONEY EBM, 1994, VET PARASITOL, V55, P245, DOI 10.1016/0304-4017(94)00648-V
   Konstantinov O.K., 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P85
   KUTTLER KL, 1988, TROP ANIM HEALTH PRO, V20, P37, DOI 10.1007/BF02239643
   KUTTLER KL, 1986, TROP ANIM HEALTH PRO, V18, P91, DOI 10.1007/BF02359719
   LAMOS AM, 1985, ANIM PROD, V41, P187
   LAWRENCE JA, 1980, VET REC, V107, P82
   LLOYD CM, 1995, VET PARASITOL, V59, P59, DOI 10.1016/0304-4017(95)94781-Z
   MAGEZ S, 1993, PARASITE IMMUNOL, V15, P635, DOI 10.1111/j.1365-3024.1993.tb00577.x
   MAHAN SM, 1995, VET PARASITOL, V57, P51, DOI 10.1016/0304-4017(94)03109-A
   Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P283
   Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P291
   Mattioli R. C., 1992, Parassitologia (Rome), V34, P109
   Mattioli R. C., 1995, Tropicultura, V13, P19
   Mattioli R. C., 1994, Parassitologia (Rome), V36, P305
   Mattioli R. C., 1996, Parassitologia (Rome), V38, P531
   Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x
   Mattioli RC, 1998, PREV VET MED, V34, P137, DOI 10.1016/S0167-5877(97)00082-2
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   Mattioli RC, 1999, MED VET ENTOMOL, V13, P33, DOI 10.1046/j.1365-2915.1999.00136.x
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P150, DOI 10.1007/BF02248959
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   McMillan DE, 1996, WORLD DEV, V24, P569, DOI 10.1016/0305-750X(95)00153-4
   MCTIER TL, 1981, J PARASITOL, V67, P813, DOI 10.2307/3280705
   MELTZER MI, 1995, TROP ANIM HEALTH PRO, V27, P129, DOI 10.1007/BF02248956
   MELTZER MI, 1993, EXP APPL ACAROL, V17, P171, DOI 10.1007/BF00118434
   Merlin P, 1986, Rev Elev Med Vet Pays Trop, V39, P403
   MILLER DK, 1984, TROP ANIM HEALTH PRO, V16, P71, DOI 10.1007/BF02239848
   MORRISON WI, 1981, EXP PARASITOL, V52, P248, DOI 10.1016/0014-4894(81)90080-1
   Morrow A N, 1993, Rev Elev Med Vet Pays Trop, V46, P317
   MULLENAX CH, 1986, P ANN M AN RES WORK, P2
   MURRAY M, 1985, VET PARASITOL, V18, P167, DOI 10.1016/0304-4017(85)90065-2
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1984, J INFECT DIS, V149, P311
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   MURRAY M, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P203
   MUSOKE AJ, 1984, IMMUNOLOGY, V52, P231
   Mwangi DM, 1998, DEV BIOL STAND, V92, P309
   Norval R A, 1990, Parassitologia, V32, P155
   NORVAL RAI, 1988, VET PARASITOL, V30, P149, DOI 10.1016/0304-4017(88)90162-8
   Norval RAI, 1997, MED VET ENTOMOL, V11, P143, DOI 10.1111/j.1365-2915.1997.tb00304.x
   Norval RAI, 1997, MED VET ENTOMOL, V11, P148, DOI 10.1111/j.1365-2915.1997.tb00305.x
   OKELLY JC, 1976, J PARASITOL, V62, P312, DOI 10.2307/3279295
   OPDEBEECK JP, 1994, VET PARASITOL, V54, P205, DOI 10.1016/0304-4017(94)90091-4
   ORINDA GO, 1994, VET PARASITOL, V53, P53, DOI 10.1016/0304-4017(94)90016-7
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   Pegram R G, 1990, Parassitologia, V32, P165
   Pegram RG, 1996, TROP ANIM HEALTH PRO, V28, P99, DOI 10.1007/BF02250733
   PEGRAM RG, 1990, MED VET ENTOMOL, V4, P327, DOI 10.1111/j.1365-2915.1990.tb00448.x
   PEGRAM RG, 1989, MED VET ENTOMOL, V3, P313, DOI 10.1111/j.1365-2915.1989.tb00234.x
   PEGRAM RG, 1995, MED VET ENTOMOL, V9, P337, DOI 10.1111/j.1365-2915.1995.tb00144.x
   RECHAV Y, 1989, MED VET ENTOMOL, V3, P333, DOI 10.1111/j.1365-2915.1989.tb00239.x
   RECHAV Y, 1991, ONDERSTEPOORT J VET, V58, P181
   RECHAV Y, 1991, MED VET ENTOMOL, V5, P29, DOI 10.1111/j.1365-2915.1991.tb00517.x
   REGE JEO, 1994, ANIM PROD, V59, P21
   ROITT I, 1991, ESSENTIAL IMMUNOLOGY, P356
   RURANGIRWA FR, 1983, PARASITE IMMUNOL, V5, P267, DOI 10.1111/j.1365-3024.1983.tb00743.x
   SCHOLTZ MM, 1991, ONDERSTEPOORT J VET, V58, P71
   SCHORDERET S, 1993, MED VET ENTOMOL, V7, P186, DOI 10.1111/j.1365-2915.1993.tb00673.x
   SEIFERT GW, 1971, AUST J AGR RES, V22, P159, DOI 10.1071/AR9710159
   SEIFERT GW, 1984, DEV ANIMAL VET SCI, V15, P553
   SHAW APM, 1987, 671 FAO
   SHAW APM, 1987, 672 FAO
   SILEGHEM MR, 1993, VET IMMUNOL IMMUNOP, V37, P123, DOI 10.1016/0165-2427(93)90060-H
   SMITH RE, 1989, VET REC, V124, P583
   SOLARI MA, 1992, MEM I OSWALDO CRUZ, V87, P143
   STACHURSKI F, 1993, VET PARASITOL, V49, P299, DOI 10.1016/0304-4017(93)90128-A
   Stachurski F, 1988, Rev Elev Med Vet Pays Trop, V41, P395
   STEWART CG, 1987, ONDERSTEPOORT J VET, V54, P341
   SUTHERST RW, 1983, AUST J AGR RES, V34, P317, DOI 10.1071/AR9830317
   SUTHERST RW, 1981, HDB PEST MANAGEMENT, P385
   TATCHELL RJ, 1992, INSECT SCI APPL, V13, P551
   TATCHELL RJ, 1988, TROP PEST MANAGE, V34, P165
   Totte P, 1993, Rev Elev Med Vet Pays Trop, V46, P189
   Totte P, 1996, VET IMMUNOL IMMUNOP, V53, P61, DOI 10.1016/0165-2427(96)05603-6
   UILENBERG G, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P297
   *UNDP, 1991, GAM87004 UNDP
   VANVLIET AHM, 1992, INT J SYST BACTERIOL, V42, P494
   VERCRUYSSE J, 1982, REV ELEV MED VET PAY, V35, P361
   WAGLAND BM, 1980, 56 ANN C AUSTR VET A, P55
   WAKELIN D, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P54
   WALKER AR, 1986, INT J PARASITOL, V16, P399, DOI 10.1016/0020-7519(86)90121-9
   WALKER AR, 1990, MED VET ENTOMOL, V4, P321, DOI 10.1111/j.1365-2915.1990.tb00447.x
   WALKER AR, 1985, INT J PARASITOL, V15, P81, DOI 10.1016/0020-7519(85)90106-7
   WALKER JB, 1987, ONDERSTEPOORT J VET, V54, P353
   WHITELAW DD, 1979, RES VET SCI, V26, P102
   WIKEL SK, 1986, VET PARASITOL, V20, P149, DOI 10.1016/0304-4017(86)90098-1
   WIKEL SK, 1994, INT J PARASITOL, V24, P59, DOI 10.1016/0020-7519(94)90059-0
   WIKEL SK, 1977, IMMUNOLOGY, V32, P457
   Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5
   WIKEL SK, 1976, IMMUNOLOGY, V30, P311
   WILLADSEN P, 1978, INT J PARASITOL, V8, P89, DOI 10.1016/0020-7519(78)90003-6
   WILLADSEN P, 1980, 56 ANN C AUSTR VET A, P60
   WILLIAMS DJL, 1991, PARASITE IMMUNOL, V13, P171, DOI 10.1111/j.1365-3024.1991.tb00273.x
   WRIGHT IG, 1988, PARASITOL TODAY, V4, P214, DOI 10.1016/0169-4758(88)90161-5
   YONOW T, 1995, INT J PARASITOL, V25, P1023, DOI 10.1016/0020-7519(95)00020-3
NR 166
TC 43
Z9 46
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD MAY 31
PY 2000
VL 75
IS 3
BP 263
EP 277
DI 10.1016/S0001-706X(00)00063-2
PG 15
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 319GZ
UT WOS:000087334300001
PM 10838210
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
AF Enwere, GC
TI Sedation in cerebral malaria
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Crawley J, 2000, LANCET, V355, P701, DOI 10.1016/S0140-6736(99)07148-2
   KUILE F, 1992, EUR J CLIN PHARMACOL, V42, P107, DOI 10.1007/BF00314929
   NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B
   WHITE NJ, 1988, LANCET, V2, P64
   WINSTANLEY PA, 1992, BR J CLIN PHARM, V33, P144
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 6
PY 2000
VL 355
IS 9215
BP 1643
EP 1644
DI 10.1016/S0140-6736(05)72544-7
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 313CD
UT WOS:000086981200045
PM 10821385
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
AF Prentice, A
TI Maternal calcium metabolism and bone mineral status
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article; Proceedings Paper
CT Symposium on Maternal Nutrition - New Developments and Implications
CY JUN 11-12, 1998
CL CNIT PARIS DEF, PARIS, FRANCE
SP Ctr Res & Informat Nutr, French Coll Obstet & Gynecol, Int Ctr Childhood & Family, French Secretary State hlth, CNIT Paris Def
HO CNIT PARIS DEF
DE bone mineral; breast-feeding; calcium; lactation; pregnancy; women;
   supplementation
ID BIOCHEMICAL MARKERS; HUMAN-PREGNANCY; LACTATION; DENSITY; WOMEN;
   HOMEOSTASIS; TURNOVER; RECOVERY; 1,25-DIHYDROXYVITAMIN-D;
   SUPPLEMENTATION
AB Human pregnancy is associated with major changes in calcium and bone metabolism and in bone mineral status before and after gestation. The changes are compatible with the uptake and mobilization of calcium by the maternal skeleton to meet the high requirement for fetal growth and for breast-milk production. Breast-feeding is accompanied by decreases in bone mineral status, increases in bone turnover rate, and reductions in urinary calcium excretion. These effects are reversed during and after weaning, and, in several skeletal regions, bone mineral content ultimately exceeds that measured after delivery. By 3-6 mo after lactation, the postpartum changes in bone mineral status of women who breast-feed largely match those of women who do not, regardless of the duration of lactation. No consistent picture has emerged of the effect of pregnancy on bone mineral status, although increases in bone turnover, calcium absorption, and urinary calcium excretion are well recognized. Events before conception may modify the bone response, particularly if conception occurs within a few months of a previous pregnancy or lactation. There is no evidence that the changes observed during lactation reflect inadequacies in calcium intake. Supplementation studies have shown that neither the bone response nor breast-milk calcium secretion is modified by increases in calcium supply during lactation, even in women with a low calcium intake. The situation in pregnancy is less clear. Calcium nutrition may influence the health of the pregnant woman, her breast-milk calcium concentration, and the bone mineralization and blood pressure of her infant, but these possibilities require formal testing.
C1 MRC Human Nutr Res, Cambridge CB4 1XJ, England.
   MRC, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Downhams Lane,Milton Rd, Cambridge CB4 1XJ, England.
CR Affinito P, 1996, J CLIN ENDOCR METAB, V81, P2314, DOI 10.1210/jc.81.6.2314
   CHAN GM, 1987, AM J CLIN NUTR, V46, P319
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   CROSS NA, 1995, AM J CLIN NUTR, V61, P514
   DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E
   GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6
   GREER FR, 1982, AM J CLIN NUTR, V36, P431
   HEANEY RP, 1971, J CLIN ENDOCR METAB, V33, P661
   Kalkwarf HJ, 1997, NEW ENGL J MED, V337, P523, DOI 10.1056/NEJM199708213370803
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4
   Kalkwarf HJ, 1996, AM J CLIN NUTR, V63, P526
   KENT GN, 1990, J BONE MINER RES, V5, P361
   KENT GN, 1991, MINER ELECTROL METAB, V17, P1
   KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384
   Kent GN, 1995, OSTEOPOROSIS INT, V5, P315
   King J C, 1992, MECH REGULATING LACT, P129
   Krebs NF, 1997, AM J CLIN NUTR, V65, P1738
   Laskey MA, 1998, AM J CLIN NUTR, V67, P685
   Laskey MA, 1997, LANCET, V349, P1518, DOI 10.1016/S0140-6736(05)62097-1
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029-7844(99)00369-5
   Morales A, 1995, J BONE MINER RES, V8, pS156
   NAYLOR KE, 1996, J BONE MINER RES, V11, pS194
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   PRENTICE A, 1994, LANCET, V344, P411, DOI 10.1016/S0140-6736(94)91440-0
   Prentice A, 1997, NEW ENGL J MED, V337, P558, DOI 10.1056/NEJM199708213370809
   PRENTICE A, 1995, BODY COMPOSITION TEC, P1, DOI 10.1017/CBO9780511525650.001
   Prentice A., 1994, AM J CLIN NUTR S, V59, p477S
   Prentice A., 1999, NUTR BONE DEV, P127
   PURDIE DW, 1988, BRIT J OBSTET GYNAEC, V95, P849, DOI 10.1111/j.1471-0528.1988.tb06568.x
   RAMAN L, 1978, AM J CLIN NUTR, V31, P466
   Ritchie LD, 1998, AM J CLIN NUTR, V67, P693
   Salle BL, 2000, AM J CLIN NUTR, V71, p1317S
   Sowers M, 1998, AM J CLIN NUTR, V67, P284
   SOWERS M, 1995, J CLIN ENDOCR METAB, V80, P2210, DOI 10.1210/jc.80.7.2210
   SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D
   SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130
   SPECKER BL, 1994, AM J CLIN NUTR, V59, P593
   SPECKER BL, 1991, OBSTET GYNECOL, V78, P56
   Villar J, 2000, AM J CLIN NUTR, V71, p1375S
   WILSON SG, 1990, CLIN ENDOCRINOL, V32, P613, DOI 10.1111/j.1365-2265.1990.tb00905.x
   Yamaga A, 1996, J CLIN ENDOCR METAB, V81, P752, DOI 10.1210/jc.81.2.752
NR 43
TC 47
Z9 47
U1 2
U2 4
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAY
PY 2000
VL 71
IS 5
SU S
BP 1312S
EP 1316S
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 307GA
UT WOS:000086644000016
PM 10799408
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Shaheen, SO
   Heyes, CB
   Goudiaby, A
   Hall, AJ
   Shiell, AW
   Jensen, H
   Marchant, A
AF Aaby, P
   Shaheen, SO
   Heyes, CB
   Goudiaby, A
   Hall, AJ
   Shiell, AW
   Jensen, H
   Marchant, A
TI Early BCG vaccination and reduction in atopy in Guinea-Bissau
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Article
DE Africa; atopy; BCG vaccination in infancy; children
ID BACILLUS-CALMETTE-GUERIN; ALLERGIC SENSITIZATION; IMMUNE-RESPONSE;
   EARLY-CHILDHOOD; HAY-FEVER; INFECTION; ASTHMA; PREVALENCE; INDUCTION;
   MEASLES
AB Background It has been proposed that certain viral and bacterial infections in early childhood may prevent allergic sensitization, by inducing Th1-type immune responses. This has led to speculation that mycobacterial vaccines might, through their Th1-stimulating properties, also protect against atopy.
   Objective To investigate whether the prevalence of atopy is lower in children who have been vaccinated with BCG in infancy than in children who have not been vaccinated.
   Methods We measured skin test reactivity to three allergens (Dermatophagoides pteronyssinus, D. farinae and cockroach) in 400 children, aged 3-14 years, as part of a follow-up study to examine the immune sequelae of measles in an urban area of Bissau, the capital of Guinea-Bissau in west Africa. Information on childhood vaccinations, including BCG in infancy, was available from child records. Of these children, 271 had been vaccinated with BCG (according to records) and 53 had not been vaccinated (no record and no BCG scar). Atopy was defined in two ways, according to the presence of any allergen reaction greater than or equal to 2 mm and any reaction greater than or equal to 3 mm.
   Results Of the children who had received BCG vaccine, 57 (21%) were atopic (any reaction greater than or equal to 2 mm), compared with 21 (40%) of the unvaccinated children [odds ratio, after controlling for potential confounding factors, 0.19 (95% CI 0.06-0.59)]. When atopy was defined using the 3-mm criterion, the reduction in atopy associated with BCG was greater the earlier the age at vaccination, and the largest reduction was seen in children vaccinated in the first week of life.
   Conclusion BCG vaccination given early in infancy may prevent the development of atopy in African children.
C1 Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.
   Projecto Saude Bandim, Bissau, Guinea Bissau.
   Minist Publ Hlth, Bissau, Guinea Bissau.
   Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, London WC1, England.
   MRC, Environm Epidemiol Unit, Southampton, Hants, England.
   MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR Aaby P., 1997, PROSPECTIVE COMMUNIT, P276
   Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1
   ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x
   Beverley PCL, 1997, IMMUNOL TODAY, V18, P413, DOI 10.1016/S0167-5699(97)01120-1
   Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41
   Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561
   Farooqi IS, 1998, THORAX, V53, P927
   FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35
   Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728
   GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0
   Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2
   HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0
   ILDIRIM I, 1992, ARCH DIS CHILD, V67, P80
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Marsh DG, 1997, NAT GENET, V15, P389
   Matricardi PM, 1997, BRIT MED J, V314, P999
   MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566
   PAUWELS R, 1983, ALLERGY, V38, P239, DOI 10.1111/j.1398-9995.1983.tb01617.x
   PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q
   Ravn P, 1997, J IMMUNOL, V158, P1949
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J
   Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726
   SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x
   Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7
   Shaheen SO, 1996, BRIT MED J, V313, P969
   Silverman M, 1997, LANCET, V350, P380, DOI 10.1016/S0140-6736(05)64130-X
   STRACHAN DP, 1989, BRIT MED J, V299, P1259
   Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X
   Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x
   VONMUTIUS E, 1994, BRIT MED J, V308, P692
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WJST M, 1994, ANN ALLERGY, V73, P450
NR 35
TC 169
Z9 173
U1 0
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0954-7894
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD MAY
PY 2000
VL 30
IS 5
BP 644
EP 650
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 314CU
UT WOS:000087037700007
PM 10792355
OA No
DA 2017-08-15
ER

PT J
AU Leaves, NI
   Dimopoulou, I
   Hayes, I
   Kerridge, S
   Falla, T
   Secka, O
   Adegbola, RA
   Slack, MPE
   Peto, TEA
   Crook, DWM
AF Leaves, NI
   Dimopoulou, I
   Hayes, I
   Kerridge, S
   Falla, T
   Secka, O
   Adegbola, RA
   Slack, MPE
   Peto, TEA
   Crook, DWM
TI Epidemiological studies of large resistance plasmids in Haemophilus
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID INFLUENZAE TYPE-B; POLYMERASE CHAIN-REACTION; HEMOPHILUS-INFLUENZAE;
   MOLECULAR EPIDEMIOLOGY; CONJUGATE VACCINE; CARRIAGE; DISEASE; REGION
AB The distribution of large conjugative Haemophilus influenzae plasmids in the nasopharyngeal haemophili of a group of people and in a large collection of 541 H. influenzae type b (Hib) isolates was studied. A newly developed PCR-based assay was used to detect the plasmids. The target sequences were chosen from sequence analysis of part of p1056, a large multiresistance plasmid isolated from a clinical Hib isolate, 1056. Fifty-nine per cent of people were found to carry beta-lactamase-positive (beta-lac(+)), ampicillin-resistant (amp(R)) haemophili with detectable plasmid sequences. Of these, 83% were in Haemophilus parainfluenzae and 17% were in H. influenzae. In the collection of 541 Hib, antibiotic resistance [beta-lac(+)amp(R), beta-lac(+)amp(R) plus tetracycline resistance (tet(R)) or tet(R)] was highly correlated with large plasmids. It was found that 2.3% of the isolates contained large cryptic plasmids (i.e. these isolates were susceptible to antibiotics). The distribution of plasmids between invasive and carried Hib did not differ significantly (25 of 245 and 23 of 276, respectively). Isolates with large plasmids occur at high frequency in the nasopharynx of the normal human population and consist of two populations in Hib, one associated with specific antibiotic resistance traits and the other cryptic. These plasmids do not appear to influence the invasiveness of Hib.
C1 John Radcliffe Hosp, Interdept Acad Unit Infect Dis & Clin Microbiol, Oxford OX3 9DU, England.
   John Radcliffe Hosp, Oxford Vaccine Grp, Oxford OX3 9DU, England.
   John Radcliffe Hosp, Publ Hlth Lab, Oxford OX3 9DU, England.
   Democritus Univ Thrace, Med Sch Alexandroupolis, Alexandroupolis, Greece.
   Med Res Council Labs, Banjul, Gambia.
   John Radcliffe Hosp, Haemophilus Reference Unit, Oxford OX3 9DU, England.
RP Crook, DWM (reprint author), John Radcliffe Hosp, Interdept Acad Unit Infect Dis & Clin Microbiol, Oxford OX3 9DU, England.
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793
   BARBOUR ML, 1993, EUR J CLIN MICROBIOL, V12, P215, DOI 10.1007/BF01967116
   BARBOUR ML, 1993, PEDIATR INFECT DIS J, V12, P478, DOI 10.1097/00006454-199306000-00005
   BARBOUR ML, 1995, J INFECT DIS, V171, P93
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BRUNTON J, 1986, REV INFECT DIS, V8, P713
   CAMPOS J, 1986, J PEDIATR-US, V108, P897, DOI 10.1016/S0022-3476(86)80923-4
   CAMPOS J, 1989, J INFECT DIS, V160, P810
   DABERNAT H, 1983, PATHOL BIOL, V31, P103
   DAUM RS, 1981, J INFECT DIS, V143, P548
   DEGRAAFF J, 1976, J BACTERIOL, V126, P439
   Dimopoulou ID, 1997, J ANTIMICROB CHEMOTH, V39, P303, DOI 10.1093/jac/39.3.303
   DIMOPOULOU ID, 1992, J INFECT DIS, V165, P1069
   ELWELL LP, 1977, J BACTERIOL, V131, P356
   FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382
   JORDENS JZ, 1993, J CLIN MICROBIOL, V31, P2981
   KILIAN M, 1976, J GEN MICROBIOL, V93, P9
   LAUFS R, 1981, J BACTERIOL, V147, P563
   LEAVES NI, 1995, J MED MICROBIOL, V43, P120
   LEAVES NI, 1994, EUR J CLIN MICROBIOL, V13, P1038, DOI 10.1007/BF02111824
   MATHIES A W JR, 1972, Journal of the Royal College of Physicians of London, V6, P139
   MENDELMAN PM, 1985, J INFECT DIS, V151, P1061
   POWELL M, 1988, J MED MICROBIOL, V27, P81
   SCHEIFELE DW, 1982, ANTIMICROB AGENTS CH, V21, P734
   SCHEIFELE DW, 1981, J INFECT DIS, V3, P495
   SLACK MPE, 1977, LANCET, V2, P906
   STUY JH, 1980, J BACTERIOL, V142, P925
   TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517
   1991, J ANTIMICROBIAL C SD, V27, P1
NR 31
TC 33
Z9 35
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD MAY
PY 2000
VL 45
IS 5
BP 599
EP 604
DI 10.1093/jac/45.5.599
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 317QR
UT WOS:000087238900007
PM 10797080
OA No
DA 2017-08-15
ER

PT J
AU Bickler, SW
AF Bickler, SW
TI Non-communicable diseases: is their emergence in industrialized
   societies related to changes in neuroendocrine function?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CALCIFICATION
AB This hypothesis suggests that industrialization alters the human neuroendocrine system. The neuroendocrine changes come about because of changes in environmental stimuli. It is further proposed that changes in neuroendocrine function can account for the contrasting pattern of non-communicable diseases in traditional and industrialized societies. The hypothesis is based on subtle clinical differences in traditional and industrialized societies, and the evolving concept of neuroendocrine regulation of physiological processes. Compared to traditional societies, individuals from industrialized communities tend to have lower pain tolerance, slower gastrointestinal transit-time, and a greater chance of having a calcified pineal gland. These changes parallel the increasing incidence of noncommunicable diseases in industrialized societies. There is sufficient reason to suspect the variations in pain tolerance, gastrointestinal transit-time and pineal gland calcification represent changes in neuroendocrine function. Programming of the neuroendocrine system by environmental events early in life is one possible mechanism whereby these changes might be effected. Understanding the physiological changes that occur with industrialization, and how environmental stimuli interact with the developing neuroendocrine system might lead to new strategies for the prevention and treatment of non-communicable diseases. (C) 2000 Harcourt Publishers,Ltd.
C1 Royal Victoria Hosp, Dept Surg, Banjul, Gambia.
RP Bickler, SW (reprint author), Univ Calif San Diego, Med Ctr, Dept Surg, Div Pediat Surg, San Diego, CA 92103 USA.
CR ADELOYE A, 1974, AM J ROENTGENOL, V122, P503
   ARENDT J, 1995, MELATONIN MAMMALIAN, P23
   Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019
   BICKLER SW, 1999, B TROPICAL MED INT H, V7, P1
   BICKLER SW, 1999, AM PED SURG ASS M RA
   Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186
   BURKITT DP, 1973, BRIT MED J, V1, P274
   DARAMOLA GF, 1972, NEUROENDOCRINOLOGY, V9, P41, DOI 10.1159/000122036
   FIELDS HL, 1995, TXB PAIN, P243
   [Anonymous], 1954, PINEAL GLAND
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Odeku E L, 1967, West Afr Med J Niger Pract, V16, P31
   REICHLIN S, 1993, NEW ENGL J MED, V329, P1246
   TEMPLIN N, 1994, WALL STREET J E 1222, P1
   TORSOLI A, 1993, ITAL J GASTROENTEROL, V25, P123
   WALKER ARP, 1970, BRIT MED J, V3, P48
   YAKSH TL, 1995, TXB PAIN
   YEE LF, 1995, WESTERN J MED, V163, P454
NR 18
TC 8
Z9 8
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY
PY 2000
VL 54
IS 5
BP 825
EP 828
DI 10.1054/mehy.1999.0959
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 322AE
UT WOS:000087487100030
PM 10859694
OA No
DA 2017-08-15
ER

PT J
AU Obaro, S
AF Obaro, S
TI Control of meningococcal disease in west Africa
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Obaro, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Bovier PA, 1999, SOC SCI MED, V48, P1205, DOI 10.1016/S0277-9536(98)00419-5
   MacLennan J, 1999, VACCINE, V17, P3086, DOI 10.1016/S0264-410X(99)00139-5
   Woods CW, 2000, LANCET, V355, P30, DOI 10.1016/S0140-6736(99)03366-8
NR 3
TC 6
Z9 6
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 1
PY 2000
VL 355
IS 9210
BP 1184
EP 1185
DI 10.1016/S0140-6736(05)72263-7
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 302TC
UT WOS:000086380900048
PM 10791403
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Obaro, S
   Morison, LA
   Greenwood, BM
AF Bojang, KA
   Obaro, S
   Morison, LA
   Greenwood, BM
TI A prospective evaluation of a clinical algorithm for the diagnosis of
   malaria in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria; clinical diagnosis; The Gambia
ID PLASMODIUM-FALCIPARUM; CHLOROQUINE; RESISTANCE; AFRICA
AB Diagnosis of clinical malaria remains difficult, especially in areas where a high proportion of the asymptomatic population have parasitaemia, for the symptoms and signs of malaria overlap with those of other common childhood diseases, such as acute lower respiratory tract infections. However, a study of symptoms and signs in a group of children who presented to Farafenni Health Centre, The Gambia with a history of recent fever identified a group of signs and symptoms which were strong predictors of malaria as opposed to other febrile illnesses. Using these predictors, an algorithm was developed which could be used by fieldworkers and which had a similar sensitivity and specificity for the diagnosis of malaria as that of an experienced paediatrician working without laboratory support. This algorithm has been validated prospectively on 518 children who presented to the Medical Research Council clinic at Basse, The Gambia with fever or a history of recent fever during a 10-month period. A fieldworker obtained a detailed history from the parent or guardian of each child and performed a clinical examination which included measurement of axillary temperature and respiratory rate. Packed cell volume was measured and a thick smear was examined for malaria parasites. A malaria score, based on the presence or absence of malaria-related signs and symptoms, was determined for 382 children who were seen at the clinic during the high transmission season. Using the cut-off score which was optimal during the previous retrospective study, a sensitivity of 70% and a specificity of 77% for a diagnosis of malaria was obtained. The optimal cut-off score for the Basse population was a score of 7; this gave a sensitivity of 88% and a specificity of 62%, figures comparable to those obtained by an experienced paediatrician without laboratory support.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Bojang, KA (reprint author), MRC Labs, Banjul, Gambia.
RI Morison, Linda/H-9738-2013
CR Armstrong Schellenberg J. R. M., 1994, Parasitology Today, V10, P439
   BASSETT MT, 1991, J TROP MED HYG, V94, P65
   BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B
   BLOLAND PB, 1993, J INFECT DIS, V167, P932
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   MENON A, 1987, LANCET, V1, P1029
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   Olaleye BO, 1998, T ROY SOC TROP MED H, V92, P300, DOI 10.1016/S0035-9203(98)91021-5
   OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X
   PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5
   Redd SC, 1996, LANCET, V347, P223, DOI 10.1016/S0140-6736(96)90404-3
   ROOTH IB, 1992, AM J TROP MED HYG, V47, P675
   ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9
   *WHO, 1992, MIN C MAL AMST NETH
   World Health Organization, 1990, WHOARI905
   *WHO, 1994, WHOMAL941070
NR 18
TC 33
Z9 33
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2000
VL 5
IS 4
BP 231
EP 236
DI 10.1046/j.1365-3156.2000.00538.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 317CG
UT WOS:000087207500002
PM 10810013
OA No
DA 2017-08-15
ER

PT J
AU Zinsstag, J
   Ankers, P
   Njie, M
   Smith, T
   Pandey, VS
   Pfister, K
   Tanner, M
AF Zinsstag, J
   Ankers, P
   Njie, M
   Smith, T
   Pandey, VS
   Pfister, K
   Tanner, M
TI Heritability of gastrointestinal nematode faecal egg counts in West
   African village N'Dama cattle and its relation to age
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE cattle-nematoda; genetics; faecal egg count; acquired immunity; N'Dama
   cattle; The Gambia
ID GENETIC-RESISTANCE; EPIDEMIOLOGY; RUMINANTS; GAMBIA
AB Offspring-dam regression was used to estimate the heritability of strongyle faecal egg counts (FEC) of traditionally raised West African N'Dama cattle in the Central River Division in The Gambia. Faecal samples were taken monthly from June-October 1992, and again from July-October 1993, including 179-463 dams and their calves sampled on each occasion. The only proven genetic relationship was the dam-offspring relationship. Gastrointestinal strongyle FEC was expressed as epg (eggs per gram faeces). Regression of offspring FEC on dam FEC, showed a heritability (h(2)) of 0.18 (95% Confidence Limits 0.10, 0.25), Heritabilities were higher at the beginning and end of the rainy season than during the months of the peak rainy season, This is in line with earlier suggestions that genetic control of faecal egg counts is most effective during periods of low parasite transmission. There was a significant (p < 0.001) increase in heritability of 0.086 +/- 0.018 with each year of age of the corresponding offspring. In view of the virtual absence of national cattle breeding systems in West Africa, which are a precondition for exploitation of heritable traits in cattle, integrated control using improved management and strategic prophylaxis remain the methods of choice to control gastrointestinal nematodes in the given conditions. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Swiss Trop Inst, CH-4002 Basel, Switzerland.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Neuchatel, Dept Zool, CH-2000 Neuchatel, Switzerland.
RP Zinsstag, J (reprint author), Swiss Trop Inst, Socinstr 7, CH-4002 Basel, Switzerland.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR BAKER RL, 1998, BREEDING RESISTANCE, P119
   BARGER IA, 1989, VET PARASITOL, V32, P21, DOI 10.1016/0304-4017(89)90153-2
   Boch J., 1983, VETERINARMEDIZINISCH
   CHIEJINA SN, 1995, HELMINTH DIS RUMINAN, P8
   Falconer DS, 1984, EINFUHRUNG QUANTITAT
   GASBARRE LC, 1990, VET PARASITOL, V37, P257, DOI 10.1016/0304-4017(90)90009-Z
   HOLGADO FD, 1997, REV INVESTIGACIONES, V25, P81
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   KLOOSTERMAN A, 1992, PARASITOL TODAY, V8, P330, DOI 10.1016/0169-4758(92)90066-B
   LEIGHTON EA, 1989, J PARASITOL, V75, P498, DOI 10.2307/3282895
   Mattioli R. C., 1992, Parassitologia (Rome), V34, P109
   NDAO M, 1995, VET RES, V26, P132
   NDAO M, 1995, VET PARASITOL, V60, P161, DOI 10.1016/0304-4017(94)00771-4
   OUATTARA L, 1992, P C ASS I TROP VET M, V2, P497
   STEAR MJ, 1994, VET PARASITOL, V54, P161, DOI 10.1016/0304-4017(94)90089-2
   Suarez V. H., 1995, Revista de Medicina Veterinaria (Buenos Aires), V76, P142
   Waller PJ, 1997, VET PARASITOL, V71, P195, DOI 10.1016/S0304-4017(97)00032-0
   *WINR INT, 1992, ASS AN AGR SUBS AFR, P57
   Zinsstag J, 1997, VET PARASITOL, V68, P143, DOI 10.1016/S0304-4017(96)01024-2
NR 19
TC 9
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR 28
PY 2000
VL 89
IS 1-2
BP 71
EP 78
DI 10.1016/S0304-4017(99)00226-5
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 299ZE
UT WOS:000086227700008
PM 10729647
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
AF Obaro, SK
TI Prospects for pneumococcal vaccination in African children
SO ACTA TROPICA
LA English
DT Review
DE Haemophilus influenzae; meningitis; B-cells
ID RESPIRATORY-TRACT INFECTIONS; UPPER RIVER DIVISION;
   STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINES; GAMBIAN CHILDREN;
   POLYSACCHARIDE VACCINE; CHILDHOOD MORTALITY; ANTIBODY-RESPONSES; GUINEAN
   CHILDREN; WEST-AFRICA
AB Streptococcus pneumoniae (pneumococcus) remains a major cause of morbidity and mortality in both developed and undeveloped countries. Accurate disease burden estimates for developing countries and Africa in particular, where diagnostic facilities are less adequate and a disease surveillance system virtually non-existent, is difficult. However, from conservative estimates, the pneumococcus is probably responsible for at least 1 million of the 4 million deaths that occur from acute lower respiratory infections in children aged less than 5 years. The global burden of disease has been accentuated by the rising menace of multi-drug resistant strains, which defy geographic and racial borders. Thus, now more than ever before, there is an urgent need to identify and implement preventive measures to avert this problem. The currently licensed pneumococcal polysaccharide vaccine, comprises 23 capsular polysaccharides of the pneumococcus, many of which are poorly immunogenic in the very vulnerable age group of under-fives. A possible solution to the problem of poor immunogenicity is to use a protein/polysaccharide conjugate Vaccine similar to that recently introduced successfully for Haemophilus influenzae type b (Hib) and using this approach, several workers have reported promising results from safety and immunogenicity studies. However, unlike Hib, the development of conjugate vaccine against pneumococcal disease is complicated by the existence of more serotypes than can be feasibly incorporated in a single conjugate Vaccine formulation. Whilst this challenge has been taken on by some vaccine manufacturers, novel approaches such as the identification or construction of protective protein antigen, common to all clinically important strains are being explored. Novel application of the pneumococcal polysaccharide vaccines in pregnancy for protection of disease in early infancy is an approach that has not been evaluated. For maximum impact, the ultimate vaccine formulation should be affordable and available to resource poor countries where the burden of disease is highest. Establishing disease surveillance systems in such countries now will greatly facilitate the introduction of the vaccines. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 MRC Labs, Fajara, Gambia.
RP Obaro, SK (reprint author), MRC Labs, POB 273, Fajara, Gambia.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Austrian R, 1976, Trans Assoc Am Physicians, V89, P184
   BARKER J, 1989, J INFECT DIS, V159, P348
   BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401
   Briles DE, 1996, ANN NY ACAD SCI, V797, P118, DOI 10.1111/j.1749-6632.1996.tb52954.x
   BRUYN GAW, 1991, EUR J CLIN MICROBIOL, V10, P897, DOI 10.1007/BF02005442
   *CHILDR VACC IN, 1996, CVI FORUM, V13, P3
   CreweBrown HH, 1997, CLIN INFECT DIS, V25, P1165
   Dagan R, 1996, J INFECT DIS, V174, P1271
   DAVIDSON M, 1994, J INFECT DIS, V170, P368
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DEVELASCO EA, 1993, VACCINE, V11, P1429, DOI 10.1016/0264-410X(93)90172-T
   DIALLO AA, 1979, NIGERIAN MED J, V9, P421
   Dick W E Jr, 1989, Contrib Microbiol Immunol, V10, P48
   English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X
   ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P323
   FATTOM A, 1990, INFECT IMMUN, V58, P2308
   FEDSON DS, 1999, VACCINES, P553
   Fedson DS, 1994, VACCINES, P517
   FEDSON DS, 1988, VACCINES, P127
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   Gilks CF, 1998, BRIT MED BULL, V54, P383
   Goebel WF, 1929, J EXP MED, V50, P521, DOI 10.1084/jem.50.4.521
   Greenwood BM, 1987, BACTERIAL MENINGITIS, P61
   HENNEBERGER PK, 1983, AM J EPIDEMIOL, V117, P484
   IKEOGU MO, 1988, ARCH DIS CHILD, V63, P1266
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   JONES V, 1998, CAN TELECOM, V12, P16
   KARMA P, 1985, AM J OTOLARYNG, V6, P173, DOI 10.1016/S0196-0709(85)80081-8
   Kurikka S, 1996, J PEDIATR-US, V128, P524, DOI 10.1016/S0022-3476(96)70364-5
   LEE CJ, 1991, CRIT REV MICROBIOL, V18, P89, DOI 10.3109/10408419109113510
   LEHMANN D, 1992, J INFECT DIS, V165, pS20
   LEHMANN D, 1991, ANN TROP PAEDIATR, V11, P247
   LEOSWKI J, 1986, WORLD HLTH STAT, V39, P138
   LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7
   MBELLE N, 1997, ICAAC TORONTO LB, V12, pP13
   MEYER RD, 1992, J HOSP INFECT, V22, P51, DOI 10.1016/S0195-6701(05)80007-6
   MIMICA I, 1971, AM J DIS CHILD, V122, P278
   MOSIER DE, 1987, VACCINES BETTER CARB, P243
   NATHOO KJ, 1993, ANN TROP PAEDIATR, V13, P253
   Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   OBARO SK, 1995, LANCET, V345, P70, DOI 10.1016/S0140-6736(95)91199-5
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   PAUL WE, 1971, J IMMUNOL, V107, P685
   PEETERS CCAM, 1991, IMMUNOL LETT, V30, P267, DOI 10.1016/0165-2478(91)90036-A
   RILEY ID, 1986, LANCET, V2, P877
   ROBINS JB, 1983, J INFECT DIS, V38, P64
   RUSSELL H, 1990, J CLIN MICROBIOL, V28, P2191
   Sampson JS, 1997, INFECT IMMUN, V65, P1967
   Shann F, 1998, LANCET, V351, P1600, DOI 10.1016/S0140-6736(05)77683-2
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Shann F, 1999, LANCET S2, V354, P7
   SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007
   STEINHOFF MC, 1994, PEDIATR INFECT DIS J, V13, P368, DOI 10.1097/00006454-199405000-00007
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
   Tharpe JA, 1996, CLIN DIAGN LAB IMMUN, V3, P227
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I
   VELLA PP, 1992, INFECT IMMUN, V60, P4977
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   WARD JI, 1992, INT C ANT AG CHEM IC
   WATSON DA, 1993, CLIN INFECT DIS, V17, P913
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   WEISTEIN L, 1974, PATHOPHYSIOLOGIC PHY, P389
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   WHITTLE HC, 1989, IMMUNOL TODAY, V10, P421
   *WHO, 1998, WHOVRDGEN9801
   Zangwill KM, 1996, J INFECT DIS, V174, P752
NR 70
TC 15
Z9 16
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD MAR 25
PY 2000
VL 75
IS 2
BP 141
EP 153
DI 10.1016/S0001-706X(99)00094-7
PG 13
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 294JE
UT WOS:000085907500001
PM 10708654
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Akinbamijo, OO
   Goossens, B
AF Osaer, S
   Akinbamijo, OO
   Goossens, B
TI Some biochemical changes following Trypanosoma congolense infection in
   Djallonke ewe lambs and breeding ewes fed on two levels of nutrition
SO ACTA TROPICA
LA English
DT Article
DE Trypanosoma congolense infection; Djallonke ewe lambs; nutrition
ID WEST-AFRICAN DWARF; SCOTTISH BLACKFACE SHEEP; VIVAX INFECTION;
   REPRODUCTIVE-PERFORMANCE; NITROGEN-METABOLISM; FEED-INTAKE; GOATS;
   PATHOPHYSIOLOGY; ENERGY; CATTLE
AB The effects of artificial Trypanosoma congolense infection and dietary level on biochemical changes were observed in 24 ewe lambs (Experiment 1) and 42 breeding ewes (Experiment 2). All animals belonged to the Djallonke breed which is known to be trypanotolerant. For both experiments, there were four treatment combinations, of which two were kept on a restricted diet (L), the other two on an at libitum diet (H). Half of each dietary group was infected with T. congolense (LI, HI), while the remainder served as uninfected controls (LC, HC). Artificial T. congolense infection took place at the age of 200 +/- 7 days in Experiment 1 and at the peak of oestrus in Experiment 2. Irrespective of dietary levels offered, total proteins in lambs and ewes and albumin in lambs declined significantly (P < 0.001) post infection. Plasma glucose concentration was reduced by the low dietary level and not by infection. Although plasma urea concentrations were slightly increased in the infected ewe lambs, adult ewes in the HI group demonstrated increased plasma urea concentrations (P < 0.05) due to an interaction between infection and diet. Neither infection nor the imposed diet induced significant changes on plasma creatinine concentrations. Transitory peaks in non-esterified fatty acids (NEFA) and beta-hydroxy butyric acid (BHBA) levels in infected ewes on low dietary level indicated temporary changes in the energy metabolism of the host. It was concluded from this study that, inspite of their trypanotolerance, Djallonke lambs and ewes demonstrated an infection effect on host metabolism pattern due to I: congolense infection. These changes reflected to some extent trypanosome-induced alteration of the nutrient metabolism, which could not always be negated by diet supplements. Nutrition, as an independent factor, did confer added benefits against the debilitating effects of trypanosomosis under the conditions of the present study. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ABOTT EM, 1986, VET PARASITOL, V20, P291
   Agricultural and Food Research Council, 1993, EN PROT REQ RUM ADV
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   ANOSA VO, 1976, TROP ANIM HLTH PROD, V8, P11
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   KATUNGUKARWAKISHAYA E, 1992, VET PARASITOL, V45, P17, DOI 10.1016/0304-4017(92)90024-4
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MCDONALD P, 1978, ANIMAL NUTR
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NIELSEN K, 1978, IMMUNOLOGY, V35, P811
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   OSAER S, 1998, VET PARASITOL, V80, P215
   Romney DL, 1997, J AGR SCI, V129, P83, DOI 10.1017/S0021859697004449
   Snedecor G. W., 1980, STAT METHODS
   *STAT AN SYST I, 1989, VER 6 11
   van Dam JTP, 1998, LIVEST PROD SCI, V53, P81, DOI 10.1016/S0301-6226(97)00127-9
   vanDam JTP, 1996, ANIM SCI, V63, P111
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   Wassink GJ, 1997, ANIM SCI, V64, P127
   WELLDE B, 1974, EXP PARASITOL, V36, P6, DOI 10.1016/0014-4894(74)90107-6
   ZWART D, 1991, J ANIM SCI, V69, P3780
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD MAR 25
PY 2000
VL 75
IS 2
BP 229
EP 241
DI 10.1016/S0001-706X(00)00060-7
PG 13
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 294JE
UT WOS:000085907500010
PM 10708663
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   O'Donovan, D
   Alabi, AS
   Milligan, P
   Yamuah, LK
   N'Gom, PT
   Harding, E
   Ariyoshi, K
   Wilkins, A
   Whittle, HC
AF Ota, MOC
   O'Donovan, D
   Alabi, AS
   Milligan, P
   Yamuah, LK
   N'Gom, PT
   Harding, E
   Ariyoshi, K
   Wilkins, A
   Whittle, HC
TI Maternal HIV-1 and HIV-2 infection and child survival in The Gambia
SO AIDS
LA English
DT Article
DE HIV-1 and HIV-2; perinatal HIV transmission; proviral load; survival
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DISEASE PROGRESSION; VIRAL LOAD; INFANTS;
   TRANSMISSION; WOMEN; ZAIRE
AB Objective: To compare the survival of children born to HIV-1 or HIV-2 seropositive mothers with that of children born to HIV-seronegative mothers and to evaluate risk factors for mortality.
   Design: Physician-blinded prospective study.
   Methods: One hundred and one HIV-1-seropositive, 243 HIV-2-seropositive pregnant women, and 468 HIV-seronegative women (control group) matched by age, parity, and health centre, were followed up in a study of mother-to-child transmission of HIV. Mothers and children were seen at 2 and 6 months of age and subsequently followed at 3-monthly intervals up to 18 months of age. HIV infection in children was diagnosed by polymerase chain reaction at 2, 9 or 18 months and by antibody assays at 18 months.
   Results: Fifteen per cent of children born to HIV-l-infected mothers died compared with 7% of children born to HIV-2-infected mothers [hazard ratio, 2.3; 95% confidence interval (CI), 1.1-4.7; P = 0.02], and 6% of HIV-seronegative mothers (hazard ratio, 2.6; 95% Cl, 1.4-5.0; P = 0.003). Six of the 17 children known to be HIV-1 infected died compared with none among the eight HIV-2-infected children (P = 0.13). High proviral load in the babies, high antenatal maternal RNA plasma viral load, and maternal death increased child mortality significantly.
   Conclusions: More children born to HIV-l-infected mothers died in comparison with those born to HIV-2-infected mothers or to mothers from the control group. This effect was due to excess death in HIV-l-infected infants which was associated with a high viral load in the affected mother and child. (C) 2000 Lippincott Williams & Wilkins.
C1 Med Res Council Labs, Banjul, Gambia.
RP Ota, MOC (reprint author), Med Res Council Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Abrams EJ, 1998, J INFECT DIS, V178, P101
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502
   Boerma JT, 1998, AIDS, V12, pS3
   Faye A, 1997, J PEDIATR-US, V130, P994, DOI 10.1016/S0022-3476(97)70290-7
   GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635
   LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004
   Lambert G, 1997, J PEDIATR-US, V130, P890, DOI 10.1016/S0022-3476(97)70274-9
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501
   RYDER RW, 1994, AIDS, V8, P673, DOI 10.1097/00002030-199405000-00015
   Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901
   TAHA TET, 1996, AIDS, V10, P112
   *US AG INT DEV, 1990, CHILD SURV 5 REP C U
   VALLEROY LA, 1990, AIDS, V4, P667, DOI 10.1097/00002030-199007000-00010
   WHITTLE H, 1994, AIDS, V8, P1021
   [Anonymous], 1995, WORLD HLTH REP 1995
NR 17
TC 26
Z9 27
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAR 10
PY 2000
VL 14
IS 4
BP 435
EP 439
DI 10.1097/00002030-200003100-00018
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 298TT
UT WOS:000086155800018
PM 10770547
OA No
DA 2017-08-15
ER

PT J
AU O'Donovan, D
   Ariyoshi, K
   Milligan, P
   Ota, M
   Yamuah, L
   Sarge-Njie, R
   Whittle, H
AF O'Donovan, D
   Ariyoshi, K
   Milligan, P
   Ota, M
   Yamuah, L
   Sarge-Njie, R
   Whittle, H
TI Maternal plasma viral RNA levels determine marked differences in
   mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia
SO AIDS
LA English
DT Article
DE mother-to-child transmission; HIV-1; HIV-2; Gambia; plasma virus; CD4
   cell count; vertical transmission
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VITAMIN-A-DEFICIENCY; INFANT-MORTALITY;
   GUINEA-BISSAU; COTE-DIVOIRE; WEST-AFRICA; INFECTION; MALARIA; ABIDJAN;
   TRIAL
AB Objectives: To determine the rates of, and risk factors for,mother-to-child transmission (MCT) of HIV-1 and HIV-2 infection in The Gambia.
   Design: A blinded, prospective, community-based cohort study of 29 549 pregnant women attending the eight largest antenatal clinics in The Gambia.
   Methods: Women were tested for HIV-1 and HIV-2 infection. infected subjects and a group of HIV-seronegative women were followed with their babies until 18 months after delivery. Maternal CD4 cell count percentages were measured before and 18 months after delivery, and the antenatal plasma viral load was determined. Babies were tested for HIV by the polymerase chain reaction and/or serology at 2, 9 and 18 months of age.
   Results: The study enrolled 144 women positive for HIV-1 and 294 for HIV-2 plus 565 seronegative pregnant women: the mean antenatal percentage CD4 cell counts of 96 HIV-1-positive, 223 HIV-2-positive and 125 HIV-seronegative mothers were 31% [95% confidence interval (Cl) 28-33], 41% (95% CI 39-42) and 47% (95% CI 45-49), respectively. The geometric mean antenatal plasma viral load of 94 HIV-1-infected women was 15 100 copies x 10(3)ml (95% Cl 10 400-19 000) which was much higher than that of 60 randomly selected HIV-2-infected women, which was 410 copies x 10(3)ml (95% CI 150-910) (P<0.001). The estimated transmission rate of HIV-1 was 24.4% (95% Cl 14.6-33.9) and that of HIV-2 was 4.0% (95% CI 1.9-7.4). Five of 17 HIV-1-positive and three of eight HIV-2-positive babies were infected after 2 months of age. Birth in the rainy season [odds ratio (OR) 2.9; 95% CI 1.2-7.2], a low postnatal CD4 cell percentage (OR for a 10% fail 2.4; 95% Cl 1.1-5.1) and a high maternal plasma viral load (OR for a 10-fold increase 2.9; 95% Cl 1.1-7.8) were risk factors for transmission that applied equally to both viruses.
   Conclusion: Low maternal HIV-2 RNA levels, which on average are 37-fold less than in HIV-1 infection, relate to the low MCT rate of HIV-2. (C) 2000 Lippincott Williams & Wilkins.
C1 MRC Labs, Banjul, Gambia.
RP Whittle, H (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI O'Donovan, Diarmuid/G-9253-2011; Milligan, Paul/D-8985-2017
OI O'Donovan, Diarmuid/0000-0001-8771-7271; Milligan,
   Paul/0000-0003-3430-3395
CR ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   ANDREASSON PA, 1993, AIDS, V7, P989
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5
   BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009
   Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009
   BULTERYS M, 1993, AIDS, V7, P1639, DOI 10.1097/00002030-199312000-00015
   COPAS JB, 1995, J R STAT SOC B, V57, P221
   DABIS F, 1992, AIDS, V7, P1139
   DATTA P, 1994, J INFECT DIS, V170, P1134
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599
   Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6
   Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X
   GRAHAM MI, 1999, LANCET, V353, P836
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Hoffman IF, 1999, AIDS, V13, P87
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6
   LUNN PG, 1980, LANCET, V1, P623
   Marseille E, 1999, LANCET, V354, P803
   MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506
   MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3
   N'Gom PT, 1997, BRIT J BIOMED SCI, V54, P251
   NDUATI RW, 1995, J INFECT DIS, V172, P1461
   NEWELL ML, 1992, LANCET, V339, P1007
   Newell ML, 1996, AIDS, V10, P1675
   *NUM ALG GROUP, 1996, NUM ALG GROUP NAG FO
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   RYDER RW, 1989, NEW ENGL J MED, V320, P637
   SEMBA RD, 1995, CLIN INFECT DIS, V21, P966
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   Stata Corp, 1997, STAT STAT SOFTW REL
   TAHA TET, 1996, AIDS, V10, P112
   WEISER B, 1994, P NATL ACAD SCI USA, V91, P8031
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   WITKOR SZ, 1997, AIDS SB, V11, pS79
NR 41
TC 94
Z9 97
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAR 10
PY 2000
VL 14
IS 4
BP 441
EP 448
DI 10.1097/00002030-200003100-00019
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 298TT
UT WOS:000086155800019
PM 10770548
OA No
DA 2017-08-15
ER

PT J
AU Thwaites, G
   Chau, TTH
   Mai, NTH
   Drobniewski, F
   McAdam, K
   Farrar, J
AF Thwaites, G
   Chau, TTH
   Mai, NTH
   Drobniewski, F
   McAdam, K
   Farrar, J
TI Tuberculous meningitis
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Review
ID LINKED IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; SHORT-COURSE
   CHEMOTHERAPY; TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS;
   NERVOUS-SYSTEM TUBERCULOSIS; LUCIFERASE REPORTER PHAGES;
   CEREBROSPINAL-FLUID; MYCOBACTERIUM-TUBERCULOSIS; RAPID DIAGNOSIS
C1 St Thomas Hosp, Dept Microbiol, London SE1 7EH, England.
   Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam.
   Univ London Kings Coll, Sch Med, PHLS Mycobacterium Reference Unit, London SE5 9PJ, England.
   Med Res Council Labs, Banjul, Gambia.
   Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford OX1 2JD, England.
RP Thwaites, G (reprint author), St Thomas Hosp, Dept Microbiol, London SE1 7EH, England.
OI Thwaites, Guy/0000-0002-2858-2087
CR AFGHANI B, 1994, CLIN INFECT DIS, V19, P1092
   AHUJA GK, 1994, TUBERCLE LUNG DIS, V75, P149, DOI 10.1016/0962-8479(94)90045-0
   ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403
   Arvanitakis Z, 1998, NEUROLOGY, V50, P1827
   ASHBY M, 1955, LANCET, V1, P65
   BAIG SM, 1995, J CLIN MICROBIOL, V33, P3040
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004
   BHARGAVA S, 1982, BRIT J RADIOL, V55, P189
   BISHBURG E, 1986, ANN INTERN MED, V105, P210
   Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008
   Bonington A, 1998, J CLIN MICROBIOL, V36, P1251
   BROOKS JB, 1990, J CLIN MICROBIOL, V28, P989
   BULLOCK MRR, 1982, J NEUROL NEUROSUR PS, V45, P1098, DOI 10.1136/jnnp.45.12.1098
   Carriere C, 1997, J CLIN MICROBIOL, V35, P3232
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Cole ST, 1998, NATURE, V393, P537
   COLLINS DM, 1995, P NATL ACAD SCI USA, V92, P8036, DOI 10.1073/pnas.92.17.8036
   Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4
   DAMATO RF, 1995, J CLIN MICROBIOL, V33, P1832
   DANNENBERG AM, 1991, IMMUNOL TODAY, V12, P228, DOI 10.1016/0167-5699(91)90035-R
   DASTUR DK, 1995, RADIOL CLIN N AM, V33, P733
   DASTUR DK, 1966, ACTA NEUROPATHOL, V6, P311
   DAVIS LE, 1993, NEUROLOGY, V43, P1775
   DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.268.12.1581
   DEMARCHAYUELA P, 1994, TUBERCLE LUNG DIS, V75, P423, DOI 10.1016/0962-8479(94)90115-5
   DONALD PR, 1995, CLIN INFECT DIS, V21, P924
   DONALD PR, 1989, J PEDIATR-US, V115, P483, DOI 10.1016/S0022-3476(89)80862-5
   Donald PR, 1998, INT J TUBERC LUNG D, V2, P704
   Dooley DP, 1997, CLIN INFECT DIS, V25, P872, DOI 10.1086/515543
   Drobniewski F, 1997, SEM RESP CRIT CARE M, V18, P419, DOI 10.1055/s-2007-1009357
   Drobniewski FA, 1998, J MED MICROBIOL, V47, P189
   DUBE MP, 1992, AM J MED, V93, P520, DOI 10.1016/0002-9343(92)90579-Z
   ELLARD GA, 1993, AM REV RESPIR DIS, V148, P650
   Eltringham IJ, 1999, J CLIN MICROBIOL, V37, P3528
   Eltringham IJ, 1999, J CLIN MICROBIOL, V37, P3524
   EMOND RTD, 1973, LANCET, V2, P234
   ESCOBAR JA, 1975, PEDIATRICS, V56, P1050
   FALCOW S, 1988, REV INFECT DIS, V10, pS274
   FARER LS, 1979, AM J EPIDEMIOL, V109, P205
   FILLEY EA, 1991, INFECT IMMUN, V59, P2567
   FORGANSMITH R, 1973, LANCET, V2, P374
   GILLESPIE SH, 1997, PRINCIPLES PRACTICE
   GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002
   GOEL A, 1990, NEUROSURGERY, V27, P418
   GREEN PH, 1836, LANCET, V2, P232
   Gulati P D, 1970, J Assoc Physicians India, V18, P281
   HEILMAN DH, 1945, AM J MED SCI, V210, P567
   HOPEWELL PC, 1994, TUBERCULOSIS PATHOGE
   HSIEH FY, 1992, NEURORADIOLOGY, V34, P197
   HUMPHRIES M, 1992, THORAX, V47, P577, DOI 10.1136/thx.47.8.577
   HUMPHRIES MJ, 1990, TUBERCLE, V71, P161, DOI 10.1016/0041-3879(90)90069-K
   HUMPHRIES MJ, 1994, CLIN TUBERCULOSIS
   ILLINGWORTH RS, 1956, LANCET, V2, P646
   JACOBS RF, 1992, PEDIATR INFECT DIS J, V11, P194, DOI 10.1097/00006454-199203000-00004
   JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123
   JENKINS PA, 1994, CLIN TUBERCULOSIS
   JEREN T, 1982, ACTA CYTOL, V26, P678
   KADIVAL GV, 1986, J CLIN MICROBIOL, V23, P901
   KALISH SB, 1983, ANN INTERN MED, V99, P630
   KAOJARERN S, 1991, CLIN PHARMACOL THER, V49, P6
   Karstaedt AS, 1998, QJM-MON J ASSOC PHYS, V91, P743, DOI 10.1093/qjmed/91.11.743
   KENDIG EL, 1960, AM REV RESPIR DIS, V82, P672
   KENNEDY DH, 1979, JAMA-J AM MED ASSOC, V241, P264, DOI 10.1001/jama.241.3.264
   KENT SJ, 1993, CLIN INFECT DIS, V17, P987
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4
   KOCH R, 1882, BER KLIN WOCHENSCHR, V19, P2211
   Kox LFF, 1995, NEUROLOGY, V45, P2228
   KRAMBOVITIS E, 1984, LANCET, V2, P1229
   Lang AM, 1998, J CLIN MICROBIOL, V36, P2191
   Lein AD, 1997, AM J MED SCI, V313, P364, DOI 10.1097/00000441-199706000-00009
   Leonard J M, 1990, Infect Dis Clin North Am, V4, P769
   LIN JJ, 1995, J NEUROL, V242, P147, DOI 10.1007/BF00936887
   LINCOLN EM, 1960, J PEDIATR-US, V57, P807, DOI 10.1016/S0022-3476(60)80132-1
   LOPEZCORTES LF, 1995, CLIN INFECT DIS, V20, P525
   LORBER J, 1960, BRIT MED J, V1, P1309
   LU CZ, 1990, LANCET, V336, P10, DOI 10.1016/0140-6736(90)91519-G
   Lurie M.B., 1964, RESISTANCE TUBERCULO
   MARDH PA, 1983, LANCET, V1, P367
   Marshall BG, 1998, J INFECTION, V36, P3, DOI 10.1016/S0163-4453(98)92838-9
   MATHAI A, 1994, J INFECTION, V29, P33, DOI 10.1016/S0163-4453(94)95006-7
   Misra UK, 1996, J NEUROL SCI, V137, P57, DOI 10.1016/0022-510X(95)00334-X
   MORI MA, 1992, ARCH INTERN MED, V152, P547, DOI 10.1001/archinte.152.3.547
   MRC, 1948, LANCET, V1, P582
   Mukamolova GV, 1998, P NATL ACAD SCI USA, V95, P8916, DOI 10.1073/pnas.95.15.8916
   NAU R, 1992, J ANTIMICROB CHEMOTH, V29, P719, DOI 10.1093/jac/29.6.719
   NEWMAN PK, 1980, J NEUROL NEUROSUR PS, V43, P188, DOI 10.1136/jnnp.43.2.188
   Nguyen LN, 1996, ARCH NEUROL-CHICAGO, V53, P771
   Orme IM, 1998, TRENDS MICROBIOL, V6, P94, DOI 10.1016/S0966-842X(98)01209-8
   Ormerod P, 1998, THORAX, V53, P536
   PablosMendez A, 1997, AM J PUBLIC HEALTH, V87, P574, DOI 10.2105/AJPH.87.4.574
   PALUR R, 1991, J NEUROSURG, V74, P64, DOI 10.3171/jns.1991.74.1.0064
   PARSONS M, 1979, TUBERCULOUS MENINGIT
   PHUAPRADIT P, 1987, Q J MED, V62, P249
   RADHAKRISHNAN VV, 1990, J MED MICROBIOL, V33, P223
   RAMACHANDRAN P, 1986, TUBERCLE, V67, P17, DOI 10.1016/0041-3879(86)90028-0
   RAMACHANDRAN P, 1989, TUBERCLE, V70, P17
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   RIBERA E, 1987, J INFECT DIS, V155, P603
   Rich AR, 1933, B JOHNS HOPKINS HOSP, V52, P5
   ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O
   SADA E, 1983, LANCET, V2, P651
   Schoeman JF, 1997, PEDIATRICS, V99, P226, DOI 10.1542/peds.99.2.226
   SELWYN PA, 1989, NEW ENGL J MED, V320, P345
   SHANKAR P, 1991, LANCET, V337, P5, DOI 10.1016/0140-6736(91)93328-7
   SHARIEF MK, 1992, J INFECT DIS, V166, P350
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   SMITH HV, 1954, BRIT MED BULL, V10, P140
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   TANDON PN, 1985, TUBERCLE, V66, P85, DOI 10.1016/0041-3879(85)90073-X
   Tartaglione Tommaso, 1998, Rays (Rome), V23, P164
   Tsenova L, 1998, J INFECT DIS, V177, P1563, DOI 10.1086/515327
   UDANI PM, 1970, J NEUROL SCI, V10, P541, DOI 10.1016/0022-510X(70)90187-5
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001
   Verdon R, 1996, CLIN INFECT DIS, V22, P982
   WATT G, 1988, J INFECT DIS, V158, P681
   World Health Organization, 1998, WORLD HLTH REP
   WILKINS EGL, 1990, LANCET, V336, P641, DOI 10.1016/0140-6736(90)92144-7
   Wilson SM, 1997, NAT MED, V3, P465, DOI 10.1038/nm0497-465
   WOOD PR, 1994, VET MICROBIOL, V40, P125, DOI 10.1016/0378-1135(94)90051-5
   Yechoor VK, 1996, ARCH INTERN MED, V156, P1710, DOI 10.1001/archinte.156.15.1710
NR 121
TC 138
Z9 154
U1 0
U2 6
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAR
PY 2000
VL 68
IS 3
BP 289
EP 299
DI 10.1136/jnnp.68.3.289
PG 11
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 286YY
UT WOS:000085477500006
PM 10675209
OA No
DA 2017-08-15
ER

PT J
AU Goetghebuer, T
   West, TE
   Wermenbol, V
   Cadbury, AL
   Milligan, P
   Lloyd-Evans, N
   Adegbola, RA
   Mulholland, EK
   Greenwood, BM
   Weber, MW
AF Goetghebuer, T
   West, TE
   Wermenbol, V
   Cadbury, AL
   Milligan, P
   Lloyd-Evans, N
   Adegbola, RA
   Mulholland, EK
   Greenwood, BM
   Weber, MW
TI Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus
   influenzae type b in children in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE meningitis; Streptococcus pneumoniae; Haemophilus influenzae; developing
   countries; children
ID LONG-TERM SEQUELAE; BACTERIAL-MENINGITIS; WEST-AFRICA; PNEUMOCOCCAL
   MENINGITIS; RISK-FACTORS; RURAL AREA; DEXAMETHASONE; DISEASE; MORTALITY;
   THERAPY
AB In developing countries, endemic childhood meningitis is a severe disease caused most commonly by Streptococcus pneumoniae or Haemophilus influenzae type b (Hib). Although many studies have shown that fatality rates associated with meningitis caused by these organisms are high in developing countries, little is known about the long-term outcome of survivors. The purpose of this study was to assess the importance of disabilities following pneumococcal and Hib meningitis in The Gambia. 257 children aged 0-12 years hospitalized between 1990 and 1995 with culture-proven S. pneumoniae (n = 134) or Hib (n = 123) meningitis were included retrospectively in the study. 48% of children with pneumococcal meningitis and 27% of children with Hib meningitis died whilst in hospital. Of the 160 survivors, 89 (55%) were followed up between September 1996 and October 1997. Of the children with pneumococcal meningitis that were traced, 58% had clinical sequelae; half of them had major disabilities preventing normal adaptation to social life. 38% of survivors of Hib meningitis had clinical sequelae, a quarter of whom had major disabilities. Major handicaps found were hearing loss, mental retardation, motor abnormalities and seizures. These data show that despite treatment with effective antibiotics, pneumococcal and Hib meningitis kill many Gambian children and leave many survivors with severe sequelae. Hib vaccination is now given routinely in The Gambia; an effective pneumococcal vaccine is needed.
C1 MRC Labs, Fajara, Gambia.
RP Goetghebuer, T (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Akpede GO, 1999, ANN TROP PAEDIATR, V19, P151, DOI 10.1080/02724939992473
   BAIRD DR, 1976, LANCET, V2, P1344
   BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BOHR V, 1985, J INFECTION, V10, P143, DOI 10.1016/S0163-4453(85)91585-3
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128
   GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004
   GREENWOOD BM, 1984, REV INFECT DIS, V6, P374
   GREENWOOD BM, 1986, J INFECTION, V12, P49, DOI 10.1016/S0163-4453(86)94891-7
   Grimwood K, 1996, J PAEDIATR CHILD H, V32, P457, DOI 10.1111/j.1440-1754.1996.tb00949.x
   HAILEMESKEL H, 1978, ACTA PAEDIATR SCAND, V67, P725, DOI 10.1111/j.1651-2227.1978.tb16250.x
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   KILPI T, 1995, PEDIATR INFECT DIS J, V14, P270, DOI 10.1097/00006454-199504000-00005
   LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502
   LINDBERG J, 1977, PEDIATRICS, V60, P1
   Macaluso A, 1996, ANN TROP PAEDIATR, V16, P193
   MBELLE N, 1997, 37 INT C ANT AG CHEM
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402
   SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003
   SELL SH, 1987, PEDIATR INFECT DIS J, V6, P775, DOI 10.1097/00006454-198708000-00035
   SHANN F, 1985, LANCET, V28, P681
   WHITTLE HC, 1973, BMJ-BRIT MED J, V3, P379
   *WHO, 1998, WHOCHD985
   *WHO, 1998, M 18 20 JUN 1997 GEN
   1993, 1993 POPULATION HOUS
NR 33
TC 67
Z9 72
U1 5
U2 9
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2000
VL 5
IS 3
BP 207
EP 213
DI 10.1046/j.1365-3156.2000.00535.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 300WG
UT WOS:000086276300009
PM 10747284
OA No
DA 2017-08-15
ER

PT J
AU Gosling, R
   Walraven, G
   Manneh, F
   Bailey, B
   Lewis, SM
AF Gosling, R
   Walraven, G
   Manneh, F
   Bailey, B
   Lewis, SM
TI Training health workers to assess anaemia with the WHO haemoglobin
   colour scale
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE anaemia; antenatal; screening; diagnosis; Africa; haemoglobin; field
   evaluation; training; community health nurses
ID MATERNAL MORTALITY; HEMOGLOBIN; ANEMIA
AB WHO recommends that all pregnant women be screened for anaemia. In rural Africa this is often done by clinical examination which is known to have variable reliability. The recently developed WHO Haemoglobin Colour Scale may be the answer to this problem as it is simple and reliable. This study examines the training procedure recommended by WHO for the Haemoglobin Colour Scale when resources are very limited. We trained 7 laboratory technicians from the Medical Research Council Laboratories Hospital, Fajara, The Gambia and 13 Community Health Nurses (CHNs) from North Bank Division East, a rural area in The Gambia, to use the Colour Scale. The CHNs used the Scale to estimate haemoglobins on all new bookings to the antenatal clinics for a period of one month and recorded how they were managed. At the end of the study period they completed a qualitative questionnaire about the scale. Both groups of trainees were successfully trained although the WHO protocol for training was impossible to follow due to resource limitations. Eight of the 13 trained CHNs used the scale in practice and recorded 307 estimations with a mean haemoglobin of 9.1 g/dl. The results were normally distributed. Six of the 9 patients with Hb readings of < 4 g/dl were managed correctly. In response to the questionnaire the CHNs thought the scale was cheap, easy and quick to use and as good as the haemoglobinometer they had used previously. The main criticism was that it was not robust enough. The development of a low-technology, cheap, simple and reliable method for measuring haemoglobin is a welcome development. However, a simpler training procedure and a standard way of measuring observer performance are necessary.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Hammersmith Hosp, WHO, Collaborating Ctr Haematol, London, England.
   MRC, Farafenni Field Stn, Banjul, Gambia.
   Dist Hlth Team, N Bank District E, Gambia.
RP Gosling, R (reprint author), 10 Kemplay Rd, London NW3 1SY, England.
CR Ekunwe E O, 1997, West Afr J Med, V16, P246
   GOSLING R, 1998, THESIS LONDON SCH HY
   Harrison Kelsey A., 1985, BR J OBSTET GYNAE S5, V92, P100
   Hoestermann CFL, 1996, TROP MED INT HEALTH, V1, P710
   Kalter HD, 1997, B WORLD HEALTH ORGAN, V75, P103
   Munster M, 1997, S AFR MED J, V87, P1522
   Rooney C., 1992, WHOMSM924
   Sheth TN, 1997, J GEN INTERN MED, V12, P102, DOI 10.1007/s11606-006-5004-x
   STOTT GJ, 1995, B WORLD HEALTH ORGAN, V73, P369
   van den Broek NR, 1999, B WORLD HEALTH ORGAN, V77, P15
   WALRAVEN GEL, 1994, BRIT J OBSTET GYNAEC, V101, P414, DOI 10.1111/j.1471-0528.1994.tb11914.x
   WARAPA FK, 1986, J TROP MED HYG, V89, P33
   World Health Organization, 1997, WORLD HLTH REP CONQ
   WHO, 1994, WHOFHEMSM9411
NR 14
TC 12
Z9 14
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2000
VL 5
IS 3
BP 214
EP 221
DI 10.1046/j.1365-3156.2000.00533.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 300WG
UT WOS:000086276300010
PM 10747285
OA No
DA 2017-08-15
ER

PT J
AU Zinsstag, J
   Ankers, P
   Njie, M
   Itty, P
   Monsan, V
   Kaufmann, J
   Smith, T
   Pandey, VS
   Pfister, K
AF Zinsstag, J
   Ankers, P
   Njie, M
   Itty, P
   Monsan, V
   Kaufmann, J
   Smith, T
   Pandey, VS
   Pfister, K
TI Effect of strategic gastrointestinal nematode control on faecal egg
   count in traditional West African cattle
SO VETERINARY RESEARCH
LA English
DT Article
DE gastrointestinal nematodes; N'Dama cattle; faecal egg count; strategic
   control; fenbendazole
ID NDAMA CATTLE; OSTERTAGIA-OSTERTAGI; LIVESTOCK PRODUCTION; GAMBIA;
   INFECTIONS; EPIDEMIOLOGY; TRYPANOTOLERANCE; SENEGAL; MODELS; SEASON
AB This paper reports on the effect of strategic anthelmintic treatments and other determinants on faecal egg counts (FEC) of Trichostrongyles in N'Dama cattle of a west African village. Initially, 527 animals from 13 private N'Dama cattle herds were monitored in a longitudinal study from October 1989 to December 1994. Each herd was stratified by age and animals were sequentially allocated to two groups with similar age distributions. One group received a single anthelmintic treatment of fenbendazole (7.5 mg/kg BW), in October 1989 (n = 250), whereas the other group remained untreated (n = 277) throughout the study. In the next rainy season (June to October), the treated animals were treated twice tin July and September). The same treatment schedule was used in the subsequent rainy seasons until December 1994. Biannual anthelmintic treatments decreased the level of FEC between 31% (late dry season) and 57% (rainy season), when compared to untreated controls. The highest levels of FEC were found during the rainy season from June to October. FEC levels decreased until 4 years of age, after which they remained on a constant low level. The variability of returns to anthelmintic treatments between herds did not seem to be influenced by FEC at the herd level. The financial evaluation of anthelmintic interventions cannot be predicted from FEC and must necessarily rely on the direct monitoring of livestock productivity parameters.
C1 Swiss Trop Inst, CH-4002 Basel, Switzerland.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   ETH Zurich, Swiss Ctr Int Agr ZIL, CH-8092 Zurich, Switzerland.
   Univ Cocody, UFR Math & Informat, Abidjan 22, Cote Ivoire.
   Swiss Embassy, Washington, DC 20008 USA.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Neuchatel, Dept Zool, CH-2000 Neuchatel, Switzerland.
RP Zinsstag, J (reprint author), Swiss Trop Inst, POB 4002, CH-4002 Basel, Switzerland.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR Boch J., 1983, VETERINARMEDIZINISCH
   d'Ieteren GDM, 1998, REV SCI TECH OIE, V17, P154
   Dorchies P, 1998, PARASITOL TODAY, V14, P468, DOI 10.1016/S0169-4758(98)01303-9
   Fall A, 1999, VET PARASITOL, V81, P235, DOI 10.1016/S0304-4017(98)00213-1
   GRONVOLD J, 1992, ACTA VET SCAND, V33, P305
   HORCHNER F, 1990, TROP MED PARASITOL, V41, P422
   Itty P, 1997, PREV VET MED, V32, P299, DOI 10.1016/S0167-5877(97)00033-0
   Itty P, 1992, EC VILLAGE CATTLE PR
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1995, TROP ANIM HEALTH PRO, V27, P76, DOI 10.1007/BF02236314
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   Kemp SJ, 1998, PARASITOL TODAY, V14, P450, DOI 10.1016/S0169-4758(98)01334-9
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   NDAO M, 1995, VET RES, V26, P132
   NDAO M, 1995, VET PARASITOL, V60, P161, DOI 10.1016/0304-4017(94)00771-4
   OUATTARA L, 1992, DTSCH STIFTUNG INT E, V2, P497
   PALING RW, 1993, VET Q, V15, P6067
   PANDEY VS, 1995, HELMINTHOLOGIA, V32, P151
   PLOEGER HW, 1990, VET PARASITOL, V36, P57, DOI 10.1016/0304-4017(90)90094-R
   SAS Institute Inc, 1996, SAS STAT SOFTW CHANG
   SMITH G, 1988, VET PARASITOL, V27, P73, DOI 10.1016/0304-4017(88)90063-5
   Smothers CD, 1999, VET PARASITOL, V81, P211, DOI 10.1016/S0304-4017(98)00206-4
   Zinsstag J, 1997, VET PARASITOL, V73, P105, DOI 10.1016/S0304-4017(97)80001-5
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
   Zinsstag J, 1997, VET PARASITOL, V68, P143, DOI 10.1016/S0304-4017(96)01024-2
NR 25
TC 6
Z9 7
U1 1
U2 2
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0928-4249
J9 VET RES
JI Vet. Res.
PD MAR-APR
PY 2000
VL 31
IS 2
BP 259
EP 266
PG 8
WC Veterinary Sciences
SC Veterinary Sciences
GA 309BM
UT WOS:000086747500007
PM 10779204
OA No
DA 2017-08-15
ER

PT J
AU Lunn, PG
AF Lunn, PG
TI The impact of infection and nutrition on gut function and growth in
   childhood
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Summer Meeting of the Nutrition-Society
CY JUN 29-JUL 02, 1999
CL UNIV GLASGOW, GLASGOW, SCOTLAND
SP Nutr Soc
HO UNIV GLASGOW
DE malnutrition; gastrointestinal enteropathy; intestine; infants;
   translocation
ID INTESTINAL PERMEABILITY; LACTOSE MALDIGESTION; PERSISTENT DIARRHEA;
   GAMBIAN INFANTS; MALNUTRITION; SUPPLEMENTATION; CHILDREN; MILK
AB Poor growth performance during infancy and early childhood is a frequent fact of life in most developing countries. Work in The Gambia has demonstrated that more than 43 % of observed growth faltering during the first 15 months of life can be explained by the presence of a mucosal enteropathy in the small intestine. Within communities the illness is very common: in the area investigated more than 95 % of infants above 8 months of age were affected, and on average they suffered a growth-limiting enteropathy for more than 75 % of their first year of life. Two mechanisms of weight loss have been defined. First, partial villus atrophy reduces absorption and digestion of lactose and probably other nutrients. Second, and more importantly, damage to the mucosal barrier allows translocation of macromolecules into the mucosa and blood, triggering both local and systemic immune and inflammatory mechanisms. Given the severity of the enteropathy it is not surprising that infants fail to grow at a normal rate. Recent findings suggest that these lesions continue throughout childhood and into adulthood. Thus, a persistence of chronic, local and systemic inflammation throughout childhood may be responsible for continued poor growth during this period. Although the nature of the enteropathy and the mechanisms of growth failure have been defined, the factors involved in the initiation and persistence of the intestinal lesion remain uncertain, making clinical management difficult. More work is clearly required to elucidate these factors and to define interventions to prevent or treat the enteropathy.
C1 MRC, Keneba, Gambia.
RP Lunn, PG (reprint author), 21 Cowslip Dr, Ely CB6 3JD, Cambs, England.
CR BRASSEUR D, 1992, ANN PEDIATR-PARIS, V39, P87
   Brewster DR, 1997, ARCH DIS CHILD, V76, P242
   BRIEND A, 1989, LANCET, V2, P319
   CAMPBELL DI, 1999, IN PRESS J PEDIAT GA
   COLE TJ, 1977, T ROY SOC TROP MED H, V71, P196, DOI 10.1016/0035-9203(77)90005-0
   Dale A, 1998, J PEDIATR GASTR NUTR, V26, P393, DOI 10.1097/00005176-199804000-00006
   ELIA M, 1987, CLIN SCI, V73, P197
   ERINOSO HO, 1992, ANN TROP PAEDIATR, V12, P359
   Fagundes Neto U, 1994, J AM COLL NUTR, V13, P51
   FORD RPK, 1985, J PEDIATR GASTR NUTR, V4, P568, DOI 10.1097/00005176-198508000-00012
   HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607
   KUKURUZOVIC RH, 1999, IN PRESS ARCH DIS CH
   LEBENTHAL E, 1984, CHRONIC DIARRHOEA CH, V6, P31
   LUNN PG, 1979, BRIT J NUTR, V41, P73, DOI 10.1079/BJN19790014
   Lunn PG, 1999, J NUTR, V129, P872
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   LUNN PG, 1993, T ROY SOC TROP MED H, V87, P371
   Lunn PG, 1997, P NUTR SOC, V56, p280A
   MENZIES IS, 1974, BIOCHEM SOC T, V2, P1042
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   NOONE C, 1986, EUR J CLIN INVEST, V16, P217, DOI 10.1111/j.1365-2362.1986.tb01332.x
   NorthropClewes CA, 1997, J PEDIATR GASTR NUTR, V24, P257, DOI 10.1097/00005176-199703000-00005
   Prentice A., 1993, S AFR J CLIN NUTR, V6, P33
   PRENTICE A, 1990, HUMAN LACTATION, V4, P88
   Raj SM, 1996, T ROY SOC TROP MED H, V90, P666, DOI 10.1016/S0035-9203(96)90425-3
   ROY SK, 1992, J PEDIATR GASTR NUTR, V15, P289, DOI 10.1097/00005176-199210000-00010
   Scrimshaw N.S., 1988, AM J CLIN NUTR S, V48, P1086
   SULLIVAN PB, 1991, J PEDIATR GASTR NUTR, V12, P195, DOI 10.1097/00005176-199102000-00010
   SULLIVAN PB, 1992, J PEDIATR GASTR NUTR, V14, P208, DOI 10.1097/00005176-199202000-00016
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
NR 31
TC 91
Z9 94
U1 0
U2 7
PU C A B INTERNATIONAL
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, WALLINGFORD OX10 8DE, OXON, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD FEB
PY 2000
VL 59
IS 1
BP 147
EP 154
DI 10.1017/S0029665100000173
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 315HQ
UT WOS:000087107700017
PM 10828184
OA No
DA 2017-08-15
ER

PT J
AU Hill, AG
   MacLeod, WB
   Joof, D
   Gomez, P
   Ratcliffe, AA
   Walraven, G
AF Hill, AG
   MacLeod, WB
   Joof, D
   Gomez, P
   Ratcliffe, AA
   Walraven, G
TI Decline of mortality in children in rural Gambia: the influence of
   village-level Primary Health Care
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE infant mortality; childhood mortality; Primary Health Care; village
   health services; The Gambia
ID TRADITIONAL BIRTH ATTENDANTS; UPPER RIVER DIVISION; MALARIA
   CHEMOPROPHYLAXIS; IMPACT; MORBIDITY; PROGRAM; INTERVENTIONS;
   CHLOROQUINE; CHILDHOOD; PREGNANCY
AB Using data from a longitudinal study conducted in 40 villages by the UK MRC in the North Bank Division of The Gambia beginning in late 1981, we examined infant and child mortality over a 15-year period for a population of about 17 000 people. Comparisons are drawn between villages with and without PHC. The extra facilities in the PHC villages include: a paid Community Health Nurse for about every 5 villages, a Village Health Worker and a trained Traditional Birth Attendant. Maternal and child health services with a vaccination programme are accessible to residents in both PHC and non-PHC villages. The data indicate that there has been a marked improvement in infant and under-five mortality in both sets of villages. Following the establishment of the PHC system in 1983, infant morality dropped from 134/1000 in 1982-83 to 69/1000 in 1992-94 in the PHC villages and from 155/1000 to 91/1000 in the non-PHC villages over the same period. Between 1982 and 83 and 1992-94, the death rates for children aged 1-4 fell from 42/1000 to 28/1000 in the PHC villages and from 45/1000 to 38/1000 in the non-PHC villages. Since 1994, when supervision of the PHC system has weakened, infant mortality rates in the PHC villages have risen to 89/1000 in 1994-96. The rates in the non-PHC villages fell to 78/1000 for this period. The under-five mortality rates in both sets of villages have converged to 34/1000 for 1994-96. When the PHC programme was well supported in the 1980s, we saw significantly lower mortality rates for the 1-4-year-olds. These differences disappeared when support for PHC was reduced after 1994. The differential effects on infant mortality are less clear cut.
C1 Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Cambridge, MA 02138 USA.
   Dept State Hlth & Social Welf, Dist Hlth Team, Banjul, Gambia.
   MRC Labs, Farafenni Field Stn, Fajara, Gambia.
RP Hill, AG (reprint author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
CR ALLEN SJ, 1990, J TROP MED HYG, V93, P313
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   Becker S, 1996, POPUL DEV REV, V22, P431, DOI 10.2307/2137715
   BERGGREN WL, 1981, NEW ENGL J MED, V304, P1324, DOI 10.1056/NEJM198105283042203
   BOBADILLA JL, 1994, 1 WORLD BANK, V1
   BOERMA JT, 1993, DEMOGRAPHY, V30, P459, DOI 10.2307/2061651
   Chabot J, 1995, AFRICAN PRIMARY HLTH
   Cham K., 1987, Health Policy and Planning, V2, P214, DOI 10.1093/heapol/2.3.214
   CHAMBERS M, 1986, REPORT HOUSEHOLD SUR
   CHEN LC, 1993, INT J EPIDEMIOL, V22, pS73
   DEFRANCISCO A, 1994, J TROP MED HYG, V97, P69
   DELAUNAY V, 1998, SITUATION DEMOGRAPHI
   *DEP STAT HLTH SOC, 1998, PUBL EXP REV HLTH SE
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Ewbank DC, 1993, EFFECTS HLTH PROGRAM
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   HILL A, 1992, MORTALITY SOC SUBSAH
   Hill AG, 1998, LANCET, V352, P1909, DOI 10.1016/S0140-6736(05)60400-X
   HILL AG, 1996, REPORT LIVING STANDA
   *IBRD WORLD BANK, 1997, WORLD DEV REP 1997
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   KASONDE JM, 1994, EXPERIENCES PRIMARY
   MACLEOD WB, 1998, ANN C POP ASS AM CHI
   MACLEOD WB, 1998, MORTALITY ANAL EVALU, P3
   Magnani RJ, 1996, INT J EPIDEMIOL, V25, P568, DOI 10.1093/ije/25.3.568
   MARRA A, 1995, POPULATION SANTE NIA
   McGregor IA, 1991, DIS MORTALITY SUBSAH, P306
   MENENDEZ C, 1994, J TROP MED HYG, V97, P244
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   *MIN HLTH GAMB, 1993, MAN MAT CHILD HLTH S
   Mosley W H, 1988, Salud Publica Mex, V30, P312
   MOSLEY WH, 1991, HEALTH POLICY PLANN, V6, P218, DOI 10.1093/heapol/6.3.218
   MOSLEY WH, 1985, HLTH POLICY SOCIAL P
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   PACQUEMARGOLIS S, 1993, GAMBIA CONTRACEPTIVE
   RIFKIN SB, 1986, SOC SCI MED, V23, P559, DOI 10.1016/0277-9536(86)90149-8
   Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7
   UNICEF, 1998, STAT WORLDS CHILDR
   *UNICEF CENTR STAT, 1997, REP PROGR MIDD GOALS
   *UNICEF GAMB, 1997, SIT AN CHILDR WOM GA
   WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804
   *WHO, 1980, COUNTR RES UT REV GA
   WHO, 1978, HLTH ALL SER WHO, V1
   World Bank, 1993, WORLD DEV REP 1993 I
   World Bank, 1997, WORLD DEV REP 1997 S
   World Bank, 1994, BETT HLTH AFR
NR 50
TC 49
Z9 49
U1 2
U2 6
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2000
VL 5
IS 2
BP 107
EP 118
DI 10.1046/j.1365-3156.2000.00528.x
PG 12
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 300UM
UT WOS:000086271300007
PM 10747270
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Camus-Randon, AM
   Mendy, M
   Goedert, JJ
   Merle, P
   Trepo, C
   Brechot, C
   Hainaut, P
   Montesano, R
AF Kirk, GD
   Camus-Randon, AM
   Mendy, M
   Goedert, JJ
   Merle, P
   Trepo, C
   Brechot, C
   Hainaut, P
   Montesano, R
TI Ser-249 p53 mutations in plasma DNA of patients with hepatocellular
   carcinoma from the Gambia
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID HEPATITIS-B VIRUS; CANCER-PATIENTS; MICROSATELLITE ALTERATIONS;
   AFLATOXIN EXPOSURE; RAS MUTATIONS; CELL-LINES; GENE; HOTSPOT; RISK;
   CODON-249
AB Background: A selective mutation, an arginine-to-serine substitution in codon 249, of the p53 gene has been identified as a "hotspot" mutation in hepatocellular carcinoma (HCC), This mutation occurs in populations that are exposed to aflatoxins and have a high prevalence of hepatitis B virus carriers. We evaluated whether this mutation could be detected in cell-free DNA isolated from the plasma of subjects from The Gambia to detect this mutation that is strongly associated with HCC. Methods: Fifty-three patients with HCC, 13 patients with cirrhosis, and 53 control subjects were prospectively recruited from The Gambia, Sixty patients, of non-African origin, with various liver pathologies were also selected from France. DNA was extracted and purified from 200-mu L aliquots of plasma. The Ser-249 p53 mutation was detected by restriction endonuclease digestion of polymerase chain reaction products from exon 7 and was confirmed by direct sequencing of the amplified DNA, Results: The Ser-249 p53 mutation was detected in plasma DNA from 19 (36%) of the 53 patients with HCC, two (15%) of the 13 patients with cirrhosis, and three (6%) of the 53 control subjects. This mutation was not detected in any plasma DNA from the European patients. The adjusted odds ratio for having the mutation was 16.4 (95% confidence interval = 3.0-90.5) for patients with HCC compared with the control subjects. Conclusion: The Ser-249 p53 mutation in plasma DNA is strongly associated with HCC in Gambian patients, This mutation was also detected at a much lower prevalence in plasma DNA from Gambian patients with cirrhosis and in Gambian control subjects, findings that may lead to the earlier detection of HCC. Use of the Ser-249 p53 mutation should facilitate further molecular epidemiologic studies on the development of HCC.
C1 Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, F-69372 Lyon 08, France.
   Int Agcy Res Canc, Banjul, Gambia.
   NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   Med Res Council Labs, Banjul, Gambia.
   INSERM U271, Lyon, France.
   Necker Hosp, Hepatol Unit, Paris, France.
RP Montesano, R (reprint author), Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
CR AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284
   Anker P, 1997, GASTROENTEROLOGY, V112, P1114, DOI 10.1016/S0016-5085(97)70121-5
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   BAILEY EA, 1996, P NATL ACAD SCI USA, V93, P535
   BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Chen XQ, 1996, NAT MED, V2, P1033
   COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   Denissenko MF, 1998, ONCOGENE, V17, P3007, DOI 10.1038/sj.onc.1202214
   Esteller M, 1999, CANCER RES, V59, P67
   FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695
   Goessl C, 1998, CANCER RES, V58, P4728
   Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Hussain SP, 1998, CANCER RES, V58, P4023
   HUSSAIN SP, 1994, ONCOGENE, V9, P2277
   *IARC, 1998, GAMB HEP INT STUD AN
   *IARC, 1994, IARC MONOGR EVAL CAR, V59
   International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V56, P245
   Jackson P. E., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P619
   Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352
   LEHMAN TA, 1991, CANCER RES, V51, P4090
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   MAYANS MV, 1990, LANCET, V336, P1107
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Parkin DM, 1999, INT J CANCER, V80, P827
   PUISIEUX A, 1991, CANCER RES, V51, P6185
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Shimizu Y, 1999, INT J CANCER, V82, P187, DOI 10.1002/(SICI)1097-0215(19990719)82:2<187::AID-IJC6>3.3.CO;2-T
   STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5
   STROUN M, 1978, CANCER RES, V38, P3546
   Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466
   Wild CP, 1999, CANCER SURV, V33, P35
   Wogan GN, 1999, HEPATOLOGY, V30, P573, DOI 10.1002/hep.510300231
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0
   ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350
NR 45
TC 99
Z9 109
U1 0
U2 0
PU NATL CANCER INSTITUTE
PI BETHESDA
PA 9030 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JAN 19
PY 2000
VL 92
IS 2
BP 148
EP 153
DI 10.1093/jnci/92.2.148
PG 6
WC Oncology
SC Oncology
GA 275KQ
UT WOS:000084819700013
PM 10639517
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Eysker, M
   Geerts, S
AF Osaer, S
   Goossens, B
   Eysker, M
   Geerts, S
TI The effects of prophylactic anthelmintic treatment on the productivity
   of traditionally managed Djallonke sheep and West African Dwarf goats
   kept under high trypanosomosis risk
SO ACTA TROPICA
LA English
DT Article
DE sheep; goats; anthelmintic treatment; trypanotolerance; productivity;
   rural development
ID HAEMONCHUS-CONTORTUS; SMALL RUMINANTS; NDAMA CATTLE;
   TRICHOSTRONGYLUS-COLUBRIFORMIS; GASTROINTESTINAL NEMATODES;
   REPRODUCTIVE-PERFORMANCE; EXPERIMENTAL-INFECTION; SEASONAL EPIDEMIOLOGY;
   GAMBIA; CONGOLENSE
AB The effects of a prophylactic anthelmintic intervention on the productivity of village based sheep and goats was studied in an area of high trypanosomosis risk in The Gambia during 2 and 3 years, respectively. In total, 223 sheep and 385 goats from five villages were included. Allocation to treatment groups (treated-control) was randomised by village, based on age and sex. Three treatments per rainy season were applied with Fenbendazole (Panacur(R), Hoechst, 2.5%, 5 mg/kg). Mean nematode egg excretion per gram faeces (EPG) of the treated groups were significantly reduced by prophylactic anthelmintic treatment, indicating the efficiency of the treatment despite the risk of rapid reinfestation. Weight gain benefits of anthelmintic treatment were observed in all age categories ( > 6 month) of sheep but not in goats. Kidding rates were significantly increased whilst the same positive trends were observed for other reproductive parameters (litter size, parturition interval) in both goats and sheep without reaching statistical significance. Birth weights of offspring born out of treated does and ewes were higher (P < 0.05) than those from the controls. In contrast, growth rates until 3 months of age were not influenced by the treatment status of the dam. Mortality rates until the age of 3 months of kids from treated does were significantly lower than of those from control does. Mean Packed Red Cell Volume (PCV) levels during the rains were significantly higher in treated goats than in control goats. The same trend was observed in sheep. In general, there were no interactions between trypanosome infections and effect of anthelmintic treatment, thus both factors acted independently. Finally, the live weight productivity index (12 months old-offspring in kg/year per dam) for treated dams was 24% and 47% higher than in control ewes and does, respectively. It can be concluded that, despite the continuous risk of trypanosome infections which has a negative impact on their productivity, a beneficial effect of anthelmintic treatment was observed in both species but most obviously in goats, measured as an increased production and improved health status. A cost-benefit analysis should be carried out in order to confirm whether prophylactic anthelmintic treatment can be recommended to farmers to increase their income from small ruminant production. Nevertheless, anthelmintic treatment will certainly optimise the trypanotolerance in these breeds. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Utrecht, Fac Vet Med, Inst Infect Dis & Immunol, Dept Parasitol & Trop Vet Med, NL-3508 TD Utrecht, Netherlands.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, ITC PMB 14, Banjul, Gambia.
CR ALBERS GAA, 1984, IMMUNOGENETIC APPROA, P41
   Ankers P, 1998, PREV VET MED, V34, P215, DOI 10.1016/S0167-5877(97)00037-8
   Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   Barger I. A., 1982, Biology and control of endoparasites. McMaster Laboratory 50th Anniversary Symposium in Parasitology, University of Sydney, 5-6 November 1981., P133
   BARGER IA, 1998, VET PARASITOL, V72, P493
   BARGER IA, 1999, VET PARASITOL, V29, P41
   BULLERDIECK P, 1996, THESIS
   COBON DH, 1992, J AGR SCI, V118, P245
   *DLS ITC, 1993, LIV CENS
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   GOOSSEN B, 1998, VET PARASITOL, V85, P25
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1998, VET REC, V142, P277
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GREENWOOD AC, 1989, REPORT SMALL RUMINAN
   HOSTE H, 1993, AM J VET RES, V54, P1886
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P153
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   KAUFMANN J, 1993, TROP ANIM HLTH PROD, V27, P76
   KIMAMBO AE, 1988, VET PARASITOL, V28, P191, DOI 10.1016/0304-4017(88)90107-0
   KIMAMBO AE, 1988, VET PARASITOL, V28, P205, DOI 10.1016/0304-4017(88)90108-2
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   NDAO M, 1995, VET RES COMMUN, V19, P205, DOI 10.1007/BF01839299
   Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Panin A, 1997, SMALL RUMINANT RES, V25, P9, DOI 10.1016/S0921-4488(96)00967-4
   PARIS J, 1982, ACTA TROP, V39, P307
   Parkins J J, 1989, Nutr Res Rev, V2, P227, DOI 10.1079/NRR19890016
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   *SAS, 1998, VERS 6 12
   SHRAW KL, 1995, INT J PARASITOL, V25, P381
   Snedecor G.W., 1980, STAT METHODS, P507
   SUMBERG JE, 1985, TROP ANIM HEALTH PRO, V17, P135, DOI 10.1007/BF02355872
   Tanner MA., 1993, TOOLS STAT INFERENCE, DOI 10.1007/978-1-4684-0192-9
   THIENPONT D, 1979, DIAGNOSE VERMINOSE D
   THOMAS RJ, 1983, INT J PARASITOL, V13, P393, DOI 10.1016/S0020-7519(83)80047-2
   Tillard E, 1997, PROD ANIM, V10, P67
   TILLARD E, 1992, 7 C INT I MED
   UPTON M, 1985, AGR SYST, V17, P65, DOI 10.1016/0308-521X(85)90014-9
   VASSILIADES G, 1984, REV ELEV MED VET PAY, V37, P293
   Waller PJ, 1997, VET PARASITOL, V71, P195, DOI 10.1016/S0304-4017(97)00032-0
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
NR 45
TC 12
Z9 12
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD JAN 5
PY 2000
VL 74
IS 1
BP 13
EP 24
DI 10.1016/S0001-706X(99)00042-X
PG 12
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 267RJ
UT WOS:000084372900003
PM 10643903
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Collinson, AC
AF Prentice, AM
   Collinson, AC
TI Does breastfeeding increase thymus size?
SO ACTA PAEDIATRICA
LA English
DT Editorial Material
ID INFANT-DEATH-SYNDROME; IMMUNE-RESPONSE; HUMAN-MILK; LEPTIN; INVOLUTION;
   INFECTION; LIFE
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC Labs, Keneba, Gambia.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
CR Alexander JW, 1998, NUTRITION, V14, P627, DOI 10.1016/S0899-9007(98)00004-5
   Boyd E, 1927, AM J DIS CHILD, V33, P867
   Boyd E, 1932, AM J DIS CHILD, V43, P1162
   BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J
   BREARLY S, 1987, J IMMUNOL, V124, P2356
   Brousset P, 1998, J CLIN PATHOL-MOL PA, V51, P170
   Chevalier Philipe, 1994, Journal of Nutritional Immunology, V3, P27, DOI 10.1300/J053v03n01_04
   CLARKE AG, 1986, IMMUNOL TODAY, V7, P204, DOI 10.1016/0167-5699(86)90105-2
   Cohen Stuart J W, 1998, AIDS, V12, P2155
   DEBATIN M, 1992, THYMUS DIAGNOSTIC IM, P15
   DOUCK DC, 1998, NATURE, V396, P690
   Dourov N, 1986, HUMAN THYMUS HISTOPH, P127
   DUTZ W, 1976, EUR J PEDIATR, V122, P117, DOI 10.1007/BF00466270
   FUKUNAGA T, 1992, FORENSIC SCI INT, V53, P69, DOI 10.1016/0379-0738(92)90134-I
   GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008
   GRECO MA, 1992, PEDIAT PATHOLOGY, P1073
   GUNTHEROTH WG, 1993, PERSPECT BIOL MED, V37, P2
   Hasselbalch H, 1999, ACTA RADIOL, V40, P41
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Haynes BF, 1999, HOSP PRACT, V34, P59
   HENRY L, 1968, J PATHOL BACTERIOL, V96, P337, DOI 10.1002/path.1700960211
   HOFMANN WJ, 1992, THYMUS DIAGNOSTIC IM, P5
   Houseknecht KL, 1997, BIOCHEM BIOPH RES CO, V240, P742, DOI 10.1006/bbrc.1997.7736
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   Kirschner DE, 1998, J ACQ IMMUN DEF SYND, V18, P95
   Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904
   LOBACH DF, 1987, J CLIN IMMUNOL, V7, P81, DOI 10.1007/BF00916002
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303
   MCCONAHEY WM, 1976, J CLIN ENDOCR METAB, V42, P1182
   MILLER JF, 1961, LANCET, V2, P748
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009
   SAVY M, 1910, PROGR MED, V27, P371
   Selye H, 1936, BRIT J EXP PATHOL, V17, P234
   SIEBERT JR, 1994, PEDIATR PATHOL, V14, P973
   Simon J., 1845, PHYSL ESSAY THYMUS G
   Smith-Kirwin SM, 1998, J CLIN ENDOCR METAB, V83, P1810, DOI 10.1210/jc.83.5.1810
   SOLOMON GF, 1981, ANNU REV MICROBIOL, V35, P155, DOI 10.1146/annurev.mi.35.100181.001103
   Thompson JMD, 2000, ACTA PAEDIATR, V89, P112, DOI 10.1080/080352500750029176
   van Baarlen J, 1989, Pediatr Pathol, V9, P261
   VANBAARLEN J, 1988, HUM PATHOL, V19, P1155, DOI 10.1016/S0046-8177(88)80146-1
   WALTER E, 1992, THYMUS DIAGNOSTIC IM, P23
   WILLICH E, 1992, THYMUS DIAGNOSTIC IM, P63
   WILLICH E, 1992, THYMUS DIAGNOSTIC IM, P1
   Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804
NR 48
TC 9
Z9 9
U1 0
U2 5
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD JAN
PY 2000
VL 89
IS 1
BP 8
EP 12
DI 10.1080/080352500750028979
PG 5
WC Pediatrics
SC Pediatrics
GA 278CK
UT WOS:000084970200005
PM 10677049
OA No
DA 2017-08-15
ER

PT J
AU Ratcliffe, AA
   Hill, AG
   Walraven, G
AF Ratcliffe, AA
   Hill, AG
   Walraven, G
TI Separate lives, different interests: male and female reproduction in the
   Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE Gambia; reproduction; gender identity; fertility; age factors; sex
   factors
ID FERTILITY; BEHAVIOR; POLICY; KENYA; MEN
AB We report the initial findings of a research programme on the fertility and reproductive health of both men and women in rural Gambia. The reproductive experiences of men and women in the population studied were very different. During the period 1993-97, the total fertility rates were 12.0 for men and 6.8 for women. For men fertility began later, reached higher levels and continued into older ages than for women. Through serial and polygynous marriages, men were able to extend their reproduction beyond what would be possible with one woman. Of the married men interviewed, 40% were married polygynously. Men's fertility preferences indicated that they recognized their reproductive potentials to be greater than those of their individual wives. On average, married men desired 15.2 children for themselves and 7.3 for each wife. In this polygynous population the means available for attaining reproductive goals were different for the two sexes, depending on the separate lives and different interests of men and women.
C1 Harvard Univ, Sch Publ Hlth, Harvard Ctr Populat & Dev Studies, Cambridge, MA 02138 USA.
   Med Res Council Labs, Farafenni Field Stn, Farafenni, Gambia.
RP Ratcliffe, AA (reprint author), Harvard Univ, Sch Publ Hlth, Harvard Ctr Populat & Dev Studies, 9 Bow St, Cambridge, MA 02138 USA.
CR Bankole A, 1998, INT FAM PLAN PERSPEC, V24, P15, DOI 10.2307/2991915
   Bawah AA, 1999, STUD FAMILY PLANN, V30, P54, DOI 10.1111/j.1728-4465.1999.00054.x
   Bledsoe C, 1998, POPUL DEV REV, V24, P15, DOI 10.2307/2808121
   BLEDSOE C, 1999, FERTILITY MALE LIFE
   BLEDSOE CH, 1994, POPUL DEV REV, V20, P81, DOI 10.2307/2137631
   Caldwell JC, 1996, J COMP FAM STUD, V27, P331
   *CENTR STAT OFF, 1993, POP CENS REP, V1
   Dodoo FNA, 1998, DEMOGRAPHY, V35, P229, DOI 10.2307/3004054
   Donadje F., 1992, NUPTIALITE FECONDITE
   DONADJE F, 1992, ONSET FERTILITY TRAN
   Ezeh AC, 1997, DEMOGRAPHY, V34, P355, DOI 10.2307/3038289
   Ezeh A. C., 1996, DEMOGRAPHIC HLTH SUR, V18
   FORTES M, 1980, UOMO, V4, P363
   FRANK O, 1987, POPUL DEV REV, V13, P209, DOI 10.2307/1973192
   GOLDMAN N, 1989, REPROD SOCIAL ORG SU
   GREENE ME, 1997, 103 POP COUNC RES PO
   HILL AG, 1996, REPORT LIVING STANDA
   MACLEOD WB, 1998, POPULATION HOUSING C
   MBIZVO MT, 1991, STUD FAMILY PLANN, V22, P31, DOI 10.2307/1966517
   McGinn T, 1989, INT FAMILY PLANNING, V15, P84, DOI 10.2307/2133195
   MUNDIGO AZ, 1998, SEM MEN FAM FORM REP
   Ngom P, 1997, STUD FAMILY PLANN, V28, P192, DOI 10.2307/2137887
   OPPONG C, 1992, FAMILY SYSTEMS CULTU
   PAGET WJ, 1990, RELATIONAL GOMPERTZ
   PICTET G, 1999, ANN M POP ASS AM
   PISON G, 1986, POPULATION, V41, P93, DOI 10.2307/1533182
   PISON G, 1982, CAHIER INED PUF, V99
   Presser HB, 1997, POPUL DEV REV, V23, P295, DOI 10.2307/2137547
   Shryock H., 1980, METHODS MAT DEMOGRAP
   SONKO S, 1997, POPULATION HOUSING C
   SPEIZER I, 1999, SOC BIOL, V42, P199
   Speizer IS, 1995, DEMOGRAPHY, V32, P533, DOI 10.2307/2061673
NR 32
TC 32
Z9 32
U1 0
U2 3
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2000
VL 78
IS 5
BP 570
EP 579
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 323KG
UT WOS:000087564100002
PM 10859851
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   Telfer, M
   Rowley, J
   Ronsmans, C
AF Walraven, G
   Telfer, M
   Rowley, J
   Ronsmans, C
TI Maternal mortality in rural Gambia: levels, causes and contributing
   factors
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE Gambia; maternal mortality; maternal age; labour complications; risk
   factors; rural population
ID TRADITIONAL BIRTH ATTENDANTS; PLACEBO-CONTROLLED TRIAL; PREGNANCY;
   TANZANIA
AB A demographic study carried out in a rural area of the Gambia between January 1993 and December 1998 recorded 74 deaths among women aged 15-49 years. Reported here is an estimation of maternal mortality among these 74 deaths based on a survey of reproductive age mortality, which identified 18 maternal deaths by verbal autopsy. Over the same period there were 4245 live births in the study area, giving a maternal mortality ratio of 424 per 100 000 live births. This maternal mortality estimate is substantially lower than estimates made in the 1980s, which ranged from 1005 to 2362 per 100 000 live births, in the same area. A total of 9 of the 18 deaths had a direct obstetric cause - haemorrhage (6 deaths), early pregnancy (2), and obstructed labour (1). Indirect causes of obstetric deaths were anaemia (4 deaths), hepatitis (1), and undetermined (4). Low standards of health care for obstetric referrals, failure to recognize the severity of the problem at the community level, delays in starting the decision-making process to seek health care, lack of transport, and substandard primary health care were identified more than once as probable or possible contributing factors to these maternal deaths.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Dept State Hlth, Div Hlth Team N Bank E, Banjul, Gambia.
   US Peace Corps, Serrekunda, Gambia.
   London Sch Hyg & Trop Med, Maternal & Child Epidemiol Unit, London WC1, England.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
CR BLEDSOE CH, 1994, POPUL DEV REV, V20, P81, DOI 10.2307/2137631
   CAMPBELL O, 1995, WHOFHEMSM9515
   Chandramohan D, 1998, STUD FAMILY PLANN, V29, P414, DOI 10.2307/172253
   De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x
   *GAMB STAT DEP HLT, 1997, UNPUB SAF MOTH NEEDS
   GRAHAM W, 1989, STUD FAMILY PLANN, V20, P17
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P598
   HILL AG, 1996, REPORT LIVING STANDA
   Hofmeyr GJ, 1998, BRIT J OBSTET GYNAEC, V105, P971
   MAINE D, 1992, SAFE MOTHERHOOD PROG
   MBARUKU G, 1995, HEALTH POLICY PLANN, V10, P71, DOI 10.1093/heapol/10.1.71
   RATCLIFFE AA, 1999, 2 SIDES STORY MALE F
   Ronsmans C, 1998, INT J EPIDEMIOL, V27, P660, DOI 10.1093/ije/27.4.660
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   TELFER M, 1999, REPORT MATERNAL HLTH
   Walraven G, 1999, TROP MED INT HEALTH, V4, P527, DOI 10.1046/j.1365-3156.1999.00441.x
   WALRAVEN GEL, 1994, BRIT J OBSTET GYNAEC, V101, P414, DOI 10.1111/j.1471-0528.1994.tb11914.x
   Weil O, 1999, LANCET, V354, P940, DOI 10.1016/S0140-6736(99)02369-7
   World Health Organization United Nations Children's Fund (Unicef), 1996, REV 1990 EST MAT MOR
NR 21
TC 50
Z9 50
U1 1
U2 4
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2000
VL 78
IS 5
BP 603
EP 613
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 323KG
UT WOS:000087564100005
PM 10859854
OA No
DA 2017-08-15
ER

PT J
AU Bickler, SW
   Sanno-Duanda, B
AF Bickler, SW
   Sanno-Duanda, B
TI Epidemiology of paediatric surgical admissions to a government referral
   hospital in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE surgery; child, hospitalized; referral and consultation; hospitals,
   public; prospective studies; Gambia
ID AFRICA
AB Introduction There is a paucity of published data on the type of conditions that require surgery among children in sub-Saharan Africa. Such information is necessary for assessing the impact of such conditions on child health and for setting priorities to improve paediatric surgical care.
   Methods Described in the article is a 29-month prospective study of all children aged <15 years who were admitted to a government referral hospital in the Gambia from January 1996 to May 1998.
   Results A total of 1726 children were admitted with surgical problems. Surgical patients accounted for 11.3% of paediatric admissions and 34 625 total inpatient days. The most common admission diagnoses were injuries (46.9%), congenital anomalies (24.3%), and infections requiring surgery(14.5%). The diagnoses that accounted for the greatest number of inpatient days were burns (18.8%), osteomyelitis (15.4%), fractures (12.7%), soft tissue injuries (3.9%), and head injuries (3.4%). Gambian children were rarely admitted for appendicitis and never admitted for hypertrophic pyloric stenosis. The leading causes of surgical deaths were burns, congenital anomalies, and injuries other than burns.
   Discussion Prevention of childhood injuries and better trauma management, especially at the primary and secondary health care levels, should be the priorities for improving paediatric surgical care in sub-Saharan Africa. Surgical care of children should be considered an essential component of child health programmes in developing countries.
C1 Univ Calif San Diego, Med Ctr, Div Pediat Surg, San Diego, CA 92103 USA.
   Royal Victoria Hosp, Dept Surg, Banjul, Gambia.
RP Bickler, SW (reprint author), Univ Calif San Diego, Med Ctr, Div Pediat Surg, 200 W Arbor Dr, San Diego, CA 92103 USA.
CR ADEYEMO AA, 1994, ANN TROP PAEDIATR, V14, P75
   Bickler SW, 2000, MED HYPOTHESES, V54, P825, DOI 10.1054/mehy.1999.0959
   BICKLER SW, 1999, B TROPICAL MED INT H, V7, P1
   BRADSHAW D, 1992, S AFR MED J, V82, P237
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Durkin MS, 1996, J TRAUMA, V41, P667, DOI 10.1097/00005373-199610000-00012
   Forjuoh SN, 1998, TROP MED INT HEALTH, V3, P349, DOI 10.1046/j.1365-3156.1998.00240.x
   MOHAN D, 1986, Indian Journal of Pediatrics, V53, P607, DOI 10.1007/BF02748664
   ODELOWO EOO, 1991, INT SURG, V76, P43
   SHIJA JK, 1980, P ASS SURG E AFRICA, V3, P169
   SIMMONS D, 1985, ARCH DIS CHILD, V60, P64
   *UN DEV PROGR, 1997, UN DEV REP 1997 UN D
   *UNICEF, 1998, STAT WOM CHILDR GAMB
NR 13
TC 58
Z9 58
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 2000
VL 78
IS 11
BP 1330
EP 1336
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 376LU
UT WOS:000165459700007
PM 11143193
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Bah, M
   Reibel, R
   Jongejan, F
AF Mattioli, RC
   Bah, M
   Reibel, R
   Jongejan, F
TI Cowdria ruminantium antibodies in acaricide-treated and untreated cattle
   exposed to Amblyomma variegatum ticks in The Gambia
SO EXPERIMENTAL AND APPLIED ACAROLOGY
LA English
DT Article
DE Amblyomma variegatum; Cowdria ruminantium; Gobra zebu cattle; MAP1-B
   ELISA; N'Dama; The Gambia
ID NDAMA CATTLE; MAP1 PROTEIN; HEARTWATER; INFECTION; INFESTATION;
   MANAGEMENT; VALIDATION; ASSAY
AB An indirect enzyme-linked immunosorbent assay (ELISA), based on the major antigenic protein 1 fragment B (MAP1-B) of Cowdria ruminantium, was used to assess seroprevalence in cattle in The Gambia. Two groups of 20 N'Dama and 20 Gobra zebu cattle were monitored for 12 months with flumethrin treatment and for another 10 months without acaricidal treatment. Two groups of 20 N'Dama and 20 Gobra cattle served as untreated controls. During the period of acaricidal treatment, the cumulative proportions of positive serum samples were 25.6 +/- 5.6% ( +/- confidence interval) and 34.7 +/- 6.8% in treated N'Dama and Gobra cattle respectively; the proportion of positive sera in untreated cattle was 52.2 +/- 6.9% in N'Damas and 61.4 +/- 7.3% in Gobras. Within breed, difference in antibody prevalence between treated and untreated cattle was significant (P < 0.001) but between breed differences were not significant. In the 10 months following suspension of acaricide application, there was an increase of proportion of positive serum samples in previously treated N'Dama and Gobra cattle. In both previously treated and untreated animals the peak of positive seroreactions occurred during and subsequent to the period of activity of Amblyomma variegatum adults. Cumulative seroprevalences in previously treated N'Dama and Gobra cattle were 32.6 +/- 6.9% and 44.7 +/- 8.5%, respectively; in untreated animals seroprevalence was 38.6 +/- 7.2% in N'Dama and 65.3 +/- 8.4% in Gobra cattle. Throughout the study period, within the N'Dama breed, the seropositive rate in previously treated cattle did not differ from that in untreated animals. Conversely, within the Gobra breed, the number of positive seroreactions was higher (P < 0.002) in untreated animals than in previously treated cattle. These results provide a support for designing A. variegatum and heartwater control strategies, if necessary, in The Gambia in relation to cattle breeds.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Free Univ Berlin, Fac Vet Med, Dept Parasitol & Trop Vet Med, Berlin, Germany.
   Univ Utrecht, Fac Vet Med, Dept Parasitol & Trop Vet Med, NL-3508 TD Utrecht, Netherlands.
   Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.
CR AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   DUPLESSIS JL, 1992, ONDERSTEPOORT J VET, V59, P75
   FRANCIS J., 1964, AUSTRALIAN VETERINARY J, V40, P247, DOI 10.1111/j.1751-0813.1964.tb08746.x
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P449
   GUEYE A, 1984, REV ELEV MED VET PAY, V37, P268
   GUEYE A, 1982, REV ELEV MED VET PAY, V35, P217
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P411
   JONGEJAN F, 1999, RICKETTSIAE RICKETTS, P373
   Koney E B, 1994, Rev Elev Med Vet Pays Trop, V47, P163
   KONEY EBM, 1990, TROP ANIM HEALTH PRO, V22, P89, DOI 10.1007/BF02239831
   Konstantinov O.K., 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P85
   Lawrence J A, 1993, Rev Elev Med Vet Pays Trop, V46, P211
   Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P283
   Maillard J C, 1993, Rev Elev Med Vet Pays Trop, V46, P291
   Mattioli R. C., 1995, Parassitologia (Rome), V37, P63
   Mattioli R. C., 1994, Parassitologia (Rome), V36, P305
   Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x
   Mattioli RC, 1998, PREV VET MED, V34, P137, DOI 10.1016/S0167-5877(97)00082-2
   Mboloi MM, 1999, CLIN DIAGN LAB IMMUN, V6, P66
   Mondry R, 1998, ANN NY ACAD SCI, V849, P262, DOI 10.1111/j.1749-6632.1998.tb11058.x
   MOREL P, 1981, PRECIS PARASITOLOGIE, P471
   NORVAL RAI, 1995, VET PARASITOL, V58, P335, DOI 10.1016/0304-4017(94)00733-S
   PROVOST A, 1987, ONDERSTEPOORT J VET, V54, P165
   van Vliet AHM, 1996, ANN NY ACAD SCI, V791, P35
   VANVLIET AHM, 1995, J CLIN MICROBIOL, V33, P2405
NR 25
TC 8
Z9 8
U1 1
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0168-8162
J9 EXP APPL ACAROL
JI Exp. Appl. Acarol.
PY 2000
VL 24
IS 12
BP 957
EP 969
DI 10.1023/A:1010645927535
PG 13
WC Entomology
SC Entomology
GA 417EV
UT WOS:000167823200008
PM 11354623
OA No
DA 2017-08-15
ER

PT J
AU Aidoo, M
   Lalvani, A
   Gilbert, SC
   Hu, JT
   Daubersies, P
   Hurt, N
   Whittle, HC
   Druihle, P
   Hill, AVS
AF Aidoo, M
   Lalvani, A
   Gilbert, SC
   Hu, JT
   Daubersies, P
   Hurt, N
   Whittle, HC
   Druihle, P
   Hill, AVS
TI Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the
   malaria vaccine candidate liver-stage antigen 3
SO INFECTION AND IMMUNITY
LA English
DT Article
ID FALCIPARUM CIRCUMSPOROZOITE PROTEIN; SPOROZOITE SURFACE PROTEIN-2;
   PLASMODIUM-FALCIPARUM; CELL EPITOPES; EXPORTED PROTEIN-1; RESPONSES;
   PROTECTION; IMMUNITY; IDENTIFICATION; IMMUNIZATION
AB The development of an effective preerythrocytic vaccine against Plasmodium falciparum malaria is likely to require inclusion of components from several preerythrocytic antigens. The association of HLA-B53 with resistance to severe malaria in West Africa provided evidence that HLA class I-restricted CD8(+) T-cell responses play a role in protective immunity in African children, supporting data from rodent models of malaria. Previously, a single epitope from liver-stage-specific antigen 1 (LSA-1) has been shown to be recognized by HLA-B53-specific cytotoxic T lymphocytes (CTL), but HLA-B53 epitopes were not found in four other antigens. In this study we measured CTL responses to peptides from the recently sequenced antigen liver-stage antigen 3 (LSA-3) and identified in it a new epitope restricted by HLA-B53. Several CTL epitopes restricted by other class I types were also identified within LSA-3 in studies in The Gambia and Tanzania. CTL were also identified to an additional P. falciparum antigen, exported protein 1 (Exp-1), the homologue of which is a protective antigen in a rodent model of malaria. These findings emphasize the diversity of P. falciparum antigens recognized by CD8(+) T cells in humans and support the inclusion of components from several antigens in new CTL-inducing vaccines against malaria.
C1 Univ Oxford, John Radcliffe Hosp, Mol Immunol Grp, Inst Mol Med,Nuffield Dept Med, Oxford OX3 9DU, England.
   Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Natl Inst Med Res, Ifakara Ctr, Kilombero, Tanzania.
   MRC Labs, Fajara, Gambia.
RP Aidoo, M (reprint author), Ctr Dis Control & Prevent, Immunogenet Sect, Div AIDS STD & TB Lab Res, Natl Ctr Infect Dis, MS-A25, Atlanta, GA 30333 USA.
RI HILL, Adrian/C-1306-2008
OI Gilbert, Sarah/0000-0002-6823-9750
CR Aidoo M, 1997, INT IMMUNOL, V9, P731, DOI 10.1093/intimm/9.5.731
   AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   BenMohamed L, 1997, EUR J IMMUNOL, V27, P1242, DOI 10.1002/eji.1830270528
   BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922
   DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511
   Doolan DL, 1996, J BIOL CHEM, V271, P17861
   Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739
   Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0
   ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   HOFFMAN SL, 1997, MALARIA VACCINE DEV, P35
   HOPE IA, 1984, NATURE, V308, P191, DOI 10.1038/308191a0
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 1996, EUR J IMMUNOL, V26, P773, DOI 10.1002/eji.1830260408
   MARCHAND C, 1990, B WORLD HEALTH ORGAN, V68, P158
   MCADAM S, 1995, J IMMUNOL, V155, P2729
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   Plebanski M, 1997, J IMMUNOL, V158, P2849
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   Renggli J, 1997, PARASITE IMMUNOL, V19, P145, DOI 10.1046/j.1365-3024.1997.d01-190.x
   SANCHEZ GI, 1994, EXP PARASITOL, V79, P59, DOI 10.1006/expr.1994.1060
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   SEDEGAH M, 1992, J IMMUNOL, V149, P966
   White KL, 1996, J IMMUNOL, V156, P3374
   WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435
   WIZEL B, 1995, J IMMUNOL, V155, P766
   YANG CF, 1995, MOL BIOCHEM PARASIT, V71, P291, DOI 10.1016/0166-6851(95)00069-D
NR 29
TC 36
Z9 37
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JAN
PY 2000
VL 68
IS 1
BP 227
EP 232
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 266LQ
UT WOS:000084301800033
PM 10603392
OA No
DA 2017-08-15
ER

PT J
AU Dumpis, U
   Hall, A
   Mendy, M
   Wansbrough, M
   Thursz, M
   Hill, A
   Whittle, H
   Karayiannis, P
AF Dumpis, U
   Hall, A
   Mendy, M
   Wansbrough, M
   Thursz, M
   Hill, A
   Whittle, H
   Karayiannis, P
TI Molecular epidemiology gives insight of the routes of transmission of
   HBV in the Gambia
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ London Imperial Coll Sci Technol & Med, London, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2000
VL 32
SU 2
BP 106
EP 106
DI 10.1016/S0168-8278(00)80741-2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 315GP
UT WOS:000087104500313
OA No
DA 2017-08-15
ER

PT J
AU Zupi, A
   Ruggiero, AM
   Insabato, L
   Senghore, N
   Califano, L
AF Zupi, A
   Ruggiero, AM
   Insabato, L
   Senghore, N
   Califano, L
TI Aggressive cemento-ossifying fibroma of the jaws
SO ORAL ONCOLOGY
LA English
DT Article
DE cemento-ossifying fibroma; jaws
ID FIBROOSSEOUS LESIONS; OSSEOUS LESIONS; TUMORS
AB The cemento-ossifying fibroma is probably the most frequent fibro-osseous lesion seen by oral pathologists. Occasionally, reports of lesions behaving in an aggresive fashion appear in the literature. At the present time, the relationship if these "aggressive" lesions to the "usual" fibromas is unclear. Two cases of "aggressive" cemento-ossifying fibroma are reported. Certainly, clinical, radiological, and histological characteristics of aggressive and usual fibromas do coincide. There are, however, diverging features warranting separation of different forms. These mild differences may be detected during preoperative assessment of the lesion, allowing a diagnosis of aggressive form to be made. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Naples Federico II, Sch Med & Surg, Dept Maxillofacial Surg, I-80131 Naples, Italy.
   Univ Naples Federico II, Sch Med & Surg, Dept Anat Pathol, I-80131 Naples, Italy.
   Royal Victoria Hosp, Banjul, Gambia.
RP Via Michelangelo Schipa 115, I-80123 Naples, Italy.
EM califano@unina.it
OI Califano, Luigi/0000-0002-3123-2221
CR ANAND SV, 1967, BRIT J SURG, V54, P901, DOI 10.1002/bjs.1800541102
   BUDAL J, 1970, ORAL SURG ORAL MED O, V30, P303, DOI 10.1016/0030-4220(70)90305-1
   DAMJANOV I, 1978, CANCER, V42, P2668, DOI 10.1002/1097-0142(197812)42:6<2668::AID-CNCR2820420623>3.0.CO;2-B
   DEHNER LP, 1973, CANCER, V31, P364, DOI 10.1002/1097-0142(197302)31:2<364::AID-CNCR2820310216>3.0.CO;2-Z
   EVERSOLE LR, 1985, ORAL SURG ORAL MED O, V60, P505, DOI 10.1016/0030-4220(85)90239-7
   FU YS, 1974, CANCER, V33, P1289, DOI 10.1002/1097-0142(197405)33:5<1289::AID-CNCR2820330514>3.0.CO;2-P
   Given J, 1979, J Oral Med, V34, P112
   Greer RO, 1987, COMPREHENSIVE MANAGE, P1510
   HOFFMAN S, 1987, ATLAS TUMOR PATHOL, P208
   Johnson L C, 1991, Acta Otolaryngol Suppl, V488, P1
   KHANNA S, 1979, J ORAL SURG, V37, P800
   KRAMER IRH, 1992, WHO INT HISTOLOGICAL, P28
   MAKEK M, 1983, NEW APPROACH DIFFERE, P162
   Putschar W G, 1974, Verh Dtsch Ges Pathol, V58, P251
   REAUME CE, 1985, J ORAL MAXIL SURG, V43, P631, DOI 10.1016/0278-2391(85)90137-5
   REED RJ, 1965, ORAL SURG ORAL MED O, V19, P214, DOI 10.1016/0030-4220(65)90295-1
   SLOOTWEG PJ, 1990, J CRANIO MAXILL SURG, V18, P125, DOI 10.1016/S1010-5182(05)80329-4
   Slootweg PJ, 1996, SEMIN DIAGN PATHOL, V13, P104
   SMITH AG, 1952, AMA ARCH PATHOL, V54, P507
   Su L, 1997, ORAL SURG ORAL MED O, V84, P301, DOI 10.1016/S1079-2104(97)90348-6
   SUMMERLIN DJ, 1994, ORAL SURG ORAL MED O, V78, P611, DOI 10.1016/0030-4220(94)90174-0
   TEST D, 1976, J ORAL SURG, V34, P907
   WALDRON CA, 1985, J ORAL MAXIL SURG, V43, P249, DOI 10.1016/0278-2391(85)90283-6
   WALDRON CA, 1993, J ORAL MAXIL SURG, V51, P828
   WALTER JM, 1979, J ORAL SURG, V37, P276
NR 25
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JAN
PY 2000
VL 36
IS 1
BP 129
EP 133
DI 10.1016/S1368-8375(99)00053-6
PG 5
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 275AC
UT WOS:000084796400023
PM 10889933
OA No
DA 2017-08-15
ER

PT J
AU Laskey, MA
   Collinson, AC
   Dibba, B
   Prentice, A
AF Laskey, MA
   Collinson, AC
   Dibba, B
   Prentice, A
TI DXA: A new insight into geophagy
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
C1 MRC, Human Nutr Res, Cambridge CB4 1XJ, England.
   MRC Keneba, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG LONDON LTD
PI GODALMING
PA SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PY 2000
VL 11
SU 3
MA P5
BP 22
EP 22
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 382RZ
UT WOS:000165837400071
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Bailey, RL
   Mahdi, OS
   Walraven, GEL
   Lindsay, SW
AF Emerson, PM
   Bailey, RL
   Mahdi, OS
   Walraven, GEL
   Lindsay, SW
TI Transmission ecology of the fly Musca sorbens, a putative vector of
   trachoma
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Musca domestica; Musca sorbens; trachoma; Chlamydia trachomatis;
   transmission; vector behaviour; The Gambia
ID GAMBIAN VILLAGE; BLINDNESS; EPIDEMIOLOGY; INFECTION; TANZANIA; IMPACT
AB Recent evidence suggests that eye-seeking flies are important trachoma vectors. We conducted a series of investigations to identify which species of synanthropic flies are potential vector(s) of this blinding disease in The Gambia. Several species of fly were caught in fish-baited attractant traps placed in villages throughout the year (1997/98) but only 2 species, Musca sorbens and M. domestica, were caught from the eyes of children. M. sorbens comprised <10% of the total number of flies caught with attractant traps but was responsible for >90% of fly-eye contacts, the remainder were made by M, domestica. All fly species were more numerous in the wet season than the dry season. Eyes of young children are considered to be the main reservoir of Chlamydia trachomatis, the causative agent of trachoma. Collections of eye-seeking flies from children showed frequent fly-eye contacts (median [interquartile range], 3 [1.5-7] every 15 min). Children with potentially infective ocular or nasal discharge had twice as many fly-eye contacts than children with no discharge (P < 0.001). There was no difference in exposure to fly-eye contacts ifa child sat inside or outside a house (P = 0.273). Female flies were more commonly caught from eyes than male (P < 0.001). The presence of Chlamydia DNA was demonstrated by PCR on 2 of 395 flies caught from the eyes of children with a current active trachoma infection. Both positive flies were M sorbens, one male and the other female. Further elucidation of M, sorbens behavioural ecology and the development of sustainable strategies to control these flies should be a priority. It is likely that M. sorbens is the principal insect vector of trachoma in The Gambia.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 5HT, England.
   Univ Durham, Dept Biol Sci, Durham DH1 3LE, England.
RP Emerson, PM (reprint author), MRC, POB 273, Banjul, Gambia.
CR BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Chavasse DC, 1999, LANCET, V353, P22, DOI 10.1016/S0140-6736(98)03366-2
   COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N
   COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   Crosskey R. W., 1993, P403
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83
   HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275
   JONES BR, 1975, T OPHTHAL SOC UK, V95, P16
   LYONS FM, 1952, B OPHTHALMOLOGY SOC, V45, P81
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295
   MACCALLAN AF, 1931, BRIT J OPHTHALMOL, V15, P361
   Munoz B, 1997, EPIDEMIOL REV, V19, P205
   Pont A.C., 1991, Fauna of Saudi Arabia, V12, P312
   REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393
   WATT J, 1948, PUBLIC HEALTH REP, V63, P1319, DOI 10.2307/4586723
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   World Health Organization, 1975, MAN PRACT ENT MAL, V13
NR 29
TC 62
Z9 62
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JAN-FEB
PY 2000
VL 94
IS 1
BP 28
EP 32
DI 10.1016/S0035-9203(00)90427-9
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 292ZH
UT WOS:000085825800012
PM 10748893
OA No
DA 2017-08-15
ER

PT J
AU Enwere, GC
   Van Hensbroek, MB
   Jaiteh, B
   Palmer, A
   Onyiorah, E
   Schneider, G
   Weber, MW
   Greenwood, BM
AF Enwere, GC
   Van Hensbroek, MB
   Jaiteh, B
   Palmer, A
   Onyiorah, E
   Schneider, G
   Weber, MW
   Greenwood, BM
TI Biochemical and haematological variables in Gambian children with
   cerebral malaria
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID FALCIPARUM-MALARIA; CLINICAL-FEATURES; AFRICAN CHILDREN; ARTEMETHER;
   INDICATORS; QUININE; TRIAL
AB Biochemical and haematological measurements were made in Gambian children who satisfied the criteria for the diagnosis of cerebral malaria over a 3-year period. Biochemical and haematological values were available for 388 and 624 children, respectively. Biochemical signs of renal and hepatic dysfunction were found and these may have contributed in a cumulative way to the high mortality seen in the study children. Cerebral involvement in children with cerebral malaria is only one, though the most important, manifestation of a multi-organ disease.
C1 MRC Labs, Fajara, Banjul, Gambia.
RP Enwere, GC (reprint author), MRC Labs, POB 273, Fajara, Banjul, Gambia.
CR DELLER JJ, 1967, MIL MED, V132, P614
   English MC, 1996, ARCH DIS CHILD, V74, P201
   Enwere G, 1998, ANN TROP PAEDIATR, V18, P275
   Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   KWIATKOWSKI D, 1993, Q J MED, V86, P91
   Maegraith B, 1972, Adv Parasitol, V10, P49, DOI 10.1016/S0065-308X(08)60172-4
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MENDIS KN, 1995, PARASITOL TODAY, V2, P1
   MILLER LH, 1994, SCIENCE, V264, P1874
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B
   OGUNYE O, 1981, TROP GEOGR MED, V33, P165
   Sowunmi A, 1996, ARCH DIS CHILD, V74, P293
   SPITZ S, 1946, Mil Surg, V99, P555
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   VANHENSBROEK MB, 1997, J INFECT DIS, V175, P220
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 19
TC 1
Z9 3
U1 0
U2 0
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 1999
VL 19
IS 4
BP 327
EP 332
DI 10.1080/02724939992158
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 247TM
UT WOS:000083236100003
PM 10716025
OA No
DA 2017-08-15
ER

PT J
AU Bailey, R
   Duong, T
   Carpenter, R
   Whittle, H
   Mabey, D
AF Bailey, R
   Duong, T
   Carpenter, R
   Whittle, H
   Mabey, D
TI The duration of human ocular Chlamydia trachomatis infection is age
   dependent
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article; Proceedings Paper
CT 3rd Meeting of the European-Society-for-Chlamydia-Research
CY SEP 11-14, 1996
CL VIENNA, AUSTRIA
SP Eur Soc Chlamydia Res
ID EPIDEMIOLOGY; REINFECTION; ANTIBODIES; RESPONSES; IMMUNITY; ANTIGENS
AB We studied the relationship between age and prevalence, duration and incidence of clinical and laboratory evidence of ocular Chlamydia trachomatis infection in a cohort of Gambian subjects examined bi-weekly for 6 months. The duration of disease and infection, estimated by stratified survival analysis, proportional hazards regression and Weibull modelling, was markedly age-dependent. The estimated median duration of disease was 13 2 weeks in 13.2-year-old subjects and 1.7 weeks in those age 15 and over. Adjustment for multiple infections, and for missing observations did not alter this trend. The cumulative incidence rate of disease was reduced threefold with age. More rapid disease resolution is the main source of reduction in prevalence of active trachoma and ocular C. trachomatis infection with age; disease incidence was reduced to a lesser extent. This age-dependent resolution may be effected by adaptive cellular immune mechanisms. Mechanisms responsible for natural immunity should receive appropriate emphasis in vaccine design.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC, Labs Fajara, Banjul, Gambia.
RP Bailey, R (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, EPIDEMIOL INFECT, V111, P315
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BRUNHAM RC, 1993, SEX TRANSM DIS, V20, P168, DOI 10.1097/00007435-199305000-00010
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   HOOK EW, 1992, AM J EPIDEMIOL, V136, P662
   Igietseme Joseph U., 1993, Regional Immunology, V5, P317
   MABEY DCW, 1987, LANCET, V2, P1491
   MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305
   Morrison R P, 1996, Infect Dis Obstet Gynecol, V4, P163
   MURRAY ES, 1973, J IMMUNOL, V110, P1518
   ORR P, 1994, CLIN INFECT DIS, V19, P876
   Parks KS, 1997, SEX TRANSM DIS, V24, P229, DOI 10.1097/00007435-199704000-00008
   QUINN TC, 1998, P 9 INT S HUM CHLAM, P285
   RAMSEY KH, 1991, INFECT IMMUN, V59, P925
   RAMSTEDT K, 1992, INT J STD AIDS, V3, P117
   TAYLOR HR, 1982, INVEST OPHTH VIS SCI, V23, P507
   TAYLOR HR, 1992, AM J TROP MED HYG, V46, P552
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82
   Ward ME, 1995, APMIS, V103, P769
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
NR 26
TC 86
Z9 87
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 1999
VL 123
IS 3
BP 479
EP 486
DI 10.1017/S0950268899003076
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 285UG
UT WOS:000085406000017
PM 10694161
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Cole, TJ
   Collinson, AC
   Poskitt, EME
   McGregor, IA
   Prentice, AM
AF Moore, SE
   Cole, TJ
   Collinson, AC
   Poskitt, EME
   McGregor, IA
   Prentice, AM
TI Prenatal or early postnatal events predict infectious deaths in young
   adulthood in rural Africa
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE adult mortality; infection; immunity; intrauterine growth retardation;
   maternal nutrition; placental function; seasonality
ID BIRTH-WEIGHT; FETAL GROWTH; CARDIOVASCULAR-DISEASE; PLACENTAL MALARIA;
   MORTALITY; EXPOSURE; LIFE; HYPOTHESIS; AFLATOXIN; HEPATITIS
AB Background Research over the past decade has suggested that prenatal and early postnatal nutrition influence the risk of developing chronic degenerative diseases up to 60 years later. We now present evidence that risk of death from infectious diseases in young adulthood is similarly programmed by early life events.
   Methods In three rural Gambian villages, affected by a marked annual seasonality in diet and disease, we have kept detailed demographic, anthropometric and health records since 1949. Fate was known with certainty for 3162 individuals (2059 alive/1103 dead, most dying in childhood). For this case-control analysis of antecedent predictors of premature mortality, all adult deaths (n = 61) were paired with two randomly selected controls matched for sex and year of birth.
   Results Mean age at death was 25 (SD: 8) years. Adult death was associated with a profound bias in month of birth with 49 cases born in the nutritionally-debilitating hungry season (Jul-Dec) versus 12 in the harvest season (Jan-Jun). Relative to harvest season the hazard ratio for early death in hungry-season births rose from 3.7 (for deaths >14.5 years, P = 0.000013) to 10.3 (for deaths >25 years, P = 0.00002). Anthropometric and haematological status at 18 months of age was identical in cases and controls, indicating an earlier origin to the defect. Most deaths for which cause was known had a definite or possible infectious aetiology; none were from degenerative diseases of affluence.
   Conclusions Early life exposures, correlated with season of birth, strongly influence susceptibility to fatal infections in young adulthood. The evidence suggests that nutritionally-mediated intrauterine growth retardation may permanently impair the development of immune function.
C1 London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, London WC1B 3DP, England.
   MRC, Keneba, Senegal.
   MRC Labs, Fajara, Gambia.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC, Int Nutr Grp, 49-51 Bedford Sq, London WC1B 3DP, England.
EM a.prentice@lshtm.ac.uk
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G9827821, G9827821(62595)]
CR AABY P, 1990, AM J EPIDEMIOL, V132, P211
   AKANA SF, 1985, AM J PHYSIOL, V249, pR527
   ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A
   Barker D. J. P., 1998, MOTHERS BABIES DIS L
   BEACH RS, 1982, J NUTR, V112, P1169
   BEISEL WR, 1992, J NUTR, V122, P591
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   BLAIR ME, 1994, LANCET, V343, P208
   BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   CATER J, 1994, LOW BIRTHWEIGHT MED, P191
   *CDC WHO, 1992, ANTHRO SOFTW CALC PE
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   CHANDRA RK, 1975, SCIENCE, V190, P189
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   COLTEY M, 1987, CELL DIFFER DEV, V22, P71, DOI 10.1016/0045-6039(87)90414-3
   Dunger DB, 1998, NAT GENET, V19, P98, DOI 10.1038/ng0598-98
   FERGUSON AC, 1978, J PEDIATR-US, V93, P52, DOI 10.1016/S0022-3476(78)80599-X
   Fievet N, 1996, PARASITE IMMUNOL, V18, P483, DOI 10.1046/j.1365-3024.1996.d01-19.x
   GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x
   GOLDBERG GR, 1994, NUTR REV, V52, P191
   Good R.A., 1964, THYMUS IMMUNOBIOLOGY
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   Hall A.J., 1994, TOXICOLOGY AFLATOXIN, P233
   Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953
   Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1
   HEIJNEN CJ, 1998, P 22 INT C PED
   Kamiyasu M, 1997, CLIN IMMUNOL IMMUNOP, V83, P302, DOI 10.1006/clin.1996.4346
   KRAMER MS, 1996, LANCET, V349, P286
   LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5
   Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146
   Mackay IR, 1997, SEMIN LIVER DIS, V17, P3, DOI 10.1055/s-2007-1007178
   MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8
   MCGREGOR IA, 1987, PARASITOLOGIA, V29, P155
   MEURIS S, 1993, AM J TROP MED HYG, V48, P603
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1998, P NUTR SOC, V57, P241, DOI 10.1079/PNS19980038
   Owens JA, 1989, ADV FETAL PHYSL, P263
   PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143
   Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757
   PHILLIPS DIW, 1993, Q J MED, V86, P247
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   RichEdwards JW, 1997, BRIT MED J, V315, P396
   ROWLAND MGM, 1981, SEASONAL DIMENSIONS, P164
   ROWLAND S G J G, 1985, Journal of Diarrhoeal Diseases Research, V3, P7
   Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   VICTORA CG, 1988, PEDIATRICS, V81, P807
   WATKINSON M, 1985, T ROY SOC TROP MED H, V79, P448, DOI 10.1016/0035-9203(85)90059-8
   WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K
   WINICK M, 1966, J NUTR, V89, P300
NR 52
TC 125
Z9 127
U1 0
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD DEC
PY 1999
VL 28
IS 6
BP 1088
EP 1095
DI 10.1093/ije/28.6.1088
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 270FB
UT WOS:000084523800011
PM 10661652
OA No
DA 2017-08-15
ER

PT J
AU Coleman, R
AF Coleman, R
TI Disability in developing countries
SO LANCET
LA English
DT Letter
RP Coleman, R (reprint author), Box 273, Banjul, Gambia.
CR Ingstad B, 1999, LANCET, V354, P757, DOI 10.1016/S0140-6736(99)06049-3
   James KC, 1999, LANCET, V354, P87, DOI 10.1016/S0140-6736(99)90060-0
   Murray CJL, 1997, B WORLD HEALTH ORGAN, V75, P377
   Ustun TB, 1999, LANCET, V354, P111, DOI 10.1016/S0140-6736(98)07507-2
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 13
PY 1999
VL 354
IS 9191
BP 1736
EP 1736
DI 10.1016/S0140-6736(05)76730-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 255CW
UT WOS:000083652800068
PM 10568610
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Leach, A
   Hall, AJ
   Obaro, S
   McAdam, KPWJ
   Smith, PG
   Greenwood, BM
AF Jaffar, S
   Leach, A
   Hall, AJ
   Obaro, S
   McAdam, KPWJ
   Smith, PG
   Greenwood, BM
TI Preparation for a pneumococcal vaccine trial in The Gambia: individual
   or community randomisation?
SO VACCINE
LA English
DT Article
ID DEVELOPING-COUNTRIES; VERBAL AUTOPSIES; CHILDREN; DISEASE; CHILDHOOD;
   LIMITATIONS; POPULATION; PREVENTION; MORTALITY; PNEUMONIA
AB In preparation for a large phase-3 trial of pneumococcal polysaccharide/conjugate vaccine among infants in The Gambia, the relative merits of community and individual randomisation were considered. The impact of vaccination might be enhanced in a community randomised trial if there was a substantial 'herd' effect. This might occur if those vaccinated comprise a substantial proportion of potential transmitters of infection. However, there are few data on the sources of pneumococcal infections in The Gambia and with the high degree of mobility of people in The Gambia, it seems unlikely that any herd effect would be strong. In the absence of a herd effect, a community-randomised trial would have lower power for the mortality end-points compared to an individually randomised trial of the same size. In addition, a community-randomised trial might not provide sufficient control against potential confounders and blinding might be difficult to sustain if the vaccine has a strong effect. An individually randomised trial seems a better strategy under the conditions prevailing in The Gambia. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Med Res Council Labs, Banjul, Gambia.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
CR BLACK S, 1998, PNEUMOCOCCAL VACCINE
   Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277
   DALLESANDRO U, 1995, LANCET, V345, P479
   DALLESANDRO U, 1996, THESIS U LONDON
   DAVIDSON M, 1994, J INFECT DIS, V170, P368
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Maude GH, 1997, INT J EPIDEMIOL, V26, P1097, DOI 10.1093/ije/26.5.1097
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SMITH PG, 1996, FIELD TRIAL HLTH INT
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   TODD JE, 1994, ANN TROP PAEDIATR, V14, P31
   TORZILLO PJ, 1995, MED J AUSTRALIA, V162, P182
NR 21
TC 18
Z9 18
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 12
PY 1999
VL 18
IS 7-8
BP 633
EP 640
DI 10.1016/S0264-410X(99)00277-7
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 256NP
UT WOS:000083731800010
PM 10547422
OA No
DA 2017-08-15
ER

PT J
AU Duraisingh, MT
   Jones, P
   Sambou, I
   Von Seidlein, L
   Pinder, M
   Warhurst, DC
AF Duraisingh, MT
   Jones, P
   Sambou, I
   Von Seidlein, L
   Pinder, M
   Warhurst, DC
TI Inoculum effect leads to overestimation of in vitro resistance for
   artemisinin derivatives and standard antimalarials: a Gambian field
   study
SO PARASITOLOGY
LA English
DT Article
DE Plasmodium falciparum; artemisinin; in vitro; susceptibility; The
   Gambia; inoculum effect
ID PLASMODIUM-FALCIPARUM; IN-VITRO; HALOFANTRINE RESISTANCE; CHLOROQUINE
   RESISTANCE; PFMDR1 GENE; MEFLOQUINE; QINGHAOSU; MALARIA; AFRICAN;
   SUSCEPTIBILITY
AB Artemisinin (QHS) and its derivatives are new antimalarials which are effective against Plasmodium falciparum parasites resistant to chloroquine (CQ). As these drugs are introduced it is imperative that resistance is monitored. In this paper we demonstrate that the inoculum size used in in vitro testing influences the measured in vitro susceptibility to QHS and its derivative dihydroartemisinin (DHA) and to mefloquine (MEF) and CQ over the range of parasitaemias routinely used in testing with the WHO in vitro microtest. An increase in parasitaemia and/or haematocrit was accompanied by a decrease in the measured sensitivity of 2 laboratory lines. In the context of a field study testing in vitro susceptibility of parasite isolates from patients with uncomplicated malaria in Fajara, The Gambia we demonstrate that failure to control for inoculum size significantly overestimates the level of resistance to QHS and DHA as well as MEF, halofantrine (HAL) and quinine (QUIN). When controlling for the inoculum effect, cross-resistance mas observed between QHS, MEF and HAL suggesting the presence of a multidrug resistance-like mechanism. These studies underline the importance of inoculum size in in vitro susceptibility testing.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Med Res Council Labs, Fajara, Gambia.
RP Warhurst, DC (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
FU Wellcome Trust
CR Alin MH, 1995, AM J TROP MED HYG, V53, P639
   Alin MH, 1997, PARASITOLOGY, V114, P503
   BARNES DA, 1992, EMBO J, V11, P3067
   BASCO LK, 1993, AM J TROP MED HYG, V49, P301
   Bray PG, 1996, MOL PHARMACOL, V50, P1551
   DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710
   GAY F, 1994, LANCET, V343, P850, DOI 10.1016/S0140-6736(94)92049-4
   Gay F, 1997, AM J TROP MED HYG, V56, P315
   GEARY TG, 1990, BIOCHEM PHARMACOL, V40, P685, DOI 10.1016/0006-2952(90)90302-2
   GLUZMAN IY, 1987, ANTIMICROB AGENTS CH, V31, P32
   HIEN TT, 1993, LANCET, V341, P603
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B
   NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7
   ONEILL MJ, 1985, PLANTA MED, V5, P394
   PEEL SA, 1994, AM J TROP MED HYG, V51, P648
   PONNUDURAI T, 1981, TROP GEOGR MED, V33, P50
   Pradines B, 1998, AM J TROP MED HYG, V58, P354
   Ritchie GY, 1996, MOL BIOCHEM PARASIT, V83, P35, DOI 10.1016/S0166-6851(96)02746-6
   TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, V2, P1765
   WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S
NR 23
TC 22
Z9 22
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD NOV
PY 1999
VL 119
BP 435
EP 440
DI 10.1017/S0031182099004953
PN 5
PG 6
WC Parasitology
SC Parasitology
GA 257YB
UT WOS:000083809400002
PM 10599075
OA No
DA 2017-08-15
ER

PT J
AU Lewallen, S
   Harding, SP
   Ajewole, J
   Schulenburg, WE
   Molyneux, ME
   Marsh, K
   Usen, S
   White, NJ
   Taylor, TE
AF Lewallen, S
   Harding, SP
   Ajewole, J
   Schulenburg, WE
   Molyneux, ME
   Marsh, K
   Usen, S
   White, NJ
   Taylor, TE
TI A review of the spectrum of clinical ocular fundus findings in
   P-falciparum malaria in African children with a proposed classification
   and grading system
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium-falciparum; ophthalmology; classification system;
   Malawi; Kenya; The Gambia
ID CEREBRAL MALARIA
AB Ocular fundus pathology in Plasmodium falciparum malaria is common and has prognostic significance. We have made a collaborative effort to document the ocular features in several populations. Based on examination of 735 patients in Malawi, Kenya and The Gambia by direct and indirect ophthalmoscopy with dilated pupils, we have determined that the 5 distinct clinical features (in order of frequency) include retinal whitening, haemorrhages, unique Vessel abnormalities, papilloedema, and cotton wool spots. Photographs and descriptions of these are presented, along with a proposed grading scheme.
C1 Univ British Columbia, St Pauls Hosp, Dept Ophthalmol, British Columbia Ctr Epidemiol & Int Ophthalmol, Vancouver, BC V6Z 1Y6, Canada.
   Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   Natl Eye Care Project, Banjul, Gambia.
   Western Eye Hosp, London, England.
   Univ Malawi, Coll Med, Wellcome Trust Labs, Zomba, Malawi.
   Univ Malawi, Coll Med, Malaria Project, Zomba, Malawi.
   Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England.
   Kenya Med Res Inst, Clin Res Ctr, Kilifi, Kenya.
   MRC Labs, Banjul, Gambia.
   Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA.
RP Lewallen, S (reprint author), Univ British Columbia, St Pauls Hosp, Dept Ophthalmol, British Columbia Ctr Epidemiol & Int Ophthalmol, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
RI White, Nicholas/I-4629-2012
OI Harding, Simon/0000-0003-4676-1158
FU Wellcome Trust
CR AISEN ML, 1983, ARCH OPHTHALMOL-CHIC, V101, P1049
   BYWATER HH, 1922, T OPHTHAL SOC UK, V42, P359
   DAVIS MW, 1982, PAPUA NEW GUINEA MED, V25, P19
   DAVIS TME, 1992, CLIN INFECT DIS, V15, P256
   GRANT WM, 1946, ARCH OPHTHALMOL-CHIC, V35, P48
   Hero M, 1997, ARCH OPHTHALMOL-CHIC, V115, P997
   HOLLER C, 1978, NOUV PRESSE MED, V39, P2554
   JEAN B, 1987, OPHTHALMOLOGICA, V195, P141
   LAGRAULET J, 1967, B SOC PATHOL EXOT, V3, P216
   Lewallen S, 1996, T ROY SOC TROP MED H, V90, P144, DOI 10.1016/S0035-9203(96)90116-9
   LEWALLEN S, 1993, OPHTHALMOLOGY, V100, P857
   LEWALLEN S, 1993, LANCET, V93, P341
   LOOAREESUWAN S, 1983, AM J TROP MED HYG, V32, P911
   MURRAY CJL, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90364-K
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   RUBENSTE.RA, 1968, AM J OPHTHALMOL, V65, P435
   RUNYAN TE, 1977, ANN OPHTHALMOL, V9, P1521
NR 17
TC 66
Z9 67
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1999
VL 93
IS 6
BP 619
EP 622
DI 10.1016/S0035-9203(99)90071-8
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 271BL
UT WOS:000084572700018
PM 10717749
OA No
DA 2017-08-15
ER

PT J
AU Snow, WF
   Rawlings, P
AF Snow, WF
   Rawlings, P
TI Methods for the rapid appraisal of African animal trypanosomosis in the
   Gambia
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article
DE trypanosomosis; cattle-parasitological diseases; rapid appraisal; tsetse
   surveys; N'Dama cattle; the Gambia
ID TSETSE CHALLENGE; NDAMA CATTLE; TRYPANOTOLERANT; PREVALENCE
AB A technique for the rapid field assessment of African animal trypanosomosis (AAT) was developed during studies in the Gambia. This involved gathering indigenous information from rapid-appraisal questionnaires addressed to local informants, the results of single tsetse/surveys and evaluations of the prevalence of trypanosome infections in village cattle. Local informants included livestock owners and herdsmen and trained personnel such as livestock assistants. The answers to the questionnaires were weighted in order to translate them into semi-quantitative ranked estimates (zero, low, medium, high or very severe) of the severity of AAT problems. A similar ranking was also defined for tsetse and prevalence data in the Gambia, The three assessment methods generally gave complementary results leading to similar conclusions about the severity of tsetse-trypanosomosis problems in a survey area; inconsistencies usually suggested that additional information was needed. The rankings of AAT intensity were used to develop management guidelines for minimising the impact of AAT at different levels through control interventions or improved livestock management. The methodology was designed to provide reliable, up-to-date and cost-effective assessments of AAT problems. Emphasis was placed on the importance of the involvement, priorities and perceptions of village livestock owners and herdsmen in making these assessments. (C) 1999 Elsevier Science B.V, All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Snow, WF (reprint author), 11 Newland Rd, Banbury OX16 8HQ, Oxon, England.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Agyemang K, 1997, VILLAGE NDAMA CATTLE
   de Almeida PJLP, 1998, VET PARASITOL, V80, P111
   FAO, 1992, TRAIN MAN TSETS CONT, V4
   Ford J., 1977, DISTRIBUTION TSETSE
   Ghirotti M., 1993, World Animal Review, P26
   Hendrickx G., 1995, World Animal Review, P68
   Hopkins JS, 1998, PREV VET MED, V37, P91, DOI 10.1016/S0167-5877(98)00101-9
   Hursey B. S., 1995, World Animal Review, P67
   *IIED, 1994, 20 RRA IIED
   ITTY P, 1992, EC VILLAGE CATTLE PR, P316
   Jordan A.M., 1986, TRYPANOSOMIASIS CONT
   KABORE I, 1995, P 8 INT C I TROP VET, P521
   LEAK SGA, 1990, INSECT SCI APPL, V11, P293
   LEPERRE P, 1994, TROP ANIM HEALTH PRO, V26, P139, DOI 10.1007/BF02241070
   Masake RA, 1997, EXP PARASITOL, V85, P193, DOI 10.1006/expr.1996.4124
   MCNAMARA JJ, 1991, ACTA TROP, V48, P127
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Murray M, 1983, LIVESTOCK PRODUCTIVI
   Nabasa J., 1995, PARTICIPATORY RURAL
   Norton GA., 1993, DECISION TOOLS PEST
   POLLOCK J, 1986, TRAINING MANUAL TSET, V1
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   Snedecor G. W., 1980, STAT METHODS
   Snow WF, 1996, AGR SYST, V51, P339, DOI 10.1016/0308-521X(95)00048-A
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   SNOW WF, 1997, UNPUB SURVEY PERCEPT
   SNOW WF, 1999, P 24 M INT SCI COUNC
   SNOW WF, 1995, P 22 M INT SCI COUNC
   SNOW WF, 1996, P 8 INT C I TROP VET, P308
   SUMBERG JE, 1992, TROP ANIM HEALTH PRO, V24, P193, DOI 10.1007/BF02356744
   VLASSOFF C, 1991, PARASITOL TODAY, V7, P37, DOI 10.1016/0169-4758(91)90186-R
   WACHER TJ, 1993, ANN TROP MED PARASIT, V87, P517
   WACHER TJ, 1994, PARASITOLOGY, V109, P149
   WATERSBAYER A, 1994, 422 GTZ DRUCK KINZ
NR 37
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
J9 PREV VET MED
JI Prev. Vet. Med.
PD OCT 31
PY 1999
VL 42
IS 2
BP 67
EP 86
DI 10.1016/S0167-5877(99)00072-0
PG 20
WC Veterinary Sciences
SC Veterinary Sciences
GA 247ZT
UT WOS:000083251400001
PM 10551427
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
AF Bojang, KA
TI The diagnosis of Plasmodium falciparum infection in Gambian children, by
   field staff using the rapid, manual, ParaSight (TM)-F test
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Article
ID MALARIA; TOOL
AB A rapid immunodiagnostic test for Plasmodium falciparum, the ParaSigh(TM)-F test, was evaluated in the diagnosis of malaria in 139 children with uncomplicated malaria, who presented at the Medical Research Council's clinic at Basse in Upper River division, The Gambia. The aim was to evaluate the performance and usefulness of the test as a diagnostic method in a malaria-endemic area, when performed by a field worker. Compared with microscopy, the test had a sensitivity of 96.5%, a specificity of 90.5%, a negative predictive value of 94.2% and a positive predictive value of 94.3%. Because of its sensitivity, specificity and simplicity, the ParaSight-F test will be of value in situations where microscopy is not possible.
C1 MRC Labs, Banjul, Gambia.
RP Bojang, KA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Banchongaksorn T, 1996, T ROY SOC TROP MED H, V90, P244, DOI 10.1016/S0035-9203(96)90231-X
   BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2
   BOJANG KA, 1999, IN PRESS TROPICAL ME
   Craig MH, 1997, T ROY SOC TROP MED H, V91, P279, DOI 10.1016/S0035-9203(97)90074-2
   Kodisinghe HM, 1997, T ROY SOC TROP MED H, V91, P398, DOI 10.1016/S0035-9203(97)90255-8
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   PREMJI Z, 1994, T ROY SOC TROP MED H, V88, P414
   SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S
   Verle P, 1996, TROP MED INT HEALTH, V1, P794
NR 9
TC 22
Z9 23
U1 0
U2 0
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD OCT
PY 1999
VL 93
IS 7
BP 685
EP 687
PG 3
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA 255KF
UT WOS:000083667500003
PM 10715695
OA No
DA 2017-08-15
ER

PT J
AU Laskey, MA
   Prentice, A
AF Laskey, MA
   Prentice, A
TI Comparison of adult and paediatric spine and whole body software for the
   Lunar dual energy X-ray absorptiometer
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID BONE-MINERAL DENSITY; OSTEOPOROSIS; PERFORMANCE; PRECISION; CHILDREN;
   MASS
AB Simple phantoms were devised to compare the performance of adult (software 3.64) and paediatric (software 3.8 g) spine and whole body software developed for the Lunar dual energy X-ray absorptiometer. Rectangular slabs of aluminium with high (1.18 g cm(-2)) and low (0.57 g cm-2) density were used to represent bone mineral. For spine measurements, the phantoms were scanned in water at depths of 5-20 cm. For whole body measurements, the phantoms were scanned with known amounts of oil and water to represent fat and lean tissue. This simulated tissue depths of 5.5-19.7 cm and body composition ranging from 14-29% fat. There were systematic differences in spine and whole body bone mineral content (BMC), bone area (BA) and bone mineral density (BMD) measurements and also between adult and paediatric software versions. The magnitude and direction of these differences were dependent on BMD of the phantom and tissue depth. Similar systematic differences were observed in vivo when volunteers were scanned using adult and paediatric software. Paediatric software enabled measurements to be made at low tissue depths. The weights of fat, lean and total soft tissue measured by the adult and paediatric whole body software were similar to the values calculated from the known composition of the phantom. Precision estimates for all softwares were excellent. In conclusion, paediatric software should improve bone mineral measurements of children but the discrepancies between adult and paediatric softwares may cause problems in longitudinal studies of skeletal growth and when compiling reference data from infancy through to adulthood.
C1 MRC, Cambridge CB4 1XJ, England.
   MRC Keneba, Keneba, Gambia.
RP Laskey, MA (reprint author), MRC, Downhams Lane,Milton Rd, Cambridge CB4 1XJ, England.
CR CHESNEY RW, 1978, AM J DIS CHILD, V132, P768
   Falcini F, 1996, J ENDOCRINOL INVEST, V19, P165
   HANGARTNER TN, 1990, BONE MINER, V9, P71, DOI 10.1016/0169-6009(90)90101-K
   HANSEN MA, 1991, BRIT MED J, V303, P961
   Joakimsen RM, 1997, OSTEOPOROSIS INT, V7, P503, DOI 10.1007/BF02652555
   JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204
   LASKEY MA, 1991, BRIT J RADIOL, V64, P1023
   LASKEY MA, 1992, EUR J CLIN NUTR, V46, P39
   MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106
   Molgaard C, 1997, ARCH DIS CHILD, V76, P9
   Njeh CF, 1997, BRIT J RADIOL, V70, P719
   OGLE GD, 1995, AM J CLIN NUTR, V61, P746
   PECK WA, 1993, AM J MED, V94, P646
   SLEMENDA CW, 1991, J BONE MINER RES, V6, P561
   TOTHILL P, 1994, BRIT J RADIOL, V67, P1210
   Ulrich CM, 1996, AM J CLIN NUTR, V63, P72
   1998, LUNAR NEWS       AUT, P10
NR 17
TC 19
Z9 19
U1 0
U2 3
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD OCT
PY 1999
VL 72
IS 862
BP 967
EP 976
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 246DH
UT WOS:000083148200008
PM 10673948
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Gatchalian, SR
   Ogunlesi, O
   Smith, A
   McCracken, GH
   Qazi, S
   Weber, AF
   Olsen, K
   Mulholland, EK
AF Weber, MW
   Gatchalian, SR
   Ogunlesi, O
   Smith, A
   McCracken, GH
   Qazi, S
   Weber, AF
   Olsen, K
   Mulholland, EK
TI Chloramphenicol pharmacokinetics in infants less than three months of
   age in the Philippines and The Gambia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE chloramphenicol; developing countries; pneumonia; meningitis; child
ID ORAL CHLORAMPHENICOL; CHILDREN; PHARMACOLOGY; SUCCINATE
AB Background. The broad antimicrobial spectrum and affordable price of chloramphenicol make it an attractive first line treatment option for children with severe illnesses in developing countries. Little is known, however, about its pharmacokinetics in young infants in these settings.
   Methods. We studied infants younger than 3 months of age hospitalized in Manila, Philippines and The Gambia with possible severe bacterial infections likely to benefit from treatment with chloramphenicol. Infants in the first week of life received intramuscular doses of 25 mg/kg chloramphenicol once daily, twice daily in the second through fourth week of life and three times daily from 5 to 12 weeks of age. Blood samples There taken at 0.5, 1, 2 and 3 h after the first dose, 1 h before the second dose and before the repetition doses on subsequent days. In the Philippines a second group of infants was treated with oral chloramphenicol according to the same dosage schedule.
   Results. Thirty-eight infants received intramuscular chloramphenicol, and 20 received oral drug. Intramuscular administration resulted in therapeutic concentrations (10 to 25 mu g/ml) in 73 to 86% of children in each of the three age groups in the first 6 h and in 50 to 80% on Days 2 and 3. Between 33 and 38% of children had potentially toxic values on Days 2 and 3. In contrast, after oral administration, only about one-half of the children reached therapeutic values in serum at any time up to Day 3 after start of treatment.
   Conclusions. Intramuscular chloramphenicol can be used as a second line drug for the treatment of severe infections in infants younger than 90 days of age, where third generation cephalosporins are not available. It quickly achieves therapeutic values in a high proportion of children. However, severe infections should not be treated with oral chloramphenicol in this age group, because therapeutic serum concentrations were inconsistently achieved.
C1 WHO, CAH, CH-1211 Geneva 27, Switzerland.
   Med Res Council Labs, Fajara, Gambia.
   Res Inst Trop Med, Metro Manila, Manila, Philippines.
   Univ Texas, SW Med Ctr, Dallas, TX USA.
RP Weber, MW (reprint author), WHO, CAH, CH-1211 Geneva 27, Switzerland.
CR BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   HELLRIEGEL KP, 1974, POSTGRAD MED J, V50, P136
   Ismail R, 1998, ANN TROP PAEDIATR, V18, P123
   KAUFFMAN RE, 1981, J PEDIATR-US, V99, P963, DOI 10.1016/S0022-3476(81)80034-0
   MCCURDY PR, 1963, BLOOD, V21, P363
   RICH ML, 1950, ANN INTERN MED, V33, P1459
   RISTUCCIA AM, 1985, THER DRUG MONIT, V7, P159, DOI 10.1097/00007691-198506000-00004
   SAEZLLORENS X, 1998, TXB PEDIAT INFECT DI, P892
   SCOTT JL, 1965, NEW ENGL J MED, V272, P1137, DOI 10.1056/NEJM196506032722201
   SHANN F, 1985, NEW ENGL J MED, V313, P410, DOI 10.1056/NEJM198508153130703
   SMITH AL, 1983, PEDIATR CLIN N AM, V30, P209
   SUTHERLAND JM, 1959, AMA J DIS CHILD, V97, P761
   TUOMANEN EI, 1981, J PEDIATR-US, V99, P968, DOI 10.1016/S0022-3476(81)80035-2
   WEISS CF, 1960, NEW ENGL J MED, V262, P787, DOI 10.1056/NEJM196004212621601
   WHO, 1995, INT MAN CHILDH ILLN
NR 15
TC 5
Z9 5
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
BP 896
EP 901
DI 10.1097/00006454-199910000-00012
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 245XA
UT WOS:000083132400011
PM 10530587
OA No
DA 2017-08-15
ER

PT J
AU Margolis, P
   Mulholland, EK
   Harrell, F
   Gove, S
   McCaul, F
   Parker, S
   Byass, P
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, N
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
AF Margolis, P
   Mulholland, EK
   Harrell, F
   Gove, S
   McCaul, F
   Parker, S
   Byass, P
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, N
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
CA WHO Young Infants Study Grp
TI Clinical prediction of serious bacterial infections in young infants in
   developing countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE bacterial infection; infants; developing countries; clinical prediction;
   clinical signs
ID ILLNESS; MANAGEMENT; CHILDREN; MODELS; SYSTEM
C1 EthioSwedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Res Inst Trop Med, Alabang, Philippines.
   Univ Virginia, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA USA.
   Univ N Carolina, Dept Pediat, Chapel Hill, NC USA.
RP Mulholland, EK (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Nolan, Terry/A-2236-2008; Carlin, John/B-3492-2012
OI Nolan, Terry/0000-0001-6018-3863; Carlin, John/0000-0002-2694-9463
CR ALTMAN DG, 1991, BRIT J CANCER, V64, P975, DOI 10.1038/bjc.1991.441
   BAKER MD, 1993, NEW ENGL J MED, V329, P1437, DOI 10.1056/NEJM199311113292001
   Gorelick MH, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e6
   GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018
   Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.3.CO;2-F
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   HEWSON PH, 1995, J PAEDIATR CHILD H, V31, P29, DOI 10.1111/j.1440-1754.1995.tb02908.x
   JASKIEWICZ JA, 1994, PEDIATRICS, V94, P390
   MARGOLIS PA, 1994, J PEDIATR-US, V124, P552, DOI 10.1016/S0022-3476(05)83133-6
   MCCARTHY PL, 1982, PEDIATRICS, V70, P802
   MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100
   Steinhoff MC, 1997, LANCET, V350, P918, DOI 10.1016/S0140-6736(97)03317-5
   Stoll BJ, 1997, CLIN PERINATOL, V24, P1
   *WHO, 1989, M RAD WORK GROUP
   *WHO, 1997, PER MORT LIST AV INF
   *WHO, 1989, WHOARI9014
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS8
NR 18
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S23
EP S31
PG 9
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000005
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, EK
   Ogunlesi, OO
   Adegbola, RA
   Weber, M
   Sam, BE
   Palmer, A
   Manary, MJ
   Secka, O
   Aidoo, M
   Hazlett, D
   Whittle, H
   Greenwood, BM
AF Mulholland, EK
   Ogunlesi, OO
   Adegbola, RA
   Weber, M
   Sam, BE
   Palmer, A
   Manary, MJ
   Secka, O
   Aidoo, M
   Hazlett, D
   Whittle, H
   Greenwood, BM
TI Etiology of serious infections in young Gambian infants
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE neonatal sepsis; meningitis; pneumonia; Streptococcus pneumoniae; group
   B Streptococcus; Salmonella spp.; respiratory syncytial virus; influenza
   virus; developing countries; Africa
ID HEMOPHILUS-INFLUENZAE; WEST-AFRICA; MENINGITIS; CARRIAGE; CHILDREN;
   SEPTICEMIA; MOTHERS; COUNTRY
AB Background. Despite improvements in infant mortality rates in many developing countries including The Gambia, neonatal mortality remains high and many neonatal deaths are caused by infection. The study described in this paper was conducted to determine the bacterial and viral etiology of serious infections in Gambian infants younger than 91 days old.
   Methods. At a first level health facility 497 infants with symptoms that could indicate serious infection were enrolled, of whom 239 with 1 or more signs of serious infection and 55 with no signs were investigated, yielding 17 cases with positive bacterial cultures of blood and/or cerebrospinal fluid, At a nearby pediatric referral hospital 198 infants were seen and 182 were investigated, yielding 35 positive bacterial cultures,
   Results. There were 15 culture positive cases of meningitis caused by Streptococcus pneumoniae (7), Streptococcus pyogenes (2), Enterobacter cloacae (2), Escherichia coli (1), Haemophilus influenzae type b (1), Streptococcus agalactiae (1) and Salmonella spp, (1), Six of these children died, Thirty-three infants without meningitis had positive blood cultures for Staphylococcus aureus (17), S. pneumoniae (3), Salmonella spp, (5), E, coli (3), other enterobacteria (4) and S. agalactiae (1), of whom 14 died, Nasopharyngeal aspirates from 438 children were investigated for common respiratory viruses. Respiratory syncytial virus was found in 51, influenza A in 46, influenza B in 22, parainfluenza in 26 and adenovirus in 16, Respiratory syncytial virus and influenza A isolates were found most frequently toward the end of the wet season. Nasopharyngeal carriage of S, pneumoniae and H, influenzae was studied in 320 infants recruited during the first year. Of these 184 (58%) were positive for S, pneumoniae and 141 (44%) were positive for H, influenzae, 18 of which were type b, Infants with a bacterial isolate from blood or cerebrospinal fluid were more likely than the rest to die, whereas those with a viral isolate were less likely to die.
   Conclusions. The most important causes of serious infections in young Gambian infants are Staphylococcus aureus, S, pneumoniae and Salmonella spp.
C1 MRC Labs, Banjul, Gambia.
   Royal Victoria Hosp, Dept Paediat, Banjul, Gambia.
   Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
RP Mulholland, EK (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
CR Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   BAKER CJ, 1990, INFECT DIS FETUS NEW
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1989, T ROY SOC TROP MED H, V83, P831, DOI 10.1016/0035-9203(89)90345-3
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   CADOZ M, 1981, B WORLD HEALTH ORGAN, V59, P575
   Chiron J P, 1977, Bull Soc Med Afr Noire Lang Fr, V22, P221
   Cisse M F, 1989, Med Trop (Mars), V49, P265
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635
   HAFFEJEE IE, 1991, J INFECTION, V22, P225, DOI 10.1016/S0163-4453(05)80003-9
   MACFARLANE DE, 1987, ACTA PAEDIATR SCAND, V76, P470, DOI 10.1111/j.1651-2227.1987.tb10501.x
   MORENO MT, 1994, PEDIATR INFECT DIS J, V13, P516
   NATHOO KJ, 1991, ANN TROP PAEDIATR, V11, P11
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   SUARA RO, 1994, J INFECT DIS, V170, P1316
   *WHO YOUNG INF STU, 1999, PEDIAT INFECT DIS S, V18, pS7
NR 18
TC 57
Z9 57
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S35
EP S41
DI 10.1097/00006454-199910001-00007
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000007
PM 10530572
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   Byass, P
   Harrell, F
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Bongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, V
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gaechalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, T
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
AF Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   Byass, P
   Harrell, F
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Bongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, V
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gaechalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, T
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
CA WHO Young Infants Study Grp
TI Conclusions from the WHO multicenter study of serious infections in
   young infants
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE WHO multicenter study; serious infections; infants; neonatal sepsis;
   clinical signs
C1 EthioSwedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Res Inst Trop Med, Alabang, Philippines.
RP Mulholland, K (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Nolan, Terry/A-2236-2008; Carlin, John/B-3492-2012
OI Nolan, Terry/0000-0001-6018-3863; Carlin, John/0000-0002-2694-9463
CR Gatchalian SR, 1999, PEDIATR INFECT DIS J, V18, pS50, DOI 10.1097/00006454-199910001-00009
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119
   KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84
   Lehmann D, 1999, PEDIATR INFECT DIS J, V18, pS42, DOI 10.1097/00006454-199910001-00008
   Lehmann D, 1999, PEDIATR INFECT DIS J, V18, pS62, DOI 10.1097/00006454-199910001-00011
   Muhe L, 1999, PEDIATR INFECT DIS J, V18, pS56, DOI 10.1097/00006454-199910001-00010
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS4
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS8
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS23
NR 11
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S32
EP S34
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000006
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Mason, K
   Carlin, K
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lamont, A
   Palmer, P
AF Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Mason, K
   Carlin, K
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lamont, A
   Palmer, P
CA WHO Young Infants Study Grp
TI Serious infections in young infants in developing countries: rationale
   for a multicenter study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE serious infections; multicenter studies; World Health Organization;
   developing countries; neonatal sepsis; infant mortality
ID NEONATAL SEPTICEMIA; CHILDREN; PNEUMONIA; ETIOLOGY; INFLUENZAE;
   MENINGITIS; CITY
C1 WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
   EthioSwedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Res Inst Trop Med, Alabang, Philippines.
RP Mulholland, K (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Nolan, Terry/A-2236-2008
OI Nolan, Terry/0000-0001-6018-3863
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ALAUSA KO, 1977, SCAND J INFECT DIS, V9, P181
   BERNARDBONNIN AC, 1985, ANN SOC BELG MED TR, V65, P59
   Bhakoo O N, 1980, Indian J Pediatr, V47, P419, DOI 10.1007/BF02759845
   CHIRON JP, 1977, B SOC MED AFR NOIRE, V3, P221
   CHOUDHURY P, 1975, Indian Pediatrics, V12, P459
   CHUGH K, 1988, Indian Journal of Pediatrics, V55, P961, DOI 10.1007/BF02727838
   Cisse M F, 1989, Med Trop (Mars), V49, P265
   DAWODU AH, 1983, NIG J PAEDIAT, V10, P1
   ELZOUKI AY, 1985, PEDIATR INFECT DIS J, V4, P527, DOI 10.1097/00006454-198509000-00017
   FREEDMAN RM, 1981, AM J DIS CHILD, V135, P140
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   HARRIS MC, 1983, PEDIATR CLIN N AM, V30, P243
   KATZ AR, 1992, CLIN INFECT DIS, V14, P298
   KHATUA S P, 1986, Indian Journal of Pediatrics, V53, P509, DOI 10.1007/BF02749537
   MACFARLANE DE, 1987, ACTA PAEDIATR SCAND, V76, P470, DOI 10.1111/j.1651-2227.1987.tb10501.x
   MONGA K, 1986, Indian Journal of Pediatrics, V53, P505, DOI 10.1007/BF02749536
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   NAEYE RL, 1977, J PEDIATR-US, V90, P965, DOI 10.1016/S0022-3476(77)80573-8
   NATHOO KJ, 1991, ANN TROP PAEDIATR, V11, P11
   OHLSSON A, 1986, ACTA PAEDIATR SCAND, V75, P540, DOI 10.1111/j.1651-2227.1986.tb10246.x
   OKOLO AA, 1985, ANN TROP PAEDIATR, V5, P123
   OMENE JA, 1979, TROP GEOGR MED, V31, P35
   SAXENA S, 1980, INDIAN PEDIATR, V17, P17
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SHARMA P P, 1987, Indian Pediatrics, V24, P1011
   Singh M, 1978, Indian J Pediatr, V45, P314, DOI 10.1007/BF02749259
   SINHA N, 1986, Indian Journal of Pediatrics, V53, P249, DOI 10.1007/BF02748516
   Stoll BJ, 1997, CLIN PERINATOL, V24, P1
   TAFARI N, 1980, CIBA FDN, V77, P55
   World Health Organization, 1996, PER MORT LIST AV INF
   World Health Organization, 1990, WHOARI905
   YARDI D, 1984, Indian Journal of Pediatrics, V51, P173, DOI 10.1007/BF02825924
NR 34
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S4
EP S7
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000002
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Margolis, P
   Mason, K
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
AF Mulholland, K
   Margolis, P
   Mason, K
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, M
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrero, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Hendrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lament, A
   Palmer, P
CA WHO Young Infants Study Grp
TI Bacterial etiology of serious infections in young infants in developing
   countries: results of a multicenter study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE infections; infants; developing countries; multicenter study; neonatal
   infections; etiology
ID POLYSACCHARIDE VACCINE; MATERNAL IMMUNIZATION; STREPTOCOCCUS; CARRIAGE;
   DISEASE
C1 AthioSwedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Res Inst Trop Med, Alabang, Philippines.
RP Mulholland, K (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Nolan, Terry/A-2236-2008; Carlin, John/B-3492-2012
OI Nolan, Terry/0000-0001-6018-3863; Carlin, John/0000-0002-2694-9463
CR BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802
   FREEDMAN RM, 1981, AM J DIS CHILD, V135, P140
   KATZ AR, 1992, CLIN INFECT DIS, V14, P298
   Lehmann D, 1997, PEDIATR INFECT DIS J, V16, P297, DOI 10.1097/00006454-199703000-00009
   Lehmann D, 1999, PEDIATR INFECT DIS J, V18, pS42, DOI 10.1097/00006454-199910001-00008
   MACFARLANE DE, 1987, ACTA PAEDIATR SCAND, V76, P470, DOI 10.1111/j.1651-2227.1987.tb10501.x
   Muhe L, 1999, PEDIATR INFECT DIS J, V18, pS56, DOI 10.1097/00006454-199910001-00010
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Mulholland K, 1996, JAMA-J AM MED ASSOC, V275, P1182
   NATHOO KJ, 1991, ANN TROP PAEDIATR, V11, P11
   NEWELL KW, 1966, B WORLD HEALTH ORGAN, V35, P863
   ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Scott JAG, 1996, CLIN INFECT DIS, V22, P973
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Stoll BJ, 1997, CLIN PERINATOL, V24, P1
   SUARA RO, 1994, J INFECT DIS, V170, P1316
   World Health Organization, 1996, PER MORT LIST AV INF
   World Health Organization, 1990, WHOARI905
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS4
   The WHO Young Infants Study Group, 1999, PEDIAT INFECT DIS S, V18, pS8
NR 21
TC 4
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S17
EP S22
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000004
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, W
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrera, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Henrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lamont, A
   Palmer, P
AF Mulholland, K
   Margolis, P
   Gove, S
   McCaul, F
   Parker, S
   John, C
   Byass, P
   Harrell, F
   Mason, K
   Carlin, J
   Ogunlesi, O
   Weber, M
   Manary, M
   Palmer, A
   Adegbola, R
   Whittle, H
   Secka, O
   Sam, B
   Hazlett, D
   Aidoo, W
   Bangali, J
   Greenwood, B
   Muhe, L
   Tilahun, M
   Lulseged, S
   Kebede, S
   Yohanes, A
   Belete, B
   Ringertz, S
   Desta, T
   Woldeyesus, K
   Tafari, N
   Lehmann, D
   Saleu, G
   Rongap, A
   Kakazo, M
   Namuigi, P
   Lupiwa, S
   Sehuko, R
   Clegg, A
   Sanders, R
   Michael, A
   Lupiwa, T
   Omena, M
   Mens, M
   Marjen, B
   Wai'in, P
   Sungu, M
   Lewis, D
   Alpers, M
   Gatchalian, S
   Quiambao, B
   Moreles, AM
   Abraham, L
   Sombrera, L
   Palladin, F
   Sariano, V
   Obach, AM
   Sunico, E
   Cedulla, T
   Eichenwald, H
   Broome, C
   Gratten, M
   Margolis, P
   Facklam, R
   Nolan, T
   Henrichsen, J
   Makela, PH
   Grandien, M
   Schachter, J
   Moore, L
   Cassell, G
   Duffy, L
   Facklam, R
   Tenover, F
   Metchock, B
   Tschappeler, H
   Hendry, M
   Lamont, A
   Palmer, P
CA WHO Young Infants Study Grp
TI Methodology for a multicenter study of serious infections in young
   infants in developing countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE multicenter study; serious infections; infants; developing countries
ID ORGANIZATION; MORTALITY; PATTERN; ILLNESS
C1 EthioSwedish Childrens Hosp, Dept Paediat & Child Hlth, Addis Ababa, Ethiopia.
   MRC Labs, Banjul, Gambia.
   Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   Res Inst Trop Med, Alabang, Philippines.
RP Mulholland, K (reprint author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland.
RI Nolan, Terry/A-2236-2008; Carlin, John/B-3492-2012
OI Nolan, Terry/0000-0001-6018-3863; Carlin, John/0000-0002-2694-9463
CR Balows A., 1991, MANUAL CLIN MICROBIO
   BLUMENSTEIN BA, 1995, CONTROL CLIN TRIALS, V16, pS4
   COAKLEY K, 1993, ASARO SURVEILLANCE U
   *ETH MIN HLTH, 1994, IND HLTH
   Farrell B, 1998, BRIT MED J, V317, P1236
   Gatchalian SR, 1999, PEDIATR INFECT DIS J, V18, pS50, DOI 10.1097/00006454-199910001-00009
   GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018
   Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.3.CO;2-F
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Lehmann D, 1999, PEDIATR INFECT DIS J, V18, pS42, DOI 10.1097/00006454-199910001-00008
   LEVENTHAL J, 1992, JCLIN PEDIAT, V21, P730
   MARGOLIS PA, 1994, J PEDIATR-US, V124, P552, DOI 10.1016/S0022-3476(05)83133-6
   MCCARTHY PL, 1982, PEDIATRICS, V70, P802
   *MIN HLTH PHIL, 1991, OFF STAT
   Muhe L, 1999, PEDIATR INFECT DIS J, V18, pS56, DOI 10.1097/00006454-199910001-00010
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   MULHOLLAND EK, 1999, PEDIAT INFECT DIS S, V18, pS4
   Shamebo D., 1990, Ethiopian Journal of Health Development, V4, P15
   SHAMEBO D, 1991, J TROP PEDIATRICS, V37, P254
   United Nations Development Programme, 1995, HUM DEV REP 1995
   *WHO, 1989, WHOARI9013
   *WHO, 1992, B WORLD HEALTH ORGAN, V70, P699
   *WHO, 1989, WHOARI9014
NR 23
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1999
VL 18
IS 10
SU S
BP S8
EP S16
PG 9
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 246XK
UT WOS:000083190000003
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Faye, JA
   Buscher, P
AF Mattioli, RC
   Faye, JA
   Buscher, P
TI Susceptibility of N'Dama cattle to experimental challenge and
   cross-species superchallenges with bloodstream forms of Trypanosoma
   congolense and T-Vivax
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE cattle-protozoa; Trypanosoma congolense; Trypanosoma vivax;
   susceptibility; cross superchallenge
ID VARIABLE ANTIGEN TYPES; AFRICAN TRYPANOSOMIASIS; MILK-PRODUCTION; BORAN
   CATTLE; ZEBU CATTLE; INFECTIONS; GAMBIA; TRYPANOTOLERANCE;
   ESTABLISHMENT; INTERFERENCE
AB Susceptibility to Trypanosoma congolense, T. vivax challenge and cross species-superchallenges, and related effects on health and productivity were assessed in N'Dama cattle. Twenty-five N'Dama bulls aged 3-4 years and previously primed with trypanosome infections through natural tsetse exposure over more than one year were used. The experimental herd was divided in five groups each composed of five randomly selected animals. Group 1 was challenged with T. congolense, Group 2 with T. vivax, Group 3 was inoculated with T. congolense followed by a cross-superchallenge with T. vivax. Group 3 was inoculated with T. vivax followed by T. congolense cross-superchallenge. Animals in Group 5 were used as controls. Both T. vivax and T congolense cross-superchallenges were carried out on Day 14 subsequent to respective initial T. congolense and T. vivax inoculations. All challenges were performed by intradermal needle inoculation of stocks of trypanosome bloodstream forms. In challenged animals (Group 1 to 4), parasitaemia profiles and packed red cell volumes (PCV) were measured for four months. Weight changes were recorded monthly and daily weight gain (DWG) computed. All cattle challenged with T. congolense became parasitaemic. Conversely, one animal in Group 2 and two in Group 3 never displayed patent T. vivax parasitaemia. Both in single (Group 1), initial (Group 3) and cross-superchallenged (Group 4) cattle higher percentage of positive blood samples and higher parasitaemia level were obtained following I congolense than T. vivax inocula (Group 2, 3 and 4) (P < 0.04 or greater). Overall the pre-challenge period, PCV values and DWGs were nearly identical in the five groups. Conversely, over the post-challenge period, cattle singly, initially and cross-superinoculated with T. congolense (Group 1, 3 and 4) displayed lower PCV values and DWGs in comparison with both control animals (Group 5) and with singly T. vivax challenged cattle (Group 2) (P < 0.05 or greater). No difference in mean PCV levels and DWGs was found between animals in Group 2 and cattle in Group 5. It was concluded that trypanotolerant N'Dama cattle suffered more from T. congolense and mixed congolertsel T. vivax infections, while pure T vivax: infection did not produce appreciable negative effects on their health and productivity. Therefore, considering that tsetse and trypanosomosis control campaigns are costly and are justified only when derived economic benefits exceed those of control, and also that an ample mosaic of fanning systems exists in West Africa, species-specific trypanosome prevalence and relative impact should be assessed in various cattle populations and breeds differing in trypanosome susceptibility before advising any intervention. Moreover, virulence and related effects of T. congolense and T. vivax endemic stocks on health and productivity in local cattle populations should also be estimated in order to counsel appropriate economic protection measures against trypanosmosis, i.e. vector control and/or strategic use of trypanocidal drugs. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
RI Buscher, Philippe/B-9956-2012
OI Buscher, Philippe/0000-0002-1926-7472
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475
   CONNOR RJ, 1987, TROP ANIM HEALTH PRO, V19, P165, DOI 10.1007/BF02239713
   DAR F K, 1972, Tropical Animal Health and Production, V4, P237, DOI 10.1007/BF02360116
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   DWINGER RH, 1986, RES VET SCI, V41, P307
   DWINGER RH, 1989, VET PARASITOL, V30, P177, DOI 10.1016/0304-4017(89)90013-7
   DWINGER RH, 1994, VET QUART, V16, P81
   *ILRAD, 1991, MECH WHICH CATTLE AC, P1
   Itty P., 1994, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V47, P333
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JORDAN AM, 1986, TRYPANSOMIASIS CONTR
   LEPERRE P, 1994, TROP ANIM HEALTH PRO, V26, P139, DOI 10.1007/BF02241070
   LUCKINS AG, 1986, PARASITOLOGY, V93, P99
   LUCKINS AG, 1990, ACTA TROP, V47, P129, DOI 10.1016/0001-706X(90)90018-U
   MATTIOLI R C, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P459
   Mattioli RC, 1998, ACTA TROP, V71, P57, DOI 10.1016/S0001-706X(98)00051-5
   MORRISON WI, 1982, J PARASITOL, V68, P755, DOI 10.2307/3280980
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   Murray M, 1983, LIVESTOCK PRODUCTIVI
   MURRAY M, 1977, PUBLICATION OUA STRC, V110, P83
   NANTULYA VM, 1986, INFECT IMMUN, V54, P444
   NAWATHE DR, 1988, TROP ANIM HEALTH PRO, V20, P141, DOI 10.1007/BF02240079
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   PARIS J, 1982, ACTA TROP, V39, P307
   ROELANTS GE, 1987, PARASITE IMMUNOL, V9, P379, DOI 10.1111/j.1365-3024.1987.tb00515.x
   Rowlands GJ, 1996, VET PARASITOL, V63, P199, DOI 10.1016/0304-4017(95)00894-2
   SHAW APM, 1987, 671 FAO, V1, P184
   SHAW APM, 1987, 672 FAO, V2, P330
   Stephen L. E., 1970, P774
   TRAIL JCM, 1990, ACTA TROP, V48, P37, DOI 10.1016/0001-706X(90)90063-6
   TRAIL JCM, 1994, VET PARASITOL, V55, P185, DOI 10.1016/0304-4017(94)00649-W
   TRAIL JCM, 1992, VET PARASITOL, V42, P213, DOI 10.1016/0304-4017(92)90063-F
   TRAIL JCM, 1993, VET PARASITOL, V45, P241, DOI 10.1016/0304-4017(93)90079-3
NR 37
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP 30
PY 1999
VL 86
IS 2
BP 83
EP 94
DI 10.1016/S0304-4017(99)00117-X
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 234TU
UT WOS:000082501100001
PM 10496692
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Usen, SO
   Weber, M
   Lloyd-Evans, N
   Jobe, K
   Mulholland, K
   McAdam, KPWJ
   Greenwood, BM
   Milligan, PJM
AF Adegbola, RA
   Usen, SO
   Weber, M
   Lloyd-Evans, N
   Jobe, K
   Mulholland, K
   McAdam, KPWJ
   Greenwood, BM
   Milligan, PJM
TI Haemophilus influenzae type b meningitis in The Gambia after
   introduction of a conjugate vaccine
SO LANCET
LA English
DT Article
ID DISEASE; TRIAL
AB After the introduction of a Haemophilus Influenzae type b (Hib) conjugate vaccine into The Gambia, the annual incidence of Hib meningitis has fallen from more than 200 per 100 000 before vaccination to 21 per 100 000 during the past 12 months.
C1 MRC Labs, Fajara, Senegal.
   Natl Hlth Lab, Banjul, Gambia.
   Dept State Hlth, Banjul, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
   London Sch Hyg & Trop Med, London WC1, England.
RP Adegbola, RA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X
NR 5
TC 44
Z9 44
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 25
PY 1999
VL 354
IS 9184
BP 1091
EP 1092
DI 10.1016/S0140-6736(99)03010-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 239PA
UT WOS:000082777500016
PM 10509502
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
AF Deen, JL
TI Health transition in India: Implications for health policy
SO NATIONAL MEDICAL JOURNAL OF INDIA
LA English
DT Editorial Material
C1 MRC, Farafenni Field Stn, Banjul, Gambia.
RP Deen, JL (reprint author), MRC, Farafenni Field Stn, Banjul, Gambia.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU ALL INDIA INST MEDICAL SCIENCES
PI NEW DELHI
PA ANSARI NAGAR, NEW DELHI 110 029, INDIA
SN 0970-258X
J9 NATL MED J INDIA
JI Natl. Med. J. India
PD SEP-OCT
PY 1999
VL 12
IS 5
BP 197
EP 198
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 265AA
UT WOS:000084215000001
PM 10612996
OA No
DA 2017-08-15
ER

PT J
AU Doherty, JF
   Sadiq, AD
   Bayo, L
   Alloueche, A
   Olliaro, P
   Milligan, P
   von Seidlein, L
   Pinder, M
AF Doherty, JF
   Sadiq, AD
   Bayo, L
   Alloueche, A
   Olliaro, P
   Milligan, P
   von Seidlein, L
   Pinder, M
TI A randomized safety and tolerability trial of artesunate plus
   sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the
   treatment of uncomplicated malaria in Gambian children
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; chemotherapy; artesunate;
   sulfadoxine-pyrimethamine; children; The Gambia
ID FALCIPARUM-MALARIA; AFRICAN CHILDREN; ANTIMALARIAL; CHLOROQUINE
AB Artemisinin derivatives, such as artesunate, have a short half-life and very rapid anti-malarial activity. Theoretically, using such agents in conjunction with well-established anti-malarial drugs such as sulfadoxine-pyrimethamine may reduce the rate of drug resistance. Such a combination has not previously been used in Africa. We have conducted a pilot safety trial of artesunate (4 mg/kg for 3 days) given with a single dose of sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine) compared to sulfadoxine-pyrimethamine alone among 40 Gambian children with uncomplicated malaria. Both regimens were safe and well tolerated and there were no adverse experiences attributed to the combination. The addition of artesunate resulted in a higher proportion of afebrile children and children with a negative blood film on Day 2, and a reduction in the proportion of gametocyte carriers, when compared to sulfadoxine-pyrimethamine alone.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Communicable Dis Cluster, World Hlth Org, WHO Special Programme Res & Training Trop Dis TDR, World Bank,UNDP, Geneva, Switzerland.
RP Doherty, JF (reprint author), Med Res Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2
   MENON A, 1987, LANCET, V1, P1029
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
   Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638
   White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
NR 7
TC 29
Z9 30
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 1999
VL 93
IS 5
BP 543
EP 546
DI 10.1016/S0035-9203(99)90376-0
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 254KH
UT WOS:000083610100029
PM 10696418
OA No
DA 2017-08-15
ER

PT J
AU Jallow, BP
   Toure, S
   Barrow, MMK
   Mathieu, AA
AF Jallow, BP
   Toure, S
   Barrow, MMK
   Mathieu, AA
TI Coastal zone of The Gambia and the Abidjan region in Cote d'Ivoire: sea
   level rise vulnerability, response strategies, and adaptation options
SO CLIMATE RESEARCH
LA English
DT Article
DE erosion; inundation; land loss; mangroves; vulnerability analysis; Bruun
   Rule
AB The aerial videotape-assisted vulnerability analysis (AVVA) technique was combined with various data sets to assess the vulnerability of the coastal zone of The Gambia to sea level rise. Land loss due to inundation, flooding, and erosion was estimated. Costs of damage and population at risk were also evaluated. Only historical data and maps were used to assess the vulnerability of the coastal zone of the Abidjan region of Cote d'Ivoire to sea level rise. Results show that with a 1 m sea level rise the whole of the capital city of Banjul will be under mean sea level in the next 50 to 60 yr as a greater part of the city is below 1 m. The mangrove systems on St. Mary's Island, Kombo St. Mary, and the strand plains in the north bank will be inundated. About 1950 billion Dalasis (US $217 million) worth of land will be lost. The most appropriate response would be to protect the whole of the coastline of Banjul, the shoreline area from the Banjul cemeteries to Laguna Beach Hotel, the infrastructure at Sarro, and the hotel complex at Cape Point. Innovative sand management, repair of the damaged groins, and construction of dikes, breakwater structures, revetments, and low-cost seawall are some of the shoreline stabilization and hardening techniques suggested for the protection of this area. For the Abidjan region, the same response strategies should be used. Adaptation responses identified for both regions include public awareness, increase in height of coastal infrastructure, urban growth planning, wetland preservation and mitigation, and development of a coastal zone management plan.
C1 Dept Water Resources, Banjul, Gambia.
   Ecole Super Travaux Publ, Yamoussoukro, Cote Ivoire.
   Natl Environm Agcy, Banjul, Gambia.
   Univ Cocody, Dept Phys, Abidjan, Cote Ivoire.
RP Jallow, BP (reprint author), Dept Water Resources, 7 Marina Parade, Banjul, Gambia.
CR ABE J, 1995, AT GEST INT ZON LITT
   BLIVI A, 1993, COASTLINES W AFRICA
   DELOR C, 1992, MEMOIRE, V4
   Dennis KC, 1995, J COASTAL RES, V14, P243
   Hands EB, 1983, HDB COASTAL PROCESSE, P167
   *IPCC, 1990, RESP STRAT AD ASS RE
   Jallow BP, 1996, CLIMATE RES, V6, P165, DOI 10.3354/cr006165
   Leatherman S., 1995, J COASTAL RES, V14, P15
   Nicholls R. J., 1995, J COASTAL RES, P26
   *PAA, 1996, PORT AUT AB UN REF A
   Pepper W., 1992, EMISSIONS SCENARIOS
   QUELENNEC RE, 1988, IDENTIFICATION COAST
NR 12
TC 12
Z9 12
U1 3
U2 27
PU INTER-RESEARCH
PI OLDENDORF LUHE
PA NORDBUNTE 23, D-21385 OLDENDORF LUHE, GERMANY
SN 0936-577X
J9 CLIMATE RES
JI Clim. Res.
PD AUG 27
PY 1999
VL 12
IS 2-3
SI SI
BP 129
EP 136
DI 10.3354/cr012129
PG 8
WC Environmental Sciences; Meteorology & Atmospheric Sciences
SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences
GA V3096
UT WOS:000171723000010
OA No
DA 2017-08-15
ER

PT J
AU Schachter, J
   West, SK
   Mabey, D
   Dawson, CR
   Bobo, L
   Bailey, R
   Vitale, S
   Quinn, TC
   Sheta, A
   Sallam, S
   Mkocha, H
   Mabey, D
   Faal, H
AF Schachter, J
   West, SK
   Mabey, D
   Dawson, CR
   Bobo, L
   Bailey, R
   Vitale, S
   Quinn, TC
   Sheta, A
   Sallam, S
   Mkocha, H
   Mabey, D
   Faal, H
TI Azithromycin in control of trachoma
SO LANCET
LA English
DT Article
ID SINGLE-DOSE AZITHROMYCIN; CONTROLLED TRIAL; CHAIN-REACTION; INFECTION;
   TANZANIA; CHILDREN
AB Background Trachoma is the leading cause of preventable blindness. Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline. We assessed the potential of community-wide azithromycin treatment for trachoma control.
   Methods Pairs of villages in trachoma endemic areas of Egypt, The Gambia, and Tanzania were matched on trachoma rates in 1-10-year-old children. Villages were randomly assigned community-wide oral azithromycin treatment (three doses with intervals of 1 week) or treatment with 1% topical tetracycline (once daily for 6 weeks). Clinical examinations were done at baseline, 2-4.5 months, and 12-14 months after treatment. Chlamydia trachomatitis was identified by ligase chain reaction (LCR). Analyses were by intention to treat. Univariate comparisons and multivariate analyses were used to compare outcomes.
   Findings LCR positivity was correlated with clinical severity, but about 30% of Egyptian and Gambian villagers with no active disease were LCR positive. Village-wide LCR positivity ranged from 16.5% (Tanzania) to 43.6% (Egypt). Treatment compliance was over 90% except in the tetracycline treatment village in Egypt. Of the participants initially LCR positive, 866 (95%) of 924 who received at least one azithromycin dose and 482 (82%) of 587 who received 28 days or more topical tetracycline, were negative at follow-up. At 1 year, village-wide LCR positivity rates were substantially lower than at baseline with both treatments; the decreases were greater with azithromycin than with tetracycline (93% vs 77% in Egypt, 78 vs 66% in The Gambia, 64 vs 55% in Tanzania). Similarly, greater reduction in clinical activity occurred after azithromycin. In multivariate analyses, factors associated with being LCR positive at 1 year were: not receiving azithromycin; age under 10 years; and LCR positivity at baseline.
   Interpretation Community-wide treatment with oral azithromycin markedly reduces C trachomatis infection and clinical trachoma in endemic areas and may be an important approach to control of trachoma.
C1 Univ Calif San Francisco, Dept Lab Med, Chlamydia Res Lab, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
   Wilmer Eye Inst, Baltimore, MD USA.
   Johns Hopkins Univ, Dept Paediat Infect Dis, Baltimore, MD USA.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Univ Alexandria, Fac Med, Dept Ophthalmol, Alexandria, Egypt.
   Univ Alexandria, High Inst Publ Hlth, Dept Epidemiol, Alexandria, Egypt.
   NIAID, Bethesda, MD 20892 USA.
   Cent Eye Hlth Fdn, Kongwa Trachoma Project, Kongwa, Tanzania.
   Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
RP Schachter, J (reprint author), Univ Calif San Francisco, Dept Lab Med, Chlamydia Res Lab, Box 0842, San Francisco, CA 94143 USA.
RI Quinn, Thomas/A-2494-2010
FU PHS HHS [P01 A135682]
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   Dawson CR, 1997, CLIN INFECT DIS, V24, P363
   DAWSON CR, 1982, B WORLD HEALTH ORGAN, V60, P347
   DAWSON CR, 1985, REV INFECT DIS, V7, P768
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   MABEY D, 1998, CHLAMYDIAL INFECT, P351
   MALATY R, 1981, J INFECT DIS, V143, P853
   MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304
   SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540
   SCHACHTER J, 1998, CHLAMYDIAL INFECT, P347
   Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   *WHO, 1996, WHOPBL9656
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 17
TC 176
Z9 178
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 21
PY 1999
VL 354
IS 9179
BP 630
EP 635
DI 10.1016/S0140-6736(98)12387-5
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 229UQ
UT WOS:000082214500011
PM 10466664
OA No
DA 2017-08-15
ER

PT J
AU Connolly, C
   Reid, A
   Davies, G
   Sturm, W
   McAdam, KPWJ
   Wilkinson, D
AF Connolly, C
   Reid, A
   Davies, G
   Sturm, W
   McAdam, KPWJ
   Wilkinson, D
TI Relapse and mortality among HIV-infected and uninfected patients with
   tuberculosis successfully treated with twice weekly directly observed
   therapy in rural South Africa
SO AIDS
LA English
DT Article
DE tuberculosis; HIV; tuberculosis relapse; rural Africa; mortality rate;
   directly observed therapy
ID COMMUNITY; DOT
AB Objective: To determine post-treatment relapse and mortality rates among HIV-infected and uninfected patients with tuberculosis treated with a twice-weekly drug regimen under direct observation (DOT).
   Setting: Hlabisa, South Africa.
   Patients: A group of 403 patients with tuberculosis (53% HIV infected) cured following treatment with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) given in hospital (median 17 days), followed by HRZE twice weekly to 2 months and HR twice weekly to 6 months in the community under DOT.
   Methods: Relapses were identified through hospital readmission and 6-monthly home visits. Relapse (culture for Mycobacterium tuberculosis) and mortality given as rates per 100 person-years observation (PYO) stratified by HIV status and history of previous tuberculosis treatment.
   Results: Mean (SD) post-treatment follow-up was 1.2 (0.4) years (total PYO = 499); 78 patients (19%) left the area, 58 (14%) died, 248 (62%) remained well and 19 (5%) relapsed. Relapse rates in HIV-infected and uninfected patients were 3.9 [95% confidence interval (CI) 1.5-6.3] and 3.6 (95% CI 1.1-6.1) per 100 PYO (P = 0.7). Probability of relapse at 18 months was estimated as 5% in each group. Mortality was four-fold higher among HIV-infected patients (17.8 and 4.4 deaths per 100 PYO for HIV-infected and uninfected patients, respectively; P < 0.0001). Probability of survival at 24 months was estimated as 59% and 81%, respectively. We observed no increase in relapse or mortality among previously treated patients compared with new patients. A positive smear at 2 months did not predict relapse or mortality.
   Conclusion: Relapse rates are acceptably low following successful DOT with a twice weekly rifampifin-containing regimen, irrespective of HIV status and previous treatment history. Mortality is substantially increased among HIV-infected patients even following successful DOT and this requires further attention. (C) 1999 Lippincott Williams & Wilkins.
C1 MRC, Ctr Epidemiol Res S Africa, Pretoria, South Africa.
   Hlabisa Hosp, Hlabisa, South Africa.
   Univ Natal, Dept Med Microbiol, ZA-4001 Durban, South Africa.
   MRC Labs, Banjul, Gambia.
RP Wilkinson, D (reprint author), Univ S Australia, S Australian Ctr Rural & Remote Hlth, Whyalla Campus,Nicolson Ave, Whyalla Norrie, SA 5608, Australia.
RI Wilkinson, David/A-6207-2008
OI Wilkinson, David/0000-0002-7265-9846
CR Chan S. L., 1994, P141
   Davies GR, 1999, AIDS, V13, P811, DOI 10.1097/00002030-199905070-00010
   DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9
   Floyd K, 1997, BRIT MED J, V315, P1407
   GILKS CF, 1998, CARE SUPPORT PEOPLE
   HOPEWELL P, 1992, CLIN INFECT DIS, V15, pS282
   Maher D, 1997, INT J TUBERC LUNG D, V1, P276
   MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P865
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204
   Raviglione M C, 1997, AIDS, V11 Suppl B, pS115
   WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9
   Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094
   Wilkinson D, 1997, TROP MED INT HEALTH, V2, P700, DOI 10.1046/j.1365-3156.1997.d01-358.x
   Wilkinson D, 1997, TROP MED INT HEALTH, V2, P747, DOI 10.1046/j.1365-3156.1997.d01-386.x
NR 14
TC 56
Z9 56
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD AUG 20
PY 1999
VL 13
IS 12
BP 1543
EP 1547
DI 10.1097/00002030-199908200-00015
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 226DT
UT WOS:000082005600015
PM 10465079
OA No
DA 2017-08-15
ER

PT J
AU Goossens, B
   Osaer, S
   Ndao, M
   Van Winghem, J
   Geerts, S
AF Goossens, B
   Osaer, S
   Ndao, M
   Van Winghem, J
   Geerts, S
TI The susceptibility of Djallonke and Djallonke-Sahelian sheep to
   Trypanosoma congolense and helminth infection under different diet
   levels
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trpanosoma congolense; sheep - protozoa; feeding and nutrition;
   Djallonke-Sahelian sheep
ID WEST-AFRICAN DWARF; GLOSSINA-MORSITANS-SUBMORSITANS; SCOTTISH BLACKFACE
   SHEEP; ACUTE OVINE HAEMONCHOSIS; ZEBU CATTLE; REPRODUCTIVE-PERFORMANCE;
   BOVINE TRYPANOSOMIASIS; IMMUNE-RESPONSES; VIVAX INFECTION; NDAMA CATTLE
AB Forty two Djallonke and 27 Djallonke-Sahelian crossbred sheep were compared during 34 weeks for their disease resistance and productivity in a multifactorial experiment including trypanosome infection, helminth infections and dietary level. Eight treatment combinations were formed in which the two breeds were balanced. Pyrexia was observed following trypanosome infection and was not different between the two breeds. However, a significant higher parasitaemia level, a shorter prepatent period and a lower antibody response in the crossbreds following infection, indicated a significant reduction of the trypanotolerance and confirmed the genetic origin of the trait. Neither helminth infection nor dietary level influenced the onset and level of parasitaemia or the level of antibody response following trypanosome infection. Trypanosome infection, helminth infection and low supplementary feeding caused independently significant reductions in PCV level and weight gain but these declines were not worse in crossbreds as compared to Djallonke. Independently, of the studied factors, crossbreds were generally heavier than Djallonke and also grew faster, especially during the second phase of the study. Crossbreds had significantly higher mean nematode egg output (epg) compared to Djallonke sheep but reduction of epg following deworming was similar in both breeds. The lower epg in the Djallonke breed indicated an innate resistance to helminths and/or more efficient immune response. Trypanosome infection tended to increase epg, confirming the immunosuppressive effect of the former. The higher body temperature in the Djallonke compared to crossbreds suggested a better heat tolerance in the former breed.
   From this study it was concluded that Djallonke-Sahelian crossbred sheep inspite of a reduced trypanotolerance and lower resistance to helminth infection, posses a higher potential to intensify mutton production as compared to the pure Djallonke. However, appropriate measures should be taken to limit disease and stress factors in order to optimise production environment for this crossbred sheep, (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
RP Goossens, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ABBOTT EM, 1986, VET PARASITOL, V20, P275, DOI 10.1016/0304-4017(86)90126-3
   ABBOTT EM, 1986, VET PARASITOL, V20, P291, DOI 10.1016/0304-4017(86)90127-5
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   ASSOKU R K G, 1981, Bulletin of Animal Health and Production in Africa, V29, P1
   AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6
   BAKER RL, 1992, P SR CRSP SCI WORKSH, V10, P79
   BAKER RL, 1995, P 6 S TROP AN HLTH P, P40
   Bengaly Z, 1993, Rev Elev Med Vet Pays Trop, V46, P563
   CHANDLER R. L., 1958, JOUR COMP PATHOL AND THERAP, V68, P253
   CHANDLER RL, 1952, ANN TROP MED PARASIT, V46, P127
   DARGIE JD, 1979, PARASITOLOGY, V78, P271
   DOLAN RB, 1987, PARASITOL TODAY, V3, P137, DOI 10.1016/0169-4758(87)90197-9
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   DWINGER RH, 1994, VET PARASITOL, V54, P353, DOI 10.1016/0304-4017(94)90002-7
   *FAO, 1991, 88 FAO
   GAMBLE HR, 1992, VET PARASITOL, V41, P211, DOI 10.1016/0304-4017(92)90081-J
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GREIG WA, 1979, BRIT VET J, V135, P113
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   Holmes PH, 1987, PARASITOLOGY, V94, P29
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   KLUGER MJ, 1980, FEVER, P31
   Lloyd S., 1987, Immune responses in parasitic infections: immunology, immunopathology, and immunoprophylaxis. Volume I: Nematodes., P1
   LOSOS GJ, 1972, VET PATHOL         S, V9
   MACKENZIE PKI, 1975, VET REC, V97, P452
   MAGNUS E, 1988, REV ASS BEL TECH LAB, V15, P321
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   McDonald P., 1988, ANIMAL NUTR
   MCGREGOR BA, 1985, AUST VET J, V62, P349, DOI 10.1111/j.1751-0813.1985.tb07664.x
   MORTELMANS J, 1976, WORLD ANIM REV, V19, P14
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   Murray M., 1979, P71
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NANTULYA VM, 1986, INFECT IMMUN, V54, P444
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   OSAER S, 1999, VET PARASITOL, V3, P215
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   PARIS J, 1982, ACTA TROP, V39, P307
   PINDER M, 1988, VET IMMUNOL IMMUNOP, V18, P245, DOI 10.1016/0165-2427(88)90069-4
   PINDER M, 1984, IMMUNOLOGY, V51, P247
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   ROBERTS C J, 1973, Tropical Animal Health and Production, V5, P220, DOI 10.1007/BF02240423
   ROELANTS GE, 1984, CONTEMP TOP IMMUNOBI, V12, P225
   *SAS I INC, 1998, STAT AN SYST I SAS
   Snedecor G. W., 1980, STAT METHODS
   THIENPONT D, 1979, DIAGNOSE VERMINOSE K
   TOURE SM, 1981, TRYPANOTOLERANCE STU
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   Wassink GJ, 1997, ANIM SCI, V64, P127
   WELLDE BT, 1981, EXP PARASITOL, V52, P219, DOI 10.1016/0014-4894(81)90077-1
NR 57
TC 18
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG 16
PY 1999
VL 85
IS 1
BP 25
EP 41
DI 10.1016/S0304-4017(99)00087-4
PG 17
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 220AC
UT WOS:000081640600003
PM 10447190
OA No
DA 2017-08-15
ER

PT J
AU Beld, M
   Penning, M
   van Putten, M
   van den Hoek, A
   Damen, M
   Klein, MR
   Goudsmit, J
AF Beld, M
   Penning, M
   van Putten, M
   van den Hoek, A
   Damen, M
   Klein, MR
   Goudsmit, J
TI Low levels of hepatitis C virus RNA in serum, plasma, and peripheral
   blood mononuclear cells of injecting drug users during long
   antibody-undetectable periods before seroconversion
SO BLOOD
LA English
DT Article
ID HCV-RNA; RISK-FACTORS; 3RD-GENERATION ASSAYS; LIVER-DISEASE; NON-A;
   INFECTION; DONORS; PREVALENCE; AMSTERDAM; VIREMIA
AB Screening of antibodies to hepatitis C virus (HCV) is widely used for monitoring the prevalence of HCV infections and to assess HCV infectivity, Among HCV-infected individuals in the general population, the interval between the detection of HCV RNA and the development of HCV antibodies is usually 5 to 6 weeks, but in rare cases, seroconversion may be prolonged up to 6 to 9 months. In this study, we tested for the presence of HCV RNA during the antibody-undetectable period of 19 drug-injecting HCV seroconverters to gain insight into the antibody-negative carrier status in this population. HCV seroconversion status was determined by testing the first and last serum samples obtained from each subject, using third-generation antibody screening and confirmation assays. Serial samples were tested for HCV-specific antibodies to establish the moment of seroconversion and HCV RNA by single reverse transcriptase-polymerase chain reaction (RT-PCR) and branched DNA assay (bDNA) in serum. Plasma and peripheral blood mononuclear cells (PBMCs) were independently collected and tested for HCV RNA, HCV RNA-positivity was confirmed by Southern blot hybridization and sequencing of serial samples. The 19 HCV seroconverters had a mean follow-up of 5 years (range, 1 to 8 years). Of the 19, 4 were human immunodeficiency virus (HIV)-infected before HCV seroconversion. HCV RNA was detected in serum before seroconversion in 12 (63.2%) of the 19 HCV seroconverters, independent of HIV status. In 7 of these 12, the antibody-undetectable period was relatively short (2 to 10 months). The other 5, who were all HIV-negative before HCV seroconversion, had intermittent low levels of HCV RNA before seroconversion for a period of more than 12 months, with a mean of 40.8 months (range, 13 to 94 months), In all 5 individuals, independent repeats of the experiments confirmed the presence of HCV RNA in serum, and in 3 of these individuals, HCV-positivity was confirmed in independently collected plasma and PBMC samples, Low levels of HCV RNA may be present during prolonged antibody-undetectable periods before seroconversion in a number of injecting drug users. Independent of HIV status, their immune system appears to be unable to respond to these low HCV RNA levels and was sometimes only activated after reinfections with distinct HCV genotypes, These results indicate that primary HCV infection may not always elicit the rapid emergence of HCV antibodies and suggests that persistent low levels of HCV RNA (regardless of the genotype) may not elicit at all or delay antibody responses for prolonged periods of time. (C) 1999 by The American Society of Hematology.
C1 Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
   Municipal Hlth Serv, Dept Publ Hlth & Environm, Amsterdam, Netherlands.
   Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands.
   MRC Labs, Banjul, Gambia.
RP Goudsmit, J (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
CR ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x
   AQUILAR C, 1996, BRIT J HAEMATOL, V93, P497
   Attia MAM, 1996, J CLIN MICROBIOL, V34, P2665
   BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1016/0270-9139(95)90511-1
   Bassett SE, 1998, J VIROL, V72, P2589
   Beld M, 1999, HEPATOLOGY, V29, P1288, DOI 10.1002/hep.510290442
   Beld M, 1998, J CLIN MICROBIOL, V36, P872
   Beld M, 1998, J CLIN MICROBIOL, V36, P3002
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   BRUISTEN SM, 1994, AIDS, V8, P1736
   BRUNETTO MR, 1994, FEMS MICROBIOL REV, V14, P259, DOI 10.1016/0168-6445(94)90041-8
   BUKH J, 1993, J INFECT DIS, V168, P1343
   BUSCH MP, 1992, TRANSFUSION, V32, P420, DOI 10.1046/j.1537-2995.1992.32592327714.x
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602
   COUROUCE AM, 1995, NEPHROL DIAL TRANSPL, V10, P234
   CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220
   DEMITRI MS, 1995, LANCET, V345, P413, DOI 10.1016/S0140-6736(95)90400-X
   Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902
   ESTEBAN R, 1993, J HEPATOL, V17, pS67, DOI 10.1016/S0168-8278(05)80427-1
   FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801
   FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513
   KAO JH, 1993, GASTROENTEROLOGY, V105, P583
   Kao JH, 1996, DIGEST DIS SCI, V41, P161, DOI 10.1007/BF02208599
   KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189
   LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6
   Laskus T, 1996, VIROLOGY, V220, P171, DOI 10.1006/viro.1996.0297
   LAVANCHY D, 1994, J CLIN MICROBIOL, V32, P2272
   Lefrere JJ, 1997, J INFECT DIS, V175, P316
   LELIE PN, 1992, J MED VIROL, V37, P203, DOI 10.1002/jmv.1890370310
   MAPLE PAC, 1994, J MED VIROL, V44, P43, DOI 10.1002/jmv.1890440109
   MAUSERBUNSCHOTEN EP, 1995, J MED VIROL, V45, P241, DOI 10.1002/jmv.1890450302
   MIENTJES GH, 1991, AIDS, V5, P35
   MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1016/0270-9139(92)90001-P
   Nubling CM, 1998, INFUSIONSTHERAPIE, V25, P86
   OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1016/0270-9139(94)90747-1
   PRINCE AM, 1992, J INFECT DIS, V165, P438
   Rezza G, 1996, SCAND J INFECT DIS, V28, P27, DOI 10.3109/00365549609027145
   SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Schmidt WN, 1997, J INFECT DIS, V176, P27, DOI 10.1086/514033
   Schmidt WN, 1997, J INFECT DIS, V176, P20, DOI 10.1086/514024
   STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093
   TAN D, 1994, ARCH VIROL, V138, P71, DOI 10.1007/BF01310039
   THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005
   VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823
   VANDENHOEK JAR, 1988, AIDS, V2, P55
   VANDOORN LJ, 1994, J INFECT DIS, V169, P1226
   WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q
   YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882
   ZAAIJER HL, 1994, TRANSFUSION, V34, P603, DOI 10.1046/j.1537-2995.1994.34794330015.x
NR 51
TC 65
Z9 66
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1200 19TH ST, NW, STE 300, WASHINGTON, DC 20036-2422 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD AUG 15
PY 1999
VL 94
IS 4
BP 1183
EP 1191
PG 9
WC Hematology
SC Hematology
GA 225FE
UT WOS:000081947100005
PM 10438705
OA No
DA 2017-08-15
ER

PT J
AU Viviani, S
   Jack, A
   Hall, AJ
   Maine, N
   Mendy, M
   Montesano, R
   Whittle, HC
AF Viviani, S
   Jack, A
   Hall, AJ
   Maine, N
   Mendy, M
   Montesano, R
   Whittle, HC
TI Hepatitis B vaccination in infancy in The Gambia: protection against
   carriage at 9 years of age
SO VACCINE
LA English
DT Article
DE HBV vaccination
ID HEPATOCELLULAR-CARCINOMA; EXPANDED PROGRAM; EFFICACY; IMMUNIZATION;
   INFECTION; CHILDREN; VILLAGES; CANCER; TAIWAN
AB To estimate the efficacy in The Gambia (West Africa) of infant hepatitis B vaccination against infection and carriage with the virus at the age of 9 years. The HBV status of 9-year old children vaccinated in infancy was compared to that of unvaccinated children of the same age. Eight percent of the vaccinated children had been infected by HBV compared to 50% of the unvaccinated control group; HBV carrier status was 0.6 and 10% respectively, resulting in a vaccine efficacy of 83% against infection and of 95% against chronic carriage. The results show that infant vaccination provides a high level of protection at the age of nine years against both HBV infection and chronic carrier status and no booster dose of vaccine is required in the first decade. These findings support the WHO recommendation for the introduction of I-IBV vaccination into the Expanded Programme on Immunization in Africa. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Int Agcy Res Canc, F-69372 Lyon 08, France.
   Int Agcy Res Canc, Gambia Hepatitis Intervent Study, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
RP Montesano, R (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
CR BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   HALL A J, 1987, Cancer Research, V47, P5782
   HALL AJ, 1989, LANCET, V1, P1057
   HALL AJ, 1993, T ROY SOC TROP MED H, V87, P333, DOI 10.1016/0035-9203(93)90154-I
   *INT AG RES CANC H, 1994, MON EV CARC RISKS HU, V59
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   KIRKWOOD BR, 1992, ESSENTIAL MED STAT, P101
   Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   SUN ZT, 1991, CANCER DETECT PREV, V15, P313
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHITTLE HC, 1990, J INFECT DIS, V161, P112
NR 18
TC 102
Z9 105
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 6
PY 1999
VL 17
IS 23-24
BP 2946
EP 2950
DI 10.1016/S0264-410X(99)00178-4
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 225KD
UT WOS:000081957300002
PM 10462228
OA No
DA 2017-08-15
ER

PT J
AU Hoare, K
   Hoare, S
   Rhodes, D
   Erinoso, HO
   Weaver, LT
AF Hoare, K
   Hoare, S
   Rhodes, D
   Erinoso, HO
   Weaver, LT
TI Effective health education in rural Gambia
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID RANDOMIZED CONTROLLED TRIAL; DOMESTIC HYGIENE; YOUNG-CHILDREN; DIARRHEA;
   VILLAGE; INTERVENTIONS; BANGLADESH; MORTALITY; MOTHERS; IMPACT
AB We aimed to measure the impact of a structured health education programme on the incidence of infectious disease in young children of a rural Gambian village, In a prospective intervention study, mothers of children under 3 years living in a rural West African village without running water (population 1600) were divided into two groups by site of residence. Group 1 (n = 70) received a fortnightly education talk on hand-washing and skin hygiene, and group 2 (n = 84) on family planning. The incidence of infectious skin and diarrhoeal, eye, and respiratory diseases were recorded at the clinics attended by all children, The mean incidence of skin infections in the children of mothers of group 1 (1.07) was significantly lower (p < 0.05) than that of group 2 (1.59) during the rainy season. Between 1981 and 1.994 the incidence of skin, diarrhoeal, and eye disease showed a statistically significant (p < 0.0001) decline following the implementation of the health education programme. There was no statistical significance in the trend for respiratory disease, the incidence of which would not be expected to be affected by hygiene education, Focused health education had a sustained beneficial effect on the health of young children living in conditions where infectious diseases and poor hygiene are common.
C1 MRC, Dunn Nutr Unit, Keneba, Gambia.
   MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
   Northumbria Univ, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
RP Weaver, LT (reprint author), Royal Hosp Sick Children, Univ Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland.
OI Hoare, Karen/0000-0002-7123-5881
CR ALAM N, 1989, INT J EPIDEMIOL, V18, P242, DOI 10.1093/ije/18.1.242
   Bolam A, 1998, BRIT MED J, V316, P805
   CAIRNCROSS S, 1987, DEV WORLD WATER, V2, P30
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P467
   HAN AM, 1989, T ROY SOC TROP MED H, V83, P128, DOI 10.1016/0035-9203(89)90737-2
   HARDY D, 1967, AM J OPHTHALMOL, V63, P15
   HILL JM, 1988, SOC SCI MED, V27, P1183, DOI 10.1016/0277-9536(88)90347-4
   Hoare K, 1991, Health Visit, V64, P19
   Hoare K, 1994, Health Visit, V67, P102
   LAMB WH, 1984, LANCET, V2, P912
   LAMB WH, 1988, REV INFECT DIS, V10, P457
   LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788
   MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295
   PORTER MJ, 1979, T R SOC TROP MED HYG, V74, P162
   ROWLAND M G M, 1978, Lancet, V1, P136
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   STANTON BF, 1987, AM J EPIDEMIOL, V125, P292
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
   WILSON JM, 1991, T ROY SOC TROP MED H, V85, P819, DOI 10.1016/0035-9203(91)90468-E
NR 20
TC 5
Z9 5
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD AUG
PY 1999
VL 45
IS 4
BP 208
EP 214
DI 10.1093/tropej/45.4.208
PG 7
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 234YH
UT WOS:000082511600004
PM 10467831
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   Weeks, A
AF Walraven, G
   Weeks, A
TI Editorial: The role of (traditional) birth attendants with midwifery
   skills in the reduction of maternal mortality
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Editorial Material
DE maternal morbidiy and mortality; midwifery; traditional birth
   attendants; birth attendants with midwifery skills; misoprostol; anaemia
ID POSTPARTUM HEMORRHAGE; ANEMIA
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Scunthorpe Gen Hosp, Dept Obstet, Scunthorpe, England.
RP Walraven, G (reprint author), MRC Labs, Farafenni Field Stn, POB 273, Banjul, Gambia.
OI Weeks, Andrew/0000-0002-1909-337X
CR BOES EGM, 1987, S AFR MED J, V71, P160
   BULLOUGH CHW, 1989, LANCET, V2, P522
   De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x
   deGroot ANJA, 1996, EUR J OBSTET GYN R B, V69, P31, DOI 10.1016/0301-2115(95)02531-6
   DUJARDIN B, 1992, LANCET, V339, P1336, DOI 10.1016/0140-6736(92)91969-F
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P598
   KWAST BE, 1994, LANCET, V343, P1399
   LENNOX CE, 1981, PAPUA NEW GUINEA MED, V24, P286
   *MACR INT INC, 1994, DEMOGRAPHIC HLTH SUR, V6, P2
   MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7
   Nazerali H, 1998, BRIT MED J, V317, P512
   PRENDIVILLE WJ, 1997, PREGNANCY CHILDBIRTH
   SCOTT G, 1995, B WORLD HEALTH ORGAN, V73, P369
   Sheth TN, 1997, J GEN INTERN MED, V12, P102, DOI 10.1007/s11606-006-5004-x
   TSUI AO, 1997, REPROD HLTH DEV COUN, P142
   van den Broek NR, 1999, B WORLD HEALTH ORGAN, V77, P15
   WALRAVEN GEL, 1994, LANCET, V344, P617, DOI 10.1016/S0140-6736(94)92004-4
   WHO, 1997, WHORHTMSM9628
   WHO UNICEF, 1996, WHOFRHMSM9611 UNICEF
NR 19
TC 37
Z9 37
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 1999
VL 4
IS 8
BP 527
EP 529
DI 10.1046/j.1365-3156.1999.00441.x
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 258RC
UT WOS:000083851500001
PM 10499075
OA No
DA 2017-08-15
ER

PT J
AU Blanchard, T
   Smith, GL
   Whittle, H
AF Blanchard, T
   Smith, GL
   Whittle, H
TI Vaccines for smallpox
SO LANCET
LA English
DT Letter
ID VIRUS ANKARA
C1 MRC Labs Fajara, Banjul, Gambia.
   Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
RP Blanchard, T (reprint author), MRC Labs Fajara, POB 273, Banjul, Gambia.
CR Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123
   Blanchard TJ, 1998, J GEN VIROL, V79, P1159
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   1999, LANCET, V353, P1539
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 31
PY 1999
VL 354
IS 9176
BP 422
EP 422
DI 10.1016/S0140-6736(99)00134-8
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 222CB
UT WOS:000081764900049
PM 10437891
OA No
DA 2017-08-15
ER

PT J
AU Cook, PM
   Whitby, D
   Calabro, ML
   Luppi, M
   Kakoola, DN
   Hjalgrim, H
   Ariyoshi, K
   Ensoli, B
   Davison, AJ
   Schulz, TF
AF Cook, PM
   Whitby, D
   Calabro, ML
   Luppi, M
   Kakoola, DN
   Hjalgrim, H
   Ariyoshi, K
   Ensoli, B
   Davison, AJ
   Schulz, TF
CA Int Collaborative Grp
TI Variability and evolution of Kaposi's sarcoma-associated herpesvirus in
   Europe and Africa
SO AIDS
LA English
DT Article
DE Kaposi's sarcoma associated herpesvirus; human herpesvirus type 8;
   Kaposi's sarcoma; K1 gene; variability; evolution; molecular
   epidemiology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8
   INFECTION; SEXUAL TRANSMISSION; UNITED-STATES; AIDS EPIDEMIC;
   ANTIBODIES; PREVALENCE; RISK; SEROPREVALENCE
AB Objective: To study the evolution of Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus type 8 in Europe and Africa.
   Design and methods: PCR and sequence analysis of the variable viral membrane glycoprotein gene K1 in 58 tumour and peripheral blood samples from patients with AIDS-related Kaposi's sarcoma (KS), 'classic' (HIV-negative) KS, transplant KS, Multicentric Castleman's Disease, other lymphoproliferative disorders, and healthy KSHV-infected individuals from the UK, Denmark, Sweden, Italy, Spain, Iceland, The Faroe Islands, Greece, The Gambia and Uganda.
   Results: Three major groups of K1 sequences were found: A, B and C, as defined previously. The K1 gene has evolved, both within and between these three groups, under positive selection. KSHV group B strains predominate in Africa and are more distant from groups A and C, found in Europe, than A and C are from each other. Within group C two subgroups, C' and C ", can be identified. Subgroup C " is more closely related to group A in a region of the K1 protein and appears to be phylogenetically close to the branchpoint between A and C. Group A and C strains are currently found in both HIV-1-infected and -uninfected Europeans, and were already present in Europe before the start of the AIDS epidemic. We found same examples of closely related K1 sequences in Italy and Denmark, but in general KSHV strains in Europe did not cluster geographically.
   Conclusion: KSHV strains in East and West Africa are closely related but phylogenetically distant from those in Europe. The two major KSHV groups in Europe are more closely related, with some strains adopting an intermediate phylogenetic position. In Europe, KSHV strains may have been disseminated at least several decades ago. Variability in the K1 region is driven by selection and does not correlate with different KSHV-related pathologies or geographic regions where clinically more aggressive HIV-negative KS ('endemic' KS) is more common. (C) 1999 Lippincott Williams & Wilkins.
C1 Univ Liverpool, Dept Med Microbiol, Mol Virol Grp, Liverpool L69 3GA, Merseyside, England.
   Inst Canc Res, London SW3 6JB, England.
   Dept Oncol Sci, Padua, Italy.
   Dept Med Sci, Modena, Italy.
   Univ Glasgow, Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland.
   Dept Epidemiol, Copenhagen, Denmark.
   MRC Labs, Fajara, Gambia.
   Inst Super Sanita Rome, Virol Lab, Rome, Italy.
RP Schulz, TF (reprint author), Univ Liverpool, Dept Med Microbiol, Mol Virol Grp, Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
RI Luppi, Mario/J-3668-2016; Ensoli, Barbara/J-9169-2016
OI Luppi, Mario/0000-0002-0373-1154; Ensoli, Barbara/0000-0002-0545-8737
CR Angeloni A, 1998, J INFECT DIS, V177, P1715, DOI 10.1086/517429
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   BERAL V, 1991, CANCER SURV, V10, P5
   Bestetti G, 1998, AIDS, V12, P541
   Blauvelt A, 1997, J INFECT DIS, V176, P771
   Boldogh I, 1996, CLIN INFECT DIS, V23, P406
   Bourboulia D, 1998, JAMA-J AM MED ASSOC, V280, P31, DOI 10.1001/jama.280.1.31-a
   Calabro M L, 1998, J Hum Virol, V1, P207
   CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   COLLANDRE H, AFO42370 GENB
   Felsenstein Joseph, 1998, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925
   Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403
   GEDDES M, 1994, BRIT J CANCER, V69, P333, DOI 10.1038/bjc.1994.60
   GEDDES M, 1995, J NATL CANCER I, V87, P1015, DOI 10.1093/jnci/87.13.1015
   Hjalgrim H, 1996, CANCER, V77, P1373
   Hjalgrim H, 1996, BRIT J CANCER, V74, P1499, DOI 10.1038/bjc.1996.572
   Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918
   Lagunoff M, 1997, VIROLOGY, V236, P147, DOI 10.1006/viro.1997.8713
   Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435
   Lee H, 1998, MOL CELL BIOL, V18, P5219
   Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0
   Luppi M, 1996, BLOOD, V87, P3903
   Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403
   Mayama S, 1998, INT J CANCER, V77, P817, DOI 10.1002/(SICI)1097-0215(19980911)77:6<817::AID-IJC2>3.0.CO;2-X
   MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152
   Melbye M, 1998, INT J CANCER, V77, P543, DOI 10.1002/(SICI)1097-0215(19980812)77:4<543::AID-IJC12>3.0.CO;2-7
   Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805
   Neipel F, 1997, J VIROL, V71, P4187
   NICHOLAS J, 1998, CANC I MONOGR, V23, P79
   Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018
   Rezza G, 1998, INT J CANCER, V77, P361, DOI 10.1002/(SICI)1097-0215(19980729)77:3<361::AID-IJC9>3.0.CO;2-M
   Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862
   Schulz TF, 1998, J GEN VIROL, V79, P1573
   Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5
   SOULIER J, 1995, BLOOD, V86, P1276
   Touloumi G, 1997, INT J CANCER, V70, P538, DOI 10.1002/(SICI)1097-0215(19970304)70:5<538::AID-IJC8>3.0.CO;2-Z
   Vieira J, 1997, J VIROL, V71, P7083
   Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395
   Zong JC, 1997, J VIROL, V71, P2505
   Zong JC, 1999, J VIROL, V73, P4156
NR 42
TC 82
Z9 83
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUL 9
PY 1999
VL 13
IS 10
BP 1165
EP 1176
DI 10.1097/00002030-199907090-00004
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 212NE
UT WOS:000081222200004
PM 10416519
OA No
DA 2017-08-15
ER

PT J
AU Hill, AG
   MacLeod, WB
   Sonko, ST
   Walraven, G
AF Hill, AG
   MacLeod, WB
   Sonko, ST
   Walraven, G
TI Improvements in childhood mortality in the Gambia
SO LANCET
LA English
DT Letter
ID CHLOROQUINE; MALARIA
C1 Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA.
   MRC Labs, Fajara, Gambia.
   Cent Stat Dept, Banjul, Gambia.
RP Hill, AG (reprint author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA.
CR DELAUNAY V, 1998, SITUATION DEMOGRAPHI
   Hill AG, 1998, LANCET, V352, P1909, DOI 10.1016/S0140-6736(05)60400-X
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   *UNICEF, 1997, PROGR NAT, P28
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 3
PY 1999
VL 354
IS 9172
BP 75
EP 75
DI 10.1016/S0140-6736(05)75344-7
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 212XP
UT WOS:000081243200056
PM 10406393
OA No
DA 2017-08-15
ER

PT J
AU Metzger, WG
   Haywood, M
   D'Alessandro, U
   Drakeley, CJ
   Weiss, H
   Bojang, K
   Targett, GAT
   Greenwood, BM
AF Metzger, WG
   Haywood, M
   D'Alessandro, U
   Drakeley, CJ
   Weiss, H
   Bojang, K
   Targett, GAT
   Greenwood, BM
TI Serological responses of Gambian children to immunization with the
   malaria vaccine SPf66
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE P. falciparum; SPf66 malaria vaccine; serology
ID PLASMODIUM-FALCIPARUM MALARIA; EFFICACY TRIAL; IMMUNOGENICITY; INFANTS;
   SAFETY; POPULATION
AB Antibody responses to the malaria vaccine SPf66 and to its constituent peptides were measured over a period of 2 years in Gambian children who had been immunized with SPf66 or with a control vaccine (inactivated polio vaccine). Three hundred and six of 308 children (99%) who had received three doses of SPf66 vaccine had antibodies to SPf66 at a level above that found in European controls who had not been exposed to malaria. Responses to the constituent peptides derived from 35.1, 55.1 and 83.1-kDa proteins were found in 88%, 97% and 97% of children, respectively, 26% had an antibody response to the NANP repeat peptide of circumsporozoite protein which is also included in the SPf66 vaccine. A response to SPf66 was found in 22% of children who had received the control vaccine. Antibody responses to NANP, 35.1, 55.1 and 83.1-kDa peptide were found in 3%, 33%, 49% and 33% of these children. Overall, no significant correlation was found between the level of anti-SPf66 antibody as the beginning of the malaria transmission season following vaccination and the subsequent risk of malaria. However; further analysis showed that among the control children who had acquired antibodies to SPf66 as a result of natural exposure to malaria, those with high levels of anti-SPf66 were less at risk of malaria, perhaps reflecting their greater previous exposure and thus immunity. In contrast, among children who had received three doses of SPf66, those with high antibody levels were at greater risk of have malaria during the subsequent malaria transmission season.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   MRC Labs, Banjul, Gambia.
RP Metzger, WG (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
RI D'Alessandro, Umberto/D-3457-2015; Metzger, Wolfram/A-6878-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; 
CR ALONSO PL, 1994, LANCET, V344, P1175
   Alonso PL, 1998, PARASITE IMMUNOL, V20, P63
   AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9
   BECK HP, 1995, AM J TROP MED HYG, V53, P284
   Bojang KA, 1998, VACCINE, V16, P62, DOI 10.1016/S0264-410X(97)00159-X
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Desowitz R. S., 1991, MALARIA CAPERS
   Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   LOPEZ MC, 1994, VACCINE, V12, P585, DOI 10.1016/0264-410X(94)90261-5
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   NOYA O, 1994, J INFECT DIS, V170, P396
   RUEBUSH TK, 1990, AM J TROP MED HYG, V43, P355
   SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
NR 15
TC 9
Z9 9
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JUL
PY 1999
VL 21
IS 7
BP 335
EP 340
PG 6
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 223EJ
UT WOS:000081827500001
PM 10417667
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Ariyoshi, K
   Frith, P
   Okouchi, Y
   Sabally, S
   Ajewole, T
   Bailey, R
   Lee, PS
   Corrah, T
   Johnson, G
   Faal, H
   Whittle, H
AF Jaffar, S
   Ariyoshi, K
   Frith, P
   Okouchi, Y
   Sabally, S
   Ajewole, T
   Bailey, R
   Lee, PS
   Corrah, T
   Johnson, G
   Faal, H
   Whittle, H
TI Retinal manifestations of HIV-1 and HIV-2 infections among hospital
   patients in The Gambia,West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE HIV-1; HIV-2; retinal manifestations; The Gambia; CMV retinitis
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME;
   CYTOMEGALOVIRUS RETINITIS; AIDS; RETINOPATHY; COUNTS
AB BACKGROUND In developed countries, 50-75 % of AIDS patients develop retinal complications and about 20-40% acquire cytomegalavirus (CMV) retinitis. We conducted a cross-sectional survey to determine prevalence of these in The Gambia where both HIV-1 and HIV-2 infection are present and the prevalence of HIV-1 is rising.
   METHOD All patients attending hospital whose percentage CD4 + cells (CD4%) was below 14, the level associated typically with an AIDS diagnosis, and one half of those whose CD4% was 14 or above were asked to join the study Fifty-six HIV-1, 52 HIV-2 and 12 dually infected patients were recruited. Photographs of the fundi were taken and interpreted independently The findings were related to the patients' percentage CD4 + cells.
   RESULTS The CD4% was < 14 in 40 patients and <:in 17 patients. Thirty-six patients were male. No cases of CMV retinitis were found. Four patients whose CD4% were 4, 5, 11 and 23 had cotton wool spots ranging in number from 1 to 14 for any one patient. The prevalence of cotton wool spots was 8% (95% CI, 0-16%) among patients with CD4% below 14 and 12% (95% CI, 0-27) among patients with CD4% below 7. One of the 4 patients had associated microaneurysm and blot haemorrhages typical of more advanced HIV microvasculopathy:
   CONCLUSION CMV retinitis is less common in The Gambia than in developed countries. Non-infectious retinopathy may also be less common.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidemiol Grp, London WC1E 7HT, England.
   Med Res Council Labs Fajara, Banjul, Gambia.
   UCL Hosp, Eye Dept, London, England.
   Royal Victoria Hosp, Dept State Hlth & Social Welf, Eye Unit, Natl Eye Care Programme, Banjul, Gambia.
   Inst Ophthalmol, London, England.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM S.Jaffar@lshtm.ac.uk
CR AMO JD, 1996, AIDS, V10, P1563
   Anglaret X, 1997, J ACQ IMMUN DEF SYND, V14, P361
   BALLINGER R, 1995, OPTOMETRY VISION SCI, V72, P305, DOI 10.1097/00006324-199505000-00006
   Castro KG, 1992, MMWR-MORBID MORTAL W, V41, P1
   Danner SA, 1995, AIDS, V9, pS3
   Greenwood J, 1997, INT J STD AIDS, V8, P358, DOI 10.1258/0956462971920253
   HARKINS T, 1995, OPTOMETRY VISION SCI, V72, P302, DOI 10.1097/00006324-199505000-00005
   HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859
   HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604
   Jabs D A, 1995, Trans Am Ophthalmol Soc, V93, P623
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   KESTELYN P, 1985, AM J OPHTHALMOL, V100, P230
   KIDD PG, 1993, AIDS, V7, P933, DOI 10.1097/00002030-199307000-00005
   KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575
   LEWALLEN S, 1994, BRIT J OPHTHALMOL, V78, P757, DOI 10.1136/bjo.78.10.757
   MONTFORTE DA, 1997, AIDS, V11, P517
   ODONOVAN D, 1996, 11 INT C AIDS VANC, P2577
   PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472
   Sarraf D, 1996, LANCET, V348, P525, DOI 10.1016/S0140-6736(96)05209-9
   SISON RF, 1991, AM J OPHTHALMOL, V112, P243
   Spaide RF, 1995, OPHTHALMOLOGY, V102, P1860
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
NR 24
TC 16
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 1999
VL 4
IS 7
BP 487
EP 492
DI 10.1046/j.1365-3156.1999.00425.x
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 225JC
UT WOS:000081953800005
PM 10470340
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Walraven, GEL
   Bailey, R
   Rowley, JTF
   Banya, WAS
   Nyan, OA
   Faal, H
   Ceesay, SM
   Milligan, PJM
   McAdam, KPWJ
AF van der Sande, MAB
   Walraven, GEL
   Bailey, R
   Rowley, JTF
   Banya, WAS
   Nyan, OA
   Faal, H
   Ceesay, SM
   Milligan, PJM
   McAdam, KPWJ
TI Is there a role for glycosuria testing in sub-Saharan Africa?
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE diabetes; glycosuria; sensitivity; PPV; likelihood ratio; The Gambia
ID IMPAIRED GLUCOSE-TOLERANCE; DEPENDENT DIABETES-MELLITUS;
   SCREENING-TESTS; PREVALENCE; TANZANIA; ADULTS; GAMBIA
AB BACKGROUND With increasing urbanization and westernization, rates of diabetes in sub-Saharan Africa (sSA) are likely to rise. Early detection and intervention plays an important role in delaying development of complications. In sSA in particular there is need for an affordable, reliable, safe, feasible test to avert human suffering and exhausting already stressed health facilities.
   METHODS Data from two large community-based studies were used to assess the value of glycosuria testing in the detection of diabetes in adults in a sub-Saharan country. A first study (A) tested participants for glycosuria by dipstick; if positive, fasting capillary glucose was measured. A later study (B) measured glucose concentration in venous blood 2 h after a 75-g glucose load; if glycaemia was greater than or equal to 10 mmol/l, urine was tested for glycosuria.
   RESULTS The positive predictive value of glycosuria for a diagnosis of diabetes (fasting glucose greater than or equal to 6.7 mmol/l) was 48%. Sensitivity was 64% (57% if a 2-h-value greater than or equal to 10 mmol/l was used as gold standard). Sensitivity was higher among overweight and/or hypertensive subjects, among elderly people in the urban area, and among subjects with higher blood glucose levels. Extrapolated specificity was 99.7%, and the likelihood ratio 190.
   CONCLUSIONS Glycosuria testing can identify a considerable number of undiagnosed diabetic patients when specially targeted at high-risk groups (obese, hypertensive, or elderly people). Dipstick glycosuria testing is an appropriate, safe, feasible test for sSA, where the prevalence of diabetes is expected to increase considerably in the near future.
C1 Med Res Council Labs, Fajara, Senegal.
   Univ London London Sch Hyg & Trop Med, Dept Clin Sci, London WC1E 7HT, England.
   DUNN Nutr Unit, Cambridge, England.
RP van der Sande, MAB (reprint author), MRC Fajara, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR American Diabetes Association, 1997, DIABETES CARE, V20, P1183
   ANDERSSON DKG, 1993, DIABETIC MED, V10, P167
   Ceesay MM, 1997, TROP MED INT HEALTH, V2, P272, DOI 10.1046/j.1365-3156.1997.d01-265.x
   *CENTR STAT DEP, 1998, POP HOUS CENS 1993 M
   Davies M, 1994, J Med Screen, V1, P78
   DAVIES MJ, 1993, Q J MED, V86, P677
   Elbagir MN, 1996, DIABETES CARE, V19, P1126, DOI 10.2337/diacare.19.10.1126
   GASSER B, 1998, ARCH INTERN MED, V158, P134
   Greenhalgh T, 1997, BRIT MED J, V315, P540
   HANSON RL, 1993, ARCH INTERN MED, V153, P2133, DOI 10.1001/archinte.153.18.2133
   King H., 1993, Ethnicity and Disease, V3, pS67
   KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157
   LACKS M, 1996, ANN MED, V28, P415
   MANT D, 1990, BRIT MED J, V300, P1053
   MCLARTY D, 1997, DIABETES AFRICA, P1
   MCLARTY DG, 1989, LANCET, V1, P871
   MCLARTY DG, 1991, PRACTICAL DIABETES D, V3, P3
   *MIN FIN EC AFF, 1995, 1993 4 HOUS ED HLTH
   NYAN OA, 1997, MED RES TROPICS
   ROLFE M, 1992, DIABETIC MED, V9, P484
   Stearne MR, 1998, BRIT MED J, V317, P703
   SWAI ABM, 1991, DIABETES, V40, P516, DOI 10.2337/diabetes.40.4.516
   TURNER RC, 1993, J HYPERTENS, V11, P309
   Turner RC, 1998, LANCET, V352, P837
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   WALD N, 1989, BRIT J OBSTET GYNAEC, V96, P389, DOI 10.1111/j.1471-0528.1989.tb02411.x
   *WHO STUD GROUP, 1985, WHO TECHN REP SER
   Wilson JMG, 1968, WHO PUBLIC HLTH PAPE, V34
   World Bank, 1993, WORLD DEV REP 1993 I
   Zimmet Paul Z., 1997, LANCET, V350, pS1, DOI 10.1016/S0140-6736(97)90020-9
NR 30
TC 8
Z9 8
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 1999
VL 4
IS 7
BP 506
EP 513
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 225JC
UT WOS:000081953800008
PM 10470343
OA No
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   van der Loeff, MS
   Berry, N
   Jaffar, S
   Whittle, H
AF Ariyoshi, K
   van der Loeff, MS
   Berry, N
   Jaffar, S
   Whittle, H
TI Plasma HIV viral load in relation to season and to Plasmodium falciparum
   parasitaemia
SO AIDS
LA English
DT Letter
ID MALARIA
C1 NIID, AIDS Res Ctr, Tokyo 2080011, Japan.
   MRC Labs, Banjul, Gambia.
   UCL, Sch Med, Dept Med Microbiol, London WC1E 6BT, England.
   Univ London London Sch Hyg & Trop Med, Trop Hlth Epidemiol Unit, London WC1E 7HT, England.
RP Ariyoshi, K (reprint author), NIID, AIDS Res Ctr, 4-7-1 Gakuen, Tokyo 2080011, Japan.
CR Berry N, 1998, J Hum Virol, V1, P457
   JAENSON TGT, 1994, T ROY SOC TROP MED H, V88, P620, DOI 10.1016/0035-9203(94)90197-X
   STEVENSON M, 1990, EMBO J, V9, P1551
   TROYEBLOMBERG M, 1994, IMMUNOL LETT, V41, P103, DOI 10.1016/0165-2478(94)90116-3
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
NR 5
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 18
PY 1999
VL 13
IS 9
BP 1145
EP 1146
DI 10.1097/00002030-199906180-00023
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 207GL
UT WOS:000080927900023
PM 10397550
OA No
DA 2017-08-15
ER

PT J
AU Allen, SJ
   O'Donnell, A
   Alexander, NDE
   Mgone, CS
   Peto, TEA
   Clegg, JB
   Alpers, MP
   Weatherall, DJ
AF Allen, SJ
   O'Donnell, A
   Alexander, NDE
   Mgone, CS
   Peto, TEA
   Clegg, JB
   Alpers, MP
   Weatherall, DJ
TI Prevention of cerebral malaria in children in Papua New Guinea by
   southeast Asian ovalocytosis band 3
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DEFECTIVE ANION TRANSPORT; PLASMODIUM-FALCIPARUM; HEREDITARY
   OVALOCYTOSIS; AE1 GENE; DISEASE; SPHEROCYTOSIS; ERYTHROCYTES;
   MELANESIANS; MUTATIONS; PARASITES
AB Southeast Asian ovalocytosis (SAO) occurs at high frequency in malarious regions of the western Pacific and may afford a survival advantage against malaria. It is caused by a deletion of the erythrocyte membrane band 3 gene and the band 3 protein mediates the cytoadherence of parasitized erythrocytes irt vitro. The SAO band 3 variant may prevent cerebral malaria but it exacerbates malaria anemia and may also increase acidosis, a major determinant of mortality in malaria. We undertook a case-control study of children admitted to hospital in a malarious region of Papua New Guinea. The SAO band 3, detected by the polymerase chain reaction, was present in 0 of 68 children with cerebral malaria compared with six (8.8%) of 68 matched community controls (odds ratio = 0, 95% confidence interval = 0-0.85). Median hemoglobin levels were 1.2 g/dl lower in malaria cases with SAO than in controls (P = 0.035) but acidosis was not affected. The remarkable protection that SAO band 3 affords against cerebral malaria may offer a valuable approach to a better understanding of the mechanisms of adherence of parasitized erythrocytes to vascular endothelium, and thus of the pathogenesis of cerebral malaria.
C1 Papua New Guinea Inst Med Res, Goroka, Papua N Guinea.
   John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.
RP Allen, SJ (reprint author), Med Res Council Labs, POB 273, Banjul, Gambia.
FU Wellcome Trust
CR Allen SJ, 1996, QJM-MON J ASSOC PHYS, V89, P779
   Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736
   ARMITAGE P, 1994, STAT METHODS MED RES, P514
   BOOTH PB, 1977, VOX SANG, V32, P99
   Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694
   CATTANI JA, 1986, AM J TROP MED HYG, V35, P3
   CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703
   CRANDALL I, 1994, PARASITOLOGY, V108, P257
   GENTON B, 1995, NATURE, V378, P564, DOI 10.1038/378564a0
   HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827
   HAYES RJ, 1992, J TROP MED HYG, V95, P157
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610
   JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022
   JAROLIM P, 1995, BLOOD, V85, P634
   Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9
   KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829
   MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562
   Mgone CS, 1996, T ROY SOC TROP MED H, V90, P228, DOI 10.1016/S0035-9203(96)90223-0
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   O'Donnell A, 1998, BRIT J HAEMATOL, V101, P407
   OLD JM, 1983, METHODS HAEMATOLOGY, P74
   SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H
   SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0
   TANNER MJA, 1993, SEMIN HEMATOL, V30, P34
   Unwin R, 1996, LANCET, V348, P1561, DOI 10.1016/S0140-6736(96)04009-3
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
   Weatherall DJ, 1996, PARASITOLOGY, V112, pS23
NR 28
TC 105
Z9 108
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 1999
VL 60
IS 6
BP 1056
EP 1060
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 214FE
UT WOS:000081317300030
PM 10403343
OA No
DA 2017-08-15
ER

PT J
AU Bennison, JJ
   Akinbamijo, OO
   Jaitner, J
   Dempfle, L
   Hendy, CRC
   Leaver, JD
AF Bennison, JJ
   Akinbamijo, OO
   Jaitner, J
   Dempfle, L
   Hendy, CRC
   Leaver, JD
TI Effects of nutrition pre-partum and post partum on subsequent
   productivity and health of N'Dama cows infected with Trypanosoma
   congolense
SO ANIMAL SCIENCE
LA English
DT Article
DE cattle; N'Dama; nutrition; productivity; Trypanosoma congolense
ID REPRODUCTIVE-PERFORMANCE; BODY CONDITION; POSTPARTUM NUTRITION; VILLAGE
   HUSBANDRY; MILK-PRODUCTION; ENERGY-INTAKE; BEEF-CATTLE; SUPPLEMENTATION;
   INTERVAL; GROWTH
AB This experiment studied the effects of body condition, long- and short-term levels of nutrition and trypanosomosis infection on the productivity of N'Dama cows using a 2 x 2 x 2 factorial cross-over design. Pre-partum, 23 cows received supplements for 6 months (H), the other group of 20 for 2 months (L). Bath groups grazed native pastures. Two days post partum, half the cows from each group were placed on a basal (B) or supplemented (S) plane of nutrition. The diet of concentrate, groundnut hay and andropogon hay was the same, only the quantities differed. Four weeks post partum half the animals in each group were inoculated with T. congolense organisms (I), the others acted as controls (C). The trial continued for a further 6 weeks.
   Pre-partum nutrition (H, L had no effect on dry-matter intake (DMI) but pre-partum feeding (H) improved post-partum productivity, evident by higher darn live weights (P < 0.05), body condition (P < 0.001), calf birth weight (P < 0.05) and calf live-weight gain (P < 0.01). Post-partum nutrition had no effect on productivity. Trypanosomosis infection caused a reduction (P < 0.05) in total DMI. The decline in groundnut hay and concentrate intake was proportionally (P < 0.001) greater in the S-I group than in the B-I group. A low plane of nutrition pre-partum depressed milk yield but increased fat concentration (P < 0.05). Infection significantly reduced milk offtake (P < 0.05). The reduction in milk offtake (P < 0.01) and calf live weight (P < 0.05) were proportionally larger in the B-I than in the S-I group. Infection caused a decline in milk protein concentration (P < 0.05) and protein yield (P < 0.01) which teas independent of dietary effects. Infection reduced (P < 0.01) the packed-cell volume but there were no interactions with diet. None of the cows was pregnant 150 days post partum but seven were cycling, 3(5) in the H-S-I group, 2(7) in the H-B-I group, 1(5) in the L-B-I group and 1(5) in the LS-C group. These results suggest that S-I cows attempted to maintain milk yield at the expense of live weight whereas the B-I cows had insufficient live-weight reserves that could be mobilized. This suggests the nutritional balance and changes in weight at the time of infection might be more important than historical planes of nutrition.
C1 Nat Resources Inst, Chatham ME4 4TB, Kent, England.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ London Wye Coll, Ashford TN25 5AH, Kent, England.
RP Bennison, JJ (reprint author), Agrimin Ltd, Elsham Wold Ind Estate, Brigg DN20 0SP, N Lincs, England.
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AGYEMANG K, 1991, ANIM REPROD SCI, V26, P51, DOI 10.1016/0378-4320(91)90065-8
   AGYEMANG K, 1993, ANIM PROD, V56, P165
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   BARTLE SJ, 1984, J ANIM SCI, V58, P1068
   LAFLAMME LF, 1992, CAN J ANIM SCI, V72, P843
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   LITTLE DA, 1991, TROP AGR, V68, P259
   LITTLE DA, 1994, TROP AGR, V71, P223
   MAEL JHH, 1988, P M INT CTR AFR INT, P219
   MARSTON TT, 1995, J ANIM SCI, V73, P657
   MCSWEENEY CS, 1993, AUST J AGR RES, V44, P1079, DOI 10.1071/AR9931079
   MOORE CP, 1983, J ANIM SCI, V57, P807
   MURRAY CM, 1977, PUBLICATION OAU STRC, V116, P247
   ORSKOV ER, 1981, BRIT J NUTR, V45, P547, DOI 10.1079/BJN19810133
   PULLAN NB, 1978, TROP ANIM HEALTH PRO, V10, P118, DOI 10.1007/BF02235322
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   RICHARDS MW, 1986, J ANIM SCI, V62, P300
   Romney DL, 1997, J AGR SCI, V129, P83, DOI 10.1017/S0021859697004449
   *STAT AN SYST I, 1994, SAS STAT GUID PERS C
   Van Soest PJ, 1982, NUTR ECOLOGY RUMINAN
   WRIGHT IA, 1992, ANIM PROD, V55, P41
NR 23
TC 4
Z9 4
U1 0
U2 0
PU BRITISH SOC ANIMAL SCIENCE
PI PENICUIK
PA PUBLICATIONS DEPT, PO BOX 3, PENICUIK EH26 ORZ, MIDLOTHIAN, SCOTLAND
SN 1357-7298
J9 ANIM SCI
JI Anim. Sci.
PD JUN
PY 1999
VL 68
BP 819
EP 829
PN 4
PG 11
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 204ZM
UT WOS:000080796600026
OA No
DA 2017-08-15
ER

PT J
AU Jobe, O
   Ariyoshi, K
   Marchant, A
   Sabally, S
   Corrah, T
   Berry, N
   Jaffar, S
   Whittle, H
AF Jobe, O
   Ariyoshi, K
   Marchant, A
   Sabally, S
   Corrah, T
   Berry, N
   Jaffar, S
   Whittle, H
TI Proviral load and immune function in blood and lymph node during HIV-1
   and HIV-2 infection
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE proviral load; cytokines; HIV-2; lymph node; HIV-1
ID VIRAL LOAD; T-CELLS; TISSUE; LYMPHOCYTES; ACTIVATION; RESPONSES;
   PHENOTYPE; DISEASE; STAGE
AB Proviral load as well as lymphocyte phenotype and function were compared in peripheral blood and lymph node compartments of 17 HIV-1, 12 HIV-2 and three dually infected patients with lymphadenopathy. The mean percentage (95% confidence interval (CI)) of CD4(+) cells was higher in lymph node mononuclear cells (LNMC) than in peripheral blood mononuclear cells (PBMC) in both infections, being 26.7% (21.1%, 32.3%) and 15.3% (10.4%, 20.2%), respectively, for HIV-1-infected patients (P = 0.0001) and 32.3% (22.7%, 41.9%) and 22.1% (13.6%, 30.6%), respectively, for HIV-2-infected patients (P = 0.02). In both types of infection, proviral load adjusted for number of CD4(+) cells was higher in LNMC than in PBMC: the geometric mean (95% CI) was 8937 (4991; 16 003) and 4384 (2260; 8503), respectively, for HIV-1 patients (P = 0.02) and 1624 (382; 6898) and 551 (147; 2058) DNA copies, respectively, for HIV-2 patients (P = 0.05). Proviral load in both compartments was closely correlated (HIV-1, r = 0.60, P = 0.01; and HIV-2, r = 0.83, P = 0.0003). In both infections, proliferation and interferon-gamma (IFN-gamma) production in response to purified protein derivative (PPD) was lower in LNMC than in PBMC, both of which, in turn, were lower than in healthy controls. These results indicate that in HIV-2 as in HIV-1 infection, infected cells have a tropism for the lymph nodes resulting in higher viral load in this compartment and lower lymphocyte responses to the recall antigen PPD which may increase susceptibility to tuberculosis.
C1 MRC Labs, Fajara, Gambia.
   UCL, Sch Med, Dept Virol, London W1N 8AA, England.
   London Sch Hyg & Trop Med, Dept Infect Dis, London WC1, England.
RP Jobe, O (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM ojobe@mrc.gm
CR Ariyoshi K, 1996, J INFECT DIS, V173, P245
   BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   FOX CH, 1991, J INFECT DIS, V164, P1051
   GRAZIOSI C, 1993, AIDS, V7, pS53, DOI 10.1097/00002030-199311002-00012
   KABILAN L, 1990, EUR J IMMUNOL, V20, P1085, DOI 10.1002/eji.1830200521
   Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199
   LAFEUILLADE A, 1993, AIDS, V11, P1527
   LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204
   Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0
   Meeusen ENT, 1996, IMMUNOL TODAY, V17, P421, DOI 10.1016/0167-5699(96)10055-4
   Meroni L, 1996, AIDS, V10, P23, DOI 10.1097/00002030-199601000-00004
   MEYAARD L, 1993, IMMUNOL TODAY, V14, P161, DOI 10.1016/0167-5699(93)90279-T
   Meylan PRA, 1996, J ACQ IMMUN DEF SYND, V13, P39, DOI 10.1097/00042560-199609000-00007
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   Ravn P, 1997, J IMMUNOL, V158, P1949
   ROSENBERG JY, 1998, IMMUNOL TODAY, V19, P10
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   TAMALET C, 1994, AIDS, V8, P1083, DOI 10.1097/00002030-199408000-00007
   Westermann J, 1997, EUR J IMMUNOL, V27, P3174, DOI 10.1002/eji.1830271214
   WHITTLE H, 1993, CLIN EXP IMMUNOL, V93, P45
NR 22
TC 8
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 1999
VL 116
IS 3
BP 474
EP 478
PG 5
WC Immunology
SC Immunology
GA 217QU
UT WOS:000081511100015
PM 10361237
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   O'Donovan, D
   Marchant, A
   Yamuah, L
   Harding, E
   Jaffar, S
   McAdam, KPWJ
   Corrah, T
   Whittle, H
AF Ota, MOC
   O'Donovan, D
   Marchant, A
   Yamuah, L
   Harding, E
   Jaffar, S
   McAdam, KPWJ
   Corrah, T
   Whittle, H
TI HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail
   to develop a Bacillus Calmette-Guerin scar
SO AIDS
LA English
DT Letter
ID NORTHERN MALAWI; BCG
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Ota, MOC (reprint author), MRC Labs, Banjul, Gambia.
RI O'Donovan, Diarmuid/G-9253-2011
OI O'Donovan, Diarmuid/0000-0001-8771-7271
CR BAHR GM, 1986, TUBERCLE, V67, P205, DOI 10.1016/S0041-3879(86)80027-7
   CHOUGNET C, 1997, 13 EUR IMM M AMST JU
   Economides A, 1998, CLIN DIAGN LAB IMMUN, V5, P230
   FINE PEM, 1986, LANCET, V2, P499
   FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35
   Fine PE., 1989, REV INFECT DIS S2, V11, P353
   LAFORCE FM, 1986, WHOEPI866
   LALLEMANTLECOEUR S, 1991, AIDS, V5, P195
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   1991, MMWR, V40, P833
NR 10
TC 18
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 28
PY 1999
VL 13
IS 8
BP 996
EP 998
DI 10.1097/00002030-199905280-00020
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 199VG
UT WOS:000080504300020
PM 10371185
OA No
DA 2017-08-15
ER

PT J
AU Davies, GR
   Connolly, C
   Sturm, AW
   McAdam, KPWJ
   Wilkinson, D
AF Davies, GR
   Connolly, C
   Sturm, AW
   McAdam, KPWJ
   Wilkinson, D
TI Twice-weekly, directly observed treatment for HIV-infected and
   uninfected tuberculosis patients: cohort study in rural South Africa
SO AIDS
LA English
DT Article
DE tuberculosis; HIV; intermittent therapy; Africa
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; 2-YEAR FOLLOW-UP;
   PULMONARY TUBERCULOSIS; THERAPY; COMMUNITY; REGIMEN; PROGRAM; IMPACT;
   DOT
AB Objective: To determine the effectiveness of twice-weekly directly observed therapy (DOT) for tuberculosis (TB) in HIV-infected and uninfected patients, irrespective of their previous treatment history. Also to determine the predictive value of 2-3 month smears on treatment outcome.
   Methods: Four hundred and sixteen new and 113 previously treated adults with culture positive pulmonary TB (58% HIV infected, 9% combined drug resistance) in Hlabisa, South Africa. Daily isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) given in hospital (median 17 days), followed by HRZE twice a week to 2 months and HR twice a week to 6 months in the community.
   Results: Outcomes at 6 months among the 416 new patients were: transferred out 2%; interrupted treatment 17%; completed treatment 3%; failure 2%; and cured 71%. Outcomes were similar among HIV-infected and uninfected patients except for death (6 versus 2%; P = 0.03). Cure was frequent among adherent HIV-infected (97%; 95% CI 94-99%) and uninfected (96%; 95% CI 92-99%) new patients. Outcomes were similar among previously treated and new patients, except for death (11 versus 4%; P = 0.01), and cure among adherent previously treated patients 97% (95% CI 92-99%) was high. Smear results at 2 months did not predict the final outcome.
   Conclusion: A twice-weekly rifampicin-containing drug regimen given under DOT cures most adherent patients irrespective of HIV status and previous treatment history. The 2 month smear may be safely omitted. Relapse rates need to be determined, and an improved system of keeping treatment interrupters on therapy is needed. Simplified TB treatment may aid implementation of the DOTS strategy in settings with high TB caseloads secondary to the HIV epidemic. (C) 1999 Lippincott Williams & Wilkins.
C1 Hlabisa Hosp, Hlabisa, South Africa.
   Univ Natal, Dept Med Microbiol, ZA-4001 Durban, South Africa.
   MRC Labs, Banjul, Gambia.
RP Wilkinson, D (reprint author), Univ Adelaide, S Australian Ctr Rural & Remote Hlth, Whyalla Norrie, SA 5608, Australia.
RI Wilkinson, David/A-6207-2008
OI Wilkinson, David/0000-0002-7265-9846
CR Caminero JA, 1996, THORAX, V51, P1130, DOI 10.1136/thx.51.11.1130
   Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0
   Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034
   Chan S. L., 1994, P141
   COHN DL, 1990, ANN INTERN MED, V112, P407
   DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9
   DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.268.12.1581
   ELLIOTT AM, 1995, J TROP MED HYG, V98, P9
   Floyd K, 1997, BRIT MED J, V315, P1407
   GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z
   HOPEWELL P, 1992, CLIN INFECT DIS   S1, V15, P282
   KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204
   RAVIGLIONE M, 1997, TUBERCULOSIS HIV CUR
   VOLMINK J, 1997, INFECT DIS MODULE CO
   World Health Organization, 1997, TREATM TUB GUID NAT
   *WHO, WHOGTB97225
   WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9
   Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094
   Wilkinson D, 1997, TROP MED INT HEALTH, V2, P700, DOI 10.1046/j.1365-3156.1997.d01-358.x
   Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016
   Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P87, DOI 10.1016/S0035-9203(97)90407-7
   Wilkinson D, 1998, INT J TUBERC LUNG D, V2, P52
   Wilkinson D, 1996, T ROY SOC TROP MED H, V90, P692, DOI 10.1016/S0035-9203(96)90440-X
   WILKINSON D, 1997, BAILLIERES CLIN IN 1
NR 25
TC 24
Z9 26
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 7
PY 1999
VL 13
IS 7
BP 811
EP 817
DI 10.1097/00002030-199905070-00010
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 194CG
UT WOS:000080174100010
PM 10357380
OA No
DA 2017-08-15
ER

PT J
AU Emerson, PM
   Lindsay, SW
   Walraven, GEL
   Faal, H
   Bogh, C
   Lowe, K
   Bailey, RL
AF Emerson, PM
   Lindsay, SW
   Walraven, GEL
   Faal, H
   Bogh, C
   Lowe, K
   Bailey, RL
TI Effect of fly control on trachoma and diarrhoea
SO LANCET
LA English
DT Article
ID GAMBIAN VILLAGE; MUSCA-DOMESTICA; TRANSMISSION; IMPACT
AB Background Domestic flies are accepted vectors of diarrhoea, but their role in trachoma transmission has never been quantified and no study has shown that fly control decreases the prevalence of trachoma. We assessed the effect of fly control on public health in a pilot study in Gambian villages.
   Methods We studied two pairs of villages-one pair in the 1997 wet season, and one pair in the 1998 dry season. For each pair, deltamethrin was sprayed for 3 months to control flies in one village whilst the other was used as a control. Fly populations were monitored with traps. We surveyed trachoma at baseline and at 3 months, and collected daily data on diarrhoea in children aged between 3 months and 5 years.
   Findings Fly control decreased numbers of muscid flies by around 75% in the intervention villages compared with controls. Trachoma prevalence was similar at baseline (wet season, prevalence in intervention village 8.8% vs control 12.2%; dry season, 18.0% vs 16.0%), but after 3 months of fly control there were 75% fewer new cases of trachoma in the intervention villages (wet season 3.7% vs 13.7%; dry season 10.0% vs 18.9%; rate ratio and relative risk of pooled data 0.25 [adjusted 95% CI 0.09-0.64], p=0.003). There was 22% less childhood diarrhoea in the wet season (14% vs 19%, period prevalence ratio 0.78 [0.64-0.95], p=0.01), and 26% less diarrhoea in the dry season (6% vs 8%; 0.74 [0.34-1.59], p=0.60) compared with controls.
   Interpretation Muscid flies are important vectors of trachoma and childhood diarrhoea in The Gambia. Deltamethrin spray is effective for fly control and may be useful for reducing trachoma and diarrhoea in some situations, but further research on sustainable fly-control methods is needed.
C1 MRC, Banjul, Gambia.
   Univ Durham, Durham DH1 3HP, England.
   Danish Bilharziasis Lab, Charlottenlund, Denmark.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Emerson, PM (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BENN C, 1992, B WORLD HEALTH ORGAN, V70, P705
   COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N
   DOLIN PJ, 1997, LANCET, V349, P151
   FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147
   FOTEDAR R, 1992, J HOSP INFECT, V20, P209, DOI 10.1016/0195-6701(92)90089-5
   GREENWOOD BM, 1993, T R SOC TROP MED S2, V87, pS2
   MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295
   Maccallan A F, 1931, Br J Ophthalmol, V15, P369, DOI 10.1136/bjo.15.7.369
   MONZON R B, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P222
   REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497
   ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P145
   TAYLOR HR, 1988, AM J TROP MED HYG, V38, P623
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P223
NR 19
TC 110
Z9 111
U1 2
U2 7
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 24
PY 1999
VL 353
IS 9162
BP 1401
EP 1403
DI 10.1016/S0140-6736(98)09158-2
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 191KD
UT WOS:000080020800013
PM 10227221
OA No
DA 2017-08-15
ER

PT J
AU Garly, ML
   Martins, CL
   Bale, C
   da Costa, F
   Dias, F
   Whittle, H
   Aaby, P
AF Garly, ML
   Martins, CL
   Bale, C
   da Costa, F
   Dias, F
   Whittle, H
   Aaby, P
TI Early two-dose measles vaccination schedule in Guinea-Bissau: good
   protection and coverage in infancy
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE measles vaccine; two-dose policy; participation rate; attack rate;
   measles; 'catchup' vaccination campaigns
ID RURAL SENEGAL; WEST-AFRICA; MORTALITY; AGE; IMMUNIZATION; EFFICACY;
   URBAN; COUNTRIES; RATES
AB Background Previous studies from Africa have suggested that there is little benefit to be gained from early two-dose measles vaccination schedules. Two-dose schedules have been associated with no improvement in coverage due to immunization of the same individuals on both occasions, low return rate, high refusal rate, low vaccine efficacy, and fear of blunting of the antibody response. Because of the poor results achieved previously with two-dose measles vaccination schedules, we studied patterns of participation, reasons for non-participation, vaccination coverage and relative efficacy of a one-dose versus a two-dose schedule in connection with the implementation of an early two-dose trial in Guinea-Bissau.
   Methods Children born from September 1994 to January 1996 were randomized into two groups receiving either two doses of measles vaccine at 6 and 9 months or one dose of inactivated polio vaccine (IPV) at 6 months and measles vaccine at 9 months.
   Results At 6 months of age 86% (1869/2181) of the children participated, and at 9 months of age participation was 87% (1775/2035). The return rate for obtaining a second dose of vaccine was 93% (1647/1773). The main reason for not participating was travelling (78%). Around 50% of those who did not take part in one vaccination took part in the other. When only children participating the first time they were called for a measles vaccination were included, the measles vaccination coverage in the one-dose,group was 59% versus 80% in the two-dose group, i.e. a 50% reduction in the risk of not being vaccinated (relative risk [RR] 0.50; confidence interval[CI] :0.43-0.57). Few measles cases have occurred in the study area since the implementation of the trial making precise estimation of the relative efficacy of the two vaccine strategies difficult, but all seven clinically diagnosed measles cases occurred in the one-dose group making the relative efficacy for the two-dose group compared with the one-dose group 100% (95% CI:35%-100%; two-tailed P = 0.016). When including maternal reports, the relative efficacy was 90% (95% exact confidence interval; two-tailed P = 25%-97%, P = 0.022).
   Conclusion In this study of a two-dose measles immunization schedule at 6 and 9 months of age there was no sign of low participation or poor return rates. The risk of not being vaccinated was lower in the two-dose group than in the one-dose group, and the relative efficacy of a two-dose versus a one-dose schedule was high. Although our results were obtained within a trial where dedicated personnel informed every participant personally about the study, we believe our results indicate that with thorough information about the population it may be possible to achieve a higher coverage with a two-dose measles vaccination schedule than a one-dose schedule. A two-dose schedule may be a feasible way to resolve the problems of low coverage and severe measles infection among infants.
C1 Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   Projecto Saude Bandim, Bissau 1004, Guinea Bissau.
   Lab Nacl Saude Publ, Bissau, Guinea Bissau.
   MRC Labs, Fajara, Gambia.
RP Garly, ML (reprint author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1995, BRIT MED J, V311, P481
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315
   CLAYTON D, 1993, STAT MODELS EPIDEMIO, P128
   CLEMENTS CJ, 1994, LANCET, V344, P174
   *EXP PROGR IMM, 1993, WORLD HEALTH FORUM, V14, P329
   Expanded Programme On Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   *EXP PROGR IMM, 1980, WKLY EPIDEMIOL REC, V55, P177
   *EXP PROGR IMM, 1979, WKLY EPIDEMIOL REC, V54, P221
   *EXP PROGR IMM, 1992, 923 WHOEPIGEN
   *EXP PROGR IMM, 1980, WKLY EPIDEMIOL REC, V55, P297
   HEYMANN DL, 1983, LANCET, V2, P1470
   HULL HF, 1983, LANCET, V1, P972
   LOENING WEK, 1983, LANCET, V2, P324
   NOKES DJ, 1990, INT J EPIDEMIOL, V19, P703, DOI 10.1093/ije/19.3.703
   ROSENTHAL SR, 1993, B WORLD HEALTH ORGAN, V71, P421
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788
   [Anonymous], 1997, MMWR, V46, P1
NR 24
TC 33
Z9 33
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD APR
PY 1999
VL 28
IS 2
BP 347
EP 352
DI 10.1093/ije/28.2.347
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 190BZ
UT WOS:000079942800026
PM 10342702
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Kora, S
   Gaye, M
   Darboe, L
AF Osaer, S
   Goossens, B
   Kora, S
   Gaye, M
   Darboe, L
TI Health and productivity of traditionally managed Djallonke sheep and
   West African dwarf goats under high and moderate trypanosomosis risk
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosoma spp.; sheep protozoa; goat; rural development; nutrition;
   helminths
ID SCOTTISH BLACKFACE SHEEP; SMALL RUMINANTS; REPRODUCTIVE-PERFORMANCE;
   NUTRITIONAL SUPPLEMENTS; EXPERIMENTAL-INFECTION; CONGOLENSE INFECTION;
   TSETSE CHALLENGE; GAMBIA; CATTLE; GLOSSINIDAE
AB Trypanosome infections, packed red cell volume levels (PCV), body weight and nematode faecal egg counts of village-based small ruminants were monitored in two areas in The Gambia with either moderate or high trypanosomosis risk for 24 and 30 months respectively. Outflows from the flock and new-born animals were recorded and data on housing and management were compiled. Reported mortality rates were higher in goats than in sheep, but for both species highest in the moderate risk area. The peak of trypanosome infections lagged the peak of tsetse densities by 1-3 months in both areas. Trypanosoma vivax was the predominant species found in the infected animals, followed by T. congolense. Trypanosome prevalence was, in general, higher in sheep than in goats but only significantly higher during Year 1 in the moderate risk area. Trypanosome infection reduced the PCV level significantly and seasonal effects indicated significantly lower PCV levels during the rains. Trypanosome infection si,significantly depressed weight gain in both species at periods where infection rates were highest. In both species considerably lower weight gains were observed during the rainy season. Abortion rates were higher in goats than in sheep in both study sites, and highest in the high-risk site. Trypanosome infection in ewes in the high risk area increased lamb mortality significantly but had no effect on birth weights, nor on growth rates up to 4 months. Offspring mortality up to 4 months was generally high at both sites. Trypanosome infection in the dam between 3.5 to 7 months post parturition significantly increased parturition interval in both species. Peak faecal egg output occurred at the end of the rainy season and was highest for both species in the moderate risk site. Poor grazing management was found responsible for a seasonal nutritional constraint. Based on these results, these breeds of sheep and goats can be considered as trypanotolerant since they are able to remain productive under high and moderate levels of trypanosome challenge. Nevertheless, trypanosomosis affected their health and production level as shown by reduced PCV levels, depressed weight gains, longer parturition intervals and higher lamb mortality. In addition, during the rains, helminth infections and poor management leading to nutritional constraints had also a negative impact on health and production and therefore influenced the innate resilience to trypanosomosis in those indigenous breeds. Adaptations in management may have an equal impact as certain disease control measures to improve biological and economical returns from small ruminants in tsetse infested rural areas. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   Bennison JJ, 1997, AGR SYST, V55, P425, DOI 10.1016/S0308-521X(97)00002-4
   *DLS ITC, 1993, LIV CENS
   FLINT S, 1985, B ENTOMOL RES, V75, P529
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1998, VET REC, V142, P277
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   GREENWOOD AC, 1989, REPORT SMALL RUMINAN
   HECKER PA, 1991, P 21 M ISCTR YAMM
   Hoare C, 1972, TRYPANOSOMES MAMMALS
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P153
   JABANG S, 1990, SUMMARY METEOROLOGIC
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1993, TROP ANIM HLTH PROD, V27, P76
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MILLIGAN PJM, 1988, PARASITOLOGY, V96, P211
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   MURRAY M, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P203
   Nash ML, 1996, VET REC, V139, P64
   Osaer S, 1999, VET PARASITOL, V80, P215, DOI 10.1016/S0304-4017(98)00193-9
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   Osaer S, 1998, ANIM REPROD SCI, V51, P97, DOI 10.1016/S0378-4320(98)00067-0
   Otesile E B, 1991, Rev Elev Med Vet Pays Trop, V44, P9
   Panin A, 1997, SMALL RUMINANT RES, V25, P9, DOI 10.1016/S0921-4488(96)00967-4
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   RUSSO SL, 1991, P WORKSH PVO U COMM, P71
   Snedecor G. W., 1980, STAT METHODS
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   SNOW WF, 1979, ACTA TROP, V36, P47
   *STAT AN SYST I SA, 1997, VERS 6 11
   SUMBERG JE, 1985, TROP ANIM HEALTH PRO, V17, P135, DOI 10.1007/BF02355872
   Tanner MA., 1993, TOOLS STAT INFERENCE, DOI 10.1007/978-1-4684-0192-9
   THIENPONT D, 1979, DIAGNOSE VERMINOSE K
   THRUSFIELD M., 1995, VET EPIDEMIOLOGY
   UPTON M, 1985, AGR SYST, V17, P65, DOI 10.1016/0308-521X(85)90014-9
   VALE GA, 1977, B ENTOMOL RES, V67, P635
   WACHER TJ, 1993, ANN TROP MED PARASIT, V87, P517
   Wassink GJ, 1997, ANIM SCI, V64, P127
NR 49
TC 14
Z9 14
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR 31
PY 1999
VL 82
IS 2
BP 101
EP 119
DI 10.1016/S0304-4017(99)00011-4
PG 19
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 187WU
UT WOS:000079811900002
PM 10321582
OA No
DA 2017-08-15
ER

PT J
AU Leach, A
   McArdle, TF
   Banya, WAS
   Krubally, O
   Greenwood, AM
   Rands, C
   Adegbola, R
   De Francisco, A
   Greenwood, BM
AF Leach, A
   McArdle, TF
   Banya, WAS
   Krubally, O
   Greenwood, AM
   Rands, C
   Adegbola, R
   De Francisco, A
   Greenwood, BM
TI Neonatal mortality in a rural area of The Gambia
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID UPPER RIVER DIVISION; HEALTH-CARE PROGRAM; CHILDHOOD MORTALITY;
   BIRTH-WEIGHT; INFANT; PATTERN; IMPACT
AB Childhood mortality in Upper River Division, The Gambia is high, 99 per 1000 mid-year population, and 27% of deaths occur in the neonatal period.(1) The aims of the present study were to describe patterns of neonatal death and to identify risk factors. Cause of death was investigated using a neonatal post-mortem questionnaire, and a population-based, matched case-control study was conducted to identify potential risk factors. The neonatal mortality rate in Upper River Division was 39 per 1000 live births (95% CI 36.8-41.2). The rates in the early and late neonatal periods were 21.0 (19.4-22.6) and 18.0 (16.5-19.5), respectively. Infection accounted for 57% of all deaths. In the early neonatal period, 30% of deaths were due to prematurity. Only 55% of babies who died presented for treatment and 84% died at home. Risk factors for neonatal death were primiparity (OR 2.18), previous stillbirth (OR 3.19), prolonged labour (OR 2.80) and pre-lacteal feeding (OR 3.38). A protective effect was seen in association with delivery by a trained traditional birth attendant (OR 0.34) and the application of shea nut butter, a traditional medicine, to the cord stump (OR 0.07). This study has identified the need to understand the reasons underlying the widespread use of pre-lacteal feeds and the barriers to health service use in this community in order to plan effective interventions.
C1 MRC Labs, Fajara, Gambia.
RP Leach, A (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM Aleach@mrc.gm
CR BERGMAN NJ, 1994, TROP DOCT, V24, P57
   De Muylder X, 1989, Paediatr Perinat Epidemiol, V3, P284
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DOWNES B, 1991, J TROP PEDIATRICS, V37, P106
   FARBMAN KS, 1993, PEDIATR INFECT DIS J, V12, P614
   FAUVEAU V, 1990, INT J EPIDEMIOL, V19, P606, DOI 10.1093/ije/19.3.606
   FOWLER MG, 1991, AM J OBSTET GYNECOL, V165, P15
   GARNER P, 1994, J TROP PEDIATRICS, V40, P24
   GRAY RH, 1991, INT J EPIDEMIOL, V20, P467, DOI 10.1093/ije/20.2.467
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   KOENIG MA, 1986, SOC SCI MED, V22, P15, DOI 10.1016/0277-9536(86)90303-5
   LAMB WH, 1984, LANCET, V2, P912
   *NAT POP COMM OFF, 1993, NAT CENS
   PISON G, 1993, INT J EPIDEMIOL, V22, P72, DOI 10.1093/ije/22.1.72
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   *SECR NAT POP COMM, 1993, POP DAT
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   TODD JE, 1994, ANN TROP PAEDIATR, V14, P31
   TRAVERSO HP, 1989, LANCET, V1, P486
   United Nations Children's Fund (UNICEF), 1996, STAT WORLDS CHILDR
   WINBERG J, 1971, LANCET, V1, P1091
NR 23
TC 40
Z9 40
U1 1
U2 2
PU CARFAX PUBLISHING
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD MAR
PY 1999
VL 19
IS 1
BP 33
EP 43
DI 10.1080/02724939992617
PG 11
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 175LM
UT WOS:000079096000005
PM 10605518
OA No
DA 2017-08-15
ER

PT J
AU Bellamy, R
   Ruwende, C
   Corrah, T
   McAdam, KPWJ
   Thursz, M
   Whittle, HC
   Hill, AVS
AF Bellamy, R
   Ruwende, C
   Corrah, T
   McAdam, KPWJ
   Thursz, M
   Whittle, HC
   Hill, AVS
TI Tuberculosis and chronic hepatitis B virus infection in Africans and
   variation in the vitamin D receptor gene
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 4th Conference of the Federation-of-Infection-Societies
CY NOV, 1997
CL MANCHESTER, ENGLAND
SP Federat Infect Soc
ID MYCOBACTERIUM-TUBERCULOSIS; SEVERE MALARIA; SUSCEPTIBILITY; ASSOCIATION;
   DEFICIENCY; TWINS
AB The active metabolite of vitamin D, 1,25 dihydroxyvitamin D3, is an important immunoregulatory hormone [1], Its effects are exerted by interaction with the vitamin D receptor, which is present on human monocytes and activated T and B lymphocytes, Variation in the vitamin D receptor gene was typed in 2015 subjects from large case-control studies of three major infectious diseases: tuberculosis, malaria, and hepatitis B virus, Homozygotes for a polymorphism at codon 352 (genotype tt) were significantly underrepresented among those with tuberculosis (chi(2) = 6.22, 1 df, P = .01) and persistent hepatitis B infection (chi(2) = 6.25, 1 df, P = .01) but not in subjects with clinical malaria compared with the other genotypes, Therefore, this genetic variant, which predisposes to low bone mineral density in many populations, may confer resistance to certain infectious diseases.
C1 Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   St Marys Hosp, Imperial Coll, Dept Med, Sch Med, London, England.
   MRC Labs, Fajara, Banjul, Gambia.
RP Hill, AVS (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.
EM adrian.hill@well.ox.ac.uk
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR Bellamy R, 1998, QJM-MON J ASSOC PHYS, V91, P13, DOI 10.1093/qjmed/91.1.13
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 1998, CURR OPIN IMMUNOL, V10, P483, DOI 10.1016/S0952-7915(98)80125-8
   Bellamy R, 1998, T ROY SOC TROP MED H, V92, P312, DOI 10.1016/S0035-9203(98)91026-4
   BELLAMY R, 1998, IN PRESS TUBER LUNG, V79
   Bellamy RJ, 1998, NOVART FDN SYMP, V217, P3, DOI 10.1002/0470846526.ch2
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   DAVIES PDO, 1985, TUBERCLE, V66, P301, DOI 10.1016/0041-3879(85)90068-6
   Eisman JA, 1996, CURR OPIN GENET DEV, V6, P361, DOI 10.1016/S0959-437X(96)80015-3
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   LIN TM, 1989, ANTICANCER RES, V9, P737
   MANOLAGAS SC, 1994, SEMIN NEPHROL, V14, P129
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
NR 15
TC 295
Z9 316
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1999
VL 179
IS 3
BP 721
EP 724
DI 10.1086/314614
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 183RF
UT WOS:000079566700029
PM 9952386
OA No
DA 2017-08-15
ER

PT J
AU Cisse, B
   Aaby, P
   Simondon, F
   Samb, B
   Soumare, M
   Whittle, H
AF Cisse, B
   Aaby, P
   Simondon, F
   Samb, B
   Soumare, M
   Whittle, H
TI Role of schools in the transmission of measles in rural Senegal -
   Implications for measles control in developing countries
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE developing countries; disease outbreaks; disease transmission; measles;
   measles vaccine; schools; vaccination
ID VACCINE FAILURE; CASE-FATALITY; MORTALITY; COMMUNITY; EFFICACY;
   IMMUNIZATION; INFECTION; CHILDREN; OUTBREAK; EXPOSURE
AB Patterns of measles transmission at school and at home were studied in 1995 in a rural area of Senegal with a high level of vaccination coverage. Among 209 case children with a median age of 8 years, there were no deaths, although the case fatality ratio has previously been 6-7% in this area. Forty percent of the case children had been Vaccinated against measles; the proportion of vaccinated children was higher among secondary cases (47%) than among index cases (33%) (prevalence ratio = 1.36, 95% confidence interval (CI) 1.04-1.76). Vaccinated index cases may have been less infectious than unvaccinated index cases, since they produced fewer clinical cases among exposed children (relative risk = 0.55, 95% CI 0.29-1.04). The secondary attack rate was lower in the schools than in the homes (relative risk = 0.31, 95% CI 0.20-0.49). The school outbreaks were protracted, with 4-5 generations of cases being seen in the two larger schools. Vaccine efficacy was found to be 57% (95% CI -23 to 85) in the schools and 74% (95% CI 62-82) in the residential compounds. Measles infection resulted in a mean of 3.8 days of absenteeism per case, though this did not appear to have an impact on the children's grades. Among the index cases, 56% of children were probably infected by neighbors in the community, and 7% were probably infected at health centers, 13% outside the community, and 24% in one of the three schools which had outbreaks during the epidemic. However, most of the school-related cases occurred at the beginning and therefore contributed to the general propagation of the epidemic. To prevent school outbreaks, it may be necessary to require vaccination prior to school entry and to revaccinate children in individual schools upon detection of cases of measles. Multidose measles vaccination schedules will be necessary to control measles in developing countries.
C1 Danish Epidemiol Sci Ctr, Statens Seruminst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.
   ORSTOM, Inst Francais Rech Sci Dev Cooperat, Dakar, Senegal.
   ORSTOM, F-34032 Montpellier, France.
   INSERM, U88, F-94415 St Maurice, France.
   Univ Fann, Ctr Hosp, Clin Malad Infect Ibrahima Diop Mar, Dakar, Senegal.
   Med Res Council Labs, Banjul, Gambia.
RP Aaby, P (reprint author), Danish Epidemiol Sci Ctr, Statens Seruminst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR AABY P, 1986, J INFECT DIS, V154, P858
   AABY P, 1985, J EPIDEMIOL COMMUN H, V39, P113, DOI 10.1136/jech.39.2.113
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Aaby P, 1996, VACCINE, V14, P226, DOI 10.1016/0264-410X(95)00178-4
   AABY P, 1992, LANCET, V340, P388, DOI 10.1016/0140-6736(92)91470-S
   BROWNLEE J, 1920, BRIT MED J, V1, P534
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   CHEN RT, 1990, J INFECT DIS, V162, P1036
   CHERRY JD, 1973, J PEDIATR-US, V82, P802, DOI 10.1016/S0022-3476(73)80070-8
   deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224
   GARENNE M, 1993, AM J EPIDEMIOL, V138, P182
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157
   Lisse I, 1998, SCAND J INFECT DIS, V30, P17
   MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   Samb B, 1997, AM J EPIDEMIOL, V145, P51
   WHITTLE H, IN PRESS LANCET
   WHITTLE HC, IN PRESS PEDIAT INFE
   *WHO, 1996, EPI NEWSLETT, V18, P1
NR 23
TC 19
Z9 19
U1 0
U2 1
PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH
PI BALTIMORE
PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD FEB 15
PY 1999
VL 149
IS 4
BP 295
EP 301
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 165ZL
UT WOS:000078551700001
PM 10025469
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Cisse, B
   Simondon, F
   Samb, B
   Soumare, M
   Whittle, H
AF Aaby, P
   Cisse, B
   Simondon, F
   Samb, B
   Soumare, M
   Whittle, H
TI Waning of vaccine-induced immunity: Is it a problem in Africa?
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
C1 Danish Epidemiol Sci Ctr, Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.
   ORSTOM, Inst Francais Rech Sci Dev Cooperat, Dakar, Senegal.
   ORSTOM, F-34032 Montpellier, France.
   INSERM, U88, F-94415 St Maurice, France.
   Univ Fann, Ctr Hosp, Clin Malad Infect Ibrahima Diop Mar, Dakar, Senegal.
   Med Res Council Labs, Banjul, Gambia.
RP Aaby, P (reprint author), Danish Epidemiol Sci Ctr, Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
CR Cisse B, 1999, AM J EPIDEMIOL, V149, P295
   GARLE ML, IN PRESS INT J EPIDE
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   Strebel P, 1999, AM J EPIDEMIOL, V149, P302
   WHITTLE H, IN PRESS LANCET
   WHITTLE HC, IN PRESS PEDIAT INFE
NR 6
TC 4
Z9 4
U1 0
U2 0
PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH
PI BALTIMORE
PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD FEB 15
PY 1999
VL 149
IS 4
BP 304
EP 305
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 165ZL
UT WOS:000078551700003
PM 10025471
OA No
DA 2017-08-15
ER

PT J
AU Cooke, AH
   Chiodini, PL
   Doherty, T
   Moody, AH
   Ries, J
   Pinder, M
AF Cooke, AH
   Chiodini, PL
   Doherty, T
   Moody, AH
   Ries, J
   Pinder, M
TI Comparison of a parasite lactate dehydrogenase-based
   immunochromatographic antigen detection assay (Optimal (R)) with
   microscopy for the detection of malaria parasites in human blood samples
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DIAGNOSIS
AB Microscopic examination of blood smears remains the gold standard for malaria diagnosis, but is labor-intensive and requires skilled operators; Rapid dipstick technology provides a potential alternative. A study was conducted in The Gambia to compare the performance of OptiMAL(R), an immunochromatographic antigen detection assay for the diagnosis of malaria using parasite lactate dehydrogenase, against standard microscopy in patients with suspected malaria. For initial diagnosis of Plasmodium falciparum, irrespective of stage, this assay had a sensitivity of 91.3%, a specificity of 92%, a positive predictive value of 87.2%, and a negative predictive value of 94.7%. The sensitivity of the test decreased markedly at parasitemias < 0.01%. This assay can be used for the diagnosis of malaria in areas where microscopy is not available and for urgent malaria diagnosis at night and at weekends, when routine laboratories are closed and when relatively inexperienced microscopists may be on duty.
C1 Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England.
   MRC Labs, Malaria Program, Banjul, Gambia.
   Vet Affairs Hosp, Portland, OR USA.
RP Chiodini, PL (reprint author), Hosp Trop Dis, Dept Clin Parasitol, 4 St Pancras Way, London NW1 0PE, England.
CR BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2
   CHIODINI PL, 1996, MED DEVICES AGENCY E
   MAKLER MT, 1993, AM J TROP MED HYG, V48, P739
   Palmer CJ, 1998, J CLIN MICROBIOL, V36, P203
   Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6
NR 5
TC 47
Z9 57
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD FEB
PY 1999
VL 60
IS 2
BP 173
EP 176
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 171RW
UT WOS:000078878700001
PM 10072131
OA No
DA 2017-08-15
ER

PT J
AU Poskitt, EME
   Cole, TJ
   Whitehead, RG
AF Poskitt, EME
   Cole, TJ
   Whitehead, RG
TI Less diarrhoea but no change in growth: 15 years' data from three
   Gambian villages
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
DE diarrhoea; growth; nutrition
ID RURAL BANGLADESH; CHILD-MORTALITY; YOUNG-CHILDREN; GLOBAL PROBLEM;
   DISEASE; INFANTS; MALNUTRITION; SUPPLEMENTATION; MAGNITUDE; MORBIDITY
AB Aims-To review diarrhoea presentations and nutritional status in young rural Gambian children over a 15 year period as a test of an earlier hypothesis that reduced diarrhoea prevalence would lead to improved growth and a reduced prevalence of malnutrition.
   Subjects and methods-Growth and morbidity were documented routinely in 1190 children under 2 years of age attending the Dunn Nutrition Group clinic at Keneba between 1979 and 1993.
   Results-The numbers of presentations with diarrhoea (1069 in 1979; 220 in 1993) and the proportion of clinic attendees with diarrhoea (30% in 1979; 8% in 1993) fell steadily between 1979 and 1993. However, at both 1 year old, mean weights (Z scores: 1979, -1.8; 1993, -1.8) and mean lengths (Z scores: 1979, -1.3; 1993, -1.7), and at 2 years old, mean weights (Z scores: 1979, -2.0; 1993, -1.9) and mean lengths (Z scores: 1979, -2.0; 1993, -2.1) did not change noticeably over the 15 year period.
   Conclusion-Major progressive reductions in clinic presentations with diarrhoea have not been associated with improved nutritional status in this population of young rural Gambian children.
C1 MRC, Human Nutr Res Ctr, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
   MRC, Dunn Nutr Grp, Banjul, Gambia.
RP Poskitt, EME (reprint author), MRC, Human Nutr Res Ctr, Dunn Nutr Unit, Downhams Lane, Cambridge CB4 1XJ, England.
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G9827821, G9827821(62595)]
CR ALAM N, 1989, INT J EPIDEMIOL, V18, P242, DOI 10.1093/ije/18.1.242
   ASHWORTH A, 1969, BRIT J NUTR, V23, P835, DOI 10.1079/BJN19690094
   BARKER DJP, 1994, MOTHERS BABIES DIS L, P80
   Barker DJP, 1992, FETAL INFANT ORIGINS, P141
   BATES CJ, 1993, BRIT J NUTR, V69, P243, DOI 10.1079/BJN19930026
   BATES CJ, 1982, T ROY SOC TROP MED H, V76, P253, DOI 10.1016/0035-9203(82)90291-7
   BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705
   BLACK RE, 1982, AM J EPIDEMIOL, V115, P305
   BRIEND A, 1989, LANCET, V2, P319
   CUTTING WAM, 1985, DIARRHOEAL DIS MALNU, P158
   Esrey SA, 1996, AM J EPIDEMIOL, V143, P608
   Galler JR, 1993, TXB PEDIAT NUTR, P173
   GRANTHAMMCGREGOR SM, 1982, DEV MED CHILD NEUROL, V24, P321
   Hoare K, 1994, Health Visit, V67, P102
   Hoare S, 1996, BRIT J NUTR, V76, P479, DOI 10.1079/BJN19960057
   JACKSON M, 1991, BRIT J NUTR, V65, P131, DOI 10.1079/BJN19910075
   KOLSKY PJ, 1993, T ROY SOC TROP MED H, V87, P43, DOI 10.1016/0035-9203(93)90537-Z
   Kolsteren PWV, 1997, ANN TROP PAEDIATR, V17, P201
   LAMB WH, 1984, LANCET, V2, P912
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   MacDonald A, 1996, ARCH DIS CHILD, V74, P81
   MATA L, 1992, AM J TROP MED HYG, V47, P16
   Murray CJL, 1994, DIS BURDEN EXPENDITU
   PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443
   Prentice A., 1993, S AFR J CLIN NUTR, V6, P33
   RAHAMAN MM, 1979, LANCET, V2, P809
   Rousham EK, 1997, ACTA PAEDIATR, V86, P46, DOI 10.1111/j.1651-2227.1997.tb08830.x
   ROWLAND MGM, 1977, T ROY SOC TROP MED H, V71, P199, DOI 10.1016/0035-9203(77)90006-2
   ROWLAND MGM, 1980, T ROY SOC TROP MED H, V74, P663, DOI 10.1016/0035-9203(80)90160-1
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   ROWLAND MGM, 1980, J TROP PEDIATRICS, V26, P54
   SCRIMSHAW NS, 1959, AM J MED SCI, V237, P367
   SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605
   SPURR GB, 1990, SOC ST HUM, V30, P24
   Weaver Lawrence T., 1995, V4, P153
   WHO, 1983, MEAS CHANG NUTR STAT
   WRIGHT CE, 1991, AM J EPIDEMIOL, V134, P887
NR 37
TC 29
Z9 30
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD FEB
PY 1999
VL 80
IS 2
BP 115
EP 119
PG 5
WC Pediatrics
SC Pediatrics
GA 162JF
UT WOS:000078341900004
PM 10325724
OA No
DA 2017-08-15
ER

PT J
AU Cane, PA
   Weber, M
   Sanneh, M
   Dackour, R
   Pringle, CR
   Whittle, H
AF Cane, PA
   Weber, M
   Sanneh, M
   Dackour, R
   Pringle, CR
   Whittle, H
TI Molecular epidemiology of respiratory syncytial virus in The Gambia
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID SUBGROUP-A; ATTACHMENT (G)PROTEIN; G-GLYCOPROTEIN; SEQUENCE; PROTEIN;
   IDENTIFICATION; INFECTIONS; LINEAGES; CHILDREN; CITY
AB Respiratory syncytial virus (RSV) infection in The Gambia occurs seasonally in association with the rainy season. This study examined the genetic variability of RSV isolates from four consecutive epidemics from 1993-6, Each epidemic was made up of a number of variants which were replaced in subsequent epidemics. Analysis of attachment (G) protein gene sequences showed that isolates were closely related to those observed in the rest of the world. However, many isolates from 1993 and 1994 were unlike other isolates observed in the developed world during this period and were more similar to isolates from 1984 in Europe. In addition, the most commonly observed genotype in the UK in the 1990s was not detected in The Gambia during this period.
C1 Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.
   Med Res Council Labs, Banjul, Gambia.
   Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.
RP Cane, PA (reprint author), Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.
FU Wellcome Trust
CR CANE PA, 1995, J VIROL, V69, P2918
   Cane PA, 1995, SEMIN VIROL, V6, P371, DOI 10.1016/S1044-5773(05)80014-9
   CANE PA, 1991, J GEN VIROL, V72, P2091, DOI 10.1099/0022-1317-72-9-2091
   Cane PA, 1997, J MED VIROL, V51, P297, DOI 10.1002/(SICI)1096-9071(199704)51:4<297::AID-JMV7>3.0.CO;2-0
   CANE PA, 1992, J VIROL METHODS, V40, P297, DOI 10.1016/0166-0934(92)90088-U
   CANE PA, 1994, J CLIN MICROBIOL, V32, P1
   CANE PA, 1991, J GEN VIROL, V72, P439
   CHERIAN T, 1990, AM J DIS CHILD, V144, P1026
   CRISTINA J, 1991, VIROLOGY, V184, P210, DOI 10.1016/0042-6822(91)90837-2
   GARCIA O, 1994, J VIROL, V68, P5448
   HAZLETT DTG, 1988, AM J TROP MED HYG, V39, P632
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   JOHNSON PR, 1987, P NATL ACAD SCI USA, V84, P5625, DOI 10.1073/pnas.84.16.5625
   NWANKWO MU, 1988, TROP GEOGR MED, V40, P309
   SANZ MC, 1994, VIRUS RES, V33, P203
   SULLENDER WM, 1991, J VIROL, V65, P5425
   Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   WERTZ GW, 1985, P NATL ACAD SCI USA, V82, P4075, DOI 10.1073/pnas.82.12.4075
NR 19
TC 17
Z9 18
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD FEB
PY 1999
VL 122
IS 1
BP 155
EP 160
DI 10.1017/S0950268896001872
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 176ZX
UT WOS:000079183300022
PM 10098799
OA No
DA 2017-08-15
ER

PT J
AU Bennett, J
   Whittle, H
   Samb, B
   Cisse, B
   Simondon, F
   Aaby, P
AF Bennett, J
   Whittle, H
   Samb, B
   Cisse, B
   Simondon, F
   Aaby, P
TI Seroconversions in unvaccinated infants: further evidence for
   subclinical measles from vaccine trials in Niakhar, Senegal
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE measles; subclinical; infants; seroconversions
ID RURAL SENEGAL; IMMUNIZATION; MORTALITY; ANTIBODY; CHILDREN
AB Background Increases in measles antibodies without rash-illnesses have been documented in previously vaccinated children exposed to measles cases. The phenomenon has been incompletely evaluated in young unvaccinated infants with immunity of maternal origin.
   Methods Monthly cohorts of newborns were prospectively randomized to vaccine and placebo control groups during a trial of high-titre vaccines in Niakhar, Senegal. Measles antibodies were assayed in blood samples of enrolled children collected at 5 months old, when controls received a placebo injection, and at 10 months, when the placebo group was given measles vaccine. Intensive prospective surveillance for measles was conducted throughout the trial.
   Results One-fifth (n =53) of the placebo controls seroconverted, with known exposure to a measles case in only three of them. None of the seroconverters developed a measles-like rash. Sixteen-fold or greater increases in titres were noted in about one-quarter of them. Compared with placebo controls who did not seroconvert, seroconverters were more likely to have had exposure to a measles case and to travel, more likely to be boys than girls, and had significantly lower baseline antibody titres. Measles was endemic in the study area throughout the trial. Seroconversions did not adversely effect subsequent nutritional indices or mortality.
   Conclusions Although laboratory errors and inadvertent injection of vaccine rather than placebo may have played some role, they do not fully explain the above observations, which are consistent with subclinical measles in the seroconverters. The possible role of subclinical measles in occult transmission, its potential effect on the type and duration of subsequent immunity, and its impact on response to primary vaccination need to be determined.
C1 Carter Ctr, Task Force Child Survival & Dev, Atlanta, GA 30307 USA.
   Rollins Sch Publ Hlth, Atlanta, GA USA.
   Med Res Council Labs, Banjul, Gambia.
   IMEA, INSERM, U13, Paris, France.
   ORSTOM, Dakar, Senegal.
   French Inst Sci Res Dev, Infect Dis Res Unit, Montpellier, France.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark.
RP Bennett, J (reprint author), Carter Ctr, Task Force Child Survival & Dev, 1 Copenhill, Atlanta, GA 30307 USA.
CR AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   BELLANTI J, 1969, NEW ENGL J MED, V280, P628, DOI 10.1056/NEJM196903202801202
   BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   CHEN RT, 1990, J INFECT DIS, V162, P1036
   Dallal GE, 1988, AM STAT, V42, P272, DOI 10.2307/2685137
   Dean A.G, 1994, EPI INFO VERSION 6 0
   HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904
   KEMPE CH, 1960, NEW ENGL J MED, V263, P162, DOI 10.1056/NEJM196007282630403
   KRESS S, 1961, AM J DIS CHILD, V101, P57
   KRUGMAN S, 1965, J PEDIATR-US, V66, P471, DOI 10.1016/S0022-3476(65)80112-3
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   WHITTLE H, 1998, IMPORTANCE SUBCLINIC
   WHITTLE HC, 1988, LANCET, V1, P963
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
NR 15
TC 14
Z9 14
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 1999
VL 28
IS 1
BP 147
EP 151
DI 10.1093/ije/28.1.147
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 172QH
UT WOS:000078935000024
PM 10195680
OA No
DA 2017-08-15
ER

PT J
AU Palmer, A
   Weber, M
   Bojang, K
   McKay, T
   Adegbola, R
AF Palmer, A
   Weber, M
   Bojang, K
   McKay, T
   Adegbola, R
TI Acute bacterial meningitis in the Gambia: A four-year review of
   paediatric hospital admissions
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Review
ID CHILDREN; THERAPY; INFANTS
AB Over a 4 year period, 1991 to 1994, 420 patients with acute bacterial meningitis were admitted to a tertiary urban hospital in The Gambia, Organisms were isolated from the cerebrospinal fluid in 64 per cent of cases, In the neonatal period Streptococcus pneumoniae was the single most common organism isolated. Amongst infants and children tbe two major pathogens were Haemophilus influenzae and S, pneumoniae, In the first year of life, children with S, pneumoniae meningitis were younger than those with H. influenzae infection (median age 3 months versus 6 months,p < 0.00003) and they had a higher case fatality rate (37 per cent versus 17 per cent,p = 0.002), In view of the high case fatality rate, there is a need to review overall case management. This will include a review of more effective antibiotics, the possible role of dexamethasone, and the inclusion of efficacious vaccines against H. influenzae and S, pneumoniae disease.
C1 Royal Victoria Hosp, Banjul, Gambia.
   Med Res Council Labs, Fajara, Gambia.
RP Weber, M (reprint author), WHO, Div Child Hlth & Dev, Geneva 27, Switzerland.
CR CADOZ M, 1981, B WORLD HEALTH ORGAN, V59, P575
   CIANA G, 1995, J TROP PEDIATRICS, V41, P164
   FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J
   Macaluso A, 1996, ANN TROP PAEDIATR, V16, P193
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201
NR 6
TC 25
Z9 26
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD FEB
PY 1999
VL 45
IS 1
BP 51
EP 53
DI 10.1093/tropej/45.1.51
PG 3
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 178VX
UT WOS:000079290800011
PM 10191594
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Jaitner, J
   Bah, M
AF Mattioli, RC
   Jaitner, J
   Bah, M
TI Efficiency and cost of strategic use of acaricide for tick control in
   N'Dama cattle in The Gambia
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE acaricide; N'Dama cattle; strategic use; tick control; The Gambia
ID BROWN EAR-TICK; AMBLYOMMA-HEBRAEUM; BONT TICK; LIVEWEIGHT GAIN;
   MILK-PRODUCTION; RHIPICEPHALUS-APPENDICULATUS; CROSSBRED CATTLE;
   ZIMBABWE; VARIEGATUM; SANGA
AB The efficiency of strategic and strategic/selective applications of flumethrin spray formulation for controlling ticks were assessed, respectively, in two groups of fourteen N'Dama cattle (Group S and Group S/S) by comparison of the number of feeding ticks with thirteen untreated N'Dama cattle (Group U) over a period of 11 months (June 1996 to April 1997). During the expected peak of tick abundance, acaricide was applied fortnightly on the whole body in animals in Group S and only on the most infested body areas in cattle in Group S/S. Weight changes and skin lesions, directly associated with tick attachment, were recorded in cattle in the three groups. The costs of the two tick control schemes were estimated. Maximum level of ticks, all species together, feeding on cattle was observed in the rainy season. Both in Group S/S and Group S, cattle carried a lower (P < 0.001) number of feeding ticks than animals in Group U over the whole study period. Percentage of tick control, over the entire period of tick investigation, was satisfactory in both acaricide-treated groups, reaching 61.2 and 75.2% in Groups S/S and S, respectively. However, the proportion of control varied according to tick species or genus. Significantly lower prevalence of skin lesions was observed on the ano-genital and udder region in cattle in Group S/S (P < 0.05) and Group S (P < 0.01) in comparison with cattle in Group U. Mean amount of acaricide solution used and relative estimated cost of treatment in cattle in Group S/S were, respectively, 25- and 14-fold lower than those in cattle in Group S. At the end of the study, animals in Groups S/S and S were, respectively, 7.2 and 15.9 kg heavier than animals in Group U. The difference was statistically significant (P < 0.02) only between Groups S and U. However, the efficiency, low cost and derived benefits of the strategic/selective acaricide application scheme indicated that it might be the most cost effective.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM Leo.Dempfle@commit.gm
CR ASSELBERGS MJ, 1989, LIVESTOCK PRODUCTION, P358
   Barre N, 1993, Rev Elev Med Vet Pays Trop, V46, P349
   DWINGER RH, 1994, VET QUART, V16, P81
   FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P19, DOI 10.1007/BF02236881
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P551
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201
   Konstantinov O.K., 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P85
   LAWRENCE JA, 1980, VET REC, V107, P82
   Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x
   Mattioli RC, 1998, PREV VET MED, V34, P137, DOI 10.1016/S0167-5877(97)00082-2
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   MELTZER MI, 1993, EXP APPL ACAROL, V17, P171, DOI 10.1007/BF00118434
   MONTENEGROJAMES S, 1992, P WORKSH HELD ILRAD, P29
   NELSON WA, 1984, J MED ENTOMOL, V21, P621
   Norval RAI, 1996, EXP APPL ACAROL, V20, P31
   NORVAL RAI, 1988, VET PARASITOL, V30, P149, DOI 10.1016/0304-4017(88)90162-8
   NORVAL RAI, 1994, EXP APPL ACAROL, V18, P383, DOI 10.1007/BF00051522
   NORVAL RAI, 1989, VET PARASITOL, V33, P329, DOI 10.1016/0304-4017(89)90142-8
   Norval RAI, 1997, MED VET ENTOMOL, V11, P143, DOI 10.1111/j.1365-2915.1997.tb00304.x
   Norval RAI, 1997, MED VET ENTOMOL, V11, P148, DOI 10.1111/j.1365-2915.1997.tb00305.x
   PEGRAM RG, 1990, MED VET ENTOMOL, V4, P327, DOI 10.1111/j.1365-2915.1990.tb00448.x
   PEGRAM RG, 1989, MED VET ENTOMOL, V3, P313, DOI 10.1111/j.1365-2915.1989.tb00234.x
   PEGRAM RG, 1995, MED VET ENTOMOL, V9, P337, DOI 10.1111/j.1365-2915.1995.tb00144.x
   Pegram R, 1993, WORLD ANIM REV, V74, P2
   STACHURSKI F, 1993, VET PARASITOL, V49, P299, DOI 10.1016/0304-4017(93)90128-A
   SUMBERG JE, 1992, TROP ANIM HEALTH PRO, V24, P193, DOI 10.1007/BF02356744
   SUTHERST RW, 1983, AUST J AGR RES, V34, P317, DOI 10.1071/AR9830317
   TATCHELL RJ, 1992, INSECT SCI APPL, V13, P551
   UILENBERG G, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P297
   *UNDP, 1991, GAM87004 UNDP
NR 32
TC 5
Z9 5
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD FEB
PY 1999
VL 13
IS 1
BP 33
EP 40
DI 10.1046/j.1365-2915.1999.00136.x
PG 8
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 180XU
UT WOS:000079411800003
PM 10194747
OA No
DA 2017-08-15
ER

PT J
AU Thomas, JE
   Dale, A
   Harding, M
   Coward, WA
   Cole, TJ
   Weaver, LT
AF Thomas, JE
   Dale, A
   Harding, M
   Coward, WA
   Cole, TJ
   Weaver, LT
TI Helicobacter pylori colonization in early life
SO PEDIATRIC RESEARCH
LA English
DT Article
ID BREATH TEST; INFECTION; PREVALENCE; CHILDREN; EPIDEMIOLOGY; DIAGNOSIS;
   RESPONSES; CHILDHOOD; COMMUNITY; DIARRHEA
AB Helicobacter pylori infection is a major cause of upper gastrointestinal disease throughout the world. Colonization begins in childhood, although little is known about its age of onset, rate, or mode of colonization. Our aim was to identify the age of acquisition of H. pylori colonization in Gambian children. A cohort of 248 Gambian children aged 3 to 45 months was studied at intervals of 3 months for 2 years, using the C-13-urea breath test, specific IgM and specific IgG serology. The prevalence of positive breath tests rose from 19% at 3 months of age to 84% by age 30 months. Elevated specific IgG and IgM antibody levels were associated with positive breath tests, although there was discrepancy between breath test results and serology, particularly IgG serology, during the Ist year of life. Neither IgG nor IgM serology could be validated as reliable diagnostic tools for infant H. pylori colonization compared with the C-13-urea breath test. Reversion to negative breath test, in association with declining specific antibody levels, occurred in 48/248 (20%) of children. On the assumption that the C-13-urea breath test is a reliable index of H. pylori colonization, we conclude that the infection is extremely common from an early age in Gambian children. Transient colonization may occur. Previous studies relying on serodiagnosis may have significantly underestimated the true early prevalence of colonization in the developing world, where the target age for intervention studies is probably early infancy.
C1 MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
   MRC, Dunn Nutr Unit, Keneba, Gambia.
RP Thomas, JE (reprint author), Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
OI Cole, Tim/0000-0001-5711-8200
CR BLECKER U, 1994, PEDIATRICS, V93, P342
   Bunn J. E. G., 1996, Gut, V39, pA47
   CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   Dubois A, 1996, INFECT IMMUN, V64, P2885
   EATON KA, 1990, J INFECT DIS, V161, P1299
   FOX JG, 1993, INFECT IMMUN, V61, P2309
   GLUPCZYNSKI Y, 1992, EUR J CLIN MICROBIOL, V11, P322, DOI 10.1007/BF01962071
   Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290
   GUELRUD M, 1994, J PEDIATR GASTR NUTR, V18, P461, DOI 10.1097/00005176-199405000-00010
   HOLCOMBE C, 1994, T ROY SOC TROP MED H, V88, P569, DOI 10.1016/0035-9203(94)90166-X
   HOLCOMBE C, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90403-D
   Hunt R H, 1996, Scand J Gastroenterol Suppl, V220, P3
   Kindermann A, 1997, GUT, V41, pA67
   KLEIN PD, 1994, AM J GASTROENTEROL, V89, P2196
   Lee A, 1996, ALIMENT PHARM THERAP, V10, P129
   Logan RPH, 1996, HELICOBACTER PYLORI, P74
   MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436
   Mion F, 1997, CLIN SCI, V93, P3
   MOLBAK K, 1994, J INFECT DIS, V169, P581
   MORRIS AJ, 1991, ANN INTERN MED, V114, P662
   PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237
   Sarker SA, 1995, DIGEST DIS SCI, V40, P2669, DOI 10.1007/BF02220458
   SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415
   SULLIVAN PB, 1990, ARCH DIS CHILD, V65, P189
   TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42
   Thijs JC, 1996, AM J GASTROENTEROL, V91, P2125
   THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L
   THOMAS JE, 1993, LANCET, V342, P121, DOI 10.1016/0140-6736(93)91327-I
   THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641
   WEAVER LT, 1993, PROGR UNDERSTANDING, P156
NR 31
TC 131
Z9 134
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD FEB
PY 1999
VL 45
IS 2
BP 218
EP 223
DI 10.1203/00006450-199902000-00010
PG 6
WC Pediatrics
SC Pediatrics
GA 163NL
UT WOS:000078411800010
PM 10022593
OA No
DA 2017-08-15
ER

PT J
AU Haywood, M
   Conway, DJ
   Weiss, H
   Metzger, W
   D'Alessandro, U
   Snounou, G
   Targett, G
   Greenwood, B
AF Haywood, M
   Conway, DJ
   Weiss, H
   Metzger, W
   D'Alessandro, U
   Snounou, G
   Targett, G
   Greenwood, B
TI The epidemiology of multiple Plasmodium falciparum infections - 12.
   Reduction in the mean number of Plasmodium falciparum genotypes in
   Gambian children immunized with the malaria vaccine SPf66
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; multiple infection; genotypes; msp1
   gene; msp2 gene; glurp gene; vaccine; The Gambia
ID TRIAL; IMMUNOGENICITY; EFFICACY; INFANTS; SAFETY; AREA
AB SPf66, a synthetic peptide Plasmodium falciparum vaccine, did not protect young Gambian children against clinical attacks of malaria. Nevertheless, Gambian children who had been vaccinated with SPf66 and who were parasitaemic at the end of the first malaria transmission season after vaccination had significantly fewer detectable P. falciparum genotypes than control children, as determined by polymerase chain reaction analysis of 3 polymorphic loci-the msp1 block 2 repeat region, the msp2 repeat region, and the R11 region of the glutamate-rich protein gene (glurp). Geometric mean numbers of genotypes were 1.66 vs. 1.87, 1.95 vs. 2.43, and 1.21 vs. 1.50 for msp1, msp2 and glurp, respectively (P=0.31, P=0.04 and P<0.01). Differences between groups became;I little more marked for msp1 and msp2 when children with symptomatic malaria were excluded. Mo significant difference was found between parasites obtained from SPf66-vaccinated or control children in the prevalences of amino acid alleles at positions 44 and 47 in the II amino acid sequence of the merozoite surface protein 1 molecule, which is present in SPf66. The reduction in the number of genotypes observed could not be explained by a difference in parasite densities between SPf66-vaccinated and control children, as geometric mean parasite densities were almost identical in the 2 groups. These observations suggest that SPf66 vaccine may have induced an immune response which reduced the incidence of new infections in immunized children or accelerated the rate of clearance of parasites of individual genotypes. However, no reduction in the prevalence or density of parasitaemia was recorded in SPf66-vaccinated children, suggesting the existence of some kind of density-dependent mechanism for controlling low levels of malaria parasitaemia.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium.
   Northwick Pk Hosp, Imperial Coll Med, Lister Unit, Dept Infect & Trop Med, Harrow HA1 3UJ, Middx, England.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Snounou, Georges/F-3352-2011; D'Alessandro, Umberto/D-3457-2015;
   Metzger, Wolfram/A-6878-2016
OI Snounou, Georges/0000-0002-6133-6398; D'Alessandro,
   Umberto/0000-0001-6341-5009; 
CR Al-Yaman F, 1997, T ROY SOC TROP MED H, V91, P709, DOI 10.1016/S0035-9203(97)90534-4
   ALONSO PL, 1994, LANCET, V344, P1175
   Alonso PL, 1998, PARASITE IMMUNOL, V20, P63
   Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991
   Berzins Klavs, 1996, P105
   Bojang KA, 1998, VACCINE, V16, P62, DOI 10.1016/S0264-410X(97)00159-X
   Contamin H, 1996, AM J TROP MED HYG, V54, P632
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   KWIATKOWSKI D, 1989, PARASITOL TODAY, V5, P264, DOI 10.1016/0169-4758(89)90261-5
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   MILLER JB, 1993, UNDERSTANDING RELATI, V2, P1
   MORENO A, 1989, BLOOD, V74, P537
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   NOYA O, 1994, J INFECT DIS, V170, P396
   SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1
   Sinnis Photini, 1996, P15
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
NR 19
TC 3
Z9 3
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD FEB
PY 1999
VL 93
SU 1
BP S65
EP S68
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 178UH
UT WOS:000079285300012
OA No
DA 2017-08-15
ER

PT J
AU Drakeley, CJ
   Secka, I
   Correa, S
   Greenwood, BM
   Targett, GAT
AF Drakeley, CJ
   Secka, I
   Correa, S
   Greenwood, BM
   Targett, GAT
TI Host haematological factors influencing the transmission of Plasmodium
   falciparum gametocytes to Anopheles gambiae ss mosquitoes
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE falciparum malaria; malaria transmission; gametocytes; anaemia
ID MALARIAL INFECTIVITY; SEXUAL DEVELOPMENT; PARASITES; ERYTHROCYTES;
   RESERVOIR; CELLS; AREA
AB We investigated the relationship between selected host haematological and parasitological parameters and the density and infectivity of Plasmodium falciparum gametocytes. 143 individuals (age range 1-62 years) attending an outpatient clinic in Farafenni, The Gambia, who had peripheral blood gametocytaemia were recruited (mean gametocyte density 123.7/mu l, range 5-17,000/mu l). Of the parameters measured, packed cell volume (PCV), reticulocyte count (RetC) and lymphocyte count (LyC) were significantly associated with gametocyte density (r = -0.17, P < 0.05; r = 0.21, P < 0.01; r = 0.18, P < 0.05, respectively). Data from membrane feeding experiments in which 15 or more mosquitoes were dissected showed that 60.7% (53/87) of gametocyte carriers infected one or more mosquitoes. Gametocyte density was strongly correlated with transmission success (TS) (r = 0.3, P < 0.005) and, in successful infections, with both mosquito prevalence (MP) (r = 0.36, P < 0.005) and mean oocyst burden (MOB) (r = 0.65, P < 0.0001). None of the other factors measured were significantly associated with any of these indices in bivariate analysis. Regression modelling showed that both gametocyte density and PCV were positively associated with gametocyte carrier infectivity to mosquitoes (LRchi 2 = 100.2 and 47.2, respectively) and, in successful infections, with MOB (beta = 0.16, t = 4.9, beta < 0.001; beta = 0.02, t = 2.3, beta < 0.05, respectively). The positive association with PCV suggests that blood meal quality influences infection probably as a nutritional requirement, however, as this effect was most apparent at high gametocyte densities, its epidemiological significance is questionable. Though the haematological parameters associated with gametocyte density are a direct consequence of asexual infection, they may also represent an adaptive mechanism for optimization of sexual stage development.
C1 MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
RP Drakeley, CJ (reprint author), Ifakara Hlth Res & Dev Ctr, POB 78373, Dar Es Salaam, Tanzania.
CR Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261
   BOUDIN C, 1993, AM J TROP MED HYG, V48, P700
   Boyd MF, 1949, MALARIOLOGY, P551
   BRYAN JH, 1979, T ROY SOC TROP MED H, V73, P463, DOI 10.1016/0035-9203(79)90179-2
   DACIE J. V., 1975, PRACTICAL HAEMATOLOG
   DEARSLY AL, 1990, PARASITOLOGY, V100, P359
   FACER CA, 1979, T ROY SOC TROP MED H, V73, P599, DOI 10.1016/0035-9203(79)90066-X
   FRANCKE L, 1993, SIGHT SOUND, V3, P50
   GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P479
   GITHEKO AK, 1992, T ROY SOC TROP MED H, V86, P355, DOI 10.1016/0035-9203(92)90216-Y
   GRAVES PM, 1988, PARASITOLOGY, V96, P251
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HURD H, 1995, PARASITOL TODAY, V11, P411, DOI 10.1016/0169-4758(95)80021-2
   JEFFERY GM, 1955, AM J TROP MED HYG, V4, P781
   MOTARD A, 1993, PARASITE IMMUNOL, V15, P21, DOI 10.1111/j.1365-3024.1993.tb00568.x
   MUIRHEADTHOMSON RC, 1957, AM J TROP MED HYG, V6, P208
   NAOTUNNE TD, 1991, J EXP MED, V173, P53
   ONO T, 1986, BIKEN J, V29, P77
   PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x
   ROSENBERG R, 1984, EXP PARASITOL, V57, P158, DOI 10.1016/0014-4894(84)90075-4
   RUTLEDGE LC, 1969, T ROY SOC TROP MED H, V63, P613, DOI 10.1016/0035-9203(69)90180-1
   SCHNEWEIS S, 1991, PARASITOL RES, V77, P458, DOI 10.1007/BF00931646
   SINDEN RE, 1983, ADV PARASIT, V22, P153, DOI 10.1016/S0065-308X(08)60462-5
   SMALLEY ME, 1971, T ROY SOC TROP MED H, V71, P1021
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P6
   Taylor LH, 1997, PARASITOL TODAY, V13, P135, DOI 10.1016/S0169-4758(97)89810-9
   TCHUINKAM T, 1993, TROP MED PARASITOL, V44, P271
   TRAGER W, 1992, J PROTOZOOL, V39, P429, DOI 10.1111/j.1550-7408.1992.tb01476.x
   WHITE NJ, 1992, ADV PARASIT, V31, P83
   *WHO, 1980, MAN BAS TECHN HLTH L, P385
NR 31
TC 56
Z9 58
U1 0
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 1999
VL 4
IS 2
BP 131
EP 138
DI 10.1046/j.1365-3156.1999.00361.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 180LG
UT WOS:000079387000009
PM 10206267
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Kora, S
   Jeffcoate, I
AF Osaer, S
   Goossens, B
   Kora, S
   Jeffcoate, I
TI Effects of Trypanosoma congolense infection and diet on puberty, age at
   first lambing and haematology changes in Djallonke ewe lambs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE sheep-protozoa; puberty; Trypanosoma congolense; feeding and nutrition;
   trypanotolerance
ID WEST-AFRICAN DWARF; SCOTTISH BLACKFACE SHEEP; REPRODUCTIVE-PERFORMANCE;
   LIVEWEIGHT CHANGES; VIVAX INFECTION; CATTLE; PATHOPHYSIOLOGY; NUTRITION;
   SUSCEPTIBILITY; DIAGNOSIS
AB The interactions between T. congolense infection and nutritional supplements on onset of puberty and age at first lambing were observed in 24 young Djallonke ewes. As experimental design, a randomised complete block design was used with four treatment combinations, of which Mo were kept on a restricted diet (L), the remainder on an unrestricted diet (H) and half of each nutritional group being infected with T. congolense (LI and HI), the remainder serving as controls (LC and HC). Infection with T. congolense took place at an average age of 6 months and 15 days. Mortality due to trypanosome infection was zero and clinical symptoms were not obvious. Intensity of parasitaemia and packed cell volume (PCV) drop following trypanosome infection were similar in both infected groups (HI and LI). High dietary supplementation resulted temporarily in a better haematopoietic response following trypanosome infection, measured as a macrocytic anaemia. Dry matter intake (DMI) was significantly depressed in the HI group immediately following infection. Trypanosome infection had a negative effect on live weight gain during the chronic phase, with the difference being most obvious in the HI group (interaction dietxinfection; p less than or equal to 0.05). Whereas trypanosome infection had no significant effect, high supplementary feeding significantly reduced the age at first cycling. Age at first lambing was similarly reduced by the diet. Trypanosome infection tended (p less than or equal to 0.09) to delay age at first lambing with a mean difference of 31.5+/-22.4 days between infected and controls. Interactions between diet and infection for age at first cycling/lambing were not significant, indicating these effects were just additive. Neither birth weights nor growth rates of offspring born to the experimental animals were significantly affected by previous trypanosome infection, nor by the diet of the dam. In contrast, lamb mortality up to 3 months of age was significantly increased by infection of the dam and most losses arose in group LI. In conclusion, the effects of trypanosome infection on puberty and age at first lambing were indirectly mediated through depression of growth rates. Nutritional supplementation enabled a better erythropoietic response to T. congolense infection and better offspring survival rates but resulted in more depressed weight gains. The results however clearly indicated the delaying effect of insufficient feeding on onset of puberty and reproductive performance in young Djallonke sheep. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Glasgow, Sch Vet, Glasgow G61 1HQ, Lanark, Scotland.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   ANOSA VO, 1976, TROP ANIM HLTH PROD, V8, P11
   *AOAC, 1975, OFF METH AN
   Bengaly Z, 1993, Rev Elev Med Vet Pays Trop, V46, P563
   BERGER Y, 1980, REV ELEV MED VET PAY, V33, P71
   BRONSON FH, 1986, BIOL REV, V61, P157, DOI 10.1111/j.1469-185X.1986.tb00465.x
   CLARKSON MJ, 1968, J COMP PATHOL, V78, P189, DOI 10.1016/0021-9975(68)90095-9
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   *FAO, 1993, RAF88100 FAO
   FOSTER DL, 1985, ENDOCRINOLOGY, V116, P375
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   HECKER PA, 1991, 21 M ISCTRC YAMM IV
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1992, RES VET SCI, V53, P80, DOI 10.1016/0034-5288(92)90089-K
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   LITTLE D, 1990, P NUTR SOC 144 M SCO
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MCDONALD P, 1978, ANIMAL NUTR
   MEYER HHD, 1986, J STEROID BIOCH, V25
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NIELSEN K, 1978, IMMUNOLOGY, V35, P811
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   PARIS J, 1982, ACTA TROP, V39, P307
   PRAKASH BS, 1987, J STEROID BIOCHEM, V28, P623, DOI 10.1016/0022-4731(87)90389-X
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   Romney DL, 1997, J AGR SCI, V129, P83, DOI 10.1017/S0021859697004449
   Snedecor G.W., 1980, STAT METHODS, P507
   *STAT AN SYST I, 1989, VERS 6 11 SAS I
   TOURE SM, 1981, 17 M ISCTRC AR NAIR
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   Wassink GJ, 1997, ANIM SCI, V64, P127
NR 38
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN 14
PY 1999
VL 80
IS 3
BP 215
EP 230
DI 10.1016/S0304-4017(98)00193-9
PG 16
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 154FJ
UT WOS:000077877800004
PM 9950345
OA No
DA 2017-08-15
ER

PT J
AU Usen, S
   Weber, M
   Mulholland, K
   Jaffar, S
   Oparaugo, A
   Omosigho, C
   Adegbola, R
   Greenwood, B
AF Usen, S
   Weber, M
   Mulholland, K
   Jaffar, S
   Oparaugo, A
   Omosigho, C
   Adegbola, R
   Greenwood, B
TI Clinical predictors of hypoxaemia in Gambian children with acute lower
   respiratory tract infection: prospective cohort study
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID PAPUA-NEW-GUINEA; DEVELOPING-COUNTRIES; SYNCYTIAL VIRUS; PNEUMONIA;
   HYPOXEMIA; SIGNS; BRONCHIOLITIS; CHILDHOOD; PROTEIN; HYPOXIA
AB Objectives To determine clinical correlates and outcome of hypoxaemia in children admitted to hospital with an acute lower respiratory tract infection.
   Design Prospective cohort study
   Setting Paediatric wards of the Royal Victoria Hospital and the hospital of the Medical Research Council's hospital in Banjul, the Gambia.
   Subjects 1072 of 42 848 children, aged 2 to 33 months, who were enrolled in a randomised trial of a Haemophilus influenzae type b vaccine in the western region or the Gambia, and who were admitted with a acute lower respiratory tract infection to two of three hospitals.
   Main outcome measures Prevalence of hypoxaemia, defined as an arterial oxygen saturation < 90% recorded by pulse oximetry, and the relation between hypoxaemia and aetiological agents.
   Results 1072 children aged 2-33 months were enrolled. Sixty three (5.9%) had an arterial oxygen saturation < 90%. A logistic regression model showed that cyanosis, a rapid respiratory rate, grunting, head nodding, an absence of a history of fever, and no spontaneous movement during examination were the best independent predictors of hypoxaemia. The presence of an inability to cry, head nodding, or a respiratory rate greater than or equal to 90 breaths/min formed the best predictors of hypoxaemia (sensitivity 70%, specificity 79%). Hypoxaemic children were five times more likely to die than non-hypoxaemic children. The presence of malaria parasitaemia had no effect on the prevalence of hypoxaemia or on its association with respiratory rate.
   Conclusion In children with an acute lower respiratory tract infection, simple physical signs that require minimal expertise to recognise can be used to determine oxygen therapy and to aid in screening for referral. The association between hypoxaemia and death highlights die need for early recognition of the condition and the potential benefit of treatment.
C1 Med Res Council Labs, Fajara, Gambia.
   WHO, Global Programme Vaccine & Immunisat, CH-1211 Geneva 27, Switzerland.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Usen, S (reprint author), Med Res Council Labs, POB 273, Fajara, Gambia.
EM susen@mrc.enda.sn
CR CANE PA, 1995, J VIROL, V69, P2918
   CHERIAN T, 1988, LANCET, V2, P125
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   DYKE T, 1994, BRIT MED J, V308, P119
   DYKE T, 1995, J TROP PEDIATRICS, V41, P196
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   HALL CB, 1979, AM J DIS CHILD, V133, P798
   LEVENE S, 1988, LANCET, V1, P415
   LOWESKI J, 1986, WORLD HLTH STAT Q, V5, P247
   LOZANO JM, 1994, ARCH DIS CHILD, V71, P323
   MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   ODEMPSEY TJD, 1993, BRIT MED J, V306, P1342
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9
   REYNOLDS E O, 1963, Br Med J, V1, P1192
   SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S
   SEATON A, 1989, CROFTON DOUGLAS RESP
   SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005
   SIMPSON H, 1967, LANCET, V1, P7
   SPITERI MA, 1988, LANCET, V1, P873
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295
   Stadie WC, 1919, J EXP MED, V30, P215, DOI 10.1084/jem.30.3.215
   WANG EEL, 1992, AM REV RESPIR DIS, V145, P106
   WEBER MW, 1997, ARCH DIS CHILD, V76, P1
   World Health Organization, 1990, WHOARI905
NR 26
TC 48
Z9 50
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD JAN 9
PY 1999
VL 318
IS 7176
BP 86
EP 91
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 157XT
UT WOS:000078087500023
PM 9880280
OA No
DA 2017-08-15
ER

PT J
AU Whittle, HC
   Aaby, P
   Samb, B
   Jensen, H
   Bennett, J
   Simondon, F
AF Whittle, HC
   Aaby, P
   Samb, B
   Jensen, H
   Bennett, J
   Simondon, F
TI Effect of subclinical infection on maintaining immunity against measles
   in vaccinated children in West Africa
SO LANCET
LA English
DT Article
ID RURAL SENEGAL; MORTALITY; EFFICACY; IMMUNIZATION; COVERAGE; EXPOSURE;
   DURATION; ANTIBODY; GAMBIA; RATES
AB Background Despite a high coverage with measles vaccines in parts of west Africa, epidemics of measles occur with reduced severity in an increasing proportion of older children who have been vaccinated. We examined the effect of exposure to natural measles on immunity in vaccinated children.
   Methods Our study was carried out in 1992 during an epidemic of measles in Niakhar, a rural area of Senegal with about 27 000 inhabitants who mostly live in compounds that include several households; within each household people live in different huts. Vaccine coverage in Niakhar was 81% at the time of our study. We measured haemagglutinin-inhibiting antibody at exposure and twice thereafter (after 4-5 weeks and at 6 months) in 36 vaccinated and 87 unvaccinated children. The frequency of measles and subclinical measles-defined as a four-fold or greater rise in antibody titre without clinical signs or symptoms-was related to intensity of exposure according to whether the index case was in the same hut, household, or compound.
   Findings Clinical measles occurred in 20 (56%) of 36 unvaccinated children and in one (1%) of 87 vaccinated children. Subclinical measles occurred in 39 (45%) of 86 vaccinated children who were exposed to measles and in four (25%) of 16 unvaccinated children. The frequency was inversely related to pre-exposure antibody concentration (p<0.001 for trend) and directly related to intensity of exposure (p=0.002 for trend), Antibody concentrations in subclinical cases increased on average by 45-fold and remained raised for at least 6 months.
   Interpretation Increased antibody titre after subclinical measles may be common in vaccinated children in West Africa where the intensity of exposure is high. As measles vaccination coverage increases, the circulation of wild measles will decrease, and vaccine-induced antibody is less likely to be boosted. Thus, new epidemics, albeit milder in form, may occur in vaccinated areas which should be recognised in campaigns to eradicate measles.
C1 MRC Labs, Banjul, Gambia.
   ORSTOM, Dakar, Senegal.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol, DK-2300 Copenhagen, Denmark.
   INSERM, U13, Paris, France.
   Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA.
RP Whittle, HC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1984, AM J EPIDEMIOL, V120, P49
   Anders JF, 1996, PEDIATR INFECT DIS J, V15, P62, DOI 10.1097/00006454-199601000-00014
   BENNETT J, IN PRESS INT J EPIDE
   BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   CHABNAZARIAN A, 1992, POPULATION SANTE NIA
   CHEN RT, 1990, J INFECT DIS, V162, P1036
   CISSE B, IN PRESS AM J EPIDEM
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224
   FORSTER SO, 1971, AFR J MED SCI, V2, P151
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303
   KRUGMAN S, 1983, REV INFECT DIS, V5, P477
   MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008
   McMurray D N, 1979, Bull Pan Am Health Organ, V13, P52
   MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1
   NORRBY E, 1995, CURR TOP MICROBIOL, V191, P167
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212
   Outlaw MC, 1997, VIRUS RES, V48, P125, DOI 10.1016/S0168-1702(96)01434-7
   Panum P.L., 1940, OBSERVATIONS MADE EP
   RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   Samb B, 1997, AM J EPIDEMIOL, V145, P51
   STETLER HC, 1986, PEDIATRICS, V77, P471
   WHITTLE H, 1988, LANCET, V2, P811
   WHITTLE HC, 1998, LANCET, V351, P866
   WHITTLE HC, IN PRESS PEDIAT INFE
NR 30
TC 78
Z9 81
U1 0
U2 3
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 9
PY 1999
VL 353
IS 9147
BP 98
EP 102
DI 10.1016/S0140-6736(98)02364-2
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 157XP
UT WOS:000078087200010
PM 10023894
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Rowley, J
   Manneh, K
AF Lienhardt, C
   Rowley, J
   Manneh, K
TI Directly observed treatment for tuberculosis
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
   Natl TB Control Programme, Banjul, Gambia.
RP Lienhardt, C (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712
   World Health Organization, 1997, WHOTB97220
   Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7
NR 3
TC 5
Z9 6
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 9
PY 1999
VL 353
IS 9147
BP 145
EP 146
DI 10.1016/S0140-6736(05)76180-8
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 157XP
UT WOS:000078087200047
PM 10023919
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Aaby, P
AF van der Loeff, MFS
   Aaby, P
TI Towards a better understanding of the epidemiology of HIV-2
SO AIDS
LA English
DT Review
DE HIV-2; epidemiology; pathogenesis; dual infection; HIV-1; transmission;
   incidence; subtypes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; TO-CHILD
   TRANSMISSION; SEXUALLY-TRANSMITTED DISEASES; ENVELOPE CROSS-REACTIVITY;
   GENITAL ULCER DISEASES; RURAL GUINEA-BISSAU; FEMALE SEX WORKERS;
   COTE-DIVOIRE; WEST-AFRICA
C1 Med Res Council Labs, Banjul, Gambia.
   Projecto Saude Bandim, Bissau, Guinea Bissau.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
RP van der Loeff, MFS (reprint author), Med Res Council Labs, POB 273, Banjul, Gambia.
CR Aaby P, 1997, AIDS, V11, P939
   Aaby P, 1996, AIDS, V10, P1585
   ABBOTT RC, 1994, J ACQ IMMUN DEF SYND, V7, P711
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   Albert J, 1996, AIDS RES HUM RETROV, V12, P821, DOI 10.1089/aid.1996.12.821
   ALBERT J, 1990, AIDS, V4, P291, DOI 10.1097/00002030-199004000-00002
   ANCELLE R, 1987, LANCET, V1, P688
   Anderson RM, 1996, AIDS, V10, P1663
   Andersson S, 1997, AIDS, V11, P1815, DOI 10.1097/00002030-199715000-00005
   ANDREASSON PA, 1993, AIDS, V7, P989
   Ariyoshi K, 1997, AIDS, V11, P1053
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   Ariyoshi K, 1998, AIDS, V12, P2504
   ARIYOSHI K, 1998, THESIS MRC LAB GAMBI
   Arya SK, 1996, P NATL ACAD SCI USA, V93, P4486, DOI 10.1073/pnas.93.9.4486
   Baqi S, 1998, J ACQ IMMUN DEF SYND, V18, P73
   Belec L, 1996, J CLIN IMMUNOL, V16, P12, DOI 10.1007/BF01540968
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Bertoletti A, 1998, J VIROL, V72, P2439
   Boillot F, 1997, INT J TUBERC LUNG D, V1, P493
   BOTTIGER B, 1990, J VIROL, V64, P3492
   Brennan CA, 1997, AIDS RES HUM RETROV, V13, P401, DOI 10.1089/aid.1997.13.401
   BRUCKER G, 1987, LANCET, V1, P223
   BRUNVEZINET F, 1987, LANCET, V1, P128
   Bryceson A, 1988, Lancet, V2, P221
   Carvalho MB, 1996, AIDS, V10, P1135
   CASSAMA L, 1997, 10 INT C AIDS STD AF
   Cavaco-Silva P, 1998, J VIROL, V72, P3418
   CavacoSilva P, 1997, LANCET, V349, P177, DOI 10.1016/S0140-6736(05)60978-6
   CAZEIN F, 1996, 11 INT C AIDS VANC
   Chen ZW, 1997, J VIROL, V71, P3953
   Chen ZW, 1996, J VIROL, V70, P3617
   Christiansen CB, 1997, LANCET, V350, P562, DOI 10.1016/S0140-6736(05)63137-6
   CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   COHEN J, 1995, SCIENCE, V268, P1566, DOI 10.1126/science.7777855
   COLEBUNDERS R, 1995, GENITOURIN MED, V71, P129
   COURPOTIN C, 1994, PEDIATR INFECT DIS J, V13, P502
   Critchlow C W, 1997, Obstet Gynecol Surv, V52, P315, DOI 10.1097/00006254-199705000-00024
   Damond F, 1998, J CLIN MICROBIOL, V36, P809
   DECOCK KM, 1994, BRIT MED J, V308, P441
   DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010
   DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   DECOCK KM, 1991, BRIT MED J, V302, P496
   DECOCK KM, 1996, AIDS WORLD, V2, P171
   Delaporte E, 1996, AIDS, V10, P903, DOI 10.1097/00002030-199607000-00014
   DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19
   DIA MC, 1996, 11 INT C AIDS VANC
   Dietrich Ursula, 1995, Trends in Microbiology, V3, P17
   DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   DUFOORT G, 1988, LANCET, V2, P510
   Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6
   Faye A, 1997, J PEDIATR-US, V130, P994, DOI 10.1016/S0022-3476(97)70290-7
   FULTZ PN, 1988, AIDS, V2, P129, DOI 10.1097/00002030-198804000-00010
   GAO F, 1994, J VIROL, V68, P7433
   GAO F, 1993, AIDS RES HUM RETROV, V9, P703, DOI 10.1089/aid.1993.9.703
   GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X
   Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001
   GRANKVIST O, 1992, J ACQ IMMUN DEF SYND, V5, P286
   Grant A D, 1997, AIDS, V11 Suppl B, pS43
   Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010
   Grassly NC, 1998, J VIROL, V72, P7895
   Greenberg AE, 1996, SCIENCE, V272, P1959
   GREENBERG AE, 1997, 10 INT C AIDS STD AF
   GREENBERG AE, 1997, 12 WORLD AIDS C GEN
   GREZ M, 1994, J VIROL, V68, P2161
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   HAWKES S, 1995, GENITOURIN MED, V71, P224
   Heredia A, 1998, AIDS RES HUM RETROV, V14, P91, DOI 10.1089/aid.1998.14.91
   Heredia A, 1997, AIDS RES HUM RETROV, V13, P899, DOI 10.1089/aid.1997.13.899
   Hunt Jeffrey C., 1997, Leukemia (Basingstoke), V11, P138
   Ishikawa K, 1998, AIDS, V12, P1419, DOI 10.1097/00002030-199812000-00003
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   JOSHI SH, 1992, 8 INT C AIDS AMST
   KANKI P, 1992, AM J EPIDEMIOL, V136, P895
   KANKI P, 1998, 12 WORLD AIDS C GEN
   Kanki P J, 1997, AIDS, V11 Suppl B, pS33
   Kanki PJ, 1996, SCIENCE, V272, P1959
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kanki P., 1994, AIDS S1, V8, pS85
   KASSIM S, 1998, 12 WORLD AIDS C GEN
   KAWAMURA M, 1989, LANCET, V1, P385
   KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005
   Langley CL, 1996, AIDS, V10, P413, DOI 10.1097/00002030-199604000-00010
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   LEGUENNO B, 1989, T ROY SOC TROP MED H, V83, P847, DOI 10.1016/0035-9203(89)90350-7
   LEONARD G, 1993, AIDS, V7, P1185
   Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6
   Libonati O, 1998, J ACQ IMMUN DEF SYND, V18, P190
   Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355
   Lucas SB, 1996, BRIT MED J, V312, P335
   MABEY DCW, 1988, BRIT MED J, V296, P83
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MARLINK R, 1998, 12 WORLD AIDS C GEN
   MARLINK R, 1996, 11 INT C AIDS VANC
   MARQUART KH, 1988, AIDS, V2, P141
   MATAGNE AK, 1998, 12 WORLD AIDS C GEN
   Matheron S, 1997, AIDS, V11, P934
   MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8
   MATHERON S, 1996, 11 INT C AIDS VANC
   Mbizvo M. T., 1996, Central African Journal of Medicine, V42, P14
   MBOUP S, 1991, AIDS, V5, pS93
   McKnight A, 1998, J VIROL, V72, P4065
   MEHENDALE SM, 1995, J INFECT DIS, V172, P1486
   MOLGUIN A, 1998, 12 WORLD AIDS C GEN
   MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008
   MOTAMIRANDA A, 1995, J INFECTION, V31, P163, DOI 10.1016/S0163-4453(95)92335-7
   MOTAMIRANDA A, 1996, 11 INT C AIDS VANC
   Mulanga-Kabeya C, 1998, AIDS, V12, P905, DOI 10.1097/00002030-199808000-00013
   NANDWANI R, 1998, INT J STD AIDS, V5, P155
   NEOGI D, 1998, 12 WORLD AIDS C GEN
   NGBICHI JM, 1995, AIDS, V9, P951, DOI 10.1097/00002030-199508000-00018
   NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002
   Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123
   NORRBY E, 1987, NATURE, V329, P248, DOI 10.1038/329248a0
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   Norrgren H, 1997, SCAND J INFECT DIS, V29, P453, DOI 10.3109/00365549709011853
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   NORRGREN H, 1997, 10 INT C AIDS STD AF
   Nunn AJ, 1997, BRIT MED J, V315, P767
   Obisesan KA, 1997, INT J GYNECOL OBSTET, V56, P271, DOI 10.1016/S0020-7292(96)02821-4
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   OTA M, 1998, 12 WORLD AIDS C GEN
   Owen SM, 1998, J VIROL, V72, P5425
   Pais P, 1996, TROP MED INT HEALTH, V1, P295, DOI 10.1046/j.1365-3156.1996.d01-47.x
   PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   PEPIN J, 1992, AIDS, V6, P489
   PEPIN J, 1991, AIDS, V5, P69
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972
   Pichard E, 1988, Med Trop (Mars), V48, P345
   PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002
   POULSEN AG, 1989, LANCET, V1, P827
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25
   PRAZUCK T, 1995, PEDIATR INFECT DIS J, V14, P940, DOI 10.1097/00006454-199511000-00004
   Rey-Cuille MA, 1998, J VIROL, V72, P3872
   REYCUILLE MA, 1998, J VIROL, V72, P6260
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   RODRIGUES JJ, 1995, BRIT MED J, V311, P283
   ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220
   ROSADO L, 1996, 11 INT C AIDS VANC
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P
   RUBSAMENWAIGMANN H, 1994, ZBL BAKT-INT J MED M, V280, P398
   SAMB ND, 1997, 10 INT C AIDS STD AF
   Sankale JL, 1996, VIROLOGY, V226, P418, DOI 10.1006/viro.1996.0671
   SANKALE JL, 1998, 12 WORLD AIDS C GEN
   Sarr AD, 1998, AIDS, V12, P131, DOI 10.1097/00002030-199802000-00002
   SassanMorokro M, 1996, J ACQ IMMUN DEF SYND, V11, P183
   SCHWARTZ DH, 1998, 12 WORLD AIDS C GEN
   SIMON F, 1998, 12 WORLD AIDS C GEN
   SIMON F, 1993, AIDS, V7, P1441
   SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480
   Smith NA, 1998, INT J STD AIDS, V9, P246
   Soriano V, 1996, EUR J CLIN MICROBIOL, V15, P383, DOI 10.1007/BF01690094
   SORIANO V, 1998, 12 WORLD AIDS C GEN
   Sullivan MT, 1998, TRANSFUSION, V38, P189, DOI 10.1046/j.1537-2995.1998.38298193104.x
   Switzer WM, 1998, J INFECT DIS, V177, P65, DOI 10.1086/513819
   Takehisa J, 1997, AIDS RES HUM RETROV, V13, P621, DOI 10.1089/aid.1997.13.621
   TEDDER RS, 1988, LANCET, V2, P927
   Tevi-Benissan C, 1998, EMERG INFECT DIS, V4, P130
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   TRAVERS K, 1997, 10 INT C AIDS STD AF
   Travers KU, 1998, AIDS, V12, P224
   *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP
   vanderEnde ME, 1996, AIDS, V10, P1649
   VERONESI R, 1987, LANCET, V2, P402
   Vetter KM, 1996, PEDIATR INFECT DIS J, V15, P438, DOI 10.1097/00006454-199605000-00011
   WAGNER HU, 1993, AIDS, V7, P1461, DOI 10.1097/00002030-199311000-00009
   WALTHER L, 1998, 12 WORLD AIDS C GEN
   WAWER MJ, 1991, BRIT MED J, V303, P1303
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   WHITLE H, 1998, 12 WORLD AIDS C GEN
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WHITTLE H, 1993, CLIN EXP IMMUNOL, V93, P45
   WHITTLE H, 1998, 12 WORLD AIDS C GEN
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   WIKTOR S, 1998, 12 WORLD AIDS C GEN
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   WILKINS A, 1991, AIDS, V5, P1127, DOI 10.1097/00002030-199109000-00012
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
   Zekeng L, 1997, AIDS, V11, P1410
   1993, CDR WEEKLY, V3, P181
   1997, FACTS HUMAN IMMUNODE
NR 195
TC 77
Z9 82
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PY 1999
VL 13
SU A
BP S69
EP S84
PG 16
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 222RR
UT WOS:000081799000009
PM 10885765
OA No
DA 2017-08-15
ER

PT J
AU West, TE
   Goetghebuer, T
   Milligan, P
   Mulholland, EK
   Weber, MW
AF West, TE
   Goetghebuer, T
   Milligan, P
   Mulholland, EK
   Weber, MW
TI Long-term morbidity and mortality following hypoxaemic lower respiratory
   tract infection in Gambian children
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID UPPER RIVER DIVISION; RISK-FACTORS; CHILDHOOD MORTALITY; PNEUMONIA;
   HYPOXEMIA; PATTERN; INFANT
AB Acute lower respiratory infections (ALRI) are the main cause of death in young children worldwide. We report here the results of a study to determine the long-term survival of children admitted to hospital with severe pneumonia. The study was conducted on 190 Gambian children admitted to hospital in 1992-94 for ALRI who survived to discharge. Of these, 83 children were hypoxaemic and were treated with oxygen, and 107 were not. On follow-up in 1996-97, 62% were traced. Of the children with hypoxaemia, 8 had died, compared with 4 of those without. The mortality rates were 4.8 and. 2.2 deaths per 100 child-years of follow-up for hypoxaemic and non-hypoxaemic children, respectively(P = 0.2). Mortality was higher for children who had been malnourished (Z-score <-2) when seen in hospital (rate ratio = 3.2; 95% confidence interval (CI)= 1.03-10.29; P = 0.045). Children with younger siblings experienced less frequent subsequent respiratory infections (rate ratio for further hospitalization with respiratory illness = 0.15; 95% Ci = 0.04-0.50; P =0.002). Children in Gambia who survive hospital admission with hypoxaemic pneumonia have a good prognosis. Survival depends more on nutritional status than on having been hypoxaemic. Investment in oxygen therapy appears justified, and efforts should be made to improve nutrition in malnourished children with pneumonia.
C1 Med Res Council Labs, Banjul, Gambia.
   Med Res Council Labs, Fajara, Senegal.
   Med Res Council Labs, CH-1211 Geneva, Switzerland.
   WHO, CH-1211 Geneva 27, Switzerland.
RP Goetghebuer, T (reprint author), Med Res Council Labs, Fajara POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174
   Fonseca W, 1996, B WORLD HEALTH ORGAN, V74, P199
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   *GOV GAMB, 1993, 1993 POP HOUS CENS G
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Man WDC, 1998, TROP MED INT HEALTH, V3, P678
   MTANGO FDE, 1989, TROP MED PARASITOL, V40, P97
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   SHAH N, 1994, J TROP PEDIATRICS, V40, P201
   SPIKA JS, 1989, ANN TROP PAEDIATR, V9, P33
   VICTORA CG, 1994, PEDIATRICS, V93, P977
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
NR 18
TC 25
Z9 25
U1 0
U2 3
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1999
VL 77
IS 2
BP 144
EP 148
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 171QA
UT WOS:000078873800009
PM 10083713
OA No
DA 2017-08-15
ER

PT J
AU Deen, JL
   Vos, T
   Huttly, SRA
   Tulloch, J
AF Deen, JL
   Vos, T
   Huttly, SRA
   Tulloch, J
TI Injuries and noncommunicable diseases: emerging health problems of
   children in developing countries
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
AB The present article identifies, for children living in developing countries, the major causes of ill-health that are inadequately covered by established health programmes. Injuries and noncommunicable diseases, notably asthma, epilepsy, dental caries, diabetes mellitus and rheumatic heart disease, are growing in significance. In countries where resources are scarce it is to be expected that increasing importance will be attached to the development and implementation of measures against these problems. Their control may benefit from the application of elements of programmes directed against infectious, nutritional and perinatal disorders, which continue to predominate.
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
   Dept Human Serv, Epidemiol Unit, Melbourne, Vic, Australia.
   London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.
   WHO, CH-1211 Geneva, Switzerland.
RP Deen, JL (reprint author), MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RI Vos, Theo/F-3324-2010
CR [Anonymous], 1996, TDRGEN961 WHO AD HOC
   HOSKING G, 1990, TROP DOCT, V20, P49
   MICHAUD C, 1993, DIS CONTROL PRIORITI
   MOONEY G, 1993, DIS CONTROL PRIORITI
   Murray CJ, 1996, GLOBAL BURDEN DIS CO
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429
   *NIH, 1995, NAT HEART LUNG BLOOD
   SANDMANN MC, 1996, TROPICAL NEUROLOGY
   SNITCOWSKY R, 1996, PEDIATRICS, V97, pS997
   VALENTINE AD, 1981, INT DENT J, V31, P23
   VAUGHAN JP, 1993, DIS CONTROL PRIORITI
   World Health Organization, 1991, GUID DEV NAT PROGR D
NR 12
TC 43
Z9 43
U1 0
U2 4
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1999
VL 77
IS 6
BP 518
EP 524
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 212RF
UT WOS:000081229500011
PM 10427938
OA No
DA 2017-08-15
ER

PT J
AU Awomoyi, A
   Marchant, A
   McAdam, K
   Blackwell, J
   Newport, M
AF Awomoyi, A
   Marchant, A
   McAdam, K
   Blackwell, J
   Newport, M
TI Genetic regulation of immune responses in tuberculosis
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Meeting Abstract
C1 MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PY 1999
SU S
MA 130
BP 30
EP 30
PG 1
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 225QX
UT WOS:000081973200129
OA No
DA 2017-08-15
ER

PT J
AU de Almeida, PJLP
   Ndao, M
   Goossens, B
   Osaer, S
AF de Almeida, PJLP
   Ndao, M
   Goossens, B
   Osaer, S
TI PCR primer evaluation for the detection of trypanosome DNA in naturally
   infected goats
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosoma brucei; Trypanosoma congolense; Trypanosoma vivax; PCR;
   goat; Gambia
ID POLYMERASE CHAIN-REACTION; TSETSE-FLIES; BRUCEI
AB The buffy coat of 76 roaming goats from the Bansang and Missira regions in Gambia, was examined for the presence of trypanosomes. From these animals, extractions from dry blood samples on filter paper were subjected to PCR using three different primer sets, ORPHON5J, GOL and TVW, specific for Trypanosoma brucei/Trypanosoma evansi, Trypanosoma congolense and Trypanosoma vivax, respectively. PCR results for T. congolense were 100% concordant with buffy coat examination. Besides the three T. vivax buffy coat-positive samples, another 15 yielded positive with the TVW primers. The ORPHON5J primers yielded no positive results. Analyses with the GOL primers of putatively negative samples, yielded aberrant band patterns whose diagnostic significance still remains to be determined. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Inst Trop Med, B-2000 Antwerp, Belgium.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP de Almeida, PJLP (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.
EM palmeid@itg.be
CR COLGAN DJ, 1993, J THEOR BIOL, V162, P289, DOI 10.1006/jtbi.1993.1088
   deAlmeida PJLP, 1997, ACTA TROP, V66, P45, DOI 10.1016/S0001-706X(97)00677-3
   DEALMEIDA PP, 1998, IN PRESS ACTA TROP
   GIBSON WC, 1987, EMBO J, V6, P2457
   GIBSON WC, 1988, PARASITOLOGY, V97, P63
   Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475
   Masiga DK, 1996, PARASITOLOGY, V112, P75
   MASSAMBA NN, 1984, PARASITOLOGY, V95, P55
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PAABO S, 1989, J BIOL CHEM, V264, P9709
   PARSONS M, 1986, NUCLEIC ACIDS RES, V14, P1703, DOI 10.1093/nar/14.4.1703
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
NR 13
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD DEC 31
PY 1998
VL 80
IS 2
BP 111
EP 116
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 148AX
UT WOS:000077531100003
OA No
DA 2017-08-15
ER

PT J
AU Hill, AG
   MacLeod, WB
   Sonko, SST
   Walraven, G
AF Hill, AG
   MacLeod, WB
   Sonko, SST
   Walraven, G
TI Improvements in childhood mortality in the Gambia
SO LANCET
LA English
DT Article
C1 Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA.
   Cent Stat Dept, Banjul, Gambia.
   MRC Labs, Fajara, Gambia.
RP Hill, AG (reprint author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   Blacker JGC, 1985, IUSSP GEN C P FLOR, V2, P287
   MACLEOD WB, 1998, POPULATION HOUSING C, V3
   MULHOLLAND K, 1997, LANCET, V349, P119
   *UNICEF, 1997, PROGR NAT, P28
NR 5
TC 12
Z9 12
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 12
PY 1998
VL 352
IS 9144
BP 1909
EP 1909
DI 10.1016/S0140-6736(05)60400-X
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148QZ
UT WOS:000077544600020
PM 9863797
OA No
DA 2017-08-15
ER

PT J
AU Enwere, G
   Van Hensbroek, MB
   Adegbola, R
   Palmer, A
   Onyiora, E
   Weber, M
   Greenwood, B
AF Enwere, G
   Van Hensbroek, MB
   Adegbola, R
   Palmer, A
   Onyiora, E
   Weber, M
   Greenwood, B
TI Bacteraemia in cerebral malaria
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID GAMBIAN CHILDREN
AB As part of a treatment trial of cerebral malaria, blood cultures were done in 276 Gambian children, aged between 1 and 9 years, with cerebral malaria. Fourteen (5%) of these were positive. The organisms isolated were Staphylococcus aureus (6), coliforms (4), Pseudomonas spp. (2), Salmonella spp. (1) and Streptococcus spp. (1). Thirteen of these children survived, most without appropriate antibiotic treatment. Most of the retrieved organisms were therefore suspected to be contaminants. Bacteraemia complicating cerebral malaria is not common in The Gambia, and routine antibiotic treatment of children with cerebral malaria is not warranted.
C1 MRC Labs, Banjul, Gambia.
   Royal Victoria Hosp, Banjul, Gambia.
RP Enwere, G (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ADEGBOLA RA, 1995, PEDIATR INFECT DIS J, V14, P920
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   AKPEDE GO, 1993, J TROP MED HYG, V96, P146
   BYGBJERG IC, 1982, T ROY SOC TROP MED H, V76, P705, DOI 10.1016/0035-9203(82)90251-6
   Commey Joo, 1994, Central African Journal of Medicine, V40, P257
   FOOTE SC, 1979, PRINCIPLES PRACTICE, P1730
   GOODAL HB, 1975, T R SOC TROP MED HYG, V75, P884
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421
   VAITTLE HC, 1989, IMMUNOL TODAY, V10, P421
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   VANHENSBROEK MB, 1997, J INFECT DIS, V175, P200
   WEINSTEIN L, 1974, PATHOPHYSIOLOGIC PHY, P389
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 15
TC 21
Z9 21
U1 0
U2 0
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 1998
VL 18
IS 4
BP 275
EP 278
PG 4
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 144WL
UT WOS:000077338600003
PM 9924581
OA No
DA 2017-08-15
ER

PT J
AU Goossens, B
   Osaer, S
   Kora, S
   Ndao, M
AF Goossens, B
   Osaer, S
   Kora, S
   Ndao, M
TI Haematological changes and antibody response in trypanotolerant sheep
   and goats following experimental Trypanosoma congolense infection
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE sheep-protozoa; goat; haematology; Trypanosoma congolense;
   trypanotolerance
ID WEST-AFRICAN DWARF; BOVINE TRYPANOSOMIASIS; CATTLE; SUSCEPTIBILITY;
   NDAMA; DIAGNOSIS; CALVES; TSETSE; PATHOGENESIS; LEUKOCYTES
AB Ten West African Dwarf (WAD) female goats and twelve Djallonke ewes were artificially infected with a West African strain of Trypanosoma congolense and monitored during 36 weeks over an acute phase (weeks 0-12) and chronic phase (weeks 13-36) to evaluate their haematological and immunological response. Parasitaemia, packed cell volume, red blood cells, haemoglobin, white blood cells and trypanosomal antibodies were assessed. Mean corpuscular volume and mean corpuscular haemoglobin concentration were calculated. The infected animals showed a persistent parasitaemia together with a chronic anaemia and significantly lower packed cell volume, red blood cell count and haemoglobin The infected sheep developed a macrocytic, hypochromic anaemia during the acute phase changing to normocytic, hypochromic during the chronic phase, whereas, the infected goats developed a normocytic, normochromic anaemia during the acute phase and normocytic, hypochromic during the chronic phase. A significant increase in WBC counts was observed only in the infected sheep during the chronic phase. Trypanosomal antibody titres were significantly higher in the infected sheep than in the infected goats. Both species an regarded as trypanotolerant but Djallonke sheep mount a better haematopoietic and immunological response to infection with T. congolense than WAD goats. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med, Serol Lab, B-200 Antwerp, Belgium.
RP Goossens, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N
   Anosa V O, 1988, Rev Elev Med Vet Pays Trop, V41, P151
   ANOSA VO, 1992, VET PATHOL, V29, P33
   AUTHIE E, 1993, PARASITE IMMUNOL, V15, P465, DOI 10.1111/j.1365-3024.1993.tb00632.x
   AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6
   Bengaly Z, 1993, Rev Elev Med Vet Pays Trop, V46, P563
   DARGIE JD, 1979, PARASITOLOGY, V78, P271
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   Edwards E. E., 1956, Annals of Tropical Medicine and Parasitology, V50, P223
   ELLIS JA, 1987, PARASITE IMMUNOL, V9, P363, DOI 10.1111/j.1365-3024.1987.tb00514.x
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GREENWOOD A, 1989, INT TRYPANOTOLERANCE
   GRIFFIN L, 1981, J COMP PATHOL, V91, P85, DOI 10.1016/0021-9975(81)90048-7
   GRIFFIN L, 1981, J COMP PATHOL, V91, P97, DOI 10.1016/0021-9975(81)90049-9
   Griffin L., 1978, Veterinary Bulletin, V48, P819
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   KAAYA G P, 1977, Bulletin of Animal Health and Production in Africa, V25, P397
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   Kramer J. W., 1966, Bulletin of Epizootic Diseases of Africa, V14, P423
   LOSOS GJ, 1972, VET PATHOL         S, V9
   LOSOS GJ, 1973, B EPIZOOT DIS AFR, V21, P231
   MACKENZIE PKI, 1978, RES VET SCI, V24, P4
   MAGNUS E, 1988, REV ASS BEL TECH LAB, V15, P321
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MORRIS JS, 1992, PRACTICE         MAR, P67
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NANTULYA VM, 1982, CLIN EXP IMMUNOL, V47, P234
   NAYLOR D C, 1971, Tropical Animal Health and Production, V3, P159, DOI 10.1007/BF02360746
   ODUYE O O, 1976, Tropical Animal Health and Production, V8, P131
   Ogunsanmi A O, 1994, Rev Elev Med Vet Pays Trop, V47, P53
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   PARIS J, 1982, ACTA TROP, V39, P307
   PINDER M, 1988, VET IMMUNOL IMMUNOP, V18, P245, DOI 10.1016/0165-2427(88)90069-4
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RIEDLER FG, 1983, D198306922
   ROELANTS GE, 1986, PARASITE IMMUNOL, V8, P1, DOI 10.1111/j.1365-3024.1986.tb00828.x
   *SAS I, 1989, STAT AN SYST I SAS V
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   VALLI VEO, 1978, VET PATHOL, V15, P732
   VALLI VEO, 1979, VET PATHOL, V16, P96
   VANDAM RH, 1981, VET PARASITOL, V8, P1, DOI 10.1016/0304-4017(81)90012-1
   WEITZ B, 1963, B WORLD HEALTH ORGAN, V28, P711
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
   WILSON A J, 1971, Tropical Animal Health and Production, V3, P133, DOI 10.1007/BF02360742
NR 48
TC 17
Z9 17
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV 27
PY 1998
VL 79
IS 4
BP 283
EP 297
DI 10.1016/S0304-4017(98)00171-X
PG 15
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 138WF
UT WOS:000076995800003
PM 9831952
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
AF Mattioli, RC
TI Comment on "A possible explanation of the apparent breed-related
   resistance in cattle to bont tick (Amblyomma hebraeum) infestations" by
   M.I. Meltzer, Veterinary Parasitology 67 (1996) 275-279
SO VETERINARY PARASITOLOGY
LA English
DT Letter
ID NDAMA; ZEBU
RP Mattioli, RC (reprint author), PMB 14, Banjul, Gambia.
CR ADAMSON D, 1991, VET PARASITOL, V38, P317, DOI 10.1016/0304-4017(91)90143-J
   MAILLARD, 1993, REV ELEV MED VET PAY, V46, P283
   MAILLARD, 1993, REV ELEV MED VET PAY, V46, P275
   MATTIOLI, PREV VET ME IN PRESS
   MATTIOLI, 1994, PARASSITOLOGIA, V36, P305
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   Meltzer MI, 1996, VET PARASITOL, V67, P275, DOI 10.1016/S0304-4017(96)01018-7
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV 16
PY 1998
VL 79
IS 3
BP 263
EP 264
PG 2
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 132ZM
UT WOS:000076662000010
PM 9823067
OA No
DA 2017-08-15
ER

PT J
AU Rowland-Jones, SL
   Dong, T
   Fowke, KR
   Kimani, J
   Krausa, P
   Newell, H
   Blanchard, T
   Ariyoshi, K
   Oyugi, J
   Ngugi, E
   Bwayo, J
   MacDonald, KS
   McMichael, AJ
   Plummer, FA
AF Rowland-Jones, SL
   Dong, T
   Fowke, KR
   Kimani, J
   Krausa, P
   Newell, H
   Blanchard, T
   Ariyoshi, K
   Oyugi, J
   Ngugi, E
   Bwayo, J
   MacDonald, KS
   McMichael, AJ
   Plummer, FA
TI Cytotoxic T cell responses to multiple conserved HIV epitopes in
   HIV-resistant prostitutes in Nairobi
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE human immunodeficiency virus-specific; cytotoxic T lymphocytes; AIDS in
   Africa; cross-clade immune responses
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOCYTE RESPONSES; DISEASE
   PROGRESSION; PROTECTIVE IMMUNITY; VACCINE DEVELOPMENT; INFECTION; GENE;
   TRANSMISSION; INDIVIDUALS; BINDING
AB Many people who remain persistently seronegative despite frequent HIV exposure have HIV-specific immune responses. The study of these may provide information about mechanisms of natural protective immunity to HIV-1. We describe the specificity of cytotoxic T lymphocyte responses to HIV in seronegative prostitutes in Nairobi who are apparently resistant to HN infection. These women have had frequent exposure to a range of African HIV-1 variants, primarily clades A, C, and D, for up to 12 yr without becoming infected. Nearly half of them have CTL directed towards epitopes previously defined for B clade virus, which are largely conserved in the A and D clade sequences. Stronger responses are frequently elicited using the A or D clade version of an epitope to stimulate CTL, suggesting that they were originally primed by exposure to these virus strains. CTL responses have been defined to novel epitopes presented by HLA class I molecules associated with resistance to infection in the cohort, HLA-A*6802 and HLA-B18. Estimates using a modified interferon-gamma Elispot assay indicate a circulating frequency of CTL to individual epitopes of between 1:3,200 and 1:50,000, Thus, HIV-specific immune responses-particularly cross-clade CTL activity-may be responsible for protection against persistent HIV infection in these African women.
C1 John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DS, England.
   Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada.
   Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya.
   MRC Unit, Fajara, Gambia.
   Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada.
RP Rowland-Jones, SL (reprint author), John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DS, England.
EM sarah.rowland-jones@ndm.ox.ac.uk
OI Fowke, Keith/0000-0001-8227-6649
CR Ada GL, 1997, AIDS RES HUM RETROV, V13, P205, DOI 10.1089/aid.1997.13.205
   Anzala AO, 1998, LANCET, V351, P1632, DOI 10.1016/S0140-6736(05)77688-1
   ANZALA OA, 1995, J INFECT DIS, V171, P686
   BAROUCH D, 1995, J EXP MED, V182, P1847, DOI 10.1084/jem.182.6.1847
   Bertoni R, 1997, J CLIN INVEST, V100, P503, DOI 10.1172/JCI119559
   Betts MR, 1997, J VIROL, V71, P8908
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Cao HY, 1997, J VIROL, V71, P8615
   CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   DELGUERCIO MF, 1995, J IMMUNOL, V154, P685
   Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396
   Fowke KR, 1998, AIDS RES HUM RETROV, V14, P1521, DOI 10.1089/aid.1998.14.1521
   Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240
   Khanna R, 1998, EUR J IMMUNOL, V28, P451, DOI 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U
   KORBER B, 1997, HIV MOL IMMUNOLOGY D
   LAIVANI A, 1997, J IMMUNOL METHODS, V210, P65
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270
   LIU R, 1996, CELL, V88, P7
   MAMMANO F, 1994, J VIROL, V68, P4927
   Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   MOSES S, 1991, AIDS, V5, P407, DOI 10.1097/00002030-199104000-00008
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   Ogg GS, 1998, AIDS, V12, P1561, DOI 10.1097/00002030-199812000-00026
   Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133
   Poss M, 1997, AIDS RES HUM RETROV, V13, P493, DOI 10.1089/aid.1997.13.493
   Putkonen P, 1997, J VIROL, V71, P4981
   Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7
   ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0
   Threlkeld SC, 1997, J IMMUNOL, V159, P1648
   Zhang CS, 1996, P NATL ACAD SCI USA, V93, P14720, DOI 10.1073/pnas.93.25.14720
NR 42
TC 322
Z9 329
U1 1
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV 1
PY 1998
VL 102
IS 9
BP 1758
EP 1765
DI 10.1172/JCI4314
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 137BW
UT WOS:000076895100014
PM 9802890
OA No
DA 2017-08-15
ER

PT J
AU Burgner, D
   Xu, WM
   Rockett, K
   Gravenor, M
   Charles, IG
   Hill, AV
   Kwiatkowski, D
AF Burgner, D
   Xu, WM
   Rockett, K
   Gravenor, M
   Charles, IG
   Hill, AV
   Kwiatkowski, D
TI Inducible nitric oxide synthase polymorphism and fatal cerebral malaria
SO LANCET
LA English
DT Article
C1 Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   MRC Labs, Banjul, Gambia.
   UCL, Cruciform Project, London, England.
RP Kwiatkowski, D (reprint author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
EM dominic@immsvr.jr2.ox.ac.uk
RI Xu, Weiming/A-6274-2008; HILL, Adrian/C-1306-2008
OI Xu, Weiming/0000-0002-7085-7814; 
CR Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557
   CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X
   HILL AV, 1989, NATURE, V352, P595
   Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8
   Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6
NR 5
TC 94
Z9 97
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 10
PY 1998
VL 352
IS 9135
BP 1193
EP 1194
DI 10.1016/S0140-6736(05)60531-4
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 128PQ
UT WOS:000076415400016
PM 9777841
OA No
DA 2017-08-15
ER

PT J
AU Von Seidlein, L
   Jaffar, S
   Greenwood, B
AF Von Seidlein, L
   Jaffar, S
   Greenwood, B
TI Untitled
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Letter
ID PROLONGATION
C1 MRC Labs, Farafenni Field Stn, Banjul, Gambia.
RP Von Seidlein, L (reprint author), MRC Labs, Farafenni Field Stn, Banjul, Gambia.
CR DAY CP, 1993, LANCET, V341, P1423
   VonSeidlein L, 1997, AM J TROP MED HYG, V56, P494
NR 2
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 1998
VL 59
IS 4
BP 503
EP 503
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 129QD
UT WOS:000076473700002
OA No
DA 2017-08-15
ER

PT J
AU Grassly, NC
   Xiang, Z
   Ariyoshi, K
   Aaby, P
   Jensen, H
   van der Loeff, MS
   Dias, F
   Whittle, H
   Breuer, J
AF Grassly, NC
   Xiang, Z
   Ariyoshi, K
   Aaby, P
   Jensen, H
   van der Loeff, MS
   Dias, F
   Whittle, H
   Breuer, J
TI Mortality among human immunodeficiency virus type 2-positive villagers
   in rural Guinea-Bissau is correlated with viral genotype
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SYNCYTIUM-INDUCING PHENOTYPE; HIV-1 INFECTION; EVOLUTIONARY TREES;
   NATURAL PROTECTION; DISEASE PROGRESSION; LOWER PREVALENCE; HOMOSEXUAL
   MEN; WEST-AFRICA; AIDS; GENE
AB We present the results of a 6-year study of 131 human immunodeficiency virus (HIV) type 2 (HIV-2)-infected individuals from a rural population in Guinea-Bissau. Proviral DNA sequences 1.3 kb in length were obtained from each individual and, together with clinical data, including proviral load and CD4 and CD8 levels, were used to assess whether viral genotype influences clinical outcome. With a phylogenetic model, a correlation was found between viral genotype and mortality; this correlation was not due to confounding factors, such as age-specific viral strains or cohabitation of patients. The data provide strong evidence for the involvement of viral genetic factors in determining HIV disease progression in vivo. The pattern of association found suggests that virulence factors are multiple and scattered throughout the HIV-2 genome and can be rapidly gained or lost by the virus through a combination of mutation and recombination. These findings may lead to the identification of viral determinants of HIV disease progression.
C1 Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England.
   St Bartholomews & Royal London Sch Med & Dent, Dept Med Microbiol, London, England.
   Medical Research Council, MRC Labs, Banjul, Gambia.
   Statens Serum Inst, Dept Epidemiol, DK-2300 Copenhagen, Denmark.
   Lab Nacl Sande Publ, Bissau, Guinea Bissau.
RP Grassly, NC (reprint author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3PS, England.
RI Grassly, Nicholas/C-6381-2008
FU Wellcome Trust
CR Aaby P, 1997, AIDS, V11, P939
   Albert J, 1996, AIDS RES HUM RETROV, V12, P821, DOI 10.1089/aid.1996.12.821
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Edwards AW, 1992, LIKELIHOOD
   FELSENSTEIN J, 1973, AM J HUM GENET, V25, P471
   FELSENSTEIN J, 1981, EVOLUTION, V35, P1229, DOI 10.1111/j.1558-5646.1981.tb04991.x
   Felsenstein J, 1996, MOL BIOL EVOL, V13, P93
   FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359
   Flaherty MT, 1997, J VIROL, V71, P5790
   FOUCHIER RAM, 1992, J VIROL, V66, P3183
   Greenberg AE, 1996, SCIENCE, V272, P1959
   Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324
   HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189
   Kanki PJ, 1996, SCIENCE, V272, P1959
   Karlsson GB, 1997, J VIROL, V71, P4218
   Kimata JT, 1997, J VIROL, V71, P7629
   KOOT M, 1993, ANN INTERN MED, V118, P681
   KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549
   MADDISON WP, 1995, MACCLADE
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   McNeil AJ, 1996, QJM-MON J ASSOC PHYS, V89, P177
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Mocroft A, 1996, AIDS, V10, P344, DOI 10.1097/00002030-199603000-00020
   MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496
   NOVEMBRE FJ, 1993, J VIROL, V67, P2466
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   SCHULZ TF, 1990, J VIROL, V64, P5177
   Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959
   SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291
   SPIJKERMAN IJB, 1995, AIDS, V9, P1085, DOI 10.1097/00002030-199509000-00016
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
NR 42
TC 18
Z9 18
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 1998
VL 72
IS 10
BP 7895
EP 7899
PG 5
WC Virology
SC Virology
GA 118WN
UT WOS:000075864100021
PM 9733826
OA No
DA 2017-08-15
ER

PT J
AU Jones, M
AF Jones, M
TI The distribution of Berhautia senegalensis Balle (Loranthaceae) in The
   Gambia
SO AFRICAN JOURNAL OF ECOLOGY
LA English
DT Article
C1 Gambia Coll, Dept Sci, Brikama, Gambia.
RP Jones, M (reprint author), Newman Coll, Dept Sci, Genners Lane,Bartley Green, Birmingham B32 3NT, W Midlands, England.
CR BAKER JG, 1891, KEW B, V58, P268
   BALLE S., 1956, BULL SOC ROY BOT BELGIQUE, V88, P133
   BALLE S, 1958, FLORA W TROPICAL AFR
   Berhaut J., 1971, FLORE ILLUSTREE SENE
   BERHAUT J, 1954, FLORE SENEGAL
   BERHAUT J., 1967, FLORE SENEGAL
   DAWE MT, 1922, LIST PLANTS COLLECTE
   HALLAM GM, 1978, FLOWERING PLANTS GAM
   Hutchinson J. L., 1927, FLORA W TROPICAL AFR
   JARVIS ACE, 1978, GAMBIAN FLOWERS TREE
   Jarvis A. E. C., 1980, CHECKLIST GAMBIAN PL
   JONES M, 1994, FLOWERING PLANTS GAM
   KASPER P, 1993, SOME COMMON FLORA GA
   PERCIVAL DA, 1968, COMMON TREES SHRUBS
   von Maydell H-J, 1986, TREES SHRUBS SAHEL
   WILLIAMS FN, 1907, B HERB BOISSIER 2, V7, P81
   WILLIAMS FN, 1907, B HERB BOISSIER 2, V7, P193
   WILLIAMS FN, 1907, B HERB BOISSIER 2, V7, P386
NR 18
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0141-6707
J9 AFR J ECOL
JI Afr. J. Ecol.
PD SEP
PY 1998
VL 36
IS 3
BP 286
EP 289
DI 10.1046/j.1365-2028.1998.00140.x
PG 4
WC Ecology
SC Environmental Sciences & Ecology
GA 122PZ
UT WOS:000076081800013
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
   Adegbola, RA
AF Secka, O
   Adegbola, RA
TI Rapid and simple Microtek biotyping method for Haemophilus influenzae
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
ID HEMOPHILUS
C1 Med Res Council Lab, Banjul, Gambia.
RP Secka, O (reprint author), Med Res Council Lab, POB 273, Banjul, Gambia.
CR BECK AE, 1978, J CLIN MICROBIOL, V7, P312
   BUTT HL, 1988, PATHOLOGY, V20, P252
   HOLMES RL, 1982, J CLIN MICROBIOL, V15, P1150
   KILIAN M, 1976, J GEN MICROBIOL, V93, P9
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PD SEP
PY 1998
VL 55
IS 3
BP 212
EP 213
PG 2
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 130KR
UT WOS:000076519700011
PM 10367409
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Leach, A
   Mulholland, K
   Hilton, S
   Demba, E
   Jaffar, S
   Greenwood, BM
AF Adegbola, RA
   Leach, A
   Mulholland, K
   Hilton, S
   Demba, E
   Jaffar, S
   Greenwood, BM
TI Antigenuria in Gambian infants following immunization with a Haemophilus
   influenzae type b polyribosylribitol phosphate tetanus toxoid protein
   conjugate (PRP-T) vaccine
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article; Proceedings Paper
CT Medical Research Council Jubilee Meeting
CY NOV 14-21, 1997
CL BANJUL, GAMBIA
SP MRC
ID OUTER-MEMBRANE PROTEIN; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE;
   NEISSERIA-MENINGITIDIS; EXCRETION; PNEUMONIA
AB During a Haemophilus influenzae type b (Hib)-conjugate vaccine trial, the prevalence nl rd duration of antigenuria after vaccination ions studied in 102 Gambian infants aged 51 to 175 days. Urine samples were collected nt 0, 1, 3, 7, 14, 21 and 28 days postvaccination and tested for Hib antigen by latex agglutination using Biomerieux and Directigen reagent kits. Biomerieux positive reactions were found in 6 of 247 (2.4%) samples from vaccinated children and in 8 of 199 (4.0%) from nonvaccinated children (chi(2) = 0.47; 1 df; p = 0.5). In contrast, Directigen positive reactions were obtained with 86/242 samples (35.5%) from vaccinated children and from 28/190 (14.7%) from non-vaccinated children (chi(2) = 22.7; 1 df; p <0.0001). The highest rate of antigenuria was detected in samples collected on Day 7 after vaccination when 24 of 30 (80%) were positive. Antigenuria following vaccination ions frequent and may complicate the use of this test as a means of diagnosing invasive Hib disease in vaccinated children. (C) 1998 Elsevier Science Inc.
C1 MRC, Lab Fajara, Banjul, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
   London Sch Hyg & Trop Med, London WC1, England.
RP MRC, Lab Fajara, POB 273, Banjul, Gambia.
CR ADEGBOLA RA, 1998, IN PRESS J INFECT DI
   AJELLO GW, 1987, J CLIN MICROBIOL, V25, P1388
   BIJLMER HA, 1989, T ROY SOC TROP MED H, V83, P831, DOI 10.1016/0035-9203(89)90345-3
   GOEPP JG, 1992, PEDIATR INFECT DIS J, V11, P2, DOI 10.1097/00006454-199201000-00002
   JONES RG, 1991, PEDIATR INFECT DIS J, V10, P557, DOI 10.1097/00006454-199108000-00001
   MARCON MJ, 1984, J CLIN MICROBIOL, V19, P333
   MILLER MA, 1995, PEDIATRICS, V95, P522
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   MURPHY TV, 1989, PEDIATR RES, V26, P491, DOI 10.1203/00006450-198911000-00026
   ROTHSTEIN EP, 1991, PEDIATR INFECT DIS J, V10, P311, DOI 10.1097/00006454-199104000-00009
   SOOD SK, 1990, J INFECT DIS, V161, P574
   SPINOLA SM, 1986, J PEDIATR-US, V109, P835, DOI 10.1016/S0022-3476(86)80705-3
   TUPASI TE, 1990, REV INFECT DIS, V12, pS929
   WITT CS, 1990, REV INFECT DIS, V12, pS1001
NR 14
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD SEP
PY 1998
VL 32
IS 1
BP 15
EP 19
DI 10.1016/S0732-8893(98)00064-9
PG 5
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 125QG
UT WOS:000076248100003
PM 9791752
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Manneh, K
   Bouchier, V
   Lahai, G
   Milligan, PJM
   McAdam, KPWJ
AF Lienhardt, C
   Manneh, K
   Bouchier, V
   Lahai, G
   Milligan, PJM
   McAdam, KPWJ
TI Factors determining the outcome of treatment of adult smear-positive
   tuberculosis cases in The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis treatment; directly observed treatment; adherence; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DIRECTLY OBSERVED THERAPY; PULMONARY
   TUBERCULOSIS; MORTALITY; HIV; AFRICA; INFECTION; ZAMBIA; COHORT
AB SETTING: Health centres in The Gambia, West Africa.
   OBJECTIVES: To identify factors determining the outcome of treatment of adult tuberculosis cases in a Tuberculosis Control Programme using directly observed treatment.
   DESIGN: Information on the outcome of treatment was collected on all tuberculosis cases registered with the Tuberculosis Control Programme in 1994 and 1995 and treated under supervision by tuberculosis control staff, nurses or village health workers. Treatment outcome was recorded as cured, completed treatment, failed, defaulted or died. Transferred-out patients were traced and their treatment outcome recorded at the health centre where they had last been seen.
   RESULTS: Data were analysed for 1357 adult smear-positive tuberculosis cases. Sputum smear conversion 2 months after the start of treatment was observed in 90% of smear-positive cases and was more likely to occur if the initial bacterial load in the sputum was low. The total cure rate was 74.6%. Female tuberculosis patients were more likely to achieve cure than males. Adjusting for sex, the cure rate was higher when treatment was provided by tuberculosis control staff in the main health centres rather than by nurses or village health workers at the peripheral level (odds ratio [OR] = 1.60, 95% confidence interval [CI] 1.23-2.09). The absence of sputum smear conversion after 2 months of chemotherapy was associated with defaulting later during treatment (OR = 2.0, 95% CI 1.15-3.57). Adjusting for age and sex, the death rate during treatment was higher in human immunodeficiency virus (HIV) positive than in HIV-negative tuberculosis patients.
   CONCLUSION: Directly observed treatment is an effective intervention for improving adherence of tuberculosis patients to treatment in a resource-poor country, provided that drugs are effectively delivered to the most peripheral level, and that health staff are adequately trained and regularly supervised. Patients with high bacterial load in initial sputum smears need to be closely supervised, as they are more likely to default from treatment.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP Lienhardt, C (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM clienhardt@gam.healthnet.org
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7
   ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055
   DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9
   DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.268.12.1581
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1
   ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U
   ENARSON DA, 1996, TUBERCULOSIS GUIDE H
   FOX W, 1958, Tubercle, V39, P269, DOI 10.1016/S0041-3879(58)80088-4
   GLYNN JR, 1995, TUBERCLE LUNG DIS S2, V76, P78, DOI 10.1016/0962-8479(95)90304-6
   Grange JM, 1997, LANCET, V350, P157, DOI 10.1016/S0140-6736(05)62344-6
   ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811
   KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011
   KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   NUNN P, 1992, AM REV RESPIR DIS, V146, P849
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Samb B, 1997, INT J TUBERC LUNG D, V1, P25
   SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311
   WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702
   WHO, 1995, WHOTB95183
   WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9
   Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094
   Zhao FZ, 1996, LANCET, V347, P358
NR 25
TC 40
Z9 41
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD SEP
PY 1998
VL 2
IS 9
BP 712
EP 718
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 119XL
UT WOS:000075923600003
PM 9755924
OA No
DA 2017-08-15
ER

PT J
AU Klein, MR
   van der Burg, SH
   Hovenkamp, E
   Holwerda, AM
   Drijfhout, JW
   Melief, CJM
   Miedema, F
AF Klein, MR
   van der Burg, SH
   Hovenkamp, E
   Holwerda, AM
   Drijfhout, JW
   Melief, CJM
   Miedema, F
TI Characterization of HLA-B57-restricted human immunodeficiency virus type
   1 Gag- and RT-specific cytotoxic T lymphocyte responses
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; LONGITUDINAL ANALYSIS; CONSERVED EPITOPES;
   PRIMARY INFECTION; CLINICAL COURSE; CELLS; AIDS; PROGRESSION; VARIANTS;
   IDENTIFICATION
AB HLA-B57 has been shown to be strongly associated with slow disease progression in human immunodeficiency virus type 1 (HIV-1)-infected patients from the Amsterdam Cohort. Since HIV-1-specific CTL can control and eliminate virus-infected cells, we sought to characterize the dominant HLA-B57-restricted CTL responses at the epitope level, It was found that HLA-B57-restricted CTL responses were targeted at multiple proteins of HIV-1, with CTL specific for Gag and RT being the most pronounced, Gag-specific CTL recognized peptides ISPRTLNAW (aa 147-155) and STLQEQIGW (aa 241-249), which had previously been reported as HLA-B57-restricted,The RT-specific CTL response in one longterm survivor studied in great detail persisted for > 10 years and was dominated by HLA-B57-restricted CTL that recognized the newly defined epitope IVLPEKDSW (RTLAI, aa 244-252), This epitope could be recognized in the context of both HLA-B*5701 and HLA-B*5801. Interestingly, three epitope variants of IVLPEKDSW were observed, which coincided with the strongest detectable CTL response to RT, One variant (T2E7) was not recognized by IVLPEKDSW-specific CTL despite the fact that this variant bound to HLA-B*5701 with a similar affinity as the index peptide. Finally, only viruses which contained the epitope index sequence were obtained suggesting efficient virus control by CTL, In conclusion, we report the characterization of dominant HIV-1 Gag- and RT-derived, HLA-B57-restricted CTL epitopes which are associated with longer time to AIDS. Further characterization of CTL responses restricted by HLA-B57 and other protective HLA alleles may contribute to the development of effective AIDS vaccines.
C1 Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands.
   Univ Amsterdam, Expt & Clin Immunol Lab, NL-1066 CX Amsterdam, Netherlands.
   Univ Leiden Hosp, Dept Immunohaematol, NL-2300 RC Leiden, Netherlands.
   Univ Leiden Hosp, Blood Bank, NL-2300 RC Leiden, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
RP Klein, MR (reprint author), Med Res Council Lab, POB 273, Banjul, Gambia.
CR Barber LD, 1997, J IMMUNOL, V158, P1660
   Bertoletti A, 1998, J VIROL, V72, P2439
   Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   BORROW P, 1994, J VIROL, V68, P6103
   Buseyne F, 1996, VIROLOGY, V225, P248, DOI 10.1006/viro.1996.0597
   Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V41, P1
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   FALK K, 1995, IMMUNOGENETICS, V41, P165, DOI 10.1007/BF00182333
   Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0
   Haas G, 1996, J IMMUNOL, V157, P4212
   Haldane J.B., 1955, ANN HUM GENET, V20, P309
   Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585
   Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324
   HUSMAN DR, 1997, ANN INTERN MED, V127, P882
   IMANISHI T, 1992, P 11 INT HIST WORKSH, P1065
   ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37
   JOHNSON RP, 1991, J IMMUNOL, V147, P1512
   KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261
   KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Keet I P, 1996, AIDS, V10 Suppl A, pS59, DOI 10.1097/00002030-199601001-00009
   KLEIN MR, 1994, J INFECT DIS, V169, P1244
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KLEIN MR, 1995, TRENDS MICROBIOL, V3, P386, DOI 10.1016/S0966-842X(00)88984-2
   KLEIN MR, 1998, IN PRESS IMMUNOLOGY
   KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330
   KOOT M, 1993, ANN INTERN MED, V118, P681
   KOUP RA, 1994, J VIROL, V68, P4650
   LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3
   MCCHESNEY M, 1990, EUR J IMMUNOL, V20, P215, DOI 10.1002/eji.1830200131
   MORTARA, 1998, J VIROLOGY, V72, P1403
   MYERS G, 1995, HUMAN RETROVIRUSES A
   PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0
   Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890
   RAUTMANN G, 1989, AIDS RES HUM RETROV, V5, P147, DOI 10.1089/aid.1989.5.147
   SAHMOUD T, 1993, AIDS, V7, P497, DOI 10.1097/00002030-199304000-00007
   SCHUITEMAKER H, 1991, J VIROL, V65, P356
   Sipsas NV, 1997, J CLIN INVEST, V99, P752, DOI 10.1172/JCI119221
   STRIJBOSCH LWG, 1987, J IMMUNOL METHODS, V97, P133, DOI 10.1016/0022-1759(87)90115-3
   TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421
   vanBaalen CA, 1997, J GEN VIROL, V78, P1913
   VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004
   VANDEGRIEND RJ, 1984, J IMMUNOL METHODS, V66, P285, DOI 10.1016/0022-1759(84)90340-5
   VANDERBURG SH, 1995, AIDS, V9, P121
   vanderBurg SH, 1997, J IMMUNOL, V159, P3648
   vanderBurg SH, 1995, HUM IMMUNOL, V44, P189, DOI 10.1016/0198-8859(95)00105-0
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484
NR 50
TC 77
Z9 78
U1 0
U2 2
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING, BERKS,
   ENGLAND RG7 1AE
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 1998
VL 79
BP 2191
EP 2201
PN 9
PG 11
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 114CY
UT WOS:000075592600014
PM 9747728
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, EK
   Adegbola, RA
AF Mulholland, EK
   Adegbola, RA
TI The Gambian Haemophilus influenzae type b vaccine trial: what does it
   tell us about the burden of Haemophilus influenzae type b disease?
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article; Proceedings Paper
CT 1st International Conference on Haemophilus Influenzae Type b Infection
   in Asia
CY DEC 17-19, 1996
CL BALI, INDONESIA
SP Assoc Med Prevent, Fdn Marcel Merieux, Childrens Vaccine Initiat
DE Haemophilus influenzae; Haemophilus influenzae type b; vaccine; The
   Gambia; pneumonia; meningitis; developing countries; disease burden
ID RESPIRATORY-TRACT INFECTIONS; LOBAR PNEUMONIA; CHILDREN; ETIOLOGY;
   MENINGITIS; INFANTS
AB The true burden of disease caused by Haemophilus influenzae type b (Hib) remains a mystery in many parts of the developing world. The most frequent manifestations of Hib disease are pneumonia and meningitis. In developing countries where it has been studied, Hib has proved to be a major cause of infant meningitis, generally occurring with greater frequency, in younger infants and with a worse outcome than in industrialized countries in the prevaccine era.
   The burden of Hib pneumonia is more difficult to define. Studies from developing countries of pneumonia etiology suggested that Hib was responsible for 5 to 10% of episodes of severe pneumonia. A Gambian study found Hib to be responsible for 7% of cases. However, a recently published trial of a Hib conjugate vaccine in Gambian infants showed that the vaccine prevented 21% of episodes of severe pneumonia in vaccine recipients, suggesting that this is the true contribution of Hib to the burden of severe pneumonia. The same trial demonstrated a mild herd effect, so this figure may be an underestimate. The biases that lead to the underestimation of the contribution of Hib to the pneumonia burden also apply to estimates of the proportion of severe pneumonia caused by Streptococcus pneumoniae. Vaccine trials may reveal the true burden of that pathogen also.
C1 WHO, Global Programme Vaccines & Immunizat, CH-1211 Geneva, Switzerland.
   MRC Labs, Banjul, Gambia.
RP Mulholland, EK (reprint author), Assoc Aide Med Prevent, 3 Ave Pasteur, F-92430 Marnes La Coquette, France.
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   Falade AG, 1997, ANN TROP PAEDIATR, V17, P315
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GREENGARD W, 1943, AM J DIS CHILD, V62, P730
   GREENWOOD B, 1992, J INFECT DIS, V165, pS26
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   SHANN F, 1984, LANCET, V2, P537
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
NR 14
TC 16
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD SEP
PY 1998
VL 17
IS 9
SU S
BP S123
EP S125
DI 10.1097/00006454-199809001-00006
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 126ZN
UT WOS:000076325400006
PM 9781744
OA No
DA 2017-08-15
ER

PT J
AU Kwara, A
   Adegbola, RA
   Corrah, PT
   Weber, M
   Achtman, M
   Morelli, G
   Caugant, DA
   Greenwood, BM
AF Kwara, A
   Adegbola, RA
   Corrah, PT
   Weber, M
   Achtman, M
   Morelli, G
   Caugant, DA
   Greenwood, BM
TI Meningitis caused by a serogroup W135 clone of the ET-37 complex of
   Neisseria meningitidis in West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Meningococcus; West Africa; vaccination
ID SUBGROUP-III; EPIDEMIC; DISEASE; CAPSULE; GAMBIA
AB Meningococci belonging to serogroup W135 caused several cases of meningococcal meningitis in The Gambia in 1995 and were isolated during a serogroup A epidemic in Mall in 1994. The eight isolates tested belonged to the same done of the ET-37 complex and differed in several bands from the pursed-field gel electrophoresis restriction pattern of serogroup C meningococci of the ET-37 complex isolated in Mall. Three of 6 patients infected in The Gambia died, indicating that this W135 clone is virulent. Vaccines that protect only against infections with meningococci belonging to serogroups A and C are usually used to control outbreaks in Africa, although vaccines containing the W135 polysaccharide are available. The findings of this study indicate that outbreaks of meningococcal meningitis in Africa can be associated with serogroup W135 infections and that serogrouping is essential before vaccination campaigns are started.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   MRC, Labs, Banjul, Gambia.
   Max Planck Inst Mol Genet, Berlin, Germany.
   Natl Inst Publ Hlth, WHO Collaborating Ctr Reference Meningococci, Oslo, Norway.
RP Greenwood, BM (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
OI Achtman, Mark/0000-0001-6815-0070
CR ACHTMAN M, 1992, J INFECT DIS, V165, P53
   ACHTMAN M, 1990, REV MED MICROBIOL, V1, P29
   Achtman M, 1995, MENINGOCOCCAL DIS, P159
   BYGRAVES JA, 1992, J GEN MICROBIOL, V138, P523
   CAUGANT DA, 1990, J INFECT DIS, V162, P867
   Claus H, 1997, MOL GEN GENET, V257, P28, DOI 10.1007/PL00008618
   CROWE BA, 1989, J INFECT DIS, V159, P686
   DENIS F, 1982, LANCET, V2, P1335
   EDWARDS U, 1994, MOL MICROBIOL, V14, P141, DOI 10.1111/j.1365-2958.1994.tb01274.x
   GREENWOOD BM, 1986, T ROY SOC TROP MED H, V80, P1006, DOI 10.1016/0035-9203(86)90303-2
   Guibourdenche M, 1996, EPIDEMIOL INFECT, V116, P115
   GUIBOURDENCHE M, 1996, 10 INT PATH NEISS C, P523
   Lapeyssonnie L., 1963, B WHO              S, V28, P3
   Morelli G, 1997, MOL MICROBIOL, V25, P1047, DOI 10.1046/j.1365-2958.1997.5211882.x
   OLYHOEK T, 1987, REV INFECT DIS, V9, P665
   Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271
   WANG JF, 1993, J INFECT DIS, V167, P1320
   WANG JF, 1992, INFECT IMMUN, V60, P5267
   WHITTLE HC, 1975, LANCET, V1, P1377
NR 19
TC 55
Z9 55
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 1998
VL 3
IS 9
BP 742
EP 746
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 122WF
UT WOS:000076093900009
PM 9754670
OA No
DA 2017-08-15
ER

PT J
AU Ishikawa, K
   Fransen, K
   Ariyoshi, K
   Nkengasong, LN
   Janssens, W
   Heyndrickx, L
   Whittle, H
   Diallo, MO
   Ghys, PD
   Coulibaly, IM
   Greenberg, AE
   Piedade, J
   Canas-Ferreia, W
   van der Groen, G
AF Ishikawa, K
   Fransen, K
   Ariyoshi, K
   Nkengasong, LN
   Janssens, W
   Heyndrickx, L
   Whittle, H
   Diallo, MO
   Ghys, PD
   Coulibaly, IM
   Greenberg, AE
   Piedade, J
   Canas-Ferreia, W
   van der Groen, G
TI Improved detection of HIV-2 proviral DNA in dually seroreactive
   individuals by PCR
SO AIDS
LA English
DT Article
DE dual seroreactivity; PCR; West Africa; HIV-2
ID POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS TYPE-2; FEMALE SEX
   WORKERS; COTE-DIVOIRE; GENETIC DIVERSITY; MIXED INFECTIONS; SOOTY
   MANGABEYS; WEST-AFRICA; ABIDJAN; AIDS
AB Objective: To improve the detection rate of HIV-2 proviral DNA in primary uncultured peripheral blood mononuclear cells (PBMC) of HIV-2-seroreactive and HIV-1-HIV-2 dually seroreactive individuals.
   Materials and methods: Two newly designed HIV-2 PCR primer pairs in the long terminal repeat (LTR) gag and gag-pol regions and a previously described env and LTR HIV-2 PCR primer pairs were tested on samples from 66 confirmed HIV-2-seropositive individuals (The Gambia, 40; Gate d'lvoire, 17; Guinea-Bissau, nine), 209 dually seroreactive individuals (The Gambia, 82; Cote d'lvoire, 127), 24 genetically characterized isolated HIV-1 strains (group M subtypes A-H and group O), one simian immunodeficiency virus (SIV) strain cpz, 10 HIV-2 isolates (subtype A, B and unidentified), two SIV(sm) isolates, and 10 seronegative samples.
   Results: All HIV-2 primers evaluated showed 100% specificity since there was no amplification observed with 24 HIV-1, one SIV(cpz) and 10 seronegative samples. One single copy of the HIV-2 genome could be detected with all outer primer pairs as well as all inner primer pairs on one PCR round used. Sensitivity of primers (at least one of the four primer pairs was positive) to HIV-2-seropositive samples was 100% (all nine) in Guinea-Bissau, 71% (12/17) in Cote d'lvoire, 100% (all 20) in Gambian AIDS patients, and 85% (17/20) in Gambian pregnant women. Doubling the PBMC of dually seroreactive individuals from 7.5 x 10(4) to 1.5 x 10(5) in the PCR revealed the presence of both HIV-1 and 2 proviral DNA in 72% (92/127) in Cote d'lvoire and 72% (59/82) in The Gambia. By doubling the number of PBMC, HIV-2 detection in dually seroreactive individuals by PCR was increased from 65 to 77% in Cote d'lvoire and from 67 to 83% in The Gambia.
   Conclusions: The use of 1.5 x 10(5) primary uncultured PBMC and the newly designed HIV-2 primer pairs allowed us to document the highest percentage (72%) ever reported of HIV-1-HIV-2 dual infections amongst HIV-1-HIV-2 dually seroreactive individuals in Cote d'lvoire and The Gambia. Improved detection of HIV-2 proviral DNA, rather than exposure to both viruses, infection with only one virus, or infection with a unique third virus containing epitopes common to both HIV-1 and HIV-2, contributes to a more accurate monitoring of the prevalence of HIV-1-HIV-2 dual infections. (C) 1998 Lippincott-Raven Publishers.
C1 Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   MRC, Fajara, Gambia.
   Project RETRO Cl, Abidjan, Cote Ivoire.
   Programme Natl Lutte Contre SIDA Malad Sexuelleme, Abidjan, Cote Ivoire.
   Ctr Dis Control & Prevent, Atlanta, GA USA.
   Inst Higiene & Med Trop, Lisbon, Portugal.
RP van der Groen, G (reprint author), Inst Trop Med, Dept Microbiol, Nationalestr 155, B-2000 Antwerp, Belgium.
RI Piedade, Joao/A-2132-2009
OI Piedade, Joao/0000-0001-6384-1737
CR Aaby P, 1997, AIDS, V11, P939
   Ariyoshi K, 1997, AIDS, V11, P1053
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Chen ZW, 1997, J VIROL, V71, P3953
   DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010
   DECOCK KM, 1994, JAMA-J AM MED ASSOC, V271, P196
   DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010
   EVANS LA, 1988, LANCET, V2, P1389
   FRANSEN K, 1995, MOL CELL PROBE, V9, P373
   GAO F, 1994, J VIROL, V68, P7433
   GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X
   GHYS PD, 1995, AIDS, V9, P955, DOI 10.1097/00002030-199508000-00019
   Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001
   GREZ M, 1994, J VIROL, V68, P2161
   HISHIDA O, 1994, AIDS, V8, P1257, DOI 10.1097/00002030-199409000-00006
   JANSSENS W, 1994, AIDS, V8, P21, DOI 10.1097/00002030-199401000-00004
   JANSSENS W, 1994, AIDS RES HUM RETROV, V10, P877
   LEE TH, 1991, AIDS, V5, P1201, DOI 10.1097/00002030-199110000-00008
   LEONARD G, 1993, AIDS, V7, P1185
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Matheron S, 1997, AIDS, V11, P934
   MYERS G, 1995, HUMAN RETROVIRUSES A
   NGBICHI JM, 1995, AIDS, V9, P951, DOI 10.1097/00002030-199508000-00018
   Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123
   Nyambi PN, 1997, AIDS RES HUM RETROV, V13, P7, DOI 10.1089/aid.1997.13.7
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y
   PEETERS M, 1994, J VIROL METHODS, V48, P23, DOI 10.1016/0166-0934(94)90085-X
   PEETERS M, 1994, AIDS RES HUM RETROV, V10, P1289, DOI 10.1089/aid.1994.10.1289
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P
   Sarr AD, 1998, AIDS, V12, P131, DOI 10.1097/00002030-199802000-00002
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   Soriano V, 1996, EUR J CLIN MICROBIOL, V15, P383, DOI 10.1007/BF01690094
   TRAVERS K, 1995, SCIENCE, V268, P1833
   Travers KU, 1998, AIDS, V12, P224
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
NR 42
TC 24
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD AUG 20
PY 1998
VL 12
IS 12
BP 1419
EP 1425
DI 10.1097/00002030-199812000-00003
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 112EH
UT WOS:000075480800003
PM 9727562
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Jaitner, J
   Clifford, DJ
   Pandey, VS
   Verhulst, A
AF Mattioli, RC
   Jaitner, J
   Clifford, DJ
   Pandey, VS
   Verhulst, A
TI Trypanosome infections and tick infestations: susceptibility in N'Dama,
   Gobra zebu and Gobra x N'Dama crossbred cattle exposed to natural
   challenge and maintained under high and low surveillance of trypanosome
   infections
SO ACTA TROPICA
LA English
DT Article
DE N'Dama; Gobra; crossbred; trypanosomosis; tick infestation;
   susceptibility
ID GLOSSINA-MORSITANS-SUBMORSITANS; DETECTION ENZYME IMMUNOASSAYS;
   RHIPICEPHALUS-APPENDICULATUS; AFRICAN TRYPANOSOMIASIS;
   AMBLYOMMA-VARIEGATUM; BORAN CATTLE; BRUCEI INFECTIONS; CONGOLENSE;
   TSETSE; IMMUNOSUPPRESSION
AB Susceptibility to trypanosome infections and tick infestations was assessed in 51 N'Dama, 48 Gobra zebu and 37 Gobra x N'Dama crossbred (F1) cattle exposed to held-tick infestations and natural high tsetse challenge over more than one year. From these cattle, 12 animals of each breed were randomly selected and examined parasitologically for trypanosome infections and packed cell volume (PCV) twice a week (high surveillance, group HS). In the remaining 100 cattle trypanosome infection and PCV were monitored monthly (low surveillance, group LS). Mortality rates were recorded in both groups. Tick infestation was quantified fortnightly from all animals in group HS and from four to seven randomly selected animals of each breed in group LS. In both HS and LS groups, trypanocidal drug treatment was administered to trypanosome positive animals with PCV equal to or less than 20% or when they showed clinical evidence (dullness, weight loss) of trypanosomosis. In both groups, N'Dama cattle exhibited a superior capacity to control trypanosome infections and limit tick burdens. Particularly, in group HS N'Dama cattle showed lower trypanosome infection rate, higher mean PCV value, lower requirement for trypanocide treatments and lower tick load than crossbred and Gobra cattle in the corresponding group (P < 0.05 or greater). This was also true in N'Damas in comparison with crossbreds in group LS. Unfortunately, the high mortality occurring in Gobra cattle in group LS did not allow within group comparative analysis between N'Dama, Gobra and crossbred cattle overall the study period. No death occurred in N'Dama cattle maintained under high surveillance of trypanosome infection, while approximately 8% of crossbreds and 50% of Gobras died of trypanosomosis. In group LS, all Gobra and more than 70% of crossbred cattle died. In this group, mortality in N'Dama was limited to less than 16%. In both groups, differences in mortality were significantly higher (P < 0.01) in Gobras than in N'Damas. Within breed, animals of the three breeds maintained under high surveillance of trypanosomal infection showed higher mean PCV values, lower tick burdens and required proportionally less trypanocide treatments than corresponding cattle in group LS. The infection rate in N'Dama under high surveillance was lower in comparison with N'Dama cattle in group LS. There was no significant difference in mortality between groups within the N'Dama breed. Conversely, mortality rates were lower in crossbred and Gobra in group PIS than in respective cattle in group LS. It was concluded that cattle of the three breeds suffered from trypanosomosis and that trypanosome infections affected tick susceptibility. However, N'Dama showed a superior ability to limit both the pathological effects of trypanosomosis and the level of tick infestations. Therefore, considering the cost of labour and consumable equipment required for a high surveillance, use of multi-disease resistant N'Dama cattle is recommended for the low-input traditional African fanning systems in areas where trypanosomosis, ticks and tick-borne diseases are constraints to livestock production. Additional comparative investigations are needed to assess the impact of high surveillance scheme of trypanosome infection in different production systems in trypanotolerant and trypanosusceptible cattle exposed to different gradients of tsetse challenge. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM Raffael_Mattioli@gam.healthnet.org
CR BENNETT GF, 1969, EXP PARASITOL, V26, P323, DOI 10.1016/0014-4894(69)90125-8
   Brown S J, 1985, Parasitol Today, V1, P166, DOI 10.1016/0169-4758(85)90175-9
   DARJI A, 1992, ANN SOC BELG MED TR, V72, P27
   DEHOUX J P, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P337
   Dossa SC, 1996, VET PARASITOL, V62, P317, DOI 10.1016/0304-4017(95)00875-6
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   EMERY DL, 1980, EXP PARASITOL, V50, P358, DOI 10.1016/0014-4894(80)90039-9
   FIVAZ BH, 1992, TROP ANIM HEALTH PRO, V24, P81, DOI 10.1007/BF02356949
   FIVAZ BH, 1989, TROP ANIM HEALTH PRO, V21, P129, DOI 10.1007/BF02236193
   FLYNN JN, 1991, IMMUNOLOGY, V74, P310
   FLYNN JN, 1992, IMMUNOLOGY, V75, P639
   FOX RGR, 1993, TROP ANIM HEALTH PRO, V25, P203, DOI 10.1007/BF02250869
   FRANCIS J., 1964, AUSTRALIAN VETERINARY J, V40, P247, DOI 10.1111/j.1751-0813.1964.tb08746.x
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P411
   HELLERHAUPT A, 1983, ANN TROP MED PARASIT, V77, P219
   Itty P, 1996, AGR ECON, V14, P33, DOI 10.1016/0169-5150(95)01170-6
   JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   KONEY EBM, 1994, VET PARASITOL, V55, P245, DOI 10.1016/0304-4017(94)00648-V
   LLOYD CM, 1993, EXP APPL ACAROL, V17, P587, DOI 10.1007/BF00053488
   MASAKE RA, 1981, CLIN EXP IMMUNOL, V43, P583
   MASAKE RA, 1983, PARASITE IMMUNOL, V5, P345, DOI 10.1111/j.1365-3024.1983.tb00750.x
   Mattioli R. C., 1994, Parassitologia (Rome), V36, P305
   Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1988, ACTA TROP, V45, P389
   MURRAY PK, 1974, IMMUNOLOGY, V27, P825
   NANTULYA VM, 1989, TROP MED PARASITOL, V40, P267
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   RAWLINGS P, 1994, MED VET ENTOMOL, V8, P57, DOI 10.1111/j.1365-2915.1994.tb00386.x
   ROELANTS GE, 1979, CLIN EXP IMMUNOL, V37, P457
   SHAPIRO SZ, 1982, INFECT IMMUN, V35, P410
   TRAIL JCM, 1992, VET PARASITOL, V42, P213, DOI 10.1016/0304-4017(92)90063-F
   WACHER TJ, 1994, PARASITOLOGY, V109, P149
   WALKER AR, 1990, MED VET ENTOMOL, V4, P321, DOI 10.1111/j.1365-2915.1990.tb00447.x
   WHITELAW DD, 1979, RES VET SCI, V26, P102
   WILSON A J, 1971, Tropical Animal Health and Production, V3, P14, DOI 10.1007/BF02356679
NR 41
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD AUG 15
PY 1998
VL 71
IS 1
BP 57
EP 71
DI 10.1016/S0001-706X(98)00051-5
PG 15
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 124QH
UT WOS:000076192900005
PM 9776143
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Usen, S
   Adegbola, R
   Weber, M
AF Mulholland, K
   Usen, S
   Adegbola, R
   Weber, M
TI Use of pneumococcal polysaccharide vaccine in children
SO LANCET
LA English
DT Letter
C1 WHO, Global Programme Vaccines & Immunizat, CH-1211 Geneva, Switzerland.
   WHO, Div Child Hlth & Dev, CH-1211 Geneva, Switzerland.
   Med Res Council Labs, Banjul, Gambia.
RP Mulholland, K (reprint author), WHO, Global Programme Vaccines & Immunizat, CH-1211 Geneva, Switzerland.
CR Booy R, 1998, LANCET, V351, P1446, DOI 10.1016/S0140-6736(98)22020-4
   RILEY ID, 1986, LANCET, V2, P877
   Shann F, 1998, LANCET, V351, P1600, DOI 10.1016/S0140-6736(05)77683-2
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 15
PY 1998
VL 352
IS 9127
BP 575
EP 576
DI 10.1016/S0140-6736(05)79286-2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 111KC
UT WOS:000075435300056
PM 9716087
OA No
DA 2017-08-15
ER

PT J
AU Obaro, S
   Leach, A
   McAdam, KWJP
AF Obaro, S
   Leach, A
   McAdam, KWJP
TI Use of pneumococcal polysaccharide vaccine in children
SO LANCET
LA English
DT Letter
C1 Med Res Council Labs, Banjul, Gambia.
   John Radcliffe Hosp, Oxford OX3 9DU, England.
RP Obaro, S (reprint author), Med Res Council Labs, POB 273, Banjul, Gambia.
CR Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Rennels MB, 1998, PEDIATRICS, V101, P604, DOI 10.1542/peds.101.4.604
   SHANN F, 1998, LANCET, V351, P1601
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
NR 5
TC 2
Z9 2
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 15
PY 1998
VL 352
IS 9127
BP 575
EP 575
DI 10.1016/S0140-6736(05)79285-0
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 111KC
UT WOS:000075435300055
PM 9716086
OA No
DA 2017-08-15
ER

PT J
AU Dolin, PJ
   Faal, H
   Johnson, GJ
   Ajewole, J
   Mohamed, AA
   Lee, PS
AF Dolin, PJ
   Faal, H
   Johnson, GJ
   Ajewole, J
   Mohamed, AA
   Lee, PS
TI Trachoma in the Gambia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Background-As part of the second National Survey of Blindness and Low Vision in the Gambia carried out in 1996, all survey participants were examined for signs of trachoma. The findings were compared with the results of the first survey in 1986, which used the same sampling strategy.
   Methods-A multistage stratified cluster random sample, with proportional probability sampling, was obtained. Stratification included settlement size (less than 400 residents, and 400 and more residents). All subjects were examined far trachoma using the simplified WHO grading system,
   Results-Of the sample of 14 110 people, 13 047 (92.5%) were examined. Active inflammatory trachoma (grade TF or TT) was found in 3.0% of all age groups and 5.9% of children aged 0-9 years old. Trichiasis was found in 3.3% and trachomatous corneal opacities in 0.9% of adults aged 30 and over. The prevalence of blinding trachomatous corneal opacities was 0.02%, compared with 0.10% 10 years previously.
   Conclusion-Compared with a previous national survey undertaken in 1986, prevalence of active trachoma has fallen by 54%. There has been an 80% relative reduction in blinding trachomatous corneal opacities over the 10 year period.
C1 Inst Ophthalmol, Int Ctr Eye Hlth, London EC1V 9EL, England.
   Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
RP Dolin, PJ (reprint author), WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland.
CR BAILEY RL, 1994, J INFECT DIS, V170, P709
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   FAAL H, IN PRESS BR J OPHTHA
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
NR 5
TC 53
Z9 53
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 1998
VL 82
IS 8
BP 930
EP 933
DI 10.1136/bjo.82.8.930
PG 4
WC Ophthalmology
SC Ophthalmology
GA 110CY
UT WOS:000075363600022
PM 9828780
OA No
DA 2017-08-15
ER

PT J
AU Whittle, HC
   Ariyoshi, K
   Rowland-Jones, S
AF Whittle, HC
   Ariyoshi, K
   Rowland-Jones, S
TI HIV-2 and T cell recognition
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Review
ID IMMUNODEFICIENCY-VIRUS TYPE-2; HIV-2-INFECTED PATIENTS; WEST-AFRICA;
   NATURAL PROTECTION; CROSS-PROTECTION; GUINEA-BISSAU; INFECTION;
   MACAQUES; MORTALITY; VACCINE
AB HIV-2 is less pathogenic and less transmissible than HIV-1. Recent research in relation to deletions in the HIV nef gene and to immune cross-reactions between infections by HIV-2, HIV-1 and simian immunodeficiency virus suggests that T cell recognition and the control of viral replication may be more efficient in HIV-2 infection than in HIV-1 infection. These insights may be crucial to the design of effective vaccines.
C1 MRC Labs, Banjul, Gambia.
   Natl Inst Infect Dis, Ctr AIDS Res, Grp 2, Tokyo 2080011, Japan.
   John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DU, England.
RP Whittle, HC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM whittle@commit.gm; ariyoshi@nih.go.jp; sarah.rowland-jones@ndm.ox.ac.uk
CR Aaby P, 1997, AIDS, V11, P939
   ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   Albert J, 1996, AIDS RES HUM RETROV, V12, P821, DOI 10.1089/aid.1996.12.821
   ALBERT J, 1990, AIDS, V4, P291, DOI 10.1097/00002030-199004000-00002
   Ariyoshi K, 1997, AIDS, V11, P1053
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   Bertoletti A, 1998, J VIROL, V72, P2439
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Bron R, 1997, J VIROL, V71, P8405
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Dittmer U, 1996, J GEN VIROL, V77, P2433, DOI 10.1099/0022-1317-77-10-2433
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Goudsmit J., 1997, VIRAL SEX NATURE AID
   Greenberg AE, 1996, SCIENCE, V272, P1959
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   HANNIBAL MC, 1993, J VIROL, V67, P5035
   HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   JALECO AC, 1994, CLIN EXP IMMUNOL, V98, P185
   JOHNSON RP, 1993, J VIROL, V67, P438
   JOHNSON RP, 1992, J EXP MED, V175, P941
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295
   Locher CP, 1997, J INFECT DIS, V176, P948
   MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P998
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   MARLINK R, 1994, SCIENCE, V265, P1578
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   MCKNIGHT A, 1998, IN PRESS J VIROL
   MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3
   NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   PINTO LA, 1995, J MED VIROL, V47, P139, DOI 10.1002/jmv.1890470206
   PINTO LA, 1993, AIDS, V7, P1389, DOI 10.1097/00002030-199310000-00016
   POULSEN AG, 1989, LANCET, V1, P827
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   Putkonen P, 1997, J VIROL, V71, P4981
   PUTKONEN P, 1995, NAT MED, V1, P914, DOI 10.1038/nm0995-914
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   ROBERTGUROFF M, 1992, J VIROL, V66, P3602
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWLANDJONES SL, 1998, IN PRESS AIDS
   ROWLANDJONESSL, 1995, NAT MED, V1, P59
   SANKALE JL, 1995, AIDS RES HUM RETROV, V11, P617, DOI 10.1089/aid.1995.11.617
   SCHULZ TF, 1990, J VIROL, V64, P5177
   SHARP P, 1994, AIDS, V8, P327
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   Switzer WM, 1998, J INFECT DIS, V177, P65, DOI 10.1086/513819
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   vanderEnde ME, 1996, AIDS, V10, P1649
   VONGEGERFELT A, 1994, VACCINE, V12, P1203, DOI 10.1016/0264-410X(94)90244-5
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
   Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7
NR 65
TC 27
Z9 27
U1 0
U2 2
PU CURRENT BIOLOGY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON W1P 6LB, ENGLAND
SN 0952-7915
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD AUG
PY 1998
VL 10
IS 4
BP 382
EP 387
DI 10.1016/S0952-7915(98)80108-8
PG 6
WC Immunology
SC Immunology
GA 110XH
UT WOS:000075406500002
PM 9722912
OA No
DA 2017-08-15
ER

PT J
AU Man, WDC
   Weber, M
   Palmer, A
   Schneider, G
   Wadda, R
   Jaffar, S
   Mulholland, EK
   Greenwood, BM
AF Man, WDC
   Weber, M
   Palmer, A
   Schneider, G
   Wadda, R
   Jaffar, S
   Mulholland, EK
   Greenwood, BM
TI Nutritional status of children admitted to hospital with different
   diseases and its relationship to outcome in The Gambia, West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE nutritional status; anthropometric; weight for age; mortality; malaria;
   bronchiolitis; pneumonia; meningitis; gastro-enteritis; malnutrition;
   outcome; The Gambia; developing countries
ID PROTEIN-ENERGY MALNUTRITION; RESPIRATORY-INFECTIONS; CEREBRAL MALARIA;
   RISK; MORBIDITY; MORTALITY; GROWTH; DETERMINANTS; INDICATORS; PNEUMONIA
AB Admission records from two paediatric units in The Gambia were used to explore the relationship between admission weight and different diseases. In total 13579 hospitalized children were analysed. For comparison, 7399 children were recruited from several surveys of well subjects to provide anthropometric values for healthy Gambian children. Compared to the control children, mean admission weights were lower for malaria (weight for age z-score: -1.602), cerebral malaria (-1.547), transfused malarial anaemia (-1.764), pneumonia (-1.735), meningitis (-1.362), gastro-enteritis (-2.497) and malnutrition (-3.786). Children with bronchiolitis did not have a significantly different weight for age than the controls. Outcome of the hospital admission was recorded and related to the weight on admission. In all disease categories the death rare rose with decreasing admission weight with the exception of bronchiolitis. For all diseases taken together, case fatality was 7.2% for children with 3 weight for age z-score above -2 Standard Deviations (SD), 9.3% between -2 and -3 SD, 15.6% between -3 and -4 SD and 22.7% for children with weight for age SD z-scores less than -4. Malnourished children are more susceptible to several infectious diseases frequently seen in developing countries and nutritional interventions, as well as standard treatment, may improve outcome.
C1 Med Res Council Labs, Fajara, Gambia.
   Imperial Coll Sci Technol & Med, Sch Med, London, England.
   Childrens Hosp, Hannover Med Sch, Hannover, Germany.
   Royal Victoria Hosp, Banjul, Gambia.
   WEC Miss Hosp, Sibanor, Gambia.
   London Sch Trop Med & Hyg, London, England.
RP Weber, M (reprint author), WHO, CHD, CH-1211 Geneva 27, Switzerland.
EM weberm@who.ch
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ADRELE WI, 1981, NIGERIAN J PAEDIAT, V8, P24
   Agrawal P B, 1995, J Indian Med Assoc, V93, P271
   AHMED SH, 1985, INDIAN J PAEDIAT, V52, P285
   ALAM N, 1989, AM J CLIN NUTR, V49, P994
   BLACK RE, 1984, AM J CLIN NUTR, V39, P87
   DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703
   EDINGTON GM, 1967, BRIT MED J, V1, P715
   EDIRISINGHE JS, 1986, ANN TROP PAEDIATR, V6, P233
   ELSAMANI FZ, 1987, J TROP MED HYG, V90, P69
   ESCOBAR JA, 1976, PEDIATRICS, V57, P123
   GOYAL SC, 1991, J TROP PEDIATRICS, V37, P143
   GREENWOOD BM, 1987, J INFECTION, V14, P167, DOI 10.1016/S0163-4453(87)92052-4
   HANLON P, 1987, LANCET, V1, P1342
   HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1
   JAMES JW, 1972, AM J CLIN NUTR, V25, P690
   KIELMANN AA, 1978, LANCET, V1, P1247
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P151, DOI 10.1016/0035-9203(95)90472-7
   KORAM KA, 1995, THESIS U LONDON
   MARSDEN P. D., 1964, TRANS ROY SOC TROP MED HYG, V58, P455, DOI 10.1016/0035-9203(64)90101-4
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   MULLA MI, 1984, J TROP PEDIATRICS, V30, P303
   ROSEN EU, 1980, S AFR MED J, V58, P1004
   ROTIMIJOHNSON AWB, 1993, J TROP PEDIATRICS, V39, P315
   ROWLAND M G M, 1978, Lancet, V1, P136
   ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   Gordon J. E, 1968, WHO MONOGR SER, V57, P3
   SMEDMAN L, 1987, AM J CLIN NUTR, V46, P369
   SNOW RW, 1991, T ROY SOC TROP MED H, V85, P585
   TOMKINS AM, 1986, BRIT J NUTR, V56, P533, DOI 10.1079/BJN19860134
   TOMKINS AM, 1989, T ROY SOC TROP MED H, V83, P282, DOI 10.1016/0035-9203(89)90681-0
   TROWBRIDGE FL, 1981, LANCET, V1, P1375
   Tshikuka JG, 1997, TROP MED INT HEALTH, V2, P374
   TUPASI TE, 1988, J INFECT DIS, V157, P615
   VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q
   VICTORA CG, 1990, AM J CLIN NUTR, V52, P391
   WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489
   World Bank, 1993, WORLD DEV REP 1993 I
NR 39
TC 50
Z9 52
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 1998
VL 3
IS 8
BP 678
EP 686
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 115YF
UT WOS:000075693400010
PM 9735938
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Jeffcoate, I
   Holmes, P
AF Osaer, S
   Goossens, B
   Jeffcoate, I
   Holmes, P
TI Effects of Trypanosoma congolense and nutritional supplements in
   Djallonke ewes on live weight during pregnancy, post partum weight,
   haematology parameters and lamb performance
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
ID SCOTTISH BLACKFACE SHEEP; AFRICAN TRYPANOSOMIASIS; LIVEWEIGHT CHANGES;
   INFECTION; PATHOPHYSIOLOGY; CATTLE; SUSCEPTIBILITY; DIAGNOSIS; NDAMA
AB The effects of Trypanosoma congolense infection and nutritional supplements on live weight changes during pregnancy, haematology traits and offspring performance were studied in 42 Djallonke ewes. A randomised block design was used to allocate ewes to four treatment combinations, of which two were on a restricted diet (L) and the remainder on an unrestricted diet (H). Half of each nutritional group were infected with T congolense (LI, HI), the remainder serving as controls (LC, HC). The degree of anaemia following infection was similar in both infection groups (P<0.001), but the erythropoietic activity, as judged by the increase in mean corpuscular volume, was significantly greater in the HI group (P<0.01). Live weight gains during pregnancy attributable to higher supplements were significantly depressed by infection (P<0.01). Post partum weight was lower in the LI group as compared with the Le control. Diet interacted significantly (P<0.01) with infection and resulted in the lowest lamb growth rates in the LI group. It was concluded that dietary supplementation of trypanosome-infected Djallonke ewes during pregnancy and lactation improves productivity in terms of ewe live weight and improved lamb growth rates to weaning.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Glasgow, Sch Vet, Glasgow G61 1QH, Lanark, Scotland.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR ABDULLAHI R, 1986, B ANIM HLTH PROD AFR, V34, P119
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   Anosa V O, 1988, Rev Elev Med Vet Pays Trop, V41, P65
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   GOOSSENS B, 1997, IN PRESS RES VET SCI
   HECKER PA, 1991, 21 M ISCTRC YAM COT
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   LITTLE D, 1990, P NUTR SOC 144 M SCO
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, ANIM REPROD SCI, V51, P97, DOI 10.1016/S0378-4320(98)00067-0
   PARIS J, 1982, ACTA TROP, V39, P307
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   *SAS I INC, 1989, STAT AN SYST I
   Snedecor G.W., 1980, STAT METHODS, P507
   Wassink GJ, 1997, ANIM SCI, V64, P127
   1993, 11 ILRAD, P1
NR 24
TC 8
Z9 8
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0034-5288
J9 RES VET SCI
JI Res. Vet. Sci.
PD JUL-AUG
PY 1998
VL 65
IS 1
BP 65
EP 69
DI 10.1016/S0034-5288(98)90029-7
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA 123DB
UT WOS:000076109600012
PM 9769075
OA No
DA 2017-08-15
ER

PT J
AU Quinones, ML
   Lines, J
   Thomson, MC
   Jawara, M
   Greenwood, BM
AF Quinones, ML
   Lines, J
   Thomson, MC
   Jawara, M
   Greenwood, BM
TI Permethrin-treated bed nets do not have a 'mass-killing effect' on
   village populations of Anopheles gambiae s.l. in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; Anopheles gambiae; vector control;
   permethrin; bed nets; children; The Gambia
ID IMPREGNATED BEDNETS; ENTOMOLOGICAL EVALUATION; MALARIA; CHILDREN; TRIAL;
   MOSQUITOS; CULICIDAE; COMPLEX; PROGRAM; DIPTERA
AB In The Gambia, the use of permethrin-treated bed nets has led to a reduction in morbidity and mortality from malaria in children. However, no clear evidence has been found for a 'mass-killing effect' on the mosquito vectors as a result of this intervention. Two further entomological studies to investigate this phenomenon have been carried out. In one study, 20 villages were paired so that bed nets in one member of each pair were treated with permethrin. In the other, a cross-over design was used in which treated and untreated bed nets were exchanged between 2 villages. Longevity, biting rate and resting density of the malaria vector population and sporozoite rates were assessed in both studies. Malaria vectors were equally abundant and long-lived, and as likely to be infective, in villages with treated bed nets as in those with untreated nets. However, a clear reduction in the density of the indoor-resting population of mosquitoes in rooms with treated bed nets was found, probably reflecting the excite-repellency of the insecticide. This study confirmed that, in The Gambia, the protection against death and morbidity from malaria seen in children using treated bed nets must be due primarily to personal protection rather than to a 'mass-killing effect' on the mosquito vector population at a village level.
C1 Medical Research Council Labs, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
RP Quinones, ML (reprint author), Univ Antioquia, PECET, Calle 62 No 52-19, Medellin, Colombia.
CR AIKINS MK, 1993, T ROYAL SOC TROPI S2, V87
   BRYAN JH, 1980, MOSQ SYST, V12, P153
   CHARLWOOD JD, 1987, MED VET ENTOMOL, V1, P319, DOI 10.1111/j.1365-2915.1987.tb00361.x
   COLUZZI M, 1985, B ZOOL, V52, P45
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   COLUZZI M, 1964, Riv Malariol, V43, P197
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   JANAKARA BR, 1995, J TROP MED HYG, V98, P73
   KARCH S, 1993, ANN SOC BELG MED TR, V73, P37
   Kere N. K., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P130
   Lindsay J. F., 1989, BASIN RES, V2, P3, DOI 10.1111/j.1365-2117.1989.tb00023.x
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   LINDSAY SW, 1993, T ROYAL SOC TROPICAL, V87
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x
   NJUNWA KJ, 1993, THESIS U LONDON
   Quinones ML, 1997, MED VET ENTOMOL, V11, P71, DOI 10.1111/j.1365-2915.1997.tb00292.x
   ROBERT V, 1991, B WORLD HEALTH ORGAN, V69, P735
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1987, B ENTOMOL RES, V77, P279
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   SOMBOON P, 1995, T ROY SOC TROP MED H, V89, P248, DOI 10.1016/0035-9203(95)90525-1
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
   THOMSON MC, 1995, MED VET ENTOMOL, V9, P413, DOI 10.1111/j.1365-2915.1995.tb00015.x
   WIRTZ RA, 1987, J MED ENTOMOL, V24, P433
NR 25
TC 39
Z9 40
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 1998
VL 92
IS 4
BP 373
EP 378
DI 10.1016/S0035-9203(98)91053-7
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 112BE
UT WOS:000075473400003
PM 9850383
OA No
DA 2017-08-15
ER

PT J
AU Erskine, JA
AF Erskine, JA
TI Talipes
SO TROPICAL DOCTOR
LA English
DT Letter
C1 Sibanor Hlth Ctr, Banjul, Gambia.
RP Erskine, JA (reprint author), Sibanor Hlth Ctr, Box 86, Banjul, Gambia.
CR HARDINGE L, 1986, PHYSIOTHERAPY, V72, P420
   Scott R, 1997, TROP DOCT, V27, P22
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD JUL
PY 1998
VL 28
IS 3
BP 186
EP 186
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 110NH
UT WOS:000075386900030
OA No
DA 2017-08-15
ER

PT J
AU Akinbamijo, OO
   Bennison, JJ
   Jaitner, J
   Dempfle, L
AF Akinbamijo, OO
   Bennison, JJ
   Jaitner, J
   Dempfle, L
TI Haematological changes in N'Dama and Gobra Zebu bulls during Trypanosoma
   congolense infection maintained under a controlled feeding regimen
SO ACTA TROPICA
LA English
DT Article
DE pair-feeding; trypanosomosis; trypanotolerance; N'Dama; Zebu; anaemia
ID ANEMIA; CATTLE; GOATS
AB Haematological changes were monitored in Gobra-Zebu and N'Dama bulls following infection with Trypanosoma congolense. The cattle were offered a diet which provided levels of protein and energy above maintenance requirement and a pair feeding regimen was used in order to eliminate the confounding anorexic effects of trypanosomosis on the traits studied. Packed red cell volume (PCV), red blood cells (RBC) and haemoglobin (Hb) were monitored weekly. Mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), and mean corpuscular volume (MCV) were derived by computation. Significant breed differences (P < 0.001) were observed in the baseline data collected with N'Dama bulls having higher (P < 0.001) values for RBC and Hb. PCV levels were similar in both breeds pre-infection. Post-infection, there was a significant (P < 0.001) infection effect on the RBC, Hb and PCV in both breeds. The pathogenic effects were more seven in the Gobra-Zebu bulls where three out of ten bulls compared with only one out of eight infected N'Dama bulls attained the low PCV threshold, treated and withdrawn from the study along with their pair mates. Throughout the infection in N'Dama cattle and during the first 6 weeks of infection in the Gobra-Zebu bulls, the infection presented a normochromic normocytic anaemia. However, in the chronic phase, the Gobra-Zebu bulls became macrocytic. The infection reduced total dry matter intake in both breeds although this persisted longer in the Gobra-Zebus. However, their pair-fed controls showed no haematological changes indicating that the anorexia was not compounding the effects of the infection. The severity and type anaemia in N'Dama correlates with their innate ability to resist the effects of trypanosome infection compared to the Gobra-Zebu bulls. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Nat Resources Inst, Chatham ME4 4TB, Kent, England.
RP Akinbamijo, OO (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   AKINBAMIJO OO, 1997, IN PRESS ANIM SCI
   ANOSA V O, 1976, Tropical Animal Health and Production, V8, P14, DOI 10.1007/BF02383360
   Anosa V O, 1988, Rev Elev Med Vet Pays Trop, V41, P65
   Holmes P. H., 1976, Pathophysiology of parasitic infection (Proc. 7th Internat. Conf. World Ass. Adv. Vet. Parasit., Thessaloniki, Greece 14-16 July, 1975)., P199
   *ILCA, 1986, AFR TRYP LIV NETW IN
   Jenkins G. C., 1985, Immunology and pathogenesis of trypanosomiasis, P13
   LEPERRE P, 1994, TROP ANIM HEALTH PRO, V26, P139, DOI 10.1007/BF02241070
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   MURRAY M, 1988, ACTA TROP, V45, P389
   MURRAY M, 1983, LIVESTOCK PRODUCTION, P5
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   ROBERTS C J, 1973, Tropical Animal Health and Production, V5, P220, DOI 10.1007/BF02240423
   ROMNEY DL, 1996, IN PRESS J AGR SCI C
   SAROR DI, 1979, VET REC, V105, P96
   SAS, 1990, SAS STAT US GUID VER, V2, P27513
   SILAYO RS, 1992, RES VET SCI, V53, P98, DOI 10.1016/0034-5288(92)90092-G
   Stephen L, 1986, TRYPANOSOMIASIS VET
NR 19
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD JUN
PY 1998
VL 69
IS 3
BP 181
EP 192
DI 10.1016/S0001-706X(97)00123-X
PG 12
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA ZQ361
UT WOS:000073853500001
PM 9638271
OA No
DA 2017-08-15
ER

PT J
AU Bennison, JJ
   Clemence, RG
   Archibald, RF
   Hendy, CRC
   Dempfle, L
AF Bennison, JJ
   Clemence, RG
   Archibald, RF
   Hendy, CRC
   Dempfle, L
TI The effects of work and two planes of nutrition on trypanotolerant
   draught cattle infected with Trypanosoma congolense
SO ANIMAL SCIENCE
LA English
DT Article
DE cattle; nutrition; trypanosomiasis; work
ID AFRICAN DWARF GOATS; VIVAX INFECTION; ZEBU CATTLE; NDAMA; SUSCEPTIBILITY
AB Thirty-two N'Dama bulls aged 3 to 4 years were used to study the interactions between work, trypanosomosis and nutrition. The bulls were randomly allocated to two treatments, working (W) and non-working (N). Half in each treatment were placed on an andropogon hay basal diet (B), the other half on a better quality groundnut hay diet (H). Five days a week, four pairs of animals in the BW group and and four pairs in the HW group pulled weighted sledges four times around a 2056-m track. Loads were set to ensure energy expenditure was equivalent to 1.4 times maintenance. After 4 weeks all 32 bulls were injected intradermally with 10(4) Trypanosoma congolense organisms. The trial continued for a further 8 weeks.
   Trypanosome infection caused a significant (P < 0.001) decline in packed cell volume (PCV), and the anaemia sons move severe (P < 0.05) in working animals; three pairs in the HW group and two pairs in the BW group were withdrawn because PCV fell below 17%. Diet had no effect on PCV or parasitaemia. Infection caused a decline in food intake (P < 0.001) but with significant interactions between diet and work. Intake patterns were similar in the BN and BW groups whilst the HW animals consumed significantly more groundnut hay compared with the HN group (P < 0.01). However, nutrition had no significant effect on lap times or the team's ability to work under trypanosomosis challenge. Post-infection, diet was the dominant factor determining weight change, HN and HW animals weighed significantly more than BN and BW animals (P < 0.01) and the interaction between period, diet and work demonstrated that BW had the lowest weights in the latter stages of the trial (P < 0 05).
   The results suggest that supplementation with better quality forages confers no benefit to an animal infected with trypanosomes. Nor can trypanotolerant cattle sustain long periods of work subjected to a primary challenge of trypanosomes.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP Bennison, JJ (reprint author), Nat Resources Inst, Cent Ave,Chatham Maritime, Chatham ME4 4TB, Kent, England.
CR *AGR RES COUNC, 1980, NUTR REQ RUM LIV
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Akinbamijo OO, 1997, ANIM SCI, V65, P151
   ALFORD RJ, 1994, THESIS U EDINBURGH
   AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   LAWRENCE PR, 1985, J AGR SCI, V105, P703
   LAWRENCE PR, 1985, DRAUGHT ANIMAL POWER, P59
   MATTHEWMAN RW, 1993, J AGR SCI, V121, P297
   MCCARTHY DO, 1985, AM J CLIN NUTR, V42, P1179
   MIERT ASJ, 1986, VET Q, V8, P266
   MUNZINGER P, 1982, 120 GATE GTZ
   MURRAY C, 1977, OAU STRC PUBLICATION, V110, P247
   MURRAY M, 1981, VET REC, V109, P503
   Murray M, 1983, LIVESTOCK PRODUCTIVI
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PAYNE RC, 1991, VET PARASITOL, V40, P197, DOI 10.1016/0304-4017(91)90100-A
   RAVINDRAN S, 1990, RES DEV ANIMAL TRACT
   ROBERTS C J, 1973, Tropical Animal Health and Production, V5, P220, DOI 10.1007/BF02240423
   Romney DL, 1997, J AGR SCI, V129, P83, DOI 10.1017/S0021859697004449
   STARKEY PR, 1981, FARMING WORK OXEN SI
   *STAT AN SYST I, 1994, SAS STAT GUID PERS C
   Sumberg J., 1992, African Livestock Research, V1, P1
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   ZWART D, 1991, J ANIM SCI, V69, P3780
NR 25
TC 3
Z9 3
U1 0
U2 0
PU BRITISH SOC ANIMAL SCIENCE
PI PENICUIK
PA PUBLICATIONS DEPT, PO BOX 3, PENICUIK EH26 ORZ, MIDLOTHIAN, SCOTLAND
SN 1357-7298
J9 ANIM SCI
JI Anim. Sci.
PD JUN
PY 1998
VL 66
BP 595
EP 605
PN 3
PG 11
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 103ZV
UT WOS:000074988500007
OA No
DA 2017-08-15
ER

PT J
AU Bennison, JJ
   Sherington, J
   Wacher, TJ
   Dempfle, L
   Leaver, JD
AF Bennison, JJ
   Sherington, J
   Wacher, TJ
   Dempfle, L
   Leaver, JD
TI Effects of Trypanosoma congolense infection and groundnut (Arachis
   hypogaea) hay supplementation on ranging, activity, and diet selection
   of N'Dama cows
SO APPLIED ANIMAL BEHAVIOUR SCIENCE
LA English
DT Article
DE cattle feeding and nutrition; food preference
ID AFRICAN DWARF GOATS; NITROGEN-METABOLISM; ENERGY-EXPENDITURE; VIVAX
   INFECTION; WHEATGRASS; PASTURE
AB The objective was to study effects of groundnut hay (GNH) supplementation and trypanosomosis infection on diet selection and grazing behaviour of N'Dama cattle in the late dry season in The Gambia. Twenty multiparous lactating cows were allocated to two groups: infected and control. The 10 cows in the infected group were intradermally injected with a Trypanosoma congolense clone known as ITC 84. Supplementary feeding with GNH commenced 14 days after infection and continued for 10 weeks. The start of supplementation coincided with peak parasitaemia, when the infected and control groups were each divided in two sub-groups of five. Animals received either 0 or 2 kg per day of fresh GNH. Each of the 10 infected cows (five supplemented and five non-supplemented) were paired with a comparable control for the duration of the trial and followed at least three times (range 3-5). Every 5 min, throughout the 9-10 h grazing day, a record was made of four activities and, if the animal was feeding, the food item identified. The distance travelled was also measured. The cattle spent 78% of their time feeding on grasses, of which Hyparrhenia rufa and Andropogon gayanus were the dominant species. Neither infection nor GNH supplementation had any effect on the diet selected. Based on the mean distance travelled, the energetic cost of walking was estimated to be 10% of the metabolizable energy (ME) required for maintenance. Trypanosomosis infection had no significant effect on grazing behaviour. However, cows supplemented with GNH spent a greater proportion of the day resting (P < 0.01); this was particularly evident in the final two grazing periods of the day. There was also a signifrcant interaction (P < 0.05) between GNH supplementation and infection in the early afternoon when the infected group supplemented with GNH spent a greater proportion of time resting and less time feeding. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Nat Resources Inst, Chatham ME4 4TB, Kent, England.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ London Wye Coll, Ashford TN25 5AH, Kent, England.
RP Bennison, JJ (reprint author), Nat Resources Inst, Cent Ave, Chatham ME4 4TB, Kent, England.
CR AFRC, 1993, EN PROT REQ RUM ADV
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   BARTON RK, 1992, J ANIM SCI, V70, P547
   BENNISON JJ, 1997, THESIS U LONDON
   BLAXTER K. L., 1963, ANIMAL PROD, V5, P27
   DERIBEIRO JM, 1977, ANIM PROD, V25, P107
   Dijkman JT, 1997, J AGR SCI, V128, P95, DOI 10.1017/S0021859696003929
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   Gordon IJ, 1988, FUNCT ECOL, V2, P15, DOI 10.2307/2389455
   HAVSTAD KM, 1982, J RANGE MANAGE, V35, P447, DOI 10.2307/3898602
   Kyriazakis I., 1993, Proceedings of the Nutrition Society, V52, p353A
   LAWRENCE PR, 1985, ACIAR P SERIES, V10, P59
   MURRAY MG, 1991, J ANIM ECOL, V60, P1029, DOI 10.2307/5429
   OSUJI PO, 1974, J RANGE MANAGE, V27, P437, DOI 10.2307/3896717
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   ROMNEY DL, 1994, 2 BIENN C AFR FEED R
   SEEBECK RM, 1971, AUST J BIOL SCI, V24, P373
   SYKES AR, 1980, RES VET SCI, V28, P63
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   WACHER TR, 1993, INTERACTIONS SEASON
   YELICH JV, 1989, EFFECT TIME S PERFOR, P43
NR 21
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1591
J9 APPL ANIM BEHAV SCI
JI Appl. Anim. Behav. Sci.
PD JUN
PY 1998
VL 58
IS 1-2
BP 1
EP 12
DI 10.1016/S0168-1591(97)00139-1
PG 12
WC Agriculture, Dairy & Animal Science; Behavioral Sciences; Veterinary
   Sciences
SC Agriculture; Behavioral Sciences; Veterinary Sciences
GA 100UA
UT WOS:000074832700001
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Mulholland, EK
   Secka, O
   Jaffar, S
   Greenwood, BM
AF Adegbola, RA
   Mulholland, EK
   Secka, O
   Jaffar, S
   Greenwood, BM
TI Vaccination with a Haemophilus influenzae type b conjugate vaccine
   reduces oropharyngeal carriage of H-influenzae type b among Gambian
   children
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HEMOPHILUS-INFLUENZAE; DISEASE; TRIAL
AB The effect of a Haemophilus influenzae type b (Hib) polyribosylribitol phosphate-tetanus toroid conjugate vaccine (Hib/PRP-T) on oropharyngeal carriage of Hib was studied during an efficacy trial in Gambian infants. Children were vaccinated with Hib/PRP-T and diphtheria-tetanus toxoids pertussis (DTP) or DTP alone at ages 2, 3, and 4 months. Groups of 1000 children aged 1-2 years were studied each year for 4 years. Hib was detected by production of a halo on antiserum agar plates. Carriage was significantly lower among children fully vaccinated with Hib/PRP-T given with DTP (4.4%; 95% confidence interval [CI], 3.8%-5.7%) than among children fully vaccinated with DTP alone (11.0%; 95% CI, 8.9%-13.0%) (protective effect adjusted by year = 60%; 95% CI, 44%-72%; P < .001). Hib carriage varied by year among nonvaccinated children. Hib conjugate vaccines are likely to produce a herd protective effect in underdeveloped communities, as recorded in Europe and the United States.
C1 Med Res Council Labs, Banjul, Gambia.
   WHO, ARI, CHD, CH-1211 Geneva, Switzerland.
   London Sch Hyg & Trop Med, London WC1, England.
RP Adegbola, RA (reprint author), Med Res Council Labs, Banjul, Gambia.
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   BARBOUR ML, 1995, J INFECT DIS, V171, P93
   BIJLMER HA, 1989, T ROY SOC TROP MED H, V83, P831, DOI 10.1016/0035-9203(89)90345-3
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GRATTEN M, 1984, J CLIN MICROBIOL, V19, P526
   MOHLEBOETANI JC, 1993, PEDIATR INFECT DIS J, V12, P589, DOI 10.1097/00006454-199307000-00009
   MPAIRWE Y, 1970, J HYG-CAMB, V68, P337
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2
   PELTOLA H, 1977, PEDIATRICS, V60, P730
   TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010
   TAKALA AK, 1991, J INFECT DIS, V164, P982
NR 14
TC 82
Z9 85
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN
PY 1998
VL 177
IS 6
BP 1758
EP 1761
DI 10.1086/517440
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA ZP618
UT WOS:000073771500049
PM 9607866
OA No
DA 2017-08-15
ER

PT J
AU Gerbase, AC
   Rowley, JT
   Mertens, TE
AF Gerbase, AC
   Rowley, JT
   Mertens, TE
TI Global epidemiology of sexually transmitted diseases
SO LANCET
LA English
DT Article
ID HIV-INFECTION; IMPACT; WOMEN
C1 WHO, CH-1211 Geneva 27, Switzerland.
   MRC Labs, Banjul, Gambia.
RP Gerbase, AC (reprint author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
CR Anderson R.M., 1992, INFECT DIS HUMANS DY
   BEHETS FMT, 1995, J INFECT DIS, V172, P764
   Brandt A., 1987, NO MAGIC BULLET
   GERBASE AC, 1998, IN PRESS GENITOURIN
   Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6
   GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7
   HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X
   LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015
   MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008
   MERTENS TE, 1997, AIDS BIOL DIAGNOSIS
   *MIN HLTH CHILD WE, 1995, NAT AIDS COORD PROGR
   *NAT I PUBL HLTH, 1993, MSIS REP
   *PAHO WHO, 1992, AIDS HIV STD ANN SUR
   Rowley J, 1998, HLTH DIMENSIONS SEX
   Ward H, 1997, HEALTH POLICY PLANN, V12, P19, DOI 10.1093/heapol/12.1.19
   Wasserheit JN, 1989, INT J GYNECOL OBST S, V3, P145
   WHO-World Health Organization, 1995, WHO GPA STD, V1, P1
   *WHO UNAIDS, 1997, SEX TRANSM DIS POL P
   [Anonymous], 1993, WORLD DEV REPORT 199
NR 19
TC 187
Z9 195
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN
PY 1998
VL 351
SU 3
BP 2
EP 4
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA ZV844
UT WOS:000074347300002
PM 9652711
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Mulholland, EK
AF Weber, MW
   Mulholland, EK
TI Pulse oximetry in developing countries
SO LANCET
LA English
DT Letter
ID OXYGEN
C1 Med Res Council Labs, Banjul, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
RP Weber, MW (reprint author), Med Res Council Labs, POB 273, Banjul, Gambia.
CR Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6
   Haldane J S, 1919, Br Med J, V2, P65
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
NR 4
TC 22
Z9 22
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 23
PY 1998
VL 351
IS 9115
BP 1589
EP 1589
DI 10.1016/S0140-6736(05)61160-9
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA ZQ497
UT WOS:000073868000066
PM 10326572
OA No
DA 2017-08-15
ER

PT J
AU Olaleye, BO
   Williams, LA
   D'Alessandro, U
   Weber, MM
   Mulholland, K
   Okorie, C
   Langerock, P
   Bennett, S
   Greenwood, BM
AF Olaleye, BO
   Williams, LA
   D'Alessandro, U
   Weber, MM
   Mulholland, K
   Okorie, C
   Langerock, P
   Bennett, S
   Greenwood, BM
TI Clinical predictors of malaria in Gambian children with fever or a
   history of fever
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; diagnosis; predictor models; children;
   The Gambia
ID PRESUMPTIVE DIAGNOSIS; PARASITE DENSITY; CASE DEFINITIONS; ENDEMIC
   AREAS; CRITERIA; AGE
AB Diagnosis of malaria in children is difficult without laboratory support because the symptoms and signs of malaria overlap with those of other febrile illnesses such as pneumonia. Nevertheless, in many parts of Africa diagnosis of malaria must be made without laboratory investigation. Therefore, a scoring system has been developed to assist peripheral health care workers in making this diagnosis. Four hundred and seven Gambian children aged 6 months to 9 years who presented to a rural clinic with fever or a recent history of fever were investigated. A diagnosis of malaria was made in 159 children who had a fever of 38 degrees C or more and malaria parasitaemia of 5000 parasites/mu L or more. Symptoms and signs in children with malaria were compared with those in children with other febrile illnesses to identify features which predicted malaria. Symptoms and signs were incorporated into various logistic regression models to test which were best independent predictors of malaria and these regression models were used to construct simple scoring systems which predicted malaria. A nine terms model predicted clinical malaria with a sensitivity of 89% and a specificity of 61%, values comparable to those obtained by an experienced paediatrician without laboratory support. The ability of peripheral health care workers to diagnose malaria using this approach is now being investigated in a prospective study.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   MRC Labs, Fajara, Banjul, Gambia.
   WHO, CH-1211 Geneva, Switzerland.
   Farafenni Hlth Ctr, Farafenni, Gambia.
RP Greenwood, BM (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI Morison, Linda/H-9738-2013; D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR BASSETT MT, 1991, J TROPICAL MED HYGIE, V94, P64
   Baudon D., 1986, MED AFRIQUE NOIRE, V33, P767
   BRYAN JH, 1979, T ROY SOC TROP MED H, V73, P463, DOI 10.1016/0035-9203(79)90179-2
   EJEZIE GC, 1992, TROP GEOGR MED, V44, P97
   GENTON B, 1994, T ROY SOC TROP MED H, V88, P537, DOI 10.1016/0035-9203(94)90152-X
   GOMES M, 1994, B WORLD HEALTH ORGAN, V72, P383
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hand D J, 1992, Stat Methods Med Res, V1, P49, DOI 10.1177/096228029200100104
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X
   Redd SC, 1996, LANCET, V347, P223, DOI 10.1016/S0140-6736(96)90404-3
   REED SC, 1992, LANCET, V340, P1140
   Rogier C, 1996, AM J TROP MED HYG, V54, P613
   ROOTH I, 1992, T ROY SOC TROP MED H, V86, P479, DOI 10.1016/0035-9203(92)90076-O
   ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P
   SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   SOWUNMI A, 1993, T ROY SOC TROP MED H, V87, P422, DOI 10.1016/0035-9203(93)90022-I
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9
NR 19
TC 32
Z9 32
U1 2
U2 5
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1998
VL 92
IS 3
BP 300
EP 304
DI 10.1016/S0035-9203(98)91021-5
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA ZV615
UT WOS:000074322800017
PM 9861403
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Jeffcoate, I
   Jaitner, J
   Kora, S
   Holmes, P
AF Osaer, S
   Goossens, B
   Jeffcoate, I
   Jaitner, J
   Kora, S
   Holmes, P
TI Effects of Trypanosoma congolense and nutritional supplements on
   establishment and outcome of pregnancy in trypanotolerant Djallonke ewes
SO ANIMAL REPRODUCTION SCIENCE
LA English
DT Article
DE sheep : pregnancy; trypanosoma congolense; feeding and nutrition
ID GONADOTROPIN-RELEASING-HORMONE; SCOTTISH BLACKFACE SHEEP; AFRICAN
   TRYPANOSOMIASIS; PROGESTERONE CONCENTRATIONS; ADRENOCORTICAL FUNCTION;
   REPRODUCTIVE DISORDERS; LUTEINIZING-HORMONE; ESTROUS-CYCLE; INFECTION;
   CATTLE
AB Interactions between Trypanosoma congolense and nutritional status were studied in 42 ewes, bred at the peak of parasitaemia after synchronisation of oestrus. As experimental design a randomised block design was used with four treatment combinations (2 x 2 factors), of which two were on a restricted diet (L), the remainder on an unrestricted diet (H) and half of each nutritional group infected with T. congolense (LI, HI), the remainder serving as controls (LC, HC). Severity of parasitaemia was not influenced by supplementation and mortality rates were higher in the HI and LC groups, but these differences were found not significant. Progesterone levels during the synchronised cycle were significantly lower in the infected groups. Levels of pregnant specific protein B (PSPB) in pregnant sheep at days 21 and 26 were not significantly affected by nutrition or infection, despite the tendency of a decrease in infected groups. T. congolense clearly affected establishment of pregnancy, as shown by lower rates of pregnancy and extended intervals between breeding and confirmation of pregnancy, nor was there any benefit of nutritional supplementation. Mean progesterone concentration during pregnancy, in those ewes which lambed, was not different between groups. The effect of the T. congolense infection on the outcome of pregnancy was not clear with the LI and HC performing well and poor pregnancy outcomes in groups HI and LC, although differences in litter size might explain these anomalies. It is concluded that the most pronounced effect of T. congolense was a negative influence on establishment of pregnancy, with nutritional supplementation unable to overcome this effect but having a beneficial influence on maintenance and successful outcome of pregnancy. However, individual exceptions indicate that same ewes cope better with thr negative effects of infection and poor nutrition. (C) 1998 Elsevier Science B.V.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Glasgow, Sch Vet, Glasgow G61 1HQ, Lanark, Scotland.
RP Osaer, S (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   BEALBY KA, 1993, P 22 M ISCTRC OAU KA
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   EDEGHERE H, 1992, VET PARASITOL, V43, P203, DOI 10.1016/0304-4017(92)90161-2
   ELHASSAN E, 1994, TROP ANIM HEALTH PRO, V26, P213, DOI 10.1007/BF02240384
   ELHASSAN E, 1989, P 20 ISCTRC OAU M MO
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   HECKER PA, 1994, 21 M ISCTRC HELD YAM
   HUMBLOT P, 1990, J REPROD FERTIL, V89, P205
   IKEDE B O, 1972, British Veterinary Journal, V128, P1
   IKEDE BO, 1988, ACTA TROP, V45, P5
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KATUNGUKARWAKISHAYA E, 1995, VET PARASITOL, V59, P207, DOI 10.1016/0304-4017(94)00748-2
   LAWSON RAS, 1983, J REPROD FERTIL, V67, P473
   LAWSON RAS, 1977, MONOGRAPH CANADA DEP, V16, P72
   LITTLE D, 1990, P NUTR SOC 144 M SCO
   LLEWELYN CA, 1987, BRIT VET J, V143, P423
   MANI AU, 1995, VET REC, V136, P518
   MAQUENA K, 1986, REV ELEV MED VET PHY, V39, P307
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MEYER HHD, 1986, J STEROID BIOCH S, V25, P139
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Mutayoba BM, 1996, EUR J ENDOCRINOL, V134, P115
   MUTAYOBA BM, 1995, RES VET SCI, V58, P174, DOI 10.1016/0034-5288(95)90073-X
   MUTAYOBA BM, 1995, ANIM REPROD SCI, V40, P203, DOI 10.1016/0378-4320(95)01425-Y
   MUTAYOBA BM, 1988, ACTA TROP, V45, P225
   MUTAYOBA BM, 1995, RES VET SCI, V58, P180, DOI 10.1016/0034-5288(95)90074-8
   OGAA JS, 1991, P 21 M ISCTRC OAU YA
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PARIS J, 1982, ACTA TROP, V39, P307
   PARR RA, 1982, J AGR SCI, V98, P39
   PRAKASH BS, 1987, J STEROID BIOCHEM, V28, P623, DOI 10.1016/0022-4731(87)90389-X
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   *SAS I, 1989, STAT ANAL SYST I SAS
   SEKONI VO, 1994, THERIOGENOLOGY, V42, P557, DOI 10.1016/0093-691X(94)90373-Q
   Snedecor G. W., 1980, STAT METHODS
   TROUNSON AO, 1974, AUST J BIOL SCI, V27, P511
   WILLARD JM, P W SECT AM SOC ANIM
   WILMUT I, 1985, THERIOGENOLOGY, V23, P107, DOI 10.1016/0093-691X(85)90076-7
   WILMUT I, 1981, J REPROD FERTIL, V61, P179
NR 44
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4320
J9 ANIM REPROD SCI
JI Anim. Reprod. Sci.
PD APR 30
PY 1998
VL 51
IS 2
BP 97
EP 109
DI 10.1016/S0378-4320(98)00067-0
PG 13
WC Agriculture, Dairy & Animal Science; Reproductive Biology
SC Agriculture; Reproductive Biology
GA ZX163
UT WOS:000074485700002
PM 9672672
OA No
DA 2017-08-15
ER

PT J
AU Jakobsen, PH
   McKay, V
   N'Jie, R
   Olaleye, BO
   D'Alessandro, U
   Zhang, GH
   Eggelte, TA
   Koch, C
   Greenwood, BM
AF Jakobsen, PH
   McKay, V
   N'Jie, R
   Olaleye, BO
   D'Alessandro, U
   Zhang, GH
   Eggelte, TA
   Koch, C
   Greenwood, BM
TI Decreased antitoxic activities among children with clinical episodes of
   Malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; FALCIPARUM-INFECTED ERYTHROCYTES; C-REACTIVE
   PROTEIN; PLASMODIUM-FALCIPARUM; PARASITE DENSITY; CYTOADHERENCE;
   TRANSMISSION; HAPTOGLOBIN; ENDOTOXIN; RECEPTOR
AB Healthy Gambian children, children with clinical Plasmodium falciparum malaria, and children with asymptomatic P. falciparum infections were studied to investigate whether antitoxic activities may contribute to protection against malarial symptoms, Markers of inflammatory reactions, soluble tumor necrosis factor receptor I, and C-reactive protein were found in high concentrations in children with symptomatic P. falciparum malaria compared with levels in children with asymptomatic P. falciparum infections or in healthy children, indicating that inflammatory reactions are induced only in children with clinical symptoms, Concentrations of soluble tumor necrosis factor receptor I and C-reactive protein were associated with levels of parasitemia, We detected antitoxic activities in sera as measured by their capacity to block toxin-induced Limulus amoebocyte lysate (LAL) activation, Symptomatic children had decreased capacity to block induction of LAL activation by P. falciparum exoantigen. The decreased blocking activity was restored in the following dry season, when the children had no clinical malaria, Symptomatic children also had the highest immunoglobulin G(IgG) reactivities to conserved P. falciparum erythrocyte membrane protein 1 and "Pfalhesin" (band #3) peptides, indicating that such IgG antibodies are stimulated by acute disease but are lost rapidly after the disease episode, Half of the children with symptomatic infections had low levels of haptoglobin, suggesting that these children had chronic P. falciparum infections which may have caused symptoms previously. Only a few of the children with asymptomatic P. falciparum infections had high parasite counts, and antitoxic immunity in the absence of antiparasite immunity appears to be rare among children in this community.
C1 Univ Copenhagen Hosp, Rigshosp, Dept Infect Dis M7722, DK-2200 Copenhagen N, Denmark.
   Univ Copenhagen Hosp, Rigshosp, Dept Clin Microbiol, Ctr Med Parasitol, DK-2200 Copenhagen, Denmark.
   Statens Serum Inst, Dept Immunol, DK-2300 Copenhagen, Denmark.
   Res Council Labs, Fajara, Gambia.
   Univ Amsterdam, Acad Med Ctr, Dept Clin Pharmacol & Pharmacotherapy, NL-1105 AZ Amsterdam, Netherlands.
RP Jakobsen, PH (reprint author), Univ Copenhagen Hosp, Rigshosp, Dept Infect Dis M7722, Tagensvej 20, DK-2200 Copenhagen N, Denmark.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALLAN RJ, 1993, INFECT IMMUN, V61, P4772
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   BATE CAW, 1994, INFECT IMMUN, V62, P3086
   BATE CAW, 1988, IMMUNOLOGY, V64, P227
   BLICK M, 1987, CANCER RES, V47, P2986
   CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703
   Eggelte TA, 1990, INT MONOGRAPH SERIES, V3, P35
   Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, PARASITOL TODAY, V7, P277
   HOGH B, 1994, INFECT IMMUN, V62, P4362
   HURT N, 1994, T ROY SOC TROP MED H, V88, P182, DOI 10.1016/0035-9203(94)90287-9
   JAKOBSEN PH, 1993, INFECT IMMUN, V61, P268
   JAKOBSEN PH, 1988, PARASITE IMMUNOL, V10, P593, DOI 10.1111/j.1365-3024.1988.tb00247.x
   JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x
   Jakobsen PH, 1996, CLIN EXP IMMUNOL, V105, P69, DOI 10.1046/j.1365-2249.1996.d01-718.x
   KOZAK W, 1995, AM J PHYSIOL-REG I, V269, pR23
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   McGuire W, 1996, T ROY SOC TROP MED H, V90, P10, DOI 10.1016/S0035-9203(96)90461-7
   PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25
   SHENTON FC, 1988, T ROY SOC TROP MED H, V82, P216, DOI 10.1016/0035-9203(88)90415-4
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1
   Zhang GH, 1995, APMIS, V103, P721
   ZHANG GH, 1994, J CLIN MICROBIOL, V32, P416
NR 26
TC 10
Z9 10
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 1998
VL 66
IS 4
BP 1654
EP 1659
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA ZD630
UT WOS:000072706100053
PM 9529094
OA No
DA 2017-08-15
ER

PT J
AU Dale, A
   Thomas, JE
   Darboe, MK
   Coward, WA
   Harding, M
   Weaver, LT
AF Dale, A
   Thomas, JE
   Darboe, MK
   Coward, WA
   Harding, M
   Weaver, LT
TI Helicobacter pylori infection, gastric acid secretion, and infant growth
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE gastric acid; growth; Helicobacter pylori; infants
ID CHILDREN; INGESTION
AB Background: Helicobacter pylori infection is very common in Gambian infants and children, who are also at risk of chronic diarrhoea and undernutrition. Acute H. pylori infection is associated with depressed gastric acid secretion, and loss of the gastric acid barrier may predispose to enteric infections.
   Methods: In a prospective study a noninvasive test of gastric acid output (measurement of change in urine acid output before and after a feed) was performed on a population of Gambian infants at high risk of H. pylori infection. The C-13 urea breath tests was used to measure the prevalence of H. pylori infection and growth was measured by serial anthropometry.
   Results: In 101 infants aged 3 to 12 months, there was a significant relation between H. pylori infection and depressed urine acid output in those aged 6 months, during weaning when growth failure and malnutrition begin. Those infants with sustained H. pylori infection grew less well than those without.
   Conclusions: We speculate that H. pylori, acquired in infancy, could be a "key that opens the door" to enteric infection in childhood, leading to recurrent diarrhoea, malnutrition, and growth failure. (C) 1998 Lippincott-Raven Publishers.
C1 MRC, Dunn Nutr Unit, Keneba, Gambia.
   MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
   Univ Newcastle Upon Tyne, Dept Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Univ Glasgow, Dept Child Hlth, Glasgow, Lanark, Scotland.
RP Weaver, LT (reprint author), Yorkhill Hosp, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland.
RI Robles-Sardin, Alma/M-7714-2015
OI Robles-Sardin, Alma/0000-0003-2044-7793
CR COULTHARD MG, 1985, EARLY HUM DEV, V11, P1174
   CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8
   GILMAN RH, 1988, GASTROENTEROLOGY, V94, P1308
   GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P974
   GRAHAM DY, 1987, LANCET, V1, P1174
   HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607
   HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28
   HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96
   Hunt RH, 1992, HELICOBACTER PYLORI, P187
   JOHNSON CD, 1990, GUT, V31, P862, DOI 10.1136/gut.31.8.862
   KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P331
   MARSHALL B, 1983, LANCET, V1, P1273
   MERGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870
   Mion F, 1997, CLIN SCI, V93, P3
   MORRIS A, 1987, AM J GASTROENTEROL, V82, P192
   MORRIS AJ, 1991, ANN INTERN MED, V114, P662
   NURKO SS, 1993, GASTROENTEROLOGY, V104, pA160
   ROWLAND M G M, 1978, Lancet, V1, P136
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   SULLIVAN PB, 1990, ARCH DIS CHILD, V65, P189
   TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42
   THOMAS JE, 1993, GUT, V34, P738, DOI 10.1136/gut.34.6.738
   WEAVER LT, 1995, T ROY SOC TROP MED H, V89, P347, DOI 10.1016/0035-9203(95)90002-0
   WEAVER LT, 1993, PEDIAT REV COMMUN, V7, P198
   WHITEHEAD RG, 1977, PROC R SOC SER B-BIO, V199, P49, DOI 10.1098/rspb.1977.0118
NR 25
TC 86
Z9 89
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD APR
PY 1998
VL 26
IS 4
BP 393
EP 397
DI 10.1097/00005176-199804000-00006
PG 5
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA ZE546
UT WOS:000072804300006
PM 9552134
OA No
DA 2017-08-15
ER

PT J
AU Rawlings, P
   Snow, WF
   Boorman, J
   Denison, E
   Hamblin, C
   Mellor, PS
AF Rawlings, P
   Snow, WF
   Boorman, J
   Denison, E
   Hamblin, C
   Mellor, PS
TI Culicoides in relation to transmission of African Horse Sickness virus
   in The Gambia
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE Culicoides; vectors; African horse sickness; orbivirus detection; The
   Gambia
ID DIPTERA; CERATOPOGONIDAE; TRYPANOSOMIASIS; IDENTIFICATION; BLUETONGUE;
   NIGERIA; TSETSE
AB Twelve light trap collections made near overnight shelters of horses and donkeys in four villages in the Central River Division of The Gambia captured fourteen species of biting midge of the genus Culicoides. Five species new to The Gambia were identified. This brought the number of recognized species of Culicoides (after a revision of C. schultzei) to twenty-nine in The Gambia. Species known or suspected as vectors of African horse sickness virus (AHSV) and bluetongue virus (BTV) comprised 83% of female captures, 65% of captures being C. imicola or its sibling species, C. miombo. Captures of female Culicoides in the late dry season were almost as large as in the early dry season, despite the extreme heat and dryness at this time of the year.
   Tests on batches of formalin-preserved female midges, using AHSV or BTV antigen capture ELISAs, did not show the presence of any virus amongst 2286 females in 240 aliquots. Nearly all Gambian equines are reportedly seropositive to AHSV and these results suggest that virus challenge from Culicoides vectors may be a factor in the health of Gambian horses and donkeys.
C1 Inst Anim Hlth, Surrey, England.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP Rawlings, P (reprint author), Univ W England, Fac Comp Studies & Math, Coldharbour Lane, Bristol BS16 1QY, Avon, England.
CR BERTRAM D. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P217, DOI 10.1016/0035-9203(58)90079-8
   Bourdin P, 1974, Rev Elev Med Vet Pays Trop, V27, P163
   CLASTRIER J., 1961, ARCH INST PASTEUR ALGERIE, V39, P302
   Cornet Michel, 1994, Bulletin de la Societe Entomologique de France, V99, P149
   Du Toit R. M., 1944, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V19, P7
   HAMBLIN C, 1991, J VIROL METHODS, V31, P285, DOI 10.1016/0166-0934(91)90166-W
   Jordan A.M., 1986, TRYPANOSOMIASIS CONT
   LEE VH, 1979, J MED ENTOMOL, V16, P76
   LEE VH, 1974, AM J VET RES, V35, P1105
   LILLIE TH, 1981, CAN ENTOMOL, V113, P419
   MARSH PM, 1986, THESIS U EDINBURGH
   MATTIOLI RC, 1992, TROP ANIM HEALTH PRO, V24, P207, DOI 10.1007/BF02356746
   MCFADZEAN JA, 1954, T ROY SOC TROP MED H, V48, P267, DOI 10.1016/0035-9203(54)90075-9
   MEISWINKEL R, 1991, ONDERSTEPOORT J VET, V58, P155
   MEISWINKEL R, 1994, VECTORS CULICOIDES S, P68
   MELLOR PS, 1993, VET RES, V24, P199
   MELLOR PS, 1984, J HYG-CAMBRIDGE, V93, P621
   *NADC, 1995, 1994 95 NAT AGR SAMP
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   RAWLINGS P, 1992, AFR LIVESTOCK RES, V2, P50
   Snow WF, 1996, AGR SYST, V51, P339, DOI 10.1016/0308-521X(95)00048-A
   SOWE J, 1990, ANIMAL TRACTION AGR
   STAUBER N, 1993, J CLIN MICROBIOL, V31, P2241
   Sumberg J., 1992, African Livestock Research, V1, P1
   WALKER AR, 1971, J HYG-CAMB, V69, P47
NR 26
TC 8
Z9 9
U1 1
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD APR
PY 1998
VL 12
IS 2
BP 155
EP 159
PG 5
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA ZP161
UT WOS:000073723100006
PM 9622369
OA No
DA 2017-08-15
ER

PT J
AU Hassan-King, M
   Adegbola, R
   Baldeh, I
   Mulholland, K
   Omosigho, C
   Oparaugo, A
   Usen, S
   Palmer, A
   Schneider, G
   Secka, O
   Weber, M
   Greenwood, B
AF Hassan-King, M
   Adegbola, R
   Baldeh, I
   Mulholland, K
   Omosigho, C
   Oparaugo, A
   Usen, S
   Palmer, A
   Schneider, G
   Secka, O
   Weber, M
   Greenwood, B
TI A polymerase chain reaction for the diagnosis of Haemophilus influenzae
   type b disease in children and its evaluation during a vaccine trial
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Haemophilus influenzae type b; polymerase chain reaction diagnosis;
   vaccine evaluation
ID STREPTOCOCCUS-PNEUMONIAE DNA; PCR; MENINGITIS
AB Background. Determination of the etiology of pneumonia in young children is difficult because blood culture, the usual method of diagnosis, is positive in only a small proportion of cases. For this reason vaccine trials that include bacterial pneumonia as an endpoint must be large.
   Objectives. To determine whether a diagnostic test based on a polymerase chain reaction could be used as an alternative to conventional blood culture for diagnosis of invasive Haemophilus influenzae type b (Hib) infections in young children investigated during the course of a large vaccine trial.
   Methods. DNA was extracted from blood culture supernatants and probed for the presence of Dib DNA with a PCR assay with primers derived from the cap gene locus of Dib, Results of the PCR assay were compared with those obtained by conventional culture techniques.
   Results. Blood cultures were obtained from 1544 children with suspected pneumonia, meningitis or septicemia and from 31 healthy control children who were contacts of cases. Blood culture supernatants were tested for Hib DNA in the PCR test. The sensitivity and specificity of a positive PCR test in blood culture supernatant as against culture of Hib from any normally sterile site were 100 and 99%, respectively. Eleven children had positive Dib PCR tests on blood culture supernatants but were negative by culture. In one of these cases Dib was isolated from a lung aspirate and in two other patients H. influenzae strains other than Bib were obtained from the cerebrospinal fluid, Eight of these 11 children were in the control group. When the results of the PCR assay were used to determine vaccine efficacy, a value of 86% was obtained compared with a figure of 95% obtained when conventional culture techniques were used.
   Conclusions. An Dib PCR assay on blood culture supernatants proved to be sensitive and specific for the diagnosis of Bib disease in children. The distribution of PCR-positive, culture-negative cases between Dib-vaccinated and control groups paralleled that of culture-positive cases, suggesting that most of these children had been infected with Dib, A trial of a highly efficacious vaccine provides a novel way for evaluating new diagnostic tests for which there is no standard diagnostic test of 100% reliability.
C1 MRC Labs, Banjul, Gambia.
   Sibanor Mission Hosp, Sibanor, Gambia.
RP Hassan-King, M (reprint author), MRC Labs, Banjul, Gambia.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1991, VACCINE, V9, P55
   FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382
   HASSANKING M, 1994, J CLIN MICROBIOL, V32, P1721
   HassanKing M, 1996, J CLIN MICROBIOL, V34, P2030
   Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X
NR 10
TC 11
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 1998
VL 17
IS 4
BP 309
EP 312
DI 10.1097/00006454-199804000-00008
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA ZH791
UT WOS:000073148000007
PM 9576385
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Belem, AMG
   Ki-Zerbo, A
   Thiry, EE
AF Mattioli, RC
   Belem, AMG
   Ki-Zerbo, A
   Thiry, EE
TI Liveweight and killing out percentage of some wild animal species of the
   Nazinga game ranch (Burkina Faso) infested by tsetse flies
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
C1 FAO Project Dev Tsetse Infested Areas W Africa, Ouagadougou 01, Burkina Faso.
   Univ Ouagadougou, Inst Dev Rural, Ouagadougou, Burkina Faso.
   FAO Project Promot Trypanotolerant Livestock W &, Banjul, Gambia.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR BOUSQUET B, 1982, DPUPV78008 FAO ROM
   DECKER DJ, 1987, RAPPORTS SPECIAUX C, V18
   *DIR NAT EL, 1991, STRAT PLAN ACT SOUS
   *FAO, 1980, BET TRYP AFR OCC CEN, V2
   Fournier A., 1987, Bulletin d'Ecologie, V18, P409
   Grootenhuis J. G., 1986, Kenya Veterinarian, V10, P45
   JACKMANN H, 1987, RAPPORTS SPECIAUX C, V15
   JANKHE HE, 1988, LIVESTOCK PRODUCTION, P3
   MARTIN GHG, 1984, WORLD ANIM REV, P40
   Mattioli R.C., 1992, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V44, P165
   MURRAY M, 1984, OUTLOOK AGR, V13, P51
   ODONOGHUE M, 1988, DISTRIBUTION BIOMASS
   SHAW APM, 1987, 671 FAO, V1
   Swenson MJ, 1984, DUKES PHYSL DOMESTIC, V10th, P15
   Trail JC, 1991, ACTA TROP, V48, P37
   VINCKE PP, 1982, GESTION FAUNE SAUVAG, P25
NR 16
TC 1
Z9 1
U1 0
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD APR
PY 1998
VL 30
IS 2
BP 137
EP 140
DI 10.1023/A:1005004018953
PG 4
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA V2637
UT WOS:000165535900008
PM 9719840
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Mulholland, EK
   Greenwood, BM
AF Weber, MW
   Mulholland, EK
   Greenwood, BM
TI Respiratory syncytial virus infection in tropical and developing
   countries
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE respiratory syncytial virus; developing countries; acute respiratory
   infections; child
ID LINKED IMMUNOSORBENT-ASSAY; RIO-DE-JANEIRO; TRACT INFECTIONS; VIRAL
   ETIOLOGY; GAMBIAN CHILDREN; YOUNG-CHILDREN; ACUTE BRONCHIOLITIS;
   CELL-CULTURE; BENIN-CITY; EPIDEMIOLOGY
AB Little is known about the epidemiology of respiratory syncytial virus (RSV) infection ill tropical and developing countries; the data currently available have been reviewed. In most studies, RSV was found to be the predominant viral cause of acute lower respiratory trace infections (ALRI) in childhood, being responsible for 27-96% of hospitalised cases (mean 65%) in which a virus was found. RSV infection is seasonal in most countries; outbreaks occur most frequently in the cold season in areas with temperate and Mediterranean climates and in the wet season in tropical countries with seasonal rainfall. The situation on islands and in areas of the inner tropics with perennial high rainfall is less clear-cut. The age group mainly affected by RSV in developing countries is children under 6 months of age (mean 39% of hospital patients with RSV). RSV-ALRI is slightly more common in boys than in girls. Very little information is available about the mortality of children infected with RSV, the frequency of bacterial co-infection, or the incidence of further wheezing after RSV. Further studies on RSV should address these questions in more detail. RSV is an important pathogen in young children in tropical and developing countries and a frequent cause of hospital admission. Prevention of RSV infection by vaccination would have a significant impact on the incidence of ALRI in children in developing countries.
C1 WHO, CH-1211 Geneva 27, Switzerland.
   Med Res Council Labs, Fajara, Gambia.
   Hannover Med Sch, Childrens Hosp, D-3000 Hannover, Germany.
   London Sch Hyg & Trop Med, London WC1, England.
RP Weber, MW (reprint author), WHO, CH-1211 Geneva 27, Switzerland.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Aderele W I, 1995, Afr J Med Med Sci, V24, P47
   AGARWAL SC, 1971, INDIAN J MED RES, V59, P19
   AHLUWALIA G, 1987, J CLIN MICROBIOL, V25, P763
   AVENDANO LF, 1991, PEDIATR INFECT DIS J, V10, P564, DOI 10.1097/00006454-199108000-00003
   BAIRD DR, 1976, LANCET, V2, P1344
   BERMAN S, 1983, PEDIATRICS, V71, P210
   BORRERO I, 1990, REV INFECT DIS, V12, pS950
   Brandenburg AH, 1997, J MED VIROL, V52, P97, DOI 10.1002/(SICI)1096-9071(199705)52:1<97::AID-JMV16>3.0.CO;2-Y
   BREWSTER D, 1989, MED J AUSTRALIA, V150, P605
   Capeding M R, 1994, Southeast Asian J Trop Med Public Health, V25, P684
   CARBALLAL G, 1990, REV INFECT DIS, V12, pS1074
   CHATTOPADHYA D, 1992, J TROP PEDIATRICS, V38, P68
   CHERIAN T, 1990, AM J DIS CHILD, V144, P1026
   DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006
   DEARRUDA E, 1991, J INFECT DIS, V164, P252
   Doraisingham S, 1981, Ann Acad Med Singapore, V10, P69
   DORAISINGHAM S, 1986, Annals Academy of Medicine Singapore, V15, P9
   DYM AM, 1986, PEDIATR INFECT DIS J, V5, P717, DOI 10.1097/00006454-198611000-00032
   ESCOBAR JA, 1976, PEDIATRICS, V57, P123
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   FREYMUTH F, 1986, J CLIN MICROBIOL, V24, P1013
   GHAFOOR A, 1990, REV INFECT DIS, V12, pS907
   GILCHRIST S, 1994, J INFECT DIS, V170, P986
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708
   GLEZEN WP, 1977, PEDIATR RES, V11, P239
   GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4
   GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005
   GREENWOOD BM, 1979, T ROY SOC TROP MED H, V73, P557, DOI 10.1016/0035-9203(79)90052-X
   GREENWOOD BM, 1996, OXFORD TXB MED, P533
   HALL CB, 1988, J PEDIATR-US, V113, P266
   HAMBLING MH, 1964, BRIT J EXP PATHOL, V45, P647
   HAYES EB, 1989, AM J DIS CHILD, V143, P316
   HAZLETT DTG, 1988, AM J TROP MED HYG, V39, P632
   HIJAZI Z, 1995, PEDIATR INFECT DIS J, V14, P322, DOI 10.1097/00006454-199504000-00016
   HILLIS WD, 1971, INDIAN J MED RES, V59, P1354
   HORTAL M, 1990, REV INFECT DIS, V12, pS995
   HORTAL M, 1990, REV INFECT DIS, V12, pS915
   HUQ F, 1990, REV INFECT DIS, V12, pS982
   JAMDAR J, 1979, INDIAN PEDIATR, V16, P685
   JAMJOOM GA, 1993, J TROP PEDIATRICS, V39, P346
   JENNINGS R, 1967, AM J EPIDEMIOL, V86, P690
   JOHN TJ, 1991, REV INFECT DIS, V13, pS463
   JOOSTING ACC, 1979, S AFR MED J, V55, P403
   KADI Z, 1990, Revue Roumaine de Virologie, V41, P197
   KHATUA SP, 1977, INDIAN PEDIATR, V14, P285
   KLOENE W, 1970, AM J EPIDEMIOL, V92, P307
   KRASINSKI K, 1985, PEDIATR INFECT DIS J, V4, P250, DOI 10.1097/00006454-198505000-00009
   LANDAU LI, 1994, THORAX, V49, P293, DOI 10.1136/thx.49.4.293
   MARTIN AJ, 1978, LANCET, V2, P1035
   MCCONNOCHIE KM, 1984, PEDIATRICS, V74, P1
   MISRA PK, 1990, J TROP PEDIATRICS, V36, P24
   MONTO AS, 1967, AM J EPIDEMIOL, V86, P78
   MORLEY D, 1963, J HYG-CAMBRIDGE, V61, P115
   *NAT CLIM DAT CTR, 1996, GLOB HIST CLIM NETW
   NUNEZ RM, 1988, PEDIATR INFECT DIS J, V7, P69, DOI 10.1097/00006454-198801000-00016
   NWANKWO MU, 1994, ANN TROP PAEDIATR, V14, P125
   NWANKWO MU, 1988, TROP GEOGR MED, V40, P309
   OLSON LC, 1973, AM J EPIDEMIOL, V97, P34
   ONG SB, 1982, B WORLD HEALTH ORGAN, V60, P137
   ONG SB, 1975, B WORLD HEALTH ORGAN, V52, P376
   OPENSHAW PJM, 1994, THORAX, V49, P101, DOI 10.1136/thx.49.2.101
   OSUNDWA VM, 1993, EUR J PEDIATR, V152, P1001, DOI 10.1007/BF01957225
   OTA WK, 1972, AM J EPIDEMIOL, V95, P371
   PHILLIPS P A, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P373
   PRICE JF, 1990, LUNG S, V168, pS414
   PUTHAVATHANA P, 1990, REV INFECT DIS, V12, pS988
   RAHMAN M, 1990, REV INFECT DIS, V12, pS899
   RAVAOARINORO M, 1986, Archives de l'Institut Pasteur de Madagascar, V52, P147
   REESE PE, 1991, J CLIN MICROBIOL, V29, P2614
   Reeves W C, 1985, Bull Pan Am Health Organ, V19, P221
   RUSSI JC, 1989, J CLIN MICROBIOL, V27, P1464
   RUUTU P, 1990, J INFECT DIS, V161, P175
   SALOMON HE, 1989, J MED VIROL, V28, P159, DOI 10.1002/jmv.1890280310
   SHANN F, 1984, LANCET, V2, P537
   SHEN JP, 1982, ACTA MICROBIOLOGICA, V22, P192
   SOBESLAVSKY O, 1977, B WORLD HEALTH ORGAN, V55, P625
   SPENCE L, 1968, AM J EPIDEMIOL, V88, P257
   STEINHOFF MC, 1985, INDIAN J MED RES, V81, P349
   SUNAKORN P, 1990, PEDIATR INFECT DIS J, V9, P873, DOI 10.1097/00006454-199012000-00003
   SUNG RYT, 1992, EPIDEMIOL INFECT, V108, P147
   SUTMOLLER F, 1995, CLIN INFECT DIS, V20, P854
   SUTMOLLER F, 1983, B WORLD HEALTH ORGAN, V61, P845
   SUWANJUTHA S, 1990, REV INFECT DIS, V12, pS923
   THOMAS EE, 1991, J CLIN MICROBIOL, V29, P632
   TUPASI TE, 1990, REV INFECT DIS, V12, pS940
   TUPASI TE, 1990, REV INFECT DIS, V12, pS929
   VATHANOPHAS K, 1990, REV INFECT DIS, V12, pS957
   Vellayappan K, 1982, J Singapore Paediatr Soc, V24, P69
   WAFULA EM, 1985, E AFR MED J, V62, P757
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   WEISSENBACHER M, 1990, REV INFECT DIS, V12, pS889
   WELLIVER RC, 1981, CRC CR REV CL LAB SC, V13, P213, DOI 10.3109/10408368109106448
   WOODTAYAKORN J, 1991, ASIAN PAC J ALLERGY, V9, P121
   ZELAYA EAC, 1994, AM J TROP MED HYG, V51, P577
   ZHANG ZJ, 1986, CHINESE MED J-PEKING, V99, P695
   1978, BRIT MED J, V2, P796
NR 100
TC 201
Z9 215
U1 0
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 1998
VL 3
IS 4
BP 268
EP 280
DI 10.1046/j.1365-3156.1998.00213.x
PG 13
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA ZP751
UT WOS:000073784800004
PM 9623927
OA No
DA 2017-08-15
ER

PT J
AU Goossens, B
   Osaer, S
   Kora, S
   Chandler, KJ
   Petrie, L
   Thevasagayam, JA
   Woolhouse, T
   Anderson, J
AF Goossens, B
   Osaer, S
   Kora, S
   Chandler, KJ
   Petrie, L
   Thevasagayam, JA
   Woolhouse, T
   Anderson, J
TI Abattoir survey of sheep and goats in The Gambia
SO VETERINARY RECORD
LA English
DT Article
ID RUMINANTS; VIRUS; TRYPANOSOMIASIS; ANTIBODIES; RINDERPEST
AB An abattoir survey of sheep and goats was carried out in The Gambia for one year, A total of 1248 goats and 438 sheep, predominantly young females, were slaughtered and sampled. Sixty per cent of the females of both species were pregnant. There were no significant differences between the dressing percentages of different breeds and age groups, Sex and stage of pregnancy had a significant influence on carcase yields in both species, In goats the highest carcase yields were obtained during the early dry season, Most of the animals were clinically healthy and there were few pathological findings postmortem, In both species, there was a seasonal fluctuation of packed cell volume (pcv), with a minimum during the rains, and although the prevalence of trypanosomiasis was low it reduced the pcv, Faecal egg counts of Trichostrongylidae were highest during the rainy season and goats had higher faecal egg and coccidial oocyst counts than sheep. In sheep, a breed difference was observed for pcv and an age difference for egg excretion, The peak or higher rates of egg excretion occurred during the rains in both species, The immune status against peste des petits ruminants was significantly lower in goats (39 per cent) than in sheep (49.5 per cent). Antibodies against bluetongue virus were found in 62.6 per cent of goats and 55.8 per cent of sheep.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Glasgow, Sch Vet, Glasgow G61 1QH, Lanark, Scotland.
   Univ Saskatchewan, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada.
   Inst Anim Hlth, World Reference Lab Foot & Mouth Dis, Woking, Surrey, England.
RP Goossens, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   Akakpo AJ, 1996, REV MED VET-TOULOUSE, V147, P447
   ANDERSON J, 1994, EPIDEMIOL INFECT, V112, P225
   ANDERSON J, 1984, J IMMUNOL METHODS, V74, P139, DOI 10.1016/0022-1759(84)90375-2
   *DEP LIV SERV AB I, 1993, LIV CENS
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GREENWOOD AC, 1989, REPORT SMALL RUMINAN
   GRETILLAT S, 1981, REV ELEV MED VET PAY, V34, P313
   JANNEH EK, 1980, REPORT CENSUS SHEEP
   MANJELI Y, 1996, P 4 SRNET BIENN C DE
   MATIKA O, 1990, P 1 BIANN C GEN ASS, P59
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PLAIZIER JCB, 1993, JOINT FAO IAEA DIV N, P7
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   ROSSITER PB, 1989, TROP ANIM HEALTH PRO, V21, P69, DOI 10.1007/BF02297348
   RUSSO SL, 1991, P WORKSH PVO U COMM, P71
   SINGLETON GH, 1995, VET REC, V136, P162
   Smith MC, 1994, GOAT MED
   SNEDECOR GW, 1980, STAT METHODS, P185
   *STAT AN SYST I SA, 1996, VERS 6 11
   Thienpont D., 1979, DIAGNOSING HELMINTHI, P40
   VERCRUYSSE J, 1983, VET PARASITOL, V13, P239, DOI 10.1016/0304-4017(83)90060-2
   WILSON RT, 1991, 88 FAO, P19
   *WOM DEV PROJ WID, 1993, SHEEP GOAT SURV 1993
NR 27
TC 14
Z9 14
U1 0
U2 3
PU BRITISH VETERINARY ASSOC
PI LONDON
PA 7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT
SN 0042-4900
J9 VET REC
JI Vet. Rec.
PD MAR 14
PY 1998
VL 142
IS 11
BP 277
EP 281
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA ZE445
UT WOS:000072793300010
PM 9569483
OA No
DA 2017-08-15
ER

PT J
AU Snow, RW
   Nahlen, B
   Palmer, A
   Donnelly, CA
   Gupta, S
   Marsh, K
AF Snow, RW
   Nahlen, B
   Palmer, A
   Donnelly, CA
   Gupta, S
   Marsh, K
TI Risk of severe malaria among African infants: Direct evidence of
   clinical protection during early infancy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM
AB Little empirical evidence from field-based studies exists on the relative magnitude or duration of clinical protection from Plasmodium falciparum malaria in infancy. A prospective study was undertaken to examine the age distribution of hospital admissions in four geographically and demographically well-defined areas with differing intensities of P. falciparum transmission. Where transmission was perennial, significant clinical protection from severe morbidity was observed up to the third month of life; in the seasonal transmission area, disease rates rose after the sixth month of life. Infants exposed to the highest rates of P. falcipanrm exposure demonstrated significant declines in the risks of severe malaria from 6 months of age. These data provide direct evidence for the very early acquisition of clinical immunity and for the existence of a period of clinical protection, which together may explain why, in these communities, the cumulative risk of malarial disease throughout childhood appears to decline with increasing transmission intensity.
C1 Kenya Med Res Inst, Wellcome Trust Collaborat Programme, Nairobi, Kenya.
   Ctr Dis Control & Prevent, Kenya Med Res Inst, Collaborat Programme, Vector Biol & Control Res Ctr, Kisumu, Kenya.
   Kenya Med Res Inst, Clin Res Ctr, Coastal Unit, Kilifi, Kenya.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Inst Mol Med,Mol Parasitol Grp, Oxford OX3 9DU, England.
   Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England.
   Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA.
   Royal Victoria Hosp, Dept Paediat, Banjul, Gambia.
RP Snow, RW (reprint author), Kenya Med Res Inst, Wellcome Trust Collaborat Programme, POB 43640, Nairobi, Kenya.
EM bobsnow@users.africaonline.co.ke
FU Wellcome Trust
CR BATES CJ, 1982, T ROY SOC TROP MED H, V76, P253, DOI 10.1016/0035-9203(82)90291-7
   Brabin B., 1990, TROP DIS B, V87, P1
   BRUCECHWATT LJ, 1952, ANN TROP MED PARASIT, V46, P173
   GARNHAM PCC, 1949, ANN TROP MED PARASIT, V43, P47
   GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189
   Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x
   MCGREGOR IA, 1964, AM J TROP MED HYG, V13, P237
   MUIRHEADTHOMSON RC, 1951, BRIT MED J, V1, P1114
   PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Williams CD, 1940, LANCET, V1, P441
   Wilson D. B., 1950, Tropical Diseases Bulletin, V47, P677
NR 13
TC 93
Z9 93
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1998
VL 177
IS 3
BP 819
EP 822
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA YY555
UT WOS:000072159900048
PM 9498474
OA No
DA 2017-08-15
ER

PT J
AU Bertoletti, A
   Cham, F
   McAdam, S
   Rostron, T
   Rowland-Jones, S
   Sabally, S
   Corrah, T
   Ariyoshi, K
   Whittle, H
AF Bertoletti, A
   Cham, F
   McAdam, S
   Rostron, T
   Rowland-Jones, S
   Sabally, S
   Corrah, T
   Ariyoshi, K
   Whittle, H
TI Cytotoxic T cells from human immunodeficiency virus type 2-infected
   patients frequently cross-react with different human immunodeficiency
   virus type 1 clades
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID LYMPHOCYTES-T; LONGITUDINAL ANALYSIS; HIV-1 INFECTION; VACCINIA VIRUS;
   PEPTIDE; RECOGNITION; RECEPTOR; CLONES; VARIANTS; ANTIGEN
AB Knowledge of immune mechanisms responsible for the cross-protection between highly divergent viruses such as human immunodeficiency virus type 1 (HIV-1) and HIV-2 may contribute to an understanding of whether virus variability may be overcome in the design of vaccine candidates which are broadly protective across the HIV subtypes. We demonstrate that despite the significant difference in virus amino acid sequence, the majority of HIV-2-infected individuals with different HLA molecules possess a dominant cytotoxic T-cell response which is able to recognize HIV-1 Gag protein. Furthermore, HLA-B5801-positive subjects show broad cross-recognition of HIV-1 subtypes since they mounted a T-cell response that tolerated extensive amino acid substitutions within HLA-B5801-restricted HIV-1 and HIV-2 epitopes. These results suggests that HLA-B5801-positive HIV-2-infected individuals have an enhanced ability to react with HIV-1 that could play a role in cross-protection.
C1 MRC Labs, Fajara, Gambia.
   John Radcliffe Hosp, Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DU, England.
RP Bertoletti, A (reprint author), UCL, Sch Med, Inst Hepatol, 69-75 Chenies Mews, London WC1E 6HX, England.
EM a.bertoletti@ucl.ac.uk
OI Bertoletti, Antonio/0000-0002-2942-0485
CR Aaby P, 1997, AIDS, V11, P939
   ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   ANDERSON RW, 1992, MOL IMMUNOL, V29, P1089, DOI 10.1016/0161-5890(92)90041-U
   Ariyoshi K, 1997, AIDS, V11, P1053
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481
   EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1
   FALK K, 1995, IMMUNOGENETICS, V41, P165, DOI 10.1007/BF00182333
   Flynn JN, 1996, J IMMUNOL, V157, P3658
   GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167
   Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0
   GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0
   GOULDER PJR, 1996, AIDS RES HUM RETROV, V12, P1891
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261
   Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0
   KULKARNI AB, 1993, J VIROL, V67, P4086
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   Maryanski JL, 1996, IMMUNITY, V4, P47, DOI 10.1016/S1074-7613(00)80297-6
   MCADAM S, UNPUB CROSS CLADE RE
   MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.immunol.5.1.305
   NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0
   PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   ROTHBARD JB, 1989, EMBO J, V8, P2321
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933
   SHIMOJO N, 1989, J IMMUNOL, V143, P2939
   TEDDER RS, 1988, LANCET, V2, P927
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917
   Wilson CC, 1997, J VIROL, V71, P1256
   WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
NR 41
TC 52
Z9 55
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 1998
VL 72
IS 3
BP 2439
EP 2448
PG 10
WC Virology
SC Virology
GA YX013
UT WOS:000071997600087
PM 9499105
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Dackour, R
   Usen, S
   Schneider, G
   Adegbola, RA
   Cane, P
   Jaffar, S
   Milligan, P
   Greenwood, BM
   Whittle, H
   Mulholland, EK
AF Weber, MW
   Dackour, R
   Usen, S
   Schneider, G
   Adegbola, RA
   Cane, P
   Jaffar, S
   Milligan, P
   Greenwood, BM
   Whittle, H
   Mulholland, EK
TI The clinical spectrum of respiratory syncytial virus disease in The
   Gambia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE respiratory syncytial virus; acute respiratory tract infection;
   bronchiolitis; Gambia; developing countries
ID SUBGROUP-A; ACUTE BRONCHIOLITIS; TRACT INFECTIONS; CHILDREN; ETIOLOGY;
   INFANTS; EPIDEMIOLOGY; PREVALENCE; HOSPITALIZATION; CITY
AB Background. Respiratory syncytial virus (RSV) is a well-recognized cause of lower respiratory tract infections in early childhood in industrialized countries, but less is known about RSV infection in developing countries.
   Methods. Four outbreaks of RSV infection that occurred between 1993 and 1996 in The Gambia, West Africa, were studied, RSV was sought by immunofluorescent staining of nasopharyngeal aspirate samples among young children who presented with respiratory infections at three hospitals in the Western Region of the country.
   Results. Five hundred seventy-four children with RSV infection were identified. The median ages of children seen in 1993 through 1996 were 3, 7, 8 and 5 months, respectively. Sixty-two percent of children <6 months old were boys. Thirteen children (2.4%) had conditions considered to increase the risk of severe RSV infection. On physical examination crepitations were heard in 80% of the children admitted to hospital, whereas wheezes were heard in only 39%. Eighty (16%) children received oxygen because of hypoxemia. Nine of 255 blood cultures (3.5%) were positive: 4 Streptococcus pneumoniae; 2 Haemophilus influenzae type b; 2 Staphylococcus aureus; and 1 Enterobacter agglomerans. Thirteen children died (2.4%), During the 4 study years 90, 25, 75 and 95% of isolates typed were RSV Subgroup A, respectively.
   Conclusions. RSV is a significant cause of lower respiratory tract infection in young children in The Gambia, causing epidemics of bronchiolitis. It poses a significant burden on the health system, especially through the demand for supplementary oxygen. The clinical spectrum of RSV disease in The Gambia is similar to that seen in developed countries; concomitant bacterial infections are uncommon.
C1 MRC Labs, Banjul, Gambia.
   Hannover Med Sch, Childrens Hosp, D-3000 Hannover, Germany.
   Royal Victoria Hosp, Banjul, Gambia.
   WEC Mission Hosp, Sibanor, Gambia.
   Univ Warwick, Dept Biol Sci, Coventry, W Midlands, England.
RP Weber, MW (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Aderele W I, 1995, Afr J Med Med Sci, V24, P47
   BERMAN S, 1990, Pediatric Emergency Care, V6, P179, DOI 10.1097/00006565-199009000-00003
   CANE PA, 1992, J VIROL METHODS, V40, P297, DOI 10.1016/0166-0934(92)90088-U
   CANE PA, 1994, J CLIN MICROBIOL, V32, P1
   Capeding M R, 1994, Southeast Asian J Trop Med Public Health, V25, P684
   CHATTOPADHYA D, 1992, J TROP PEDIATRICS, V38, P68
   CHERIAN T, 1990, AM J DIS CHILD, V144, P1026
   *COMM PULM NOM AM, 1977, ATS NEWS, P3
   DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006
   DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736
   Doraisingham S, 1981, Ann Acad Med Singapore, V10, P69
   DORAISINGHAM S, 1986, Annals Academy of Medicine Singapore, V15, P9
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   FREYMUTH F, 1991, J CLIN MICROBIOL, V29, P653
   GHAFOOR A, 1990, REV INFECT DIS, V12, pS907
   GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4
   GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005
   GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007
   HALL CB, 1988, J PEDIATR-US, V113, P266
   HALL CB, 1990, J INFECT DIS, V162, P1283
   HAZLETT DTG, 1988, AM J TROP MED HYG, V39, P632
   HENDRY RM, 1989, J INFECT DIS, V160, P185
   HIJAZI Z, 1995, PEDIATR INFECT DIS J, V14, P322, DOI 10.1097/00006454-199504000-00016
   HORTAL M, 1990, REV INFECT DIS, V12, pS915
   JOHN TJ, 1991, REV INFECT DIS, V13, pS463
   LAVIA WV, 1992, J PEDIATR-US, V121, P503
   MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   NWANKWO MU, 1994, ANN TROP PAEDIATR, V14, P125
   NWANKWO MU, 1988, TROP GEOGR MED, V40, P309
   ONG SB, 1982, B WORLD HEALTH ORGAN, V60, P137
   REESE PE, 1991, J CLIN MICROBIOL, V29, P2614
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   SUNG RYT, 1992, EPIDEMIOL INFECT, V108, P147
   SUTMOLLER F, 1995, CLIN INFECT DIS, V20, P854
   SUWANJUTHA S, 1990, REV INFECT DIS, V12, pS923
   TSUTSUMI H, 1988, J CLIN MICROBIOL, V26, P1171
   TUPASI TE, 1990, REV INFECT DIS, V12, pS929
   WAFULA EM, 1985, E AFR MED J, P757
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
   WEBER MW, IN PRESS B WHO
   *WHO, 1995, MANAG CHILDH ILLN
   World Health Organization Programme for the Control of Acute Respiratory Infections, 1990, WHOARI905
   ZELAYA EAC, 1994, AM J TROP MED HYG, V51, P577
NR 46
TC 63
Z9 64
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 1998
VL 17
IS 3
BP 224
EP 230
DI 10.1097/00006454-199803000-00010
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA ZB564
UT WOS:000072485200009
PM 9535250
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Dampha, K
   Bah, M
   Verhulst, A
   Pandey, VS
AF Mattioli, RC
   Dampha, K
   Bah, M
   Verhulst, A
   Pandey, VS
TI Effect of controlling natural field-tick infestation on the growth of
   N'Dama and Gobra zebu cattle in the Gambia
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article
DE cattle; parasitological diseases; cattle growth; The Gambia
ID AMBLYOMMA-VARIEGATUM; LIVEWEIGHT GAIN; AFRICAN TRYPANOSOMIASIS; HOST
   SUSCEPTIBILITY; CROSSBRED CATTLE; PRODUCTIVITY; TSETSE; ZAMBIA
AB The effect of tick infestations on liveweight gain (LWG) was assessed by comparison of weight changes in flumethrin-treated N'Dama and Gobra zebu cattle (16-20 months old) with respective control groups submitted to natural tick challenge over 1 year. Flumethrin was applied monthly, fortnightly or weekly. Preventive treatments against anaplasmosis, babesiosis and trypanosomosis were given. Mortality rate was recorded and post mortem examinations carried out. In both treated and control animals, significantly fewer Hyalomma spp. and Amblyomma variegatum were found on N'Dama than on Gobra zebu cattle. Both breeds were equally susceptible to Rhipicephalus senegalensis infestation. Total annual tick burdens did not cause significant differences in LWG between acaricide-treated and control cattle in either breeds. LWG was also not affected during or after the annual peak of tick infestation (composed mainly by A. variegatum and R. senegalensis). Equally-high mortality (35%), due to unidentified causes, was recorded in acaricide-treated and control Gobra cattle; mortality in N'Dama cattle was 7.5%. In both breeds, about the 90% of mortality occurred at the end of the dry season. Breed differences in tick burden confirm previous results. If tick-borne infections do nor influence LWG or mortality, then it is concluded that intensive tick control is not justifiable in Gambian livestock. (C) 1998 Elsevier Science B.V.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM raffael_mattioli@gam.healthnet.org
CR AESCHLIMANN A, 1967, Acta Tropica, V24, P281
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Barre N, 1993, Rev Elev Med Vet Pays Trop, V46, P349
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DECASTRO JJ, 1993, PARASITOL TODAY, V9, P13
   FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P19, DOI 10.1007/BF02236881
   FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P131, DOI 10.1007/BF02236231
   FOX RGR, 1993, TROP ANIM HEALTH PRO, V25, P203, DOI 10.1007/BF02250869
   Gershwin M.E., 1985, NUTR IMMUNITY
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P411
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P551
   JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201
   KAISER MN, 1988, PREV VET MED, V6, P199, DOI 10.1016/0167-5877(88)90031-1
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KONEY EBM, 1994, VET PARASITOL, V55, P245, DOI 10.1016/0304-4017(94)00648-V
   Mattioli R. C., 1995, Tropicultura, V13, P19
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   Morel P. C., 1958, Revue d'Elevage Med vet Pays trop (ns), V11, P153
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   NORVAL RAI, 1989, VET PARASITOL, V33, P329, DOI 10.1016/0304-4017(89)90142-8
   PEGRAM RG, 1990, MED VET ENTOMOL, V4, P327, DOI 10.1111/j.1365-2915.1990.tb00448.x
   PEGRAM RG, 1989, MED VET ENTOMOL, V3, P313, DOI 10.1111/j.1365-2915.1989.tb00234.x
   Pegram R, 1993, WORLD ANIM REV, V74, P2
   SCHOLTZ MM, 1991, ONDERSTEPOORT J VET, V58, P71
   SHAW APM, 1987, TRYPANOTOLERANT CATT, V2
   SHAW APM, 1987, TRYPANOTOLERANT CATT, V1
   Snedecor G.W., 1971, STAT METHODS
   STACHURSKI F, 1993, VET PARASITOL, V49, P299, DOI 10.1016/0304-4017(93)90128-A
   TATCHELL RJ, 1988, TROP PEST MANAGE, V34, P165
   WACHER TJ, 1994, PARASITOLOGY, V109, P149
NR 32
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
J9 PREV VET MED
JI Prev. Vet. Med.
PD FEB 27
PY 1998
VL 34
IS 2-3
BP 137
EP 146
DI 10.1016/S0167-5877(97)00082-2
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA ZK396
UT WOS:000073316600006
PM 9604263
OA No
DA 2017-08-15
ER

PT J
AU Ankers, P
   Itty, P
   Zinsstag, J
   Trawally, S
   Pfister, K
AF Ankers, P
   Itty, P
   Zinsstag, J
   Trawally, S
   Pfister, K
TI Biannual anthelmintic treatments in village Djallonke sheep in The
   Gambia: effects on productivity and profitability
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article
DE sheep; The Gambia; helminths; anthelmintics; productivity
ID RUMINANTS; NIGERIA
AB An on-farm deworming trial was conducted between 1991 and 1995 on traditionally managed Djallonke sheep in The Gambia to assess the impact on productivity and profitability of prophylactic biannual anthelmintic treatments. Fifteen private flocks with an average of 25 animals per flock participated in the experiment. Half of each flock was dewormed twice a year while the other half served as the control group. The two productivity traits that were significantly improved by the treatment scheme tested were the number of lambs per lambing which increased from 1.11 +/- 0.31 (Mean +/- S.D.) to 1.19 +/- 0.39 and the number of lambings per year which improved from 1.04 +/- 0.53 to 1.22 +/- 0.47. The mortality and weight at 12 months were not significantly affected by the treatment. Monitoring of sheep sales in the flocks and on surrounding markets allowed the calculation of a rate of return to the treatment scheme tested of 246%. Despite large variations in returns, the scheme studied is recommended as over 90% of the adopting farmers would yield positive returns to their investment. (C) 1998 Elsevier Science B.V.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Swiss Fed Inst Technol, Swiss Ctr Int Agr, CH-8092 Zurich, Switzerland.
   Swiss Fed Inst Technol, Dept Agr Econ, CH-8092 Zurich, Switzerland.
   Ctr Suisse Rech Sci, Abidjan 01, Cote Ivoire.
   Lab Pfister, CH-3018 Bern, Switzerland.
RP Ankers, P (reprint author), Rue Riettes, CH-1145 Biere, Switzerland.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   FABIYI JP, 1987, INT J PARASITOL, V17, P435, DOI 10.1016/0020-7519(87)90119-6
   FALL A, 1982, 3 CIPEA RECH
   FAUGERE O, 1991, UNPUB PROPHYLAXIES C
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Rombaut D, 1976, Rev Elev Med Vet Pays Trop, V29, P157
   SUMBERG JE, 1985, TROP ANIM HEALTH PRO, V17, P135, DOI 10.1007/BF02355872
   Thys E, 1990, Rev Elev Med Vet Pays Trop, V43, P187
   TUAH AK, 1985, TROP ANIM HEALTH PRO, V17, P107, DOI 10.1007/BF02360783
   UPTON M, 1985, AGR SYST, V17, P65, DOI 10.1016/0308-521X(85)90014-9
   VASSILIADES G, 1984, REV ELEV MED VET PAY, V37, P293
NR 12
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
J9 PREV VET MED
JI Prev. Vet. Med.
PD FEB 27
PY 1998
VL 34
IS 2-3
BP 215
EP 225
DI 10.1016/S0167-5877(97)00037-8
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA ZK396
UT WOS:000073316600012
PM 9604269
OA No
DA 2017-08-15
ER

PT J
AU Jakobsen, PH
   Rasheed, FN
   Bulmer, JN
   Theisen, M
   Ridley, RG
   Greenwood, BM
AF Jakobsen, PH
   Rasheed, FN
   Bulmer, JN
   Theisen, M
   Ridley, RG
   Greenwood, BM
TI Inflammatory reactions in placental blood of Plasmodium
   falciparum-infected women and high concentrations of soluble E-selectin
   and a circulating P-falciparum protein in the cord sera
SO IMMUNOLOGY
LA English
DT Article
ID ADHESION MOLECULE-1; MALARIA; PREGNANCY; SUSCEPTIBILITY; RESPONSES;
   INDUCTION; DISEASE; AFRICA; VCAM-1; MICE
AB To better understand reasons for increased susceptibility to malaria in pregnancy; and the interrelationships between maternal malaria, local immune reactions and the development of the fetus, concentrations of soluble interleukin-10 (IL-10), cytokine receptors, adhesion molecules, a Plasmodium falciparum protein, glutamate-rich protein (GLURP) and antibodies to P. falciparum rhoptry-associated protein-1 were measured among 105 Gambian women and their neonates. Peripheral blood concentrations of IL-10, soluble cytokine receptors and soluble adhesion molecules were found to be different from those concentrations measured in the placenta. Markers of inflammatory reactions: IL-10, sIL-2R, sIL-4R, and soluble tumour necrosis factor receptor I (sTNF-RI) were found in high concentrations in the placenta, indicating that inflammatory reactions take place in the placenta which has been regarded as an immunoprivileged site. Concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intracellular adhesion molecule-1 (sICAM-1), potential adhesion receptors for malaria parasites, were associated with an active P. falciparum infection in the placenta although the associations did not reach significance. P. falciparum exoantigen, GLURP, was detected in cord blood indicating transplacental passage of malarial antigens. Concentrations of E-selectin were higher in cord blood samples compared with peripheral blood samples, This appeared to be associated with development of cord endothelial cells and not with P. falciparum infection.
C1 Copenhagen Univ Hosp, Dept Clin Microbiol, Ctr Med Parasitol, DK-2200 Copenhagen N, Denmark.
   Copenhagen Univ Hosp, Dept Infect Dis, DK-2200 Copenhagen, Denmark.
   Univ Newcastle Upon Tyne, Dept Pathol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   MRC Labs, Fajara, Gambia.
   Statens Serum Inst, Biotechnol Sector, DK-2300 Copenhagen, Denmark.
   F Hoffmann La Roche & Co Ltd, Preclin Res, Div Pharma, CH-4002 Basel, Switzerland.
RP Jakobsen, PH (reprint author), 7806 Copenhagen Univ Hosp, Dept Clin Microbiol, Tagensvej 20, DK-2200 Copenhagen N, Denmark.
CR BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0
   BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   DRUILHE P, 1976, NOUV PRESSE MED, V5, P1430
   Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   GARIN YJF, 1985, ARCH FR PEDIATR, V42, P917
   GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1
   Jakobsen PH, 1996, AM J TROP MED HYG, V55, P642
   JAKOBSEN PH, 1994, IMMUNOLOGY, V83, P665
   Kraling BM, 1996, AM J PATHOL, V148, P1181
   KWEE L, 1995, DEVELOPMENT, V121, P489
   Maubert B, 1997, INFECT IMMUN, V65, P1251
   MCGREGOR I, 1984, T ROY SOC TROP MED H, V78, P1
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183
   RASHEED FN, 1993, AM J TROP MED HYG, V48, P154
   RASHEED FN, 1995, PARASITE IMMUNOL, V17, P1, DOI 10.1111/j.1365-3024.1995.tb00960.x
   RASHEED FN, 1994, MED HYPOTHESES, V42, P76, DOI 10.1016/0306-9877(94)90079-5
   RIDLEY RG, 1990, MOL BIOCHEM PARASIT, V41, P125, DOI 10.1016/0166-6851(90)90103-S
   Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539
   Smith NC, 1996, PARASITOL TODAY, V12, P4, DOI 10.1016/0169-4758(96)80637-5
   STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P122
   TAYLORROBINSON AW, 1993, SCIENCE, V260, P931
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
NR 28
TC 36
Z9 37
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD FEB
PY 1998
VL 93
IS 2
BP 264
EP 269
PG 6
WC Immunology
SC Immunology
GA YY214
UT WOS:000072124700017
PM 9616377
OA No
DA 2017-08-15
ER

PT J
AU Zinsstag, J
   Ankers, P
   Ndao, M
   Bonfoh, B
   Pfister, K
AF Zinsstag, J
   Ankers, P
   Ndao, M
   Bonfoh, B
   Pfister, K
TI Multiparasitism, production and economics in domestic animals in
   sub-Saharan West Africa
SO PARASITOLOGY TODAY
LA English
DT Editorial Material
ID CROPPING PASTURE SYSTEM; NDAMA CATTLE; GASTROINTESTINAL NEMATODES;
   SEASONAL EPIDEMIOLOGY; SMALL RUMINANTS; DRY SEASON; GAMBIA; PARASITES;
   SENEGAL
C1 Ctr Suisse Rech Sci, Abidjan 01, Cote Ivoire.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   VSF CH, Banjul, Gambia.
   Univ Neuchatel, CH-2007 Neuchatel, Switzerland.
RP Zinsstag, J (reprint author), Ctr Suisse Rech Sci, 01 BP 1303, Abidjan 01, Cote Ivoire.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   ANKERS P, IN PRESS PREV VET ME
   Bonfoh B, 1995, Rev Elev Med Vet Pays Trop, V48, P321
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P268
   Itty P., 1997, Quarterly Journal of International Agriculture, V36, P153
   ITTY P, IN PRESS PREV VET ME
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   KAUFMANN J, 1993, TROP ANIM HLTH PROD, V27, P76
   MATTILI RC, 1994, TROP ANIM HEALTH PRO, V26, P102, DOI 10.1007/BF02239909
   Mattioli R. C., 1995, Tropicultura, V13, P19
   NDAO M, 1995, VET RES, V26, P132
   NDAO M, 1995, VET PARASITOL, V60, P161, DOI 10.1016/0304-4017(94)00771-4
   NDAO M, 1995, VET RES COMMUN, V19, P205, DOI 10.1007/BF01839299
   NDAO M, 1995, REV MED VET-TOULOUSE, V146, P129
   OUEDRAOGO A, IN PRESS TROP ANIM H
   VONKAUFMANN R, 1990, IBIEHM ILCA BIOECONO
   ZINSSTAG J, 1994, VET PARASITOL, V54, P309, DOI 10.1016/0304-4017(94)90103-1
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
   Zinsstag J, 1997, VET PARASITOL, V68, P143, DOI 10.1016/S0304-4017(96)01024-2
   ZINSSTAG J, IN PRESS VET PARASIT
NR 22
TC 12
Z9 13
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0169-4758
J9 PARASITOL TODAY
JI Parasitol. Today
PD FEB
PY 1998
VL 14
IS 2
BP 46
EP 49
DI 10.1016/S0169-4758(97)01183-6
PG 4
WC Parasitology
SC Parasitology
GA YW031
UT WOS:000071888700002
PM 17040694
OA No
DA 2017-08-15
ER

PT J
AU Muller, O
   Corrah, T
   Katabira, E
   Plummer, F
   Mabey, D
AF Muller, O
   Corrah, T
   Katabira, E
   Plummer, F
   Mabey, D
TI Antiretroviral therapy in sub-Saharan Africa
SO LANCET
LA English
DT Letter
C1 Univ Heidelberg, Sch Med, Dept Trop Hyg & Publ Hlth, D-69120 Heidelberg, Germany.
   Makarere Med Sch, Dept Med, Kampala, Uganda.
   MRC, Banjul, Gambia.
   Univ Nairobi, Nairobi, Kenya.
   London Sch Hyg & Trop Med, Dept Clin Sci, London WC1, England.
RP Muller, O (reprint author), Univ Heidelberg, Sch Med, Dept Trop Hyg & Publ Hlth, D-69120 Heidelberg, Germany.
CR CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605
   Hogg RS, 1997, LANCET, V350, P1406, DOI 10.1016/S0140-6736(05)65188-4
   MULLER O, 1993, LANCET, V342, P1117, DOI 10.1016/0140-6736(93)92101-X
NR 4
TC 8
Z9 8
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 3
PY 1998
VL 351
IS 9095
BP 68
EP 68
DI 10.1016/S0140-6736(05)78051-X
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA YP205
UT WOS:000071253100062
PM 9433449
OA No
DA 2017-08-15
ER

PT J
AU Peeling, RW
   Bailey, RL
   Conway, DJ
   Holland, MJ
   Campbell, AE
   Jallow, O
   Whittle, HC
   Mabey, DCW
AF Peeling, RW
   Bailey, RL
   Conway, DJ
   Holland, MJ
   Campbell, AE
   Jallow, O
   Whittle, HC
   Mabey, DCW
TI Antibody response to the 60-kDa chlamydial heat-shock protein is
   associated with scarring trachoma
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 3rd European Meeting for Chlamydial Infections
CY SEP 11-15, 1996
CL VIENNA, AUSTRIA
ID ANTIGENS; PATHOGENESIS; DISEASE; HYPERSENSITIVITY; INFECTION
AB To determine if serum antibody response to the 60-kDa chlamydial heat-shock protein (Chsp60) was associated with scarring trachoma, responses to Chlamydia trachomatis and to Chsp60 from 148 Gambian subjects with trachomatous scarring and from 148 controls without clinical evidence of disease from trachoma-endemic communities were characterized, Chsp60 response was found in 32% of cases and 16% of controls (P <.001), Although C, trachomatis titer was also higher in cases than controls, the prevalence of Chsp60 response between the 2 groups remained significantly different after stratifying for C, trachomatis titer (weighted odds ratio [OR] = 2.1, P =.02), Chsp60 response and C, trachomatis serovar A titer of greater than or equal to 128 were independently associated with scarring trachoma. The presence of HLA class II allele DRB1*0701 was positively correlated with Chsp60 response (OR = 2.6, P =.02), and DQ2B1*0301 and DQB1*0501 were negatively associated (OR = 0.42, P <.001; OR = 0.55, P =.46, respectively).
C1 Lab Ctr Dis Control, Chlamydia Lab, Ctr Hlth Sci, Winnipeg, MB R3A 1R9, Canada.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Kauur Hlth Ctr, Kauur Cent River Div, Kauur, Gambia.
   MRC, Banjul, Gambia.
RP Peeling, RW (reprint author), Lab Ctr Dis Control, Chlamydia Lab, Ctr Hlth Sci, MS 673C,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.
CR BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BEATTY WL, 1993, P NATL ACAD SCI USA, V90, P3998, DOI 10.1073/pnas.90.9.3998
   BRUNHAM RC, 1994, INFECT AGENT DIS, V3, P218
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   FRIEDANK HM, 1995, EUR J CLIN MICROBIOL, V14, P1063
   HAYES LJ, 1995, J INFECT DIS, V172, P268
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Kimani J, 1996, J INFECT DIS, V173, P1437
   MABEY DCW, 1991, J CLIN PATHOL, V44, P285, DOI 10.1136/jcp.44.4.285
   MABEY DCW, 1987, LANCET, V2, P1491
   MORRISON RP, 1989, J EXP MED, V170, P1271, DOI 10.1084/jem.170.4.1271
   PATTON DL, 1994, J INFECT DIS, V169, P680
   TOYE B, 1993, J INFECT DIS, V168, P1236
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1615
NR 15
TC 58
Z9 60
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN
PY 1998
VL 177
IS 1
BP 256
EP 259
DI 10.1086/517367
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA YM597
UT WOS:000071080700042
PM 9419202
OA No
DA 2017-08-15
ER

PT J
AU McClean, P
   Harding, M
   Coward, WA
   Prentice, A
   Austin, S
   Weaver, LT
AF McClean, P
   Harding, M
   Coward, WA
   Prentice, A
   Austin, S
   Weaver, LT
TI Bile salt-stimulated lipase and digestion of non-breast milk fat
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE bile salt-stimulated lipase; breast milk; C-13 breath test; fat
   digestion
ID INFANTS; LIPOLYSIS
AB Background: (13) Carbon (C-13)-lipid breath tests are an effective, noninvasive way of repeatedly measuring fat digestion. The purpose of this study was to assess the contribution of bile salt-stimulated lipase (BSSL) in human milk to the digestion of non-breast-milk fat in Gambian infants.
   Methods: Twelve Gambian infants (aged 3-8 months) were studied on 4 days. C-13-Trioctanoin (7.5 mg/kg, digested by BSSL preduodenal and pancreatic lipases) and C-13-cholesteryl octanoate (25 mg/kg, digested by BSSL and pancreatic lipases) were used as substrates. The percentage dose recovery (PDR) of C-13 in breath during 5 hours was compared after ingestion of each substrate with fresh, expressed breast milk (FBM) or heated, expressed breast milk (HBM). Gas isotope ratio-mass spectrometry was used to measure C-13 enrichment, and breast milk samples were analysed for esterase activity.
   Results: Heating breast milk significantly decreased esterase activity (mean +/- SD values: FBM = 12.2 +/- 2.9 IU/ml; HEM = 0.5 +/- 0.3 IU/ml), and there was no difference in the volumes of milk ingested on each test day (approximately 50 ml). The PDR of C-13 was comparable to that previously described in healthy English infants and was not increased by BSSL. The mean +/- SD PDR of C-13 from trioctanoin was 36.3 +/- 8.4% for FBM and 34.6 +/- 6.3% for HEM (NS). From cholesteryl octanoate, the mean +/- SD PDR of C-13 was 24.3 +/- 8.7% for FBM and 27.1 +/- 7.5% for HBM (NS).
   Conclusions: Bile salt-stimulated lipase may enhance fat digestion in younger or malnourished infants who have a greater degree of pancreatic enzyme deficiency. However, this study suggests that it does not increase the digestion of non-breastmilk fat in healthy, well-nourished infants aged 3 to 8 months from an underprivileged background, who typically ingest frequent small quantities of breast milk.
C1 MRC, Dunn Nutr Unit, Cambridge CB4 1XJ, England.
   MRC, Dunn Nutr Unit, Keneba, Gambia.
RP McClean, P (reprint author), St James Univ Hosp, Dept Paediat, Beckett St, Leeds LS9 7TF, W Yorkshire, England.
CR ALEMI B, 1981, PEDIATRICS, V68, P484
   Amarri S, 1997, ARCH DIS CHILD, V76, P349
   BARBEZAT GO, 1968, PEDIATRICS, V42, P77
   BOEHM G, 1991, J PEDIATR GASTR NUTR, V12, P324, DOI 10.1097/00005176-199104000-00006
   CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8
   GREENBERGER NJ, 1966, J CLIN INVEST, V45, P217, DOI 10.1172/JCI105334
   HAMOSH M, 1981, J CLIN INVEST, V67, P838, DOI 10.1172/JCI110101
   HAMOSH M, 1989, PEDIATRICS, V83, P86
   HERNELL O, 1974, BIOCHIM BIOPHYS ACTA, V369, P234, DOI 10.1016/0005-2760(74)90254-9
   LEBENTHAL E, 1980, PEDIATRICS, V66, P556
   MCCLEAN P, 1993, ARCH DIS CHILD, V69, P366
   MURPHY MS, 1990, ARCH DIS CHILD, V65, P574
   Prentice Andrew, 1986, HUMAN LACTATION, P13
   SAUNIERE JF, 1988, AM J CLIN NUTR, V458, P1233
   SCHOELLER DA, 1977, J LAB CLIN MED, V90, P412
   SCHWABE AD, 1964, J APPL PHYSIOL, V19, P335
   Shiau Y.F., 1987, PHYSL GASTROINTESTIN, P1527
   WATKINS JB, 1977, J LAB CLIN MED, V90, P422
NR 18
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD JAN
PY 1998
VL 26
IS 1
BP 39
EP 42
DI 10.1097/00005176-199801000-00007
PG 4
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA YN816
UT WOS:000071210700007
PM 9443118
OA No
DA 2017-08-15
ER

PT B
AU N'Jai, O
AF N'Jai, O
BE Daniel, JN
   Roshetko, JM
TI Comparison of groundnut hay, sesame seed cake, Leucaena leucocephala,
   and Gliricidia sepium as protein sources for rams
SO NITROGEN FIXING TREES FOR FODDER PRODUCTION
SE FOREST, FARM, AND COMMUNITY TREE RESEARCH REPORTS
LA English
DT Proceedings Paper
CT International Workshop on Nitrogen Fixing Trees for Fodder Production
CY MAR 20-25, 1995
CL PUNE, INDIA
SP Winrock Int, Forest Farm & Community Tree Network, BAIF Dev Res Fdn
AB In the Gambia, groundnut hay (GNH) and sesame seed cake (SSC) are used as supplements for the feeding of rams under grazing and zero-grazing conditions. Although GNH is widely available, there are periodic shortages of SSC. Therefore, two experiments were conducted during the dry season to study the potential of using the protein-rich leaves of trees as an alternative feed source to supplement grazing or confined rams. The objective of the first experiment was to investigate the effects of supplementing food with Leucaena leucocephela (leucaena), Gliricidia sepium (gliricidia), or GNH on the daily liveweight gain (DLWG) of grazing rams, The average DLWG for the groups that were fed leucaena, gliricidia, and GNH during the first 28 days of the trial were 51.8, 61.9, and 79.8 g/day, respectively. At 48 days, average DLWGs were 53.47 and 57.99 g/day for the leucaena-and GNH-fed groups. The second trial examined the performance of rams fed GNH ad libitum and supplemented with two levels of SSC, leucaena, or gliricidia to provide 15 or 30 g crude protein/day. The rams supplemented with the higher level of gliricidia attained the highest DLWG at 83.73 g/day, whereas those supplemented with the lower level of SSC had the lowest level of DLWG at 68.25 g/day. The six treatment means were not significantly different. Because DLWG values with tree foliage were comparable to those obtained with traditional feed sources, appropriate methods of integrating leucaena and gliricidia in traditional sheep production systems should be explored.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
RP N'Jai, O (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WINROCK INT INST AGRICULTURAL DEVELOPMENT
PI MORRILTON
PA FACT NET 38 WINROCK DRIVE, MORRILTON, AR 72110-9537 USA
BN 1-57360-011-3
J9 FOR FARM COMM TREE R
PY 1998
SI SI
BP 170
EP 180
PG 11
WC Agronomy; Forestry
SC Agriculture; Forestry
GA BL07W
UT WOS:000074199600025
OA No
DA 2017-08-15
ER

PT J
AU Maudlin, I
   Welburn, SC
   Milligan, PJM
AF Maudlin, I
   Welburn, SC
   Milligan, PJM
TI Trypanosome infections and survival in tsetse
SO PARASITOLOGY
LA English
DT Article
DE Trypanosoma brucei rhodesiense; Trypanosoma congolense; tsetse; survival
ID GLOSSINA-MORSITANS-MORSITANS; FEEDING-BEHAVIOR;
   REPRODUCTIVE-PERFORMANCE; SALIVARIAN TRYPANOSOMES; INCREASED
   SENSITIVITY; DIPTERA; RATES; SUSCEPTIBILITY; CONGOLENSE; VECTOR
AB The effect of trypanosome infection on vector survival was observed in a line of Glossina morsitans morsitans selected for susceptibility to trypanosome infection. The differential effects of midgut and salivary gland infections on survival were examined by exposing flies to infection with either Trypanosoma congolense which colonizes midgut and mouthparts or Trypanosoma brucei rhodesiense which colonizes midgut and salivary glands. A comparison of the survival distributions of uninfected flies with those exposed to infection showed that salivary gland infection significantly reduces tsetse survival; midgut infection had little or no effect on the survival of tsetse. The significance of these findings is discussed in relation to the vectorial capacity of wild flies.
C1 Univ Glasgow, Anderson Coll, Inst Biomed & Life Sci, Div Mol Genet,Tsetse Res Grp, Glasgow G11 6NU, Lanark, Scotland.
   Medical Research Council Labs, Banjul, Gambia.
RP Maudlin, I (reprint author), Univ Glasgow, Anderson Coll, Inst Biomed & Life Sci, Div Mol Genet,Tsetse Res Grp, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
FU Wellcome Trust
CR Baker J. R., 1957, Annals of Tropical Medicine and Parasitology, V51, P121
   BURSELL E, 1981, PARASITOLOGY, V82, P107
   CLEMENTS AN, 1981, J APPL ECOL, V18, P373, DOI 10.2307/2402401
   Collett Dave, 1994, MODELLING SURVIVAL D
   CORNELISSEN AWCA, 1985, NUCLEIC ACIDS RES, V13, P4661, DOI 10.1093/nar/13.13.4661
   DALE C, 1995, PARASITOLOGY, V111, P187
   Dye C., 1995, P260, DOI 10.1017/CBO9780511629396.010
   DYE C, 1990, PARASITOLOGY, V101, P409
   GARG ML, 1970, APPLIED STATISTICS, V19, P152, DOI 10.2307/2346545
   GOLDER TK, 1982, ANN TROP MED PARASIT, V76, P483
   GOLDER TK, 1984, ACTA TROP, V41, P77
   GOLDER TK, 1987, ACTA TROP, V44, P325
   HARLEY JMB, 1966, B ENTOMOL RES, V57, P23
   HARLEY JMB, 1967, B ENTOMOL RES, V57, P459
   Jackson CHN, 1940, ANN EUGENIC, V10, P332
   JENNI L, 1980, NATURE, V283, P383, DOI 10.1038/283383a0
   LESTER H. M. O., 1928, BULL ENT RES [LONDON], V19, P39
   MAKUMI JN, 1991, MED VET ENTOMOL, V5, P35, DOI 10.1111/j.1365-2915.1991.tb00518.x
   Maudlin I., 1990, Acta Tropica, V48, P9
   MAUDLIN I, 1990, B SOC FRANCAISE P S2, V8, P788
   Milligan PJM, 1995, EXP PARASITOL, V81, P409, DOI 10.1006/expr.1995.1132
   MOLOO SK, 1985, ANN TROP MED PARASIT, V79, P223
   MOLOO SK, 1983, PARASITOLOGY, V86, P51
   NITCHEMAN S, 1988, ANN PARASIT HUM COMP, V63, P163
   NITCHEMAN S, 1990, ANN TROP MED PARASIT, V84, P483
   OKOTH JO, 1986, ANN TROP MED PARASIT, V80, P459
   PATEL NY, 1982, INSECT SCI APPL, V3, P35
   PHELPS RJ, 1978, J APPL ECOL, V15, P743, DOI 10.2307/2402772
   ROGERS D, 1973, Acta Tropica, V30, P24
   RYAN L, 1984, ACTA TROP, V41, P355
   RYAN L, 1986, ENTOMOL GEN, V12, P77
   RYAN L, 1982, ANN SOC BELG MED TR, V62, P291
   WELBURN SC, 1987, ANN TROP MED PARASIT, V81, P453
   WELBURN SC, 1991, PARASITOLOGY, V102, P201
   WOOLHOUSE MEJ, 1993, PARASITOLOGY, V106, P479
   WOOLHOUSE MEJ, 1994, INT J PARASITOL, V106, P479
   YOUNG CJ, 1983, ANN TROP MED PARASIT, V77, P467
NR 37
TC 9
Z9 10
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PY 1998
VL 116
SU S
BP S23
EP S28
PG 6
WC Parasitology
SC Parasitology
GA 100CU
UT WOS:000074797400004
PM 9695107
OA No
DA 2017-08-15
ER

PT J
AU Usen, S
   Adegbola, R
   Mulholland, K
   Jaffar, S
   Hilton, S
   Omosigho, C
   Lahai, G
   Corrah, T
   Palmer, A
   Schneider, G
   Weber, M
   Greenwood, B
AF Usen, S
   Adegbola, R
   Mulholland, K
   Jaffar, S
   Hilton, S
   Omosigho, C
   Lahai, G
   Corrah, T
   Palmer, A
   Schneider, G
   Weber, M
   Greenwood, B
TI Epidemiology of invasive pneumococcal disease in the Western Region, The
   Gambia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pneumococcus; children; The Gambia
ID RESPIRATORY-TRACT INFECTIONS; DEVELOPING-COUNTRIES; ANTIBODY-RESPONSE;
   CONJUGATE VACCINE; CHILDREN; PNEUMONIA; ETIOLOGY; POPULATION; CHILDHOOD;
   INFANTS
AB Background. Streptococcus pneumoniae is a major cause of morbidity and mortality in young children in the developing world, The recent development of pneumococcal polysaccharide/protein conjugate vaccines may make possible prevention of this infection, However, little is known about the epidemiology of invasive pneumococcal disease in children in the developing world,
   Objectives, To determine the incidence and epidemiologic features of invasive pneumococcal disease in children resident in a semiurban area of The Gambia.
   Method, The study was part of a large trial of an Haemophilus influenzae type b vaccine that recruited 42 848 children at the age of 2 months during the period March, 1993, to October, 1995, Follow-up of study children continued until December 31, 1995; therefore the first children to enter the trial were followed for 2.5 years and the last for just a few months. During the period of surveillance, 2256 children were investigated for possible invasive pneumococcal disease when they presented to a hospital or health center, Results, We detected 110 cases of pneumococcal disease. Pneumonia was the most common form of invasive pneumococcal disease observed (75.5% of patients), The incidence of pneumococcal disease was 224 [95% confidence interval (CI) 171, 277] per 100 000 child years among children ages 2 to 11 months, 139 (95% CI 93, 184) per 100 000 among children ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among children ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19, 46 and 2 were isolated most frequently, Susceptibility to pneumococcal disease was not increased significantly among Haemophilus influenzae type b-vaccinated children,
   Conclusions, The pneumococcus is a major cause of bacterial infection in The Gambia, A proposed nine-valent pneumococcal conjugate vaccine for developing countries containing conjugates of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74%% of cases of invasive pneumococcal disease in children resident in the Western Region of The Gambia.
C1 MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   WHO, CH-1211 Geneva, Switzerland.
   Royal Victoria Hosp, Banjul, Gambia.
   WEC Mission Hosp, Sibanor, Gambia.
RP Usen, S (reprint author), MRC Labs Fajara, POB 273, Banjul, Gambia.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   ADEGBOLA RA, 1995, PEDIATR INFECT DIS J, V14, P920
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BAER M, 1995, LANCET, V345, P661, DOI 10.1016/S0140-6736(95)90570-7
   BURMAN LA, 1985, REV INFECT DIS, V7, P133
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277
   DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328
   DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715
   DAVIDSON M, 1994, J INFECT DIS, V170, P368
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   DIOP MI, 1979, PATHOL BIOL, V27, P543
   DOUGLAS RM, 1984, J INFECT DIS, V149, P861
   DOUGLAS RM, 1983, J INFECT DIS, V148, P131
   ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   Giesecke J, 1997, LANCET, V349, P699, DOI 10.1016/S0140-6736(05)60136-5
   Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010
   Leowski J, 1986, World Health Stat Q, V39, P138
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ONEILL KP, 1989, BRIT MED J, V298, P1061
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SHINEFIELD HR, 1995, PEDIATR INFECT DIS J, V14, P978, DOI 10.1097/00006454-199511000-00011
   SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
   WITT CS, 1991, CLIN EXP IMMUNOL, V83, P219
NR 28
TC 62
Z9 66
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 1998
VL 17
IS 1
BP 23
EP 28
DI 10.1097/00006454-199801000-00006
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA YT537
UT WOS:000071617000005
PM 9469390
OA No
DA 2017-08-15
ER

PT J
AU Lisse, I
   Samb, B
   Whittle, H
   Jensen, H
   Soumare, M
   Simondon, F
   Aaby, P
AF Lisse, I
   Samb, B
   Whittle, H
   Jensen, H
   Soumare, M
   Simondon, F
   Aaby, P
TI Acute and long-term changes in T-lymphocyte subsets in response to
   clinical and subclinical measles. A community study from rural Senegal
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID INCREASED MORTALITY; EXCESS MORTALITY; BLOOD SMEARS; CELL;
   IMMUNOSUPPRESSION; IMMUNIZATION; VACCINATION; POPULATIONS; COUNTRIES;
   INFECTION
AB To investigate the possibility of long-term suppression of T-lymphocyte subsets, me examined children exposed to measles at home during an epidemic in rural Senegal, at time of exposure and 1 and 6 months later. The measles case fatality ratio mas 1%. Subclinical measles was common among vaccinated children exposed to measles (45%), Both clinical and subclinical cases of measles showed a significant rise in absolute CD4 count in the incubation period. In the prodromal phase and the first week after the rash, the lymphocyte percentage, the white blood cell count and the absolute CD4 cell numbers mere signficantly reduced. There vc as no persistent decrease of absolute CD4 or CD8 numbers at Ir 6 months after exposure, Measles infection was followed by significant changes in the subset composition, both CD? and CD8 percentages being significantly higher in the second month after measles than among non-seroresponders, These changes were more marked among girls, since they had significantly higher CD4 percentages and CD4/CD8 ratios than boys in the convalescence phase. In conclusion, measles infection is not associated with a long-term suppression of CD4 + or CD8 + T-lymphocytes.
C1 Univ Copenhagen, Hvidovre Hosp, Dept Pathol, DK-2650 Hvidovre, Denmark.
   ORSTOM, Unite Rech Malad Infect & Parasitaires, Dakar, Senegal.
   MRC Labs, Banjul, Gambia.
   Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
   Univ Cheikh Anta Diop, Dakar, Senegal.
RP Lisse, I (reprint author), Univ Copenhagen, Hvidovre Hosp, Dept Pathol, DK-2650 Hvidovre, Denmark.
CR AABY P, 1990, AM J EPIDEMIOL, V132, P211
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009
   ALPERT G, 1984, J INFECT DIS, V149, P1018
   ARNEBORN P, 1983, INFECT IMMUN, V39, P29
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   COOVADIA HM, 1978, ARCH DIS CHILD, V53, P861
   DAGAN R, 1987, J MED VIROL, V22, P175, DOI 10.1002/jmv.1890220209
   ERBER WN, 1984, LANCET, V1, P1042
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M, 1987, RISQUES DECES ASS DI
   Garenne ML, 1982, THESIS U PENNSYLVANI
   GRIFFIN DE, 1993, J INFECT DIS, V168, P275
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   JOFFE MI, 1983, J CLIN INVEST, V72, P971, DOI 10.1172/JCI111069
   Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228
   KIEPIELA P, 1987, SCAND J INFECT DIS, V19, P185, DOI 10.3109/00365548709032397
   Lisse IM, 1997, SCAND J IMMUNOL, V45, P637, DOI 10.1046/j.1365-3083.1997.d01-440.x
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   OHGA S, 1992, EUR J PEDIATR, V151, P492, DOI 10.1007/BF01957751
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   WESLEY A, 1978, CLIN EXP IMMUNOL, V32, P540
   WHITTLE HC, 1988, LANCET, V1, P963
NR 27
TC 13
Z9 13
U1 0
U2 0
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PY 1998
VL 30
IS 1
BP 17
EP 21
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA ZX429
UT WOS:000074514900004
PM 9670353
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Obaro, SK
   DAlessandro, U
   Bennett, S
   Langerock, P
   Targett, GAT
   Greenwood, BM
AF Bojang, KA
   Obaro, SK
   DAlessandro, U
   Bennett, S
   Langerock, P
   Targett, GAT
   Greenwood, BM
TI An efficacy trial of the malaria vaccine SPf66 in Gambian infants -
   second year of follow-up
SO VACCINE
LA English
DT Article
DE malaria; Plasmodium falciparum; malaria vaccine; SPf66
ID PLASMODIUM-FALCIPARUM MALARIA; SYNTHETIC VACCINE; IMMUNE-RESPONSE;
   CHILDREN; POPULATION
AB In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI -20%, 30%] and 2% [95% CI -26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up. (C) 1997 Elsevier Science Ltd.
C1 LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
   INST TROP MED PRINCE LEOPOLD,B-2000 ANTWERP,BELGIUM.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR Alonso PL, 1996, J INFECT DIS, V174, P367
   ALONSO PL, 1994, LANCET, V344, P1175
   BECK HP, 1995, AM J TROP MED HYG, V53, P284
   COOPER JA, 1993, PARASITOL TODAY, V9, P50, DOI 10.1016/0169-4758(93)90031-A
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   LEACH A, 1965, PARASITE IMMUNOL, V17, P441
   MURILLO LA, 1992, PARASITE IMMUNOL, V14, P87, DOI 10.1111/j.1365-3024.1992.tb00008.x
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   NOYA O, 1994, J INFECT DIS, V170, P396
   PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
NR 15
TC 13
Z9 15
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN
PY 1998
VL 16
IS 1
BP 62
EP 67
DI 10.1016/S0264-410X(97)00159-X
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA YK437
UT WOS:A1998YK43700010
PM 9607010
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Wilkins, A
   Ngom, PT
   Sabally, S
   Corrah, T
   Bangali, JE
   Rolfe, M
   Whittle, HC
AF Jaffar, S
   Wilkins, A
   Ngom, PT
   Sabally, S
   Corrah, T
   Bangali, JE
   Rolfe, M
   Whittle, HC
TI Rate of decline of percentage CD4(+) cells is faster in HIV-1 than in
   HIV-2 infection
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE HIV-1; HIV-2; CD4 decline; pathogenesis; The Gambia
ID GUINEA-BISSAU; AIDS; TRANSMISSION; PATTERNS; SENEGAL; COUNTS
AB Increasing evidence suggests that the pathogenesis of HIV-1 is different from that of HIV-2. Thus, we have measured, longitudinally at various times over a median follow-up of 2.1 years, the percentage CD4(+) cells of 94 patients infected with HIV-1 and 164 patients infected with HIV-2. The pattern of decline of CD4% over time was linear for patients with either infection. Multilevel statistical modeling techniques showed that after stratifying for HIV status, the rate of decline of CD4% was faster among patients who died than among those who survived (difference in rate of decline = 2.34% CD4(+) cells/year; p = 0.0002). After stratifying for survival status, the rate of decline was faster and less variable among patients infected with HIV-1 than among patients infected with HIV-2 (difference in rate of decline = 1.12% CD4(+) cells/year; p = 0.05). The proportion of patients who showed no fall in CD4(+) cells was higher in HIV-2 than in HIV-1 infection (p = 0.026). These data suggest fundamental differences between the two infections, with HIV-1 being more pathogenic resulting in a faster and more homogeneous rate of decline than HIV-2. In HIV-2 infection, disease in many patients progresses slowly, but in some the advance is just as fast as that in HIV-1 infection. The reasons for this marked heterogeneity need elucidation to understand the disease and to target therapeutic interventions against HIV-2 in those most at risk.
C1 Univ London London Sch Hyg & Trop Med, Dept Trop & Infect Dis, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   Royal Victoria Hosp, Banjul, Gambia.
   MRC Labs, Fajara, Senegal.
RP Jaffar, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Trop & Infect Dis, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.
CR DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   Goldstein H, 1995, MULTILEVEL STAT MODE
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63
   LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421
   Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MIYAZAKI M, 1995, INT J STD AIDS, V6, P75
   PHILLIPS A, 1992, J ACQ IMMUN DEF SYND, V5, P920
   PHILLIPS AN, 1991, LANCET, V337, P389
   PHILLIPS AN, 1992, AIDS, V6, P735, DOI 10.1097/00002030-199207000-00018
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
NR 19
TC 52
Z9 52
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD DEC 15
PY 1997
VL 16
IS 5
BP 327
EP 332
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YM287
UT WOS:000071048500003
PM 9420309
OA No
DA 2017-08-15
ER

PT J
AU Zinsstag, J
   Ankers, P
   Itty, P
   Njie, M
   Kaufmann, J
   Pandey, VS
   Pfister, K
AF Zinsstag, J
   Ankers, P
   Itty, P
   Njie, M
   Kaufmann, J
   Pandey, VS
   Pfister, K
TI Effect of strategic gastrointestinal nematode control on fertility and
   mortality of N'Dama cattle in The Gambia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE cattle, nematoda; N'Dama cattle; fertility; mortality; control methods;
   fenbendazole; The Gambia; Sudano-Guinean savanna; West Africa
ID PARASITE CONTROL; PERFORMANCE; CALVES; DESIGN
AB A large-scale longitudinal study was undertaken to investigate the effects of a strategic treatment of gastrointestinal nematodes on the mortality and fertility of N'Dama cattle under village conditions. Initially, 1046 animals from 26 private N'Dama cattle herds, were monitored from October 1989 to December 1994. Each herd was stratified by age and the animals were randomly allocated to two groups with a similar average age. One group received a single anthelmintic treatment of fenbendazole (Panacur(TM), 7.5 mg/kg BW, Hoechst Veterina AG) in October 1989, whereas the other group remained untreated. In July 1990, the herds were subdivided into two different treatment schemes. In the herds of scheme 1, the treated animals (Treatment group I) were treated once (in August), whereas in the herds of scheme 2, the treated animals (Treatment group II) were treated twice (in July and September). The same treatment schedule was used in the subsequent rainy seasons until December 1994. One group in every herd of both schemes served as control (Treatment group 0) and received no anthelmintic treatment throughout the study. The average annual cumulative incidence mortality between 0-1 year was more than two times higher in treated animals compared to their controls (21% against 7.5%). No differences were found in older age categories. Survival analysis confirmed differences in mortality from 0-1 year, but were not significant in proportional hazard models. The 25% quantiles of age at first calving was used to quantify differences between twice treated animals (50.2 months) and its controls (58.3 months) which represents a decrease of 8 months in twice treated animals. Annual calving rates of twice treated animals were 52.2% compared to 43.6% in the control group (P < 0.001), which is an increase of 8.6% to the control rate, Possible causes of increased mortality in 0-1 year old treated calves an discussed. We can conclude that in the present epidemiological situation and the given parasite spectrum, gastro-intestinal nematodes mainly affect host fertility. Strategic control of gastro-intestinal nematodes is thus recommended for young heifers up to their age of first calving provided the overall financial analysis of the intervention is beneficial. (C) 1997 Elsevier Science B.V.
C1 Ctr Suisse Rech Sci, Abidjan, Cote Ivoire.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   ETH Zentrum, Swiss Ctr Int Agr, Dept Agr Econ, SOL, CH-8092 Zurich, Switzerland.
   Bundesamt Vet, CH-3097 Liebefeld, Switzerland.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Neuchatel, Dept Zool, CH-2000 Neuchatel, Switzerland.
RP Zinsstag, J (reprint author), Ctr Suisse Rech Sci, 01 BP 1303, Abidjan, Cote Ivoire.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR AGYEMANG K, 1991, ANIM REPROD SCI, V26, P51, DOI 10.1016/0378-4320(91)90065-8
   Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   Armitage P., 1987, STAT METHODS MED RES
   BOCH J, 1983, VET PARASITOLOGIE
   CHARTIER C, 1991, REV MED VET-TOULOUSE, V142, P57
   CHIEJINA SN, 1995, EQUATOR, V7, P10
   COX DR, 1972, J R STAT SOC B, V34, P187
   FALL A, 1982, EVALUATION PRODUCTIV
   GIBBS HC, 1993, VET PARASITOL, V46, P271, DOI 10.1016/0304-4017(93)90064-T
   HANSEN JW, 1995, 6 S TROP AN HLTH PRO
   HAWKINS JA, 1993, VET PARASITOL, V46, P159, DOI 10.1016/0304-4017(93)90056-S
   Horchner F., 1987, Mitteilungen der Osterreichischen Gesellschaft fur Tropenmedizin und Parasitologie, V9, P173
   Itty P, 1992, EC VILLAGE CATTLE PR
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   Leperre P., 1992, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V45, P55
   Martin S.W., 1987, VET EPIDEMIOLOGY PRI
   MCDERMOTT JJ, 1994, PREV VET MED, V18, P175, DOI 10.1016/0167-5877(94)90074-4
   NJIE A, 1991, TROP ANIM HEALTH PRO, V23, P45, DOI 10.1007/BF02361269
   OKELLY JC, 1988, ANIM REPROD SCI, V16, P177, DOI 10.1016/0378-4320(88)90011-5
   PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1
   SACHS L, 1984, ANGEWANDTE STAT ANWE
   SAS Institute, 1996, SAS STAT SOFTW CHANG
   SRIKITJAKARN L, 1987, TROP MED PARASITOL, V38, P191
   STAMMBERGER I, 1993, 14 C WORLD ASS ADV V
   TUCKER CM, 1989, ASAS WS P, V40, P339
   VONKAUFMANN R, 1990, USERS MANUAL TECHNIC
   WIESNER EE, 1993, HANDLEXIKON TIERARZT
   ZAJAC AM, 1991, VET PARASITOL, V40, P281, DOI 10.1016/0304-4017(91)90108-8
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
   Zinsstag J, 1997, VET PARASITOL, V68, P143, DOI 10.1016/S0304-4017(96)01024-2
NR 30
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD DEC 15
PY 1997
VL 73
IS 1-2
BP 105
EP 117
DI 10.1016/S0304-4017(97)80001-5
PG 13
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA YQ594
UT WOS:000071403500012
PM 9477497
OA No
DA 2017-08-15
ER

PT J
AU Falade, AG
   Mulholland, EK
   Adegbola, RA
   Greenwood, BM
AF Falade, AG
   Mulholland, EK
   Adegbola, RA
   Greenwood, BM
TI Bacterial isolates from blood and lung aspirate cultures in Gambian
   children with lobar pneumonia
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID ETIOLOGY
AB As part of a study of the aetiology of pneumonia in malnourished and well nourished children, 100 children aged between 3 and 58 months with pneumonia were investigated using blood culture and culture of lung or pleural aspirates. In 44 children one species of bacterium was isolated from blood (6), lung culture (30), or both (8), while in eight children two species were isolated. In four of these eight children, one organism was isolated from blood culture, while a different organism was isolated from lung or pleural aspirate, indicating that blood culture does not always reflect the true aetiology of pneumonia. In this group of children with lobar pneumonia or empyema, blood culture alone yielded a bacterial pathogen in 18 (18%) cases, while the addition of percutaneous lung aspiration or pleural aspiration increased the yield to 52 (52%). In experienced hands the procedure of percutaneous lung aspiration is safe. It gave significant therapeutic advantages to the six children in this series from whom Staphylococcus aureus or Mycobacterium tuberculosis were isolated.
C1 MRC LABS,FAJARA,GAMBIA.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BALE JR, 1990, REV INFECT DIS, V12, pS861
   FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299
   SHANN F, 1984, LANCET, V2, P537
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
NR 5
TC 44
Z9 49
U1 0
U2 0
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 1997
VL 17
IS 4
BP 315
EP 319
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA YK183
UT WOS:A1997YK18300003
PM 9578790
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   vanHensbroek, MB
   Palmer, A
   Banya, WAS
   Jaffar, S
   Greenwood, BM
AF Bojang, KA
   vanHensbroek, MB
   Palmer, A
   Banya, WAS
   Jaffar, S
   Greenwood, BM
TI Predictors of mortality in Gambian children with severe malaria anaemia
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID AFRICAN CHILDREN; TRANSMISSION; TRANSFUSION
AB Severe malaria anaemia is a frequent cause of admission to hospital in tropical Africa and about 10% of children with this condition die. To determine ways in which mortality might be reduced we have studied risk factors for a fatal outcome in 173 children with severe malaria anaemia who were assigned to receive blood transfusion because they had a packed cell volume of less than 12% and/or signs of respiratory distress. Twenty-three children died (13%); in 15 cases (65%) death occurred before blood transfusion was given. The presence of respiratory distress was found to be the most important predictor of death. Children with severe malaria anaemia and signs of respiratory distress must therefore be transfused as soon as possible.
C1 ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
CR BLOLAND PB, 1993, J INFECT DIS, V167, P932
   BOJANG KA, 1997, T R SOC TROP MED HYG
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   JAGER H, 1990, AIDS, V4, P571
   LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O
   Marsh K, 1996, ANN TROP MED PARASIT, V90, P395
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   TAYLOR TE, 1993, Q J MED, V86, P99
NR 11
TC 40
Z9 40
U1 0
U2 4
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD DEC
PY 1997
VL 17
IS 4
BP 355
EP 359
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA YK183
UT WOS:A1997YK18300009
PM 9578796
OA No
DA 2017-08-15
ER

PT J
AU N'Gom, PT
   Jaffar, S
   Ricard, D
   Wilkins, A
   Ariyoshi, K
   Morgan, G
   Da Silva, AP
   Whittle, HC
AF N'Gom, PT
   Jaffar, S
   Ricard, D
   Wilkins, A
   Ariyoshi, K
   Morgan, G
   Da Silva, AP
   Whittle, HC
TI Immune stimulation by syphilis and malaria in HIV-2-infected and
   uninfected villagers in West Africa
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE HIV-2 infection; malaria; syphilis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; PLASMODIUM-FALCIPARUM; HIV-1
   INFECTION; ACTIVATION; CHILDREN; AIDS; IMMUNOSUPPRESSION; NEOPTERIN
AB Go-infections such as Mycobacterium tuberculosis (TB) and Pneumocystis pneumonia may affect the progress of HIV infection and speed the onset of death. As malaria and syphilis are both endemic in West Africa we examined their effects on HIV-2 infection, for these may also accelerate the progress of disease. A community-based case-control study was undertaken in a rural village in Guinea-Bissau, West Africa. One hundred and fifty asymptomatic subjects seropositive for HIV-2 and 154 age- and sex-matched controls were enrolled. Venous blood samples taken into EDTA were stained within six hours of collection with CD4 and CD8 monoclonal antibodies and processed by Q-Prep machine in the field. The stained cells were then transported on ice by road and analysed by FACS-can at the base laboratory in The Gambia within a week. The mean CD4% was significantly lower and geometric mean neopterin and beta(2)-microglobulin levels were significantly higher in the HIV-2-infected subjects than in the controls (P < 0.01 for all cases venus all controls). The mean CD4% was lower and beta(2)-microglobulin level was higher in both HIV-2 and control subjects with active or past syphilis when compared with subjects with no syphilis; however, syphilis did not have a marked effect on plasma neopterin level. Malaria infection raised neopterin levels, but had little effect on CD4%. Overall multiple regression analysis allowing for HIV-2 infection and other variables showed that syphilis lowered CD4% (P=0.01) and raised beta(2)-microglobulin levels (P=0.05) and malaria raised neopterin levels (P=0.05). The conclusions are that HIV-2 infection is associated with lower CD4% and higher neopterin and beta(2)-microglobulin levels than controls, and co-infection with syphilis is associated with a further lowering of CD4%, suggesting a worse suppression of the immune system. Co-infection with malaria is associated with a modest immune disturbance.
C1 MRC Labs, Banjul, Gambia.
   Inst Child Hlth, London, England.
   Minist Hlth, Bissau, Guinea Bissau.
RP N'Gom, PT (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   BROWN AE, 1990, CLIN EXP IMMUNOL, V82, P97
   BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002
   CAYLA JA, 1993, LANCET, V342, P50, DOI 10.1016/0140-6736(93)91913-7
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6
   FITZGERALD TJ, 1992, INFECT IMMUN, V60, P3475
   GREENWOOD BM, 1972, LANCET, V1, P169
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   HO M, 1986, J INFECT DIS, V153, P763
   HOOK EW, 1989, J INFECT DIS, V160, P530
   MARGOLICK JB, 1987, J IMMUNOL, V138, P1719
   MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911
   PANTALEO G, 1993, NEW ENGL J MED, V328, P327
   REIBNEGGER G, 1991, CANCER DETECT PREV, V15, P483
   RICHARD D, 1994, AIDS, V8, P977
   SCHRIER RD, 1993, J VIROL, V67, P5713
   SNOW RW, 1989, ANN TROP MED PARASIT, V83, P559
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE HC, 1990, CLIN EXP IMMUNOL, V80, P213
   WILLIAMSON WA, 1978, LANCET, V1, P1328
   ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813
NR 23
TC 7
Z9 8
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PD DEC
PY 1997
VL 54
IS 4
BP 251
EP 255
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA YP643
UT WOS:000071299500005
PM 9624734
OA No
DA 2017-08-15
ER

PT J
AU Doherty, T
   Pinder, M
AF Doherty, T
   Pinder, M
TI Malaria prevention: Where do we go from here?
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
AB The prevention of malaria, let alone its eradication, remains a dream for the populations of endemic areas, and there seem to be little grounds for optimism about controlling the disease. Three papers published in the past year, however, concerning topics as diverse as malaria in pregnancy, preliminary data with a novel candidate vaccine and gametocytocidal therapy, suggest that there may be just a glimmer of hope. And then, as always, there are bed nets...
RP Doherty, T (reprint author), MRC LABS,MALARIA PROGRAMME,POB 273,BANJUL,GAMBIA.
CR Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6
NR 5
TC 0
Z9 0
U1 0
U2 0
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD DEC
PY 1997
VL 10
IS 6
BP 466
EP 468
DI 10.1097/00001432-199712000-00010
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA YH380
UT WOS:A1997YH38000010
OA No
DA 2017-08-15
ER

PT J
AU GhaemMaghami, S
   Bailey, RL
   Mabey, DCW
   Hay, PE
   Mahdi, OSM
   Joof, HM
   Whittle, HC
   Ward, ME
   Lewis, DJM
AF GhaemMaghami, S
   Bailey, RL
   Mabey, DCW
   Hay, PE
   Mahdi, OSM
   Joof, HM
   Whittle, HC
   Ward, ME
   Lewis, DJM
TI Characterization of B-cell responses to Chlamydia trachomatis antigens
   in humans with trachoma
SO INFECTION AND IMMUNITY
LA English
DT Article
ID ANTIBODY-SECRETING CELLS; ORAL IMMUNIZATION; SOLID-PHASE;
   IMMUNE-RESPONSE; INFECTION; MUCOSAL; CHOLERA; EPIDEMIOLOGY;
   IMMUNOBLASTS; INFERTILITY
AB The circulating B-cell responses to Chlamydia trachomatis of 60 children and 34 adults in The Gambia were characterized in a cross-sectional study of different grades of trachoma, using the enzyme-linked immunospot (ELISPOT) assay, Antibody-secreting cells (ASCs) specific to chlamydial major outer membrane protein (MOMP), heat shock protein 60, and whole elementary bodies were detected in children with no evidence of ocular disease, and the immunoglobulin (IgA) response was significantly increased in those with follicular trachoma, In marked contrast, children with the most intense ocular inflammation paradoxically had an almost completely absent B-cell response of all isotypes and to all chlamydial antigens, but with normal serum IgG and IgA responses, which was even lower than in the group with no ocular inflammation, Adults with or without evidence of trachomatous scarring had equivalent numbers of circulating B cells, principally IgA, to all chlamydial antigens. Plasmablasts secreting antibodies to MOMP were present in the urine of children in the absence of urogenital infection detectable by PCR, and relative numbers were 8 to 25 times higher than in blood, suggesting site-specific homing within a common mucosal immune system, These results suggest that ELISPOT assay of ongoing B-cell responses detects suppression of chlamydia-specific IgA ASCs during the proinflammatory response to ocular chlamydial infection seen in intense trachoma, which may play a role in tissue damage leading to trachomatous scarring.
C1 ST GEORGE HOSP,SCH MED,DIV INFECT DIS,LONDON SW17 0RE,ENGLAND.
   ST GEORGE HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON SW17 0RE,ENGLAND.
   LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1,ENGLAND.
   UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MOL MICROBIOL,SOUTHAMPTON,HANTS,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
OI Lewis, David JM/0000-0003-3105-9075
CR BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1993, EPIDEMIOL INFECT, V111, P315
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BAILEY RL, 1996, P EUR SOC CHLAMYDIAL, V3, P177
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   BRUNHAM RC, 1985, J INFECT DIS, V152, P1275
   BRUNHAM RC, 1987, J INFECT DIS, V155, P749
   BRUNHAM RC, 1994, INFECT AGENT DIS, V3, P218
   BRUNHAM RC, 1992, J INFECT DIS, V165, P1076
   BRUNHAM RC, 1983, INFECT IMMUN, V39, P1491
   CASTELLOBRANCO LR, 1993, CLIN SCI, V84, P6
   CASTELLOBRANCO LRR, 1994, VACCINE, V12, P65, DOI 10.1016/0264-410X(94)90012-4
   CUI ZD, 1991, INFECT IMMUN, V59, P1465
   CZERKINSKY C, 1991, INFECT IMMUN, V59, P996
   CZERKINSKY C, 1993, CLIN INFECT DIS, V16, pS106
   CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3
   FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381
   Hall J G, 1980, Monogr Allergy, V16, P100
   HO F, 1986, EUR J IMMUNOL, V16, P1297, DOI 10.1002/eji.1830161018
   HOLMGREN J, 1992, CURR OPIN IMMUNOL, V4, P387, DOI 10.1016/S0952-7915(06)80027-0
   HOLT PG, 1984, J IMMUNOL METHODS, V74, P1, DOI 10.1016/0022-1759(84)90360-0
   JOHANSSON E, 1995, CLIN IMMUNOL IMMUNOP, V76, pS43
   Johansson M, 1997, INFECT IMMUN, V65, P1032
   KANTELE A, 1986, J INFECT DIS, V153, P1126
   LEWIS DJM, 1991, EUR J IMMUNOL, V21, P2087, DOI 10.1002/eji.1830210917
   MAGEE DM, 1995, INFECT IMMUN, V63, P516
   Malinverni R, 1996, CURR OPIN INFECT DIS, V9, P150, DOI 10.1097/00001432-199606000-00004
   MANCLARK CR, 1986, MANUAL CLIN IMMUNOLO, V3, P388
   MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892
   MESTECKY J, 1988, AM J KIDNEY DIS, V12, P378
   Morrison R P, 1991, Semin Immunol, V3, P25
   PAL S, 1994, INFECT IMMUN, V62, P3354
   PAL S, 1992, INFECT IMMUN, V60, P5294
   PEELING RW, 1996, P EUR SOC CHLAMYDIAL, V3, P73
   PICKETT MA, 1988, MOL MICROBIOL, V2, P681, DOI 10.1111/j.1365-2958.1988.tb00077.x
   QUIDINGJARBRINK M, 1995, EUR J IMMUNOL, V25, P322, DOI 10.1002/eji.1830250203
   RAHMAN MU, 1992, RHEUM DIS CLIN N AM, V18, P67
   SALMI M, 1995, J EXP MED, V181, P137, DOI 10.1084/jem.181.1.137
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1
   SOWA S, 1969, J HYG-CAMB, V67, P699
   SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282
   TREHARNE JD, 1985, REV INFECT DIS, V7, P760
   VanCott JL, 1996, J IMMUNOL, V156, P1504
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1615
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1133
   Ward ME, 1995, APMIS, V103, P769
   WATSON RR, 1973, INFECT IMMUN, V7, P597
   WILLIAMS DM, 1987, INFECT IMMUN, V55, P223
NR 50
TC 13
Z9 13
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 1997
VL 65
IS 12
BP 4958
EP 4964
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YJ227
UT WOS:A1997YJ22700010
PM 9393782
OA No
DA 2017-08-15
ER

PT J
AU Goossens, B
   Osaer, S
   Kora, S
   Jaitner, J
   Ndao, M
   Geerts, S
AF Goossens, B
   Osaer, S
   Kora, S
   Jaitner, J
   Ndao, M
   Geerts, S
TI The interaction of Trypanosoma congolense and Haemonchus contortus in
   Djallonke sheep
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Haemonchus contortus; Trypanosoma congolense; interaction; Djallonke
   sheep; trypanotolerance; genetic resistance
ID AFRICAN TRYPANOSOMIASIS; NDAMA CATTLE; INFECTIONS; GAMBIA;
   SUSCEPTIBILITY; DIAGNOSIS
AB The interaction between Trypanosoma congolense and Haemonchus contortus was studied in 5 groups of 8 Djallonke sheep. Two groups received a single infection with either H. contortus or T. congolense, and 2 groups were infected with T. congolense followed by H. contortus (TH) or vice versa (HT). One group was kept as uninfected controls. Mortality due to infection was observed only in the dual infection groups. In the TH group, the effects were more acute whereas in the HT group they were more chronic. No significant differences in weight gain could be demonstrated between infected and control groups. Djallonke sheep are able to withstand a single infection with either T. congolense or H. contortus, which confirms their trypanotolerant nature and provides preliminary indication of resistance against helminth infections. However, when exposed to successive infections with both parasites, some of the animals lose this tolerance. (C) 1997 Australian Society for Parasitology. Published by Elsevier Science Ltd.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, Dept Anim Hlth, B-2000 Antwerp, Belgium.
RP Goossens, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   Anosa V O, 1988, Rev Elev Med Vet Pays Trop, V41, P65
   ASSOKU R K G, 1981, Bulletin of Animal Health and Production in Africa, V29, P1
   BAKER RL, 1995, P 6 S TROP AN HLTH P, P40
   Bengaly Z, 1993, Rev Elev Med Vet Pays Trop, V46, P563
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   DWINGER RH, 1994, VET PARASITOL, V54, P353, DOI 10.1016/0304-4017(94)90002-7
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   GAMBLE HR, 1992, VET PARASITOL, V41, P211, DOI 10.1016/0304-4017(92)90081-J
   GOOSSENS B, IN PRESS RES VET SCI
   GRIFFIN L, 1981, J COMP PATHOL, V91, P85, DOI 10.1016/0021-9975(81)90048-7
   GRIFFIN L, 1981, J COMP PATHOL, V91, P97, DOI 10.1016/0021-9975(81)90049-9
   Holmes PH, 1987, PARASITOLOGY, V94, P29
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   MACKENZIE DM, 1975, VET REC, V97, P452
   MCKENNA PB, 1973, RES VET SCI, V14, P312
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   NANTULYA VM, 1982, CLIN EXP IMMUNOL, V47, P234
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PARIS J, 1982, ACTA TROP, V39, P307
   PRESTON JM, 1979, RES VET SCI, V26, P134
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   ROBERTS JL, 1981, VET PARASITOL, V8, P165, DOI 10.1016/0304-4017(81)90044-3
   Snedecor G. W., 1980, STAT METHODS
   THIENPONT D, 1979, DIAGNOSE VERMINOSE D
NR 25
TC 27
Z9 27
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD DEC
PY 1997
VL 27
IS 12
BP 1579
EP 1584
DI 10.1016/S0020-7519(97)00094-5
PG 6
WC Parasitology
SC Parasitology
GA YQ662
UT WOS:000071410700015
PM 9467745
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Obaro, SK
   Leach, A
   D'Alessandro, U
   Bennett, S
   Metzger, W
   Ballou, WR
   Targett, GAT
   Greenwood, BM
AF Bojang, KA
   Obaro, SK
   Leach, A
   D'Alessandro, U
   Bennett, S
   Metzger, W
   Ballou, WR
   Targett, GAT
   Greenwood, BM
TI Follow-up of Gambian children recruited to a Pilot safety and
   immunogenicity study of the malaria vaccine SPf66
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE malaria; vaccine; SPf66; Gambian children
ID TRIAL; EFFICACY; INFANTS
AB A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5% level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Med Res Council Labs, Fajara, Gambia.
   Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Immunol, Washington, DC 20307 USA.
RP Greenwood, BM (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RI D'Alessandro, Umberto/D-3457-2015; Metzger, Wolfram/A-6878-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; 
CR ALONSO PL, 1994, LANCET, V344, P1175
   BOJANG KA, 1997, IN PRESS VACCINE
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   GRAYSTON JT, 1962, ANN NY ACAD SCI, V98, P352, DOI 10.1111/j.1749-6632.1962.tb30558.x
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P595, DOI 10.1016/0035-9203(89)90364-7
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   TANNER M, 1995, PARASITOL TODAY, V11, P10, DOI 10.1016/0169-4758(95)80098-0
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
NR 11
TC 9
Z9 9
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD DEC
PY 1997
VL 19
IS 12
BP 579
EP 581
DI 10.1046/j.1365-3024.1997.d01-171.x
PG 3
WC Immunology; Parasitology
SC Immunology; Parasitology
GA YQ115
UT WOS:000071350000006
PM 9458470
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
   Huo, ZM
   Banya, WAS
   Henderson, MC
   Monteil, MA
   Leach, A
   Greenwood, BM
AF Obaro, SK
   Huo, ZM
   Banya, WAS
   Henderson, MC
   Monteil, MA
   Leach, A
   Greenwood, BM
TI A glycoprotein pneumococcal conjugate vaccine primes for antibody
   responses to a pneumococcal polysaccharide vaccine in Gambian children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Streptococcus pneumoniae; pneumococcal vaccines; immunologic priming
ID INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; CAPSULAR POLYSACCHARIDE;
   YOUNG-CHILDREN; DISEASE; SERUM
AB Background. Streptococcus pneumoniae is a major cause of acute respiratory infections and acute bacterial meningitis in children, Pneumococcal polysaccharide vaccines are poorly immunogenic in this highly vulnerable group, but pro tein polysaccharide conjugate vaccines are likely to be more effective.
   Objectives. To determine whether immunization of infants with a pneumococcal conjugate vaccine induces immunologic memory.
   Methods. Eighty-four Gambian children, who had been vaccinated previously with two or three doses of a pentavalent pneumococcal conjugate vaccine (CRM197) or with a Haemophilus influenzae type b (Hib) conjugate vaccine were immunized when approximately 2 years old with a 23-valent pneumococcal polysaccharide vaccine, and a blood sample was obtained 10 days later, Pneumococcal antibody titers in prevaccination and postvaccination sera were measured by enzyme-linked immunosorbent assay and by an opsonophagocytic assay.
   Results. On revaccination with a pneumococcal polysaccharide vaccine, children who had previously received pneumococcal conjugate vaccine had higher antibody concentrations to each of the five polysaccharide components of the conjugate vaccine than did control children. For type 6B polysaccharide, which is poorly immunogenic in young children, postvaccination antibody concentrations were 0.37, 27.6 and 50.9 mu g/ml in children who had received no previous pneumococcal immunization or two or three doses of conjugate vaccine, respectively. Type 14 antibodies produced after revaccination were of high avidity and had opsonic activity.
   Conclusion. Vaccination of young infants with two or three doses of a pneumococcal conjugate vaccine primes the immune system to respond strongly and rapidly on subsequent exposure to pneumococcal polysaccharide.
C1 MRC LABS, FAJARA, GAMBIA.
   CHELSEA & WESTMINSTER HOSP, DEPT IMMUNOL, LONDON, ENGLAND.
   ERIC WILLIAMS MED SCI COMPLEX, DEPT PATHOL & MICROBIOL, CHAMPS FLEURS, TRINID & TOBAGO.
   LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND.
CR DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715
   ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   KIM YT, 1978, IMMUNOLOGY, V34, P669
   Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   LORTAN JE, 1993, CLIN EXP IMMUNOL, V91, P54
   MCDONALD RA, 1988, J IMMUNOL METHODS, V106, P191
   OBARO SK, 1996, IMMUNOL LETT, V49, P3
   OBrien KL, 1996, PEDIATR INFECT DIS J, V15, P425, DOI 10.1097/00006454-199605000-00009
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590
   RILEY ID, 1986, LANCET, V2, P877
   STEIN KE, 1990, INT CONGR SER, V862, P189
   STEINHOFF MC, 1994, PEDIATR INFECT DIS J, V13, P368, DOI 10.1097/00006454-199405000-00007
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
NR 16
TC 63
Z9 64
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD DEC
PY 1997
VL 16
IS 12
BP 1135
EP 1140
DI 10.1097/00006454-199712000-00007
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA YL245
UT WOS:A1997YL24500006
PM 9427458
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Babiker, A
   Darbyshire, J
   Nunn, A
   Barreto, S
   Alonso, P
   Badaro, R
   Barros, F
   Victoria, C
   Binka, F
   Biryahwaho, B
   Byabamazima, C
   Sempala, S
   Tugume, B
   Kalebu, P
   KengeyaKayondo, J
   Whitworth, J
   Paxton, L
   Convit, J
   Corrah, T
   McAdam, K
   Datta, M
   Dowlati, Y
   Fine, P
   Hall, A
   Hayes, R
   Jaffar, S
   Ross, D
   Smith, P
   deFrancisco, A
   Godal, T
   John, J
   Lansang, MA
   TanTorres, T
   Morrow, R
   Nicoll, A
   Peckham, C
   Serwadda, D
   Tanner, M
AF Aaby, P
   Babiker, A
   Darbyshire, J
   Nunn, A
   Barreto, S
   Alonso, P
   Badaro, R
   Barros, F
   Victoria, C
   Binka, F
   Biryahwaho, B
   Byabamazima, C
   Sempala, S
   Tugume, B
   Kalebu, P
   KengeyaKayondo, J
   Whitworth, J
   Paxton, L
   Convit, J
   Corrah, T
   McAdam, K
   Datta, M
   Dowlati, Y
   Fine, P
   Hall, A
   Hayes, R
   Jaffar, S
   Ross, D
   Smith, P
   deFrancisco, A
   Godal, T
   John, J
   Lansang, MA
   TanTorres, T
   Morrow, R
   Nicoll, A
   Peckham, C
   Serwadda, D
   Tanner, M
TI Ethics of HIV trials
SO LANCET
LA English
DT Letter
C1 EPIDEMIOL RES UNIT, COPENHAGEN, DENMARK.
   UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON W1N 8AA, ENGLAND.
   CTR PESQUISAS RENE RACHOU FIOCRUZ, LAB EPIDEMIOL, BELO HORIZONTE, MG, BRAZIL.
   HOSP CLIN BARCELONA, EPIDEMIOL RES UNIT, BARCELONA, SPAIN.
   UNIV FED BAHIA, BRAZILIAN SOC INFECT DIS, SALVADOR, BA, BRAZIL.
   UNIV FED PELOTAS, DEPT SOCIAL MED, PELOTAS, BRAZIL.
   MINIST HLTH, NAVRONGO HLTH RES CTR, NAVRONGO, GHANA.
   AREA HOSP VARGAS, INST BIOMED, CARACAS, VENEZUELA.
   MRC LABS, BANJUL, GAMBIA.
   INDIAN COUNCIL MED RES, TB RES CTR, MADRAS, TAMIL NADU, INDIA.
   CTR RES & TRAINING SKIN DIS & LEPROSY, TEHRAN, IRAN.
   LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND.
   ICDDR B, PUBL HLTH SCI DIV, DHAKA, BANGLADESH.
   WHO, UNDP, WORLD BANK, SPECIAL PROGRAMME RES & TRAINING TROP DIS, GENEVA, SWITZERLAND.
   CHRISTIAN MED COLL & HOSP, VELLORE, TAMIL NADU, INDIA.
   UNIV PHILIPPINES, COLL MED, CLIN EPIDEMIOL UNIT, MANILA, PHILIPPINES.
   JOHNS HOPKINS UNIV, DEPT INT HLTH, BALTIMORE, MD USA.
   PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND.
   INST CHILD HLTH, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND.
   MAKERERE UNIV, SCH MED, INST PUBL HLTH, KAMPALA, UGANDA.
   SWISS TROP INST, CH-4002 BASEL, SWITZERLAND.
RI Barreto, Sandhi Maria/A-5140-2012; Epidemiologicas, Centro de pesquisas
   /D-4561-2013
OI Barreto, Sandhi Maria/0000-0003-4392-5428; 
CR Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   [Anonymous], 1997, LANCET, V350, P897
NR 3
TC 10
Z9 10
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 22
PY 1997
VL 350
IS 9090
BP 1546
EP 1546
DI 10.1016/S0140-6736(97)26047-2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA YH115
UT WOS:A1997YH11500043
PM 9388413
OA No
DA 2017-08-15
ER

PT J
AU Bennison, JJ
   Barton, D
   Jaitner, J
AF Bennison, JJ
   Barton, D
   Jaitner, J
TI The production objectives and feeding strategies of ruminant livestock
   owners in The Gambia: Implications for policy makers
SO AGRICULTURAL SYSTEMS
LA English
DT Article
ID GROUNDNUT CAKE; NDAMA
AB A Participatory Rural Appraisal (PRA), using preference scoring matrices, was used to assess the production objectives of livestock owners in The Gambia. The PRA was then used in conjunction with gross margin analyses and discounted cash flows to assess the social, economic and technical constraints to the supplementation of cattle in The Gambia. The PRA survey indicated that cattle are primarily kept as a means of savings, Farmers placed a value on manure that equalled domestic milk consumption and exceeded that of milk sales. Equines, bulls, and cows in one district, were important for draught and transport; small ruminants were kept primarily, as an investment and for ceremonial purposes. The gross margin analyses of productivity responses indicated that supplementation is not financially attractive in the short-term, i.e. for a single lactation or fattening period. However, discounted cash flows demonstrated that supplementation is worthwhile in the long-term particularly for draught cattle where multiple benefits accrue. Adoption of long-term supplementation strategies in cows is further constrained by transport, feed availability and the distribution of costs and benefits between cattle owners and hired herdsman. (C) 1997 Elsevier Science Ltd.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   ALFORD RJ, 1994, THESIS U EDINBURGH
   *DLS, 1994, ANN LIV CENS
   Gittinger J. Price, 1972, EC ANAL AGR PROJECTS
   Itty P, 1992, EC VILLAGE CATTLE PR
   KIRSOPPREED K, 1994, 20 RRA IIED SUST AGR
   LAWRY SW, 1987, 23 GARD GAMB MIN AGR
   LITTLE DA, 1991, TROP AGR, V68, P259
   RUSSO SL, 1986, 11 GAMB MIN AGR COL
   SOWE JM, 1988, FOALING MORTALITY EQ
   SOWE JM, 1993, RES DEV ANIMAL TRACT, P273
   Sumberg J., 1992, African Livestock Research, V1, P1
   SUMBERG J, 1988, LIVESTOCK DEV POLICY
   TANNER JC, 1995, TROP ANIM HEALTH PRO, V27, P113, DOI 10.1007/BF02236323
NR 14
TC 19
Z9 20
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0308-521X
J9 AGR SYST
JI Agric. Syst.
PD NOV
PY 1997
VL 55
IS 3
BP 425
EP 444
DI 10.1016/S0308-521X(97)00002-4
PG 20
WC Agriculture, Multidisciplinary
SC Agriculture
GA XM789
UT WOS:A1997XM78900005
OA No
DA 2017-08-15
ER

PT J
AU Hoyer, PF
   Weber, M
AF Hoyer, PF
   Weber, M
TI Ultrasound in developing world
SO LANCET
LA English
DT Letter
C1 MRC LABS,BANJUL,GAMBIA.
   HANNOVER MED SCH,CHILDRENS HOSP,D-3000 HANNOVER,GERMANY.
CR Mindel S, 1997, LANCET, V350, P426, DOI 10.1016/S0140-6736(97)03340-0
NR 1
TC 8
Z9 8
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 1
PY 1997
VL 350
IS 9087
BP 1330
EP 1330
DI 10.1016/S0140-6736(05)62498-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA YD689
UT WOS:A1997YD68900065
PM 9357439
OA No
DA 2017-08-15
ER

PT J
AU Barak, P
   Jobe, BO
   Krueger, AR
   Peterson, LA
   Laird, DA
AF Barak, P
   Jobe, BO
   Krueger, AR
   Peterson, LA
   Laird, DA
TI Effects of long-term soil acidification due to nitrogen fertilizer
   inputs in Wisconsin
SO PLANT AND SOIL
LA English
DT Article
DE acidity; cation exchange capacity; exchangeable acidity; N fertilizers;
   organic anions
ID NITRATE
AB Agroecosystems are domesticated ecosystems intermediate between natural ecosystems and fabricated ecosystems, and occupy nearly one-third of the land areas of the earth. Chemical perturbations as a result of human activity are particularly likely in agroecosystems because of the intensity of that activity, which include nutrient inputs intended to supplement native nutrient pools and to support greater biomass production and removal. At a long-term fertility trial in South-Central Wisconsin, USA, significant increases in exchangeable acidity were accompanied by decreases in cation exchange capacity (CEC), base saturation, and exchangeable Ca2+ and Mg2+ with application of ammoniacal N fertilizer. Plant analysis shows that a considerable portion of the alkalinity generated by assimilation of N (and to a lesser extent by S) is sequestered in the above-ground plant parts as organic anions and is not returned to the soil if harvested. Elemental analysis of Ca-saturated soil clays indicates an loss of 16% of the CEC of the soil clay and minor increases in Fe and Al. The reversibility of these changes due to prolonged acidification is doubtful if the changes are due to soil weathering.
C1 Univ Wisconsin, Dept Soil Sci, Madison, WI 53706 USA.
   Natl Agr Res Inst, Yundum, Gambia.
   Univ Wisconsin, Dept Hort, Madison, WI 53706 USA.
   USDA, Natl Soil Tilth Lab, Ames, IA USA.
RP Barak, P (reprint author), Univ Wisconsin, Dept Soil Sci, 1525 Observ Dr, Madison, WI 53706 USA.
RI Laird, David/E-8598-2014
CR ABER JD, 1989, BIOSCIENCE, V39, P378, DOI 10.2307/1311067
   Barak P, 1996, SOIL SCI SOC AM J, V60, P630
   BARAK P, 1992, SOIL SCI, V154, P184, DOI 10.1097/00010694-199209000-00002
   Barnhisel R. I., 1989, Minerals in Soil Environments, SSSA Book Series, no. 1., P729
   BLEVINS RL, 1977, AGRON J, V69, P383
   BOUMAN OT, 1995, SOIL SCI SOC AM J, V59, P1488
   BRIMHALL GH, 1991, GEODERMA, V51, P51, DOI 10.1016/0016-7061(91)90066-3
   *COL STAT U, 1993, NADP NTN ANN DAT SUM
   Cox G. W., 1979, AGR ECOLOGY
   DIJKSHOORN W, 1967, PLANT SOIL, V26, P129, DOI 10.1007/BF01978680
   DISE NB, 1995, FOREST ECOL MANAG, V71, P153, DOI 10.1016/0378-1127(94)06092-W
   DRISCOLL CT, 1993, WATER AIR SOIL POLL, V67, P319, DOI 10.1007/BF00478152
   EDWARDS AP, 1965, NATURE, V205, P208, DOI 10.1038/205208a0
   HELLING CHARLES S., 1964, SOIL SCI SOC AMER PROC, V28, P517
   JSTODDARD J, 1909, ENV CHEM LAKES RESER, P223
   LAIRD DA, 1991, SOIL SCI SOC AM J, V55, P274
   LAIRD DA, 1991, SOIL SCI SOC AM J, V55, P1499
   LIU Y, 1995, THESIS IOWA ST U AME
   Liu YJ, 1997, SOIL SCI SOC AM J, V61, P310
   McBride M. B., 1989, Minerals in Soil Environments, SSSA Book Series, no. 1., P35
   MEISTER RT, 1995, FARM CHEM HDB 95, V81
   Odum E.P, 1984, AGR ECOSYSTEMS UNIFY, P5
   PETERSON LA, 1980, COMMUN SOIL SCI PLAN, V11, P993, DOI 10.1080/00103628009367098
   PIERRE WH, 1973, AGRON J, V65, P91
   Poss R, 1995, PLANT SOIL, V177, P85, DOI 10.1007/BF00010340
   SCHWAB AP, 1989, SOIL SCI SOC AM J, V53, P1412
   SHAINBERG I, 1974, SOIL SCI SOC AM J, V38, P751
   Sposito G, 1989, CHEM SOILS
   Steel RG, 1980, PRINCIPLES PROCEDURE
   Sumner M. E., 1996, Methods of soil analysis. Part 3 - chemical methods., P1201
   Uehara G., 1981, MINERALOGY CHEM PHYS
   VANBEUSICHEM ML, 1988, PLANT PHYSIOL, V86, P914, DOI 10.1104/pp.86.3.914
   VANBREEMEN N, 1983, PLANT SOIL, V75, P283
NR 33
TC 133
Z9 164
U1 2
U2 86
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0032-079X
J9 PLANT SOIL
JI Plant Soil
PD NOV
PY 1997
VL 197
IS 1
BP 61
EP 69
DI 10.1023/A:1004297607070
PG 9
WC Agronomy; Plant Sciences; Soil Science
SC Agriculture; Plant Sciences
GA YP813
UT WOS:000071317700008
OA No
DA 2017-08-15
ER

PT J
AU D'Alessandro, U
   Olaleye, B
   Langerock, P
   Bennett, S
   Cham, K
   Cham, B
   Greenwood, BM
AF D'Alessandro, U
   Olaleye, B
   Langerock, P
   Bennett, S
   Cham, K
   Cham, B
   Greenwood, BM
TI The Gambian National Impregnated Bed Net Programme: evaluation of
   effectiveness by means of case-control studies
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; prevention; bed nets; permethrin; The
   Gambia
ID RISK-FACTORS; CHILDREN; MALARIA; MORTALITY; PERMETHRIN; EFFICACY
AB Two case-control studies, one on mortality and the other on malaria morbidity, were carried out in order to evaluate the impact of the Gambian National Insecticide Bed Net Programme during the second year of intervention and to explore the feasibility of such a study for the evaluation of programme effectiveness. For the mortality study, children 1-9 years old who died during the 1993 rainy: season were matched by age and sex with 2 healthy controls from the same village. For the morbidity study, children 1-9 years old attending Fatoto or Jahalia Health Centres in The Gambia and who had fever and parasitaemia greater than or equal to 5000/mu L were matched by age with a child attending the health centres without fever or parasitaemia. An additional healthy control was recruited from the case's village. Na impact of insecticide-treated bed nets on mortality was detected and this was in keeping with the results obtained by prospective surveillance. A protective effect of insecticide-treated nets on malaria morbidity was detected when cases were compared with controls recruited at the health centres. However, this disappeared when cases were compared with controls recruited from the cases' villages, The mortality case-control study suggested. that reducing the time between onset of disease and treatment may have an important impact on childhood mortality. Ln order to calculate programme cost-effectiveness, important for informed resource allocations to be made by health managers, it is essential to obtain evidence of effectiveness. This can be done by means of case-control studies, which are easier to carry out and require fewer resources than prospective surveillance. Nevertheless, it is necessary to be conscious of their pitfalls, particularly of the bias involved in the choice of cases and controls. The measurement of insecticide on the nets of the cases or controls is essential for such studies.
C1 Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium.
   MRC Labs, Fajara, Senegal.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Minist Hlth, Banjul, Gambia.
RP D'Alessandro, U (reprint author), Inst Trop Med Prince Leopold, Dept Protozool, Natl Str 155, B-2000 Antwerp, Belgium.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   CHAM MK, IN PRESS HLTH POLICY
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DAlessandro U, 1995, T ROY SOC TROP MED H, V89, P596, DOI 10.1016/0035-9203(95)90401-8
   DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8
   DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P151, DOI 10.1016/0035-9203(95)90472-7
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Lengeler C., 1996, Bulletin of the World Health Organization, V74, P325
   MULLER O, 1994, LANCET, V344, P1699, DOI 10.1016/S0140-6736(94)90481-2
   RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205
   SELBY JV, 1994, EPIDEMIOL REV, V16, P90
   SMITH PG, 1978, INT J EPIDEMIOL, V16, P159
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33
NR 16
TC 29
Z9 29
U1 0
U2 4
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1997
VL 91
IS 6
BP 638
EP 642
DI 10.1016/S0035-9203(97)90502-2
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA YQ186
UT WOS:000071357700004
PM 9509168
OA No
DA 2017-08-15
ER

PT J
AU vanderSande, MAB
   Bailey, R
   Faal, H
   Banya, WAS
   Dolin, P
   Nyan, OA
   Ceesay, SM
   Walraven, GEL
   Johnson, GJ
   McAdam, KPWJ
AF vanderSande, MAB
   Bailey, R
   Faal, H
   Banya, WAS
   Dolin, P
   Nyan, OA
   Ceesay, SM
   Walraven, GEL
   Johnson, GJ
   McAdam, KPWJ
TI Nationwide prevalence study of hypertension and related non-communicable
   diseases in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE hypertension; obesity; diabetes; clustering; The Gambia
ID AMBULATORY BLOOD-PRESSURE; INSULIN-RESISTANCE; HYPERINSULINEMIA;
   POPULATIONS; EUROPEANS; TANZANIA
AB The prevalence of hypertension, diabetes and obesity in The Gambia was assessed in a 1% population sample of 6048 adults over 15 years of age. 572 (9.5%) Subjects were hypertensive according to WHO criteria (a diastolic blood pressure (DBP) of 95 mmHg or above and/or a systolic blood pressure (SEP) of 160 mmHg or above); 325 (5.4%) had a DBP of 95 mmHg or above, and 39 (2.3%) a DBP of 105 mmHg or above; 428 (7.1%) had a SBP of 160 mmHg or above. By less conservative criteria (a DBP of 90 mmHg or above and/or SBP of 140 mmHg or above), 24.2% of subjects were hypertensive. The prevalence of hypertension. was similar in the major ethnic groups and in urban and rural communities. Age and obesity were risk factors for hypertension; female sex was an additional risk factor for diastolic hypertension. Several communities had a prevalence of diastolic hypertension double the national rate, and significant community clustering of diastolic hypertension (P < 0.01) was confirmed by Monte Carlo methods. Genetic and/or localized environmental factors (such as diet or Schistosoma haematobium infection), may be involved. 140 (2.3%) subjects were obese. Obesity was associated with female sex, increasing age, urban environment, non-manual work and diastolic hypertension. Only 14 (0.3%) subjects were found to be diabetic. Hypertension appears to be very prevalent in The Gambia, with a substantial population at risk of developing target organ damage. Further studies to delineate this risk and appropriate interventions to reduce it are needed.
C1 MRC LABS,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   UNIV LONDON,INST OPHTHALMOL,INT CTR EYE HLTH,LONDON WC1E 7HU,ENGLAND.
CR AKINKUGBE OO, 1990, J HYPERTENS, V8, pS233
   Antonios TFT, 1996, LANCET, V348, P250, DOI 10.1016/S0140-6736(96)01463-8
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   Berg K, 1996, GENETIC APPROACHES TO NONCOMMUNICABLE DISEASES, P27
   BONNER G, 1994, J CARDIOVASC PHARM, V24, pS39
   BRANDS MW, 1995, J NUTR, V125, pS1725
   CHATURVEDI N, 1993, HYPERTENSION, V22, P90
   CHATURVEDI N, 1994, J AM COLL CARDIOL, V24, P1499
   COOPER R, 1994, J HYPERTENS, V12, P215
   Corvol P, 1996, GENETIC APPROACHES TO NONCOMMUNICABLE DISEASES, P47
   DWYER JH, 1995, LANCET, V346, P392, DOI 10.1016/S0140-6736(95)92777-8
   Elliott P, 1996, BRIT MED J, V312, P1249
   EVANS JG, 1971, BRIT MED B, V23, P37
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   FEACHEM RGA, 1991, HLTH ADULTS DEV WORL
   FUJIMOTO WY, 1995, OBES RES, V3, pS179
   GILLES WH, 1994, AM J MED SCI, V308, P271
   HALL JE, 1995, P SOC EXP BIOL MED, V208, P317
   Hypertension in Diabetes Study Group, 1993, J HYPERTENS, V11, P309
   Kaufman Jay, 1993, Ethnicity and Disease, V3, pS83
   King H., 1993, Ethnicity and Disease, V3, pS67
   Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676
   MBUYAMBAKABANGU JR, 1987, J HYPERTENS, V5, P371, DOI 10.1097/00004872-198706000-00018
   *MIN FIN EC AFF, 1995, HOUS ED HLTH SURV RE
   Mosley W. H., 1993, DIS CONTROL PRIORITI, P673
   MUGUSI F, 1995, ACTA DIABETOL, V32, P28
   OBEL AOK, 1988, TROP GEOGR MED, V40, P93
   POBEE JOM, 1977, T ROY SOC TROP MED H, V71, P66, DOI 10.1016/0035-9203(77)90211-5
   POULTER N, 1984, HYPERTENSION, V6, P810
   POULTER NR, 1990, BRIT MED J, V300, P967
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   RUTLEDGE DR, 1994, DRUGS, V47, P914, DOI 10.2165/00003495-199447060-00005
   Shaper A G, 1969, East Afr Med J, V46, P273
   SHARP PS, 1995, HYPERTENSION, V25, P1322
   SIMMONS D, 1986, J EPIDEMIOLOGY COMMU, V14, P238
   SWAI ABM, 1993, INT J EPIDEMIOL, V22, P651, DOI 10.1093/ije/22.4.651
   WALKER R, 1994, T ROY SOC TROP MED H, V88, P609, DOI 10.1016/0035-9203(94)90193-7
   Ward R., 1990, HYPERTENSION PATHOPH, P81
   WEIDMANN P, 1995, J HYPERTENS, V13, pS65, DOI 10.1097/00004872-199508001-00010
   WILKINS HA, 1977, ANN TROP MED PARASIT, V71, P179
   World Bank, 1993, WORLD DEV REP
NR 41
TC 47
Z9 47
U1 0
U2 6
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 1997
VL 2
IS 11
BP 1039
EP 1048
DI 10.1046/j.1365-3156.1997.d01-184.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA YH487
UT WOS:A1997YH48700005
PM 9391506
OA No
DA 2017-08-15
ER

PT J
AU Akinbamijo, OO
   Bennison, JJ
   Romney, DL
   Wassink, GJ
   Jaitner, J
   Clifford, DJ
   Dempfle, L
AF Akinbamijo, OO
   Bennison, JJ
   Romney, DL
   Wassink, GJ
   Jaitner, J
   Clifford, DJ
   Dempfle, L
TI An evaluation of food intake, digestive physiology and live-weight
   changes in N'dama and Gobra zebu bulls following experimental
   Trypanosoma congolense infection
SO ANIMAL SCIENCE
LA English
DT Article
DE body weight; cattle; digestibility; food intake; trypanotolerance
ID AFRICAN DWARF GOATS; VIVAX INFECTION; NITROGEN-METABOLISM; FEED-INTAKE;
   T-VIVAX; CATTLE; SUSCEPTIBILITY; TEMPERATURE; CHALLENGE; ANEMIA
AB The effects of experimental Trypanosoma congolense infection on the digestive physiology and nutrient utilization in Gobra zebu and N'Dama cattle were Examined in a 16-week trial. A pair-feeding procedure permitted examination of the effects of both food intake and trypanosomosis infection. Twenty Gobra and 16 N'dama bulls aged between 1 and 2 years were paired on a live-weight basis within each breed. One of each pair was chosen at random to serve as an uninfected control while the other was inoculated intradermally with 10(4) T. congolense in mice blood in the 6th week of the experiment. Packed cell volume and parasitaemia data were collected weekly throughout the trial. Total dry-matter intake (TDMI) and live-weight changes were measured weekly in all animals during the 16-week trial. Rate of passage (RoP) and dry matter digestibility were evaluated before and after infection.
   While infection significantly depressed TDMI in both breeds (P < 0.05), neither infection nor breed affected the RoP and the apparent digestibility of the dry matter. Significant changes in live weight attributable solely to the infection were observed in both breeds. Loss of body weight was more severe (P < 0.05) in infected Gobra bulls compared with N'dama bulls possibly implying a superior efficiency of nutrient utilization by the N'dama during infection. In the course of the trial, one N'dama and three Gobra bulls that presented severe clinical symptoms of trypanosomosis were treated and withdrawn from the experiment along with their pair-fed controls.
   In conclusion, the RoP and the digestive efficiency were not affected by infection and breed differences. Also, the trypanotolerance mechanism does not seem to be affected by anorexia but rather by the ability to conserve body reserves during infection.
C1 NAT RESOURCES INST,LIVESTOCK SECT,CHATHAM ME4 4TB,KENT,ENGLAND.
   UNIV GLASGOW,SCH VET,DEPT VET PHYSIOL,GLASGOW G61 1QH,LANARK,SCOTLAND.
RP Akinbamijo, OO (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR *AGR RES COUNC, 1980, NUTR REQ RUM LIV
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AKINBAMIJO OO, 1992, VET QUART, V14, P95
   AKINBAMIJO OO, 1994, THESIS WAGENINGEN AG
   AKOL GWO, 1986, VET IMMUNOL IMMUNOP, V11, P361, DOI 10.1016/0165-2427(86)90038-3
   ANENE BM, 1991, BRIT VET J, V147, P275
   ANOSA VO, 1980, J COMP PATHOL, V90, P155, DOI 10.1016/0021-9975(80)90036-5
   *ASS OFF AN CHEM, 1980, OFF METH AN
   DESOWITZ R. W., 1959, ANN TROP MED AND PARASITOL, V53, P293
   DHANOA MS, 1985, BRIT J NUTR, V53, P663, DOI 10.1079/BJN19850076
   GREIG WA, 1979, BRIT VET J, V135, P113
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   Murray M., 1982, Advances in parasitology. Volume 21., P1
   MURRAY M, 1988, ACTA TROP, V45, P389
   Murray M, 1983, LIVESTOCK PRODUCTIVI
   MURRAY M, 1987, ILCA ILRAD LIVESTOCK, P133
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   ROMNEY DL, IN PRESS J AGR SCI C
   SILAYO RS, 1992, RES VET SCI, V53, P98, DOI 10.1016/0034-5288(92)90092-G
   *STAT AN SYST I, 1994, US GUID STAT VERS 6
   Stephen L, 1986, TRYPANOSOMIASIS VET
   UDEN P, 1980, J SCI FOOD AGR, V31, P625, DOI 10.1002/jsfa.2740310702
   VEENENDAAL GH, 1979, ANN RECH VET, V10, P202
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   WASSINK GJ, 1993, VET QUART, V15, P5
   ZWART D, 1991, J ANIM SCI, V69, P3780
   ZWART D, 1989, ANN SOC BELG MED TR, V69, P105
NR 29
TC 9
Z9 9
U1 1
U2 2
PU DURRANT PERIODICALS
PI EAST LOTHIAN
PA WINTON LEA PENCAITLAND, EAST LOTHIAN EH34 5AY, SCOTLAND
SN 1357-7298
J9 ANIM SCI
JI Anim. Sci.
PD OCT
PY 1997
VL 65
BP 151
EP 158
PN 2
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA YA452
UT WOS:A1997YA45200002
OA No
DA 2017-08-15
ER

PT J
AU vonSeidlein, L
   Jaffar, S
   Pinder, M
   Haywood, M
   Snounou, G
   Gemperli, B
   Gathmann, I
   Royce, C
   Greenwood, B
AF vonSeidlein, L
   Jaffar, S
   Pinder, M
   Haywood, M
   Snounou, G
   Gemperli, B
   Gathmann, I
   Royce, C
   Greenwood, B
TI Treatment of African children with uncomplicated falciparum malaria with
   a new antimalarial drug, CGP 56697
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 5th Western Pacific Congress on Chemotherapy and Infectious Disease
CY DEC 01-04, 1996
CL SINGAPORE
ID PLASMODIUM-FALCIPARUM; QINGHAOSU ARTEMISININ; ARTEMETHER
AB New antimalarial drugs are urgently needed. The use of short courses of the new antimalarial drug artemether as monotherapy has been limited by secondary malaria episodes following parasite clearance. Therefore, a new antimalarial drug, CGP 56697, has been developed, which combines artemether with a longer-acting antimalarial agent, benflumetol. A safety trial was undertaken in 60 Gambian children 1-6 years old with uncomplicated Plasmodium falciparum malaria. All children treated with CGP 56697 cleared their parasites 72 h after the start of treatment. No neurologic, cardiac, or other adverse reactions were observed. Second episodes of falciparum malaria were recorded in 16 (27%) of the children. Second infections were more frequent during the rainy season than during the dry season. Molecular epidemiologic studies suggested that 12 of the 14 second episodes of malaria in children treated with CGP 56697 were due to new infections. CGP 56697 proved to be a safe and effective antimalarial drug in African children.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.
   NORTHWICK PK HOSP & CLIN RES CTR,IMPERIAL COLL SCH MED,DEPT INFECT & TROP MED,LISTER UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND.
   INT CLIN RES,BASEL,SWITZERLAND.
   MRC LABS,BANJUL,GAMBIA.
RP vonSeidlein, L (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI Snounou, Georges/F-3352-2011
OI Snounou, Georges/0000-0002-6133-6398
CR BREWER TG, 1994, AM J TROP MED HYG, V51, P251
   DUTTA GP, 1990, J PARASITOL, V76, P849, DOI 10.2307/3282804
   *I MICR EP, 1993, BENFL REG DOSS
   Kain KC, 1996, MOL BIOCHEM PARASIT, V79, P167, DOI 10.1016/0166-6851(96)02656-4
   KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571
   KUMAR N, 1990, PARASITOL RES, V76, P214, DOI 10.1007/BF00930817
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   Meshnick SR, 1996, MICROBIOL REV, V60, P301
   MUELLER O, 1996, TROP MED INT HEALTH, V1, P124
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   VonSeidlein L, 1997, AM J TROP MED HYG, V56, P494
   WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P3, DOI 10.1016/0035-9203(94)90459-6
NR 14
TC 55
Z9 55
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT
PY 1997
VL 176
IS 4
BP 1113
EP 1116
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA XZ465
UT WOS:A1997XZ46500041
PM 9333180
OA No
DA 2017-08-15
ER

PT J
AU vonSeidlein, L
   Jammeh, K
   Bailey, R
   Doherty, T
AF vonSeidlein, L
   Jammeh, K
   Bailey, R
   Doherty, T
TI The utility of using a distended abdomen to predict intestinal parasites
   in asymptomatic children
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Letter
RP vonSeidlein, L (reprint author), MRC LABS,FAJARA,GAMBIA.
CR CROMPTON DWT, 1993, B WORLD HEALTH ORGAN, V71, P1
   Goodman L, 1990, PHARM BASIS THERAPEU
   HALL A, 1993, T ROY SOC TROP MED H, V87, P241, DOI 10.1016/0035-9203(93)90108-3
   Moody A. H., 1996, MANSONS TROPICAL DIS, P1738
NR 4
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD OCT
PY 1997
VL 43
IS 5
BP 311
EP 312
DI 10.1093/tropej/43.5.311-a
PG 2
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA YD213
UT WOS:A1997YD21300014
PM 9364133
OA No
DA 2017-08-15
ER

PT J
AU Atabani, SF
   Obeid, OE
   Chargelegue, D
   Aaby, P
   Whittle, H
   Steward, MW
AF Atabani, SF
   Obeid, OE
   Chargelegue, D
   Aaby, P
   Whittle, H
   Steward, MW
TI Identification of an immunodominant neutralizing and protective epitope
   from measles virus fusion protein by using human sera from acute
   infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID B-CELL EPITOPES; T-CELL; SYNTHETIC PEPTIDES; ANTIBODY-RESPONSE; DISEASE
   VIRUS; MICE; INHIBITION; PARAMYXOVIRUSES; HEMAGGLUTININ; HETEROGENEITY
AB Polyclonal sera obtained from African children with acute measles were used to screen a panel of 15-mer overlapping peptides representing the sequence of measles virus (MV) fusion (F) protein. An immunodominant antigenic region from the F protein (p32; amino acids 388 to 402) was found to represent an amino acid sequence within the highly conserved cysteine-rich domain of the F protein of paramyxoviruses. Epitope mapping of this peptide indicated that the complete 15-amino-acid sequence was necessary for high-affinity interaction with anti-MV antibodies. Immunization of two strains of mice with the p32 peptide indicated that it was immunogenic and could induce antipeptide antibodies which cross-reacted with and neutralized MV infectivity in vitro. Moreover, passive transfer of antipeptide antibodies conferred significant protection against fatal rodent-adapted MV-induced encephalitis in susceptible mice. These results indicate that this epitope represents a candidate for inclusion in a future peptide vaccine for measles.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
RI Obeid, OE/B-4727-2015; Obeid, O.E/D-9831-2015
OI Obeid, OE/0000-0001-6962-9737; Obeid, O.E/0000-0001-8468-2720
CR AABY P, 1990, AM J EPIDEMIOL, V132, P211
   ALBRECHT P, 1981, J VIROL METHODS, V3, P251, DOI 10.1016/0166-0934(81)90062-8
   BUCKLAND R, 1987, J GEN VIROL, V6, P1695
   CHOPPIN PW, 1981, J INFECT DIS, V143, P352
   CROWE JE, 1995, VACCINE, V13, P847, DOI 10.1016/0264-410X(94)00074-W
   CURRAN MD, 1992, ARCH VIROL, V126, P159, DOI 10.1007/BF01309692
   DRILLIEN R, 1988, P NATL ACAD SCI USA, V85, P1252, DOI 10.1073/pnas.85.4.1252
   FRANCIS MJ, 1987, IMMUNOLOGY, V61, P1
   FRANCIS MJ, 1987, J GEN VIROL, V68, P2687, DOI 10.1099/0022-1317-68-10-2687
   GNANN JW, 1987, J VIROL, V61, P2639
   Halsey NA, 1983, RECENT ADV IMMUNIZAT, P4
   HULL JD, 1987, VIROLOGY, V159, P368, DOI 10.1016/0042-6822(87)90475-2
   MALVOISIN E, 1990, J VIROL, V64, P5160
   MULLER CP, 1993, VIRUS RES, V30, P271, DOI 10.1016/0168-1702(93)90095-5
   NORRBY E, 1972, INFECT IMMUN, V6, P240
   OBEID OE, 1994, VIRUS RES, V32, P69, DOI 10.1016/0168-1702(94)90062-0
   OBEID OE, 1995, J VIROL, V69, P1420
   PALKER TJ, 1989, J IMMUNOL, V142, P3610
   PARTIDOS CD, 1990, J GEN VIROL, V71, P2099, DOI 10.1099/0022-1317-71-9-2099
   PORTNER A, 1987, VIROLOGY, V57, P556
   RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9
   RICHARDSON C, 1986, VIROLOGY, V155, P508, DOI 10.1016/0042-6822(86)90212-6
   SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P2248
   STEWARD MW, 1995, J VIROL, V69, P7668
   STEWARD MW, 1972, IMMUNOLOGY, V22, P747
   TOYODA T, 1988, J VIROL, V62, P4427
   WHITTLE HC, 1988, LANCET, V1, P811
   WHO (World Health Organization), 1996, FIGHT DIS FOST DEV
   WIESMULLER KH, 1992, J GEN VIROL, V73, P2211, DOI 10.1099/0022-1317-73-9-2211
   WILD TF, 1994, J VIROL, V68, P7546
   Wild TF, 1997, J GEN VIROL, V78, P107
   YILMA T, 1988, SCIENCE, V242, P1058, DOI 10.1126/science.3194758
NR 32
TC 16
Z9 16
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 1997
VL 71
IS 10
BP 7240
EP 7245
PG 6
WC Virology
SC Virology
GA XW142
UT WOS:A1997XW14200011
PM 9311797
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Janneh, L
   Corr, N
   Faye, JA
   Pandey, VS
   Verhulst, A
AF Mattioli, RC
   Janneh, L
   Corr, N
   Faye, JA
   Pandey, VS
   Verhulst, A
TI Seasonal prevalence of ticks and tick-transmitted haemoparasites in
   traditionally managed N'Dama cattle with reference to strategic tick
   control in the Gambia
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE tick prevalence; haemoparasites; N'Dama cattle; tick control; The Gambia
ID COWDRIA-RUMINANTIUM; BOVINE BABESIOSIS; ZEBU CATTLE; ANAPLASMOSIS;
   SUSCEPTIBILITY; TRYPANOSOMIASIS; EPIDEMIOLOGY; INFESTATION; NUTRITION;
   INFECTION
AB A survey of tick spatial and seasonal distribution in traditional managed N'Dama cattle over I year old was carried out in The Gambia over 16 months. Presence of Anaplasma marginale and Babesia spp. in the blood smears and their antibodies in the serum of same animals were also examined. Tick species, in decreasing order of abundance, were: Boophilus geigy, Rhipicephalus senegalensis, B. decoloratus, Hyalomma truncatum, H.marginatum rufipes and Amblyomma variegatum. All tick species peaked during the rainy season. Additional B.geigy peaks occurred towards the end of the dry season. The most infested animal body areas were anogenital, udder and abdomen. A.variegatum, Hyalomma spp. and, to a lesser extent, Boophilus spp. showed strong preferences for these anatomical regions. Overall prevalence of A.marginale, B.bigemina and B.bovis haemoparasites were 3.2%, 0.9% and 0.1%, respectively. Peaks of A.marginale and B.bigemina occurred at the end of the rainy season-beginning of the dry season; an additional A.marginale peak was observed at mid-end dry season. Overall antibody seroprevalence were 29.6% for A.marginale, 44.7% for B. bigemina and 5.2% for B. bovis; monthly fluctuations in percentage of seroreactors were limited. Endemic stability ford.marginale and B.bigemina is postulated. Implications of the outcomes are discussed in relation to tick-control strategy in The Gambia.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
RP Mattioli, RC (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   ALI M, 1993, TROP ANIM HEALTH PRO, V25, P215, DOI 10.1007/BF02250871
   BARNARD DR, 1990, EXP APPL ACAROL, V9, P259, DOI 10.1007/BF01193432
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DABOE M, 1991, LIVESTOCK SECTOR REV
   Deem SL, 1996, VET PARASITOL, V61, P133, DOI 10.1016/0304-4017(95)00820-9
   FIVAZ BH, 1993, TROP ANIM HEALTH PRO, V25, P131, DOI 10.1007/BF02236231
   GONCALVES VSP, 1995, THESIS U READING
   Gueye A, 1990, Rev Elev Med Vet Pays Trop, V42, P517
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P411
   JONGEJAN F, 1994, REV SCI TECH OIE, V13, P1201
   JONGEJAN F, 1988, TROP ANIM HEALTH PRO, V20, P234, DOI 10.1007/BF02239989
   KAISER MN, 1988, PREV VET MED, V6, P199, DOI 10.1016/0167-5877(88)90031-1
   KASPER P, 1993, SIFTUNG WALDERHALTUN
   KEUSCH GT, 1986, ANNU REV NUTR, V6, P131
   Koney E B, 1994, Rev Elev Med Vet Pays Trop, V47, P163
   Konstantinov O.K., 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P85
   KUTTLER KL, 1988, TROP ANIM HEALTH PRO, V20, P37, DOI 10.1007/BF02239643
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MATTIOLI RC, 1995, TROP ANIM HEALTH PRO, V27, P95, DOI 10.1007/BF02236320
   MILLER DK, 1984, TROP ANIM HEALTH PRO, V16, P71, DOI 10.1007/BF02239848
   MONTENEGROJAMES S, 1990, AM J VET RES, V51, P1518
   MONTENEGROJAMES S, 1992, REV CIENTIFICA FCV L, V2, P23
   Morel P. C., 1958, Revue d'Elevage Med vet Pays trop (ns), V11, P153
   MOREL P. C., 1964, REV E LEV AGE MED VETERIN AIRE PAYS TROP, V17, P581
   MURRAY M, 1981, VET REC, V109, P503
   NORVAL RAI, 1988, VET PARASITOL, V30, P149, DOI 10.1016/0304-4017(88)90162-8
   NORVAL RAI, 1995, VET PARASITOL, V58, P335, DOI 10.1016/0304-4017(94)00733-S
   PAYNE RC, 1990, TROP ANIM HEALTH PRO, V22, P53, DOI 10.1007/BF02243500
   PEGRAM RG, 1995, MED VET ENTOMOL, V9, P337, DOI 10.1111/j.1365-2915.1995.tb00144.x
   Pegram R, 1993, WORLD ANIM REV, V74, P2
   PEREZ E, 1994, PREV VET MED, V20, P23, DOI 10.1016/0167-5877(94)90105-8
   Snow WF, 1996, AGR SYST, V51, P339, DOI 10.1016/0308-521X(95)00048-A
   SUTHERST RW, 1981, HDB PEST MANAGEMENT, P385
   TATCHELL RJ, 1992, INSECT SCI APPL, V13, P551
   UILENBERG G, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P297
   VERCRUYSSE J, 1982, REV ELEV MED VET PAY, V35, P361
   1991, UNDPGAM87004
NR 38
TC 15
Z9 15
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD OCT
PY 1997
VL 11
IS 4
BP 342
EP 348
DI 10.1111/j.1365-2915.1997.tb00420.x
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA YN412
UT WOS:000071166100008
PM 9430113
OA No
DA 2017-08-15
ER

PT J
AU Itty, P
   Zinsstag, J
   Ankers, P
   Njie, M
   Pfister, K
AF Itty, P
   Zinsstag, J
   Ankers, P
   Njie, M
   Pfister, K
TI Returns from strategic anthelmintic treatments in village cattle in the
   Gambia
SO PREVENTIVE VETERINARY MEDICINE
LA English
DT Article
ID NDAMA CATTLE; LIVESTOCK
AB A large-scale study was undertaken to investigate the effects of two systematic anthelmintic treatments on village cattle productivity in the Gambia. Treated animals had significantly higher performance in terms of live weights and age at first calving, but the mortality rate of 0- to 1-yr-old cattle appeared to be negatively affected. These results and financial data on treatment costs were used in a herd simulation model to assess the profitability of the intervention. Treatment was profitable on average, but the risks of losing money were large and average returns were sensitive to various hypotheses examined. The treatment regimen studied can only be recommended in certain herds and further research is needed to identify the factors determining the negative response in other herds. (C) 1997 Elsevier Science B.V.
C1 ETH ZENTRUM,SWISS CTR INT AGR ZIL,CH-8092 ZURICH,SWITZERLAND.
   ETH ZENTRUM SOL,SWISS FED INST TECHNOL,DEPT AGR ECON,CH-8092 ZURICH,SWITZERLAND.
   CTR SUISSE RECH SCI,ABIDJAN,COTE IVOIRE.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   GRAUB AG,CH-3018 BERN,SWITZERLAND.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR ANDERS P, 1994, REV ELEV MED VET PAY, V47, P201
   BAPTIST R, 1988, AGR SYST, V28, P67, DOI 10.1016/0308-521X(88)90022-4
   CHARTIER C, 1991, REV MED VET-TOULOUSE, V142, P57
   FABIYI JP, 1987, INT J PARASITOL, V17, P435, DOI 10.1016/0020-7519(87)90119-6
   FALL A, 1989, RAPPORT SUIVI ETABLE
   Gittinger J.P., 1982, EC ANAL AGR PROJECTS
   Hamon R., 1972, AGRON TROP, V27, P592
   Horchner F., 1987, Mitteilungen der Osterreichischen Gesellschaft fur Tropenmedizin und Parasitologie, V9, P173
   HORCHNER F, 1990, TROP MED PARASITOL, V41, P422
   Itty P., 1995, Quarterly Journal of International Agriculture, V34, P372
   ITTY P, 1992, EC VILLAGE CATTLE CH
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   KAUFMANN J, 1993, TROP ANIM HLTH PROD, V27, P76
   NAGARAJAN G, 1995, WORLD DEV, V23, P1115, DOI 10.1016/0305-750X(95)00038-E
   SAS, 1989, SAS STAT US GUID VER, V2
   SUMBERG JE, 1992, TROP ANIM HEALTH PRO, V24, P193, DOI 10.1007/BF02356744
   von Kaufmann R., 1990, ILCA BIOECONOMIC HER
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
   Zinsstag J, 1997, VET PARASITOL, V68, P143, DOI 10.1016/S0304-4017(96)01024-2
   ZINSSTAG J, 1997, IN PRESS VET PARASIT
   ZINSSTAG J, 1992, P 7 INT C I TROP VET, V2, P575
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-5877
J9 PREV VET MED
JI Prev. Vet. Med.
PD OCT
PY 1997
VL 32
IS 3-4
BP 299
EP 310
DI 10.1016/S0167-5877(97)00033-0
PG 12
WC Veterinary Sciences
SC Veterinary Sciences
GA YK333
UT WOS:A1997YK33300013
PM 9443336
OA No
DA 2017-08-15
ER

PT J
AU Erskine, JA
AF Erskine, JA
TI Surgical ascariasis in children
SO TROPICAL DOCTOR
LA English
DT Letter
RP Erskine, JA (reprint author), SIBANOR HLTH CTR,BOX 86,BANJUL,GAMBIA.
CR Pandit SK, 1997, TROP DOCT, V27, P13
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 1997
VL 27
IS 4
BP 253
EP 253
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XX865
UT WOS:A1997XX86500037
PM 9316390
OA No
DA 2017-08-15
ER

PT J
AU Ceesay, SM
   Prentice, AM
   Cole, TJ
   Foord, F
   Weaver, LT
   Poskitt, EME
   Whitehead, RG
AF Ceesay, SM
   Prentice, AM
   Cole, TJ
   Foord, F
   Weaver, LT
   Poskitt, EME
   Whitehead, RG
TI Effects on birth weight and perinatal mortality of maternal dietary
   supplements in rural Gambia: 5 year randomised controlled trial
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID AFRICAN WOMEN; PREGNANCY; ENERGY
AB Objective: To test the efficacy in terms of birth weight and infant survival of a diet supplement programme in pregnant African women through a primary healthcare system.
   Design: 5 year controlled trial of all pregnant women in 28 villages randomised to daily supplementation with high energy groundnut biscuits (4.3MJ/day) for about 20 weeks before delivery (intervention) or after delivery (control).
   Setting: Rural Gambia
   Subjects: Chronically undernourished women (twin bearers excluded), yielding 2047 singleton live births and 35 stillbirths.
   Main outcome measures: Birth weight; prevalence of low birth weight (<2500 g); head circumference; birth length; gestational age; prevalence of stillbirths; neonatal and postneonatal mortality.
   Results: Supplementation increased weight gain in pregnancy and significantly increased birthweight, particularly during the nutritionally debilitating hungry season (June to October). Weight gain increased by 201 g (P<0.001) in the hungry season, by 94 g (P<0.01) in the harvest season (November to May), and by 136 g (P<0.001) over the whole year The odds ratio for low birthweight babies in supplemented women was 0.61 (95% confidence interval 0.47 to 0.79, P<0.001). Head circumference was significantly Increased (P<0.01), but by only 3.1 mm. Birth length and duration of gestation were not affected. Supplementation significantly reduced perinatal mortality: the odds ratio was 0.47 (0.23 to 0.99, P<0.05) for stillbirths and 0.54 (0.35 to 0.85, P<0.01) for all deaths in first week of life. Mortality after 7 days was unaffected.
   Conclusion: Prenatal dietary supplementation reduced retardation in intrauterine growth when effectively targeted at genuinely at-risk mothers. This was associated with a substantial reduction in the prevalence of stillbirths and in early neonatal mortality. The intervention can be successfully delivered through a primary healthcare system.
C1 MRC, DUNN NUTR UNIT, KENEBA, GAMBIA.
   MRC, DUNN CLIN NUTR CTR, CAMBRIDGE CB2 2DH, ENGLAND.
OI Cole, Tim/0000-0001-5711-8200
CR ASHWORTH A, 1985, B WORLD HEALTH ORGAN, V63, P165
   Barker DJ, 1992, FETAL INFANT ORIGINS
   BELSEY MA, 1993, NESTLE NUTR WORKS SE, V31, P1
   CARRHILL R, 1985, DEV EXPLOITATION EMP
   DOWNES B, 1991, J TROP PEDIATRICS, V37, P106
   Herrera M. G., 1980, Maternal nutrition during pregnancy and lactation, P252
   KRAMER MS, 1993, AM J CLIN NUTR, V58, P627
   KUSIN JA, 1993, P NUTR SOC, V52, P19, DOI 10.1079/PNS19930033
   LAWRENCE M, 1987, AM J CLIN NUTR, V45, P1442
   Lechtig A., 1980, Maternal nutrition during pregnancy and lactation, P285
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   PARKIN JM, 1976, ARCH DIS CHILD, V51, P259
   POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1983, LANCET, V1, P489
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   PRENTICE AM, 1991, ACTA PAEDIATR SCAND, P67
   PRENTICE AM, 1984, ENERGY INTAKE ACTIVI, P3
   Rush D, 1989, EFFECTIVE CARE PREGN, P255
   Stein Z., 1975, FAMINE HUMAN DEV DUT
   SUSSER M, 1981, AM J CLIN NUTR, V34, P784
NR 21
TC 236
Z9 243
U1 1
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD SEP 27
PY 1997
VL 315
IS 7111
BP 786
EP 790
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA XY911
UT WOS:A1997XY91100023
PM 9345173
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
   Yan, L
   Jarjou, LMA
   Dibba, B
   Laskey, MA
   Stirling, DM
   FairweatherTait, S
AF Prentice, A
   Yan, L
   Jarjou, LMA
   Dibba, B
   Laskey, MA
   Stirling, DM
   FairweatherTait, S
TI Vitamin D status does not influence the breast-milk calcium
   concentration of lactating mothers accustomed to a low calcium intake
SO ACTA PAEDIATRICA
LA English
DT Article
DE breast milk; calcium; lactation; vitamin D
ID GAMBIAN MOTHERS
AB Plasma 25-hydroxy-vitamin D and boast-milk calcium concentration were measured at 3 months of lactation in 60 Gambian mothers accustomed to a low calcium diet, of whom 30 were consuming a calcium supplement and 30 were receiving a placebo, and in 48 British mothers. The plasma 25-hydroxy-vitamin D concentration of the Gambian women was not affected by either calcium supplementation (supplemented, 64.4 +/- 1.5 nmol l(-1); placebo, 64.9 +/- 3.5 nmol l(-1); mean +/- SE) or season. The British average was lower (53.9 +/- 3.0 nmol l(-1), p = 0.004), owing to marked seasonal effects. The breast-milli calcium concentration was lower in The Gambia (supplemented, 5.38 +/- 0.13 nmol l(-1), placebo, 5.10 +/- 0.13 mmol l(-1); British, 6.93 +/- 0.15 mmol l(-1), p < 0.0001). There was no relationship between plasma 25-hydroxy-vitamin D and breast-milk calcium concentration in any group. There was no trend towards lower breast-milk calcium concentration in women with vitamin D status towards the bottom of the normal range or in British women during the winter. This study provides no support for the hypothesis that breast-milk calcium concentration is influenced by vitamin D status or that lactating women with a low calcium intake are at particular risk of vitamin D deficiency.
C1 INST FOOD RES, NORWICH NR4 7UA, NORFOLK, ENGLAND.
   MRC, DUNN NUTR UNIT, KENEBA, GAMBIA.
RP Prentice, A (reprint author), MRC, DUNN NUTR UNIT, DOWNHAMS LANE, MILTON RD, CAMBRIDGE CB4 1XJ, ENGLAND.
RI Fairweather-Tait, Susan/K-4251-2012
CR ABBOTTS J, 1995, ANN CLIN BIOCHEM, V32, P591
   CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0
   Department of Health, 1991, DIET REF VAL FOOD EN, V41
   FRASER DR, 1994, ADV EXP MED BIOL, V352, P237
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   LASKEY MA, 1991, ANN CLIN BIOCHEM, V28, P49
   LASKEY MA, 1997, P NUTR SOC, pA6
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   PRENTICE A, 1994, LANCET, V344, P411, DOI 10.1016/S0140-6736(94)91440-0
   SPECKER BL, 1994, AM J CLIN NUTR S, V59, P484
NR 10
TC 27
Z9 27
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD SEP
PY 1997
VL 86
IS 9
BP 1006
EP 1008
DI 10.1111/j.1651-2227.1997.tb15189.x
PG 3
WC Pediatrics
SC Pediatrics
GA XY528
UT WOS:A1997XY52800021
PM 9343285
OA No
DA 2017-08-15
ER

PT J
AU Buxadera, AM
   Dempfle, L
AF Buxadera, AM
   Dempfle, L
TI Genetic and environmental factors affecting some reproductive traits of
   Holstein cows in Cuba
SO GENETICS SELECTION EVOLUTION
LA English
DT Article
DE Holstein cattle breed; reproduction traits; genetic parameters; tropical
   conditions
ID MILK-PRODUCTION; CONCEPTION RATE; DAIRY-CATTLE; YIELD; FERTILITY
AB A total of 226 651 fertility records of dairy cows obtained from 1980 to 1988 was studied in order to determine the environmental and genetic factors affecting the reproductive performance of Holstein cows under Cuban conditions. Only 43.9% of the inseminated females were pregnant at first service however, for heifers this value was 63.1%. The seasonal variability was higher for heifers and for primiparous than for older lactating cows. The best performance was found from February to April, whereas during the hot and humid summer (July to September) poorer results were obtained. Age at calving or number of calvings was another important environmental source of variation: the earlier the calving the poorer is the next reproductive performance. The genetic analyses were made within calving number with the REML procedure. For heifers (226 sires, 45 575 records) the heritability and the genetic coefficient of variation were: 2.26 and 10.94%, 3.24 and 11.24%, and 3.04 and 6.19% for conception rate (CR), numbers of services per conception (SG) and conception status (CS = 1/SG); respectively. For first calving females (280 sires, 43 647 records) the results were: 1.94 and 15.93%, 3.25 and 12.80%, and 3.47 and 9.47% for CR, SG and CS, respectively. For the second and third calving, the results were poorer. For the calving interval and days open, the heritabilities were between 1.86 and 4.64%. The results of SG were selected as the best and more useful traits showing high genetic correlations (> 0.60) for the same traits in different calving number.
C1 Ctr Invest Para Mejoramiento Anim, Havana, Cuba.
   Int Trypanotolerance Ctr, Banjul, Gambia.
RP Buxadera, AM (reprint author), Care of Menissier F, INRA, Genet Quantitat & Appl Stn, F-78352 Jouy En Josas, France.
CR BERGER PJ, 1981, J DAIRY SCI, V64, P114
   BLANCHARD PJ, 1983, J DAIRY SCI, V66, P1947
   BUXADERA AM, 1989, CUBAN J AGR SCI, V23, P9
   BUXADERA AM, 1993, REV CUBANA REPROD AN, V19, P3
   BUXADERA AM, 1988, B RESENA CIMA, V6
   BUXADERA AM, 1983, 4 REUN ACPA 1983, P69
   BUXADERA AM, 1981, P ALPA, V16, P161
   CALEYO M, 1989, 8 JORN CIMA NOV 1989
   CALO LL, 1973, J ANIM SCI, V37, P676
   CARAL J, 1984, C INRA, V20, P491
   De Kruif A, 1975, Tijdschr Diergeneeskd, V100, P1089
   DELOSREYES A, 1985, THESIS LA HABANA
   DEMONTY, 1984, C INRA, V20, P285
   DEMPFLE L, 1983, GENET SEL EVOL, V15, P425, DOI 10.1186/1297-9686-15-3-425
   Distl O, 1982, P 2 WORLD C GEN APPL, V7, P580
   FOOTE RH, 1978, SEARCH AGR ANIM SCI, V8, P18
   GUERRA D, 1987, 2 JORN ACPA MAY 29 3
   HANSEN LB, 1983, J DAIRY SCI, V66, P306
   HEIMAN MM, 1982, BREEDING ISRAELI HOL
   INGRAHAM RH, 1974, J DAIRY SCI, V57, P476
   JANSEN J, 1986, THESIS NETHERLANDS
   JANSON L, 1980, 45 SWED U AGR SCI GE
   KENNEDY BW, 1981, CAN J GENET CYTOL, V23, P565
   LIN CY, 1984, J DAIRY SCI, V67, P2389
   MAIJALA K, 1987, J ANIM BREED GENET, V104, P53
   PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.2307/2334389
   PONCE HR, 1992, AVANCES PRODUCCION L, P131
   Prada N., 1984, REV ACPA, V3, P20
   RAHEJA KL, 1989, J DAIRY SCI, V72, P2625
   RON M, 1984, J DAIRY SCI, V67, P854
   STRANDBERG E, 1988, P 6 WORL C AN PROD G
   THATCHER WW, 1974, J DAIRY SCI, V57, P360
   THATCHER WW, 1984, C INRA, V20, P265
   VANRADEN PM, 1987, 82 M ADSA JUN 21 24
   VONBAPTIST R, 1973, ZUCHTUNG, V45, P339
   WADZAUSKAS FC, 1986, J DAIRY SCI, V69, P290
   WELLER JI, 1989, J DAIRY SCI, V72, P2644, DOI 10.3168/jds.S0022-0302(89)79405-4
   1978, BREEDING ARTIFICIAL
NR 38
TC 3
Z9 3
U1 0
U2 0
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0999-193X
J9 GENET SEL EVOL
JI Genet. Sel. Evol.
PD SEP-OCT
PY 1997
VL 29
IS 5
BP 469
EP 482
PG 14
WC Agriculture, Dairy & Animal Science; Genetics & Heredity
SC Agriculture; Genetics & Heredity
GA YX337
UT WOS:000072030100005
OA gold
DA 2017-08-15
ER

PT J
AU Thursz, MR
   Thomas, HC
   Greenwood, BM
   Hill, AVS
AF Thursz, MR
   Thomas, HC
   Greenwood, BM
   Hill, AVS
TI Heterozygote advantage for HLA class-II type in hepatitis B virus
   infection
SO NATURE GENETICS
LA English
DT Letter
ID POLYMORPHISM; SELECTION; ANTIGENS; ALLELE
C1 MRC LABS,FAJARA,GAMBIA.
   UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.
RP Thursz, MR (reprint author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,SCH MED ST MARYS,ACAD DEPT MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND.
RI HILL, Adrian/C-1306-2008; Thomas, Howard/A-3152-2009
CR ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137
   ALMARRI A, 1994, LANCET, V344, P1194, DOI 10.1016/S0140-6736(94)90510-X
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   DOHERTY PC, 1975, LANCET, V1, P1406
   GILLESPIE JH, 1985, THEOR POPUL BIOL, V27, P222, DOI 10.1016/0040-5809(85)90011-5
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277
   HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0
   SNELL GD, 1968, FOLIA BIOL-PRAGUE, V14, P335
   TAKAHATA N, 1990, GENETICS, V124, P967
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
NR 11
TC 210
Z9 219
U1 0
U2 14
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 1997
VL 17
IS 1
BP 11
EP 12
DI 10.1038/ng0997-11
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA XU724
UT WOS:A1997XU72400006
PM 9288086
OA No
DA 2017-08-15
ER

PT J
AU Jakobsen, PH
   Kurtzhals, JAL
   Riley, EM
   Hviid, L
   Theander, TG
   MorrisJones, S
   Jensen, JB
   Bayoumi, RAL
   Ridley, RG
   Greenwood, BM
AF Jakobsen, PH
   Kurtzhals, JAL
   Riley, EM
   Hviid, L
   Theander, TG
   MorrisJones, S
   Jensen, JB
   Bayoumi, RAL
   Ridley, RG
   Greenwood, BM
TI Antibody responses to Rhoptry-Associated Protein-1 (RAP-1) of Plasmodium
   falciparum parasites in humans from areas of different malaria
   endemicity
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE malaria; antibodies; Rhoptry-Associated; Protein-1
ID SEQUENCE; SUDAN; REACTIVITY; CHILDREN; IMMUNITY; ANTIGEN
AB Plasma IgM and IgG antibody reactivities against the recombinant Plasmodium falciparum protein, Rhoptry, Associated Protein-1 (rRAP-1) were measured by ELISA in individuals from Sudan, Indonesia, Kenya and The Gambia living in areas of different malaria endemicity. IgG and IgM reactivities to rRAP-1 increased with malaria endemicity. IgG reactivities were associated with spleen rates in Indonesia with high malaria endemicity while IgM reactivities were associated with spleen rates in Kenya with low malaria endemicity. Ige and IgM reactivities to rRAP-1 increased during acute episodes of P. falciparum malaria in Sudanese adults and IgG reactivities remained high one month after treatment in all adults tested Antibody reactivities to rRAP-1 in Gambian children in the dry season were higher in children with parasitaemia than in children without detectable parasitaemia. Antibody reactivities were not associated with protection against clinical episodes in the following rainy season brit higher antibody reactivities were detectable at the end of the rainy season. There was no difference in antibody reactivity to rRAP-1 between Gambian children with mild or severe malaria.
C1 UNIV COPENHAGEN,INST MED MICROBIOL & IMMUNOL,COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   BRIGHAM YOUNG UNIV,DEPT MICROBIOL,PROVO,UT 84602.
   UNIV KHARTOUM,DEPT BIOCHEM,KHARTOUM,SUDAN.
   F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES,CH-4002 BASEL,SWITZERLAND.
RP Jakobsen, PH (reprint author), UNIV COPENHAGEN HOSP,DEPT CLIN MICROBIOL,DEPT INFECT DIS,CTR MED PARASITOL,TAGENSVEJ 20,DK-2200 COPENHAGEN N,DENMARK.
RI Riley, Eleanor/C-8960-2013; Theander, Thor/F-6714-2015
OI Riley, Eleanor/0000-0003-3447-3570; Theander, Thor/0000-0002-3509-7514;
   Bayoumi, Riad/0000-0001-8177-8129; Hviid, Lars/0000-0002-1698-4927
FU NIAID NIH HHS [AI 16312]
CR BAYOUMI RA, 1986, AM J TROP MED HYG, V35, P45
   ERUNKULU OA, 1992, CLIN EXP IMMUNOL, V89, P296
   GUPTA S, 1994, PARASITE IMMUNOL, V16, P361, DOI 10.1111/j.1365-3024.1994.tb00361.x
   HARNYUTTANAKORN P, 1992, MOL BIOCHEM PARASIT, V55, P177, DOI 10.1016/0166-6851(92)90138-A
   HOWARD RF, 1993, INFECT IMMUN, V61, P2960
   Howard RF, 1996, MOL BIOCHEM PARASIT, V77, P95, DOI 10.1016/0166-6851(96)02576-5
   HOWARD RF, 1992, MOL BIOCHEM PARASIT, V51, P327, DOI 10.1016/0166-6851(92)90083-V
   JAKOBSEN PH, 1993, INFECT IMMUN, V61, P268
   JAKOBSEN PH, 1994, CLIN EXP IMMUNOL, V96, P98
   Jakobsen PH, 1996, AM J TROP MED HYG, V55, P642
   JAKOBSEN PH, 1991, T ROY SOC TROP MED H, V85, P26, DOI 10.1016/0035-9203(91)90141-K
   JENSEN JB, 1984, P NATL ACAD SCI-BIOL, V81, P922, DOI 10.1073/pnas.81.3.922
   JENSEN JB, 1983, INFECT IMMUN, V41, P1302
   RIDLEY RG, 1990, MOL BIOCHEM PARASIT, V41, P125, DOI 10.1016/0166-6851(90)90103-S
   RIDLEY RG, 1990, PARASITOLOGY, V101, P187
   RILEY EM, 1991, EUR J IMMUNOL, V21, P1019, DOI 10.1002/eji.1830210424
   STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P122
   THEANDER TG, 1990, IMMUNOL LETT, V25, P237, DOI 10.1016/0165-2478(90)90121-6
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
NR 19
TC 16
Z9 16
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD SEP
PY 1997
VL 19
IS 9
BP 387
EP 393
DI 10.1046/j.1365-3024.1997.d01-234.x
PG 7
WC Immunology; Parasitology
SC Immunology; Parasitology
GA XZ007
UT WOS:A1997XZ00700001
PM 9347514
OA No
DA 2017-08-15
ER

PT J
AU Goossens, B
   Osaer, S
   Kora, S
AF Goossens, B
   Osaer, S
   Kora, S
TI Long-term effects of an experimental infection with Trypanosoma
   congolense on reproductive performance of trypanotolerant Djallonke ewes
   and West African Dwarf does
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
ID ADRENOCORTICAL FUNCTION; GOATS; SHEEP; PITUITARY; DISORDERS; DIAGNOSIS;
   CATTLE
AB Ten West African Dwarf (WAD) does and 12 Djallonke ewes were artificially infected with a West African strain of Trypanosoma congolense and observed over two years. The infected animals showed a chronic anaemia together with a persistent parasitaemia but very low mortality and increase in body weights was not significantly different from the control. In the infected sheep significant differences were found in offspring production at three and five months due to a higher mortality among the lambs. The infected goats had more abortions and stillbirths and period to first kidding, total number of parturitions, production at birth, one, three and five months were significantly different from the controls. A productivity index was calculated and revealed that a chronic T congolense infection significantly decreases the productivity of WAD goats during two years whereas in Djallonke sheep, the loss in productivity is recovered after one year. Although both species are regarded as trypanotolerant, the Djallonke sheep show a better tolerance to a chronic T congolense infection that the WAD goats.
RP Goossens, B (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR Anosa V O, 1988, Rev Elev Med Vet Pays Trop, V41, P65
   BEALBY KA, 1993, INT SCI COUNC TRYP R
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   EDEGHERE H, 1992, VET PARASITOL, V43, P203, DOI 10.1016/0304-4017(92)90161-2
   ELHASSAN E, 1989, INT SCI COUNC TRYP R
   *FAO, 1980, 20 FAO, V1
   *FAO, 1980, 20 FAO, V2
   GRIFFIN L, 1979, TROP ANIM HEALTH PRO, V11, P133, DOI 10.1007/BF02237789
   Griffin L., 1978, Veterinary Bulletin, V48, P819
   IKEDE BO, 1988, ACTA TROP, V45, P5
   IKEDE BO, 1972, BRIT VET J, V128, pR1
   KANYARI PWN, 1983, TROP ANIM HEALTH PRO, V15, P153, DOI 10.1007/BF02239926
   LLEWELYN CA, 1987, BRIT VET J, V143, P423
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MUTAYOBA BM, 1995, RES VET SCI, V58, P174, DOI 10.1016/0034-5288(95)90073-X
   MUTAYOBA BM, 1988, RES VET SCI, V44, P140
   MUTAYOBA BM, 1988, ACTA TROP, V45, P225
   MUTAYOBA BM, 1995, RES VET SCI, V58, P180, DOI 10.1016/0034-5288(95)90074-8
   OGAA JS, 1991, INT SCI COUNC TRYP R
   Osaer S, 1997, SMALL RUMINANT RES, V24, P213, DOI 10.1016/S0921-4488(96)00944-3
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   SEKONI VO, 1994, THERIOGENOLOGY, V42, P557, DOI 10.1016/0093-691X(94)90373-Q
   Snedecor G.W., 1980, STAT METHODS, P507
   SUMBERG JE, 1985, TROP ANIM HEALTH PRO, V17, P135, DOI 10.1007/BF02355872
   WILSON RT, 1989, ANIM REPROD SCI, V20, P265, DOI 10.1016/0378-4320(89)90075-4
NR 29
TC 26
Z9 26
U1 0
U2 0
PU BRITISH VETERINARY ASSOC
PI LONDON
PA 7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT
SN 0034-5288
J9 RES VET SCI
JI Res. Vet. Sci.
PD SEP-OCT
PY 1997
VL 63
IS 2
BP 169
EP 173
DI 10.1016/S0034-5288(97)90013-8
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA YL595
UT WOS:A1997YL59500014
PM 9429253
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Palmer, A
   vanHensbroek, MB
   Banya, WAS
   Greenwood, BM
AF Bojang, KA
   Palmer, A
   vanHensbroek, MB
   Banya, WAS
   Greenwood, BM
TI Management of severe malarial anaemia in Gambian children
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; children; anaemia; blood transfusion;
   iron therapy; The Gambia
ID FALCIPARUM-MALARIA; AFRICAN CHILDREN; IRON; CHILDHOOD; ANEMIA
AB The optimum management of children with severe malarial anaemia is still uncertain. Hence, we have undertaken a study to determine whether iron treatment is as effective at restoring haemoglobin levels one month after presentation as blood transfusion without iron treatment in children with moderately severe malarial anaemia. Two hundred and eighty-seven children with a packed cell volume (PCV) <15% and malaria infection were recruited into the study; 173 children were assigned to receive blood transfusion because they had a PCV <12% and/or signs of respiratory distress and the remaining 114 children were allocated at random to receive either blood transfusion (58) or treatment with oral iron (56) for 28 d. Twenty-four children died, 23 in the most severely anaemic group. Fifteen children (65%) died before transfusion was given and most deaths occurred within the first 4 h of admission. One child died in the iron treatment group and 10 subsequently required transfusion. Among the severely anaemic children, those with respiratory distress were at greater risk of death than those without respiratory distress. After 28 d, haematological restoration was significantly better in children who had received iron than in those treated by blood transfusion (P=0.02). Children who received malaria chemoprophylaxis after discharge from hospital had fewer episodes of malaria and subsequent admissions to a hospital or health centre than those who did not. Children with severe anaemia and clinical signs of respiratory distress must be identified quickly and transfused as soon as possible. However, for less severely anaemic children who are clinically stable, iron therapy offers an alternative to transfusion provided such children can be kept under surveillance and transfused subsequently should this become necessary.
C1 ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
RP Bojang, KA (reprint author), MRC LABS,BANJUL,GAMBIA.
CR BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6
   BENEDIKT HR, 1993, ACTA TROP, V55, P47
   BLOLAND PB, 1993, J INFECT DIS, V167, P932
   GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1988, LANCET, V1, P1121
   HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12
   HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1
   LACRITZ EM, 1992, LANCET, V340, P524
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   Strickland G T, 1970, Am J Trop Med Hyg, V19, P910
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
NR 17
TC 35
Z9 36
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 1997
VL 91
IS 5
BP 557
EP 561
DI 10.1016/S0035-9203(97)90025-0
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA YD434
UT WOS:A1997YD43400019
PM 9463667
OA No
DA 2017-08-15
ER

PT J
AU Egan, A
   Waterfall, M
   Pinder, M
   Holder, A
   Riley, E
AF Egan, A
   Waterfall, M
   Pinder, M
   Holder, A
   Riley, E
TI Characterization of human T- and B-cell epitopes in the C terminus of
   Plasmodium falciparum merozoite surface protein 1: Evidence for poor
   T-cell recognition of polypeptides with numerous disulfide bonds
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HUMORAL IMMUNE-RESPONSES; ESCHERICHIA-COLI; AOTUS MONKEYS; ANTIGEN GENE;
   MALARIA; RECOMBINANT; FRAGMENT; ANTIBODIES; EXPRESSION; PRECURSOR
AB We have investigated the relationship between cellular and humoral immune responses to defined epitopes of the C terminus of merozoite surface protein 1 (MSP-1) of the human malaria parasite, Plasmodium falciparum, in immune blood donors, Sera from almost all donors contained antibodies to the 33-kDa processing product of the MAD20 allele of MSP-1 (MSP-1(33)), but these antibodies did not cross-react with the equivalent sequence of the Wellcome allele, In contrast, T-cell responses to MSP-1(33) are directed towards epitopes that are conserved between the two allelic families, Only 50% of adult blood donors possessed antibodies which recognized the 19-kDa processing product of MSP-1 (MSP-1(19)), These antibodies predominantly recognized conserved epitopes involving both of the constituent epidermal growth factor-like domains of MSP-1(19). T-cell responses were found in only 26% (for recombinant proteins) or 44% (for synthetic peptides) of donors and were directed mainly at dimorphic sequences of the protein, There was no obvious association, at an individual level, between the presence of antibodies and the detection of T-cell proliferative or gamma interferon responses, suggesting that the T cells identified in this manner are not providing significant levels of help to B cells. T-cell responses to reduced recombinant proteins and linear peptides were more prevalent than responses to disulfide-bonded proteins, suggesting that the complex disulfide-bonded structure of native MSP-1(19) may inhibit antigen processing or presentation.
C1 UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,DIV BIOL SCI,ASHWORTH LABS,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND.
   NATL INST MED RES,LONDON NW7 1AA,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
RI Holder, Anthony/A-7554-2013; Riley, Eleanor/C-8960-2013
OI Holder, Anthony/0000-0002-8490-6058; Riley, Eleanor/0000-0003-3447-3570
FU Medical Research Council [MC_U117532067]; Wellcome Trust
CR AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   ANDERSSON G, 1989, J IMMUNOL METHODS, V125, P89, DOI 10.1016/0022-1759(89)90081-1
   BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C
   BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Chang SP, 1996, INFECT IMMUN, V64, P253
   CHAPPEL JA, 1993, MOL BIOCHEM PARASIT, V60, P303, DOI 10.1016/0166-6851(93)90141-J
   COLLINS DS, 1991, J IMMUNOL, V147, P4054
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   CRISANTI A, 1988, SCIENCE, V240, P1324, DOI 10.1126/science.2453924
   DALY TM, 1993, INFECT IMMUN, V61, P2462
   EGAN A, 1995, THESIS U EDINBURGH E
   EGAN AF, 1995, INFECT IMMUN, V63, P456
   Egan AF, 1996, J INFECT DIS, V173, P765
   EGAN AF, UPUB
   ETLINGER HM, 1991, INFECT IMMUN, V59, P3498
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GUTTINGER M, 1991, INT IMMUNOL, V3, P899, DOI 10.1093/intimm/3.9.899
   HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0
   HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37
   HOLDER AA, 1988, PARASITE IMMUNOL, V10, P607, DOI 10.1111/j.1365-3024.1988.tb00248.x
   JENSEN PE, 1993, J IMMUNOL, V150, P3347
   JONGWUTIWES S, 1993, MOL BIOCHEM PARASIT, V59, P95, DOI 10.1016/0166-6851(93)90010-U
   JONGWUTIWES S, 1992, MOL BIOCHEM PARASIT, V51, P81, DOI 10.1016/0166-6851(92)90203-V
   KASLOW DC, 1994, MOL BIOCHEM PARASIT, V63, P283, DOI 10.1016/0166-6851(94)90064-7
   KUMAR S, 1995, MOL MED, V1, P325
   LING IT, 1994, PARASITE IMMUNOL, V16, P63
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   MURPHY VF, 1990, PARASITOLOGY, V100, P177
   PETERSON MG, 1988, MOL CELL BIOL, V8, P2664
   QUAKYI IA, 1994, J IMMUNOL, V153, P2082
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014
   SINIGAGLIA F, 1988, J IMMUNOL, V140, P3568
   TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022
   WATERFALL M, UNPUB
NR 40
TC 88
Z9 88
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 1997
VL 65
IS 8
BP 3024
EP 3031
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA XM714
UT WOS:A1997XM71400005
PM 9234749
OA No
DA 2017-08-15
ER

PT J
AU Romney, DL
   NJie, A
   Clifford, D
   Holmes, PH
   Richard, D
   Gill, M
AF Romney, DL
   NJie, A
   Clifford, D
   Holmes, PH
   Richard, D
   Gill, M
TI The influence of plane of nutrition on the effects of infection with
   Trypanosoma congolense in trypanotolerant cattle
SO JOURNAL OF AGRICULTURAL SCIENCE
LA English
DT Article
ID AFRICAN DWARF GOATS; VIVAX INFECTION; FEED-INTAKE; LIVEWEIGHT CHANGES;
   NDAMA; DIAGNOSIS; ENERGY; BRUCEI; EWES
AB Thirty-two N'Dama heifers were offered ad libitum Andropogon hay plus 10.2 g/kg liveweight (LW) groundnut hay (GNH) (L) or 10.2 g/kg LW GNH and 3.9 g/kg LW groundnut cake (GNC) (H). After 4 weeks on the diets, half of each group were infected intradermally with Trypanosoma congolense clone (ITC 50) (LI and HI). Peak parasitaemia occurred 6-8 days after infection and started to decrease c. 56 days later. No differences in parasitaemia were observed between LI and HI animals. Packed cell volume (PCV) fell in all treatments (by 5.4, 13.8, 3.7 and 9.4 units after 49-63 days post-infection (p.i.) for the L, LI, H and HI groups respectively) and significant effects of infection and diet were observed. GNH and GNC intakes were maintained during the trial; however, infected animals had a decreased intake of Andropogon hay. LI animals lost significantly more weight during the experimental period than the non-infected controls (-71.4 v. -13.7 g/day). Meanwhile, HI animals gained less weight compared with the H group (52.2 v. 167.6 g/day). Weight losses appeared to be due to decreased food intake. In the period 54-58 days p.i., plasma concentrations of albumin were lower and plasma protein was higher in infected animals. Plasma cholesterol concentrations were also lower in infected animals 54-68 days p.i. Plasma urea concentrations were higher in supplemented animals but were not affected by infection. The results showed that animals on a higher plane of nutrition showed less severe clinical signs of infection. However, for all the parameters considered, the magnitude of the difference between groups on different diets was similar for both infected and control animals, suggesting that mechanisms of resistance were not affected by the planes of nutrition considered.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   UNIV GLASGOW,SCH VET,GLASGOW G61 1QH,LANARK,SCOTLAND.
   CTR COOPERAT INT RECH AGRON DEV,F-34032 MONTPELLIER 1,FRANCE.
RP Romney, DL (reprint author), NAT RESOURCES INST,CENT AVE,CHATHAM ME4 4TB,KENT,ENGLAND.
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P387
   AKINBAMIJO OO, 1994, J AGR SCI, V123, P379
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   FAGBEMI BO, 1990, VET PARASITOL, V35, P29, DOI 10.1016/0304-4017(90)90114-Q
   Forbes J. M., 1986, VOLUNTARY FOOD INTAK
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   KATUNGUKARWAKIN.E, 1992, THESIS U GLASGOW
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   LITTLE DA, 1991, TROP AGR, V68, P259
   LIU SM, 1994, P SOC NUTR PHYSL, V3, P227
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1987, AFRICAN TRYPANOTOLER, P133
   NANTULYA VM, 1984, INFECT IMMUN, V43, P735
   REYNOLDS L, 1988, Small Ruminant Research, V1, P175, DOI 10.1016/0921-4488(88)90034-X
   TRAORELEROUX T, 1987, ACTA TROP, V44, P315
   VEENENDAAL GH, 1976, RES VET SCI, V21, P271
   VERSTEGEN MWA, 1991, J ANIM SCI, V69, P1667
   WASSINK GJ, 1993, VET QUART, V15, P5
   ZWART D, 1991, J ANIM SCI, V69, P3780
NR 21
TC 7
Z9 7
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0021-8596
J9 J AGR SCI
JI J. Agric. Sci.
PD AUG
PY 1997
VL 129
BP 83
EP 89
DI 10.1017/S0021859697004449
PN 1
PG 7
WC Agriculture, Multidisciplinary
SC Agriculture
GA XR829
UT WOS:A1997XR82900010
OA No
DA 2017-08-15
ER

PT J
AU Lahai, GP
   Mulholland, EK
   Hilton, S
   Fegan, G
   Inskip, H
   Yuuni, O
   Bangali, JE
   Greenwood, BM
AF Lahai, GP
   Mulholland, EK
   Hilton, S
   Fegan, G
   Inskip, H
   Yuuni, O
   Bangali, JE
   Greenwood, BM
TI Data management for an efficacy trial of a vaccine in the Gambia
SO METHODS OF INFORMATION IN MEDICINE
LA English
DT Article
DE Haemophilus influenzae; randomised; data management; the Gambia; data
   quality
ID INFLUENZAE TYPE-B; TROPICAL EPIDEMIOLOGY; MICROCOMPUTER
AB An individually randomised double-blind trial of PRP-T Hib conjugate vaccine was conducted in the Gambia between 1993 and 1995, in which 42,848 children were randomised into one of 10 groups, five corresponding to vaccine and five to placebo. Basic demographic data were collected on all children, and administration details of all doses of EPI vaccines were recorded. In addition, details on all doses of vaccines were recorded on each child's home-based health card; 2,681 episodes of possible Hib disease were investigated and for each episode detailed clinical data were collected. These investigations yielded 50 cases of confirmed Hib disease, which formed the basis of the final efficacy results. In all 50 cases, the data on the children's health card, describing the doses of study vaccine received exactly, matched the vaccination database which was filled with data returned from the clinics. The data-management procedures are described in detail in this paper.
C1 SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.
RP Lahai, GP (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
OI Inskip, Hazel/0000-0001-8897-1749
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   BYASS P, 1989, J TROP MED HYG, V92, P330
   BYASS P, 1989, J TROP MED HYG, V92, P282
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GREENWOOD B, 1992, J INFECT DIS, V165, pS26
   Pradhan Elizabeth Kimbrough, 1994, Controlled Clinical Trials, V15, P220
   SHAPIRO ED, 1993, JAMA-J AM MED ASSOC, V269, P264, DOI 10.1001/jama.269.2.264
   STEPHENS J, 1989, METHOD INFORM MED, V28, P155
NR 9
TC 1
Z9 1
U1 0
U2 0
PU F K SCHATTAUER VERLAG GMBH
PI STUTTGART
PA P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY
SN 0026-1270
J9 METHOD INFORM MED
JI Methods Inf. Med.
PD AUG
PY 1997
VL 36
IS 3
BP 214
EP 220
PG 7
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA XU934
UT WOS:A1997XU93400008
PM 9293721
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Cole, TJ
   Poskitt, EME
   Sonko, BJ
   Whitehead, RG
   McGregor, IA
   Prentice, AM
AF Moore, SE
   Cole, TJ
   Poskitt, EME
   Sonko, BJ
   Whitehead, RG
   McGregor, IA
   Prentice, AM
TI Season of birth predicts mortality in rural Gambia
SO NATURE
LA English
DT Letter
C1 MRC, DUNN NUTR UNIT, BANJUL, GAMBIA.
RP Moore, SE (reprint author), MRC, DUNN NUTR UNIT, HILLS RD, CAMBRIDGE CB2 2DH, ENGLAND.
OI Cole, Tim/0000-0001-5711-8200
CR AABY P, 1993, INT J EPIDEMIOL, V22, P156, DOI 10.1093/ije/22.1.156
   Barker DJP, 1994, MOTHERS BABIES DIS L
   BEACH RS, 1982, SCIENCE, V218, P469, DOI 10.1126/science.7123244
   BEISEL WR, 1992, J NUTR, V122, P591
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   CEESAY SM, IN PRESS BRIT MED J
   CHANDRA RK, 1974, LANCET, V2, P1393
   CHANDRA RK, 1993, P NUTR SOC, V52, P77, DOI 10.1079/PNS19930039
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   WINNICK M, 1971, PEDIATRICS, V47, P969
NR 11
TC 166
Z9 168
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUL 31
PY 1997
VL 388
IS 6641
BP 434
EP 434
DI 10.1038/41245
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA XN553
UT WOS:A1997XN55300032
PM 9242401
OA No
DA 2017-08-15
ER

PT J
AU Jepson, A
   SisayJoof, F
   Banya, W
   HassanKing, M
   Frodsham, A
   Bennett, S
   Hill, AVS
   Whittle, H
AF Jepson, A
   SisayJoof, F
   Banya, W
   HassanKing, M
   Frodsham, A
   Bennett, S
   Hill, AVS
   Whittle, H
TI Genetic linkage of mild malaria to the major histocompatibility complex
   in Gambian children: Study of affected sibling pairs
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID HLA
C1 MRC LABS,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
RP Jepson, A (reprint author), UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR BENNETT S, 1993, T ROY SOC TROP MED H, V87, P286, DOI 10.1016/0035-9203(93)90130-I
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   JEPSON AP, 1995, J INFECT DIS, V172, P316
   KRUGLYAK L, 1995, AM J HUM GENET, V57, P439
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
NR 5
TC 54
Z9 56
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD JUL 12
PY 1997
VL 315
IS 7100
BP 96
EP 97
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA XL252
UT WOS:A1997XL25200023
PM 9240049
OA No
DA 2017-08-15
ER

PT J
AU Benn, CS
   Aaby, PA
   Bale, C
   Olsen, J
   Michaelsen, KF
   George, N
   Whittle, H
AF Benn, CS
   Aaby, PA
   Bale, C
   Olsen, J
   Michaelsen, KF
   George, N
   Whittle, H
TI Randomised trial of effect of vitamin A supplementation on antibody
   response to measles vaccine in Guinea-Bissau, west Africa
SO LANCET
LA English
DT Article
ID CHILDREN; TETANUS; AGE
AB Background WHO has recommended vitamin A supplementation for children aged 6 months or older in developing countries at the same time as immunisation. One study has reported significantly lower seroconversion ratios among children who have received vitamin A supplements with measles vaccine at age 6 months. The aim of our study was to assess the effect of Vitamin A supplementation on antibody response to measles vaccination at age 9 months, which is the more common age for immunisation in developing countries.
   Methods In an urban community in Guinea-Bissau, we did a randomised, double-blind, placebo-controlled study of the effect of simultaneous Vaccination and vitamin A supplementation in 462 children who received either a two-dose schedule of measles vaccine at the ages of 6 months and 9 months (150 infants) or one dose of measles vaccine at age 9 months (312 infants). Children were followed up to the age of 18 months and a blood sample was then collected to assess the antibody response.
   Findings 397 (86%) of the children took part in the follow-up (52 [11%] had moved and 13 [3%] had died). Among children who received a two-dose vaccine schedule, seroconversion was 98%. There was no difference in seroconversion or geometric mean titre (GMT) for children receiving vitamin A compared with children receiving no supplement. Among children receiving only one dose of measles vaccine at age 9 months, seroconversion was 95%. The GMT was significantly higher in children receiving vitamin A than in those receiving no supplement (3704 vs 2439 mIU; GMT ratio 1.52 [1.22-1.88]). The effect on plasma antibody concentration in the blood was stronger for boys (3902 vs 1916 mIU; GMT ratio 2.04 [1.53-2.72]) than for girls (3502 vs 3017 mIU; GMT ratio 1.16 [0.85-1.58]) who had received Vitamin A with measles vaccine, In a multivariate analysis of variance adjusted for sex, vitamin A supplementation was associated with higher antibody titres (p<0.001). There was a significant interaction between vitamin A supplementation and sex (p=0.02).
   Interpretation There is no indication that simultaneous administration of measles vaccine and vitamin A supplements has a negative effect on measles immunity. Among the children who had received two doses of measles vaccine at the ages of 6 months and 9 months, supplements of vitamin A had no significant effect. Among children only receiving one dose of measles Vaccine at age 9 months, 100 000 IU vitamin A increased antibody concentrations, especially for boys.
C1 PROJECTO SAUDE DE BANDIM,BISSAU,GUINEA BISSAU.
   STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN S,DENMARK.
   ROYAL VET & AGR UNIV,RES DEPT HUMAN NUTR,COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
OI Michaelsen, Kim F/0000-0003-0449-0839
CR AABY P, 1993, BRIT MED J, V307, P1308
   AABY P, 1995, CROWDING HLTH LOW IN
   BENN CS, 1995, LANCET, V346, P503
   BROWN KH, 1980, AM J CLIN NUTR, V33, P212
   FRIIS H, IN PRESS AM J CLIN N
   JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9
   KUTTY P M, 1981, Acta Vitaminologica et Enzymologica, V3, P231
   MOLBAK K, 1994, BRIT MED J, V308, P1403
   Molbak K, 1997, AM J CLIN NUTR, V65, P149
   ROSS D, 1995, LANCET, V345, P1317, DOI 10.1016/S0140-6736(95)92531-7
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SEMBA RD, 1992, J NUTR, V122, P101
   SEMBA RD, 1995, LANCET, V345, P1330
   UZOECHINA ON, 1994, ANN TROP PAEDIATR, V14, P157
   WHITTLE H, 1988, LANCET, V2, P811
   World Health Organization, 2008, WHO LAB MAN EX HUM S, P1
   YASSAI MB, 1989, J TROP PEDIATRICS, V35, P247
NR 17
TC 91
Z9 92
U1 0
U2 3
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 12
PY 1997
VL 350
IS 9071
BP 101
EP 105
DI 10.1016/S0140-6736(96)12019-5
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA XK114
UT WOS:A1997XK11400010
PM 9228962
OA No
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   vanderLoeff, MS
   Sabally, S
   Cham, F
   Corrah, T
   Whittle, H
AF Ariyoshi, K
   vanderLoeff, MS
   Sabally, S
   Cham, F
   Corrah, T
   Whittle, H
TI Does HIV-2 infection provide cross-protection against HIV-1 infection?
SO AIDS
LA English
DT Letter
ID T-CELLS
RP Ariyoshi, K (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR BOTTIGER B, 1990, J VIROL, V64, P3492
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Fowke K. R., 1996, LANCET, V348, P1247
   NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   WILKINS A, 1991, AIDS, V5, P1127, DOI 10.1097/00002030-199109000-00012
   Wyand MS, 1996, J VIROL, V70, P3724
NR 9
TC 27
Z9 28
U1 0
U2 0
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD JUL
PY 1997
VL 11
IS 8
BP 1053
EP 1054
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA XH111
UT WOS:A1997XH11100015
PM 9223741
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   VanHensbroek, MB
   Palmer, A
   Schneider, G
   Greenwood, B
AF Jaffar, S
   VanHensbroek, MB
   Palmer, A
   Schneider, G
   Greenwood, B
TI Predictors of a fatal outcome following childhood cerebral malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CLINICAL-FEATURES; CHILDREN
AB Despite prompt treatment with an effective anti-malarial drug, cerebral malaria still has a mortality of 20-30%. To identify factors that may contribute to this high fatality rate, we have studied the relationship between clinical and laboratory features and a fatal outcome in 624 Gambian children with strictly defined cerebral malaria. One hundred twenty-four children (21.5%) died. Three-quarters of the deaths occurred within 24 hr of admission. Multiple logistic regression analysis showed that a cold periphery (odds ratio [OR] = 2.7), a deep coma (OR = 2.0), and hypoglycemia (OR = 4.1) were the clinical signs and laboratory parameters that predicted death most strongly. More than 90% of the children who died had at least one of these conditions. Also, children with elevated urea levels on admission or those who experienced multiple episodes of hypoglycemia or multiple convulsions subsequently were more likely to die. A combination of clinical and laboratory abnormalities can identify a group of children with cerebral malaria who are most at risk of dying, who require intensive care and who are candidates for new forms of therapy.
C1 ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
   SIBANOR HLTH CTR,SIBANOR,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
   UNIV AMSTERDAM,DEPT TROP MED,AMSTERDAM,NETHERLANDS.
RP Jaffar, S (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
CR BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HENSBROEK MBV, 1997, J INFECT DIS, V175, P200
   HENSBROEK MBV, 1997, IN PRESS J PEDIAT
   HENSBROEK MBV, 1996, NEW ENGL J MED, V335, P69
   Kirkwood B.R, 1988, ESSENTIALS MED STAT
   MARSH K, 1995, NEW ENGL J MED, V332, P399
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   PETO R, 1978, BIOMEDICINE, V28, P24
   STURCHER D, 1988, PARASITOL TODAY, V5, P39
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   WHITE NJ, 1987, LANCET, V1, P708
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
NR 13
TC 53
Z9 53
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 1997
VL 57
IS 1
BP 20
EP 24
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XM907
UT WOS:A1997XM90700004
PM 9242312
OA No
DA 2017-08-15
ER

PT J
AU Newport, MJ
   Blackwell, JM
AF Newport, MJ
   Blackwell, JM
TI Genetic susceptibility to tuberculosis
SO BAILLIERES CLINICAL INFECTIOUS DISEASES
LA English
DT Review
DE mycobacteria; genetic susceptibility
ID TUMOR-NECROSIS-FACTOR; BACILLUS-CALMETTE-GUERIN; CHRONIC
   GRANULOMATOUS-DISEASE; POLYMERASE CHAIN-REACTION; HUMAN-LEUKOCYTE
   ANTIGEN; NITRIC-OXIDE SYNTHASE; PULMONARY TUBERCULOSIS;
   NATURAL-RESISTANCE; MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA
AB Racial differences, twin studies, and Mendelian segregation of disease in families support the hypothesis that susceptibility to tuberculosis is genetically regulated. Complex segregation analysis of disease in multicase families suggests that one or two major loci are involved. Attempts to identify these genes involve both genome scanning and analysis of candidate gene regions. Current data do not support a major role for the human homologue (NRAMP1) of the murine natural resistance gene (Nramp1 =Ity/Lsh/Bcg) in controlling susceptibility to tuberculosis, although there is evidence to support a role for this gene in susceptibility to leprosy and rheumatoid arthritis. Population studies have identified allelic associations between disease phenotypes and polymorphic markers in other candidate gene regions, including the region containing the gene NOS2A encoding inducible nitric oxide synthase, polymorphisms within the genes encoding class I (A,B,) and class II (DR) molecules of the major histocompatibility complex (MHC), polymorphisms within the MHC class III region loci TNF-alpha/beta, and functional polymorphisms in gene (VDR) encoding the receptor for the active metabolite (1,25-dihydroxyvitamin D3) of vitamin D. However, these findings have not been found uniformly in all populations. No evidence has been found for linkage to, or allelic association with, disease susceptibility and intronic markers within the candidate gene (IL-4) encoding interleukin 4. However, allelic associations between these polymorphic IL-4 markers and quantitative traits measuring immune response to mycobacterial antigens have been observed, suggesting that this region of the genome may be important in determining response to BCG vaccination. Analysis of multicase families in which extreme susceptibility to atypical mycobacterial infection segregates as a single recessive genetic disorder has identified the receptor for interferon-gamma as another important candidate gene (IFN-gamma R) for mycobacterial disease susceptibility. This is currently being examined in tuberculosis family studies. Work continues to determine the global importance of these various candidate genes in determining susceptibility to tuberculosis, and to analyse new candidate genes identified using a genome scanning approach. These genetic studies should improve our understanding of the molecular and cellular mechanisms which determine susceptibility to tuberculosis.
C1 ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.
RP Newport, MJ (reprint author), MED RES LABS,POB 273,BANJUL,GAMBIA.
RI Blackwell, Jenefer/H-3015-2015
CR ABEL L, 1988, AM J HUM GENET, V42, P256
   ABEL L, 1996, BRAZ J GENET, V19, P113
   AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   ALARIF LI, 1979, AM REV RESPIR DIS, V120, P1275
   APPELBERG R, 1990, CLIN EXP IMMUNOL, V80, P324, DOI 10.1111/j.1365-2249.1990.tb03288.x
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853
   BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683
   BARTON CH, 1995, MOL MED, V1, P267
   BETTINOTTI MP, 1993, IMMUNOGENETICS, V38, P74, DOI 10.1007/BF00216397
   BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1
   Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9
   BLACKWELL JM, 1995, MOL MED, V1, P194
   BLACKWELL JM, 1994, IMMUNOL LETT, V43, P99, DOI 10.1016/0165-2478(94)00161-8
   BLACKWELL JM, 1991, IMMUNOL LETT, V30, P241, DOI 10.1016/0165-2478(91)90032-6
   BLACKWELL JM, 1997, IN PRESS PHILOS T B
   BOTHAMLEY GH, 1989, J INFECT DIS, V59, P549
   BRADLEY DJ, 1979, CLIN EXP IMMUNOL, V37, P7
   BRADLEY DJ, 1974, NATURE, V250, P353, DOI 10.1038/250353a0
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   BREWERTON DA, 1973, LANCET, V1, P904
   BROWN IN, 1982, IMMUNOLOGY, V47, P149
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500
   CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C
   Casanova JL, 1996, PEDIATRICS, V98, P774
   Castes M, 1993, Biol Res, V26, P233
   Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5
   CHANDANAYINGYONG D, 1988, ASIAN PAC J ALLERGY, V6, P77
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   COX RA, 1982, AM REV RESPIR DIS, V126, P653
   DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0
   DAVIES PDO, 1985, TUBERCLE, V66, P301, DOI 10.1016/0041-3879(85)90068-6
   DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682
   DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   DONLON TA, 1990, GENOMICS, V6, P548, DOI 10.1016/0888-7543(90)90485-D
   Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280
   DUGAS B, 1995, IMMUNOL TODAY, V16, P574, DOI 10.1016/0167-5699(95)80080-8
   ENGBAEK HC, 1964, ACTA TUBERC PNEUM SC, V45, P105
   FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x
   FINE PEM, 1981, INT J LEPROSY, V49, P437
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2
   GOTO Y, 1984, INFECT IMMUN, V46, P135
   Govoni G, 1996, INFECT IMMUN, V64, P2923
   GRANGE JM, 1982, TUBERCLE, V63, P3, DOI 10.1016/S0041-3879(82)80004-4
   GRANGE JM, 1985, TUBERCLE, V66, P187, DOI 10.1016/0041-3879(85)90035-2
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GRAVES DT, 1995, CRIT REV ORAL BIOL M, V6, P109
   GROS P, 1981, J IMMUNOL, V127, P2417
   HAFEZ M, 1985, TUBERCLE, V66, P35, DOI 10.1016/0041-3879(85)90051-0
   HAILE RWC, 1985, HUM HERED, V35, P43, DOI 10.1159/000153514
   HAWKINS BR, 1988, AM REV RESPIR DIS, V138, P1616
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904
   HOLMANS P, 1995, AM J HUM GENET, V57, P1221
   HWANG CH, 1985, AM REV RESPIR DIS, V132, P382
   IRVING SG, 1990, NUCLEIC ACIDS RES, V18, P3261, DOI 10.1093/nar/18.11.3261
   JIANG YL, 1992, J IMMUNOL, V148, P2423
   JIANG ZF, 1983, TISSUE ANTIGENS, V22, P86
   John S, 1997, J RHEUMATOL, V24, P199
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Kallmann FJ, 1943, J HERED, V34, P293
   Kallmann Franz J., 1943, AMER REV TUBERC, V47, P549
   KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435
   KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419
   KAYE PM, 1989, RES IMMUNOL, V140, P810, DOI 10.1016/0923-2494(89)90038-2
   Keet I P, 1996, AIDS, V10 Suppl A, pS59, DOI 10.1097/00002030-199601001-00009
   KOCH ROBERT, 1932, AMER REV TUBERC, V25, P285
   KOMENKO AG, 1990, TUBERCLE, V71, P187
   KRAMNIK I, 1994, IMMUNOLOGY, V81, P618
   LADEL CH, 1995, EUR J IMMUNOL, V25, P838, DOI 10.1002/eji.1830250331
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231
   LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728
   Lang T, 1997, INFECT IMMUN, V65, P380
   LEE S Y, 1976, Seoul Journal of Medicine, V17, P159
   LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4
   Lewis LA, 1996, IMMUNOGENETICS, V44, P309, DOI 10.1007/BF02602562
   LIU J, 1995, AM J HUM GENET, V56, P845
   LURIE MB, 1965, BACTERIOL REV, V29, P466
   MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3
   Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6
   MANOLAGAS SC, 1989, P SOC EXP BIOL MED, V191, P238
   Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Medina E, 1996, J EXP MED, V183, P1045, DOI 10.1084/jem.183.3.1045
   MEHRA NK, 1990, TROP MED PARASITOL, V41, P352
   MEHRABIAN M, 1991, GENOMICS, V9, P200, DOI 10.1016/0888-7543(91)90239-B
   MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   MORTON NE, 1991, ANN HUM GENET, V55, P301, DOI 10.1111/j.1469-1809.1991.tb00857.x
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293
   ORME I, 1985, PROG LEUK BIOL, V3, P285
   Ott J., 1991, ANAL HUMAN GENETIC L
   PAPIHA SS, 1985, TUBERCLE, V66, P25, DOI 10.1016/0041-3879(85)90050-9
   PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C
   PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367
   PIERREAUDIGIER C, 1997, IN PRESS CLIN INFECT
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   PIRMEZ C, 1990, J IMMUNOL, V145, P3100
   PLANT J, 1979, CLIN EXP IMMUNOL, V37, P1
   PLANT J, 1974, NATURE, V248, P345, DOI 10.1038/248345a0
   PLANT JE, 1982, NATURE, V297, P510, DOI 10.1038/297510a0
   POPELOV LE, 1996, TUBERCLE LUNG DIS, V77, P77
   PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748
   RADZIOCH D, 1995, CIRC SHOCK, V44, P115
   Rajalingam R, 1996, J INFECT DIS, V173, P669
   ROACH TIA, 1994, INFECT IMMUN, V62, P1176
   ROACH TIA, 1995, IMMUNOLOGY, V85, P106
   ROOK GAW, 1987, IMMUNOLOGY, V62, P229
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159
   ROSENTHAL I, 1973, Z IMMUNITATSFORSCH, V144, P424
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   SEGAL AW, 1992, J INHERIT METAB DIS, V15, P683, DOI 10.1007/BF01799624
   SELBY R, 1978, TISSUE ANTIGENS, V11, P403, DOI 10.1111/j.1399-0039.1978.tb01275.x
   SERJEANTSON S, 1979, ANN HUM BIOL, V6, P375, DOI 10.1080/03014467900003761
   SERJEANTSON SW, 1983, IMMUNOL REV, V70, P89, DOI 10.1111/j.1600-065X.1983.tb00711.x
   SHAM PC, 1995, ANN HUM GENET, V59, P323, DOI 10.1111/j.1469-1809.1995.tb00751.x
   Shaw MA, 1996, J MED GENET, V33, P672, DOI 10.1136/jmg.33.8.672
   SHAW MA, 1997, IN PRESS TUBERCLE LU
   SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   SIELING PA, 1994, IMMUNOBIOLOGY, V191, P378
   SIMMONDS B, 1963, TUBERCULOSIS TWINS
   SINGH SPN, 1983, J INFECT DIS, V148, P676
   SINGH SPN, 1983, TISSUE ANTIGENS, V21, P380
   SKAMENE E, 1994, IMMUNOBIOLOGY, V191, P451
   SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0
   SKAMENE E, 1984, IMMUNOGENETICS, V19, P111
   Smith F. B., 1988, RETREAT TUBERCULOSIS
   STEAD WW, 1992, ANN INTERN MED, V116, P937
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   TAKATA H, 1978, TISSUE ANTIGENS, V11, P61, DOI 10.1111/j.1399-0039.1978.tb01225.x
   TAUBER AI, 1983, MEDICINE, V62, P286
   TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   TODD JR, 1990, REV INFECT DIS, V12, P63
   TROWSDALE J, 1993, TRENDS GENET, V9, P117, DOI 10.1016/0168-9525(93)90205-V
   UCHIYAMA N, 1981, J PEDIATR-US, V98, P785
   VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59
   VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D
   VOULDOUKIS I, 1995, P NATL ACAD SCI USA, V92, P7804, DOI 10.1073/pnas.92.17.7804
   WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619
   WICKS I, 1994, IMMUNOL TODAY, V15, P553, DOI 10.1016/0167-5699(94)90214-3
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
   XU XP, 1986, IMMUNOL INVEST, V15, P327
   YAMAMURA M, 1992, J IMMUNOL, V149, P1470
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
   YANAGAWA T, 1994, J CLIN ENDOCR METAB, V79, P227, DOI 10.1210/jc.79.1.227
   ZACHARIAE CO, 1990, J EXP MED, V171, P217
   ZERVAS J, 1987, BRIT J DIS CHEST, V81, P147, DOI 10.1016/0007-0971(87)90132-X
NR 157
TC 6
Z9 6
U1 0
U2 2
PU BAILLIERE TINDALL
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 1071-6564
J9 BAILLIERE CLIN INF D
JI Baillieres Clin. Infect. Dis.
PD JUL
PY 1997
VL 4
IS 2
BP 207
EP 229
PG 23
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YC718
UT WOS:A1997YC71800007
OA No
DA 2017-08-15
ER

PT J
AU Malin, A
   McAdam, K
AF Malin, A
   McAdam, K
TI Mycobacterial diseases - Most worthy opponents - Preface
SO BAILLIERES CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 MED RES COUNCIL UK LABS,POB 273,BANJUL,GAMBIA.
RP Malin, A (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BAILLIERE TINDALL
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 1071-6564
J9 BAILLIERE CLIN INF D
JI Baillieres Clin. Infect. Dis.
PD JUL
PY 1997
VL 4
IS 2
BP R13
EP R17
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YC718
UT WOS:A1997YC71800001
OA No
DA 2017-08-15
ER

PT J
AU vanHensbroek, MB
   Palmer, A
   Jaffar, S
   Schneider, G
   Kwiatkowski, D
AF vanHensbroek, MB
   Palmer, A
   Jaffar, S
   Schneider, G
   Kwiatkowski, D
TI Residual neurologic sequelae after childhood cerebral malaria
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID AFRICAN CHILDREN; HYPOGLYCEMIA
AB Background: Cerebral malaria is an important cause of pediatric hospital admissions in the tropics. It commonly leads to neurologic sequelae, but the risk factors for this remain unclear and the long-term outcome unknown.
   Objective: The purpose of this study was to identify the common forms of neurologic sequelae that occur after cerebral malaria, their evolution over time, and the major clinical risk factors for residual disability.
   Study design: Prospective study in 624 children admitted with cerebral malaria to two hospitals in The Gambia, West Africa.
   Results: We found that 23.3% of survivors had neurologic sequelae on discharge from the hospital. By 1 month the proportion had decreased to 8.6%, and at 6 months only 4.4% of survivors were found to have residual neurologic sequelae. The most common forms of neurologic sequelae were paresis and ataxia, often found in combination with other neurologic abnormalities. In a multiple logistic regression analysis, depth of coma on admission, multiple convulsions, and duration of unconsciousness were the only three independent risk factors. Hypoglycemia and lactate acidosis were not predictive of sequelae, although they are important risk factors for fatality.
   Conclusion: This finding raises the possibility that fatal outcome and neurologic sequelae arise from separate pathologic processes.
C1 UNIV OXFORD, JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND.
   SIBANON HLTH CTR, SIBANON, GAMBIA.
   ROYAL VICTORIA HOSP, MRC LABS, BANJUL, GAMBIA.
   ROYAL VICTORIA HOSP, DEPT PAEDIAT, BANJUL, GAMBIA.
   UNIV AMSTERDAM, ACAD MED CTR, DEPT TROP MED, NL-1105 AZ AMSTERDAM, NETHERLANDS.
CR AKEDE GO, 1993, J TROP PEDIATRICS, V39, P350
   BONDI FS, 1992, T ROY SOC TROP MED H, V86, P17, DOI 10.1016/0035-9203(92)90420-H
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   CARME B, 1993, AM J TROP MED HYG, V48, P216
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201
   PETO R, 1978, BIOMEDICINE, V28, P24
   vanHensbroek MB, 1996, J INFECT DIS, V174, P1091
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
   WHITE NJ, 1987, LANCET, V1, P708
NR 14
TC 86
Z9 88
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 1997
VL 131
IS 1
BP 125
EP 129
DI 10.1016/S0022-3476(97)70135-5
PN 1
PG 5
WC Pediatrics
SC Pediatrics
GA XP113
UT WOS:A1997XP11300025
PM 9255203
OA No
DA 2017-08-15
ER

PT J
AU vonSeidlein, L
   Duraisingh, MT
   Drakeley, CJ
   Bailey, R
   Greenwood, BM
   Pinder, M
AF vonSeidlein, L
   Duraisingh, MT
   Drakeley, CJ
   Bailey, R
   Greenwood, BM
   Pinder, M
TI Polymorphism of the Pfmdr1 gene and chloroquine resistance in Plasmodium
   falciparum in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; drug resistance; chloroquine;
   artemisinin; dihydroartemisinin; genotype; Pfmdr1 gene; The Gambia
ID POLYMERASE CHAIN-REACTION; RANDOMIZED TRIAL; MALARIA; SENSITIVITY;
   MEFLOQUINE; AFRICA; SUSCEPTIBILITY; AMPLIFICATION; PYRIMETHAMINE;
   MUTATIONS
AB To assess the level of resistance to chloroquine (CQ) of Plasmodium falciparum in The Gambia in 1995-1996 we measured susceptibility in vivo by quantifying parasitaemia of children with mild malaria on days 4 and 8 after treatment, Pretreatment blood samples were used for susceptibility testing in vitro by the World Health Organization microtest and the prevalence of the tyrosine (tyr)(86) allele of the Pfmdr1 gene was assessed by the polymerase chain reaction and restriction fragment length polymorphism analysis. Seven of 42 children (17%) treated with CQ remained parasitaemic on day 4 and required a change of antimalarial treatment. Susceptibility assays Cr vitro were performed an 50 P. falciparum isolates obtained rained from eligible children before treatment; 36 (72%) were resistant to CQ (greater than or equal to 1.6 mu mol/L). The median minimum inhibitory concentration (MIC) of artemether was 3.38 nmol/L (range 0.42-13.51 nmol/L) and the median MIC of dihydroartemisinin was 0.88 nmol/L (range 0.22-14.04 nmol/L). Susceptibility in vitro to CQ and the Pfmdr1 genotype were determined for 31 fresh isolates. The allele was present in Ii of 22 isolates found to be resistant to CQ in vitro, but in none of the 9 isolates which mere susceptible (Fisher's exact test, P=0.005). All P. falciparum isolates with the tyr(86) allele were CQ resistant in vitro, but since only half of all resistant isolates contained the allele, additional explanations for CQ resistance are required.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL & CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
CR ADAGU IS, 1995, T ROY SOC TROP MED H, V89, P132
   Alin MH, 1995, AM J TROP MED HYG, V53, P639
   AWADELKARIEM FM, 1992, T ROY SOC TROP MED H, V86, P587, DOI 10.1016/0035-9203(92)90140-8
   Basco LK, 1995, MOL BIOCHEM PARASIT, V74, P157, DOI 10.1016/0166-6851(95)02492-1
   BASCO LK, 1993, AM J TROP MED HYG, V49, P301
   BASCO LK, 1993, TROP MED PARASITOL, V44, P111
   BRANDICOURT O, 1986, AM J TROP MED HYG, V35, P717
   BURCHARD GD, 1984, TROPENMED PARASITOL, V35, P1
   DOURY JC, 1992, TROP MED PARASITOL, V43, P197
   Duraisingh MT, 1997, PARASITOLOGY, V114, P205, DOI 10.1017/S0031182096008487
   FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0
   FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9
   FREAN JA, 1992, T ROY SOC TROP MED H, V86, P29, DOI 10.1016/0035-9203(92)90426-D
   GILLES HM, 1993, B CHWATTS ESSENTIAL, P146
   KYRONSEPPA H, 1984, LANCET, V1, P1244
   LEBRAS J, 1986, LANCET, V2, P1043
   MENON A, 1987, LANCET, V1, P1029
   MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   NEEQUAYE J, 1986, LANCET, V1, P153
   PANTON LJ, 1985, T ROY SOC TROP MED H, V79, P484, DOI 10.1016/0035-9203(85)90072-0
   Ringwald P, 1996, LANCET, V347, P24, DOI 10.1016/S0140-6736(96)91558-5
   SALAKO LA, 1987, LANCET, V1, P572
   SANSONETTI PJ, 1985, LANCET, V1, P1154
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0
   WERNSDORFER WH, 1991, PHARMACOL THERAPEUT, V50, P95
   WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, V2, P1765
   *WHO, 1987, MAP872 WHO
   *WHO, 1994, WHOMAL941070
   WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S
NR 31
TC 52
Z9 53
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 1997
VL 91
IS 4
BP 450
EP 453
DI 10.1016/S0035-9203(97)90281-9
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XU339
UT WOS:A1997XU33900034
PM 9373652
OA No
DA 2017-08-15
ER

PT J
AU Snow, RW
   Omumbo, JA
   Lowe, B
   Molyneux, CS
   Obiero, JO
   Palmer, A
   Weber, MW
   Pinder, M
   Nahlen, B
   Obonyo, C
   Newbold, C
   Gupta, S
   Marsh, K
AF Snow, RW
   Omumbo, JA
   Lowe, B
   Molyneux, CS
   Obiero, JO
   Palmer, A
   Weber, MW
   Pinder, M
   Nahlen, B
   Obonyo, C
   Newbold, C
   Gupta, S
   Marsh, K
TI Relation between severe malaria morbidity in children and level of
   Plasmodium falciparum transmission in Africa
SO LANCET
LA English
DT Article
ID INDICATORS; MORTALITY
AB Background Malaria remains a major cause of mortality and morbidity in Africa; Many approaches to malaria control involve reducing the chances of infection but little is known of the relations between parasite exposure and the development of effective clinical immunity so the longterm effect of suck approaches to control on the pattern and frequency of malaria cannot be predicted.
   Methods We have prospectively recorded paediatric admissions with severe malaria over three to five years from five discrete communities in The Gambia and Kenya, Demographic analysis of the communities exposed to disease risk allowed the estimation of age-specific rates for severe malaria. Within each community the exposure to Plasmodium falciparum infection was determined through repeated parasitological and serological surveys among children and infants,We used acute respiratory-tract infections (ARI) as a comparison.
   Findings 3556 malaria admissions were recorded for the five sites. Marked differences were observed in age, clinical spectrum and rates of severe malaria between the five sites, Paradoxically, the risks of severe disease in childhood were lowest among populations with the highest transmission intensities, and the highest disease risks were observed among populations exposed to low-to-moderate intensities of transmission. For severe malaria, for example, admission rates (per 1000 per year) for children up to their 10th birthday were estimated as 3.9, 25.8, 25.9, 16.7 and 18.0 in the five communities; the forces of infection estimated for those communities (new infections per infant per month) were 0.001, 0.034, 0.050, 0.093, and 0.176, respectively. Similar trends were noted for cerebral malaria and for severe malaria anaemia but not for ARI. Mean age of disease decreased with increasing transmission intensity.
   Interpretation We propose that a critical determinant of life-time disease risk is the ability to develop clinical immunity early in life during a period when other protective mechanisms may operate. In highly endemic areas measures which reduce parasite transmission,and thus immunity, may lead to a change in both the clinical spectrum of severe disease and the overall burden of severe malaria morbidity.
C1 UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,MOL PARASITOL GRP,INST MOL MED,OXFORD OX3 9DU,ENGLAND.
   KENYA GOVT MED RES CTR,CLIN RES CTR,COASTAL UNIT,KILIFI,KENYA.
   ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
   MRC,FAJARA,GAMBIA.
   CTR DIS CONTROL,KENYA MED RES INST,COLLABORAT PROGRAMME,VECTOR BIOL & CONTROL RES CTR,KISUMU,KENYA.
   CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA.
   UNIV OXFORD,WELLCOME CTR EPIDEMIOL INFECT DIS,DEPT ZOOL,OXFORD OX1 2JD,ENGLAND.
RP Snow, RW (reprint author), KENYA GOVT MED RES CTR,WELLCOME TRUST COLLABORAT PROGRAMME,POB 43640,NAIROBI,KENYA.
OI Newbold, Chris/0000-0002-9274-3789
FU Wellcome Trust
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Arriaga E. E., 1994, POPULATION ANAL MICR
   Brabin B., 1990, Tropical Diseases Bulletin, V87, pR1
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   English M, 1996, AM J TROP MED HYG, V55, P521
   EWBANK DC, 1981, AGE MISREPORTING AGE, P1
   GARNHAM PCC, 1949, ANN TROP MED PARASIT, V43, P47
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   LACRITZ EM, 1992, LANCET, V340, P524
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MCGREGOR IA, 1970, CLIN EXP IMMUNOL, V7, P51
   MESELAAR D, 1959, TROP GEOG MED, V11, P157
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   MULLHOLLAND EK, 1997, LANCET, V349, P1191
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   Snow RW, 1996, AM J TROP MED HYG, V55, P144
   SNOW RW, 1994, INT J EPIDEMIOL, V23, P1013, DOI 10.1093/ije/23.5.1013
   SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   SNOW RW, 1994, EVALUATION IMPACT HL, P297
   TODD JE, 1994, ANN TROP PAEDIATR, V14, P31
   Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   WARRELL DA, 1990, T R SOC TROP MED S2, V84
   *WHO, 1950, TECH REP SER WHO, V38, P1
   Wilson D. B., 1950, Tropical Diseases Bulletin, V47, P677
NR 29
TC 434
Z9 436
U1 0
U2 44
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 7
PY 1997
VL 349
IS 9066
BP 1650
EP 1654
DI 10.1016/S0140-6736(97)02038-2
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA XD100
UT WOS:A1997XD10000008
PM 9186382
OA No
DA 2017-08-15
ER

PT J
AU Newport, MJ
AF Newport, MJ
TI Unravelling the genetic basis of susceptibility to infectious diseases
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; INTERFERON-GAMMA RECEPTOR;
   BACILLUS-CALMETTE-GUERIN; T-CELLS; IMMUNE-RESPONSE;
   ENVIRONMENTAL-INFLUENCES; SCHISTOSOMA-MANSONI; ALTERED RESPONSES; SEVERE
   MALARIA; MUTANT MICE
AB It has become increasingly apparent that host genetic factors influence the outcome of host-pathogen interactions, Recent advances in human gene mapping, in parallel with developments in our understanding of the immune mechanisms involved in resistance to infectious disease, have opened new avenues of research towards unravelling the genetic basis of susceptibility to infectious disease.
RP Newport, MJ (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ABEL L, 1991, AM J HUM GENET, V48, P959
   AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119
   BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1
   Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9
   Blackwell JM, 1996, PARASITOLOGY, V112, pS67
   BRADLEY DJ, 1974, NATURE, V250, P353, DOI 10.1038/250353a0
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   BREDIUS RGM, 1994, J INFECT DIS, V170, P848
   CASANOVA JL, 1997, PRIMARY IMMUNODEFICI
   Chakravartti MR, 1973, TOPICS HUMAN GENETIC, VI, P1
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   COUISSINIERPARIS P, 1995, EUR J IMMUNOL, V25, P2295, DOI 10.1002/eji.1830250827
   Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0
   Davenport MP, 1996, MOL MED TODAY, V2, P38, DOI 10.1016/1357-4310(96)88757-0
   DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8
   DRAJIC T, 1996, NATURE, V381, P667
   FEENEY AJ, 1996, J CLIN INVEST, V10, P2277
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2
   Goddard EA, 1996, PEDIATR INFECT DIS J, V15, P419, DOI 10.1097/00006454-199605000-00008
   Guler ML, 1996, SCIENCE, V271, P984
   Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5
   Hill AVS, 1996, PARASITOLOGY, V112, pS75
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301
   JEPSON AP, 1997, IN PRESS BMJ
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435
   KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419
   LADEL CH, 1995, EUR J IMMUNOL, V25, P838, DOI 10.1002/eji.1830250331
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728
   LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MALATY HM, 1994, ANN INTERN MED, V120, P982
   Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181
   Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   MCLEOD R, 1995, CURR OPIN IMMUNOL, V7, P539, DOI 10.1016/0952-7915(95)80100-6
   Nadel S, 1996, J INFECT DIS, V174, P878
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NEWPORT MJ, 1997, MYCOBACTERIAL INFECT
   NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987
   Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412
   PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C
   PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367
   PIERREAUDIGIER C, 1997, IN PRESS CLIN INFECT
   REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.immunol.13.1.151
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   SANGSTER MY, 1994, J VIROL, V68, P448
   SCALZO AA, 1995, GENOMICS, V27, P435, DOI 10.1006/geno.1995.1074
   Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540
   SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   Weatherall DJ, 1996, PARASITOLOGY, V112, pS23
   WEBER JL, 1989, AM J HUM GENET, V44, P388
NR 76
TC 2
Z9 2
U1 0
U2 0
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD JUN
PY 1997
VL 10
IS 3
BP 233
EP 238
DI 10.1097/00001432-199706000-00013
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA XF676
UT WOS:A1997XF67600013
OA No
DA 2017-08-15
ER

PT J
AU Ponnighaus, JM
   Lienhardt, C
   Lucas, S
   Fine, PEM
   Sterne, JAC
AF Ponnighaus, JM
   Lienhardt, C
   Lucas, S
   Fine, PEM
   Sterne, JAC
TI Comparison of bacillary indexes in slit-skin smears, skin and nerve
   biopsies; a study from Malawi
SO INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES
LA English
DT Article
ID MYCOBACTERIUM-LEPRAE; LEPROSY; CLASSIFICATION; DIAGNOSIS
AB Data analyzed in this paper were collected within the framework of the Lepra Evaluation Project, an epidemiological study of leprosy in Karonga District, northern Malawi. For 212 patients information on the number of skin lesions, slit-skin smear and skin biopsy results were available. Among 61 patients with a single lesion none were slit-skin-smear positive and two had bacilli detected in skin biopsies. In contrast, among 119 patients with four or more lesions 34 (28.6%) versus 59 (49.6%) had bacilli detectable in slit-skin smears or skin biopsies, respectively.
   In a further 47 patients skin biopsy results could be compared with split-nerve biopsy results. In 20 of 47 patients the bacterial indexes (BIs) were identical in skin and nerve biopsies, while in 26 of 47 patients the BIs were higher in nerve than in skin biopsies. This difference, which is consistent with several other studies in the literature, provides an insight into the pathogenesis of leprosy.
C1 LEPRA,CHILUMBA,MALAWI.
   MRC,BANJUL,GAMBIA.
   UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT HISTOPATHOL,LONDON SE1 7EH,ENGLAND.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
CR Antia N H, 1976, Lepr Rev, V47, P175
   BECXBLEUMINCK M, 1989, INT J LEPROSY, V57, P540
   Bryceson A, 1990, LEPROSY
   FINE PEM, 1992, INT J LEPROSY, V60, P71
   Georgiev G D, 1987, Indian J Lepr, V59, P373
   Hastings R, 1985, LEPROSY
   JOB CK, 1989, INT J LEPROSY, V57, P532
   KAUR S, 1993, LEPROSY REV, V64, P110
   Kumar SKA, 1996, LEPROSY REV, V67, P119
   MCDOUGALL AC, 1987, INT J LEPROSY, V53, P88
   NEGESSE Y, 1993, LEPROSY REV, V64, P104
   NILSEN R, 1989, LEPROSY REV, V60, P28
   Pearson J M, 1975, Lepr Rev, V46, P199
   PEDLEY JC, 1980, J NEUROL NEUROSUR PS, V43, P198, DOI 10.1136/jnnp.43.3.198
   Ponnighaus J M, 1995, Indian J Lepr, V67, P35
   PONNIGHAUS JM, 1988, T ROY SOC TROP MED H, V82, P803, DOI 10.1016/0035-9203(88)90002-8
   PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359
   PONNIGHAUS JM, 1987, INT J LEPROSY, V53, P454
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   RIDLEY DS, 1973, J PATHOL, V111, P191, DOI 10.1002/path.1711110307
   RIDLEY DS, 1986, INT J LEPROSY, V54, P596
   Srinivasan H, 1982, Lepr India, V54, P275
   STONER GL, 1979, LANCET, V315, P994
   *WHO EXP COMM LEPR, 1988, WHO TECH REP SER, V768
   *WHO STUD GROUP, 1982, WHO TECH REP SER, V675
NR 25
TC 14
Z9 14
U1 0
U2 0
PU AMER LEPROSY MISSION
PI BATON ROUGE
PA GWL HANSENS DISEASE CENTER, LSU VET SCHOOL, RM 11022, SOUTH STADIUM DR,
   BATON ROUGE, LA 70803-9999
SN 0148-916X
J9 INT J LEPROSY
JI Int. J. Lepr. Other Mycobact. Dis.
PD JUN
PY 1997
VL 65
IS 2
BP 211
EP 216
PG 6
WC Microbiology; Pathology; Tropical Medicine
SC Microbiology; Pathology; Tropical Medicine
GA XX628
UT WOS:A1997XX62800008
PM 9251593
OA No
DA 2017-08-15
ER

PT J
AU Lienhardt, C
   Rodrigues, LC
AF Lienhardt, C
   Rodrigues, LC
TI Estimation of the impact of the human immunodeficiency virus infection
   on tuberculosis: tuberculosis risks re-visited?
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculosis; HIV infection; tuberculosis control; tuberculosis
   epidemiology
ID HIV-INFECTION; PULMONARY TUBERCULOSIS; CLINICAL-FEATURES; EPIDEMIOLOGY;
   AFRICA; ZAIRE; TRANSMISSION; MORTALITY; KINSHASA; TYPE-1
AB The human immunodeficiency virus (HIV) infection has both a direct and an indirect effect on the incidence of tuberculosis. The direct effect is due to the increased number of cases among HIV-infected individuals because of their enhanced susceptibility to the disease. The indirect effect is increased transmission of Mycobacterium tuberculosis infection in a community with high levels of dual infection, as a consequence of infectious cases occurring in HIV-infected persons. The risk of infection by M. tuberculosis in the population will then increase, as will the number of tuberculosis cases in the general population. According to the World Health Organization, over 4 million people are estimated to be dually infected with HIV and M. tuberculosis worldwide. In 1990, it was estimated that 300 000 new TB cases (4% of total new cases) were attributable to HIV infection; around 1.4 million cases are expected per year by 2000 (equivalent to about 14% of expected cases), thus increasing the reservoir of tuberculosis patients capable of transmitting the infection to others, and increasing the burden on the already overstretched National Tuberculosis Control Programmes, especially in resource-poor countries. This paper is a review of methods suggested to quantify the effect of the interaction between HIV infection and tuberculosis at population level, and more particularly the effect of HIV on the risk of tuberculosis infection.
RP Lienhardt, C (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403
   ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439
   BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501
   CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570
   COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404
   DECOCK KM, 1991, BRIT MED J, V302, P496
   DECOCK KM, 1994, TUBERCULOSIS BACK FU
   DIPERRI G, 1989, LANCET, V2, P1502
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302
   ELLIOTT AM, 1990, BRIT MED J, V301, P412
   ELLIOTT AM, 1993, AIDS, V7, P981
   ENARSON D, 1991, TUBERCULOSIS GUIDE H
   FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K
   GODFREYFAUSSETT P, 1992, T ROY SOC TROP MED H, V86, P472, DOI 10.1016/0035-9203(92)90072-K
   GOODGAME RW, 1990, NEW ENGL J MED, V323, P283
   Hennekens CH, 1987, EPIDEMIOLOGY MED
   HEYMANN SJ, 1993, T ROY SOC TROP MED H, V87, P406, DOI 10.1016/0035-9203(93)90014-H
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540
   JOHNSON M, 1991, AM REV RESPIR DIS S1, V143, P280
   KASEKA N, 1991, 7 INT C AIDS FLOR IT, P49
   KLAUSNER JD, 1993, J INFECT DIS, V168, P106
   LONG R, 1991, AM REV RESPIR DIS, V143, P69
   MANGIAROTTI V, C HIV OTH END DIS AF
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6
   NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G
   NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1
   Okwera A., 1990, Morbidity and Mortality Weekly Report, V39, P638
   PORTER JDH, 1992, T ROY SOC TROP MED H, V86, P467, DOI 10.1016/0035-9203(92)90069-O
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79
   ROUILLON A, 1976, TUBERCLE, V57, P275
   SCHULZER M, 1994, INT J EPIDEMIOL, V23, P400, DOI 10.1093/ije/23.2.400
   SCHULZER M, 1992, TUBERCLE LUNG DIS, V73, P52, DOI 10.1016/0962-8479(92)90080-4
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901
   SLUTKIN G, 1986, B INT UNION TUBERC L, V63, P21
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247
   STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5
   Styblo K, 1980, Adv Tuberc Res, V20, P1
   Styblo K, 1990, Bull Int Union Tuberc Lung Dis, V65, P28
   Styblo K., 1985, B INT UNION TUBERC, V60, P117
   STYBLO K, 1991, SELECTED PAPERS KNCV, V24
   SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149
   Sutherland I, 1991, Bull Int Union Tuberc Lung Dis, V66, P189
   Sutherland I, 1976, Adv Tuberc Res, V19, P1
   *WHO, 1992, GLOB PROGR AIDS CURR
   *WHO, B WORLD HEALTH ORGAN, V70, P17
   *WHO, 1991, WHO WORKSH GEN 20 22
NR 51
TC 34
Z9 35
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JUN
PY 1997
VL 1
IS 3
BP 196
EP 204
PG 9
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA YJ999
UT WOS:A1997YJ99900002
PM 9432364
OA No
DA 2017-08-15
ER

PT J
AU Faal, HB
AF Faal, HB
TI The Gambia: Approaches to blindness
SO LANCET
LA English
DT Article
RP Faal, HB (reprint author), ROYAL VICTORIA HOSP,NATL EYE CARE PROGRAMME,EYE UNIT,BANJUL,GAMBIA.
CR FAAL H, 1989, BR J OPHTHALMOL, V73, P2
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN
PY 1997
VL 349
SU 3
BP 23
EP 23
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA XG041
UT WOS:A1997XG04100020
OA No
DA 2017-08-15
ER

PT J
AU Cham, MK
AF Cham, MK
TI The Gambia: Treated bednets
SO LANCET
LA English
DT Article
RP Cham, MK (reprint author), MRC LABS,FAJARA,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN
PY 1997
VL 349
SU 3
BP 26
EP 26
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA XG041
UT WOS:A1997XG04100023
OA No
DA 2017-08-15
ER

PT J
AU Lisse, IM
   Bottiger, B
   Christensen, LB
   Knudsen, K
   Aaby, P
   Gottschau, A
   Urassa, W
   Mhalu, F
   Biberfeld, G
   Brattegaard, K
   Diallo, K
   NGom, PT
   Whittle, H
AF Lisse, IM
   Bottiger, B
   Christensen, LB
   Knudsen, K
   Aaby, P
   Gottschau, A
   Urassa, W
   Mhalu, F
   Biberfeld, G
   Brattegaard, K
   Diallo, K
   NGom, PT
   Whittle, H
TI Evaluation of T cell subsets by an immunocytochemical method compared to
   flow cytometry in four countries
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LYMPHOCYTE SUBSETS; BLOOD SMEARS; INFECTION; IMMUNODEFICIENCY;
   COMMUNITY; MARKERS; ASSAY; CD4+
AB The authors tested an alternative method for CD4 and CD8 T lymphocytes enumeration, the immunoalkaline phosphatase method (IA), in three African countries and in Denmark. The IA determinations from 136 HIV antibody positive and 105 HIV antibody negative individuals were compared to the corresponding results obtained by flow cytometry (FC) performed in the respective countries. The authors found good correspondence between the two methods for measurements of CD4 and CD8 T lymphocytes independent of serological status and geographical site. However, the CD4 and CD8 T lymphocyte values obtained by the two methods are not interchangeable as LA compared to FC consistently gives higher percentage of CD4 T lymphocytes, and lower percentages of CD8 T lymphocytes. Mean differences between the two methods did not differ between the three African countries indicating that the IA method provides systematic results. Replicate measurements suggested good correspondence between results obtained by IA. By using an IA level of < 300 CD4 T lymphocytes/mu l, the sensitivity was 81% and specificity 96% for detecting an FC level of < 200 CD4 T lymphocytes/mu l. Using an IA level of < 20% CD4 T lymphocytes, the sensitivity was 89% and specificity 95% for detecting an FC level of < 14% CD4 T lymphocytes, The FC and IA methods had the same internal correspondence between low absolute CD4 T cell counts and low CD4 percentages; the sensitivity and specificity for detecting a low absolute CD4 T cell count with a low CD4 percentage was 92% and 68% for FC and 91% and 73% for IA, respectively. The LA method is 10-fold cheaper than FC, is independent of advanced laboratory facilities, and does not need immediate processing of samples as blood smears can be stored,for long periods. The LA method is therefore suitable for use in areas with limited resources and laboratory facilities where there is a need for immunological surveillance in hospital or community studies.
C1 DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK.
   STATENS SERUM INST,DEPT BIOSTAT,DK-2300 COPENHAGEN,DENMARK.
   MUHIMBILI UNIV,COLL HLTH SCI,DEPT IMMUNOL & MICROBIOL,DAR ES SALAAM,TANZANIA.
   SWEDISH INST INFECT DIS CONTROL,DEPT IMMUNOL,STOCKHOLM,SWEDEN.
   PROJECT RETRO CI,ABIDJAN,COTE IVOIRE.
   MRC LABS,BANJUL,GAMBIA.
RP Lisse, IM (reprint author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT PATHOL,DK-2650 HVIDOVRE,DENMARK.
CR Altman DG, 1991, PRACTICAL STAT MED R
   BOTTIGER B, 1989, SCAND J INFECT DIS, V21, P507, DOI 10.3109/00365548909037878
   ERBER WN, 1984, LANCET, V1, P1042
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   FERREIRA OC, 1994, J ACQ IMMUN DEF SYND, V7, P1224
   GERNOW A, 1995, CLIN IMMUNOL IMMUNOP, V76, P135, DOI 10.1006/clin.1995.1107
   *GLOB PROGR AIDS, 1992, INTR ALT METH CD4 LY
   LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004
   LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   MOLBAK K, 1994, PARASITE IMMUNOL, V16, P275, DOI 10.1111/j.1365-3024.1994.tb00349.x
   MOLBAK K, 1995, AM J EPIDEMIOL, V143, P79
   ROBINSON G, 1992, LANCET, V340, P485, DOI 10.1016/0140-6736(92)91807-K
   TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114
   WINTROBE MM, 1981, CLIN HEMATOLOGY, P12
   1992, LANCET, V340, P1199
NR 20
TC 8
Z9 8
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUN
PY 1997
VL 45
IS 6
BP 637
EP 644
DI 10.1046/j.1365-3083.1997.d01-440.x
PG 8
WC Immunology
SC Immunology
GA XF251
UT WOS:A1997XF25100008
PM 9201303
OA No
DA 2017-08-15
ER

PT J
AU Dolin, PJ
   Faal, H
   Johnson, GJ
   Minassian, D
   Sowa, S
   Day, S
   Ajewole, J
   Mohamed, AA
   Foster, A
AF Dolin, PJ
   Faal, H
   Johnson, GJ
   Minassian, D
   Sowa, S
   Day, S
   Ajewole, J
   Mohamed, AA
   Foster, A
TI Reduction of trachoma in a sub-Saharan village in absence of a disease
   control programme
SO LANCET
LA English
DT Article
AB Background Trachoma is a leading cause of blindness in the developing world and is most prevalent among people who live in poor rural communities in arid locations.
   Methods We analysed the results of surveys of trachoma prevalence in Marakissa, a rural village in The Gambia. These surveys were undertaken in 1959, by the Medical Research Council, and in 1987 and 1996 by the Gambian National Eye Care Programme.
   Findings During this 37-year period, the prevalence of active inflammatory trachoma among children aged 0-9 years fell from 65.7 cases per 100 children in 1959 to 2.4 cases per 100 children in 1996. The prevalence also fell dramatically among people of 10-19 years (52.5 to 1.4 per 100) and among people of 20 years and older (36.7 to 0 cases per 100).
   Interpretation The dramatic fall in disease occurrence was paralleled by improvements in sanitation, water supply, education, and access to health care in the village. Of particular importance is that the decline in trachoma occurred without any trachoma-specific intervention.
C1 ROYAL VICTORIA HOSP, NATL EYE CARE PROGRAMME, BANJUL, GAMBIA.
RP Dolin, PJ (reprint author), UCL, INT CTR EYE HLTH, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND.
CR COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295
   MacCallan AF, 1936, TRACHOMA
   SOWA S, 1965, MED RES COUNC SPECIA, V308
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
NR 7
TC 54
Z9 54
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 24
PY 1997
VL 349
IS 9064
BP 1511
EP 1512
DI 10.1016/S0140-6736(97)01355-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA XA901
UT WOS:A1997XA90100010
PM 9167460
OA No
DA 2017-08-15
ER

PT J
AU VonSeidlein, L
   Jaffar, S
   Greenwood, B
AF VonSeidlein, L
   Jaffar, S
   Greenwood, B
TI Prolongation of the QTc interval in African children treated for
   falciparum malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID HALOFANTRINE; QUININE; QUINIDINE; PHARMACOKINETICS; CHLOROQUINE
AB Antimalarial drugs can affect the heart and trigger life-threatening arrhythmias. However, little is known about the frequency with which cardiac abnormalities occur during uncomplicated attacks of malaria. Therefore, we have studied the electrocardiograms of 139 Gambian children with uncomplicated falciparum malaria who were treated with co-artemether, pyrimethamine/sulfadoxine, or chloroquine. The QTc intervals were measured on presentation, and four and eight days after treatment. No significant differences in mean QTc or heart rate were found between children in the three treatment groups on days 0, 4, or 8. After adjustment for the type of antimalarial therapy in an analysis of variance, the mean (SD) QTc intervals on days 0, 4, and 8 were 402 (22.6), 416 (23.1), and 405 (24.3) msec, respectively. The mean QTc on day 4 was significantly longer than the mean QTc on days 0 or 8 (P < 0.01 in both cases). A quadratic line was fitted for QTc against time for each antimalarial therapy. No significant differences were found between the quadratic lines of the three groups. A weak association was found between QTc and the degree of parasitemia (r = 0.17, P = 0.04) and temperature (r = -0.23, P = 0.01) measured on day 0. The QTcs were measured in 18 children who experienced a second episode of malaria. The changes in QTc observed during second episodes were similar to those observed during the first attack. Changes in QTc in five children who developed severe malaria were similar to those found in the remaining children who did not develop severe malaria. This study indicates that the QTc interval changes during the early phase of malaria and this change is independent of the type of antimalarial therapy given.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
RP VonSeidlein, L (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
CR Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
   BHAVNANI SM, 1995, ANN PHARMACOTHER, V29, P33
   BRYK AS, 1993, HIERARCHICAL LINEAR
   BUSTOS MDG, 1994, TROP MED PARASITOL, V45, P83
   CASTOT A, 1993, LANCET, V341, P1541, DOI 10.1016/0140-6736(93)90685-A
   Fourcade L, 1995, Med Trop (Mars), V55, P182
   Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202
   KARBWANG J, 1993, LANCET, V342, P501, DOI 10.1016/0140-6736(93)91631-U
   KARBWANG J, 1993, BRIT J CLIN PHARMACO, V35, P265
   KARBWANG J, 1993, BRIT J CLIN PHARMACO, V35, P444
   LAOTHAVORN P, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P51
   LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31
   Matson PA, 1996, AM J TROP MED HYG, V54, P229
   MONLUN E, 1995, T ROY SOC TROP MED H, V89, P430, DOI 10.1016/0035-9203(95)90041-1
   *MULT MOD PROJ, 1993, GUID ML3 NEW US
   NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M
   PARK MK, 1992, READ PEDIAT ECGS
   SHELDON R, 1995, CIRCULATION, V92, P2944
   TAN HL, 1995, ANN INTERN MED, V122, P701
   TOIVONEN L, 1994, CLIN CARDIOL, V17, P403
   Touze JE, 1996, AM J TROP MED HYG, V54, P225
   WARRELL DA, 1990, T ROY SOC TROP MED H, V2, P1
   WATT G, 1993, AM J TROP MED HYG, V49, P645
   WHITE NJ, 1983, J CARDIOVASC PHARM, V5, P173, DOI 10.1097/00005344-198303000-00001
NR 24
TC 26
Z9 26
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 1997
VL 56
IS 5
BP 494
EP 497
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XC536
UT WOS:A1997XC53600003
OA No
DA 2017-08-15
ER

PT J
AU Aidoo, M
   Lalvani, A
   Whittle, HC
   Hill, AVS
   Robson, KJH
AF Aidoo, M
   Lalvani, A
   Whittle, HC
   Hill, AVS
   Robson, KJH
TI Recombinant vaccinia viruses for the characterization of Plasmodium
   falciparum-specific cytotoxic T lymphocytes: Recognition of processed
   antigen despite limited re-stimulation efficacy
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE cytotoxic T lymphocyte; malaria; peptide; processed antigen; recombinant
   viruses
ID CIRCUMSPOROZOITE PROTEIN; MALARIA SPOROZOITES; CELL EPITOPES;
   HEPATITIS-B; EXPRESSION; SURFACE; NYVAC; THROMBOSPONDIN; POLYMORPHISM;
   GLYCOPROTEIN
AB Cytotoxic T lymphocytes (CTL) have been implicated in immunity to Plasmodium falciparum infection and disease. We have previously described the use of peptides to define malaria-specific CTL epitopes. To determine whether these peptide epitopes are processed intracellularly from the whole antigen we have developed recombinant vaccinia viruses (rVV) expressing three malaria antigens: thrombospondin-related adhesive protein (TRAP), Pfs16 and the C-terminal half of liver-stage antigen (LSA)-1. Target cells infected with recombinant viruses were lysed by malaria-specific CTL from semi-immune African donors. We also tested the ability of cells infected with these recombinant vaccinia viruses to re-stimulate malaria-specific CTL in peripheral blood lymphocytes from malaria immune adults, Two other pox virus recombinants, NYVAC, an attenuated vaccinia virus, and ALVAC, a canarypox virus, both expressing malaria antigens were also evaluated for their ability to stimulate malaria-specific CTL. In contrast to peptide, none of these Viruses successfully re-stimulated CTL from the peripheral blood lymphocytes of semi-immune donors, The ability of human CTL from naturally exposed individuals to recognize processed antigen supports the relevance of these cells in protective immunity to malaria.
C1 UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND.
   JOHN RADCLIFFE HOSP,INST MOL MED,MRC,MOL HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849
   BEERSMA MFC, 1993, J IMMUNOL, V151, P4455
   BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445
   BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922
   BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403
   COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442
   DOOLAN DL, 1993, INT IMMUNOL, V5, P37, DOI 10.1093/intimm/5.1.37
   GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9
   HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877
   KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0
   Lalvani A, 1996, EUR J IMMUNOL, V26, P773, DOI 10.1002/eji.1830260408
   Lanar DE, 1996, INFECT IMMUN, V64, P1666
   LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X
   LOHR HF, 1993, J INFECT DIS, V168, P1133
   LUBAKI MN, 1994, AIDS RES HUM RETROV, V10, P1427, DOI 10.1089/aid.1994.10.1427
   Mackett M, 1985, DNA CLONING PRACTICA, P191
   MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L
   MOELANS IIMD, 1995, MOL BIOCHEM PARASIT, V72, P179, DOI 10.1016/0166-6851(95)00072-9
   PAOLETTI E, 1995, DEV BIOL STAND, V84, P159
   ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126
   ROBSON KJH, 1995, EMBO J, V14, P3883
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   ROBSON KJH, 1991, MOL BIOCHEM PARASIT, V46, P19, DOI 10.1016/0166-6851(91)90195-C
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   SEDEGAH M, 1992, J IMMUNOL, V149, P966
   TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767
   TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B
   TAYLOR J, 1991, VACCINE, V9, P190, DOI 10.1016/0264-410X(91)90152-V
   TAYLOR J, 1992, VIROLOGY, V187, P321, DOI 10.1016/0042-6822(92)90321-F
   Tine JA, 1996, INFECT IMMUN, V64, P3833
   Trager W., 1976, SCIENCE, V193, P674
   VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004
   WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573
   WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435
   YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0
   ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O
   ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0
NR 42
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD MAY
PY 1997
VL 9
IS 5
BP 731
EP 737
DI 10.1093/intimm/9.5.731
PG 7
WC Immunology
SC Immunology
GA XD240
UT WOS:A1997XD24000010
PM 9184918
OA No
DA 2017-08-15
ER

PT J
AU TroyeBlomberg, M
   Fogdell, A
   ElGhazali, G
   Larsson, A
   King, MH
   SisayJoof, F
   Olerup, O
   Grunewald, J
   Jepson, A
AF TroyeBlomberg, M
   Fogdell, A
   ElGhazali, G
   Larsson, A
   King, MH
   SisayJoof, F
   Olerup, O
   Grunewald, J
   Jepson, A
TI Analysis of the T-cell receptor V beta usage in monozygotic and
   dizygotic twins living in a Plasmodium falciparum endemic area in West
   Africa
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PERIPHERAL-BLOOD LYMPHOCYTES; PRIMERS PCR-SSP; GENE USAGE; HLA GENES;
   EXPRESSION; MALARIA; CD4+; SELECTION; AMPLIFICATION; ANTIBODIES
AB To investigate the influence of genetic and/or environmental factors in the development and shaping of the human peripheral T cell repertoire the authors studied the T-cell receptor (TCR) V beta usage in 10 adult monozygous (Mz) and nine dizygous (Dz) twin pairs living in a Plasmodium falciparum endemic area in West Africa. The TCR repertoire was determined using a small panel of anti-V beta specific monoclonal antibodies (MoAbs) using conventional immunofluorescence assays. The results revealed that the V beta repertoire was similar to that recently described for a Caucasian population using a similar panel of antibodies. The frequencies of particular V beta genes tested were influenced neither by anti-malarial antibody titres nor by parasite densities, indicating that the P. falciparum parasite is not a dominating factor in determining the peripheral T cell repertoire. All donors were human leucocyte antigen (HLA) class I and II typed; no association was found between the expression of any V beta genes and MHC haplotype. The V beta usage was more concordant within the Mz than within the Dz pairs. For a group comprising four HLA class II identical individuals, the average within-pair difference was significantly greater than for the whole Mz group, but similar to that seen for the total Dz group. Thus, the data suggest that genetic, rather than environmental, factors have a profound effect on the shaping of the human circulating T cell repertoire and that the major genetic factors are encoded by non-HLA class II genes.
C1 KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM,SWEDEN.
   MRC,BANJUL,GAMBIA.
   KAROLINSKA INST,DEPT IMMUNOL,MTC,S-10401 STOCKHOLM,SWEDEN.
   UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND.
RP TroyeBlomberg, M (reprint author), UNIV STOCKHOLM,DEPT IMMUNOL,S-10691 STOCKHOLM,SWEDEN.
RI Troye-Blomberg, Marita/B-9210-2016
OI Troye-Blomberg, Marita/0000-0002-2804-0325
FU Wellcome Trust
CR AKOLKAR PN, 1993, J IMMUNOL, V150, P2761
   AKOLKAR PN, 1995, SCAND J IMMUNOL, V42, P248, DOI 10.1111/j.1365-3083.1995.tb03651.x
   BORGULYA P, 1991, EMBO J, V10, P913
   COSSARIZZA A, 1991, EUR J IMMUNOL, V21, P1571, DOI 10.1002/eji.1830210637
   DAVEY MP, 1991, HUM IMMUNOL, V32, P194, DOI 10.1016/0198-8859(91)90056-F
   DAVEY MP, 1994, J IMMUNOL, V152, P152
   GEURSEN A, 1993, CLIN EXP IMMUNOL, V94, P201
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GRUNEWALD J, 1991, EUR J IMMUNOL, V21, P819, DOI 10.1002/eji.1830210342
   GRUNEWALD J, 1992, INT IMMUNOL, V4, P643, DOI 10.1093/intimm/4.6.643
   GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139
   HAWES GE, 1993, J IMMUNOL, V150, P2033
   HILL AVS, 1994, PHILOS T ROY SOC B, V346, P379, DOI 10.1098/rstb.1994.0155
   HVIID L, 1991, EUR J IMMUNOL, V21, P1249, DOI 10.1002/eji.1830210523
   IMBERTI L, 1990, EUR J IMMUNOL, V20, P2817, DOI 10.1002/eji.1830201244
   Jepson A, 1997, INFECT IMMUN, V65, P872
   LEHTINEN T, 1980, SCAND J IMMUNOL, V12, P309, DOI 10.1111/j.1365-3083.1980.tb00072.x
   LOVERIDGE JA, 1991, IMMUNOLOGY, V74, P203
   MALHOTRA U, 1992, J IMMUNOL, V149, P1802
   MOSS PAH, 1992, ANNU REV IMMUNOL, V10, P71, DOI 10.1146/annurev.immunol.10.1.71
   MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x
   PERLMANN H, 1984, J EXP MED, V159, P1686, DOI 10.1084/jem.159.6.1686
   Riley EM, 1996, PARASITOLOGY, V112, pS39
   ROTH MP, 1994, IMMUNOGENETICS, V39, P281
   SJOBERG K, 1992, P NATL ACAD SCI USA, V89, P2101, DOI 10.1073/pnas.89.6.2101
   TERASAKI PI, 1974, MANUAL TISSUE TYPING, P67
   TROYEBLOMBERG M, 1991, INT IMMUNOL, V3, P1043, DOI 10.1093/intimm/3.10.1043
   TROYEBLOMBERG M, 1994, CRIT REV IMMUNOL, V14, P131
   WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x
NR 31
TC 8
Z9 8
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD MAY
PY 1997
VL 45
IS 5
BP 541
EP 545
DI 10.1046/j.1365-3083.1997.d01-421.x
PG 5
WC Immunology
SC Immunology
GA WY418
UT WOS:A1997WY41800014
PM 9160100
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Sabally, S
   Corrah, T
   West, B
   Mabey, D
AF Adegbola, RA
   Sabally, S
   Corrah, T
   West, B
   Mabey, D
TI Increasing prevalence of penicillinase-producing Neisseria gonorrhoeae
   and the emergence of high-level, plasmid-mediated tetracycline
   resistance among gonococcal isolates in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Neisseria gonorrhoeae; resistance; tetracycline
ID ANTIMICROBIAL SUSCEPTIBILITY; AUXOTYPE
AB One hundred and three strains of Neisseria gonorrhoeae isolated from a periurban STD clinic in The Gambia were studied for antimicrobial susceptibility, plasmid profile, and serogroup using standard procedures. Seventy-nine (77%) were penicillinase producers (PPNG) and fully resistant to penicillin (MIC greater than or equal to 8 mg/l). One isolate showed chromosomally induced resistance to penicillin (MIC 2 mg/l). None of the isolates was sensitive to tetracycline; 16 (16%) showed intermediate resistance (MICs 1-8 mg/l) and 87 (84%) showed high-level plasmid-mediated resistance (TRP IG) (MICs >10 mg/l). This is the first report of TRNG in The Gambia. Only 6 (6%) strains were fully sensitive to trimethoprim-sulphamethoxazole (MIC <8 mg/l); 78 (76%) showed intermediate level resistance (MICs 8-16 mg/l) and 19 (18%) were fully resistant (MIC >32 mg/l). Indications of an increase in MIC to ciprofloxacin and ceftriaxone were found in 6 (6%) and 1 (1%) strains, respectively, although all remained fully sensitive (MICs 0.004-0.03 mg/l and 0.001-0.015 mg/l). All PPNG and TRNG strains carried the 3.2 MDa and 25.2 MDa plasmids, respectively. ALI isolates carried the 2.6 MDa cryptic plasmid and 9 (3 PPNG and 6 non-PPNG) carried the 24.5 MDa conjugative plasmid. Forty-four (43%) strains were typed group WI, 58 (56%) WII/III and I had cross-reacting antigens. Because PPNG are frequently encountered and high-level TRNG is now prevalent, the newer cephalosporins and quinolones must now be considered as first-line drugs for the treatment of gonorrhoea in The Gambia.
C1 MRC LABS,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
CR BOGAERTS J, 1993, GENITOURIN MED, V69, P196
   Centers for Disease Control (CDC), 1985, MMWR-MORBID MORTAL W, V34, P563
   ISON CA, 1992, GENITOURIN MED, V68, P356
   JOHNSON AP, 1987, EPIDEMIOL INFECT, V99, P669
   LIND I, 1991, GENITOURIN MED, V67, P107
   MABEY D, 1994, GENITOURIN MED, V70, P1
   MABEY DCW, 1982, BRIT MED J, V285, P571
   MASON PR, 1990, SEX TRANSM DIS, V17, P63, DOI 10.1097/00007435-199004000-00003
   MORSE SA, 1986, ANTIMICROB AGENTS CH, V30, P664
   NZANSE H, 1984, SEXUALLY TRANSMITTED, V11, P376
   OSOBA AO, 1986, AFR J SEX TRANSM DIS, V2, P51
   ROBERTS Y, 1989, NEW STATESMAN SOC, V2, P18
   VANDYCK E, 1992, GENITOURIN MED, V68, P111
   WEST B, 1995, GENITOURIN MED, V71, P9
   1993, WHOGPASTD931
NR 15
TC 17
Z9 18
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 1997
VL 2
IS 5
BP 428
EP 432
DI 10.1046/j.1365-3156.1997.d01-295.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XE387
UT WOS:A1997XE38700004
PM 9217698
OA No
DA 2017-08-15
ER

PT J
AU Outlaw, MC
   Jaye, A
   Whittle, HC
   Pringle, CR
AF Outlaw, MC
   Jaye, A
   Whittle, HC
   Pringle, CR
TI Clustering of haemagglutinin gene sequences of measles viruses isolated
   in the Gambia
SO VIRUS RESEARCH
LA English
DT Article
DE measles virus; haemagglutinin (H) gene sequences; Gambian isolates;
   clustering
ID STRAINS
AB Partial nucleotide sequences of the haemagglutinin (H) gene of 18 measles viruses isolated in the Gambia during 1994 and 1995 show a high degree of homology (> 98.5%) when compared with each other. These sequences form a cluster distinct from measles viruses isolated from other geographic regions and from the sequences of vaccine strains and two isolates from the Gambia From earlier years. Despite the low level of genetic heterogeneity observed, a common feature of the Gambian isolates is the prescence of three nucleotide changes (at positions 7963, 8649 and 8653) not observed in isolates from other locations. (C) 1997 Elsevier Science B.V.
C1 UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
CR BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0
   *CDC, 1993, MMWR-MORBID MORTAL W, V42, P925
   CDC, 1991, MMWR-MORBID MORTAL W, V40, P369
   *CDC, 1992, MMWR-MORBID MORTAL W, V41, P522
   *CDC, 1994, MMWR-MORBID MORTAL W, V43, P673
   GALINSKI MS, 1991, PARAMYXOVIRUSES, P537
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   HU AH, 1994, J GEN VIROL, V75, P2173, DOI 10.1099/0022-1317-75-9-2173
   KAWAMOTO A, 1995, ARCH VIROL, V140, P349, DOI 10.1007/BF01309868
   OUTLAW MC, 1995, VIRUS RES, V39, P3, DOI 10.1016/0168-1702(95)00060-4
   RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173
   ROTA JS, 1992, VIROLOGY, V188, P135, DOI 10.1016/0042-6822(92)90742-8
   ROTA JS, 1994, VIRUS RES, V31, P317, DOI 10.1016/0168-1702(94)90025-6
   Rota JS, 1996, J INFECT DIS, V173, P32
   ROTA PA, 1994, VIROLOGY, V198, P724, DOI 10.1006/viro.1994.1086
   SCHULTZ TF, 1992, J GEN VIROL, V93, P1581
   SMOAK BL, 1994, J INFECT DIS, V170, P216
   TAYLOR MJ, 1991, J GEN VIROL, V72, P83, DOI 10.1099/0022-1317-72-1-83
   WEISS R, 1992, SCIENCE, V258, P546, DOI 10.1126/science.1329205
NR 19
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
J9 VIRUS RES
JI Virus Res.
PD MAY
PY 1997
VL 48
IS 2
BP 125
EP 131
DI 10.1016/S0168-1702(96)01434-7
PG 7
WC Virology
SC Virology
GA XA565
UT WOS:A1997XA56500002
PM 9175250
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Hilton, S
   Adegbola, R
   Usen, S
   Oparaugo, A
   Omosigho, C
   Weber, M
   Palmer, A
   Schneider, G
   Jobe, K
   Lahai, G
   Jaffar, S
   Secka, O
   Lin, K
   Ethevenaux, C
   Greenwood, B
AF Mulholland, K
   Hilton, S
   Adegbola, R
   Usen, S
   Oparaugo, A
   Omosigho, C
   Weber, M
   Palmer, A
   Schneider, G
   Jobe, K
   Lahai, G
   Jaffar, S
   Secka, O
   Lin, K
   Ethevenaux, C
   Greenwood, B
TI Randomised trial of Haemophilus influenzae type-b tetanus protein
   conjugate for prevention of pneumonia and meningitis in Gambian infants
SO LANCET
LA English
DT Article
ID HEMOPHILUS-INFLUENZAE; WEST-AFRICA; CHILDREN; VACCINE; CARRIAGE;
   EFFICACY; DISEASE; EPIDEMIOLOGY; HIB
AB Background In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib.
   Methods Between March, 1993, and October, 1995, 42 848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months. Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate, by lumbar puncture, chest radiograph, or percutaneous lung aspirate. Children were followed up for between 5 and 36 months.
   Findings The median ages at which children received the study vaccine were 11 weeks, 18 weeks, and 24 weeks. 83% of children enrolled received all three doses of vaccine. 17 cases of culture-positive Hib pneumonia, 28 of Hib meningitis, and five of other forms of invasive Hib disease were detected amongst the study children. The efficacy of the vaccine for the prevention of all invasive disease after three doses was 95% (PRP-T vaccinees 1, controls 19 [95% CI 67-100]), for the prevention of Hib pneumonia after two or three doses, 100% (vaccinees 0, controls 10 [55-100]), and for the prevention of radiologically defined pneumonia at any time after enrolment, 21.1% (PRP-T vaccinees 198, controls 251 [4.6-34.9]).
   Interpretation PRP-T conjugate Hib vaccine prevented most cases of meningitis and pneumonia due to Hib in Gambian. infants. The reduction in the overall incidence of radiologically defined pneumonia in PRP-T vaccinees suggests that about 20% of episodes of pneumonia in young Gambian children are due to Hib. The introduction of Hib vaccines into developing countries should substantially reduce childhood mortality due to pneumonia and meningitis.
C1 MRC LABS,FAJARA,GAMBIA.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
   SIBANOR MISS HOSP,SIBANOR,SENEGAL.
   MINIST HLTH,MED & HLTH DEPT,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   NATL VACCINE PROGRAM OFF,WASHINGTON,DC.
   PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1989, T ROY SOC TROP MED H, V83, P831, DOI 10.1016/0035-9203(89)90345-3
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1
   CHOO KE, 1990, ANN TROP PAEDIATR, V10, P89
   FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382
   FERRECCIO C, 1990, PEDIATR INFECT DIS J, V9, P488, DOI 10.1097/00006454-199007000-00007
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GRATTEN M, 1984, J CLIN MICROBIOL, V19, P526
   GREENWOOD B, 1992, J INFECT DIS, V165, pS26
   Greenwood M, 1915, Proc R Soc Med, V8, P113
   HONIG PJ, 1973, J PEDIATR-US, V83, P215, DOI 10.1016/S0022-3476(73)80478-0
   Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008
   MPAIRWE Y, 1970, J HYG-CAMB, V68, P337
   Mulholland EK, 1996, VACCINE, V14, P905, DOI 10.1016/0264-410X(95)00260-8
   Murray CJ, 1996, GLOBAL BURDEN DIS
   RILEY HD, 1965, AM J DIS CHILD, V110, P24
   SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503
   TAKALA AK, 1991, J INFECT DIS, V164, P982
   WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006
   WARD JI, 1988, J CLIN MICROBIOL, V26, P72
NR 24
TC 301
Z9 317
U1 0
U2 5
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 26
PY 1997
VL 349
IS 9060
BP 1191
EP 1197
DI 10.1016/S0140-6736(96)09267-7
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA WW717
UT WOS:A1997WW71700007
PM 9130939
OA No
DA 2017-08-15
ER

PT J
AU Xiang, Z
   Ariyoshi, K
   Wilkins, A
   Dias, F
   Whittle, H
   Breuer, J
AF Xiang, Z
   Ariyoshi, K
   Wilkins, A
   Dias, F
   Whittle, H
   Breuer, J
TI HIV type 2 pathogenicity is not related to subtype in rural guinea
   bissau
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID VIRUS TYPE-2; WEST-AFRICA; INFECTION; MORTALITY; AREA
AB Data from an MRC case-control study in rural Guinea Bissau suggest older HIV-2 carriers (aged 55 to 80 years) appear, over a period of 2 years, to have a mortality similar to that of uninfected controls, whereas in HIV-2 carriers under the age of 55 there is a significantly higher mortality, compared with uninfected controls.(1,2) Genotyping of viruses from both groups revealed only subtype a to be circulating, Thus, although putative nonpathogenic HIV-2 subtypes have been described in patients from West Africa,(3) these do not appear to be contributing significantly to the nonpathogenic clinical phenotype in this population.
C1 LONDON HOSP,COLL MED,DEPT VIROL,LONDON E1 1BB,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
   LAB NATL SANDE PUBL,BISSAU,GUINEA BISSAU.
CR BRUNVEZINET F, 1987, LANCET, V1, P128
   CDC, 1992, MMWR-MORBID MORTAL W, V41, P678
   GAO F, 1994, J VIROL, V68, P7433
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3
   PEPIN J, 1991, AIDS, V5, P116
   POULSEN AG, 1989, LANCET, V1, P827
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 10
TC 16
Z9 16
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR 10
PY 1997
VL 13
IS 6
BP 501
EP 505
DI 10.1089/aid.1997.13.501
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA WT421
UT WOS:A1997WT42100008
PM 9100992
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Usen, S
   Palmer, A
   Jaffar, S
   Mulholland, EK
AF Weber, MW
   Usen, S
   Palmer, A
   Jaffar, S
   Mulholland, EK
TI Predictors of hypoxaemia in hospital admissions with acute lower
   respiratory tract infection in a developing country
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
DE hypoxaemia; clinical signs; pneumonia; developing countries
ID PAPUA-NEW-GUINEA; CLINICAL SIGNS; CHILDREN; HYPOXEMIA; PNEUMONIA
AB Since oxygen has to be given to most children in developing countries on the basis of clinical signs without performing blood gas analyses, possible clinical predictors of hypoxaemia were studied. Sixty nine children between the ages of 2 months and 5 years admitted to hospital with acute lower respiratory tract infection and an oxygen saturation (SaO(2)) < 90% were compared with 67 children matched for age and diagnosis from the same referral hospital with an SaO(2) of 90% or above (control group 1), and 44 unreferred children admitted to a secondary care hospital with acute lower respiratory infection (control group 2). Using multiple logistic regression analysis, sleepiness, arousal, quality of cry, cyanosis, head nodding, decreased air entry, nasal flaring, and upper arm circumference were found to be independent predictors of hypoxaemia on comparison of the cases with control group 1. Using a simple model of cyanosis or head nodding or not crying, the sensitivity to predict hypoxaemia was 59%, and the specificity 94% and 93% compared to control groups 1 and 2, respectively; 80% of the children with an SaO(2) < 80% were identified by the combination of these signs. Over half of the children with hypoxaemia could be identified with a combination of three signs: extreme respiratory distress, cyanosis, and severely compromised general status. Further prospective validation of this model with other datasets is warranted. No other signs improved the sensitivity without compromising specificity. If a higher sensitivity is required, pulse oximetry has to be used.
C1 ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
RP Weber, MW (reprint author), MED RES COUNCIL LABS,POB 273,FAJARA,BANJUL,GAMBIA.
CR DYKE T, 1995, J TROP PEDIATRICS, V41, P196
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   LOZANO JM, 1994, ARCH DIS CHILD, V71, P323
   MARGOLIS PA, 1994, J PEDIATR-US, V124, P552, DOI 10.1016/S0022-3476(05)83133-6
   MORRISON B, 1955, LANCET, V2, P737
   MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9
   SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005
   SIMPSON H, 1967, LANCET, V1, P7
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295
   Stadie WC, 1919, J EXP MED, V30, P215, DOI 10.1084/jem.30.3.215
   World Health Organization, 1993, WHOARI9328
   World Health Organization, 1990, WHOARI905
   World Bank, 1993, WORLD DEV REP
NR 15
TC 47
Z9 50
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD APR
PY 1997
VL 76
IS 4
BP 310
EP 314
PG 5
WC Pediatrics
SC Pediatrics
GA WU812
UT WOS:A1997WU81200005
PM 9166021
OA No
DA 2017-08-15
ER

PT J
AU Osaer, S
   Goossens, B
   Sauveroche, B
   Dempfle, L
AF Osaer, S
   Goossens, B
   Sauveroche, B
   Dempfle, L
TI Evaluation of the semen quality and reproductive performance of
   trypanotolerant Djallonke rams following an artificial infection with
   Trypanosoma congolense
SO SMALL RUMINANT RESEARCH
LA English
DT Article
DE Djallonka rams; semen quality; trypanosomosis; trypanotolerance; the
   Gambia
ID AFRICAN TRYPANOSOMIASIS; VIVAX INFECTION; SHEEP; DIAGNOSIS; BRUCEI;
   GOATS; SUSCEPTIBILITY; LESIONS; CATTLE
AB Following an experimental infection with Trypanosoma congolense, the semen quality and reproductive performance of 17 mature Djallonke rams was studied during a period of 26 weeks. The rams were randomly divided into three groups, namely one control group (G1) and two infected groups (G2 and G3). During the 5 weeks pre-infection the normal semen parameters were assessed. Following infection, moderate clinical symptoms associated with trypanosomosis were seen among the infected rams. Thirteen weeks post-infection, diminazene aceturate was administered to group 3. Both the treated group and the control group had significantly better weights than the infected group in the period following the trypanocidal treatment. The impact of trypanosomosis on the reproductive performance of the rams was seen in reduced libido with a higher rate of refusals and on semen quality with some temporary effects on mass motility, percentage live sperm cells and minor sperm cell abnormalities. However, these temporary changes in semen parameters were not significant when analysed as impact of infection. From the present study it was concluded that reproductive performance was not significantly impaired following artificial T. congolense infection. In addition, the Djallonke rams also showed an important clinical tolerance. However, significant differences between rams indicated a large variation in clinical response and reproductive performance following trypanosome infection. (C) 1997 Elsevier Science B.V.
C1 FAO REG PROJECT RAF 88 100,BANJUL,GAMBIA.
RP Osaer, S (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR ADEYEMO O, 1989, ANIM REPROD SCI, V22, P21
   AGU WE, 1986, ANIM REPROD SCI, V11, P123, DOI 10.1016/0378-4320(86)90111-9
   AKPAVIE SO, 1987, RES VET SCI, V42, P1
   ANOSA VO, 1980, RES VET SCI, V28, P151
   APTED PIC, 1970, AFRICAN TRYPANOSOMIA, P667
   Barth AD, 1989, ABNORMAL MORPHOLOGY
   BATAILLE JL, 1990, THESIS TOULOUSE
   BOERSMA A, 1989, ANN SOC BELG MED TR, V69, P127
   Boly H., 1991, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V44, P475
   Chemineau P, 1991, 83 FAO
   CLOE LC, 1989, FASO REV ELEV MED VE, V42, P457
   DJABAKOU K, 1984, AVETONOU TOGO, V3, P47
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   GRUNDLER G, 1988, TRYPANOTOLERANCE PRO, V5, P17
   IKEDE BO, 1988, ACTA TROP, V45, P5
   IKEDE BO, 1979, RES VET SCI, V26, P145
   ISOUN TT, 1974, TROPENMED PARASITOL, V25, P469
   KAAYA G P, 1980, Bulletin of Animal Health and Production in Africa, V28, P1
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   KIMATA DM, 1994, ACTA TROP, V57, P69, DOI 10.1016/0001-706X(94)90094-9
   LOSOS GJ, 1972, VET PATHOL S, V9, P10
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   MUTAYOBA BM, 1993, P 22 M ISC TRC KAMP
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   OTT RS, 1987, ELEVAGE INSEMINATION, V221, P15
   PARIS J, 1982, ACTA TROP, V39, P307
   SEKONI VO, 1988, BRIT VET J, V144, P388
   SEKONI VO, 1992, BRIT VET J, V148, P501
   Snedecor G. W., 1980, STAT METHODS
   TOURE SM, 1981, TRYPANOTOLERANCE STU
   Wenkoff MS, 1988, EVALUATION BULLS BRE
NR 33
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4488
J9 SMALL RUMINANT RES
JI Small Ruminant Res.
PD APR
PY 1997
VL 24
IS 3
BP 213
EP 222
DI 10.1016/S0921-4488(96)00944-3
PG 10
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA XD059
UT WOS:A1997XD05900008
OA No
DA 2017-08-15
ER

PT J
AU Plebanski, M
   Aidoo, M
   Whittle, HC
   Hill, AVS
AF Plebanski, M
   Aidoo, M
   Whittle, HC
   Hill, AVS
TI Precursor frequency analysis of cytotoxic T lymphocytes to
   pre-eryrthrocytic antigens of Plasmodium falciparum in West Africa
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SPOROZOITE SURFACE PROTEIN-2; CIRCUMSPOROZOITE PROTEIN; VACCINE
   DEVELOPMENT; PERIPHERAL-BLOOD; CELL RESPONSES; MALARIA; VIRUS; GENE;
   EPITOPES; SPECIFICITY
AB Some individuals living in malaria-endemic areas have CTL to Plasmodium falciparum liver stage Ags. We have quantified these CTL responses using limiting dilution analysis studies on the peripheral blood cells of naturally exposed Gambian donors. CTL precursor frequencies were determined to a wide range of epitopes derived from different liver stage Ags (liver stage protein 1, circumsporozoite protein, thrombospondin-related anonymous protein, and sporozoite threonine/asparagine-rich protein) restricted through common HLA alleles present in this population (HLA-A2.1, -A2.2, -B7, -B8, -B35, and B53). Precursor frequencies were between 17 and 98/million PBMC and correlated with the levels of specific lysis in parallel bulk cultures. The quantitative nature of limiting dilution assay analysis revealed varying degrees of immunodominance in the CTL responses to different epitopes within single proteins (thrombospondin related anonymous protein: tr42, tr43, tr26, tr29, and tr39; circumsporozoite protein: cp6, cp26, and cp29) and within individual donors. The temporal stability of some of these CTL responses was determined over a 4-yr period. This is the first quantitative study of CTL specific for any plasmodial species or nonviral pathogen in humans and provides a basis for a multiepitope approach to malaria vaccination.
C1 MRC LABS,FAJARA,GAMBIA.
RP Plebanski, M (reprint author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,NUFFIELD DEPT MED,OXFORD OX3,ENGLAND.
RI HILL, Adrian/C-1306-2008
FU Wellcome Trust
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4
   ALP NJ, 1990, J IMMUNOL METHODS, V129, P269, DOI 10.1016/0022-1759(90)90447-4
   BORYSIEWICZ LK, 1988, EUR J IMMUNOL, V18, P269, DOI 10.1002/eji.1830180214
   CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249
   CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105
   COULLIN I, 1994, J EXP MED, V180, P1129
   COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2
   DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383
   Dong T, 1996, EUR J IMMUNOL, V26, P335, DOI 10.1002/eji.1830260210
   DOOLAN DL, 1992, INFECT IMMUN, V60, P675
   ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E
   ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567
   FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V67, P255, DOI 10.1016/0166-6851(94)00138-3
   GIRDLESTONE J, 1993, IMMUNOGENETICS, V38, P430
   GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707
   GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   KUSONOKI Y, 1993, MICROBIOL IMMUNOL, V37, P461
   Lalvani A, 1996, EUR J IMMUNOL, V26, P773, DOI 10.1002/eji.1830260408
   LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085
   LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79
   LUCHIARI M, 1994, INT IMMUNOL, V6, P1739
   MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300
   MAZZOCCHI A, 1994, INT J CANCER, V58, P330, DOI 10.1002/ijc.2910580304
   MEHTADAMANI A, 1994, J IMMUNOL, V153, P996
   MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   PLEBANSKI M, 1992, IMMUNOLOGY, V75, P86
   PLEBANSKI M, 1994, EUR J IMMUNOL, V25, P1783
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   ROPKE M, 1995, SCAND J IMMUNOL, V42, P98, DOI 10.1111/j.1365-3083.1995.tb03631.x
   ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G
   SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413
   SLOBOD KS, 1993, CLIN EXP IMMUNOL, V93, P363, DOI 10.1111/j.1365-2249.1993.tb08186.x
   TARACHA ELN, 1995, INFECT IMMUN, V63, P1258
   TASWELL C, 1981, J IMMUNOL, V126, P1614
   WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573
   WIZEL B, 1995, J EXP MED, V182, P1435, DOI 10.1084/jem.182.5.1435
   WIZEL B, 1995, J IMMUNOL, V155, P766
   ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O
NR 44
TC 53
Z9 53
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 15
PY 1997
VL 158
IS 6
BP 2849
EP 2855
PG 7
WC Immunology
SC Immunology
GA WM435
UT WOS:A1997WM43500043
PM 9058821
OA No
DA 2017-08-15
ER

PT J
AU Greenwood, BM
AF Greenwood, BM
TI What can be expected from malaria vaccines?
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Article; Proceedings Paper
CT 5th CEC Malaria Contract Holders Meeting
CY MAY 29-31, 1995
CL COPENHAGEN, DENMARK
SP CEC, EU, INCO, European Commission DGXII, Danish Ministry Foreign Affairs, DANIDA
ID FALCIPARUM TRANSMISSION
AB The first generation of malaria vaccines may not be effective enough to provide reliable protection against malaria for travellers to endemic areas. Nevertheless, these vaccines may be able to produce a useful degree of protection against death and severe morbidity from malaria in the populations of such areas. Pre-erythrocytic vaccines may provide this kind of protection by lengthening the prepatent period; blood-stage vaccines may achieve this effect by reducing parasitaemia. Because clinical immunity to malaria among residents of endemic areas reflects a complex balance between the parasite and its host, it is possible that partially effective vaccines could exert a harmful rather than a beneficial effect. Trials of malaria vaccines in the population of endemic areas must, therefore, progress with caution.
C1 MRC,BANJUL,GAMBIA.
CR BEIER JC, 1991, MED VET ENTOMOL, V5, P71, DOI 10.1111/j.1365-2915.1991.tb00523.x
   CLARK IA, 1991, PARASITOL TODAY, V7, P205, DOI 10.1016/0169-4758(91)90142-B
   Field J. W., 1937, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V30, P569, DOI 10.1016/S0035-9203(37)90070-1
   Fulginiti V, 1967, JAMA-J AM MED ASSOC, V202, P101
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   PREMAWANSA S, 1994, PARASITE IMMUNOL, V16, P35, DOI 10.1111/j.1365-3024.1994.tb00302.x
   ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1
   SOWA S, 1969, J HYG-CAMB, V67, P699
   TAYLOR K, 1992, CLIN EXP IMMUNOL, V90, P1
NR 12
TC 3
Z9 3
U1 0
U2 0
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD MAR
PY 1997
VL 91
SU 1
BP S9
EP S13
PG 5
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA WU063
UT WOS:A1997WU06300003
OA No
DA 2017-08-15
ER

PT J
AU Kent, JP
   McElligott, AG
   Budgey, HV
AF Kent, JP
   McElligott, AG
   Budgey, HV
TI Ground-roosting in domestic fowl (Gallus gallus domesticus) in The
   Gambia: The anticipation of night
SO BEHAVIOURAL PROCESSES
LA English
DT Article
DE circadian rhythm; domestic fowl; ground-roosting; photosensitivity
ID BEHAVIOR; LIGHT
AB The ground-roosting behaviour of a semi-feral population of domestic hens with broods of chicks was measured in The Gambia, West Africa. Although neither day length nor time of sunset changed significantly over the duration of the study (January-March 1995), mean daily light intensity showed a significant increase. This resulted in an increasingly rapid decline in light intensity at dusk as the season progressed. Hens went to roost significantly later in the day, and at lower light levels, over the course of the season. The results support a model suggesting that the cue to start roosting is a certain light level, constant over the season, but the 'settling period' required means that the hens finally roost at later times and at lower light levels as the season progresses. (C) 1997 Elsevier Science B.V.
C1 ST JOSEPHS POULTRY FDN,BWAIM,GAMBIA.
CR APPLIN DG, 1982, BIOL PERIODICITIES N
   BHATTI BM, 1978, BRIT POULTRY SCI, V19, P333, DOI 10.1080/00071667808416485
   BHATTI BM, 1978, BRIT POULTRY SCI, V19, P365, DOI 10.1080/00071667808416488
   Brady J., 1979, BIOL CLOCKS
   BRADY J, 1982, BIOL CLOCKS
   Brady J, 1982, BIOL TIMEKEEPING
   Bruckner GH, 1933, Z PSYCHOL PHYSIOL SI, V128, P1
   DAVIS DE, 1955, ECOLOGY, V36, P424
   DAVIS GJ, 1970, ANIM BEHAV, V18, P362, DOI 10.1016/S0003-3472(70)80049-5
   Gwinner E., 1975, AVIAN BIOL, VV, P221
   Hader D-P, 1987, GEN PHOTOBIOLOGY
   KENT JP, 1992, BEHAV PROCESS, V27, P37, DOI 10.1016/0376-6357(92)90038-F
   KLEINBAUM DG, 1988, APPLIED REGRESSION A
   McBride G., 1969, Animal Behaviour Monographs, V2, P127
   MORRIS TR, 1973, POULTRY SCI, V52, P423
   Palmer JD, 1976, INTRO BIOL RHYTHMS
   PETHERICK JC, 1991, APPL ANIM BEHAV SCI, V32, P219, DOI 10.1016/S0168-1591(05)80045-0
   PITTENDRIGH CS, 1964, AM NAT, V98, P261, DOI 10.1086/282327
   PITTENDRIGH CS, 1972, P NATL ACAD SCI USA, V69, P2734, DOI 10.1073/pnas.69.9.2734
   REEBS SG, 1994, ANIM BEHAV, V48, P89, DOI 10.1006/anbe.1994.1214
   REEBS SG, 1986, CAN J ZOOL, V64, P1614, DOI 10.1139/z86-243
   Saunders DS, 1977, INTRO BIOL RHYTHMS
   Siegel S., 1956, NONPARAMETRIC STAT B
   SWINGLAND IR, 1976, ANIM BEHAV, V24, P154, DOI 10.1016/S0003-3472(76)80109-1
   WOODGUSH DGM, 1978, BIOL BEHAV, V3, P193
   WORKMAN L, 1989, ANIM BEHAV, V38, P596, DOI 10.1016/S0003-3472(89)80004-1
   Zar JH, 1984, BIOSTATISTICAL ANAL
NR 27
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-6357
J9 BEHAV PROCESS
JI Behav. Processes
PD MAR
PY 1997
VL 39
IS 3
BP 271
EP 278
DI 10.1016/S0376-6357(96)00764-4
PG 8
WC Psychology, Biological; Behavioral Sciences; Zoology
SC Psychology; Behavioral Sciences; Zoology
GA WP546
UT WOS:A1997WP54600008
PM 24897334
OA No
DA 2017-08-15
ER

PT J
AU Jepson, A
   Banya, W
   SisayJoof, F
   HassanKing, M
   Nunes, C
   Bennett, S
   Whittle, H
AF Jepson, A
   Banya, W
   SisayJoof, F
   HassanKing, M
   Nunes, C
   Bennett, S
   Whittle, H
TI Quantification of the relative contribution of major histocompatibility
   complex (MHC) and non-MHC genes to human immune responses to foreign
   antigens
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MEROZOITE SURFACE-ANTIGEN; MALARIA VACCINE CANDIDATE; T-CELL
   RECOGNITION; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; PF155
   RESA; POLYMORPHISM; CHILDREN; REGIONS; DISEASE
AB Understanding the extent to which genetic factors influence the immune response is important in the development of subunit vaccines. Associations with HLA gene polymorphisms appear insufficient to explain the range of variation in immune responses to vaccines and to infections by major pathogens. In this study of Gambian twins we report that regulation of the immune response to a variety of antigens from Plasmodium falciparum and Mycobacterium tuberculosis is controlled by factors which are encoded by genes that lie both within and outside the major histocompatibility complex (MHC). We define the relative contribution of these genes, which varies for different antigens. The cumulative genetic contribution of non-MHC genes to the total phenotypic variance exceeds that of the MHC encoded genes.
C1 MRC LABS,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
CR BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   BLACKWELL CC, 1991, BRIT MED J, V303, P825
   BREDIUS RGM, 1994, J INFECT DIS, V170, P848
   BROWN AE, 1992, AM J TROP MED HYG, V47, P440
   DAVEY MP, 1994, J IMMUNOL, V152, P315
   DZIEGIEL M, 1991, AM J TROP MED HYG, V44, P306
   Falconer D., 1981, INTRO QUANTITATIVE G
   FENTON B, 1991, MOL CELL BIOL, V11, P963
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   GUTTINGER M, 1991, INT IMMUNOL, V3, P899, DOI 10.1093/intimm/3.9.899
   HAVERKORN MJ, 1975, TRANSPLANT REV, V22, P120
   HOLDER AA, 1987, PARASITOLOGY, V94, P199
   JEPSON A, UNPUB
   Jepson AP, 1996, J INFECTION, V33, P1, DOI 10.1016/S0163-4453(96)92605-5
   KONRADSEN HB, 1993, CLIN EXP IMMUNOL, V92, P532
   KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0
   LIEBERMAN R, 1972, J EXP MED, V136, P790, DOI 10.1084/jem.136.4.790
   MALATY HM, 1994, ANN INTERN MED, V120, P982
   MALO D, 1994, TRENDS GENET, V10, P365, DOI 10.1016/0168-9525(94)90133-3
   MARTIN M, 1995, HUM MOL GENET, V4, P423, DOI 10.1093/hmg/4.3.423
   PERKINS DL, 1989, J EXP MED, V170, P279, DOI 10.1084/jem.170.1.279
   PUEL A, 1995, J IMMUNOL, V154, P5799
   RAO DC, 1974, AM J HUM GENET, V26, P331
   RILEY E, 1990, IMMUNOL LETT, V25, P221, DOI 10.1016/0165-2478(90)90119-B
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RILEY EM, 1992, INT IMMUNOL, V4, P1055, DOI 10.1093/intimm/4.9.1055
   RILEY EM, 1991, T ROY SOC TROP MED H, V85, P436, DOI 10.1016/0035-9203(91)90207-F
   RILEY EM, 1991, EUR J IMMUNOL, V21, P1019, DOI 10.1002/eji.1830210424
   RILEY EM, 1990, J IMMUNOL, V144, P4810
   Rodrigues V, 1996, AM J HUM GENET, V59, P453
   ROSENBERG WM, 1992, CURR EYE RES, V11, pS17
   RZEPCZYK CM, 1992, J IMMUNOL, V148, P1197
   RZEPCZYK CM, 1990, IMMUNOL LETT, V25, P155, DOI 10.1016/0165-2478(90)90108-3
   SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0
   SETTE A, 1989, J IMMUNOL, V143, P289
   SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0
   SJOBERG K, 1992, P NATL ACAD SCI USA, V89, P2101, DOI 10.1073/pnas.89.6.2101
   SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8
   THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684
   TROYEBLOMBERG M, 1989, J IMMUNOL, V143, P3043
   TROYEBLOMBERG M, 1991, INT IMMUNOL, V3, P1043, DOI 10.1093/intimm/3.10.1043
   TROYEBLOMBERG M, 1994, IMMUNOL LETT, V43, P59, DOI 10.1016/0165-2478(94)00163-4
   Vogel F, 1986, HUMAN GENETICS
   WILLIAMS CJ, 1992, COMPUT METH PROG BIO, V38, P167, DOI 10.1016/0169-2607(92)90084-K
   WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x
NR 45
TC 88
Z9 89
U1 2
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 1997
VL 65
IS 3
BP 872
EP 876
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA WK953
UT WOS:A1997WK95300004
PM 9038290
OA No
DA 2017-08-15
ER

PT J
AU Conway, DJ
   Holland, MJ
   Bailey, RL
   Campbell, AE
   Mahdi, OSM
   Jennings, R
   Mbena, E
   Mabey, DCW
AF Conway, DJ
   Holland, MJ
   Bailey, RL
   Campbell, AE
   Mahdi, OSM
   Jennings, R
   Mbena, E
   Mabey, DCW
TI Scarring trachoma is associated with polymorphism in the tumor necrosis
   factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha
   levels in tear fluid
SO INFECTION AND IMMUNITY
LA English
DT Article
ID OCULAR CHLAMYDIAL INFECTION; ECTOPIC PREGNANCY; FIBROSIS; PATHOGENESIS;
   RESPONSES; ANTIGENS; GROWTH; REGION; BETA
AB Tumor necrosis factor alpha (TNF-alpha) may play a central role in the disease pathogenesis which occurs as a consequence of chlamydial infection, To investigate the importance of TNF-alpha gene promoter polymorphisms and TNF-alpha levels in tear fluid in scarring trachoma, a large matched-pair case-control study was performed in The Gambia, The -308A allele was present in a higher proportion of patients (28.4%) than controls (18.4%), with an increasing association for homozygotes (chi(2) for trend, P = 0.032; allele frequency, 0.163 in patients and 0.099 in controls; chi(2), P = 0.025), For the -238A allele, the association was similar but not significant, The disease association was highly significant when the number of either -308A or -238A sites in an individual was considered (P = 0.003). TNF-alpha promoter alleles are tightly linked to some HLA class I and II alleles, but multivariate analysis confirmed that the disease associations were independent of HLA, although a class I allele, A*6802, is also associated with disease. TNF-alpha was more frequently detected in tear samples from patients (27.6%) than from controls (15.9%), increasingly so for higher levels of detectable TNF-alpha (P = 0.015), Among patients, detectable TNF-alpha in tears was highly associated with the presence of ocular chlamydial infection (P < 0.001), The results indicate that TNF-alpha plays a major role in the tissue damage and scarring which occurs as a consequence of Chlamydia trachomatis infection.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
OI Conway, David/0000-0002-8711-3037
CR ABRAHAM LJ, 1993, CLIN EXP IMMUNOL, V92, P14
   BAILEY RL, 1994, J INFECT DIS, V170, P709
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BOBU L, 1996, INFECT IMMUN, V64, P3273
   BORDER WA, 1994, NEW ENGL J MED, V331, P1286
   Bouma G, 1996, CLIN EXP IMMUNOL, V103, P391
   BRINKMAN BMN, 1995, IMMUNOLOGY S1, V86, P75
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Chen G, 1996, CLIN EXP IMMUNOL, V104, P154, DOI 10.1046/j.1365-2249.1996.d01-647.x
   CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164
   CHOW WH, 1987, EPIDEMIOL REV, V9, P70
   Conway DJ, 1996, J INFECT DIS, V174, P643
   DALFONSO S, 1994, IMMUNOGENETICS, V39, P150
   DARVILLE T, 1995, INFECT IMMUN, V63, P4675
   DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163
   DEKOSSODO S, 1994, EUR J IMMUNOL, V24, P769, DOI 10.1002/eji.1830240342
   ELIAS JA, 1988, J CLIN INVEST, V81, P325, DOI 10.1172/JCI113324
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   INGALLS RR, 1995, INFECT IMMUN, V63, P3125
   Kirkwood B.R, 1988, ESSENTIALS MED STAT
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655
   PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0
   POCLOT F, 1993, EUR J IMMUNOL, V23, P224
   SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482
   SHEMERAVNI Y, 1988, INFECT IMMUN, V56, P2503
   SHEMERAVNI Y, 1989, INFECT IMMUN, V57, P3484
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   TAYLOR HR, 1992, AM J TROP MED HYG, V46, P552
   VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.immunol.10.1.411
   WILLIAMS DM, 1990, INFECT IMMUN, V58, P1572
   WILLIAMS DM, 1989, INFECT IMMUN, V57, P1351
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Wilson A. G., 1994, BR J RHEUMATOL S1, V33, P89
NR 37
TC 158
Z9 159
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 1997
VL 65
IS 3
BP 1003
EP 1006
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA WK953
UT WOS:A1997WK95300023
PM 9038309
OA No
DA 2017-08-15
ER

PT J
AU Duraisingh, MT
   Drakeley, CJ
   Muller, O
   Bailey, R
   Snounou, G
   Targett, GAT
   Greenwood, BM
   Warhurst, DC
AF Duraisingh, MT
   Drakeley, CJ
   Muller, O
   Bailey, R
   Snounou, G
   Targett, GAT
   Greenwood, BM
   Warhurst, DC
TI Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of
   Plasmodium falciparum by chloroquine and amodiaquine
SO PARASITOLOGY
LA English
DT Article
DE pfmdr 1; chloroquine; amodiaquine; allele; selection
ID WHOLE-BLOOD CONCENTRATIONS; MULTIDRUG-RESISTANCE GENE; HALOFANTRINE
   RESISTANCE; MALARIA; AMPLIFICATION; MEFLOQUINE; DESETHYLCHLOROQUINE;
   DISPOSITION; KENYA
AB The 4-aminoquinolines chloroquine (CQ) and amodiaquine (AM) were used to treat Gambian children with uncomplicated falciparum malaria in a randomized drug trial. Blood samples were taken immediately before treatment (day 0), and at day 7 and day 28 after treatment. Samples from those parasitologically positive at day 7 following treatment (' early positives') and those positive at day 28 but negative at day 7 ('late positives') have been studied by PCR followed by restriction enzyme digestion to determine the allelic status of the pfmdr 1 locus at the codon-86 position (asparagine or tyrosine), previously associated with resistance to CQ. A significantly higher prevalence of the tyr-86 allele was observed in samples taken immediately before treatment (day 0) in the early positives group when compared with the late positives group. This suggests the tyr-86 allele contributes to drug resistance in the early positives group. This association remained significant for both CQ and AM groups, implying a common genetic basis of resistance. Predominance of the allele at day 7 is consistent with a strong selection in the first week following treatment. In the late positives group, a significantly higher prevalence of the tyr-86 allele was observed in the samples at day 28 when compared with those at day 0, suggestive of selection during the period day 7 to day 28. Differences were observed in the extent of this selection in the CQ and AM groups. The samples were genotyped at 3 unlinked polymorphic loci. These analyses suggested that most parasites observed at day 7 were probably recrudescences whereas most of those at day 28 were reinfections.
C1 MRC LABS,BANJUL,GAMBIA.
   NORTHWICK PK HOSP & CLIN RES CTR,LISTER UNIT,HARROW HA1 3UK,MIDDX,ENGLAND.
RP Duraisingh, MT (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI Snounou, Georges/F-3352-2011
OI Snounou, Georges/0000-0002-6133-6398
FU Wellcome Trust
CR Adagu IS, 1996, T ROY SOC TROP MED H, V90, P90, DOI 10.1016/S0035-9203(96)90491-5
   ADAGU IS, 1995, T ROY SOC TROP MED H, V89, P132
   BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1
   BARNES DA, 1992, EMBO J, V11, P3067
   Basco LK, 1995, MOL BIOCHEM PARASIT, V74, P157, DOI 10.1016/0166-6851(95)02492-1
   BRANDLINGBENNETT AD, 1988, T ROY SOC TROP MED H, V82, P833, DOI 10.1016/0035-9203(88)90009-0
   Bruce-Chwatt LJ, 1986, CHEMOTHERAPY MALARIA
   CHILDS GE, 1986, AM J TROP MED HYG, V40, P7
   CHURCHILL FC, 1985, LIFE SCI, V36, P53, DOI 10.1016/0024-3205(85)90285-1
   COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143
   EKONG RM, 1993, PARASITOLOGY, V106, P107
   ELKARIEM FMA, 1992, T R SOC TROP MED HYG, V86, P587
   FITCH CD, 1986, PARASITOL TODAY, V2, P329
   FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0
   FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9
   FREAN JA, 1992, T ROY SOC TROP MED H, V86, P29, DOI 10.1016/0035-9203(92)90426-D
   HELLGREN U, 1989, B WORLD HEALTH ORGAN, V67, P197
   HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
   MENON A, 1987, LANCET, V2, P1029
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   PEEL SA, 1994, AM J TROP MED HYG, V51, P648
   PUSSARD E, 1987, EUR J CLIN PHARMACOL, V33, P409, DOI 10.1007/BF00637639
   PUSSARD E, 1994, FUNDAMENTALS CLIN PH, V3, P1
   ROMBO L, 1986, T ROY SOC TROP MED H, V80, P763, DOI 10.1016/0035-9203(86)90380-9
   VANES HHG, 1994, MOL CELL BIOL, V14, P2419
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   VOLKMAN SK, 1995, P NATL ACAD SCI USA, V92, P8921, DOI 10.1073/pnas.92.19.8921
   WATKINS WM, 1984, LANCET, V1, P357
   WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O
   WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4
   WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S
   WINSTANLEY PA, 1990, BRIT J CLIN PHARMACO, V29, P695
NR 32
TC 111
Z9 112
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD MAR
PY 1997
VL 114
BP 205
EP 211
DI 10.1017/S0031182096008487
PN 3
PG 7
WC Parasitology
SC Parasitology
GA WR199
UT WOS:A1997WR19900001
PM 9075340
OA No
DA 2017-08-15
ER

PT J
AU David, KP
   Marbiah, NT
   Lovgren, P
   Greenwood, BM
   Petersen, E
AF David, KP
   Marbiah, NT
   Lovgren, P
   Greenwood, BM
   Petersen, E
TI Hyperpigmented dermal macules in children following the administration
   of Maloprim(R) for malaria chemoprophylaxis
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium spp.; chemoprophylaxis; Maloprim(R);
   pyrimethamine/dapsone; side effect; hyperpigmented dermal macules;
   children
ID RURAL GAMBIAN CHILDREN; MORTALITY; WORKERS
AB The occurrence of an unexpected side effect following the use of Maloprim(R) (pyrimethamine/dapsone) for malaria chemosuppression in 3-59 months old children in Sierra Leone is reported. As part of a trial of chemoprophylaxis and insecticide-impregnated bed nets, 2000 children received either Maloprim(R) or placebo; 4% of children who received Maloprim(R) fortnightly for more than 3 months developed hyperpigmented macules, whereas none of the children who received placebo did so. Histopathological examination of full thickness skin biopsies showed macrophages containing melanin in the dermal layer. Clustering of cases was noted among siblings, suggesting the possible involvement of genetic factors in the pathogenesis of these skin reactions. One child was accidentally re-exposed to Maloprim(R) after the drug had been withdrawn and he developed a severe reaction. No other serious side effect was noted. Hyperpigmented lesions similar to those reported in this study have been described previously in patients with leprosy treated with dapsone, and the dapsone component of Maloprim(R) is the likely cause of the skin reactions seen in children given this drug for malaria chemoprophylaxis.
C1 EC MALARIA PROJECT,BO,SIERRA LEONE.
   LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.
   HVIDOVRE UNIV HOSP,DEPT PATHOL,COPENHAGEN,DENMARK.
   MRC LABS,BANJUL,GAMBIA.
RP David, KP (reprint author), STATENS SERUM INST,PARASITOL LAB,ARTILLERIVEJ 5,DK-2300 COPENHAGEN S,DENMARK.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   BARNISH G, 1993, ANN TROP MED PARASIT, V87, P137
   Barnish G, 1993, Parassitologia, V35 Suppl, P1
   Binka FN, 1996, TROP MED INT HEALTH, V1, P147
   BROWNE S. G., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P495, DOI 10.1016/0035-9203(59)90026-4
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   GREENWOOD BM, 1988, LANCET, V1, P1121
   HUTCHINSON DBA, 1986, HUM TOXICOL, V5, P221
   MARBIAH NT, 1995, THESIS U LONDON
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   PETERSEN E, 1993, PARASSITOLOGIA S, P81
   PICARD J, 1992, T ROY SOC TROP MED H, V86, P580, DOI 10.1016/0035-9203(92)90135-Y
   PICARD J, 1993, T ROYAL SOC TROPIC S, V87
   POIZOTMARTIN I, 1991, PRESSE MED, V20, P632
   Talwat E N, 1983, Australas J Dermatol, V24, P69, DOI 10.1111/j.1440-0960.1983.tb00254.x
   THAM SN, 1988, SINGAPORE MED J, V29, P300
NR 17
TC 10
Z9 10
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1997
VL 91
IS 2
BP 204
EP 208
DI 10.1016/S0035-9203(97)90225-X
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA WY965
UT WOS:A1997WY96500030
PM 9196770
OA No
DA 2017-08-15
ER

PT J
AU Deming, MS
   Linkins, RW
   Jaiteh, KO
AF Deming, MS
   Linkins, RW
   Jaiteh, KO
TI The clinical efficacy of trivalent oral polio vaccine in The Gambia by
   season of vaccine administration
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID EPIDEMIC POLIOMYELITIS; ENDEMIC DISEASE; CHLOROQUINE; ROTAVIRUS
AB An epidemic of poliomyelitis caused by poliovirus type 1 occurred in The Gambia in 1986. To determine if a relationship existed between the failure of trivalent oral poliovirus vaccine (OPV) to prevent poliomyelitis and the season when children were vaccinated, 46 children 1-7 years old with poliomyelitis who had received three card-documented doses of OPV were compared with 260 controls who had also received three card-documented doses. Controls were individually matched with children who had poliomyelitis by age, sex, and residence. Children with poliomyelitis were more likely to have received doses in the rainy season (odds ratio describing the linear trend of each additional dose in the rainy season, 1.7; 95% confidence interval, 1.05-2.9). This finding extends previous observations of seasonal difference in the immunogenicity of OPV in The Gambia by showing that season of administration was associated with increased risk of vaccine failure nationwide for a several-year period.
C1 CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30341.
   MINIST HLTH SOCIAL WELF & WOMENS AFFAIRS,MED & HLTH DEPT,BANJUL,GAMBIA.
   WHO,GLOBAL PROGRAMME VACCINES,CH-1211 GENEVA,SWITZERLAND.
RP Deming, MS (reprint author), CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,NATL CTR INFECT DIS,INT HLTH PROGRAM OFF,ATLANTA,GA 30341, USA.
CR DEMING MS, 1992, AM J EPIDEMIOL, V135, P393
   GAIL MH, 1981, BIOMETRIKA, V68, P703, DOI 10.1093/biomet/68.3.703
   GYHRS A, 1991, AM J TROP MED HYG, V45, P613
   HANLON P, 1987, ANN TROP PAEDIATR, V7, P238
   HANLON P, 1987, LANCET, V1, P1342
   LEBARON C, 1994, 34 INT C ANT AG CHEM, P229
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   OTATUME S, 1975, JPN J MICROBIOL, V19, P201
   OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381
   PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   WHO, 1995, J INFECT DIS, V171, P1097
   *WHO GLOB PROGR VA, 1995, WHO PUBL
NR 13
TC 11
Z9 11
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB
PY 1997
VL 175
SU 1
BP S254
EP S257
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA WG180
UT WOS:A1997WG18000043
PM 9203725
OA No
DA 2017-08-15
ER

PT J
AU Thiesen, B
   Greenwood, B
   Brieske, N
   Achtman, M
AF Thiesen, B
   Greenwood, B
   Brieske, N
   Achtman, M
TI Persistence of antibodies to meningococcal IgA1 protease versus decay of
   antibodies to group A polysaccharide and Opc protein
SO VACCINE
LA English
DT Article
DE antibody persistence; antibody decline; synthetic peptides
ID A NEISSERIA-MENINGITIDIS; SEROGROUP-A; CONJUGATE VACCINE; WEST-AFRICA;
   CHILDREN; INFANTS; IMMUNIZATION; EPIDEMIC; IMMUNOGENICITY; EFFICACY
AB Sera were taken over a 5 year period from Gambian children vaccinated in 1983, when aged 1-4 years, with A+C meningococcal capsular polysaccharide, ELISA tests were devised to determine the concentrations of immunoglobulin A, G and M reacting with A polysaccharide and of IgG reacting with Ope protein, IgA1 pretense and an internal 104mer peptide derived from IgA1 pretense, Vaccination resulted in a brief rise of antibodies to A polysaccharide followed by decline to pre-immunization levels, IgM levels were very high even before vaccination. Antibodies to Ope protein stimulated by natural exposure also declined over the 5 year period. In contrast, antibodies stimulated by natural exposure to IgA1 protease or to the internal peptide remained constant or increased (final geometric mean level of 47 mu g IgG ml(-1)). We speculate that healthy carriage of Neisseria meningitidis or Haemophilus influenzae is responsible for this increase in IgG concentration. Published by Elsevier Science Ltd.
C1 MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY.
   MRC,BANJUL,GAMBIA.
OI Achtman, Mark/0000-0001-6815-0070
CR ACHTMAN M, 1991, J INFECT DIS, V164, P375
   ACHTMAN M, 1988, J EXP MED, V168, P507, DOI 10.1084/jem.168.2.507
   Achtman M, 1995, MENINGOCOCCAL DIS, P159
   ANDERSON EL, 1994, INFECT IMMUN, V62, P3391
   BIJIMER HA, 1989, T R SOC TROP MED HYG, V83, P831
   BINKIN N, 1982, LANCET, V2, P315
   BISELLI R, 1993, SCAND J IMMUNOL, V37, P644, DOI 10.1111/j.1365-3083.1993.tb01677.x
   BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297
   BRANDT BL, 1975, J INFECT DIS, V131, pS69
   BROOKS GF, 1992, J INFECT DIS, V166, P1316
   BROWN P, 1969, AM J EPIDEMIOL, V90, P514
   BUTZ S, 1994, PEPTIDE RES, V7, P20
   CALANDRA GB, 1993, VACCINE, V11, pS58, DOI 10.1016/0264-410X(93)90162-Q
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   CEESAY SJ, 1993, J INFECT DIS, V167, P1212
   CROWE BA, 1989, J INFECT DIS, V159, P686
   DECOSSIO MEF, 1992, J INFECT DIS, V166, P1322
   ERWA HH, 1973, B WORLD HEALTH ORGAN, V49, P301
   FADEN H, 1993, J INFECT DIS, V168, P452
   FOMSGAARD A, 1987, J IMMUNOASSAY, V8, P333, DOI 10.1080/15321818708057032
   GOLD R, 1978, J INFECT DIS, V138, P731
   GOLD R, 1979, J INFECT DIS, V140, P690
   GOLDSCHN.I, 1973, J INFECT DIS, V128, P769
   Gotschlich E C, 1975, Monogr Allergy, V9, P245
   GOTSCHLICH EC, 1972, J CLIN INVEST, V51, P89, DOI 10.1172/JCI106801
   GREENWOOD BM, 1986, T ROY SOC TROP MED H, V80, P1006, DOI 10.1016/0035-9203(86)90303-2
   GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P756, DOI 10.1016/0035-9203(80)90195-9
   GUNN TR, 1993, NEW ZEAL MED J, V106, P499
   HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8
   ISACSON J, 1994, PEDIATR INFECT DIS J, V13, P22, DOI 10.1097/00006454-199401000-00006
   KAYHTY H, 1980, J INFECT DIS, V142, P861
   KING JC, 1993, AM J DIS CHILD, V147, P558
   KRUGMAN S, 1983, REV INFECT DIS, V5, P477
   LEPOW ML, 1977, PEDIATRICS, V60, P673
   MAKELA O, 1983, EUR J IMMUNOL, V13, P815, DOI 10.1002/eji.1830131007
   Makela P.H., 1977, J INFECT DIS S, V136, P43
   MOHAMMED I, 1984, J INFECTION, V9, P197, DOI 10.1016/S0163-4453(84)91468-3
   MORELLI G, 1994, MOL MICROBIOL, V11, P175, DOI 10.1111/j.1365-2958.1994.tb00299.x
   MULHOLLAND EK, 1993, ANN TROP PAEDIATR, V13, P153
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   PLIKAYTIS BD, 1994, J CLIN MICROBIOL, V32, P2441
   POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0
   RAUTONEN N, 1986, J IMMUNOL, V137, P2670
   REINGOLD AL, 1985, LANCET, V2, P114
   ROSENQVIST E, 1993, J INFECT DIS, V167, P1065
   RUMKE HC, 1993, VACCINE, V11, P1113, DOI 10.1016/0264-410X(93)90071-5
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
   WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667
   WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645
   WANG JF, 1993, J INFECT DIS, V167, P1320
   WANG JF, 1992, INFECT IMMUN, V60, P5267
   ZANGWILL KM, 1994, J INFECT DIS, V169, P847
   ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7
NR 53
TC 18
Z9 18
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB
PY 1997
VL 15
IS 2
BP 209
EP 219
DI 10.1016/S0264-410X(96)00138-7
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA WK883
UT WOS:A1997WK88300017
PM 9066040
OA No
DA 2017-08-15
ER

PT J
AU Samb, B
   Aaby, P
   Whittle, H
   Seck, AMC
   Simondon, F
AF Samb, B
   Aaby, P
   Whittle, H
   Seck, AMC
   Simondon, F
TI Decline in measles case fatality ratio after the introduction of measles
   immunization in rural senegal
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE immunization; infection; measles; mortality
ID MORTALITY; CHILDREN; COMMUNITY; INFECTION; VACCINES
AB The epidemiology of measles has been investigated in Niakhar, a rural area of Senegal, during two periods, 1983-1986 and 1987-1990. Following a major increase in immunization coverage beginning in 1987, the case fatality ratio for all ages declined fourfold from the first to the second period (relative risk (RR) = 0.24, 95% confidence interval (Ci) 0.13-0.46). The measles incidence for children under 10 years of age declined by 69% (95% CI 65-72) and the risk of dying of measles by 91% (95% CI 82-95). Vaccinated children who contracted measles had significantly lower case fatality ratio than unvaccinated children with measles (p = 0.038). Children infected by an immunized case tended to have lower case fatality ratio than those infected by an unimmunized index case (p = 0.104) and immunized index cases generated fewer secondary cases than unimmunized index cases (p < 0.001). Respiratory complications were more common in secondary cases infected by an index case with respiratory complications than by an index case without such complications (RR = 1.60, 95% CI 1.08-2.37), which suggests that severe cases give rise to further severe cases. As expected, there was a significant increase in the proportion of vaccinated cases in the second period (RR = 1.41, 95% CI 1.00-1.98). Mean age at infection increased from 4 to 7 years between the two periods and the change in age structure accounted for 20% of the decline in case fatality ratio. Measles immunization may contribute to lower mortality directly through reduced incidence and indirectly through increases in age at infection, less severe infection for immunized cases and changes in transmission patterns leading to reduced severity of measles.
C1 STATENS SERUM INST,DEPT EPIDEMIOL RES,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK.
   ORSTOM,UNITE RECH MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   INSERM U13,PARIS,FRANCE.
   MRC LABS,BANJUL,GAMBIA.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
CR AABY P, 1986, J INFECT DIS, V154, P858
   AABY P, 1991, MED VIROL, V10, P83
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Aaby P, 1992, Ann Epidemiol, V2, P257
   AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443
   AABY P, 1992, LANCET, V340, P388, DOI 10.1016/0140-6736(92)91470-S
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CHERRY JD, 1973, J PEDIATR-US, V82, P802, DOI 10.1016/S0022-3476(73)80070-8
   CHRISTENSEN PE, 1953, ACTA MED SCAND, V144, P313
   CHRISTENSEN PE, 1953, ACTA MED SCAND, V144, P430
   COOVADIA HM, 1981, J INFECT DIS, V144, P142
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Foster SO, 1984, POPUL DEV REV, V10, P119, DOI 10.2307/2807958
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M., 1987, RISQUES DECES ASSOCI
   Garenne ML, 1982, THESIS U PENNSYLVANI
   *MEASL VACC COMM, 1966, BMJ-BRIT MED J, V1, P441
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   *WHO, 1992, MEASL CONTR 1990 PLA
NR 23
TC 33
Z9 33
U1 1
U2 3
PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH
PI BALTIMORE
PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JAN 1
PY 1997
VL 145
IS 1
BP 51
EP 57
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA WA787
UT WOS:A1997WA78700007
PM 8982022
OA No
DA 2017-08-15
ER

PT J
AU Brown, MA
   Jepson, A
   Young, A
   Whittle, HC
   Greenwood, BM
   Wordsworth, BP
AF Brown, MA
   Jepson, A
   Young, A
   Whittle, HC
   Greenwood, BM
   Wordsworth, BP
TI Ankylosing spondylitis in west Africans - Evidence for a non-HLA-B27
   protective effect
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID HLA-B27 SUBTYPES; DISEASE
AB Objective-To determine the prevalence of ankylosing spondylitis in the Fula ethnic group in The Gambia, and relate the disease prevalence to the B27 frequency and subtype distribution of that population.
   Methods-215 first degree relatives of 48 B27 positive Fula twin pairs, and 900 adult Fula males were screened for ankylosing spondylitis by clinical and, where appropriate, radiographic means. The B27 prevalence was determined by PCR/sequence specific oligonucleotides on finger prick samples from 100 unrelated Fula, and B27 subtype distribution by SSCP on unrelated B27 positive individuals. This data were then compared with the prevalence of ankylosing spondylitis among B27 positive Caucasians.
   Results-No case of ankylosing losing spondylitis was seen. Six per cent of Fula are B27 positive, of which 32% are B*2703 and 68% B*2705. Assuming the penetrance of ankylosing spondylitis in B27 positive Fula is the same as in B27 positive Caucasians, the probability of not observing any cases of ankylosing spondylitis among the Fula examined is remote (P = 6.7 x 10(-6)). Similarly, the chance of not seeing any cases among those expected to be either B*2705 or B*2703 was small (P = 3.2 x 10(-4) for B*2705, and P = 0.02 for B*2703).
   Conclusions-The risk of developing ankylosing spondylitis in B27 positive Fula is lower than in B27 positive Caucasians. This is not explained by the B27 subtype distribution among Fula, and suggests the presence of some non-B27 protective factor reducing the prevalence of ankylosing spondylitis in this population.
C1 MRC LABS,FAJARA,GAMBIA.
RP Brown, MA (reprint author), WELLCOME TRUST CTR HUMAN GENET,WINDMILL RD,OXFORD OX3 7BN,ENGLAND.
OI Brown, Matthew A/0000-0003-0538-8211
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353
   Brown MA, 1996, ANN RHEUM DIS, V55, P268, DOI 10.1136/ard.55.4.268
   COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8
   DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
   GRAN JT, 1985, ANN RHEUM DIS, V44, P359, DOI 10.1136/ard.44.6.359
   HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8
   IITIA A, 1992, PCR METH APPL, P157
   JEPSON AP, 1995, J INFECT DIS, V172, P316
   KHAN MA, 1977, J RHEUMATOL, V4, P39
   Khan Muhammad Asim, 1995, Current Opinion in Rheumatology, V7, P263, DOI 10.1097/00002281-199507000-00001
   LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x
   MCMICHAEL A, 1991, RES IMMUNOL, V142, P475, DOI 10.1016/0923-2494(91)90050-S
NR 13
TC 78
Z9 80
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JAN
PY 1997
VL 56
IS 1
BP 68
EP 70
DI 10.1136/ard.56.1.68
PG 3
WC Rheumatology
SC Rheumatology
GA WF388
UT WOS:A1997WF38800014
PM 9059145
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Mulholland, EK
   Jaffar, S
   Troedsson, H
   Gove, S
   Greenwood, BM
AF Weber, MW
   Mulholland, EK
   Jaffar, S
   Troedsson, H
   Gove, S
   Greenwood, BM
TI Evaluation of an algorithm for the integrated management of childhood
   illness in an area with seasonal malaria in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID DIARRHEAL DISEASE; GLOBAL PROBLEM; DIAGNOSIS; MAGNITUDE; PNEUMONIA;
   CHILDREN
AB Most of the 12.4 million deaths occurring every year among under-5-year-olds in developing countries could be prevented by the application of simple treatment strategies. So that health professionals who have had limited training can identify and classify the common Childhood diseases, WHO developed a treatment algorithm (the integrated Management of Childhood Illness (IMCI) or Sick Child algorithm), a prototype of which was tested in 440 Gambian children aged between 2 months and 5 years. The children were first assessed by a trained field worker using the algorithm, and then by a paediatrician whose clinical diagnosis was supported by laboratory investigations and, when indicated, a chest X-ray.
   Compared with the paediatrician's diagnosis, the sensitivity and specificity of the draft IMCI algorithm were, respectively, 81% and 89% for the detection of pneumonia, 67% and 96% for dehydration, 87% and 8% for malaria parasitaemia (any level), 100% and 9% for malaria parasitaemia (above 5000 parasites/mu l), 100% and 99% for measles, 31% and 97% for otitis media, and 89% and 90%;for malnutrition. Among the children admitted by the physician, 45% had been recommended for admission by the algorithm. Intermittent fever, chills and sweats did not help in discriminating between malaria and non-malarious fevers; shivering or shaking of the body had a sensitivity of only 35%. While the algorithm dealt with, the majority of presenting complaints, the most common problems not addressed by the chart were skin rashes (21%), mouth problems (8%), and eye problems (6%).
   The draft IMCI algorithm proved to be effective in the diagnosis of pneumonia, gastroenteritis, measles and malnutrition, but not malaria where its use without microscopy would result in considerable overtreatment, especially in a low transmission area or during a low transmission season in countries with seasonal malaria. The current algorithm would benefit from expansion to cover management of localized infections as well as skin, mouth and eye problems.
C1 MRC Labs, Banjul, Gambia.
   Hannover Med Sch, Childrens Hosp, D-3000 Hannover, Germany.
   WHO, Div Diarrhoeal & Acute Resp Dis Control, CH-1211 Geneva, Switzerland.
RP Weber, MW (reprint author), MRC Labs, POB 273, Banjul, Gambia.
CR BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2
   BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705
   DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   GOMES M, 1994, B WORLD HEALTH ORGAN, V72, P383
   Henderson R H, 1990, Scand J Infect Dis Suppl, V76, P7
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X
   ORENSTEIN WA, 1994, ISRAEL J MED SCI, V30, P469
   ROOTH I, 1992, T ROY SOC TROP MED H, V86, P479, DOI 10.1016/0035-9203(92)90076-O
   ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P
   SIMOES EAF, 1992, LANCET, V340, P1502, DOI 10.1016/0140-6736(92)92757-7
   SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605
   *WHO PROGR CONTR D, 1994, WHOCDD9446
   *WHO PROGR CONTR D, 1994, WHOARI9433
   World Bank, 1993, WORLD DEV REP 1993
NR 17
TC 76
Z9 78
U1 1
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1997
VL 75
SU 1
BP 25
EP 32
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 119NJ
UT WOS:000075902300003
PM 9529715
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Kellingray, SD
   Palmer, A
   Jaffar, S
   Mulholland, EK
   Greenwood, BM
AF Weber, MW
   Kellingray, SD
   Palmer, A
   Jaffar, S
   Mulholland, EK
   Greenwood, BM
TI Pallor as a clinical sign of severe anaemia in children: an
   investigation in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID ANEMIA; AFRICA
AB Anaemia associated with malaria is a major public health problem in African countries. Since most primary health facilities have to rely on physical signs and not laboratory tests to detect anaemic patients who need referral for blood transfusion, we have assessed the reliability of simple clinical signs to predict severe anaemia.
   A trained field assistant examined 368 children admitted to a tertiary care hospital, assessing the pallor of their eyelids (conjunctiva), palms and nailbeds, counting the respiratory rate and looking for signs of respiratory distress. After the children's admission, their packed cell volume (PCV) was measured, and the need for transfusion and the outcomes were noted. A second observer examined 173 of these children so that interobserver variability in the detection of clinical signs could be assessed.
   A total of 27% of the 368 children had a PCV of <15%. In a multiple regression analysis, definite pallor of the conjunctiva, definite pallor of the palms, and a "sick" appearance of the child were identified as independent significant predictors of a PCV of <15%. The best predictor was a combination of definite pallor of the conjunctiva and pallor of the palms, with a sensitivity of 80% and a specificity of 85%. inclusion of signs of respiratory distress did not improve the prediction. Pallor was a reproducible sign (weighted kappa statistic for the comparison between two observers: kappa = 0.6 for conjunctival pallor). We conclude that pallor can be used as a sign for referring children who may require blood transfusion.
C1 MRC Labs, Banjul, Gambia.
   Univ Hannover, Sch Med, Childrens Hosp, Hannover, Germany.
   Univ Reading, Dept Biostat, Reading RG6 2AH, Berks, England.
   Royal Victoria Hosp, Paediat Unit, Banjul, Gambia.
RP Weber, MW (reprint author), MRC Labs, POB 273, Banjul, Gambia.
RI Leary, Sam/B-4456-2016
CR ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Fleiss JL, 1981, STAT METHODS RATES P
   HEDBERG K, 1993, AM J TROP MED HYG, V48, P365
   HOLZER BR, 1993, ACTA TROP, V55, P47, DOI 10.1016/0001-706X(93)90047-F
   LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O
   Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25
NR 7
TC 30
Z9 32
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1997
VL 75
SU 1
BP 113
EP 118
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 119NJ
UT WOS:000075902300012
PM 9529724
OA No
DA 2017-08-15
ER

PT J
AU Holland, MJ
   Conway, DJ
   Blanchard, TJ
   Mahdi, OMS
   Bailey, RL
   Whittle, HC
   Mabey, DCW
AF Holland, MJ
   Conway, DJ
   Blanchard, TJ
   Mahdi, OMS
   Bailey, RL
   Whittle, HC
   Mabey, DCW
TI Synthetic peptides based on Chlamydia trachomatis antigens identify
   cytotoxic T lymphocyte responses in subjects from a trachoma-endemic
   population
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE cytotoxic T lymphocyte; trachoma; HLA
ID INFECTED TARGET-CELLS; MICE; TUBERCULOSIS; PROTECTION; IMMUNITY;
   MALARIA; CLONES
AB CD8(+) cytotoxic T lymphocytes (CTL) recognize peptide antigens in the context of class I MHC antigen molecules. To identify peptides capable of eliciting anti-Chlamydia trachomatis CTL responses, 13 synthetic peptides conforming to human leucocyte antigen (HLA)-B8- or -B35-predicted binding motifs were synthesized using sequences based on C. trachomatis major outer membrane protein (MOMP) and heat shock protein 60 (hsp60). Two of 11 HLA-B35-predicted binding peptides were able to stabilize HLA-B35 in an in vitro binding assay. All peptides were tested in CTL assays using peripheral blood mononuclear cells (PBMC) isolated from 26 HLA-B8 or -B35 individuals resident in a trachoma-endemic community. Responses to MOMP and hsp60 peptides were identified in a minority of both HLA-B8 and -B35 individuals. Two of 12 HLA-B8 subjects responded to MOMP and 1/13 to hsp60 peptides. Responses in HLA-B35 subjects were similar, 1/13 subjects responding to MOMP and 2/13 to hsp60 peptides. CTL responses were observed only in children resolving current infection and in adults without scarring of the conjunctiva. These results suggest that anti-chlamydial CTL occur at low levels in peripheral blood, but may be important in the resolution of naturally acquired human ocular chlamydial infection.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   MRC,FAJARA,GAMBIA.
OI Conway, David/0000-0002-8711-3037
CR AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BEATTY PR, 1994, IMMUNOLOGY, V153, P5183
   Borysiewicz LK, 1996, LANCET, V347, P1523, DOI 10.1016/S0140-6736(96)90674-1
   BREWERTON DA, 1973, LANCET, V2, P996
   BUZONIGATEL D, 1992, IMMUNOLOGY, V77, P284
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   DONG T, 1996, EUR J IMMUNOL, V26, P336
   ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909
   HARBOE M, 1991, CLIN EXP IMMUNOL, V86, P2
   HASSELL AB, 1992, CLIN EXP IMMUNOL, V88, P442
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   HOLLAND MJ, 1994, P 8 INT S HUM CHLAM, P103
   Igietseme Joseph U., 1993, Regional Immunology, V5, P317
   IGIETSEME JU, 1994, INFECT IMMUN, V62, P5195
   KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363
   Kimani J, 1996, J INFECT DIS, V173, P1437
   LANDERS DV, 1991, INFECT IMMUN, V59, P3774
   MAGEE DM, 1995, INFECT IMMUN, V63, P516
   MORRISON RP, 1995, INFECT IMMUN, V63, P4661
   ORME IM, 1992, J IMMUNOL, V148, P189
   POPE M, 1994, IMMUNOLOGY, V81, P177
   QVIGSTAD E, 1984, ACTA PATH MICRO IM C, V92, P153
   RAMSEY KH, 1991, INFECT IMMUN, V59, P925
   Rasmussen SJ, 1996, INFECT IMMUN, V64, P1944
   ROLLWAGEN FM, 1986, J IMMUNOL, V136, P1418
   SCHACHTER J, 1978, HUMAN CHLAMYDIAL INF, P63
   SILVA CL, 1994, IMMUNOLOGY, V82, P244
   STAGG AJ, 1992, P EUR SOC CHLAM RES, P77
   STARNBACH MN, 1994, J IMMUNOL, V153, P5183
   SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222
   TAYLOR HR, 1992, AM J TROP MED HYG, V46, P552
   Tsuji K, 1992, P 11 INT HIST WORKSH
NR 36
TC 25
Z9 26
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 1997
VL 107
IS 1
BP 44
EP 49
DI 10.1046/j.1365-2249.1997.2511129.x
PG 6
WC Immunology
SC Immunology
GA WC592
UT WOS:A1997WC59200008
PM 9010255
OA No
DA 2017-08-15
ER

PT J
AU Leach, A
   Twumasi, PA
   Kumah, S
   Banya, WS
   Jaffar, S
   Forrest, BD
   Granoff, DM
   LiButti, DE
   Carlone, GM
   Pais, LB
   Broome, CV
   Greenwood, BM
AF Leach, A
   Twumasi, PA
   Kumah, S
   Banya, WS
   Jaffar, S
   Forrest, BD
   Granoff, DM
   LiButti, DE
   Carlone, GM
   Pais, LB
   Broome, CV
   Greenwood, BM
TI Induction of immunologic memory in gambian children by vaccination in
   infancy with a group A plus group C meningococcal polysaccharide-protein
   conjugate vaccine
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; NEISSERIA-MENINGITIDIS; GROUP-A; ANTIBODY;
   IMMUNOGENICITY; AGE
AB Two hundred twenty-one Gambian children vaccinated previously with one, two, or three doses of a meningococcal conjugate vaccine or two doses of polysaccharide vaccine before the age of 6 months were revaccinated at the age of 18-24 months with either meningococcal polysaccharide, conjugate, or inactivated polio vaccines. Children who had previously received one, two, or three doses of conjugate vaccine had significantly (P < .001) higher anti-group C meningococcal antibody levels following revaccination than did children vaccinated with a polysaccharide vaccine for the first time. Children vaccinated previously with two doses of polysaccharide vaccine had a lower group C antibody response than did control children. Group A antibody responses following revaccination of children who had previously received polysaccharide or conjugate vaccine were nor significantly higher than those in control children. Thus, immunologic memory was probably induced by the group C but not by the group A component of the conjugate vaccine.
C1 CTR DIS CONTROL & PREVENT,ATLANTA,GA.
   CHIRON BIOCINE,EMERYVILLE,CA.
   MRC LABS,FAJARA,BANJUL,GAMBIA.
CR ANDERSON EL, 1994, INFECT IMMUN, V62, P3391
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   CESSAY SJ, 1993, J INFECT DIS, V167, P1212
   CONSTANTINO P, 1992, VACCINE, V10, P691
   DECKER MD, 1993, J PEDIATR-US, V122, P410, DOI 10.1016/S0022-3476(05)83428-6
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475
   GOLD R, 1977, J INFECT DIS, V136, pS31
   GRANOFF DM, 1993, J INFECT DIS, V168, P663
   GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2
   Greenwood BM, 1987, BACTERIAL MENINGITIS, P61
   HOLDER PK, 1995, CLIN DIAGN LAB IMMUN, V2, P132
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   REINGOLD AL, 1985, LANCET, V2, P114
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
NR 15
TC 146
Z9 152
U1 1
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN
PY 1997
VL 175
IS 1
BP 200
EP 204
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA WA937
UT WOS:A1997WA93700033
PM 8985221
OA No
DA 2017-08-15
ER

PT J
AU Lisse, IM
   Aaby, P
   Whittle, H
   Jensen, H
   Engelmann, M
   Christensen, LB
AF Lisse, IM
   Aaby, P
   Whittle, H
   Jensen, H
   Engelmann, M
   Christensen, LB
TI T-lymphocyte subsets in West African children: Impact of age, sex, and
   season
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTHY-CHILDREN; REFERENCE RANGES; NORMAL
   VALUES; CELL SUBSETS; BLOOD SMEARS; WHOLE-BLOOD; POPULATION; INFECTION;
   SUBPOPULATIONS
AB Objective: There has been no reference material for T-lymphocyte subsets for normal children in developing countries. We therefore used T-lymphocyte subset determinations among children in three different studies in Guinea-Bissau to construct age-related reference material and to examine possible determinants of T-lymphocyte subset levels.
   Methods: A total of 803 healthy West African children younger than 6 years were included in the three community studies of T-lymphocyte subsets among twins and singletons, after measles infection and after measles immunization. We used the immunoalkaline phosphatase method to determine T-lymphocyte subsets.
   Results: We found differences by age, sex, and season, whereas there were no significant differences by birth order, twinning, or ethnic group. The CD4(+) percentage declined from birth to age 2 years, at which time it started to increase to higher levels at age 4 to 5 years. The CD8(+) percentage increased gradually from early infancy to age 2 to 4 years. The leukocyte count peaked at age 12 to 23 months and declined thereafter, whereas the lymphocyte percentage peaked at age 1 to 5 months and declined gradually thereafter. Compared with dry-season results, the lymphocyte percentage, the absolute lymphocyte count, the absolute CD4(+) T-lymphocyte count, and the CD4(+)/CD8(+) ratio were significantly lower during the rainy season, whereas the CD8(+) percentage was increased during the rainy season. Girls had higher CD4(+)/CD8(+) ratios and lower CD8(+) percentages than did boys.
   Conclusions: Compared with the limited data on T-lymphocyte subsets available from healthy children in developed countries, Guinean children have markedly lower CD4(+) percentages and CD4(+)/CD8(+) ratios and higher lymphocyte percentages during the first 2 years of life, when the pressure of infections is particularly high in Africa.
C1 HVIDOVRE UNIV HOSP, DEPT PATHOL, COPENHAGEN, DENMARK.
   STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, DK-2300 COPENHAGEN, DENMARK.
   ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, COPENHAGEN, DENMARK.
   MRC, BANJUL, GAMBIA.
CR AABY P, 1990, J INFECT DIS, V162, P1043
   Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   ARNEBORN P, 1983, INFECT IMMUN, V39, P29
   BORKOWSKY W, 1992, J PEDIATR-US, V120, P371, DOI 10.1016/S0022-3476(05)80899-6
   BROUN GO, 1966, NEW ENGL J MED, V275, P1410, DOI 10.1056/NEJM196612222752504
   CARNEY WP, 1981, J IMMUNOL, V126, P2114
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5
   DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484
   ERBER WN, 1984, LANCET, V1, P1042
   ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   GOTO M, 1989, J GERONTOL, V44, pM51
   HIGA K, 1992, PAIN, V51, P111, DOI 10.1016/0304-3959(92)90015-4
   KIEPIELA P, 1989, ANN TROP PAEDIATR, V9, P199
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   KOTYLO PK, 1991, ARCH PATHOL LAB MED, V115, P181
   KOTYLO PK, 1993, AM J CLIN PATHOL, V100, P111
   LEVI FA, 1988, J CLIN INVEST, V81, P407, DOI 10.1172/JCI113333
   LEWIS DE, 1986, J IMMUNOL, V137, P3777
   LIFSON JD, 1985, CLIN IMMUNOL IMMUNOP, V36, P151, DOI 10.1016/0090-1229(85)90116-3
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   LUFT BJ, 1984, J INFECT DIS, V150, P761
   MATSUMOTO K, 1985, J CLIN LAB IMMUNOL, V16, P143
   MCKINNEY RE, 1992, PEDIATR INFECT DIS J, V11, P639
   MOLBAK K, 1994, PARASITE IMMUNOL, V16, P275, DOI 10.1111/j.1365-3024.1994.tb00349.x
   Molbak K, 1996, AM J EPIDEMIOL, V143, P79
   MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008
   NDUKA N, 1988, HAEMATOLOGIA, V21, P57
   PARKER JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P187, DOI 10.1016/0090-1229(90)90097-A
   POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25
   REMY N, 1991, EUR J PEDIATR, V150, P230, DOI 10.1007/BF01955518
   VANHATTUM J, 1984, SCAND J GASTROENTERO, V19, P497
   WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018
   WECKER NJ, 1993, CLIN INFECT DIS, V17, P123
   *WHO OFF RES DIAGN, 1992, INTR ALT METH CD4 LY
   WINTROBE MM, 1981, CLIN HEMATOLOGY, P12
   YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017
NR 41
TC 58
Z9 58
U1 2
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JAN
PY 1997
VL 130
IS 1
BP 77
EP 85
DI 10.1016/S0022-3476(97)70313-5
PG 9
WC Pediatrics
SC Pediatrics
GA WD718
UT WOS:A1997WD71800015
PM 9003854
OA No
DA 2017-08-15
ER

PT J
AU Quinones, ML
   Lines, JD
   Thomson, MC
   Jawara, M
   Morris, J
   Greenwood, BM
AF Quinones, ML
   Lines, JD
   Thomson, MC
   Jawara, M
   Morris, J
   Greenwood, BM
TI Anopheles gambiae gonotrophic cycle duration, biting and exiting
   behaviour unaffected by permethrin-impregnated bednets in The Gambia
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE Anopheles gambiae; impregnated bednets; malaria control; vector control;
   permethrin; The Gambia
ID TREATED BED NETS; EXPERIMENTAL HUT TRIALS; PAPUA-NEW-GUINEA; MALARIA
   VECTORS; TARGETED CHEMOPROPHYLAXIS; WEST-AFRICA; RURAL AREA; MOSQUITO
   NETS; INSECTICIDE; CHILDREN
AB Permethrin-impregnated bednets protect children against malaria in The Gambia, where Anopheles gambiae complex mosquitoes are the main vectors of malaria. However, no effect has been found on mosquito density, parous rates or sporozoite rates in An.gambiae sensu lato populations; only a reduction in the numbers of mosquitoes resting indoors in rooms with treated bednets. A possible explanation for this paradox is that exposure to treated bednets leads to changed vector behaviour such as a shift in biting time, a diversion to biting outdoors instead of indoors, to biting animals instead of humans, or to increased duration of the gonotrophic cycle. To investigate these possibilities, we observed the biting and exiting behaviour of An.gambiae in ten pairs of villages, in half of which the residents used permethrin-treated bednets. The possible influence of treated bednets on the gonotrophic cycle length was evaluated by mark-release-recapture experiment.
   No significant difference was found between villages with treated and untreated bednet in the indoor/outdoor ratio of human biting, in mean biting times or in human blood indices of An.gambiae females found resting indoors in the mornings. The proportions of unfed, fed or gravid An.gambiae females collected in exit traps, and the number of females exiting showed no significant differences between rooms with treated and untreated bednets. Indications for a gonotrophic cycle length of 2 days were found. No evidence for any change in duration of the gonotrophic cycle in relation to exposure to treated bednets was found, although the number of recaptures was low in the villages with treated bednets.
   Since equal numbers of infective An.gambiae were found in villages with treated or untreated bednets, and no changes in mosquito behaviour were detected, we cannot account for how children are protected against malaria by treated bednets. One possibility is that mosquitoes divert to bite other hosts, including adults.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   BRYAN JH, 1980, MOSQ SYST, V12, P153
   CARNEVALE P, 1992, T ROY SOC TROP MED H, V86, P362, DOI 10.1016/0035-9203(92)90219-3
   CHARLWOOD JD, 1987, MED VET ENTOMOL, V1, P319, DOI 10.1111/j.1365-2915.1987.tb00361.x
   CHARLWOOD JD, 1987, PAPUA NEW GUINEA MED, V30, P199
   COLUZZI M, 1985, B ZOOL, V52, P45
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   COLUZZI M, 1964, Riv Malariol, V43, P197
   CURTIS CF, 1992, MEMORIAS I O CRUZ S3, V88, P363
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Darriet F, 1984, WHOVBC84899
   Gilles MT, 1968, ANOPHELINAE AFRICA S, P343
   GILLIES MT, 1987, NAOPHELINAE AFRICA S
   HII JLK, 1995, ANN TROP MED PARASIT, V89, P521
   HOSSAIN MI, 1989, MED VET ENTOMOL, V3, P367, DOI 10.1111/j.1365-2915.1989.tb00243.x
   KARCH S, 1993, ANN SOC BELG MED TR, V73, P37
   LI ZZ, 1987, WHOVBC87939
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   LINDSAY SW, 1992, B ENTOMOL RES, V82, P49
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P263, DOI 10.1111/j.1365-2915.1989.tb00226.x
   LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x
   NJAU RJA, 1993, INSECT SCI APPL, V14, P575
   PLEASS RJ, 1993, B ENTOMOL RES, V83, P133
   QUINONES ML, 1996, THESIS U LONDON
   ROBERT V, 1991, B WORLD HEALTH ORGAN, V69, P735
   Rozendaal J. A., 1989, TROP DIS B, V86, P1
   SERVICE MW, 1986, B ENTOMOL RES, V76, P321
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1987, B ENTOMOL RES, V77, P279
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   TAYLOR B, 1975, T ROY ENT SOC LONDON, V127, P277
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
   THOMSON MC, 1995, MED VET ENTOMOL, V9, P413, DOI 10.1111/j.1365-2915.1995.tb00015.x
   THOMSON RCM, 1947, B ENTOMOL RES, V38, P449
   Zoulani A., 1994, Annales de la Societe Belge de Medecine Tropicale, V74, P83
NR 40
TC 20
Z9 21
U1 1
U2 18
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD JAN
PY 1997
VL 11
IS 1
BP 71
EP 78
DI 10.1111/j.1365-2915.1997.tb00292.x
PG 8
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA WK470
UT WOS:A1997WK47000011
PM 9061680
OA No
DA 2017-08-15
ER

PT J
AU Magbity, EB
   Marbiah, NT
   Maude, G
   Curtis, CF
   Bradley, DJ
   Greenwood, BM
   Petersen, E
   Lines, JD
AF Magbity, EB
   Marbiah, NT
   Maude, G
   Curtis, CF
   Bradley, DJ
   Greenwood, BM
   Petersen, E
   Lines, JD
TI Effects of community-wide use of lambdacyhalothrin-impregnated bednets
   on malaria vectors in rural Sierra Leone
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE Anopheles gambiae; malaria vector; malaria control; lambdacyhalothrin;
   randomized trial; bednets; mass effect; personal protection; Sierra
   Leone
ID ANOPHELES-GAMBIAE COMPLEX; TREATED BED NETS; ENTOMOLOGICAL EVALUATION;
   BURKINA-FASO; AREA; TRANSMISSION; INSECTICIDE; TRIAL; POPULATION;
   MOSQUITOS
AB The effect of community-wide use of bednets treated with lambdacyhalothrin 10 mg/m(2) on the malaria vector Anopheles gambiae (forest form) was evaluated in Sierra Leone. Sixteen similar villages near the town of Bo were randomly allocated either to remain without nets or to receive treated bednets for all inhabitants, with effect from June 1992. Mosquitoes were sampled using human biting catches on verandas, light-trap catch (beside an occupied untreated bednet), window exit-trap catch and pyrethrum spray collections. During the first year of intervention (June 1992 to July 1993) the treated bednets provided personal protection for people sleeping under them, but had very little impact on densities of An.gambiae collected on human bait. The human blood index (HBI) of An.gambiae was not affected (HBI = 99% in villages with and without nets). An.gambiae parous rates were significantly reduced in all intervention villages, but malaria sporozoite rates fell in only some of the villages. These results are intermediate between those obtained from other projects in Tanzania and Burkina Faso, where treated bednets reduced man-biting, parity and sporozoite rates, versus The Gambia where treated bednets had no significant impact on any of these factors. Possible reasons for these contrasted findings are discussed.
C1 MED RES CTR,BO,SIERRA LEONE.
   MRC,FAJARA,GAMBIA.
   STATE SERUM INST,DEPT PARASITOL,COPENHAGEN,DENMARK.
RP Magbity, EB (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
CR ARAMRATTANA A, 1993, THESIS U LONDON
   ARMAH GE, 1997, IN PRESS MED VET ENT, V11
   ARREDONDOJIMENE.JI, 1997, MED ENTOMOL, V11, P85
   BARNISH G, 1993, ANN TROP MED PARASIT, V87, P125
   Barnish G, 1993, Parassitologia, V35 Suppl, P1
   Bockarie M.J., 1993, Parassitologia (Rome), V35, P5
   BOCKARIE MJ, 1994, ANN TROP MED PARASIT, V88, P251
   CARNEVALE P, 1988, B SOC PATHOL EXOT, V81, P832
   CHARLWOOD JD, 1987, MED VET ENTOMOL, V1, P319, DOI 10.1111/j.1365-2915.1987.tb00361.x
   CHENG HL, 1995, B WORLD HEALTH ORGAN, V73, P321
   COLUZZI M, 1985, B ZOOL, V52, P45
   Curtis C. F., 1990, Appropriate technology in vector control., P5
   Curtis C. F., 1992, Review of Medical and Veterinary Entomology, V80, P543
   Curtis CF, 1996, MED VET ENTOMOL, V10, P1, DOI 10.1111/j.1365-2915.1996.tb00075.x
   Curtis CF, 1996, TROP MED INT HEALTH, V1, P137
   Darriet F, 1984, WHOVBC84899
   Das P. K., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P513
   DETINOVA TS, 1962, WHO MONOGR SER, V47
   GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0
   Gillies M, 1987, PUBLICATIONS S AFRIC, V55
   GILLIES MT, 1965, B ENTOMOL RES, V56, P237
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   HUAILU C, 1995, B WORLD HEALTH ORGAN, V73, P312
   JANAKARA BR, 1995, J TROP MED HYG, V98, P73
   KARCH S, 1993, ANN SOC BELG MED TR, V73, P37
   LEGOFF G, 1992, MEM I OSWALDO CRUZ, V87, P355
   Lengeler C, 1996, NET GAIN NEW METHOD
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P263, DOI 10.1111/j.1365-2915.1989.tb00226.x
   Lines J, 1996, TROP MED INT HEALTH, V1, P616
   LINES JD, 1991, B ENTOMOL RES, V81, P77
   LINES JD, 1996, NET GAIN NEW METHOD, P17
   Macdonald G., 1957, EPIDEMIOLOGY CONTROL
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   MARBIAH NT, 1997, IN PRESS AM J TROPIC, V40
   Mbogo CNM, 1996, MED VET ENTOMOL, V10, P251, DOI 10.1111/j.1365-2915.1996.tb00739.x
   MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x
   Petersen E, 1993, Parassitologia, V35 Suppl, P81
   QUINONES ML, 1997, MED ENTOMOL, V11, P69
   ROBERT V, 1991, B WORLD HEALTH ORGAN, V69, P735
   Rozendaal J. A., 1989, Tropical Diseases Bulletin, V86, pR1
   SERVICE MW, 1986, B ENTOMOL RES, V76, P321
   SNOW RW, 1987, B ENTOMOL RES, V77, P279
   SOMBOON P, 1995, T ROY SOC TROP MED H, V89, P248, DOI 10.1016/0035-9203(95)90525-1
   SUDIA WILLIAM D., 1962, MOSQUITO NEWS, V22, P126
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
   *WHO, 1975, MANUAL PRACTICAL ENT
   WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P39
NR 49
TC 18
Z9 19
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD JAN
PY 1997
VL 11
IS 1
BP 79
EP 86
DI 10.1111/j.1365-2915.1997.tb00293.x
PG 8
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA WK470
UT WOS:A1997WK47000012
PM 9061681
OA No
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Leach, A
   Greenwood, AM
   Jepson, A
   Muller, O
   Ota, MOC
   Bojang, K
   Obaro, S
   Greenwood, BM
AF Jaffar, S
   Leach, A
   Greenwood, AM
   Jepson, A
   Muller, O
   Ota, MOC
   Bojang, K
   Obaro, S
   Greenwood, BM
TI Changes in the pattern of infant and childhood mortality in Upper River
   Division, The Gambia, from 1989 to 1993
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE childhood mortality; The Gambia; post-mortem questionnaires; malaria;
   ARI
ID HEALTH-CARE PROGRAM; RURAL SENEGAL; WEST-AFRICA; MORBIDITY; CHILDREN;
   MALARIA; IMMUNIZATION; IMPACT; DEATHS; TITER
AB A surveillance system was used to detect births and deaths in children in a large, rural, West African population from 1989 to 1993. Cause of death was investigated using post-mortem questionnaires. Overall infant (age 0-11 months) and child (ages 1-4 years) mortality rates of 80.1 and 18.8 per 1000 per year were recorded. These were reasonably consistent over the period of surveillance. The most frequent cause of death in infants tvas acute respiratory infection (ARI), whereas in children it was malaria: these two conditions accounted fur 41% of the deaths in children under 5 years old. Other leading causes of death were acute gastroenteritis, malnutrition, and septicaemia. Deaths attributed to ARI decreased over the 5-year period, but mortality rates from other causes were either unchanged or increased slightly. Mortality from all causes peaked in the rainy season and was slightly higher in villages which were part of a primary health care programme than in those which were not. There were also no differences between male and female mortality rates beyond one year or age. Despite the introduction of a number of health Interventions, there has been no major change in the overall pattern of mortality in children in a rural area of The Gambia, Malaria and ARI remain the main causes of death.
C1 MRC LABS,BANJUL,W AFRICA,GAMBIA.
   UNIV OXFORD,INST MOL MED,DEPT HUMAN GENET,OXFORD OX1 2JD,ENGLAND.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.
RP Jaffar, S (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   CANTRELLE P, 1969, TRAVAUX DOCUMENTS OR, V1, P7
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181
   *GOV GAMB, 1993, POP DAT BANK
   Gray R, 1990, 10 J HOPK U SCH HYG
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   MCGREGOR I A, 1964, West Afr Med J, V13, P251
   MENON A, 1991, J TROP MED HYG, V94, P268
   PISON G, 1984, POPULATION STUDIES, P1
   ROBERTSON RL, 1985, J TROP MED HYG, V88, P343
   Smith PG, 1991, METHODS FIELD TRIALS
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   TODD JE, 1994, ANN TROP PAEDIATR, V14, P31
NR 23
TC 98
Z9 100
U1 2
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JAN
PY 1997
VL 2
IS 1
BP 28
EP 37
DI 10.1046/j.1365-3156.1997.d01-131.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA WE330
UT WOS:A1997WE33000005
PM 9018300
OA No
DA 2017-08-15
ER

PT J
AU Zinsstag, J
   Ankers, P
   Dempfle, L
   Njie, M
   Kaufmann, J
   Itty, P
   Pfister, K
   Pandey, VS
AF Zinsstag, J
   Ankers, P
   Dempfle, L
   Njie, M
   Kaufmann, J
   Itty, P
   Pfister, K
   Pandey, VS
TI Effect of strategic gastrointestinal nematode control on growth of
   N'Dama cattle in Gambia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE gastrointestinal nematodes; N'Dama cattle; liveweight; strategic
   control; fenbendazole; Gambia; sudano-guinean savannah; West Africa
ID TROPICS
AB From October 1989 to December 1994, a longitudinal study on the control of gastrointestinal nematodes was done on 1000 N'Dama cattle in 20 private herds in Gambia. Each herd was divided into two groups with an even distribution of age and sex, One group received a single anthelmintic treatment of Fenbendazole, Panacur Hoechst Veterinar GmbH, 7.5 mg kg(-1) BW in October 1989, whereas the other group served as an untreated control. In July 1990, the herds were subdivided into two different treatment schemes, In the herds of the first scheme the treated animals (Treatment group I) were treated once (in August), whereas in the herds of the second scheme the treated animals (Treatment group II) were treated twice (in July and September). The same treatment schedule was used in the subsequent rainy seasons until December 1994. One group in every herd served as control (Treatment group 0) and received no anthelmintic treatment throughout the study,
   One annual fenbendazole treatment had no significant effect on liveweights, whereas two annual treatments significantly increased liveweights of the age group 12-24 and 24-36 months by 9.4%, and 17.5%, respectively, Animals less than 12 months old had 6.3% higher liveweights after two treatments, the difference was statistically not significant (P < 0.06). Average weights of 3- and 4-year-old, twice-treated animals were 13.1% and 8.2%, respectively, higher compared with their controls. No effect of anthelminthic treatment on liveweights was found in 5-year-old and older animals. Herd structure analysis demonstrated that overall male offtake rates ranged from 12 to 28% in the 3-, 4- and 5-year-old age categories. The age categories within which deworming improves liveweights thus coincides with the age at which males are mainly sold. These results suggest that biannual metaphylactic treatments (end of July and beginning of September) of all animals from birth to an age of 4 years should be recommended, provided that the financial analysis demonstrates the profitability of this intervention.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   BUNDESAMT VET,CH-3097 LIEBEFELD,SWITZERLAND.
   ETH ZENTRUM,SOL,DEPT AGR ECON,CH-8092 ZURICH,SWITZERLAND.
   UNIV NEUCHATEL,DEPT ZOOL,CH-2000 NEUCHATEL,SWITZERLAND.
   INST TROP MED PRINCE LEOPOLD,B-2000 ANTWERP,BELGIUM.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Ankers P, 1994, Rev Elev Med Vet Pays Trop, V47, P201
   BAIN RK, 1986, OUTLOOK AGR, V15, P10
   Boch J., 1983, VETERINARMEDIZINISCH
   DWINGER RH, 1994, VET PARASITOL, V54, P353, DOI 10.1016/0304-4017(94)90002-7
   FABIYI JP, 1987, INT J PARASITOL, V17, P435, DOI 10.1016/0020-7519(87)90119-6
   Graber M, 1968, Rev Elev Med Vet Pays Trop, V21, P71
   HOLMES PH, 1994, VET PARASITOL, V54, P299, DOI 10.1016/0304-4017(94)90101-5
   HOLMES PH, 1991, T ROY SOC TROP MED H, V85, P163, DOI 10.1016/0035-9203(91)90007-L
   HORCHNER F, 1990, TROP MED PARASITOL, V41, P422
   Itty P, 1992, EC VILLAGE CATTLE PR
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   Leperre P., 1992, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V45, P55
   LITTLE DA, 1991, TROP ANIM HEALTH PRO, V23, P126, DOI 10.1007/BF02361198
   NDAO M, 1995, VET RES COMMUN, V19, P205, DOI 10.1007/BF01839299
   VASSILIADES G, 1978, REV ELEV MED VET PAY, V31, P157
   *WINR INT, 1992, ASS AN AGR SUBS AFR
   Zinsstag J., 1993, Landwirtschaft Schweiz, V6, P583
   ZINSSTAG J, 1994, ACTA TROP, V58, P99, DOI 10.1016/0001-706X(94)90049-3
   ZINSSTAG J, 1994, C BOOK C SOC OUEST A, P77
   ZINSSTAG J, 1992, P 7 INT C I TROP VET, V2, P575
NR 21
TC 14
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 1997
VL 68
IS 1-2
BP 143
EP 153
DI 10.1016/S0304-4017(96)01024-2
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA WL309
UT WOS:A1997WL30900015
PM 9066060
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Ariyoshi, K
   Buckner, M
   Jensen, H
   Berry, N
   Wilkins, A
   Richard, D
   Larsen, O
   Dias, F
   Melbye, M
   Whittle, H
AF Aaby, P
   Ariyoshi, K
   Buckner, M
   Jensen, H
   Berry, N
   Wilkins, A
   Richard, D
   Larsen, O
   Dias, F
   Melbye, M
   Whittle, H
TI Age of wife as a major determinant of male-to-female transmission of
   HIV-2 infection: A community study from rural West Africa
SO AIDS
LA English
DT Article
DE age-related; concordance; couples; female-to-male transmission;
   Guinea-Bissau; HIV-2; proviral load; susceptibility; male-to-female
   transmission
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WOMAN SEXUAL TRANSMISSION; HETEROSEXUAL
   TRANSMISSION; GUINEA-BISSAU; RISK-FACTORS; PARTNERS; COHORT; PREVALENCE;
   MORTALITY; COUPLES
AB Objective: To examine whether proviral load is important for transmission between spouses, since we have previously found that the proviral load of HIV-2 predicts the severity of infection.
   Design: Proviral load was examined in 121 HIV-2-infected adults in a rural area of Guinea-Bissau, For the 68 subjects who had a spouse of known HIV status the risk of the spouse being infected was examined.
   Methods: Statistical methods for dependent data were used, because several couples were polygamous.
   Results: Twenty-seven HIV-2-infected men had 52 current wives of whom 17 (33%) were HIV-2-seropositive. Forty-one HIV-2-infected women had 36 current husbands of known HIV serostatus; nine (25%) were HIV-2-positive. In univariate analyses, concordance of female partners of HIV-2-infected men increased with a previous history of prostitution, age of wire, lack of age difference between the spouses, number of previous husbands, number of wives of the man, and the proviral load. The only significant predictor of concordance in multivariate analyses when wives with a history of prostitution were excluded was an age of 45 years or older [odds ratio (OR), 8.68; 95% confidence interval (CI), 2.34-32.22]. this tendency was not explained by the length of current marriage. Although husbands with a high proviral load were more likely to have concordant spouses than those with a low proviral load (< 20 copies/10(5) CD4 cells), this association was not statistically significant (OR, 2.59; 95% Cl, 0.90-7.46). Among spouses of HIV-2-infected women, none of the examined factors, including previous prostitution or proviral load in the woman, predicted whether the husband was HIV-2-infected.
   Conclusions: Women appear to be more susceptible to HIV-2 infection after 40-45 years of age. The apparent change in susceptibility may be a major reason for the distinctive age pattern of HIV-2 infection observed in West Africa.
C1 MRC, BANJUL, GAMBIA.
   UCL, SCH MED, DIV VIROL, LONDON W1N 8AA, ENGLAND.
   LAB NACL SAUDE PUBL, BISSAU, GUINEA BISSAU.
RP Aaby, P (reprint author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, ARTILLERIVEJ 5, DK-2300 COPENHAGEN S, DENMARK.
CR Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Cohen J, 1996, SCIENCE, V272, P805, DOI 10.1126/science.272.5263.805
   DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601
   DEVINCENZI I, 1992, BRIT MED J, V304, P809
   HOGSBORG M, 1992, SEXUAL BEHAV NETWORK, P203
   LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   NGICHI JM, 1995, AIDS, V9, P951
   NICOLOSI A, 1994, J ACQ IMMUN DEF SYND, V7, P296
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705
   POULSEN AG, 1989, LANCET, V1, P827
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497
   SEIDLIN M, 1993, AIDS, V7, P1247, DOI 10.1097/00002030-199309000-00015
   STUVER SO, 1993, J INFECT DIS, V167, P57
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 20
TC 38
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV
PY 1996
VL 10
IS 13
BP 1585
EP 1590
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA VR234
UT WOS:A1996VR23400019
PM 8931796
OA No
DA 2017-08-15
ER

PT J
AU vanHensbroek, MB
   Palmer, A
   Onyiorah, E
   Schneider, G
   Jaffar, S
   Dolan, G
   Memming, H
   Frenkel, J
   Enwere, G
   Bennett, S
   Kwiatkowski, D
   Greenwood, B
AF vanHensbroek, MB
   Palmer, A
   Onyiorah, E
   Schneider, G
   Jaffar, S
   Dolan, G
   Memming, H
   Frenkel, J
   Enwere, G
   Bennett, S
   Kwiatkowski, D
   Greenwood, B
TI The effect of a monoclonal antibody to tumor necrosis factor on survival
   from childhood cerebral malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; NITRIC-OXIDE; CHILDREN; INDICATORS
AB Tumor necrosis factor (TNF) is thought to play a key role in the pathogenesis of cerebral malaria, A double-blind, placebo-controlled trial of an anti-TNF monoclonal antibody (B-C7) comprised 610 Gambian children with cerebral malaria, with mortality and residual neurologic sequelae as primary study end points, Sixty (19.9%) of 302 children who received B-C7 died compared with 64 (20.8%) of 308 children who received placebo (adjusted odds ratio [OR], 0.90; 95% confidence interval [CI], 0.57-1.42), Residual neurologic sequelae were detected in 15 (6.8%) of 221 survivors from the B-C7 group and in 5 (2.2%) of 225 survivors of the placebo group (adjusted OR, 3.35; 95% CI, 1.08-10.4), The monoclonal antibody used in this study did not improve survival in cerebral malaria and was associated with a significant increase in neurologic sequelae, A possible explanation of the latter observation is that the antibody acts to retain TNF within the circulation and thereby prolongs its effects on vascular endothelium.
C1 ACAD MED CTR,DEPT PEDIAT,NL-1105 AZ AMSTERDAM,NETHERLANDS.
   MRC,FAJARA,GAMBIA.
   ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
   SIBANOR HLTH CTR,SIBANOR,GAMBIA.
   ACAD MED CTR,DEPT TROP MED,AMSTERDAM,NETHERLANDS.
   ACAD MED CTR,DEPT PAEDIAT,AMSTERDAM,NETHERLANDS.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.
   JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.
RP vanHensbroek, MB (reprint author), ACAD MED CTR,DEPT TROP MED F4,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.
CR ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323
   BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0
   CLARK IA, 1991, PARASITOL TODAY, V7, P205, DOI 10.1016/0169-4758(91)90142-B
   DIPARRA G, 1995, J INFECT DIS, V171, P1317
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918
   HERVE P, 1992, BLOOD, V79, P3362
   KREMSNER PG, 1993, IMMUNOLOGY, V78, P286
   KWIATKOWSKI D, 1993, Q J MED, V86, P91
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   KWIATKOWSKI D, 1995, T ROY SOC TROP MED H, V89, P215, DOI 10.1016/0035-9203(95)90501-4
   LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   PETO R, 1978, BIOMEDICINE, V28, P24
   ROCKETT KA, 1991, INFECT IMMUN, V59, P3280
   SUITTERS AJ, 1994, J EXP MED, V179, P849, DOI 10.1084/jem.179.3.849
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   [Anonymous], 1995, LANCET, V345, P669
NR 20
TC 139
Z9 142
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 1996
VL 174
IS 5
BP 1091
EP 1097
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA VN181
UT WOS:A1996VN18100027
PM 8896514
OA No
DA 2017-08-15
ER

PT J
AU Snow, WF
   Wacher, TJ
   Rawlings, P
AF Snow, WF
   Wacher, TJ
   Rawlings, P
TI Observations on the prevalence of trypanosomosis in small ruminants,
   equines and cattle, in relation to tsetse challenge, in The Gambia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE trypanosomosis; goat; sheep; horse; donkey; Glossina spp;
   epidemiology-protozoa; Gambia
ID GLOSSINA-MORSITANS-SUBMORSITANS; TRYPANOTOLERANT CATTLE; NDAMA;
   SUSCEPTIBILITY; CONGOLENSE; INFECTION; DIPTERA; MODEL
AB The prevalence of trypanosome infections in Djallonke sheep and West African Dwarf goals at different sites in The Gambia showed a significant, positive correlation with contemporary assessments of tsetse challenge. A similar correlation was observed in village N'Dama cattle which showed comparable prevalence values in the same areas. Trypanosome prevalences also tended to be higher in horses and donkeys in areas with high tsetse challenge compared with sites with relatively few flies. A ranking of the numbers of tsetse blood-meals from cattle, small ruminants and equines (1:0.06: > 0.03) corresponded with the estimated biomass of these livestock groups (1:0.09:0.05), Observations on the grazing ranges of livestock showed that, while cattle foraged widely into tsetse-infested habitat, sheep, goats and donkeys remained closer to the villages, This difference indicated that, under the management system practised in The Gambia, small ruminants and equines were probably exposed to a lower level of tsetse attack than cattle.
RP Snow, WF (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   CLAUSEN PH, 1989, LIVESTOCK PRODUCTION, P318
   CLAXTON JR, 1992, ACTA TROP, V50, P219, DOI 10.1016/0001-706X(92)90078-C
   DWINGER RH, 1994, VET QUART, V16, P81
   GREENWOOD AC, 1989, SMALL RUMINANT HLTH
   GRIFFIN L, 1979, TROP ANIM HEALTH PRO, V11, P133, DOI 10.1007/BF02237789
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   HENDY CRC, 1988, LIVESTOCK PRODUCTION, P289
   *ILRAD, 1989, 4 ILRAD
   LEAK SGA, 1990, INSECT SCI APPL, V11, P293
   Leak S. G. A., 1988, LIVESTOCK PRODUCTION, P43
   LEAK SGA, 1989, P 20 M ISCTRC MOMB, P523
   LOUM B, 1989, LIV DEV PROJ REP 5 C
   MATTIOLI RC, 1990, UNPUB PRELIMINARY RE
   MILLIGAN PJM, 1988, PARASITOLOGY, V96, P211
   MURRAY M, 1981, VET REC, V109, P503
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   RAWLINGS P, 1992, AFR LIVESTOCK RES, V2, P50
   ROGERS DJ, 1988, PARASITOLOGY, V97, P193
   RURANGIRWA FR, 1986, ACTA TROP, V43, P379
   SNOW WF, 1987, 2 INT TRYP CTR
   STAAK C, 1981, TROPENMED PARASITOL, V32, P97
   Sumberg J., 1992, African Livestock Research, V1, P1
   VALE GA, 1977, B ENTOMOL RES, V67, P635
   WACHER TJ, 1993, ANN TROP MED PARASIT, V87, P517
   WACHER TJ, 1994, PARASITOLOGY, V109, P149
NR 28
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV 1
PY 1996
VL 66
IS 1-2
BP 1
EP 11
DI 10.1016/S0304-4017(96)01003-5
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA VZ276
UT WOS:A1996VZ27600001
PM 8988551
OA No
DA 2017-08-15
ER

PT J
AU Mattioli, RC
   Faye, JA
AF Mattioli, RC
   Faye, JA
TI A comparative study of the parasitological buffy coat technique and an
   antigen enzyme immunoassay for trypanosome diagnosis in sequential
   Trypanosoma congolense infections in N'Dama, Gobra zebu and N'Dama x
   Gobra crossbred cattle
SO ACTA TROPICA
LA English
DT Article
DE Trypanosoma congolense; buffy coat technique; antigen enzyme
   immunoassay; diagnosis; African cattle breeds
ID AFRICAN TRYPANOSOMIASIS; IMMUNE-RESPONSES; T-BRUCEI; SUSCEPTIBILITY;
   VIVAX; ANTIBODIES; CHALLENGE
AB The buffy coat/dark ground techniques (BCT) and an antigen enzyme immunoassay (Ag-ELISA) were compared for the diagnosis of trypanosome infection in N'Dama, Gobra zebu and N'Dama x Gobra (F1) crossbred cattle following two sequential experimental Trypanosoma congolense infections. Both first and second challenge were performed by intradermal needle inoculation of trypanosome bloodstream forms. During the course of the first challenge, the overall trypanosome percentage of positive cases detected by BCT in blood samples was higher (P < 0.001) in comparison with that obtained by Ag-ELISA in tested serum samples of the three cattle breeds, Conversely, in the second infection the overall number of infections detected by BCT was lower in N'Dama (P < 0.005) and F1 (P < 0.001) than that obtained using Ag-ELISA; nearly identical positive rates were detected by the two diagnostic techniques in Gobra zebus. Both in the first and second T congolense challenge, positive rate obtained using BCT significantly decreased as the infection progressed. On the other hand, the positive rate given by Ag-ELISA and its sensitivity manifested a significant opposite trend during the course of the first infection. No relationship between progression of infection and Ag-ELISA positive rate as well as Ag-ELISA. sensitivity was found in the second T. congolense challenge. The Ag-ELISA was less than 50% sensitive in detecting circulating antigens during the first 2 months of the primary infection. However, it showed a high and stable sensitivity throughout the second trypanosome infection, It was concluded that the Ag-ELISA was suitable for use in detecting chronic or repeated infections but needs to be combined with BCT to provide reliable results.
RP Mattioli, RC (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   GUIDOT G, 1982, REV ELEV MED VET PAY, V35, P233
   Jordan A.M., 1986, TRYPANOSOMIASIS CONT, P357
   KASHIWAZAKI Y, 1994, VET PARASITOL, V55, P57, DOI 10.1016/0304-4017(94)90055-8
   MASAKE RA, 1991, J PARASITOL, V77, P231, DOI 10.2307/3283087
   MORE SJ, 1991, TROP MED PARASITOL, V42, P91
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Nantulya V.M., 1990, Revue Scientifique et Technique Office International des Epizooties, V9, P357
   NANTULYA VM, 1984, INFECT IMMUN, V43, P735
   NANTULYA VM, 1987, PARASITE IMMUNOL, V9, P421, DOI 10.1111/j.1365-3024.1987.tb00520.x
   NANTULYA VM, 1989, TROP MED PARASITOL, V40, P267
   PALING RW, 1991, PARASITE IMMUNOL, V13, P427, DOI 10.1111/j.1365-3024.1991.tb00295.x
   PARIS J, 1982, ACTA TROP, V39, P307
   PINDER M, 1988, VET IMMUNOL IMMUNOP, V18, P245, DOI 10.1016/0165-2427(88)90069-4
   PINDER M, 1984, IMMUNOLOGY, V51, P247
   TRAIL JCM, 1992, VET PARASITOL, V42, P213, DOI 10.1016/0304-4017(92)90063-F
   VERY P, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P325
NR 19
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD OCT
PY 1996
VL 62
IS 2
BP 71
EP 81
DI 10.1016/S0001-706X(96)00033-2
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA VY996
UT WOS:A1996VY99600002
PM 8988308
OA No
DA 2017-08-15
ER

PT J
AU Jakobsen, PH
   Theander, TG
   Hviid, L
   MorrisJones, S
   Jensen, JB
   Bayoumi, RAL
   Greenwood, BM
   Bygbjerg, IC
   Heegaard, PMH
AF Jakobsen, PH
   Theander, TG
   Hviid, L
   MorrisJones, S
   Jensen, JB
   Bayoumi, RAL
   Greenwood, BM
   Bygbjerg, IC
   Heegaard, PMH
TI Antibody reactivities to glutamate-rich peptides of Plasmodium
   falciparum parasites in humans from areas of different malaria
   endemicity
SO APMIS
LA English
DT Article
DE malaria; antibodies; glutamate-rich protein; acidic-basic repeat antigen
ID HUMAN MONOCLONAL-ANTIBODY; CLINICAL IMMUNITY; GAMBIAN CHILDREN;
   IMMUNOGLOBULIN-M; SUDAN; ANTIGENS; PROTEIN; INDIVIDUALS; INHIBITION
AB Synthetic P. falciparum peptides were evaluated as tools in epidemiological investigations of malaria. Plasma IgM and IgG antibody reactivities against synthetic peptides covering sequences of glutamate-rich protein (GLURP) and acidic-basic repeat antigen (ABRA) were measured by ELISA in individuals from malaria-endemic areas of Sudan, Indonesia and The Gambia to study antibody responses to these peptides in donors living in areas of different malaria endemicity. IgG and IgM reactivities to the peptides increased with malaria endemicity, although there were no differences in reactivities to the GLURP peptide between non-exposed donors and donors living in areas of low malaria endemicity. IgG reactivities to the GLURP peptide in Sudanese adults were high one month after treatment in all adults tested, while IgG reactivities to the ABRA peptide were infrequent. IgM responses to the peptides tested were shortlived in most patients. In Gambian children with malaria, IgM reactivities but not IgG antibody reactivities against the ABRA peptide were higher in those with mild malaria than in those with severe malaria. The peptides may be useful in future epidemiological studies, especially in areas of low malaria endemicity.
C1 UNIV COPENHAGEN,INST MED MICROBIOL & IMMUNOL,DK-1168 COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   BRIGHAM YOUNG UNIV,DEPT MICROBIOL,PROVO,UT 84602.
   UNIV KHARTOUM,DEPT BIOCHEM,KHARTOUM,SUDAN.
   UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN,DENMARK.
RP Jakobsen, PH (reprint author), UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT INFECT DIS M7722,CTR MED PARASITOL,DEPT CLIN MICROBIOL,DK-2200 COPENHAGEN N,DENMARK.
RI Theander, Thor/F-6714-2015
OI Theander, Thor/0000-0002-3509-7514; Bayoumi, Riad/0000-0001-8177-8129;
   Hviid, Lars/0000-0002-1698-4927
FU NIAID NIH HHS [AI 16312]
CR AHLBORG N, 1991, MOL BIOCHEM PARASIT, V46, P89, DOI 10.1016/0166-6851(91)90202-H
   Atherton E., 1989, SOLID PHASE PEPTIDE
   BAYOUMI RA, 1986, AM J TROP MED HYG, V35, P45
   BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S
   BOUDIN C, 1993, J CLIN MICROBIOL, V31, P636
   DZIEGIEL M, 1993, INFECT IMMUN, V61, P103
   ELHASSAN IM, 1995, AM J TROP MED HYG, V53, P78
   ERUNKULU OA, 1992, CLIN EXP IMMUNOL, V89, P296
   HOGH B, 1992, AM J TROP MED HYG, V46, P307
   JAKOBSEN PH, 1994, CLIN EXP IMMUNOL, V96, P98
   JENSEN JB, 1984, P NATL ACAD SCI-BIOL, V81, P922, DOI 10.1073/pnas.81.3.922
   JENSEN JB, 1983, INFECT IMMUN, V41, P1302
   MATTEI D, 1989, PARASITE IMMUNOL, V11, P15, DOI 10.1111/j.1365-3024.1989.tb00645.x
   STAHL HD, 1986, MOL BIOL MED, V3, P351
   THEANDER TG, 1990, IMMUNOL LETT, V25, P237, DOI 10.1016/0165-2478(90)90121-6
   UDOMSANGPETCH R, 1989, NATURE, V338, P763, DOI 10.1038/338763a0
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
   WEBER JL, 1988, J BIOL CHEM, V26, P11421
NR 18
TC 5
Z9 5
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0903-4641
J9 APMIS
JI APMIS
PD OCT
PY 1996
VL 104
IS 10
BP 734
EP 740
PG 7
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA VX603
UT WOS:A1996VX60300007
PM 8980624
OA No
DA 2017-08-15
ER

PT J
AU Hoare, S
   Poppitt, SD
   Prentice, AM
   Weaver, LT
AF Hoare, S
   Poppitt, SD
   Prentice, AM
   Weaver, LT
TI Dietary supplementation and rapid catch-up growth after acute diarrhoea
   in childhood
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE diarrhoea; growth; children; dietary supplementation
ID YOUNG-CHILDREN; DEVELOPING-COUNTRIES; MALNUTRITION; PROTEIN;
   REQUIREMENTS; PERMEABILITY; MANAGEMENT; PROGRAMS
AB Diarrhoea is a major cause of short-term growth faltering in children of the developing world. If catch-up weight gain is delayed by inadequate dietary intake, or by further bouts of diarrhoea, progressive growth failure occurs. To test the hypothesis that early refeeding is as effective as later feeding after acute diarrhoea with weight loss, we measured the effects of a timed dietary intervention on weight gain after acute diarrhoea in underweight Gambian children, Thirty-four children aged 4-22 months with weight loss following acute diarrhoea were given a high-energy-protein supplement for 14 d beginning either immediately after rehydration or a fortnight later, With a 50 % increase in energy intake and a 100 % increase in protein intake there was a rapid and highly significant (P < 0.001) gain in weight within a fortnight whether the supplement was given immediately or 2 weeks after presentation, Rates of weight increase were similar whether supplementation was provided early or late, but over the full 28 d (of intervention and non-intervention) children who received late supplementation had greater overall weight gain (P < 0.02) than those supplemented early, Vigorous and early feeding with a high-energy-protein supplement should be central to the management of malnourished children with acute diarrhoea in developing countries, and may be as important as control of diarrhoea in preventing malnutrition and growth failure, This may be achieved in the community using locally available foods, in the face of continuing diarrhoea.
C1 MRC,DUNN NUTR GRP,KENEBA,GAMBIA.
   MRC,DUNN NUTR GRP,CAMBRIDGE CB4 1XJ,ENGLAND.
CR ASHWORTH A, 1986, NUTR REV, V44, P157
   BECKER S, 1990, AM J CLIN NUTR, V53, P1499
   Black R E, 1991, Acta Paediatr Scand Suppl, V374, P133
   BRIEND A, 1990, EUR J CLIN NUTR, V44, P611
   BRIEND A, 1989, LANCET, V2, P319
   Brown K H, 1991, Acta Paediatr Scand Suppl, V374, P151
   BROWN KH, 1984, PEDIATRICS, V73, P119
   BROWN KH, 1991, J PEDIATR-US, V118, pS92, DOI 10.1016/S0022-3476(05)81434-9
   CHUNG AW, 1948, J PEDIATR-US, V33, P14, DOI 10.1016/S0022-3476(48)80148-4
   DOWNES RM, 1992, P NUTR SOC, V51, pA78
   FEACHEM RG, 1983, B WORLD HEALTH ORGAN, V61, P967
   FJELD CR, 1989, AM J CLIN NUTR, V50, P1266
   HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607
   HEIKENS GT, 1989, EUR J CLIN NUTR, V43, P145
   HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637
   HOYLE B, 1980, AM J CLIN NUTR, V33, P2365
   HUDSON GJ, 1980, ECOL FOOD NUTR, V10, P9
   JACKSON AA, 1990, P NUTR SOC, V49, P507, DOI 10.1079/PNS19900059
   Scrimshaw NS, 1990, ACTIVITY ENERGY EXPE, P185
   KENNEDY E, 1988, NUTR DEV, P77
   LAMB WH, 1984, LANCET, V1, P912
   LEBENTHAL E, 1989, TXB GASTROENEROLOGY
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   LUTTER CK, 1989, AM J CLIN NUTR, V50, P1
   Molla A., 1983, DIARRHEA MALNUTRITIO, P113
   MOY RJD, 1991, LANCET, V337, P600
   PRENTICE A, 1990, BREASTFEEDING NUTR I, P88
   PRENTICE AM, 1988, LANCET, V2, P1066
   Prentice Andrew, 1986, HUMAN LACTATION, P13
   RIVERA JA, 1991, AM J CLIN NUTR, V54, P62
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   ROWLAND MGM, 1978, EPIDEMIOLOGY PROTEIN, P8
   SCHORLING JB, 1991, LANCET, V337, P599
   SULLIVAN PB, 1991, J PEDIATR GASTR NUTR, V12, P195, DOI 10.1097/00005176-199102000-00010
   SULLIVAN PB, 1992, J PEDIATR GASTR NUTR, V14, P208, DOI 10.1097/00005176-199202000-00016
   TRUSWELL AS, 1983, NUTR ABSTR REV, V53, P960
   Waterlow JC, 1992, PROTEIN ENERGY MALNU
   WEAVER LT, 1991, GUT, V32, P1231
   WHITEHEAD RG, 1977, AM J CLIN NUTR, V30, P1545
   WHO (World Health Organization), 1985, WHO TECHN REP SER, V724
   1991, LANCET, V338, P604
NR 41
TC 19
Z9 19
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT
PY 1996
VL 76
IS 4
BP 479
EP 490
DI 10.1079/BJN19960057
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA VT066
UT WOS:A1996VT06600002
PM 8942357
OA No
DA 2017-08-15
ER

PT J
AU Edmunds, WJ
   Medley, GF
   Nokes, DJ
   OCallaghan, CJ
   Whittle, HC
   Hall, AJ
AF Edmunds, WJ
   Medley, GF
   Nokes, DJ
   OCallaghan, CJ
   Whittle, HC
   Hall, AJ
TI Epidemiological Patterns of hepatitis B virus (HBV) in highly endemic
   areas
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID ASYMPTOMATIC CARRIER MOTHERS; PERINATAL TRANSMISSION; SURFACE-ANTIGEN;
   VERTICAL TRANSMISSION; HEPATOCELLULAR-CARCINOMA; IMMUNE GLOBULIN;
   ETHNIC-GROUPS; CORE ANTIGEN; INFANTS BORN; INFECTION
AB This paper uses meta-analysis of published data and a deterministic mathematical model of hepatitis B virus (HBV) transmission to describe the patterns of HBV infection in high endemicity areas. We describe the association between the prevalence of carriers and a simple measure of the rate of infection, the age at which half the population have been infected (A(50)), and assess the contribution of horizontal and perinatal transmission to this association. We found that the two main hyper-endemic areas of sub-Saharan Africa and east Asia have similar prevalences of carriers and values of A(50), and that there is a negative nonlinear relationship between A(50) and the prevalence of carriers in high endemicity areas (Spearman's Rank, P = 0.0086). We quantified the risk of perinatal transmission and the age-dependent rate of infection to allow a comparison between the main hyper-endemic areas. East Asia was found to have higher prevalences of HBeAg positive mothers and a greater risk of perinatal transmission from HBeAg positive mothers than sub-Saharan Africa, though the differences were not statistically significant. However, the two areas have similar magnitudes and age-dependent rates of horizontal transmission. Results of a simple compartmental model suggest that similar rates of horizontal transmission are sufficient to generate the similar patterns between A(50) and the prevalences of carriers. Interrupting horizontal transmission by mass immunization is expected to have a significant, nonlinear impact on the rate of acquisition of new carriers.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
RP Edmunds, WJ (reprint author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.
RI Medley, Graham/B-7289-2008
OI Medley, Graham/0000-0002-0030-7278
FU Wellcome Trust
CR ALNAKIB B, 1986, ANN TROP PAEDIATR, V6, P239
   ALWARD WLM, 1985, J INFECT DIS, V151, P604
   Anderson R, 1991, INFECT DIS HUMANS
   ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259
   ANDRE FE, 1990, VACCINE, V8, pS74, DOI 10.1016/0264-410X(90)90222-8
   Barin F, 1981, Prog Med Virol, V27, P148
   BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94
   BEASLEY RP, 1983, LANCET, V2, P1099
   BEASLEY RP, 1981, LANCET, V2, P388
   BEASLEY RP, 1981, LANCET, V2, P1129
   BISWAS SC, 1989, T ROY SOC TROP MED H, V83, P698, DOI 10.1016/0035-9203(89)90401-X
   BORTOLOTTI F, 1981, GUT, V22, P499, DOI 10.1136/gut.22.6.499
   BORTOLOTTI F, 1990, GASTROENTEROLOGY, V99, P805
   BOTHA JF, 1984, LANCET, V1, P1210
   BOUTIN JP, 1990, T ROY SOC TROP MED H, V84, P283, DOI 10.1016/0035-9203(90)90288-P
   BOWRY TR, 1983, J INFECT DIS, V148, P1122
   CHEN DS, 1985, J MED VIROL, V16, P309, DOI 10.1002/jmv.1890160402
   CHUNG DC, 1988, J MED VIROL, V26, P411, DOI 10.1002/jmv.1890260408
   COURSAGET P, 1986, LANCET, V2, P1143
   COURSAGET P, 1991, LANCET, V337, P1180, DOI 10.1016/0140-6736(91)92857-X
   COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102
   DEINHARDT F, 1980, J INFECT DIS, V141, P299
   DERSO A, 1978, BRIT MED J, V1, P949
   DEVIRGILIIS S, 1985, ARCH DIS CHILD, V60, P56
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   FERET E, 1987, AM J EPIDEMIOL, V125, P140
   GEBRESELASSIE L, 1983, B WORLD HEALTH ORGAN, V61, P991
   GHENDON Y, 1990, Vaccine, V8, pS129, DOI 10.1016/0264-410X(90)90233-C
   GOUDEAU A, 1983, LANCET, V2, P1103
   GREENFIELD C, 1986, J MED VIROL, V19, P135, DOI 10.1002/jmv.1890190205
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419
   HADLER SC, 1991, VIRAL INFECT HUMANS, P351
   HAUKENES G, 1987, J INFECTION, V15, P183, DOI 10.1016/S0163-4453(87)93249-X
   HU MD, 1983, J INFECT DIS, V147, P360
   HWANG LY, 1985, J MED VIROL, V15, P265, DOI 10.1002/jmv.1890150307
   HYAMS KC, 1988, J MED VIROL, V24, P191, DOI 10.1002/jmv.1890240208
   HYAMS KC, 1989, AM J TROP MED HYG, V40, P200
   IWARSON S, 1971, Scandinavian Journal of Infectious Diseases, V3, P93
   KHASHIWAGI S, 1984, AM J EPIDEMIOL, V120, P617
   LAU YL, 1991, J INFECT DIS, V165, P1111
   LEE AKY, 1978, J INFECT DIS, V138, P668
   LINGAO AL, 1986, AM J EPIDEMIOL, V123, P473
   MARGOLIS HS, 1993, J INFECT DIS, V168, P9
   MARINIER E, 1985, J PEDIATR-US, V106, P843, DOI 10.1016/S0022-3476(85)80371-1
   MAYNARD JE, 1990, VACCINE, V8, pS18, DOI 10.1016/0264-410X(90)90209-5
   MAYNARD JE, 1989, REV INFECT DIS, V11, pS574
   MAZZUR S, 1981, AM J EPIDEMIOL, V113, P510
   MCMAHON BJ, 1985, J INFECT DIS, V151, P599
   MCMAHON BJ, 1992, GASTROENTEROLOGY, V103, P590
   MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051
   MILNE A, 1985, New Zealand Medical Journal, V98, P529
   NAYAK NC, 1987, J MED VIROL, V21, P137, DOI 10.1002/jmv.1890210205
   NIELSEN JO, 1971, NEW ENGL J MED, V285, P1157, DOI 10.1056/NEJM197111182852101
   OKADA K, 1975, J PEDIATR-US, V87, P360, DOI 10.1016/S0022-3476(75)80635-4
   OVERBY LR, 1982, VIRAL HEPATITIS, P169
   PANDA SK, 1988, J MED VIROL, V24, P343, DOI 10.1002/jmv.1890240311
   PANDA SK, 1986, LANCET, V2, P919
   PEARCE N, 1988, NEW ZEAL MED J, V101, P788
   PONGPIPAT D, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P582
   PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814
   PROZESKY OW, 1983, S AFR MED J, V64, P891
   RENIERS J, 1987, J TROP MED HYG, V90, P249
   SCHWEITZER IL, 1973, GASTROENTEROLOGY, V65, P277
   SCHWEITZER IL, 1975, AM J MED SCI, V270, P287, DOI 10.1097/00000441-197509000-00008
   SHIRAKI K, 1980, J PEDIATR-US, V97, P768, DOI 10.1016/S0022-3476(80)80261-7
   SHIRAKI K, 1977, AM J DIS CHILD, V131, P644
   SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621
   Sokal R.R., 1969, BIOMETRY
   STEVENS CE, 1979, J MED VIROL, V3, P237, DOI 10.1002/jmv.1890030310
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   SWENSON PD, 1991, MANUAL CLIN MICROBIO, P959
   TABOR E, 1985, J MED VIROL, V15, P113, DOI 10.1002/jmv.1890150203
   TASSOPOULOS NC, 1987, GASTROENTEROLOGY, V92, P1844
   Tong M J, 1981, Prog Med Virol, V27, P137
   TORRES JR, 1991, REV INFECT DIS, V13, P52
   TOUKAN AU, 1990, AM J EPIDEMIOL, V132, P220
   TSEGA E, 1988, INT J EPIDEMIOL, V17, P874, DOI 10.1093/ije/17.4.874
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WONG VCW, 1984, LANCET, V1, P921
   WONG VCW, 1980, BRIT J OBSTET GYNAEC, V87, P958, DOI 10.1111/j.1471-0528.1980.tb04458.x
NR 81
TC 86
Z9 86
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 1996
VL 117
IS 2
BP 313
EP 325
PG 13
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA VM420
UT WOS:A1996VM42000011
PM 8870629
OA No
DA 2017-08-15
ER

PT J
AU Baker, DA
   Drakeley, CJ
   Ong, CSL
   Lulat, AGMI
   Greenwood, BM
   Targett, GAT
AF Baker, DA
   Drakeley, CJ
   Ong, CSL
   Lulat, AGMI
   Greenwood, BM
   Targett, GAT
TI Humoral immune responses in Gambians to Pfs16, an immunodominant,
   Plasmodium falciparum integral membrane protein
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE P-falciparum gametocyte; sporozoite invasion; Pfs16; humoral immunity
ID MALARIA; TRANSMISSION; ANTIBODIES; SPOROZOITES; ANTIGENS; SURFACE; CELLS
AB Naturally acquired humoral immune responses to Pfs16, an integral membrane protein expressed in Plasmodium falciparum gametocytes and sporozoites, were investigated in The Gambia. A high prevalence of antibodies to this molecule was detected by peptide ELISA. Ninety-three per cent of the people taking part in a survey at the end of the rainy season (November) had serum antibodies to one or more synthetic peptides spanning the sequence, 88% reacted with one particular peptide sequence (IMLIILSGIVGFRVK) whereas only one out of ten non-Gambians (taking anti-malarial prophylaxis with no history of infection) reacted with the peptide. Epitope mapping with mouse MoAbs has shown that this peptide is located on a part of the molecule differing from immunodominant regions of the molecule identified in a previous study in Papua New Guinea.
C1 UNIV BRITISH COLUMBIA,DEPT PATHOL & LAB MED,VANCOUVER,BC V5Z 1M9,CANADA.
   MRC LABS,FAJARA,GAMBIA.
RP Baker, DA (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
OI Baker, David/0000-0002-5490-8933
FU Wellcome Trust
CR BAKER DA, 1994, PARASITOLOGY, V108, P129
   BAKER DA, 1995, MOL BIOCHEM PARASIT, V72, P193, DOI 10.1016/0166-6851(95)00073-A
   BRUCE MC, 1990, NUCLEIC ACIDS RES, V18, P3637, DOI 10.1093/nar/18.12.3637
   EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7
   GRAVES PM, 1991, PARASITE IMMUNOL, V13, P291, DOI 10.1111/j.1365-3024.1991.tb00283.x
   HARTE PG, 1985, IMMUNOLOGY, V56, P1
   KASLOW DC, 1993, CURR OPIN IMMUNOL, V5, P557, DOI 10.1016/0952-7915(93)90037-S
   MOELANS IIMD, 1992, PARASITOL TODAY, V8, P118, DOI 10.1016/0169-4758(92)90278-A
   MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L
   MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V46, P311, DOI 10.1016/0166-6851(91)90056-C
   MOELANS IIMD, 1995, MOL BIOCHEM PARASIT, V72, P179, DOI 10.1016/0166-6851(95)00072-9
   MULLER HM, 1993, EMBO J, V12, P2881
   NUDELMAN S, 1989, J IMMUNOL, V143, P996
   PEIRIS JSM, 1988, AM J TROP MED HYG, V39, P26
   RAWLINGS DJ, 1992, MOL BIOCHEM PARASIT, V56, P239, DOI 10.1016/0166-6851(92)90173-H
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   RODRIGUEZ R, 1990, AM J TROP MED HYG, V43, P339
   Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x
NR 18
TC 6
Z9 6
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD OCT
PY 1996
VL 18
IS 10
BP 527
EP 533
DI 10.1046/j.1365-3024.1996.d01-17.x
PG 7
WC Immunology; Parasitology
SC Immunology; Parasitology
GA VN532
UT WOS:A1996VN53200006
PM 9226690
OA No
DA 2017-08-15
ER

PT J
AU LloydEvans, N
   ODempsey, TJD
   Baldeh, I
   Secka, O
   Demba, E
   Todd, JE
   McArdle, TF
   Banya, WS
   Greenwood, BM
AF LloydEvans, N
   ODempsey, TJD
   Baldeh, I
   Secka, O
   Demba, E
   Todd, JE
   McArdle, TF
   Banya, WS
   Greenwood, BM
TI Nasopharyngeal carriage of pneumococci in Gambian children and in their
   families
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Pneumococcus; nasopharyngeal carriage; Gambian children
ID PAPUA-NEW-GUINEA; UPPER RESPIRATORY-TRACT; STREPTOCOCCUS-PNEUMONIAE;
   DEVELOPING-COUNTRIES; ETIOLOGY; SURVEILLANCE; ACQUISITION; INFECTIONS;
   POPULATION; INFLUENZAE
AB Background. Nasopharyngeal carriage of pneumococci is prevalent among children in developing countries but little is known about the relationship of nasopharyngeal carriage to invasive disease or about the way in which pneumococci spread within households.
   Objectives. To determine the prevalence of nasopharyngeal carriage in healthy and sick. Gambian children and to investigate transmission within households.
   Methods. Nasopharyngeal swabs were obtained by the per nasal route and cultured for pneumococci on selective media. Pneumococci were serotyped with the use of latex particles coated with type-specific antisera.
   Results. Pneumococci mere isolated from the nasopharynx of 73 (90.1%) of 81 children with invasive pneumococcal disease, 86 (76.1%) of 113 healthy, age-matched control children and 911 (85.1%) of 1071 sick children. Pneumococci belonging to serotypes 1, 14 and 12 were isolated significantly more frequently from cases than from matched controls. In 43 (76.8%) of 56 children with invasive disease, pneumococci isolated from the nasopharynx and from the blood or other sterile site belonged to the same serotype. Pneumococci of the same serotype as the bacterium responsible for invasive disease in a child mere obtained from 72 (8.5%) of 843 family members, most frequently from young siblings of the case patient;
   Conclusion. Nasopharyngeal carriage of pneumococci is more prevalent among young Gambian children than among adults and invasive infections are probably acquired more frequently from siblings than from parents. However, further studies are needed to confirm this hypothesis with more discriminating markers than polysaccharide serotyping.
C1 GAMBIA GOVT MED RES COUNCIL UNIT,FAJARA,BANJUL,GAMBIA.
   MRC,FAJARA,BANJUL,GAMBIA.
CR BINGEN EH, 1994, CLIN MICROBIOL REV, V7, P311
   CRAIN MJ, 1990, INFECT IMMUN, V58, P3293
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FREDERIKSEN B, 1988, J TROP PEDIATRICS, V34, P114
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   GRAY BM, 1980, J INFECT DIS, V142, P923
   GREENFIELD S, 1971, J INFECT DIS, V123, P67
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   GWALTNEY JM, 1975, SPREAD STREPTOCOCCUS, V2, P62
   HENDLEY JO, 1975, J INFECT DIS, V132, P55
   HODGES RG, 1946, AM J HYG, V44, P207
   KLEIN JO, 1981, REV INFECT DIS, V3, P246
   LAFONG AC, 1988, J CLIN PATHOL, V41, P230, DOI 10.1136/jcp.41.2.230
   Leowski J, 1986, World Health Stat Q, V39, P138
   LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X
   MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   ODEMPSEY TJD, 1996, PEDIATR INFECT DIS J, P431
   PICKERING H, 1988, T ROY SOC TROP MED H, V82, P911, DOI 10.1016/0035-9203(88)90039-9
   SHANN F, 1984, LANCET, V2, P537
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   VIERING TP, 1989, J INFECT DIS, V160, P76
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   [Anonymous], 1992, LANCET, V339, P396
NR 26
TC 99
Z9 103
U1 1
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1996
VL 15
IS 10
BP 866
EP 871
DI 10.1097/00006454-199610000-00007
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA VL708
UT WOS:A1996VL70800005
PM 8895917
OA No
DA 2017-08-15
ER

PT J
AU Hoestermann, CFL
   Ogbaselassie, G
   Wacker, J
   Bastert, G
AF Hoestermann, CFL
   Ogbaselassie, G
   Wacker, J
   Bastert, G
TI Maternal mortality in the main referral hospital in The Gambia, West
   Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE maternal mortality; causes of death; pre-eclampsia; substandard care
   factors; West Africa
ID CESAREAN-SECTION; PREGNANCY; DETERMINANTS; VILLAGES; TANZANIA; HEALTH;
   GUINEA; LEVEL; RATES
AB A retrospective analysis of 78 maternal deaths was performed during 1991-1992 to estimate maternal mortality at tie maternity unit of the main tertiary level hospital in The Gambia. The non-abortion maternal mortality ratio (MMR) was 736 per 100000 live births. Among the direct causes, haemorrhage caused most deaths (24%), followed by hypertensive disorders in pregnancy (HDP) (21%). Sepsis was the main cause of death in 15%. Anaemia led among rhs indirect causes of death (8%) and was a co-factor in 41% of all deaths. Substandard care factors other than medical causes were determined involving health care facilities, staff, drugs and equipment, and patient-related factors. Well known risk factors of low age (less than or equal to 19 years) and nulliparity were highly represented in the maternal death group, and delivery by Caesarean section occurred more than threefold compared to the overall Caesarean section rats. Taking haemorrhage as an example, it is demonstrated that the way diagnoses are grouped significantly affects the statistical elaboration of maternal deaths.
C1 BETHESDA HOSP,DUISBURG,GERMANY.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
   UNIV HEIDELBERG HOSP,HEIDELBERG,GERMANY.
CR BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   BOERMA JT, 1989, STUD FAMILY PLANN, V20, P245, DOI 10.2307/1966761
   BOERMA T, 1987, SOC SCI MED, V24, P551, DOI 10.1016/0277-9536(87)90345-5
   DEMUYLDER X, 1993, HEALTH POLICY PLANN, V8, P101, DOI 10.1093/heapol/8.2.101
   DEMUYLDER X, 1989, J TROP MED HYG, V92, P89
   DEMUYLDER X, 1990, ARCH GYNECOL OBSTET, V247, P131
   DOH AS, 1989, INT J GYNECOL OBSTET, V30, P317, DOI 10.1016/0020-7292(89)90817-5
   GRAHAM W, 1989, STUD FAMILY PLANN, V20, P125, DOI 10.2307/1966567
   GRAHAM WJ, 1992, SOC SCI MED, V35, P967, DOI 10.1016/0277-9536(92)90236-J
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635
   HARRISON KA, 1985, BRIT J OBSTET GYN  S, V5, P100
   KAMPIKAHO A, 1991, E AFR MED J, V68, P624
   LAMB WH, 1984, LANCET, V2, P912
   MAIER K, 1993, INT J GYNECOL OBSTET, V41, P81, DOI 10.1016/0020-7292(93)90158-S
   NORDBERG EM, 1984, BRIT MED J, V289, P92
   ROBILLARD PY, 1994, LANCET, V344, P973, DOI 10.1016/S0140-6736(94)91638-1
   STOKOE U, 1991, AUST NZ J OBSTET GYN, V31, P8, DOI 10.1111/j.1479-828X.1991.tb02754.x
   THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7
   THONNEAU P, 1992, INT J GYNECOL OBSTET, V39, P87, DOI 10.1016/0020-7292(92)90902-U
   TOURE B, 1992, INT J GYNECOL OBSTET, V37, P89, DOI 10.1016/0020-7292(92)90487-4
   *UN CHILDR FUND, 1992, STAT WORLDS CHILDR 1
   URRIO TF, 1991, E AFR MED J, V68, P81
   VANDENBROEK N, 1989, INT J GYNECOL OBSTET, V28, P337, DOI 10.1016/0020-7292(89)90605-X
   VANROOSMALEN J, 1995, TROP GEOGR MED, V47, P19
   WALRAVEN GEL, 1994, BRIT J OBSTET GYNAEC, V101, P414, DOI 10.1111/j.1471-0528.1994.tb11914.x
   World Health Organization, 1991, MAT MORT GLOB FACTB
   *WHO, 1992, INT STAT CLASS DIS R, P1238
NR 28
TC 29
Z9 29
U1 1
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 1996
VL 1
IS 5
BP 710
EP 717
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VV947
UT WOS:A1996VV94700020
PM 8911458
OA No
DA 2017-08-15
ER

PT J
AU Brown, MA
   Jepson, A
   Young, A
   Whittle, HC
   Greenwood, BM
   Wordsworth, BP
AF Brown, MA
   Jepson, A
   Young, A
   Whittle, HC
   Greenwood, BM
   Wordsworth, BP
TI Spondyloarthritis in the Gambia - Evidence for a non-HLA B27 protective
   effect.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
C1 NUFFIELD ORTHOPAED CTR,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0004-3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD SEP
PY 1996
VL 39
IS 9
SU S
BP 1063
EP 1063
PG 1
WC Rheumatology
SC Rheumatology
GA VH883
UT WOS:A1996VH88301064
OA No
DA 2017-08-15
ER

PT J
AU Holland, MJ
   Bailey, RL
   Conway, DJ
   Culley, F
   Miranpuri, G
   Byrne, GI
   Whittle, HC
   Mabey, DCW
AF Holland, MJ
   Bailey, RL
   Conway, DJ
   Culley, F
   Miranpuri, G
   Byrne, GI
   Whittle, HC
   Mabey, DCW
TI T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells
   (PBMC); Responses to antigens of Chlamydia trachomatis in subjects with
   severe trachomatous scarring
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE cell-mediated immunity; Chlamydia trachomatis; cytokines
ID IMMUNE-RESPONSES; INFECTION; LYMPHOCYTES; CLONES; CYTOKINES; FIBROSIS;
   DISEASE; INVITRO
AB Increased stimulation of Th2 cytokines may contribute to the development of persistent ocular chlamydial infection, resulting in the blinding pathological changes of trachoma. Proliferation and cytokine production profiles of PBMC in response to stimulation with antigens of Chlamydia trachomatis were compared in 30 patients with severe conjunctival scarring due to trachoma and in 30 age-, sex- and location-matched controls. Interferon-gamma (IFN-gamma) and IL-4 were detected at the single-cell level by ELISPOT assay. Transcription of the genes encoding IFN-gamma, IL-4 and IL-10 was detected in mRNA isolated from parallel cultures of PBMC using reverse transcriptase-polymerase chain reaction (RT-PCR). incubation with the chlamydial heat shock protein (hsp)60 resulted in increased numbers of IL-4-producing cells in PBMC isolated from patients with scarring disease and increased secretion of IFN-gamma from PBMC of control subjects. Incubation with the chlamydial major outer membrane protein (MOMP) increased the number of IFN-gamma-producing cells in the control group only. Messenger RNA encoding IL-4 was only detected in PBMC of patients with scarring disease after in vitro stimulation with chlamydial antigens, bur IFN-gamma mRNA and IL-10 mRNA were also more frequently detected in this group. Thirty-eight subjects were HLA-DRB1 and -DQB1 typed. Associations were observed between certain HLA class II alleles and cellular immune responses to chlamydial antigens. No HLA associations were found with clinical status, and overall we found no evidence of strong associations and the type of immune response. These data are consistent with a role for Th2 cells and cytokines in the pathogenesis of trachomatous scarring.
C1 LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1,ENGLAND.
   UNIV WISCONSIN,MED SCI CTR,DEPT MICROBIOL & IMMUNOL,MADISON,WI.
   MRC LABS,BANJUL,GAMBIA.
OI Conway, David/0000-0002-8711-3037
FU NIAID NIH HHS [R01 AI019782]
CR BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Beatty Wandy L., 1994, Trends in Microbiology, V2, P94, DOI 10.1016/0966-842X(94)90542-8
   BEATTY WL, 1993, P NATL ACAD SCI USA, V90, P3998, DOI 10.1073/pnas.90.9.3998
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   BUZONIGATEL D, 1992, IMMUNOLOGY, V77, P284
   CHEEVER AW, 1994, J IMMUNOL, V153, P753
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   FILGUEIRA L, 1993, CELL IMMUNOL, V150, P205, DOI 10.1006/cimm.1993.1190
   GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   IGIETSEME JU, 1994, INFECT IMMUN, V62, P5195
   MABEY DCW, 1991, CLIN EXP IMMUNOL, V86, P37
   MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663
   PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x
   PICKETT MA, 1988, MOL MICROBIOL, V2, P681, DOI 10.1111/j.1365-2958.1988.tb00077.x
   QVIGSTAD E, 1983, SCAND J IMMUNOL, V18, P299, DOI 10.1111/j.1365-3083.1983.tb01801.x
   QVIGSTAD E, 1983, SCAND J IMMUNOL, V18, P291, DOI 10.1111/j.1365-3083.1983.tb01800.x
   QVIGSTAD E, 1983, ACTA PATH MICRO IM C, V91, P203
   RAMSEY KH, 1991, INFECT IMMUN, V59, P925
   SCHACHTER J, 1978, HUMAN CHLAMYDIAL INF, P63
   SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x
   STARNBACH MN, 1994, J IMMUNOL, V153, P5183
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   Tsuji K, 1992, P 11 INT HIST WORKSH
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1615
   WILLIAMS DM, 1984, J INFECT DIS, V149, P630
   WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
   Yang X, 1996, J IMMUNOL, V156, P4338
   ZHONG GM, 1992, INFECT IMMUN, V60, P3143
NR 30
TC 98
Z9 99
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD SEP
PY 1996
VL 105
IS 3
BP 429
EP 435
DI 10.1046/j.1365-2249.1996.d01-792.x
PG 7
WC Immunology
SC Immunology
GA VG771
UT WOS:A1996VG77100006
PM 8809130
OA No
DA 2017-08-15
ER

PT J
AU Conway, DJ
   Holland, MJ
   Campbell, AE
   Bailey, RL
   Krausa, P
   Peeling, RW
   Whittle, HC
   Mabey, DCW
AF Conway, DJ
   Holland, MJ
   Campbell, AE
   Bailey, RL
   Krausa, P
   Peeling, RW
   Whittle, HC
   Mabey, DCW
TI HLA class I and II polymorphisms and trachomatous scarring in a
   Chlamydia trachomatis endemic population
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ECTOPIC PREGNANCY; RESPONSES; ANTIGENS; INFECTION
AB Immune responses to Chlamydia trachomatis contribute to protection from infection and to immunopathologic disease, To test whether subjects' HLA class I (A, B, and Cw) or class II (DR beta 1 and DQ beta 1) types influence risk of trachomatous scarring from chronic infection with C. trachomatis, 153 cases and pair-matched controls in Gambia were studied, No HLA type was associated with protection from scarring, indicating that protective immune responses are not limited to only one or a few HLA-restricted epitopes in C. trachomatis antigens, One class I antigen, HLA-A28, was significantly more common among cases than controls (25.8% vs, 15.9%, respectively; McNemar's odds ratio [OR], 1.88; 95% confidence interval [CI] = 1.01-3.49; P = .046). In DNA subtyping of the A28 specificity, the A*6801 allele was equally common among cases and controls, but the A*6802 allele was significantly overrepresented among cases (McNemar's OR, 3.14; 95% CI = 1.32-7.44; P = .009). This association may be due to an immunopathologic HLA-A*6802-restricted cytotoxic T lymphocyte response.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   INST MOL MED,NUFFIELD DEPT MED,MOL IMMUNOL GRP,OXFORD,ENGLAND.
   LAB CTR DIS CONTROL,BUR MICROBIOL,NATL LAB SEXUALLY TRANSMITTED DIS,WINNIPEG,MB,CANADA.
   MRC,BANJUL,GAMBIA.
OI Conway, David/0000-0002-8711-3037
CR BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BEATTY PR, 1994, J IMMUNOL, V153, P4588
   BRUNHAM RC, 1992, J INFECT DIS, V165, P1076
   CHOW WH, 1987, EPIDEMIOL REV, V9, P70
   Davenport MP, 1996, MOL MED TODAY, V2, P38, DOI 10.1016/1357-4310(96)88757-0
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   KRAUSA P, 1996, TISSUE ANTIGENS, V47, P239
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   McCloskey D. J., 1993, HDB HLA TYPING TECHN, P175
   MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   STARNBACH MN, 1994, J IMMUNOL, V153, P5183
   Tsuji K, 1992, P 11 INT HIST WORKSH
   WAGAR EA, 1990, J INFECT DIS, V162, P922
   ZHONG GM, 1992, INFECT IMMUN, V60, P3143
NR 15
TC 46
Z9 47
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP
PY 1996
VL 174
IS 3
BP 643
EP 646
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA VE493
UT WOS:A1996VE49300031
PM 8769629
OA No
DA 2017-08-15
ER

PT J
AU AbleThomas, U
AF AbleThomas, U
TI Models of renewable energy technology transfer to developing countries
SO RENEWABLE ENERGY
LA English
DT Article; Proceedings Paper
CT World Renewable Energy Congress - Renewable Energy, Energy Efficiency
   and the Environment
CY JUN 15-21, 1996
CL DENVER, CO
AB This paper will discuss the benefits and needs for renewable energy technology transfer to developing countries. It will also assess and discuss the different models or channels of renewable energy technology transfer for successful dissemination in developing countries.
RP AbleThomas, U (reprint author), GAMBIA CIVIL AVIAT AUTHOR,DEPT ENGN,BANJUL INT AIRPORT,POB 285,BANJUL,GAMBIA.
CR ABLETHOMAS R, 1994, WORLD REN EN C READ, V3, P247
   ABLETHOMAS U, 1994, THESIS U NORTHUMBRIA
   ABLETHOMAS U, 1994, P 12 EUR PHOT SOL EN, P2041
   ABLETHOMAS U, 1995, P WORLD SOL EN C KAR
   ILGEN TL, 1987, TRADING TECHNOLOGY
   JOHNSTON A, 1986, NEW TECHNOLOGIES DEV
   OZAWA T, 1985, ASIAN DEV REV, V3
NR 7
TC 6
Z9 6
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD SEP-DEC
PY 1996
VL 9
IS 1-4
BP 1104
EP 1107
DI 10.1016/0960-1481(96)88471-0
PG 4
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA UV259
UT WOS:A1996UV25900120
OA No
DA 2017-08-15
ER

PT J
AU DAlessandro, U
   Langerock, P
   Bennett, S
   Frances, N
   Cham, K
   Greenwood, BM
AF DAlessandro, U
   Langerock, P
   Bennett, S
   Frances, N
   Cham, K
   Greenwood, BM
TI The impact of a national impregnated bed net programme on the outcome of
   pregnancy in primigravidae in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; insecticide-treated bed nets; pregnancy;
   The Gambia
ID MALARIA; PROPHYLAXIS; CHILDREN; CHEMOPROPHYLAXIS; CLASSIFICATION;
   PREVENTION; MORTALITY; DENSITY; AFRICA; GUINEA
AB In 1992, the Gambian national impregnated bed net programme (NIBP) introduced insecticide treatment of bed nets into half of the primary health care villages in The Gambia. One component of the evaluation of this programme was the determination of whether it had any impact on the outcome of pregnancy in primigravidae. From February 1992, 651 primigravidae were recruited into the study. Less than 50% of them used an insecticide-treated bednet. During the rainy season the prevalence of Plasmodium falciparum among primigravidae was lower, fewer babies were classified as premature, and the mean birth weight was higher in villages where treated bed nets were used than in control villages. Therefore, during the rainy season, despite the low use of insecticide-treated bed nets by Gambian primigravidae, the NIBP had some impact on the outcome of pregnancy, particularly on the percentage of premature babies, and this was probably due to the decreased risk of malaria infection achieved during this period.
C1 MRC,BANJUL,GAMBIA.
   INST TROP MED PRINCE LEOPOLD,DEPT PARASITOL,B-2000 ANTWERP,BELGIUM.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND.
   MINIST HLTH & SOCIAL WELFARE,BANJUL,GAMBIA.
RP DAlessandro, U (reprint author), INST TROP MED PRINCE LEOPOLD,DEPT PARASITOL,NATL STR 155,B-2000 ANTWERP,BELGIUM.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   BRABIN B, 1991, RISK SEVERITY MALARI
   BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1
   BRABIN BJ, 1988, T ROY SOC TROP MED H, V82, P677, DOI 10.1016/0035-9203(88)90192-7
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   CHOI HW, 1995, AM J TROP MED HYG, V52, P377
   COT M, 1992, AM J TROP MED HYG, V46, P21
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DAlessandro U, 1995, T ROY SOC TROP MED H, V89, P596, DOI 10.1016/0035-9203(95)90401-8
   DOLAN G, 1993, T ROY SOC TROP MED H, V87, P620, DOI 10.1016/0035-9203(93)90262-O
   FLEMING AF, 1984, ANN TROP MED PARASIT, V78, P395
   FULLERTON WT, 1962, LANCET, V1, P75
   GARNER P, 1994, B WORLD HEALTH ORGAN, V72, P89
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   HAMILTON PJ, 1972, T ROY SOC TROP MED H, V66, P594, DOI 10.1016/0035-9203(72)90305-7
   HERD N, 1981, CENT AFR J MED, V27, P62
   KORTMAN HF, 1972, THESIS U AMSTERDAM U
   MACGREGOR IA, 1987, PARASITOLOGIA, V29, P153
   MACGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MACGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   MORLEY D, 1964, BRIT MED J, V1, P667
   MUTABINGWA TK, 1994, ACTA TROP, V57, P239, DOI 10.1016/0001-706X(94)90070-1
   NOSTEN F, 1994, J INFECT DIS, V169, P595
   OKONOFUA FE, 1992, J TROPICAL MED HYGIE, V9, P309
   PRIMHAK RA, 1989, ANN TROP PAEDIATR, V9, P65
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   TAUFA T, 1978, PAPUA NEW GUINEA MED, V21, P197
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   World Health Organisation, 1984, WHO TECHN REP SER
NR 32
TC 68
Z9 69
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 1996
VL 90
IS 5
BP 487
EP 492
DI 10.1016/S0035-9203(96)90289-8
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VP901
UT WOS:A1996VP90100004
PM 8944251
OA No
DA 2017-08-15
ER

PT J
AU DAlessandro, U
AF DAlessandro, U
TI An efficacy trial of a malaria vaccine in Gambian infants and comparison
   with insecticide-treated bednets
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Article; Proceedings Paper
CT 7th Malaria Meeting of the British-Society-for-Parasitology
CY SEP 18-20, 1995
CL UNIV LONDON, LONDON, ENGLAND
SP Brit Soc Parasitol
HO UNIV LONDON
ID BED NETS; WEST-AFRICA; CHILDREN; MORTALITY; SPF66
AB The SPf66 hybrid malaria vaccine is a polymeric, synthetic protein with amino-acid sequences derived from the pre-erythrocytic and asexual-blood-stage proteins of Plasmodium falciparum. SPf66 has already been found to have a 31% protective efficacy in Tanzanian children aged 1-5 years who lived in an area of intensive malaria transmission. A randomized, double-blind, placebo-controlled trial of SPf66 was carried out in Gambian infants. Overall, 630 children, aged 6-11 months at the time of the first dose, each received three doses of SPf66 or inactivated polio vaccine (IPV). Morbidity was monitored during the following rainy season by means of active and passive case detection. Cross-sectional surveys were carried out at the beginning and at the end of the rainy season. Analysis of efficacy was restricted to 547 of the children (316 receiving SPf66 and 231 IPV). Although the efficacy of SPf66 on the first or only clinical attack was found to be 8% when results were compared with those for the children given the placebo (IPV), the malarial vaccine had no significant effect on fever with any parasitaemia, the overall incidence of clinical attacks, packed-cell volumes, parasite prevalences or spleen rates. Compared with the present vaccine, insecticide-treated bednets appear to offer better prospects for control of malaria in Africa.
C1 MRC LABS,FAJARA,BANJUL,GAMBIA.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ALONSO PL, 1994, LANCET, V344, P1175
   Armstrong Schellenberg J. R. M., 1994, Parasitology Today, V10, P439
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
NR 10
TC 5
Z9 5
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD AUG
PY 1996
VL 90
IS 4
BP 373
EP 378
PG 6
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA VB462
UT WOS:A1996VB46200004
PM 8944081
OA No
DA 2017-08-15
ER

PT J
AU ODempsey, TJD
   McArdle, TF
   Morris, J
   LloydEvans, N
   Baldeh, I
   Laurence, BE
   Secka, O
   Greenwood, BM
AF ODempsey, TJD
   McArdle, TF
   Morris, J
   LloydEvans, N
   Baldeh, I
   Laurence, BE
   Secka, O
   Greenwood, BM
TI A study of risk factors for pneumococcal disease among children in a
   rural area of West Africa
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE pneumococcal disease; children; West Africa
ID VITAMIN-A SUPPLEMENTATION; RESPIRATORY-TRACT INFECTIONS; YOUNG GAMBIAN
   CHILDREN; INDOOR AIR-POLLUTION; STREPTOCOCCUS-PNEUMONIAE;
   HEMOPHILUS-INFLUENZAE; DEVELOPING-COUNTRIES; CHILDHOOD MORTALITY;
   EPIDEMIOLOGY; BACTEREMIA
AB Background. Pneumoccal infection is one of the leading causes of pneumonia, meningitis and septicaemia in developing countries. We have investigated possible risk factors for pneumococcal disease among children living in a rural area of The Gambia.
   Methods. A prospective case-control study was conducted in which children with pneumococcal infection were identified from among children attending out-patient and under-fives clinics and matched according to age with healthy children selected randomly from the local community. A questionnaire was used to investigate possible nutritional, medical, socioeconomic and environmental risk factors for pneumococcal disease.
   Results. An increased risk of pneumococcal disease was associated with poor weight gain, a history of serious illness in the previous 6 months, exposure to cigarette smoke or being carried on mother's back while cooking. The risk of pneumococcal disease was reduced among children whose mothers had a personal source of income.
   Conclusions. The incidence of pneumococcal disease could be reduced by improving nutrition and taking steps to identify and rehabilitate those children whose weight is faltering or falling. Encouraging mothers to develop greater financial independence may also be beneficial. Reduced exposure to smoke should be promoted by improving ventilation in kitchens, introducing more efficient and less polluting stoves, keeping children away from smoky environments and discouraging parental smoking.
C1 MRC,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.
   GAMBIA GOVT,MED RES COUNCIL UNIT,BANJUL,GAMBIA.
CR ANDERSSON B, 1986, J INFECT DIS, V153, P232
   ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424
   BROOME CV, 1980, J INFECT DIS, V141, P119
   BURKE JP, 1971, AM J DIS CHILD, V121, P353
   COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2
   COLLEY JRT, 1974, LANCET, V2, P1031
   DAULAIRE NMP, 1992, BRIT MED J, V304, P207
   DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174
   Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208
   FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447
   GLASZIOU PP, 1993, BRIT MED J, V306, P366
   GREENWOOD BM, 1987, OXFORD TXB MED, P182
   HANSMAN D, 1985, J HYG-CAMBRIDGE, V95, P677
   HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L
   JACOBS NM, 1979, PEDIATRICS, V64, P296
   KLEIN JO, 1981, REV INFECT DIS, V3, P246
   LEEDER S, 1976, BR J PREV SOC MED, V30, P303
   LEPAGE P, 1981, LANCET, V2, P409
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   PANDEY MR, 1989, LANCET, V1, P427
   PAYLINGWRIGHT G, 1945, J HYG CAMB, V44, P15
   PICKERING H, 1988, T ROY SOC TROP MED H, V82, P911, DOI 10.1016/0035-9203(88)90039-9
   RHAMATHULLAH L, 1990, NEW ENGL J MED, V323, P929
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   SOMMER A, 1986, LANCET, V1, P1169
   SOMMER A, 1984, AM J CLIN NUTR, V40, P1090
   SOMMER A, 1983, LANCET, V2, P585
   TUPASI TE, 1990, REV INFECT DIS, V12, pS1047
   VICTORA CG, 1987, LANCET, V2, P319
   VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O
   WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6
NR 31
TC 56
Z9 59
U1 1
U2 8
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 1996
VL 25
IS 4
BP 885
EP 893
DI 10.1093/ije/25.4.885
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA VH220
UT WOS:A1996VH22000027
PM 8921471
OA No
DA 2017-08-15
ER

PT J
AU HassanKing, M
   Baldeh, I
   Adegbola, R
   Omosigho, C
   Usen, SO
   Oparaugo, A
   Greenwood, BM
AF HassanKing, M
   Baldeh, I
   Adegbola, R
   Omosigho, C
   Usen, SO
   Oparaugo, A
   Greenwood, BM
TI Detection of Haemophilus influenzae and Streptococcus pneumoniae DNA in
   blood culture by a single PCR assay
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; GAMBIAN CHILDREN; ETIOLOGY
AB A multiplex PCR assay was developed to screen blood cultures from children in The Gambia with suspected pneumonia for the simultaneous detection of Haemophilus influenzae type b and Streptoccus pneumoniae isolates. Analysis of 295 blood cultures showed that PCR detected the organisms in all samples positive by culture in two samples infected with H. influenzae type b and four samples infected with S. pneumoniae that were culture negative, indicating that this method is sensitive for detecting these organisms in blood cultures.
RP HassanKing, M (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   HASSANKING M, 1994, J CLIN MICROBIOL, V32, P1721
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   RADSTROM P, 1994, J CLIN MICROBIOL, V32, P2738
   SILVERMAN M, 1977, ARCH DIS CHILD, V52, P925
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
NR 8
TC 26
Z9 27
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 1996
VL 34
IS 8
BP 2030
EP 2032
PG 3
WC Microbiology
SC Microbiology
GA UW859
UT WOS:A1996UW85900036
PM 8818907
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Palmer, A
   Jaffar, S
   Mulholland, EK
AF Weber, MW
   Palmer, A
   Jaffar, S
   Mulholland, EK
TI Humidification of oxygen with unheated humidifiers in tropical climates
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE humidification; oxygen therapy; acute respiratory infections; developing
   countries
ID CHILDREN; HYPOXEMIA; INFECTION
AB In developing countries, oxygen therapy in hospitals is frequently humidified with unheated bubble-through humidifiers. We assessed the efficacy of humidification under such circumstances. The water temperature in the humidifier and the ambient air temperature were measured and compared to the oxygen flow rate. It was calculated that oxygen was cooled in the humidifier by 6.12 degrees C (95% CI: 5.88; 6.35) per liter of flow for flow rates up to 2 l/min. Using the average temperatures on the hospital ward in January and August, and the WHO-recommended flow rates of 0.5 l/min and 1 l/min, the relative humidity of the oxygen delivered to a child was estimated to be between 34% and 56%. We conclude that unheated bubble-through humidifiers achieve low humidity in oxygen in tropical climates. Some of the complications associated with the use of nasopharyngeal catheters for the delivery of oxygen might be explained by this, as oxygen of low humidity and temperature is delivered directly into the posterior nasopharynx. (C) 1996 Wiley-Liss, Inc.
C1 HANNOVER MED SCH,CHILDRENS HOSP,D-3000 HANNOVER,GERMANY.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
RP Weber, MW (reprint author), MRC,POB 273,FAJARA,BANJUL,GAMBIA.
CR FOWLE FE, 1934, SMITHSONIAN PHYSICAL
   KLEIN M, 1989, LANCET, V1, P493
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   *SPSS INC, 1992, SPSS BAS SYST US GUI, P520
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   *WHO PROGR CONTR A, 1990, WHOARI905 WHO PROGR
   *WHO PROGR CONTR A, 1993, WHOARI9328 WHO PROGR
NR 7
TC 2
Z9 2
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 8755-6863
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD AUG
PY 1996
VL 22
IS 2
BP 125
EP 128
DI 10.1002/(SICI)1099-0496(199608)22:2<125::AID-PPUL8>3.0.CO;2-P
PG 4
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA VF083
UT WOS:A1996VF08300012
PM 8875587
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
   Adegbola, RA
   Banya, WAS
   Greenwood, BM
AF Obaro, SK
   Adegbola, RA
   Banya, WAS
   Greenwood, BM
TI Carriage of pneumococci after pneumococcal vaccination
SO LANCET
LA English
DT Letter
C1 UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
RP Obaro, SK (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010
NR 1
TC 241
Z9 243
U1 0
U2 5
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 27
PY 1996
VL 348
IS 9022
BP 271
EP 272
DI 10.1016/S0140-6736(05)65585-7
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA UZ286
UT WOS:A1996UZ28600055
PM 8684225
OA No
DA 2017-08-15
ER

PT J
AU vanHensbroek, MB
   Onyiorah, E
   Jaffar, S
   Schneider, G
   Palmer, A
   Frenkel, J
   Enwere, G
   Forck, S
   Nusmeijer, A
   Bennett, S
   Greenwood, B
   Kwiatkowski, D
AF vanHensbroek, MB
   Onyiorah, E
   Jaffar, S
   Schneider, G
   Palmer, A
   Frenkel, J
   Enwere, G
   Forck, S
   Nusmeijer, A
   Bennett, S
   Greenwood, B
   Kwiatkowski, D
TI A trial of artemether or quinine in children with cerebral malaria
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; MALAWIAN CHILDREN; HYPOGLYCEMIA
AB Background Cerebral malaria has a mortality rate of 10 to 30 percent despite treatment with parenteral quinine, a situation that may worsen with the spread of quinine resistance. Artemether is a new antimalarial agent that clears parasites from the circulation more rapidly than quinine, but its effect on mortality is unclear.
   Methods We conducted a randomized, unblinded comparison of intramuscular artemether and intramuscular quinine in 576 Gambian children with cerebral malaria. The primary end points of the study were mortality and residual neurologic sequelae.
   Results Fifty-nine of the 288 children treated with artemether died in the hospital (20.5 percent), as compared with 62 of the 288 treated with quinine (21.5 percent). Among the 418 children analyzed at approximately five months for neurologic disease, residual neurologic sequelae were detected in 7 of 209 survivors treated with artemether (3.3 percent) and 11 of 209 survivors treated with quinine (5.3 percent, P = 0.5). After adjustment for potential confounders, the odds ratio for death was 0.84 (95 percent confidence interval, 0.53 to 1.32) in the artemether group, and for residual neurologic sequelae, 0.51 (95 percent confidence interval, 0.17 to 1.47). There were fewer local reactions at the injection site with artemether than with quinine (0.7 percent vs. 5.9 percent, P = 0.001).
   Conclusions Artemether is as effective as quinine in the treatment of cerebral malaria in children. (C) 1996, Massachusetts Medical Society.
C1 MRC LABS,FAJARA,GAMBIA.
   SIBANOR HLTH CTR,SIBANOR,SENEGAL.
   ROYAL VICTORIA HOSP,DEPT PEDIAT,BANJUL,GAMBIA.
   UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS.
   LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND.
   UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.
RP vanHensbroek, MB (reprint author), UNIV AMSTERDAM,ACAD MED CTR,DEPT TROP MED F4,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.
RI Nusmeier, Anneliese/P-9219-2015
OI Nusmeier, Anneliese/0000-0002-2668-3597
CR Brewer T G, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS33
   HIEN TT, 1993, LANCET, V341, P603
   KWIATKOWSKI D, 1993, Q J MED, V86, P91
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   NOSTEN F, 1993, T ROY SOC TROP MED H, V87, P305, DOI 10.1016/0035-9203(93)90139-H
   PETO R, 1978, BIOMEDICINE, V28, P24
   PUKRITTAYAKAMEE S, 1994, T ROY SOC TROP MED H, V88, P324, DOI 10.1016/0035-9203(94)90102-3
   SALAKO LA, 1994, T ROY SOC TROP MED H, V88, P89, DOI 10.1016/0035-9203(94)90515-0
   TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E
   TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602
   WALLER D, 1990, T ROY SOC TROP MED H, V84, P488, DOI 10.1016/0035-9203(90)90009-4
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
   White N J, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS41
   WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201
   WHITE NJ, 1987, LANCET, V1, P708
   *WHO, 1994, INT C EL LEPR WHO, P21
   [Anonymous], 1995, LANCET, V345, P669
NR 18
TC 196
Z9 197
U1 0
U2 6
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 11
PY 1996
VL 335
IS 2
BP 69
EP 75
DI 10.1056/NEJM199607113350201
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA UW353
UT WOS:A1996UW35300001
PM 8649492
OA No
DA 2017-08-15
ER

PT J
AU Snow, WF
   Norton, GA
   Rawlings, P
AF Snow, WF
   Norton, GA
   Rawlings, P
TI Application of a systems approach to problem analysis of African animal
   trypanosomiasis in the Gambia
SO AGRICULTURAL SYSTEMS
LA English
DT Article
ID NDAMA CATTLE; HOST SUSCEPTIBILITY; CHALLENGE; MODELS; ZEBU
AB The application of systems analysis techniques identified a number of key factors which will determine future developments in the Gambian livestock industry, with especial reference to traditionally managed trypanotolerant, N'dama cattle, and the importance of tsetse and trypanosomiasis. Different components of the analysis repeatedly identified the following key factors: human population growth; declining rainfall; loss of tree cover; trends in land-use including increased areas under cultivation, reduced fallowing and reduced access for grazing; livestock numbers; prices for groundnuts (the main cash crop) and cattle; and indicators of national wealth reflecting cash available to invest in livestock or to purchase livestock products. In many areas tsetse and trypanosomiasis appear to be in decline as a result of habitat destruction but they are likely to persist in others where trypanotolerant animals face a high risk of trypanosomiasis infection and active control may bring significant benefits. Several of the identified trends raise doubts concerning the long-term sustainability of traditional grazing on common land, although improved, intensive management strategies can do much to alleviate these problems. Copyright (C) 1996 Published by Elsevier Science Ltd.
RP Snow, WF (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   AGYEMANG K, 1991, P 21 M INT SCI COUNC, P171
   BAUER B, 1992, TROP MED PARASITOL, V43, P41
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DECOSSE PJ, 1992, UNPUB STRUCTURAL CHA
   DUNSMORE JR, 1976, AGR DEV GAMBIA AGR E
   DWINGER RH, VET QUART, V16, P81
   FALL A, 1992, RAF88100, P27
   GILBERT E, 1990, AGR SYST, V33, P327, DOI 10.1016/0308-521X(90)90059-Y
   HAY RA, 1994, ESTABLISHMENT BASELI
   Itty P, 1992, EC VILLAGE CATTLE PR
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   *LIV SECT REV, 1991, GAM87004 UNDP
   MANN RD, 1975, UNPUB CGAMLRP75
   MULLER A, 1983, 10 DFS FOR INV SERV
   MURRAY M, 1981, VET REC, V109, P503
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   Nash TAM, 1948, TSETSE FLIES BRIT W
   Norton GA, 1993, DECISION TOOLS PEST, P279
   Ormerod W. E., 1986, Land Use Policy, V3, P85, DOI 10.1016/0264-8377(86)90047-5
   *POP HOUS CENS, 1983, STAT SETTL, V4
   RAWLINGS P, 1993, B ENTOMOL RES, V83, P625
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   ROGERS DJ, 1990, INSECT SCI APPL, V11, P331
   SHAW APM, 1987, 672 FOOD AGR ORG UN, V2
   Slingenbergh J., 1992, World Animal Review, V70-71, P30
   Sumberg J., 1992, African Livestock Research, V1, P1
   SUMBERG J, 1988, UNPUB NOTES CATTLE S
   SUMBERG JE, 1992, TROP ANIM HEALTH PRO, V24, P193, DOI 10.1007/BF02356744
   TROLLDALEN JM, 1991, 10 NORAGRIC OCC PAP
   Vale G.A., 1985, Parasitology Today, V1, P106, DOI 10.1016/0169-4758(85)90005-5
NR 33
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0308-521X
J9 AGR SYST
JI Agric. Syst.
PD JUL
PY 1996
VL 51
IS 3
BP 339
EP 356
DI 10.1016/0308-521X(95)00048-A
PG 18
WC Agriculture, Multidisciplinary
SC Agriculture
GA UT376
UT WOS:A1996UT37600005
OA No
DA 2017-08-15
ER

PT J
AU Suara, RO
   Piedra, PA
   Glezen, WP
   Adegbola, RA
   Weber, M
   Mulholland, EK
   Greenwood, BM
   Whittle, H
AF Suara, RO
   Piedra, PA
   Glezen, WP
   Adegbola, RA
   Weber, M
   Mulholland, EK
   Greenwood, BM
   Whittle, H
TI Prevalence of neutralizing antibody to respiratory syncytial virus in
   sera from mothers and newborns residing in the Gambia and in the United
   States
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID MATERNAL ANTIBODY; COTTON RATS; INFECTION; IMMUNITY
AB The prevalence of maternal respiratory syncytial virus (RSV)-neutralizing antibodies has been documented in developed countries, but there is little information from developing countries. We assessed the prevalence of RSV-neutralizing antibody in sera from Gambian women and their newborns and compared them with their American counterparts during a similar period. The geometric mean titers of maternal antibodies to RSV subgroup A in the two populations were similar, while titers of antibodies to RSV subgroup B in Gambian mothers were significantly higher (8.7 +/- 1.4 versus 7.9 +/- 1.3 [mean +/- standard deviation], P < 0.001). The titers of neutralizing antibody in newborns in both populations correlated with the neutralizing-antibody titers of their mothers. Thus, the status of neutralizing antibody to both major RSV subgroups was comparable among infants and mothers in a developing country, The Gambia, and those in a developed country, the United States.
C1 BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030.
   UK MRC LABS,BANJUL,GAMBIA.
FU NIAID NIH HHS [N01 AI-15126]
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   ENGLUND JA, 1994, PEDIATR INFECT DIS J, V13, P449, DOI 10.1097/00006454-199405000-00037
   ENGLUND JA, 1995, J INFECT DIS, V171, P99
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   HUQ F, 1990, REV INFECT DIS, V12, pS982
   LAMPRECHT CL, 1976, J INFECT DIS, V134, P211
   Leowski J, 1986, World Health Stat Q, V39, P138
   MCCORMACK JB, 1980, J CLIN INVEST, V134, P1141
   OGLIVIE MM, 1981, J MED VIROL, V7, P263
   PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3
   PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X
   PIEDRA PA, 1994, 34 INT C ANT AG CHEM, P191
   PRINCE GA, 1985, J VIROL, V55, P517
   SIBER GR, 1994, J INFECT DIS, V169, P1368
   WEBER MJ, UNPUB
NR 20
TC 19
Z9 19
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD JUL
PY 1996
VL 3
IS 4
BP 477
EP 479
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA UV503
UT WOS:A1996UV50300021
PM 8807217
OA No
DA 2017-08-15
ER

PT J
AU Jakobsen, PH
   Mckay, V
   NJie, R
   Olaleye, BO
   DAlessandro, U
   Bendtzen, K
   Schousboe, I
   Greenwood, BM
AF Jakobsen, PH
   Mckay, V
   NJie, R
   Olaleye, BO
   DAlessandro, U
   Bendtzen, K
   Schousboe, I
   Greenwood, BM
TI Soluble products of inflammatory reactions are not induced in children
   with asymptomatic Plasmodium falciparum infections
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE Plasmodium falciparum; malaria; asymptomatic infections; cytokines;
   beta(2)-glycoprotein I
ID TUMOR-NECROSIS-FACTOR; FACTOR INDUCTION; MALARIA; PHOSPHATIDYLINOSITOL;
   EXOANTIGENS; ANTIBODIES
AB A proportion of children with Plasmodium falciparum infection have a high parasitaemia without accompanying fever, indicative of different clinical thresholds of parasitaemia. Higher levels of IL-10, IL-1Ra and sIL-4R but not sIL-2R were found in children with P. falciparum malaria, compared with levels in children with asymptomatic P. falciparum infections and in healthy children. Concentrations of IL-10 and IL-1Ra were correlated with levels of parasitaemia, but the association of cytokine levels with disease was independent of the association with parasitaemia. Children may tolerate a high parasitaemia by neutralizing the parasite-derived toxins. When studying potential anti-toxic molecules we found that children with symptomatic infections had lower concentrations of a phospholipid-binding molecule, beta(2)-glycoprotein I (beta(2)-GPI), compared with children with asymptomatic infections or healthy children. In conclusion, cytokines were found in much higher concentrations in children with symptomatic P. falciparum malaria than in children with asymptomatic infections, whilst the former had lower concentrations of beta(2)-GPI.
C1 UNIV HOSP,RIGSHOSP,DEPT INFECT DIS,CTR MED PARASITOL,RHIMA CTR,DK-2200 COPENHAGEN N,DENMARK.
   UNIV COPENHAGEN,INST MED MICROBIOL & IMMUNOL,COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   UNIV HOSP,RIGSHOSP,INST INFLAMMAT RES,RHIMA CTR,COPENHAGEN,DENMARK.
   UNIV COPENHAGEN,PANUM INST,INST MED BIOCHEM & GENET,DK-2200 COPENHAGEN,DENMARK.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALLAN RJ, 1993, INFECT IMMUN, V61, P4772
   BATE CAW, 1994, INFECT IMMUN, V62, P3086
   BATE CAW, 1992, INFECT IMMUN, V60, P1894
   BATE CAW, 1988, IMMUNOLOGY, V64, P227
   BATE CAW, 1992, IMMUNOLOGY, V76, P35
   FACER CA, 1994, CLIN EXP IMMUNOL, V95, P304
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, PARASITOL TODAY, V7, P277
   JAKOBSEN PH, 1994, INFECT IMMUN, V62, P4374
   JAKOBSEN PH, 1994, CLIN EXP IMMUNOL, V96, P98
   JAKOBSEN PH, 1993, IMMUNOLOGY, V79, P653
   JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   PEYRON F, 1994, CLIN EXP IMMUNOL, V95, P300
   PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25
   SCHOUSBOE I, 1982, J BIOCHEM BIOPH METH, V6, P105, DOI 10.1016/0165-022X(82)90056-2
NR 18
TC 14
Z9 14
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUL
PY 1996
VL 105
IS 1
BP 69
EP 73
DI 10.1046/j.1365-2249.1996.d01-718.x
PG 5
WC Immunology
SC Immunology
GA UU850
UT WOS:A1996UU85000012
PM 8697638
OA No
DA 2017-08-15
ER

PT J
AU Aspray, TJ
   Prentice, A
   Cole, TJ
   Sawo, Y
   Reeve, J
   Francis, RM
AF Aspray, TJ
   Prentice, A
   Cole, TJ
   Sawo, Y
   Reeve, J
   Francis, RM
TI Low bone mineral content is common but osteoporotic fractures are rare
   in elderly rural Gambian women
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
ID RISK-FACTORS; DISTAL FOREARM; UNITED-STATES; HIP FRACTURE; DENSITY;
   PREMENOPAUSAL; CALCIUM; BRITISH; WHITE; SPINE
AB Osteoporosis is reported to be rare in Black Africa. The low fracture incidence among North American black women is explained by a high peak bone mass and preservation of bone mineral into old age, To assess whether this is the case among Black African women, we measured bone mineral content (BMC) and bone mineral density (BMD), using single- and dual-photon absorptiometry, in 195 rural Gambian women aged over 44 years and 391 white women of comparable age from three centers in the U.K. Measurements were made at the midshaft of the radius, distal radius, lumbar spine, and femoral neck The influence of height, weight, and nationality on BMC and BMD was analyzed, BMC and BMD decreased,vith age at all sites, Age, decreasing weight, but not height were independently associated with lower BMC at all sites, BMC in Gambian women was lower than in British women by 31% at the lumbar spine and 16% at the midshaft of the radius, After adjustment for age, height, and weight, BMC among Gambian women remained 24% lower at the lumbar spine and 10% lower at the radius, In women aged over 64 years, BMC at the lumbar spine was 42% lower and BMD was 31% lower in The Gambia (for all comparisons, p < 0.005), We conclude that bone mineral mass is not preserved in elderly Gambian women, However, minimal trauma fractures are rare in this population, These results challenge the concept of BMC as a primary determinant of fracture risk.
C1 MRC,CLIN RES CTR,LONDON,ENGLAND.
   MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
RP Aspray, TJ (reprint author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT GERIATR MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.
RI Reeve, Jonathan/C-7551-2012
OI Reeve, Jonathan/0000-0002-4364-2682; Cole, Tim/0000-0001-5711-8200
CR ADEBAJO AO, 1991, AGE AGEING, V20, P435, DOI 10.1093/ageing/20.6.435
   ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1
   AWBREY B J, 1984, Journal of Orthopaedic Research, V2, P314, DOI 10.1002/jor.1100020402
   BEVIER WC, 1989, J BONE MINER RES, V4, P421
   BLOOM RA, 1982, SKELETAL RADIOL, V8, P56
   BOHR H, 1985, CALCIFIED TISSUE INT, V37, P340, DOI 10.1007/BF02553698
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   DENT CE, 1968, BRIT MED J, V4, P76
   Elffors L, 1994, OSTEOPOROSIS INT, V4, P253
   FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374
   GOLDSMITH NF, 1973, J BONE JOINT SURG AM, VA 55, P1276
   JOHNSON FJ, 1990, OSTEOPOROSIS, P140
   KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477
   KNOBEL J, 1992, S AFR MED J, V82, P185
   LACEY JM, 1991, J BONE MINER RES, V6, P651
   LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247
   MANGAROO J, 1985, BONE, V6, P135, DOI 10.1016/8756-3282(85)90045-6
   MAY H, 1994, AGE AGEING, V23, P235, DOI 10.1093/ageing/23.3.235
   MAZESS RB, 1987, BONE MINER, V2, P211
   MEIER DE, 1991, J CLIN ENDOCR METAB, V72, P703
   MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254
   MELTON LJ, 1993, BONE, V14, pS1
   NORDIN B. E. C., 1966, CLIN ORTHO RELAT RES, V45, P17
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1990, BONE MINER, V10, P211, DOI 10.1016/0169-6009(90)90263-F
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   REEVE J, 1995, CALCIFIED TISSUE INT, V57, P105, DOI 10.1007/BF00298429
   RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462
   SCHAADT O, 1988, CALCIFIED TISSUE INT, V42, P123
   SOLOMON L, 1979, LANCET, V2, P1326
   STEVENSON JC, 1989, BRIT MED J, V298, P924
   TROTTER M, 1960, J BONE JOINT SURG AM, V42, P50
   WHO, 1994, ASS FRACT RISK ITS A, P130
NR 34
TC 77
Z9 77
U1 0
U2 8
PU BLACKWELL SCIENCE INC
PI CAMBRIDGE
PA 238 MAIN ST, CAMBRIDGE, MA 02142
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 1996
VL 11
IS 7
BP 1019
EP 1025
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA UT138
UT WOS:A1996UT13800020
PM 8797124
OA No
DA 2017-08-15
ER

PT J
AU Weber, MW
   Mulholland, EK
AF Weber, MW
   Mulholland, EK
TI Oxygen delivery: Nasopharyngeal catheter or nasal prongs? Reply
SO JOURNAL OF PEDIATRICS
LA English
DT Letter
RP Weber, MW (reprint author), MRC, FAJARA, BANJUL, GAMBIA.
CR CAMPOS JMS, 1994, CLIN PEDIATR, V33, P127
   FAN LL, 1983, J PEDIATR-US, V103, P923, DOI 10.1016/S0022-3476(83)80717-3
   SHANN F, 1988, LANCET, V2, P1238
   *WHO PROGR CONTR A, 1993, OXYG THER AC RESP IN
   WHO Programme for Control of Acute Respiratory Infections, 1990, AC RESP INF CHILDR C
NR 5
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 1996
VL 129
IS 1
BP 186
EP 186
DI 10.1016/S0022-3476(96)70236-6
PG 1
WC Pediatrics
SC Pediatrics
GA UY272
UT WOS:A1996UY27200049
OA No
DA 2017-08-15
ER

PT J
AU Muntendam, AH
   Jaffar, S
   Bleichrodt, N
   vanHensbroek, MB
AF Muntendam, AH
   Jaffar, S
   Bleichrodt, N
   vanHensbroek, MB
TI Absence of neuropsychological sequelae following cerebral malaria in
   Gambian children
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; children; neuropsychological sequelae
ID MORTALITY
AB Cerebral malaria causes major neurological sequelae in a proportion of survivors and may lead to neuropsychological sequelae in children who seem to have made a good recovery. If this is the case, cerebral malaria could have a dramatic impact on the development of thousands of African children. The present study was carried out to provide information on the incidence and type of neuropsychological sequelae in children who survive the disease without major neurological sequelae. A matched case-control study design was used in which 36 pairs of children were assessed. The cases had been treated for cerebral malaria a mean of 3.4 years before testing. No evidence of a serious long-term impact on most assessed neuropsychological functions was found in these children. Only in the balance test did cases perform less well than their matched controls, but the difference between the 2 groups was only of borderline significance. These findings suggest that the long-term impact of cerebral malaria on the development of children who recover without major neurological sequelae is not as serious as had been feared.
C1 MRC,BANJUL,GAMBIA.
   FREE UNIV AMSTERDAM,DEPT IND & ORG PSYCHOL & TEST DEV,AMSTERDAM,NETHERLANDS.
RP Muntendam, AH (reprint author), UNIV AMSTERDAM,ACAD MED CTR,UNIT INFECT DIS & TROP MED F4,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.
CR BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0
   BLEICHRODT N, 1985, REVISIE AMSTERDAMSE
   Boonpucknavig V., 1988, Malaria: principles and practice of malariology. Volume 1., P673
   BORNSTEIN RA, 1993, AIDS, V7, P519, DOI 10.1097/00002030-199304000-00011
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   CARME B, 1993, AM J TROP MED HYG, V48, P216
   CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2
   DAGUE P, 1972, MENTAL TESTS CULTURA, P63
   DRENTH PJD, 1968, AMSTERDAMSE KINDER I
   GIBBS CJ, 1991, NEW ISSUES NEUROSCIE, V10, P93
   GRAU GE, 1994, PARASITOL TODAY, V10, P408, DOI 10.1016/0169-4758(94)90236-4
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HAMERS JHM, 1991, LEERTEST ETNISHE MIN
   Kolb B., 1990, FUNDAMENTALS HUMAN N
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   SPREEN DO, 1984, HUMAN DEV NEUROPSYCH
   STERNBERG RJ, 1990, HDB HUMAN INTELLIGEN, P3
   SUNDBERG ND, 1981, ADV PSYCHOL ASSESS, V5, P460
   WARRELL DA, 1990, T ROYAL SOC TROPI S2, V84
NR 19
TC 31
Z9 34
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 1996
VL 90
IS 4
BP 391
EP 394
DI 10.1016/S0035-9203(96)90518-0
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VF184
UT WOS:A1996VF18400014
PM 8882184
OA No
DA 2017-08-15
ER

PT J
AU Pate, MA
   Adegbola, RA
   Ison, C
   Corrah, T
AF Pate, MA
   Adegbola, RA
   Ison, C
   Corrah, T
TI Neisseria gonorrhoeae endocarditis
SO TROPICAL DOCTOR
LA English
DT Article
RP Pate, MA (reprint author), MRC LABS,BANJUL,GAMBIA.
CR GILSON B J, 1960, U S Armed Forces Med J, V11, P1375
   ISON CA, 1992, GENITOURIN MED, V68, P356
   JONES M, 1950, AM HEART J, V40, P106, DOI 10.1016/0002-8703(50)90154-2
   Spink WW, 1937, J AMER MED ASSOC, V109, P325
NR 4
TC 2
Z9 2
U1 0
U2 0
PU ROYAL SOC MEDICINE SERVICES LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD JUL
PY 1996
VL 26
IS 3
BP 131
EP 131
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VA375
UT WOS:A1996VA37500012
PM 8783959
OA No
DA 2017-08-15
ER

PT J
AU ODempsey, TJD
   McArdle, T
   Ceesay, SJ
   Banya, WAS
   Demba, E
   Secka, O
   Leinonen, M
   Kayhty, H
   Francis, N
   Greenwood, BM
AF ODempsey, TJD
   McArdle, T
   Ceesay, SJ
   Banya, WAS
   Demba, E
   Secka, O
   Leinonen, M
   Kayhty, H
   Francis, N
   Greenwood, BM
TI Immunization with a pneumococcal capsular polysaccharide vaccine during
   pregnancy
SO VACCINE
LA English
DT Article
DE pneumococcal vaccine; pregnancy
ID RESPIRATORY-TRACT INFECTIONS; ANTIBODY-RESPONSE; DEVELOPING-COUNTRIES;
   CONJUGATE VACCINES; PLACENTAL MALARIA; GAMBIAN CHILDREN; ETIOLOGY;
   PNEUMONIA; SUBCLASS; INFANTS
AB The feasibility of preventing invasive pneumococcal infections during the first few months of life by immunization during pregnancy has been investigated. One hundred and fifty Gambian women were immunized with either a 23-valent pneumococcal polysaccharide vaccine or a meningococcal polysaccharide vaccine during the last trimester of pregnancy. Pregnant women showed a good antibody response to five of the six pneumococcal polysaccharides tested (types 1, 3, 5, 6, 14 and 19) but not to type 6 polysaccharide. Mean cord blood/maternal blood IgG antibody ratios varied from 24% (type 1) to 49% (type 3) and differed substantially between individual mother/infant pairs. Pneumococcal antibody levels were higher at birth in infants of women immunized with pneumococcal polysaccharide vaccine than in control infants. However, these antibodies disappeared vapidly during the first few months of life and it is uncertain how much clinical protection against pneumococcal infection maternal immunization would have provided. Copyright (C) 1996 Elsevier Science Ltd.
C1 NATL PUBL HLTH INST,HELSINKI,FINLAND.
   CHARING CROSS & WESTMINSTER HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND.
RP ODempsey, TJD (reprint author), MRC LABS,FAJARA,BANJUL,GAMBIA.
CR BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   DOUGLAS RM, 1983, J INFECT DIS, V148, P131
   EINHORN MS, 1987, J PEDIATR-US, V111, P783, DOI 10.1016/S0022-3476(87)80268-8
   FATTOM A, 1990, INFECT IMMUN, V58, P2309
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   GREENWOOD BM, 1972, LANCET, V1, P169
   JOHNSON PM, 1981, PLACENTA, V2, P355, DOI 10.1016/S0143-4004(81)80031-8
   KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009
   Leowski J, 1986, World Health Stat Q, V39, P138
   MCGREGOR IA, 1962, T R SOC TROP MED HYG, V36, P364
   MULHOLLAND K, IN PRESS J AM MED AS
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   ODempsey TJD, 1996, ARCH DIS CHILD, V74, pF43, DOI 10.1136/fn.74.1.F43
   ODEMPSEY TJD, IN PRESS PEDIAT INFE
   PATON JC, 1991, INFECT IMMUN, V59, P2297
   PEETERS CCAM, 1991, IMMUNOL LETT, V30, P267, DOI 10.1016/0165-2478(91)90036-A
   POMAT WS, 1994, INFECT IMMUN, V62, P1848
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   STEINHOFF MC, 1994, PEDIATR INFECT DIS J, V13, P368, DOI 10.1097/00006454-199405000-00007
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
   VANDERSTRAETEN C, 1986, NEW ENGL J MED, V315, P712
   VINCENTBALLEREAU F, 1985, PATHOL BIOL, V33, P764
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   WILLIAMSON WA, 1978, LANCET, V1, P1328
NR 29
TC 63
Z9 65
U1 0
U2 2
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL
PY 1996
VL 14
IS 10
BP 963
EP 970
DI 10.1016/0264-410X(96)00009-6
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA VD960
UT WOS:A1996VD96000005
PM 8873389
OA No
DA 2017-08-15
ER

PT J
AU Westermark, P
   Sletten, K
   Westermark, GT
   Raynes, J
   McAdam, KPWJ
AF Westermark, P
   Sletten, K
   Westermark, GT
   Raynes, J
   McAdam, KPWJ
TI A protein AA-variant derived from a novel serum AA protein, SAA1 delta,
   in an individual from Papua New Guinea
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID AMINO-ACID-SEQUENCE; AMYLOID FIBRIL PROTEIN; COMPONENT; PATIENT
AB A major protein AA amyloid protein was purified and characterised from a Papua New Guinean individual. This AA protein differed from all previously characterised SAA variants by the combination of Ala52, Val57, Asn60, Phe68, Phe69 and Gly72. Since the prevalence of AA-amyloidosis is unusually high in Papua New Guinea this AAS must originate from a novel SAA delta which may represent a particularly amyloidogenic variant. (C) 1996 Academic Press, Inc.
C1 UNIV OSLO,DEPT BIOCHEM,BIOTECHNOL CTR OSLO,N-0316 OSLO,NORWAY.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   MED RES COUNCIL LABS,FAJARA,GAMBIA.
RP Westermark, P (reprint author), LINKOPING UNIV HOSP,DEPT PATHOL 1,S-58185 LINKOPING,SWEDEN.
RI Raynes, John/G-7932-2011
OI Raynes, John/0000-0002-8536-1328
CR ANDERS RF, 1976, TROP GEOGR MED, V28, P273
   ANDERS RF, 1976, CLIN EXP IMMUNOL, V24, P49
   BABA S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P195, DOI 10.1016/0925-4439(92)90068-X
   BABA S, 1995, HUM MOL GENET, V4, P1083, DOI 10.1093/hmg/4.6.1083
   BEACH CM, 1992, BIOCHEM J, V282, P615
   BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835
   COOKE RA, 1970, MED J AUSTRALIA, V2, P1177
   DWULET FE, 1988, BIOCHEMISTRY-US, V27, P1677, DOI 10.1021/bi00405a044
   Fontana A, 1972, Methods Enzymol, V25, P419, DOI 10.1016/S0076-6879(72)25037-6
   GUSTAVSSON A, 1994, AM J PATHOL, V144, P1301
   HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635
   KLUVEBECKERMAN B, 1988, J CLIN INVEST, V82, P1670, DOI 10.1172/JCI113779
   LEVIN M, 1972, J CLIN INVEST, V51, P2773, DOI 10.1172/JCI107098
   MCADAM KPW, IN PRESS PAPUA NEW G
   MCADAM KPWJ, 1978, PAPUA NEW GUINEA MED, V21, P69
   MEEK RL, 1986, J EXP MED, V163, P499, DOI 10.1084/jem.163.3.499
   MOYNER K, 1980, SCAND J IMMUNOL, V11, P549, DOI 10.1111/j.1365-3083.1980.tb00023.x
   PRAS M, 1968, J CLIN INVEST, V47, P924
   PRELLI F, 1991, SCAND J IMMUNOL, V33, P783, DOI 10.1111/j.1365-3083.1991.tb02553.x
   RAYNES JG, 1991, AMYLOID AND AMYLOIDOSIS 1990, P119
   SHIROO M, 1987, SCAND J IMMUNOL, V26, P709, DOI 10.1111/j.1365-3083.1987.tb02307.x
   SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x
   SYVERSEN PV, 1994, SCAND J IMMUNOL, V39, P88, DOI 10.1111/j.1365-3083.1994.tb03344.x
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   WESTERMARK GT, 1990, AM J PATHOL, V137, P377
   WESTERMARK GT, 1989, SCAND J IMMUNOL, V30, P605, DOI 10.1111/j.1365-3083.1989.tb02468.x
NR 26
TC 14
Z9 16
U1 1
U2 3
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 14
PY 1996
VL 223
IS 2
BP 320
EP 323
DI 10.1006/bbrc.1996.0892
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA UR696
UT WOS:A1996UR69600021
PM 8670280
OA No
DA 2017-08-15
ER

PT J
AU Giadom, B
   DeVeer, GE
   VanHensbroek, MB
   Corrah, PT
   Jaffar, S
   Greenwood, BM
AF Giadom, B
   DeVeer, GE
   VanHensbroek, MB
   Corrah, PT
   Jaffar, S
   Greenwood, BM
TI A comparative study of parenteral chloroquine, quinine and
   pyrimethamine-sulfadoxine in the treatment of Gambian children with
   complicated, non-cerebral malaria
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID FALCIPARUM-MALARIA; TREATMENT POLICY; WEST-AFRICA; RESISTANCE; EFFICACY;
   KENYA; AREA
AB Ninety-two children with complicated, but not cerebral, Plasmodium falciparum malaria, aged 1-9 years, were recruited between August 1992 and December 1994 to an open, randomized trial of parenteral chloroquine (28), pyrimethamine-sulfadoxine (P-S) (36) and quinine (28). The median fever clearance time was shorter for chloroquine (27 hours) than for quinine (42 hours) or for P-S (36 hours) (p = 0.02 and p = 0.06, respectively). The parasite clearance times were similar for chloroquine and P-S, but significantly shorter for chloroquine compared with quinine (54 hours vs 66 hours) (p = 0.007) and for P-S compared with quinine (42 hours vs 66 hours) (p < 0.001). However, three children who received chloroquine and three who received P-S required a change to treatment with quinine because of a clinical failure of their initial treatment. Four children died, one in the chloroquine group, one in the quinine group and two in the P-S group. Despite a high level of chloroquine resistance in the community, the majority of Gambian children with complicated malaria responded satisfactorily to parenteral chloroquine given under supervision. The clinical failure rates of chloroquine and P-S were similar. Parenteral chloroquine and P-S remain adequate treatments for complicated, non-cerebral malaria in Gambian children, provided children can be kept under close clinical observation so as to detect early any treatment failures. Parenteral P-S has the advantage that only one dose is required.
C1 MRC LABS,BANJUL,GAMBIA.
CR BLOLAND PB, 1993, J INFECT DIS, V167, P932
   BRANDLINGBENNETT AD, 1988, T ROY SOC TROP MED H, V82, P833, DOI 10.1016/0035-9203(88)90009-0
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   COOK GC, 1988, LANCET, V1, P32
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   MULLER O, UNPUB RANDOMISED TRI
   NEVILL CG, 1990, LANCET, V336, P185, DOI 10.1016/0140-6736(90)91713-K
   PALUKU KM, 1988, T ROY SOC TROP MED H, V82, P353, DOI 10.1016/0035-9203(88)90113-7
   SALAKO LA, 1990, T ROY SOC TROP MED H, V84, P641, DOI 10.1016/0035-9203(90)90131-W
   SIMAO F, 1991, T ROY SOC TROP MED H, V85, P341, DOI 10.1016/0035-9203(91)90283-5
   VANHENSBROEK B, 1995, IN PRESS T R SOC TRO
   WEBSTER LT, 1985, GOODMAN GILMANS PHAR, P1029
   WHITE NJ, 1989, LANCET, V2, P1313
   1990, T R SOC TROP MED S2, V84, P2
NR 16
TC 1
Z9 1
U1 0
U2 0
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD JUN
PY 1996
VL 16
IS 2
BP 85
EP 91
PG 7
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA UM855
UT WOS:A1996UM85500001
PM 8790670
OA No
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   Mulholland, EK
   Falade, AG
   Secka, O
   SargeNjai, R
   Corrah, T
   Palmer, A
   Schneider, G
   Greenwood, BM
AF Adegbola, RA
   Mulholland, EK
   Falade, AG
   Secka, O
   SargeNjai, R
   Corrah, T
   Palmer, A
   Schneider, G
   Greenwood, BM
TI Haemophilus influenzae type b disease in the western region of the
   Gambia: Background surveillance for a vaccine efficacy trial
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID HEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE; CHILDREN; EPIDEMIOLOGY;
   SUSCEPTIBILITY; PREVALENCE; MENINGITIS; HIB
AB In preparation for a field trial of an Haemophilus influenzas type b conjugate vaccine in the Western Region of The Gambia, a 3-year prospective study was undertaken to determine the incidence of Hib disease and the vaccination status of affected children. One hundred and eighty-two children with invasive Hib disease were found; 141 (77%) had meningitis, 31 (17%) pneumonia and 10 (6%) other forms of invasive disease. The estimated annual incidence rates for all invasive Hib diseases were 274 and 73 per 100 000 in children aged <1 and <5 years, respectively. For meningitis, the rate was 222 per 100 000 per year in children aged <1 year. Children with meningitis were significantly younger than those with pneumonia (median age 7 months, interquartile range [IQR] 5-9, vs 12 months, IQR 6-15 (p = 0.002)) and younger than those with other forms of Hib disease. Of 142 children for whom vaccination status was known, 18 had received no DPT, 36 had received one, 40 had received two and 48 had received three doses. This study confirmed the high incidence of systemic Hib disease among Gambian children and the need to vacciniate at an early age. It provided the background epidemiological data required for the successful planning of an Hib vaccine trial which is now in progress.
C1 MRC LABS,FAJARA,GAMBIA.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   AHONKHAI VI, 1990, PEDIATRICS, V85, P676
   BARBOUR ML, 1995, J INFECT DIS, V171, P93
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   BIJLMER HA, 1994, J ANTIMICROB CHEMOTH, V34, P275, DOI 10.1093/jac/34.2.275
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   CADOZ M, 1981, B WORLD HEALTH ORGAN, V59, P575
   COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2
   COULEHAN JL, 1984, PUBLIC HEALTH REP, V99, P404
   DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4
   ESKOLA J, 1992, J INFECT DIS S1, V165, P137
   GLEZEN WP, 1992, J INFECT DIS, V165, pS134
   GRANOFF DM, 1984, J IMMUNOGENET, V11, P181
   GREENWOOD B, 1992, J INFECT DIS, V165, pS26
   HANSMAN D, 1986, LANCET, V2, P927
   HUSSEY G, 1994, ANN TROP PAEDIATR, V14, P97
   KILIAN M, 1976, J GEN MICROBIOL, V93, P9
   Kohn JL, 1936, AM J DIS CHILD, V51, P1095
   MAKELA PH, 1992, J INFECT DIS, V165, pS2
   MUNSON RS, 1989, REV INFECT DIS, V11, pS588
   MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246
   MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2
   *REP GAMB, 1993, POP HOUS CENS
   SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503
   SANTOSHAM M, 1992, J INFECT DIS S1, V165, P144
   TAKALA AK, 1991, J INFECT DIS, V164, P982
   VADHEIM CM, 1994, DEV CLIN USES HAEMOP, P231
   WARD JI, 1986, J INFECT DIS, V153, P17
   WEINBERG GA, 1990, B WORLD HEALTH ORGAN, V68, P179
   WEINBERG GA, 1989, J INFECT DIS, V160, P634
NR 32
TC 33
Z9 33
U1 0
U2 1
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD JUN
PY 1996
VL 16
IS 2
BP 103
EP 111
PG 9
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA UM855
UT WOS:A1996UM85500004
PM 8790673
OA No
DA 2017-08-15
ER

PT J
AU Taylor, RR
   Egan, A
   McGuinness, D
   Jepson, A
   Adair, R
   Drakely, C
   Riley, E
AF Taylor, RR
   Egan, A
   McGuinness, D
   Jepson, A
   Adair, R
   Drakely, C
   Riley, E
TI Selective recognition of malaria antigens by human serum antibodies is
   not genetically determined but demonstrates some features of clonal
   imprinting
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE antibodies; clonal imprinting; HLA; malaria; non-HLA genes; twins
ID MEROZOITE SURFACE PROTEIN-1; HUMORAL IMMUNE-RESPONSES; BLOOD-STAGE
   ANTIGENS; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; REPETITIVE
   SEQUENCES; HOLOENDEMIC AREA; WEST-AFRICA; HLA-DR; PARASITE
AB Malaria infection induces the production of serum antibodies to a variety of malaria antigens but the prevalence of antibodies to any particular antigen is typically much less than 100%, It has been assumed that non-responsiveness to defined antigens in malaria immune subjects is due to HLA-mediated restriction of the immune response. In this study we have investigated the role of HLA and non-HLA genes in the antibody response to two merozoite surface antigens (MSP1 and MSP2) and a sexual stage antigen (Pfs260/230) of Plasmodium falciparum, and conclude that host genotype is not a major determinant of responsiveness, Although antibody levels vary in accordance with seasonal variations in malaria transmission in semi-immune children, antibody levels remain stable in clinically immune adults, Antigen recognition is selective with individual donors showing consistent high titre responses to some antigens/epitopes whilst consistently failing to recognize adjacent regions/epitopes from the same protein, An alternative explanation, consistent with the data presented here, is that selective antibody responses to malaria antigens in immune individuals result from a process akin to clonal imprinting (original antigenic sin).
C1 UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,ASHWORTH LABS,DIV BIOL SCI,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND.
   MRC LABS,FAJARA,GAMBIA.
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU Wellcome Trust
CR ALYAMAN F, 1994, AM J TROP MED HYG, V51, P593
   ANDERS RF, 1988, PROG ALLERGY, V41, P148
   BJORKMAN A, 1990, PARASITE IMMUNOL, V12, P115, DOI 10.1111/j.1365-3024.1990.tb00941.x
   BJORKMAN A, 1991, PARASITE IMMUNOL, V13, P301, DOI 10.1111/j.1365-3024.1991.tb00284.x
   BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BROWN AE, 1989, TISSUE ANTIGENS, V34, P200, DOI 10.1111/j.1399-0039.1989.tb01737.x
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   CARTER R, 1989, J EXP MED, V169, P135, DOI 10.1084/jem.169.1.135
   CHAPPEL JA, 1993, MOL BIOCHEM PARASIT, V60, P303, DOI 10.1016/0166-6851(93)90141-J
   CHOUGNET C, 1990, AM J TROP MED HYG, V43, P234
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   CONWAY DJ, 1991, PARASITOLOGY, V103, P7
   DELGIUDICE G, 1986, J IMMUNOL, V137, P2952
   DESTGROTH SF, 1966, J EXP MED, V124, P347, DOI 10.1084/jem.124.3.347
   DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331
   DRUILHE P, 1987, INFECT IMMUN, V55, P888
   EGAN AF, 1994, INFECT IMMUN, V63, P456
   FENTON B, 1991, MOL CELL BIOL, V11, P963
   FRANCIS T, 1953, ANN INTERN MED, V39, P203
   GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9
   GOOD MF, 1988, SCIENCE, V242, P574, DOI 10.1126/science.2902690
   GOOD MF, 1993, PARASITE IMMUNOL, V15, P187, DOI 10.1111/j.1365-3024.1993.tb00599.x
   GRAVES PM, 1988, PARASITE IMMUNOL, V10, P209, DOI 10.1111/j.1365-3024.1988.tb00215.x
   GRAVES PM, 1989, CLIN EXP IMMUNOL, V78, P418
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277
   HOFFMAN SL, 1986, NEW ENGL J MED, V315, P601, DOI 10.1056/NEJM198609043151001
   LEW AM, 1989, J IMMUNOL, V142, P4012
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   MATTEI D, 1989, PARASITE IMMUNOL, V11, P15, DOI 10.1111/j.1365-3024.1989.tb00645.x
   MCCUTCHAN TF, 1988, PROG ALLERGY, V41, P173
   OLERUP O, 1991, P NATL ACAD SCI USA, V88, P8480, DOI 10.1073/pnas.88.19.8480
   ONG CSL, 1990, PARASITE IMMUNOL, V12, P447, DOI 10.1111/j.1365-3024.1990.tb00980.x
   PERLMANN H, 1989, IMMUNOL REV, V112, P113
   PERLMANN HK, 1987, J CLIN MICROBIOL, V25, P2347
   PREMAWANSA S, 1994, PARASITE IMMUNOL, V16, P35, DOI 10.1111/j.1365-3024.1994.tb00302.x
   QUAKYI IA, 1989, AM J TROP MED HYG, V41, P125
   READ D, 1994, PARASITE IMMUNOL, V16, P511, DOI 10.1111/j.1365-3024.1994.tb00305.x
   RILEY E, 1992, IMMUNOL TODAY, V13, P333, DOI 10.1016/0167-5699(92)90165-4
   RILEY EM, 1995, PARASITE IMMUNOL, V17, P11, DOI 10.1111/j.1365-3024.1995.tb00961.x
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RILEY EM, 1992, INT IMMUNOL, V4, P1055, DOI 10.1093/intimm/4.9.1055
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1991, T ROY SOC TROP MED H, V85, P436, DOI 10.1016/0035-9203(91)90207-F
   RILEY EM, 1994, PARASITE IMMUNOL, V16, P55
   RILEY EM, 1991, EUR J IMMUNOL, V21, P1019, DOI 10.1002/eji.1830210424
   RILEY EM, 1990, J IMMUNOL, V144, P4810
   SJOBERG K, 1992, P NATL ACAD SCI USA, V89, P2101, DOI 10.1073/pnas.89.6.2101
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
   TROYEBLOMBERG M, 1991, INT IMMUNOL, V3, P1043, DOI 10.1093/intimm/3.10.1043
   VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193
   WALLIKER D, 1994, INT J PARASITOL, V24, P799, DOI 10.1016/0020-7519(94)90006-X
   WANG Z, 1987, ANN HUM GENET, V51, P269
   WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V58, P355, DOI 10.1016/0166-6851(93)90058-6
   WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V62, P125, DOI 10.1016/0166-6851(93)90186-2
   WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.immunol.8.1.737
NR 60
TC 72
Z9 72
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD JUN
PY 1996
VL 8
IS 6
BP 905
EP 915
DI 10.1093/intimm/8.6.905
PG 11
WC Immunology
SC Immunology
GA UU915
UT WOS:A1996UU91500011
PM 8671680
OA No
DA 2017-08-15
ER

PT J
AU Knudsen, KM
   Aaby, P
   Whittle, H
   Rowe, M
   Samb, B
   Simondon, F
   Sterne, J
   Fine, P
AF Knudsen, KM
   Aaby, P
   Whittle, H
   Rowe, M
   Samb, B
   Simondon, F
   Sterne, J
   Fine, P
TI Child mortality following standard, medium or high titre measles
   immunization in West Africa
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE measles; high titre measles vaccines; childhood mortality; sex-specific
   mortality; combined analysis; vaccine safety
ID LONG-TERM SURVIVAL; EDMONSTON-ZAGREB; GUINEA-BISSAU; RURAL SENEGAL;
   TITER; VACCINE; COMMUNITY; EFFICACY; SCHWARZ; INFANTS
AB Background. The World Health Organization (WHO) recommended the use of high titre measles vaccine in 1989. Subsequent long term follow-up of several trials yielded results suggesting higher mortality among children inoculated with medium and high titre vaccines compared to standard titre vaccines, although none of the individual trials found significant differences in mortality.
   Methods. Long term survival after standard, medium and high titre measles Vaccines has been investigated in a combined analysis of all West African trials with mortality data. In trials from Guinea-Bissau, The Gambia and Senegal, children received medium or high titre vaccines from 4 months of age and were compared to control groups recruited at the same time later receiving standard titre vaccine from 9 months of age. All children were followed up to at least 3 years old.
   Results. Combining trials of high titre vaccines showed higher mortality among the high titre group compared to the standard group: mortality ratio (MR) = 1.33 (95% CI : 1.02-1.73). Mortality among recipients of medium titre vaccines was not different from that in the standard vaccine group, MR = 1.11 (95% CI : 0.54-2.27). In a combined analysis by sex, the adjusted mortality ratios comparing high titre vaccine with standard vaccine were 1.86 (95% CI : 1.28-2.70) for females and 0.91 (95% CI : 0.61-1.35) for males. The trials were not designed to study long term mortality. Adjustments for several possible sources of bias did not alter the results.
   Conclusions. The combined analysis showed a decreased survival related to high titre measles vaccine compared with standard titre vaccines, though solely among females. As a result of these studies from West Africa and a study from Haiti, WHO has recommended that high titre measles vaccine no longer be used.
C1 UNIV COPENHAGEN,DEPT BIOSTAT,COPENHAGEN,DENMARK.
   ORSTOM,UR MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
RP Knudsen, KM (reprint author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,5 ARTILLERIVEJ,DK-2300 COPENHAGEN,DENMARK.
CR AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1988, LANCET, V2, P809
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, 1994, EPIDEMIOL INFECT, V112, P413
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   HOLT EA, 1990, PEDIATRICS, V85, P188
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   LEON ME, 1993, J INFECT DIS, V168, P1097
   MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   TIDJANI O, 1989, LANCET, V2, P1357
   WHITTLE H, 1988, LANCET, V2, P811
   WHITTLE HC, 1988, LANCET, V1, P963
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   *WHO, 1991, EPRIRD912
   1990, WHO WEEKLY EPIDEM RE, V65, P6
   1991, WEEKLY EPIDEMIOL REC, V66, P249
   1992, WEEKLY EPIDEMIOL REC, V67, P357
NR 26
TC 58
Z9 58
U1 1
U2 3
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD JUN
PY 1996
VL 25
IS 3
BP 665
EP 673
DI 10.1093/ije/25.3.665
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA VC482
UT WOS:A1996VC48200027
PM 8671571
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, EK
   Hoestermann, A
   Ward, JI
   Maine, N
   Ethevenaux, C
   Greenwood, BM
AF Mulholland, EK
   Hoestermann, A
   Ward, JI
   Maine, N
   Ethevenaux, C
   Greenwood, BM
TI The use of Haemophilus influenzae type b-tetanus toxoid conjugate
   vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian
   infants
SO VACCINE
LA English
DT Article
DE Haemophilus influenzae type b; diphtheria-tetanus-pertussis vaccine;
   combined vaccine
ID MEMBRANE PROTEIN COMPLEX; YOUNG INFANTS; OROPHARYNGEAL CARRIAGE;
   SEROLOGIC RESPONSES; UNITED-STATES; POLYSACCHARIDE; IMMUNOGENICITY;
   CHILDREN; SYRINGE; SAFETY
AB In preparation for an efficacy trial of PRP-T Haemophilus influenzae type b conjugate vaccine, 251 Gambian infants were randomized to receive three doses of PRP-T and diphtheria-tetanus pertussis (DTP) vaccines at 2, 3 and 4 months of age, either by separate injections, or combined in the same syringe. One month after the third dose, there was no difference between antiPRP levels in those infants who received the vaccines separately (GMT 5.83 mu g ml(-1)), and those who received the vaccines combined (GMT 5.57 mu g ml(-1)). The proportions achieving levels of 1.0 mu g ml(-1) were 89% and 92% in the ''separate'' and ''combined'' vaccine groups, respectively. There were no significant differences between groups in levels of antibody to diphtheria or tetanus. Geometric mean titres of antibody directed against pertussis antigens in the ''separate'' and ''combined'' groups were as follows: pertussis toxin 14.2 and 13.1 ELISA units (EU) ml(-1); filamentous haemagglutinin 12.2 and 9.7 EU ml(-1); pertactin 17.2 and 9.0 EU ml(-1) (P<0.05), fumbrial 2/3 antigens 449 and 364 EU ml(-1). The combination of PRP-T and DTP in the syringe prior to administration is safe and immunogenic. The lower levels of anti-pertussis antibody are of unknown clinical significance. Copyright (C) 1996 Elsevier Science Ltd.
C1 UNIV CALIF LOS ANGELES,HARBOR MED CTR,CTR VACCINE RES,TORRANCE,CA 90509.
   GHIS,MRC LABS,BANJUL,GAMBIA.
   CLIN RES,DEPT MED,DIRECT MED,F-69348 LYON 07,FRANCE.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
RP Mulholland, EK (reprint author), WHO,ARI,CDE,CH-1211 GENEVA,SWITZERLAND.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   AVENDANO A, 1993, PEDIATR INFECT DIS J, V12, P638, DOI 10.1097/00006454-199308000-00003
   BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002
   BIJIMER HA, 1990, J INFECT DIS, V161, P1210
   BIJIMER HA, 1994, DEV USES HAEMOPHILUS, P247
   BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004
   BYASS P, 1988, COMPUT BIOL MED, V18, P179, DOI 10.1016/0010-4825(88)90045-5
   CAMPBELL H, 1990, PEDIATRICS, V86, P102
   CLEMENS JD, 1992, JAMA-J AM MED ASSOC, V267, P673, DOI 10.1001/jama.267.5.673
   DAGAN R, 1994, PEDIATR INFECT DIS J, V13, P356, DOI 10.1097/00006454-199405000-00005
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004
   ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201
   FARR RS, 1958, J INFECT DIS, V103, P239
   FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GOLD R, 1994, PEDIATR INFECT DIS J, V13, P348, DOI 10.1097/00006454-199405000-00004
   GREENBERG DP, 1994, J INFECT DIS, V170, P76
   KAPLAN SL, 1992, AM PED SOC SOC PED R
   MULHOLLAND EK, 1993, PEDIATR INFECT DIS J, V12, P632, DOI 10.1097/00006454-199308000-00002
   MULHOLLAND EK, 1993, ANN TROP PAEDIATR, V13, P153
   MULHOLLAND EK, 1994, ANN TROP PAEDIATR, V14, P183
   MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1
   MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2
   PARADISO PR, 1992, JAMA-J AM MED ASSOC, V268, P1685, DOI 10.1001/jama.268.13.1685
   SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503
   SCHEIFELE D, 1993, CAN MED ASSOC J, V149, P1105
   Swan AV, 1969, APPL STAT, V18, P65, DOI 10.2307/2346440
   TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010
   TAKALA AK, 1991, J INFECT DIS, V164, P982
   TALL FR, 1992, MED MALADIES INFECT, V22, P1173, DOI 10.1016/S0399-077X(05)81433-7
   WARD JI, 1988, J CLIN MICROBIOL, V26, P72
   WATEMBERG N, 1991, PEDIATR INFECT DIS J, V10, P758, DOI 10.1097/00006454-199110000-00008
   Wolynetz M. S, 1979, APPL STAT, V28, P185, DOI 10.2307/2346748
NR 34
TC 18
Z9 19
U1 0
U2 0
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN
PY 1996
VL 14
IS 9
BP 905
EP 909
DI 10.1016/0264-410X(95)00260-8
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA VA098
UT WOS:A1996VA09800009
PM 8843633
OA No
DA 2017-08-15
ER

PT J
AU ODempsey, TJD
   McArdle, TF
   LloydEvans, N
   Baldeh, I
   Lawrence, BE
   Secka, O
   Greenwood, B
AF ODempsey, TJD
   McArdle, TF
   LloydEvans, N
   Baldeh, I
   Lawrence, BE
   Secka, O
   Greenwood, B
TI Pneumococcal disease among children in a rural area of West Africa
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pneumococcal disease; pneumococcus; Africa; children
ID RESPIRATORY-TRACT INFECTIONS; DEVELOPING-COUNTRIES; CHARLESTON COUNTY;
   GAMBIAN CHILDREN; SOUTH-CAROLINA; ETIOLOGY; PNEUMONIA; BACTEREMIA;
   INFANTS; EPIDEMIOLOGY
AB Background, The pneumococcus is a frequent cause of pneumonia and other serious infections among young children in developing countries, Defining the pattern of pneumococcal infection in these countries is important so that, with the advent of pneumococcal conjugate vaccines, rational vaccination policies can be developed,
   Methods, Children younger than 5 years of age who attended clinics in a rural area of The Gambia, West Africa, were screened by assistants during a a-year period, Children with predefined features suggestive of a diagnosis of pneumonia, meningitis or septicemia were referred to the Medical Research Council Field Station at Basse for investigation,
   Results, Of 2898 children investigated 103 cases of invasive pneumococcal disease (70 definite and 33 probable) were identified, suggesting that the incidence of this infection in the study community is at least 554/100 000/year in children younger than 1 year of age and 240/100 000/year in those younger than 5 years, rates many times higher than those found in industrialized societies, The mean age of presentation was 15 months; more boys than girls were affected, Cases of pneumonia were encountered 8 times more frequently than those of meningitis, Antibiotic resistance was rarely found and cases of pneumonia, but not meningitis, responded well to treatment, Case-fatality rates in children with pneumonia and meningitis were 1 and 55%, respectively, The most prevalent pneumococcal serotypes were types 6, 14, 19, 1 and 5,
   Conclusion, About 60% of invasive pneumococcal infection in children in this community could potentially be prevented by a nine-valent pneumococcal conjugate vaccine (types 1, 4, 5, 6B, 9, 14, 18, 19F and 23) given at the ages of 2, 3 and 4 months.
C1 MRC LABS,BANJUL,GAMBIA.
   GAMBIA GOVT,MRC UNIT,BANJUL,GAMBIA.
CR ANDREASSON PA, 1993, AIDS, V7, P989
   BAIRD DR, 1976, LANCET, V2, P1344
   BIJLMER HA, 1990, J INFECT DIS, V161, P1201
   BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401
   BURMAN LA, 1985, REV INFECT DIS, V7, P133
   CONNOR EB, 1971, MEDICINE, V50, P97
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277
   DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328
   DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715
   DAVIDSON M, 1994, J INFECT DIS, V170, P368
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DEFRANCISCO A, 1994, J TROP MED HYG, V97, P69
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   ESKILA J, 1992, JAMA-J AM MED ASSOC, V268, P3323
   FILICE GA, 1980, AM J EPIDEMIOL, V112, P828
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004
   GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009
   Greenwood BM, 1987, BACTERIAL MENINGITIS, P61
   HASSANKING M, 1994, J CLIN MICROBIOL, V32, P1721
   ISTRE GR, 1987, J INFECT DIS, V156, P732
   JACOBS NM, 1979, PEDIATRICS, V64, P296
   KLEIN JO, 1981, REV INFECT DIS, V3, P246
   Leowski J, 1986, World Health Stat Q, V39, P138
   MAR ID, 1979, PATHOL BIOL, V27, P543
   MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   ONEILL KP, 1989, BRIT MED J, V298, P1061
   RUDOLPH KM, 1993, J CLIN MICROBIOL, V31, P2661
   SHANN F, 1984, LANCET, V2, P537
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   STEINHOFF MC, 1993, LANCET, V342, P630, DOI 10.1016/0140-6736(93)91754-A
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   WILKINS HA, 1991, AIDS, V5, P1127
NR 36
TC 93
Z9 96
U1 0
U2 4
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY
PY 1996
VL 15
IS 5
BP 431
EP 437
DI 10.1097/00006454-199605000-00010
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA UK327
UT WOS:A1996UK32700009
PM 8724066
OA No
DA 2017-08-15
ER

PT J
AU Bethell, DB
   Phuong, PT
   Phuong, CXT
   Nosten, F
   Waller, D
   Davis, TME
   Day, NPJ
   Crawley, J
   Brewster, D
   Pukrittayakamee, S
   White, NJ
AF Bethell, DB
   Phuong, PT
   Phuong, CXT
   Nosten, F
   Waller, D
   Davis, TME
   Day, NPJ
   Crawley, J
   Brewster, D
   Pukrittayakamee, S
   White, NJ
TI Electrocardiographic monitoring in severe falciparum malaria
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; electrocardiography
ID CHLOROQUINE; TOXICITY; CHILDREN
AB Electrocardiographic monitoring over 24 h was performed with 53 patients with severe Plasmodium falciparum malaria (11 adults and 42 children) to assess the frequency of unrecognized cardiac arrhythmias. Nine patients (17%) died, 5 during the monitoring period and 4 afterwards. Pauses lasting 2-3 s were observed in 3 children, a single coupler in one, and a further child experienced frequent supraventricular ectopic beats which had nor been detected clinically. In none of the patients who died could death be attributed to cardiac arrhythmia. Furthermore, no abnormality was detected which could have resulted from the often large doses of quinine, chloroquine or the artemisinin derivatives used for treatment. These results suggest that the heart is remarkably resilient even in the face of heavy parasite sequestration and other viral organ dysfunction, and that deaths from cardiac arrhythmias in severe malaria are rare. The need for routine cardiac monitoring of patients with severe and complicated P. falciparum malaria is questionable.
C1 CHO QUAN HOSP, CTR TROP DIS, HO CHI MINH CITY, VIETNAM.
   SHOKLO MALARIA RES UNIT, MAE SOT, THAILAND.
   DONG NAI PAEDIAT CTR, BIEN HOA, VIETNAM.
   ROYAL VICTORIA HOSP, BANJUL, GAMBIA.
   MRC, FAJARA, GAMBIA.
   MAHIDOL UNIV, FAC TROP MED, BANGKOK, THAILAND.
RP Bethell, DB (reprint author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, CTR TROP MED, LEVEL 7, OXFORD OX3 9DU, ENGLAND.
RI White, Nicholas/I-4629-2012; Davis, Timothy/M-5144-2014
OI Davis, Timothy/0000-0003-0749-7411; Nosten, Francois/0000-0002-7951-0745
FU Wellcome Trust
CR BREWER TG, 1994, AM J TROP MED HYG, V51, P251
   BREWER TG, 1994, T ROYAL SOC TROP MED, V88
   BUTLER T, 1973, AM J TROP MED HYG, V22, P439
   BYGBJERG IC, 1982, T ROY SOC TROP MED H, V76, P705, DOI 10.1016/0035-9203(82)90251-6
   Dudgeon LS, 1918, Q J MED, V12, P372
   Gaskell JF, 1920, Q J MED, V13, P381
   JAMES MFM, 1985, ANN TROP MED PARASIT, V79, P123
   LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31
   MACPHERSON GG, 1985, AM J PATHOL, V119, P19
   NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M
   Sharma S N, 1987, J Assoc Physicians India, V35, P251
   SPRAGUE HB, 1946, AM HEART J, V31, P426, DOI 10.1016/0002-8703(46)90424-3
   SUPANARANOND W, 1993, EUR J CLIN PHARMACOL, V44, P325, DOI 10.1007/BF00316467
   WHITE NJ, 1992, ADV PARASIT, V31, P83
   WHITE NJ, 1988, NEW ENGL J MED, V319, P1493, DOI 10.1056/NEJM198812083192301
   WHITE NJ, 1983, J CARDIOVASC PHARM, V5, P173, DOI 10.1097/00005344-198303000-00001
   WHITE NJ, 1989, LANCET, V2, P1313
   *WHO, 1990, T ROYAL SOC TROP M S, V84
NR 18
TC 34
Z9 34
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1996
VL 90
IS 3
BP 266
EP 269
DI 10.1016/S0035-9203(96)90241-2
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UT794
UT WOS:A1996UT79400020
PM 8758072
OA No
DA 2017-08-15
ER

PT J
AU McGuire, W
   Hill, AVS
   Greenwood, BM
   Kwiatkowski, D
AF McGuire, W
   Hill, AVS
   Greenwood, BM
   Kwiatkowski, D
TI Circulating ICAM-1 levels in falciparum malaria are high but unrelated
   to disease severity
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; intercellular adhesion molecule 1;
   tumour necrosis factor; interleukin 1
ID INTERCELLULAR-ADHESION MOLECULE-1; HUMAN CEREBRAL MALARIA;
   PLASMODIUM-FALCIPARUM; E-SELECTIN; SEQUESTRATION; DISTINCT; GAMMA;
   CELLS; SITE
AB Intercellular adhesion molecule 1 (ICAM-1) mediates the binding of Plasmodium falciparum to vascular endothelium. In a case-control study of falciparum malaria in Gambian children, we have looked for evidence that a generalized increase in expression of ICAM-1 is associated with cerebral malaria. Plasma levels of circulating ICAM-1 (cICAM-1) were significantly higher in 246 children with acute malaria than in 156 children with non-malarial illnesses. cICAM-1 levels correlated with levels of tumour necrosis factor (TNF), interleukin 1 alpha (IL-1 alpha) and interferon gamma, supporting the view that these cytokines are responsible for a general upregulation of ICAM-1 expression in malaria. However, while it has been previously shown that TNF and IL-1 alpha levels were related to disease severity, this was not the case for cICAM-1. It may be that differences in the distribution of ICAM-1, rather than its total level of expression, are critical in determining the clinical outcome in malaria.
C1 JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.
   JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
RI HILL, Adrian/C-1306-2008
CR BECKER JC, 1991, J IMMUNOL, V147, P4398
   BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0
   BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S
   BERENDT AR, 1990, PARASITOL TODAY, V6, P247, DOI 10.1016/0169-4758(90)90184-6
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   DELORON P, 1994, CLIN INFECT DIS, V19, P480
   DUSTIN ML, 1986, J IMMUNOL, V137, P245
   GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O
   GRANINGER W, 1994, J CLIN PATHOL, V47, P653, DOI 10.1136/jcp.47.7.653
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   HVIID L, 1993, IMMUNOL LETT, V36, P51, DOI 10.1016/0165-2478(93)90068-D
   JAKOBSEN PH, 1994, IMMUNOLOGY, V83, P665
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R
   ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0
   TURNER GDH, 1994, AM J PATHOL, V145, P1057
NR 20
TC 18
Z9 18
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1996
VL 90
IS 3
BP 274
EP 276
DI 10.1016/S0035-9203(96)90244-8
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UT794
UT WOS:A1996UT79400022
PM 8758074
OA No
DA 2017-08-15
ER

PT J
AU Onyiorah, E
   vanHensbroek, MB
   Jah, MS
   Greenwood, B
AF Onyiorah, E
   vanHensbroek, MB
   Jah, MS
   Greenwood, B
TI Early clinical failures after pyrimethamine-sulfadoxine treatment of
   uncomplicated falciparum malaria
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; pyrimethamine-sulfadoxine; treatment
   failure; The Gambia
ID THERAPY; AFRICA
C1 UNIV AMSTERDAM,ACAD MED CTR,DEPT TROP MED,1105 AZ AMSTERDAM,NETHERLANDS.
   MRC LABS,FAJARA,GAMBIA.
   MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA.
   LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1,ENGLAND.
CR BLOLAND PB, 1993, J INFECT DIS, V167, P932
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   KWIATKOWSKI D, 1995, T ROY SOC TROP MED H, V89, P215, DOI 10.1016/0035-9203(95)90501-4
   PINICHPONGSE S, 1982, B WORLD HEALTH ORGAN, V60, P907
   Boele van Hensbroek M, 1995, T ROY SOC TROP MED H, V89, P672
   WATKINS WM, 1993, AM J TROP MED HYG, V49, P106
NR 6
TC 19
Z9 19
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1996
VL 90
IS 3
BP 307
EP 308
DI 10.1016/S0035-9203(96)90265-5
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UT794
UT WOS:A1996UT79400035
PM 8758087
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Samb, B
   Simondon, F
   Knudsen, K
   Seck, AMC
   Bennett, J
   Markowitz, L
   Whittle, H
AF Aaby, P
   Samb, B
   Simondon, F
   Knudsen, K
   Seck, AMC
   Bennett, J
   Markowitz, L
   Whittle, H
TI A comparison of vaccine efficacy and mortality during routine use of
   high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in
   rural Senegal
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE measles; vaccines; Edmonston-Zagreb; Schwarz standard; Senegal
ID TITER; IMMUNIZATION; CHILDREN; AGE
AB Vaccine efficacy and mortality in successive cohorts of children who routinely received either Edmonston-Zagreb high-titre (EZ-HT) or Schwarz standard (SW-STD) measles vaccines have been examined in a rural area of Senegal. The 2 vaccines were equally protective against measles infection (vaccination efficacy: EZ-HT 94%; SW-STD 93%). Children who did not attend a scheduled session to receive measles vaccine had a higher mortality rate between 9 months and 2 years of age than did children receiving either EZ-HT (mortality ratio [MR] = 1.81, 95% confidence interval [CI] 1.06-3.08) or SW-STD measles vaccine (MR=1.74, 95% CI 0.95-3.21). Children of either sex vaccinated with EZ-HT had lower mortality than their equivalents who had not received any measles vaccine. There was no difference in overall mortality between recipients of EZ-HT and SW-STD (MR=0.96, 95% CI 0.70-1.30). Using a Cox regression analysis to adjust for sex, age and significant background factors (season and death of mother), mortality rates tended to be lower for male recipients of EZ-HT than for boys receiving SW-STD (MR=0.73, 95% CI 0.50-1.11) and higher for girls receiving EZ-HT than for girls receiving SW-STD (MR=1.30, 95% CI 0.81-2.09) (rest of interaction between sex and vaccine, P=0.067). The tendency to reduced survival benefit for girls following receipt of high-titre measles vaccines substantiated observations from randomized trials in Guinea-Bissau, Senegal, and Haiti. Existing data provide little support for the notion that high-titre vaccine is deleterious bur it may not have the same beneficial effects as standard-titre measles vaccine.
C1 ORSTOM,UR MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
   CTR DIS CONTROL,ATLANTA,GA 30333.
   MRC LABS,BANJUL,GAMBIA.
RP Aaby, P (reprint author), STATENS SERUM INST,EPIDEMIOL RES UNIT,DANISH EPIDEMIOL SCI CTR,ARTILLERIVEJ 5,DK-2300 COPENHAGEN S,DENMARK.
CR AABY P, 1993, BRIT MED J, V307, P1308
   AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1995, BRIT MED J, V311, P481
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, IN PRESS VACCINE
   COX DR, 1972, J R STAT SOC B, V34, P187
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M, 1994, LANCET, V334, P261
   GARENNE M., 1987, RISQUES DECES ASSOCI
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   LEON ME, 1993, J INFECT DIS, V168, P1097
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   SAMB B, 1995, J INFECT DIS, V171, P506
   TIDJANI O, 1989, LANCET, V2, P1357
   WHITTLE H, 1988, LANCET, V2, P811
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   1990, WEEKLY EPIDEMIOLOGIC, V65, P5
   1992, WEEKLY EPIDEMIOLOGIC, V67, P357
NR 26
TC 17
Z9 17
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1996
VL 90
IS 3
BP 326
EP 330
DI 10.1016/S0035-9203(96)90275-8
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UT794
UT WOS:A1996UT79400044
PM 8758096
OA No
DA 2017-08-15
ER

PT J
AU Conway, DJ
   Holland, MJ
   Bailey, RL
   Mahdi, S
   Mabey, DCW
AF Conway, DJ
   Holland, MJ
   Bailey, RL
   Mahdi, S
   Mabey, DCW
TI Scarring trachoma is associated with polymorphism in the TNF-alpha gene
   promoter and with elevated TNF-alpha in tear fluid
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR 30
PY 1996
VL 10
IS 6
BP 1075
EP 1075
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA UK861
UT WOS:A1996UK86101304
OA No
DA 2017-08-15
ER

PT J
AU Mulholland, K
   Suara, RO
   Siber, G
   Roberton, D
   Jaffar, S
   NJie, J
   Baden, L
   Thompson, C
   Anwaruddin, R
   Dinan, L
   Glezen, WP
   Francis, N
   Fritzell, B
   Greenwood, BM
AF Mulholland, K
   Suara, RO
   Siber, G
   Roberton, D
   Jaffar, S
   NJie, J
   Baden, L
   Thompson, C
   Anwaruddin, R
   Dinan, L
   Glezen, WP
   Francis, N
   Fritzell, B
   Greenwood, BM
TI Maternal immunization with Haemophilus influenzae type b
   polysaccharide-tetanus protein conjugate vaccine in the Gambia
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID HEMOPHILUS-INFLUENZAE; PREGNANT-WOMEN; CAPSULAR POLYSACCHARIDE; SERUM
   ANTIBODIES; CHILDREN; INFANTS; MENINGITIS; PROTECTION
AB Objective.-To evaluate maternal responses to Haemophilus influenzae type b (Hib) polysaccharide-tetanus protein conjugate vaccine (polyribosylribitol phosphate-tetanus or PRP-T) given to pregnant Gambian women, the transplacental transfer of antibody, and the effect of maternal immunization on infant responses to the vaccine.
   Design.-An open, randomized immunogenicity study.
   Setting.-A busy urban health center in The Gambia.
   Study participants.-A total of 451 pregnant women enrolled during the third trimester of pregnancy.
   Intervention.-Study participants were randomized to three groups. In one group, mothers were given PRP-T during the third trimester and their infants were given PRP-T at 2, 3, and 4 months of age, In the second group, mothers received PRP-T and infants were given inactivated poliovirus vaccine. In the third group, mothers received meningococcal A and C vaccine, and their infants received PRP-T.
   Main Outcome Measures.-Anti-PRP antibody measurements of maternal, cord, and infant blood.
   Results.-Vaccinated women had a marked increase in total anti-PRP antibody (geometric mean titer, 9.0 mu g/mL), which was greatest in women in their first or second pregnancy, Previous tetanus vaccination during the same pregnancy and high concentrations of antitetanus antibody were associated with lower anti-PRP responses. In infants of PRP-T recipients, cord blood anti-PRP IgG concentrations were 61% of simultaneous maternal concentrations, In vaccinated infants of vaccinated mothers, geometric mean anti-PRP antibody concentrations at birth, 2 months of age, and 5 months of age were 1.92, 0.35, and 2.84 mu g/mL, respectively, while in vaccinated infants of unvaccinated mothers, the corresponding concentrations were 0.29, 0.12, and 3.91 mu g/mL. At 2 months of age, 60% of infants of vaccinated mothers and 26% of infants of unvaccinated mothers had anti-PRP antibody concentrations considered to be protective (>0.15 mu g/mL).
   Conclusions.-In areas where much invasive Hib disease occurs in infants younger than 6 months, maternal immunization may help to reduce the risk of Hib disease in infants too young for immunization.
C1 MRC LABS,FAJARA,GAMBIA.
   DANA FARBER CANC INST,BOSTON,MA 02115.
   UNIV ADELAIDE,DEPT PAEDIAT,ADELAIDE,SA 5001,AUSTRALIA.
   BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030.
   CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND.
   PASTEUR MERIEUX SERUMS & VACCINS,MARNES COQUETTE,FRANCE.
FU NIAID NIH HHS [AI 15126]
CR ABDULRAUF A, 1990, PEDIATR INFECT DIS J, V9, P918, DOI 10.1097/00006454-199012000-00012
   ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   AMSTEY MS, 1985, AM J OBSTET GYNECOL, V153, P607
   BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802
   BIJLMER HA, 1990, J INFECT DIS, V161, P1210
   BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247
   BLACK RE, 1980, B WORLD HEALTH ORGAN, V58, P927
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   Burckhardt A. E., 1879, DTSCH ARCH KLIN MED, V24, P506
   CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0
   Cohen P, 1943, J AMER MED ASSOC, V121, P656
   DEJOHN D, 1989, LANCET, V2, P1415
   DRAPER NR, 1981, APPLIED REGRESSION A
   ENGLUND JA, 1995, J INFECT DIS, V171, P99
   ENGLUND JA, 1993, J INFECT DIS, V168, P647
   FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542
   GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071
   GLEZEN WP, 1992, J INFECT DIS, V165, pS134
   HERZENBERG LA, 1980, NATURE, V285, P664, DOI 10.1038/285664a0
   INSEL RA, 1986, MANUAL CLIN LABORATO, P379
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   KURIKKA S, 1995, PEDIATRICS, V95, P815
   MAKELA PH, 1992, J INFECT DIS, V165, pS2
   Montgomery D., 1982, INTRO LINEAR REGRESS
   MULHOLLAND EK, 1994, LANCET, V343, P794, DOI 10.1016/S0140-6736(94)91870-8
   MULHOLLAND EK, 1994, ANN TROP PAEDIATR, V14, P83
   MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2
   SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503
   SHAPIRO ED, 1993, JAMA-J AM MED ASSOC, V269, P264, DOI 10.1001/jama.269.2.264
   SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005
   TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010
   TAKALA AK, 1991, J INFECT DIS, V164, P982
   TALL FR, 1992, MED MALADIES INFECT, V22, P1173, DOI 10.1016/S0399-077X(05)81433-7
   VINCENTBALLEREAU F, 1985, PATHOL BIOL, V33, P764
   ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X
   ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7
NR 36
TC 45
Z9 46
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 17
PY 1996
VL 275
IS 15
BP 1182
EP 1188
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA UE625
UT WOS:A1996UE62500030
PM 8609686
OA No
DA 2017-08-15
ER

PT J
AU Weber, M
AF Weber, M
TI Measles on dark skin
SO MONATSSCHRIFT KINDERHEILKUNDE
LA German
DT Article
RP Weber, M (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   CLEMENTS CJ, 1992, RAPPORT TRIMEST STAT, V45, P285
   HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304
   ROSENTHAL SR, 1993, B WORLD HEALTH ORGAN, V71, P421
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   WHITTLE HC, 1979, T ROY SOC TROP MED H, V73, P66, DOI 10.1016/0035-9203(79)90132-9
   WHITTLE HC, 1987, OXFORD TXB MED, P589
   World Bank, 1993, WORLD DEV REP
   *WORLD BANK, 1995, MAN CHILDH ILLN
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0026-9298
J9 MONATSSCHR KINDERH
JI Mon.schr. Kinderheilkd.
PD APR
PY 1996
VL 144
IS 4
BP 413
EP 414
PG 2
WC Pediatrics
SC Pediatrics
GA UH902
UT WOS:A1996UH90200014
OA No
DA 2017-08-15
ER

PT J
AU Banya, WAS
   ODempsey, TJD
   McArdle, T
   LloydEvans, N
   Greenwood, BM
AF Banya, WAS
   ODempsey, TJD
   McArdle, T
   LloydEvans, N
   Greenwood, BM
TI Predictors for a positive blood culture in African children with
   pneumonia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE blood culture; pneumonia; African children
ID DEVELOPING-COUNTRIES; BACTEREMIA
AB Background. Blood culture isolation rates for children with pneumonia are generally low. Therefore it would be helpful if epidemiologic studies could identify children who have a higher than average chance of yielding a positive culture.
   Methods. Simple clinical and laboratory predictors of a positive blood culture were investigated in 1222 children younger than 5 years of age with pneumonia who presented at rural dispensaries in The Gambia, West Africa.
   Results. A high temperature (chi square for linear trend, 24.1; P < 0.0001), a rapid respiratory rate (chi square for linear trend, 6.33; P = 0.010), dehydration (odds ratio, 2.33; P < 0.001), nasal flaring (odds ratio, 2.06; P = 0.001), grunting (odds ratio, 4.01; P < 0.001), dullness to percussion (odds ratio, 2.31; P < 0.001), bronchial breathing (odds ratio, 2.61; P < 0.001) and diminished breath sounds (odds ratio, 2.07; P < 0.001) were positive predictors for a positive blood culture. Wheezing (odds ratio, 0.16; P < 0.001) and malaria parasitemia (odds ratio, 0.26; P = 0.008) were negative predictors.
   A combination of these findings were used to assess how the number of cultures taken might be reduced without substantially reducing the yield of positive cultures. For example it was found that exclusion of children with a temperature of < 38.0 degrees C and/or a respiratory rate of < 50/ min and/or wheezing would have reduced the number of cultures taken by 55.6% but would have led to a loss of only 31.3% of positive cultures.
   Conclusion. Careful selection of children investigated by blood culture could help to reduce the work required during the preparations for and conduct of pneumococcal vaccine trials.
RP Banya, WAS (reprint author), MRC LABS,BANJUL,GAMBIA.
CR BARAFF LJ, 1993, PEDIATRICS, V92, P1
   BERKOWITZ FE, 1984, AM J DIS CHILD, V138, P551
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   ESKOLA J, 1994, DEV CLIN USES HAEMOP, P419
   LEE CJ, 1994, CRIT REV MICROBIOL, P201
   Leowski J, 1986, World Health Stat Q, V39, P138
   LEPAGE P, 1987, LANCET, V1, P1458
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P368
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
NR 10
TC 17
Z9 17
U1 0
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 1996
VL 15
IS 4
BP 292
EP 297
DI 10.1097/00006454-199604000-00003
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA UE892
UT WOS:A1996UE89200002
PM 8866796
OA No
DA 2017-08-15
ER

PT J
AU Leach, A
   Ceesay, SJ
   Banya, WAS
   Greenwood, BM
AF Leach, A
   Ceesay, SJ
   Banya, WAS
   Greenwood, BM
TI Pilot trial of a pentavalent pneumococcal polysaccharide/protein
   conjugate vaccine in Gambian infants
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pneumococcus; conjugate vaccine; Gambian infants
ID RESPIRATORY-TRACT INFECTIONS; ANTIBODY-RESPONSE; DEVELOPING-COUNTRIES;
   CHILDREN; ETIOLOGY; PNEUMONIA; IMMUNOGENICITY; TYPE-19F
AB Background. Invasive pneumococcal disease is a major cause of mortality and morbidity in young children in developing countries. Pneumococcal polysaccharide/protein conjugate vaccines, which are likely to be immunogenic in the very young, offer a potential way for preventing these infections. Therefore a pilot safety and immunogenicity study of a five-valent conjugate vaccine has been undertaken in an area of rural Africa where invasive pneumococcal disease is prevalent.
   Methods. Thirty Gambian infants were vaccinated with 3 doses of a five-valent pneumococcal conjugate vaccine containing 5 mu g of type 6B, 14, 18, 19F and 23F polysaccharides conjugated to the diphtheria toxin mutant protein CRM(197) at the ages of 2, 3 and 4 months; 30 infants received 2 doses at the ages of 2 and 4 months and 30 infants who received three doses of a Haemophilus influenzae type b vaccine acted as controls. Local and systemic reactions were recorded after vaccination and antibody titers were measured by an enzyme-linked immunosorbent assay.
   Results. No serious local or systemic reactions to vaccination were recorded. Antibody responses to each component of the vaccine were demonstrated. One month after immunization with three doses of vaccine, antibody titers were 3 to 11 times higher than before vaccination (postvaccination titers ranged from 2.49 mu g/ml for type 19 polysaccharide to 7.59 mu g/ml for type 14). Elevated titers were well-maintained during the subsequent 4 months. Three doses of vaccine induced higher titers than did two doses. Antibody titers increased 2- to 3-fold over the period of immunization in children who received H. influenzae type b vaccine.
   Conclusions. A five-valent pneumococcal conjugate vaccine proved safe and immunogenic in Gambian infants. However. a vaccine containing a larger number of serotypes will be necessary to achieve a maximal clinical impact.
C1 MRC LABS,BANJUL,GAMBIA.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Banya WAS, 1996, PEDIATR INFECT DIS J, V15, P292, DOI 10.1097/00006454-199604000-00003
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   DOUGLAS RM, 1983, J INFECT DIS, V148, P131
   FATTOM A, 1990, INFECT IMMUN, V58, P2309
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009
   Leowski J, 1986, World Health Stat Q, V39, P138
   ODEMPSEY TJD, IN PRESS PEDIATR INF
   PATON JC, 1991, INFECT IMMUN, V59, P2297
   PEETERS CCAM, 1991, IMMUNOL LETT, V30, P267, DOI 10.1016/0165-2478(91)90036-A
   POMAT WS, 1994, INFECT IMMUN, V62, P1848
   SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S
   SCHNEERSON R, 1992, INFECT IMMUN, V60, P3528
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   STEINHOFF MC, 1994, PEDIATR INFECT DIS J, V13, P368, DOI 10.1097/00006454-199405000-00007
   TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
   VELLA PP, 1992, INFECT IMMUN, V60, P4977
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
NR 22
TC 72
Z9 73
U1 0
U2 4
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 1996
VL 15
IS 4
BP 333
EP 339
DI 10.1097/00006454-199604000-00010
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA UE892
UT WOS:A1996UE89200009
PM 8866803
OA No
DA 2017-08-15
ER

PT J
AU Palmer, A
   Weber, M
AF Palmer, A
   Weber, M
TI Ecthyma gangrenosum
SO TROPICAL DOCTOR
LA English
DT Article
RP Palmer, A (reprint author), ROYAL VICTORIA HOSP,PAEDIAT UNIT,BANJUL,GAMBIA.
CR BOISSEAU AM, 1992, J AM ACAD DERMATOL, V27, P415, DOI 10.1016/0190-9622(92)70210-7
   FAST M, 1979, CAN MED ASSOC J, V120, P332
   FERGIE JE, 1991, PEDIATR INFECT DIS J, V10, P496, DOI 10.1097/00006454-199107000-00003
   HEFFNER RW, 1960, AM J DIS CHILD, V99, P154
   VANDENBROEK PJ, 1979, J INFECTION, V1, P263, DOI 10.1016/S0163-4453(79)91329-X
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC MEDICINE SERVICES LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD APR
PY 1996
VL 26
IS 2
BP 80
EP 80
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UJ492
UT WOS:A1996UJ49200011
PM 8685973
OA No
DA 2017-08-15
ER

PT J
AU Walraven, G
   vanRoosmalen, J
AF Walraven, G
   vanRoosmalen, J
TI Umbilical cord prolapse in rural Africa
SO LANCET
LA English
DT Letter
C1 UNIV LEIDEN HOSP,DEPT OBSTET,2300 RC LEIDEN,NETHERLANDS.
RP Walraven, G (reprint author), MRC LABS,BANJUL,GAMBIA.
CR BARRET JM, 1991, AM J OBSTET GYNECOL, P654
   Panter KR, 1996, LANCET, V347, P74, DOI 10.1016/S0140-6736(96)90207-X
   VANROOSMALEN J, 1995, TROP GEOGR MED, V47, P19
   WALRAVEN GEL, 1995, EUR J OBSTET GYN R B, V58, P131, DOI 10.1016/0028-2243(94)01989-4
   1991, WKLY EPIDEMIOL REC, V66, P345
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR 16
PY 1996
VL 347
IS 9003
BP 773
EP 773
DI 10.1016/S0140-6736(96)90132-4
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA TZ982
UT WOS:A1996TZ98200072
PM 8602045
OA No
DA 2017-08-15
ER

PT J
AU Viviani, S
AF Viviani, S
TI Brazilian Indians' unmet health needs
SO LANCET
LA English
DT Letter
RP Viviani, S (reprint author), MRC LABS,INT AGCY RES CANC,FAJARA,GAMBIA.
CR CSILLAG C, 1995, LANCET, V346, P1619, DOI 10.1016/S0140-6736(95)91943-0
   PETERS JF, 1984, SOC BIOL, V27, P272
NR 2
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR 2
PY 1996
VL 347
IS 9001
BP 623
EP 624
DI 10.1016/S0140-6736(96)91326-4
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA TX694
UT WOS:A1996TX69400073
PM 8596358
OA No
DA 2017-08-15
ER

PT J
AU vanHensbroek, MB
   Kwiatkowski, D
   vandenBerg, B
   Hoek, FJ
   vanBoxtel, CJ
   Kager, PA
AF vanHensbroek, MB
   Kwiatkowski, D
   vandenBerg, B
   Hoek, FJ
   vanBoxtel, CJ
   Kager, PA
TI Quinine pharmacokinetics in young children with severe malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; ALPHA-1-ACID GLYCOPROTEIN; INTRAMUSCULAR
   QUININE; MALAWIAN CHILDREN; PLASMA-PROTEINS; BINDING; SERUM
AB Children less than two years of age represent a substantial proportion of severe malaria cases in Africa. The standard treatment is parenteral quinine, but little is known about the pharmacokinetics and toxicity of quinine in this age group. We have studied the pharmacokinetics of quinine after intravenous (iv) and intramuscular (im) administration in a group of 20 children less than two years of age with severe malaria. A loading dose of 20 mg/kg of quinine dihydrochloride was followed by 10 mg/kg at 12-hr intervals. The im quinine was very rapidly absorbed, reaching high peak concentrations of 16.4 +/- 3.7 mg/L (mean +/- SD) in 1.1 +/- 0.4 hr. Mean peak levels after iv administration were also high (17.5 +/- 2.4 mg/L). Free quinine levels at 4 hr postadministration ranged from 0.27 to 1.89 mg/L (0.87 +/- 0.53 mg/L). At 2 hr and 4 hr after commencing treatment, an electrocardiogram showed a significant lengthening of the QRS interval compared with baseline (15.6 +/- 21.4%; P = 0.007 and 17.3 +/- 21.9%; P = 0.006 at 2 hr and 4 hr, respectively), whereas this was not observed in a control group of nine older children (age range = 24 months to 10 years) receiving the same im dosage regimen. Free and total quinine levels were not significantly correlated with changes in the QRS interval. Levels of alpha(1)-acid glycoprotein, which binds quinine within the circulation, did not differ between the younger and the older children. These findings raise the possibility that young children are more susceptible to quinine toxicity than older children, and indicate the need for further evaluation of quinine dosage regimens in this age group.
C1 JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.
   UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN PHARMACOL,1105 AZ AMSTERDAM,NETHERLANDS.
   UNIV AMSTERDAM,ACAD MED CTR,SPECIAL LAB MED & SURG,1105 AZ AMSTERDAM,NETHERLANDS.
   UNIV AMSTERDAM,ACAD MED CTR,DEPT TROP MED F4,1105 AZ AMSTERDAM,NETHERLANDS.
   UNIV AMSTERDAM,ACAD MED CTR,DEPT INFECT DIS & TROP MED,1105 AZ AMSTERDAM,NETHERLANDS.
   MRC,FAJARA,GAMBIA.
CR BATEMAN DN, 1985, Q J MED, V54, P125
   BOLAND ME, 1985, LANCET, V1, P384
   DYSON EH, 1985, BRIT MED J, V291, P31
   EDSTEIN M, 1983, J CHROMATOGR, V278, P445, DOI 10.1016/S0378-4347(00)84807-0
   GARSON AG, 1990, SCI PRACTICE PEDIATR, V1, P750
   KREMER JMH, 1988, PHARMACOL REV, V40, P1
   LERMAN J, 1989, CLIN PHARMACOL THER, V46, P219
   MANDEL WJ, 1980, CARDIAC ARRHYTHMIAS, P96
   MANSOR SM, 1991, BRIT J CLIN PHARMACO, V32, P317
   MANSOR SM, 1990, T ROY SOC TROP MED H, V84, P482, DOI 10.1016/0035-9203(90)90007-2
   MEURS AAH, 1989, PRAKTISCHE ELECTROCA, P104
   MIHALY GW, 1987, BRIT J CLIN PHARMACO, V24, P769
   Ross R, 1921, BRIT MED J, V2, P1
   ROUTLEDGE PA, 1986, BRIT J CLIN PHARMACO, V22, P499
   SHANN F, 1985, J PEDIATR-US, V106, P506, DOI 10.1016/S0022-3476(85)80692-2
   SILAMUT K, 1985, AM J TROP MED HYG, V34, P681
   STEPHENS JWW, 1921, ANN TROP MED PARASIT, V12, P113
   WALLER D, 1990, T ROY SOC TROP MED H, V84, P488, DOI 10.1016/0035-9203(90)90009-4
   WATANAGOON Y, 1986, BRIT MED J, V293, P11
   WHITE NJ, 1983, AM J TROP MED HYG, V32, P456
   WHITE NJ, 1982, AM J MED, V73, P564, DOI 10.1016/0002-9343(82)90337-0
   WINSTANLEY P, 1993, T ROY SOC TROP MED H, V87, P201, DOI 10.1016/0035-9203(93)90494-B
   1990, T R SOC TROP MED H S
NR 23
TC 30
Z9 30
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 1996
VL 54
IS 3
BP 237
EP 242
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA UE418
UT WOS:A1996UE41800004
PM 8600757
OA No
DA 2017-08-15
ER

PT J
AU Egan, AF
   Morris, J
   Barnish, G
   Allen, S
   Greenwood, BM
   Kaslow, DC
   Holder, AA
   Riley, EM
AF Egan, AF
   Morris, J
   Barnish, G
   Allen, S
   Greenwood, BM
   Kaslow, DC
   Holder, AA
   Riley, EM
TI Clinical immunity to Plasmodium falciparum malaria is associated with
   serum antibodies to the 19-kDa C-terminal fragment of the merozoite
   surface antigen, PfMSP-1
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID WEST-AFRICA; MORBIDITY; PROTEIN; RECOGNITION; INVASION; CHILDREN;
   MONKEYS
AB The development of an effective malaria vaccine depends upon identification of antigens that are targets of protective immune responses, An immunoepidemiologic approach has been used to investigate the relationship between antibody responses to a defined region of the major merozoite surface protein of Plasmodium falciparum (PfMSP-1(19)) and resistance to clinical malaria in 2 populations of children from West Africa, After allowing for the confounding effects of age, antibodies to PfMSP-1(19) were shown to provide similar to 40% protection against clinical malaria in children in Sierra Leone, In Gambian children, antibodies to one of the epidermal growth factor-like motifs of PfMSP-1(19) were strongly associated with resistance to both clinical malaria and high levels of parasitemia.
C1 UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,DIV BIOL SCI,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND.
   LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.
   NATL INST MED RES,LONDON NW7 1AA,ENGLAND.
   MRC LABS,BO,SIERRA LEONE.
   MRC LABS,FAJARA,GAMBIA.
   NIH,MALARIA RES LAB,BETHESDA,MD 20892.
RI Holder, Anthony/A-7554-2013
OI Holder, Anthony/0000-0002-8490-6058
FU Medical Research Council [MC_U117532067]; Wellcome Trust
CR BARNISH G, 1996, IN PRESS AN TROP MED
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389
   CHAPPEL JA, 1993, MOL BIOCHEM PARASIT, V60, P303, DOI 10.1016/0166-6851(93)90141-J
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   EGAN AF, 1994, INFECT IMMUN, V63, P456
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   KASLOW DC, 1994, MOL BIOCHEM PARASIT, V63, P283, DOI 10.1016/0166-6851(94)90064-7
   LING IT, 1994, PARASITE IMMUNOL, V16, P63
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   PERRIN LH, 1984, J EXP MED, V160, P441, DOI 10.1084/jem.160.2.441
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1991, T ROY SOC TROP MED H, V85, P436, DOI 10.1016/0035-9203(91)90207-F
   SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014
NR 15
TC 248
Z9 252
U1 2
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1996
VL 173
IS 3
BP 765
EP 769
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA TW806
UT WOS:A1996TW80600039
PM 8627050
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
AF Obaro, SK
TI Management of acute bacterial meningitis
SO LANCET
LA English
DT Letter
RP Obaro, SK (reprint author), MRC,MRC LABS,POB 273,BANJUL,GAMBIA.
CR BRADLEY JS, 1994, PEDIATR INFECT DIS J, V13, P823, DOI 10.1097/00006454-199409000-00015
   GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004
   KILPI T, 1995, PEDIATR INFECT DIS J, V14, P270, DOI 10.1097/00006454-199504000-00005
   PRASAD K, 1995, J NEUROL NEUROSUR PS, V59, P31, DOI 10.1136/jnnp.59.1.31
   Tunkel AR, 1995, LANCET, V346, P1675, DOI 10.1016/S0140-6736(95)92844-8
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 24
PY 1996
VL 347
IS 9000
BP 538
EP 538
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA TW697
UT WOS:A1996TW69700043
PM 8596282
OA No
DA 2017-08-15
ER

PT J
AU Jallow, BP
   Barrow, MKA
   Leatherman, SP
AF Jallow, BP
   Barrow, MKA
   Leatherman, SP
TI Vulnerability of the coastal zone of The Gambia to sea level rise and
   development of response strategies and adaptation options
SO CLIMATE RESEARCH
LA English
DT Article; Proceedings Paper
CT Workshop on Vulnerability and Adaptation of African Ecosystems to Global
   Climate Change
CY MAR 07-15, 1995
CL HARARE, ZIMBABWE
SP US Country Studies Program
DE coastal vulnerability; sea level rise impacts; Gambian coast
AB The coastal zone of The Gambia consists of 70 km open ocean coast and 200 km sheltered coast. Only about 20 km of the open coastline is significantly developed and this includes Banjul (the capital city), Bakau and Cape St. Mary, Fajara and the Tourism Development Area (TDA). Tourism is the most important economic sector in the coastal zone and contributes about 10% of the government revenue. Fisheries and agriculture are also important coastal industries. In this study the Aerial Videotape-assisted Vulnerability Analysis (AVVA) technique has been used to provide a detailed analysis of vulnerability to sea level rise, and adaptation strategies have been identified. The data used includes a video recording of the coastline, color infrared and black and white aerial photography, topographic maps, bathymetric maps, a geological map of The Gambia and still photographs. The data have been used to characterize the coastal zone into 9 geomorphological units, wherein the cultural and heritage sites of economic importance have been delineated and characterized according to their biophysical and economic importance. Future erosion rates have been projected by applying the Bruun Rule, and future total land loss due to inundation in response to global warming and accelerated sea level rise has been determined. The sea level rise scenarios considered are 0.2 m, 0.5 m, and 1.0 m per century. Inundation is estimated to be about 92.32 x 10(6) m(2) for a 1.0 m sea level rise, 45.89 x 10(6) m(2) for a 0.5 m sea level rise and 4.96 x 10(6) m(2) for a 0.2 m sea level rise. The greater part of this area lost will be wetlands and mangrove systems important for fish spawning areas and habitats for wildlife. Shoreline retreat is estimated to vary between about 6.8 m in cliffy areas to about 880 m for more flat and sandy areas based on the Bruun Rule. Population and physical structures at risk have been determined. Attempts have been made to report this loss in monetary terms, but firm figures are not yet available. Only one unit of the coastal zone has been evaluated. In this unit, it is expected that the capital city will be completely lost through both erosion and inundation within 50 to 60 yr with a total of 42000 persons displaced. Lands and physical structures to be lost are estimated at US$ 217 million. Response strategies and adaptation options identified include: innovative sand management, building and rehabilitation of groins, construction of revetments to protect important areas, construction of sea-walls/bulkheads, public outreach and awareness, building regulations and urban growth planning, wetland preservation and mitigation, and development of a coastal zone management plan.
C1 NATL ENVIRONM AGCY,BANJUL,GAMBIA.
   UNIV MARYLAND,DEPT GEOG,LAB COASTAL RES,COLLEGE PK,MD 20742.
RP Jallow, BP (reprint author), DEPT WATER RESOURCES,7 MARINA PARADE,BANJUL,GAMBIA.
CR Dennis KC, 1995, J COASTAL RES, V14, P243
   *GPA, 1991, TID DIST TABL BANJ R
   Hands EB, 1983, HDB COASTAL PROCESSE, P167
   *IPCC, 1990, RESP STRAT AD ASS
   Leatherman S., 1995, J COASTAL RES, V14, P15
   Nicholls R. J., 1995, J COASTAL RES, P26
   Pepper W., 1992, EMISSIONS SCENARIOS
   QUELENNEC RE, 1988, IDENTIFICATION COAST
   *UNEP, 1992, COAST ER GAMB
   WHYTE WJ, 1988, GEOLOGY MINERAL RESO
NR 10
TC 13
Z9 14
U1 4
U2 23
PU INTER-RESEARCH
PI OLDENDORF LUHE
PA NORDBUNTE 23, D-21385 OLDENDORF LUHE, GERMANY
SN 0936-577X
J9 CLIMATE RES
JI Clim. Res.
PD FEB 19
PY 1996
VL 6
IS 2
BP 165
EP 177
DI 10.3354/cr006165
PG 13
WC Environmental Sciences; Meteorology & Atmospheric Sciences
SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences
GA UD549
UT WOS:A1996UD54900012
OA No
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   CheingsongPopov, R
   Wilkins, A
   Corrah, T
   Weber, J
   Whittle, H
AF Ariyoshi, K
   CheingsongPopov, R
   Wilkins, A
   Corrah, T
   Weber, J
   Whittle, H
TI HIV-1 subtype B in West Africa
SO LANCET
LA English
DT Letter
C1 ST MARYS HOSP,SCH MED,DEP GU & COMMUNICABLE DIS,LONDON,ENGLAND.
RP Ariyoshi, K (reprint author), MRC LABS,FAJARA,GAMBIA.
CR Bobkov A, 1996, AIDS RES HUM RETROV, V12, P169, DOI 10.1089/aid.1996.12.169
   CHEINGSONGPOPOV R, 1994, AIDS RES HUM RETROV, V10, P1379, DOI 10.1089/aid.1994.10.1379
   JANSSENS W, 1994, AIDS, V8, P21, DOI 10.1097/00002030-199401000-00004
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   WILLIAMSON C, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91543-5
NR 5
TC 6
Z9 6
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 3
PY 1996
VL 347
IS 8997
BP 328
EP 328
DI 10.1016/S0140-6736(96)90503-6
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA TT485
UT WOS:A1996TT48500048
PM 8569384
OA No
DA 2017-08-15
ER

PT J
AU Miele, M
   Donato, F
   Hall, AJ
   Whittle, H
   Chapot, B
   Bonatti, S
   DeFerrari, M
   Artuso, M
   Gallerani, E
   Abbondandolo, A
   Montesano, R
   Wild, CP
AF Miele, M
   Donato, F
   Hall, AJ
   Whittle, H
   Chapot, B
   Bonatti, S
   DeFerrari, M
   Artuso, M
   Gallerani, E
   Abbondandolo, A
   Montesano, R
   Wild, CP
TI Aflatoxin exposure and cytogenetic alterations in individuals from The
   Gambia, West Africa
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE aflatoxin; cytogenetic alteration; biomonitoring; molecular epidemiology
ID HEPATITIS-B VIRUS; HEPATOCELLULAR-CARCINOMA; CHROMOSOME-ABERRATIONS;
   PERIPHERAL-BLOOD; ALBUMIN ADDUCTS; LYMPHOCYTES; INVIVO; RAT; DAMAGE;
   CELLS
AB Aflatoxin-albumin adducts in peripheral blood provide a measure of exposure to aflatoxin over the previous 2-3 months. In the present study, the levels of these adducts were determined in a group of individuals from The Gambia, West Africa and were compared in a cross-sectional study to the levels of various cytogenetic alterations (chromosomal aberrations, micronuclei, sister chromatid exchanges) in the same individuals to test whether an increase in genetic damage is associated with an increased exposure in this population. Of 35 subjects tested for aflatoxin-albumin adducts, all but 3 were positive. There were no correlations between the adduct level and the number of cytogenetic abnormalities at the individual level. A comparison of the cytogenetic alterations was made between Gambian individuals and a group of 22 healthy people from Italy where aflatoxin exposure is expected to be low. The levels of structural chromosomal aberrations, sister chromatid exchanges and micronuclei were all higher in the former group. Overall, these data are indicative of a higher exposure to genotoxins in Gambian subjects, one of which are aflatoxins, but suggest that more specific genetic markers of aflatoxin exposure are required to further examine the link between aflatoxin exposure and genetic alterations.
C1 INT AGCY RES CANC,UNIT ENVIRONM CARCINOGENESIS,F-69372 LYON 08,FRANCE.
   IST NAZL RIC CANC,I-16132 GENOA,ITALY.
   UNIV BRESCIA,INST HYG,BRESCIA,ITALY.
   LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
FU NIEHS NIH HHS [1P01ES06052]
CR AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284
   ALBERTINI RJ, 1985, NATURE, V316, P369, DOI 10.1038/316369a0
   ANWAR WA, 1994, MUTAT RES, V322, P61, DOI 10.1016/0165-1218(94)90033-7
   ARMITAGE P, 1987, STATISTICAL METHODS
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   CARIELLO NF, 1994, CANCER RES, V54, P4436
   Chapot B., 1991, TECHNIQUES DIAGNOSTI, P135
   CHATTERJEE B, 1989, MUTAT RES, V210, P49, DOI 10.1016/0027-5107(89)90043-2
   COUNTRYMAN PI, 1976, MUTAT RES, V41, P321, DOI 10.1016/0027-5107(76)90105-6
   DIXON WJ, 1993, BMDP STATISTICAL SOF
   GAN LS, 1988, CARCINOGENESIS, V9, P1323, DOI 10.1093/carcin/9.7.1323
   GOTO K, 1978, CHROMOSOMA, V66, P351, DOI 10.1007/BF00328535
   HOLLSTEIN MC, 1993, INT J CANCER, V53, P51, DOI 10.1002/ijc.2910530111
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   IARC, 1993, IARC MON EV CARC RIS, V56
   ITO Y, 1989, MUTAT RES, V222, P253, DOI 10.1016/0165-1218(89)90141-9
   KULKA U, 1993, MUTAGENESIS, V8, P193, DOI 10.1093/mutage/8.3.193
   LAMBERT B, 1984, HUM GENET, V67, P94, DOI 10.1007/BF00270564
   LI SY, 1990, MUTAT RES, V242, P219, DOI 10.1016/0165-1218(90)90087-I
   Lovell D.P., 1989, STAT EVALUATION MUTA, P184
   MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384
   MERRY DE, 1985, AM J HUM GENET, V37, P425
   MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5
   NUESSE M, 1989, Mutagenesis, V4, P174
   OKOYE ZSC, 1990, BIOCHEM PHARMACOL, V40, P2560, DOI 10.1016/0006-2952(90)90100-Y
   OZTURK M, 1991, LANCET, V338, P1356
   RANEY KD, 1992, CHEM RES TOXICOL, V5, P470, DOI 10.1021/tx00028a004
   REUTERWALL C, 1991, SCAND J WORK ENV HEA, V17, P123
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   SCHWARTZ GG, 1990, BIOL MARKERS EPIDEMI, P147
   SIMON D, 1991, CANCER RES, V51, P6176
   VANPOPPEL G, 1993, CANCER EPIDEM BIOMAR, V2, P441
   VINE MF, 1990, BIOL MARKERS EPIDEMI, P124
   WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1986, J CELL BIOCHEM, V30, P171, DOI 10.1002/jcb.240300206
   1990, MUTAT RES, V241, P325
NR 38
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD FEB 1
PY 1996
VL 349
IS 2
BP 209
EP 217
DI 10.1016/0027-5107(95)00180-8
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA TX479
UT WOS:A1996TX47900006
PM 8600352
OA No
DA 2017-08-15
ER

PT J
AU Muller, O
   vanHensbroek, MB
   Jaffar, S
   Drakeley, C
   Okorie, C
   Joof, D
   Pinder, M
   Greenwood, B
AF Muller, O
   vanHensbroek, MB
   Jaffar, S
   Drakeley, C
   Okorie, C
   Joof, D
   Pinder, M
   Greenwood, B
TI A randomized trial of chloroquine, amodiaquine and
   pyrimethamine-sulphadoxine in Gambian children with uncomplicated
   malaria
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria; chloroquine-resistance; The Gambia
ID PLASMODIUM-FALCIPARUM MALARIA; RESISTANT MALARIA; WEST-AFRICA; EFFICACY;
   KENYA; SULFADOXINE; PROPHYLAXIS; INFECTIONS
AB The increasing occurrence of chloroquine-resistant Plasmodium falciparum in sub-Saharan Africa makes it essential to reconsider current recommendations for the treatment of uncomplicated P. falciparum malaria. In an open, randomized trial, we have compared chloroquine (CQ), amodiaquine (AQ), and pyrimethamine-sulphadoxine (PS) in rural Gambian children with uncomplicated P. falciparum malaria. Three hundred children were randomly assigned at the time of consultation (D0) to oral treatment with 25 mg/kg CQ, 25 mg/kg AQ (bath given over 3 days), or 1.25/25 mg/kg PS. They were reviewed on day 7 (D7) and day 28 (D28) for symptoms, malaria parasitaemia, and packed cell volume (PCV). Significantly more children treated with PS compared to CQ (17 vs 7%, P=0.03) or AQ (17 vs 3%, P=0.001) returned with clinical complaints during the first 3 days after treatment. Five of these patients had a generalized convulsion (1 from the AQ group, 4 from the PS group), of whom 4 developed cerebral malaria. At D7, significantly more patients treated with CQ compared to AQ (25 vs 7%, P=0.0009) or PS (25 vs 4%, P=0.0001) were parasitaemic. By D28, the cumulative number of parasitological failures was significantly higher in the CQ group compared to the AQ group (65 vs 35%, P=0.0001), and significantly higher in the AB group compared to the PS group (35 vs 14%, P=0.001). Overall, 91% of parasitological failures observed during the study period were symptomatic and were consequently treated with an alternative antimalarial drug. Over the 28-day study period the mean PCV increased significantly less in the CQ group than in the PS group (1.2 vs 3.8%, P=0.016) and was lower in the CQ group than in the AQ group (1.2 vs 2.7%, P=0.12, not significant). These results suggest that PS acts more slowly than 4-aminoquinolines in controlling the clinical features of malaria, and that AQ can be considered as an interim alternative to CQ in the first-line therapy of uncomplicated malaria in African areas of high CQ resistance.
C1 MRC LABS,FAJARA,BANJUL,GAMBIA.
   MINIST HLTH,BANJUL,GAMBIA.
CR BLOLAND PB, 1993, J INFECT DIS, V167, P932
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   *CDC, 1985, MMWR-MORBID MORTAL W, V34, P185
   DELORON P, 1984, LANCET, V1, P1303
   FADAT G, 1991, LANCET, V338, P1092, DOI 10.1016/0140-6736(91)91959-X
   GREENWOOD BM, 1987, PARASITOL TODAY, V3, P206, DOI 10.1016/0169-4758(87)90061-5
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HATTON CSR, 1986, LANCET, V1, P411
   IRARE SGM, 1991, TROPICAL GEOGRAPHICA, V43, P252
   KAMUGISHA J, 1994, TROP GEOGR MED, V46, P364
   KEUTER M, 1992, TROP GEOGR MED, V44, P1
   KEUTER M, 1990, BRIT MED J, V301, P466
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   MENON A, 1987, LANCET, V2, P1029
   *MIN HLTH LAB SOC, 1985, NAT P0RIM HEALTH PRO, P1
   NEFTEL KA, 1986, BRIT MED J, V292, P721
   NEVILL CG, 1994, 6 INT C INF DIS PRAG
   PANTON LJ, 1985, T ROY SOC TROP MED H, V79, P484, DOI 10.1016/0035-9203(85)90072-0
   PAPPAIOANOU M, 1988, B WORLD HEALTH ORGAN, V66, P477
   PINCHEPONGSE S, 1982, B WORLD HEALTH ORGAN, V60, P907
   SPENCER HC, 1984, LANCET, V1, P956
   STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313
   SUDRE P, 1992, INT J EPIDEMIOL, V21, P146, DOI 10.1093/ije/21.1.146
   WATKINS WM, 1984, LANCET, V1, P357
   *WHO, 1990, TECHN REP SER, V805
NR 26
TC 72
Z9 72
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 1996
VL 1
IS 1
BP 124
EP 132
DI 10.1046/j.1365-3156.1996.d01-13.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VV943
UT WOS:A1996VV94300016
PM 8673817
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Samb, B
   Simondon, F
   Knudsen, K
   Seck, AMC
   Bennett, J
   Markowitz, L
   Whittle, H
AF Aaby, P
   Samb, B
   Simondon, F
   Knudsen, K
   Seck, AMC
   Bennett, J
   Markowitz, L
   Whittle, H
TI Five year follow-up of morbidity and mortality among recipients of
   high-titre measles vaccines in Senegal
SO VACCINE
LA English
DT Article
DE Edmonston-Zagreb measles vaccine; high titre; measles; measles
   immunization; Schwarz measles vaccine; vaccine efficacy
ID RURAL SENEGAL; TITER; CHILDREN
AB At 3-5 years of age, female recipients of Edmonston-Zagreb high-titre (EZ-HT) and Schwarz high-titre (SW-HT) measles vaccine had lower survival rates than female recipients of Schwarz standard measles vaccine (SW-STD) in Guinea-Bissau, Senegal and Haiti. In senegal, the children who received high-titre vaccines have now been followed to the age of 5-7 years to determine whether the difference in mortality persisted, and whether differences in vaccine efficacy were apparent. At this age there was no difference in mortality between female recipients of high-titre and standard titre measles vaccines. There was no indication that high-titre EZ-HT vaccine at 5 months (EZ-HT, 5m) provided suboptimal protection, as vaccine efficacy after exposure was 97% and 95%, respectively, for EZ-HT, 5m and SW-STD, 10m vaccines, whereas SW-HT, 5m vaccine had an efficacy of 81%. The difference in mortality between recipients of high-titre vaccines and SW-STD observed in several studies during the first few years after vaccination may be explained by non-specific beneficial effects of the standard measles vaccine rather than a harmful effect of the high-titre vaccines.
C1 ORSTOM,UR MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
   CTR DIS CONTROL,ATLANTA,GA 30333.
   MRC LABS,BANJUL,GAMBIA.
RP Aaby, P (reprint author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,COPENHAGEN,DENMARK.
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9
   AABY P, 1994, LANCET, V344, P1226, DOI 10.1016/S0140-6736(94)90539-8
   Cutts FT, 1993, WHOEPIGEN9317
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   DILRAJ A, 1994, LANCET, V343, P1366, DOI 10.1016/S0140-6736(94)92505-4
   Expanded Programme on Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   GARENNE M, 1994, LANCET, V344, P261, DOI 10.1016/S0140-6736(94)93027-9
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   IKIC D, 1972, Annales Immunologiae Hungaricae, V16, P175
   LEON ME, 1993, J INFECT DIS, V168, P1097
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   SAMB B, 1995, J INFECT DIS, V171, P506
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
NR 19
TC 8
Z9 8
U1 0
U2 2
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB
PY 1996
VL 14
IS 3
BP 226
EP 229
DI 10.1016/0264-410X(95)00178-4
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA UD336
UT WOS:A1996UD33600008
PM 8920704
OA No
DA 2017-08-15
ER

PT J
AU Bobkov, A
   CheingsongPopov, R
   Salminen, M
   McCutchan, F
   Louwagie, J
   Ariyoshi, K
   Whittle, H
   Weber, J
AF Bobkov, A
   CheingsongPopov, R
   Salminen, M
   McCutchan, F
   Louwagie, J
   Ariyoshi, K
   Whittle, H
   Weber, J
TI Complex mosaic structure of the partial envelope sequence from a Gambian
   HIV type 1 isolate
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
C1 UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 1NY,ENGLAND.
   HENRY M JACKSON FDN,ROCKVILLE,MD 20850.
   MIL MED CONSORTIUM APPL RETROVIRAL RES,ROCKVILLE,MD 20850.
   INNOGENET NV,GHENT,BELGIUM.
   MRC LABS,FAJARA,GAMBIA.
RI Salminen, Mika/D-8784-2013
OI Salminen, Mika/0000-0003-3020-0866
CR BOBKOV A, 1994, AIDS, V8, P1649, DOI 10.1097/00002030-199412000-00002
   CHEINGSONGPOPOV R, 1993, J INFECT DIS, V168, P292
   CHEINGSONGPOPOV R, 1995, UNPUB DEV PEPTIDE SE
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DUMITRESCU O, 1994, J INFECT DIS, V169, P281
   MYERS G, 1993, HUMAN RETROVIRUS AID
   ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5163
NR 9
TC 12
Z9 12
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN 20
PY 1996
VL 12
IS 2
BP 169
EP 171
DI 10.1089/aid.1996.12.169
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA TV295
UT WOS:A1996TV29500011
PM 8834467
OA No
DA 2017-08-15
ER

PT J
AU Obaro, SK
AF Obaro, SK
TI Serum, breast milk, and infant antibody after maternal immunisation with
   pneumococcal vaccine
SO LANCET
LA English
DT Letter
RP Obaro, SK (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR BREDIUS RGM, 1994, J INFECT DIS, V170, P848
   DEVELASCO EA, 1995, J INFECT DIS, V172, P562
   KANIUK AS, 1992, SCAND J IMMUNOL S11, V36
   SCHUR PH, 1973, CLIN IMMUNOL IMMUNOP, V2, P62, DOI 10.1016/0090-1229(73)90036-6
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
NR 5
TC 3
Z9 3
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 20
PY 1996
VL 347
IS 8995
BP 192
EP 192
DI 10.1016/S0140-6736(96)90376-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA TQ244
UT WOS:A1996TQ24400044
PM 8544562
OA No
DA 2017-08-15
ER

PT B
AU Jallow, BP
AF Jallow, BP
BE Smith, JB
   Bhatti, N
   Menzhulin, GV
   Benioff, R
   Campos, M
   Jallow, B
   Rijsberman, F
   Budyko, M
   Dixon, RK
TI Response strategies and adaptive measures to potential sea-level rise in
   The Gambia
SO ADAPTING TO CLIMATE CHANGE: AN INTERNATIONAL PERSPECTIVE
LA English
DT Proceedings Paper
CT International Conference on Climate Change Adaptation
CY MAY 22-25, 1995
CL ST PETERSBURG, RUSSIA
SP Russian Fed Serv Hydrometeorol & Environm Monitoring, US Country Studies Program, Netherlands Minist Foreign Affairs, Directorate Gen Int Cooperat
RP Jallow, BP (reprint author), DEPT WATER RESOURCES,7 MARINA PARADE,BANJUL,GAMBIA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
BN 0-387-94639-X
PY 1996
BP 299
EP 310
PG 12
WC Agronomy; Ecology; Environmental Sciences; Water Resources
SC Agriculture; Environmental Sciences & Ecology; Water Resources
GA BF01A
UT WOS:A1996BF01A00025
OA No
DA 2017-08-15
ER

PT J
AU ODempsey, TJD
   McArdle, T
   Ceesay, SJ
   Secka, O
   Demba, E
   Banya, WAS
   Francis, N
   Greenwood, BM
AF ODempsey, TJD
   McArdle, T
   Ceesay, SJ
   Secka, O
   Demba, E
   Banya, WAS
   Francis, N
   Greenwood, BM
TI Meningococcal antibody titres in infants of women immunised with
   meningococcal polysaccharide vaccine during pregnancy
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
DE meningococcal polysaccharide vaccine; cord blood:maternal antibody
   ratios; placental transfer; immunity
ID BACTERIAL-MENINGITIS; DISEASE; POPULATION; CHILDHOOD; MORTALITY
AB Seventy five Gambian women were immunised with a single dose of a group A+group C meningococcal polysaccharide vaccine during the last trimester of pregnancy. IgG antibody titres were measured in mothers and in their infants by an enzyme-linked immunosorbent assay (ELISA). All women had a good response to vaccination and maternal antibodies were high at the time of delivery (23.2 mu g/ml for group A antibodies and 14.3 mu g/ml for group C antibodies). only a proportion of However, antibody crossed the placenta; blood:maternal antibody ratios were 30% for group A antibody and 44% for group C antibody, respectively. Considerable variability in cord blood:maternal blood ratios was seen between individuals. This could not be related to age, parity, or ethnic group. Mean group A and group C cord blood:maternal blood ratios were lower in women with serological evidence of syphilis than in seronegative women, and diminished transfer of group A antibody was noted in women with active malarial infection of the placenta. Antibody titres declined rapidly in infants and by the age of 3-4 months these had reached control values.
   Maternal immunisation may give infants some protection against group A and group C meningococcal disease but only during the first few months of life.
C1 MRC,FAJARA,BANJUL,GAMBIA.
   CHARING CROSS HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND.
CR BAKER CJ, 1983, PEDIATRICS, V71, P923
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   CARVALHO ADA, 1977, LANCET, V2, P809
   CONSTANTINO P, 1992, VACCINE, V10, P691
   DANKNER WM, 1993, PEDIATR INFECT DIS J, V12, P98
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   FORTNUM HM, 1993, ARCH DIS CHILD, V68, P763
   GOLDACRE MJ, 1976, LANCET, V1, P28
   HOLDER PK, 1995, CLIN DIAGN LAB IMMUN, V2, P132
   MCCORMICK JB, 1980, J CLIN INVEST, V65, P1141, DOI 10.1172/JCI109768
   PALMER SR, 1992, J INFECTION, V25, P321, DOI 10.1016/0163-4453(92)91699-C
   SATO H, 1979, AM J DIS CHILD, V133, P1240
   TWUMASI PA, 1995, J INFECT DIS, V171, P632
NR 15
TC 27
Z9 30
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JAN
PY 1996
VL 74
IS 1
SI SI
BP F43
EP F46
DI 10.1136/fn.74.1.F43
PG 4
WC Pediatrics
SC Pediatrics
GA TR884
UT WOS:A1996TR88400008
PM 8653435
OA No
DA 2017-08-15
ER

PT B
AU AbleThomas, U
   Hill, R
AF AbleThomas, U
   Hill, R
GP IEEE
TI Techno-economic comparison of PV and diesel systems for
   telecommunications and aviation navigational AIDS
SO CONFERENCE RECORD OF THE TWENTY FIFTH IEEE PHOTOVOLTAIC SPECIALISTS
   CONFERENCE - 1996
LA English
DT Proceedings Paper
CT 25th IEEE Photovoltaic Specialists Conference
CY MAY 13-17, 1996
CL WASHINGTON, DC
SP IEEE, IEEE, Electron Device Soc
C1 GAMBIA CIVIL AVIAT AUTHOR,DEPT ENGN,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-3167-2
PY 1996
BP 1481
EP 1484
DI 10.1109/PVSC.1996.564416
PG 4
WC Engineering, Aerospace; Engineering, Electrical & Electronic; Materials
   Science, Multidisciplinary; Optics
SC Engineering; Materials Science; Optics
GA BG63B
UT WOS:A1996BG63B00356
OA No
DA 2017-08-15
ER

PT J
AU Hill, WG
   Caballero, A
   Dempfle, L
AF Hill, WG
   Caballero, A
   Dempfle, L
TI Prediction of response to selection within families
SO GENETICS SELECTION EVOLUTION
LA English
DT Article
DE artificial selection; selection index; accuracy of selection; response;
   effective population size
ID ORDER STATISTICS
AB The distinction is clarified between two different uses of the term 'within-family selection', either to imply that one individual of each sex is selected from each family or to imply that individuals are selected on their deviation from family mean, in which case families may not be equally represented. In the short term, selection on within-family deviation is expected to give higher responses, but in the long term, selection within families is expected to give higher responses as the effective population size is larger. The two schemes are the same, however, if only two individuals of each sex are recorded in each family.
C1 INT TRYPANOTOLERANCE CTR, BANJUL, GAMBIA.
RP Hill, WG (reprint author), UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, W MAINS RD, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND.
RI Caballero, Armando/H-5358-2015
OI Caballero, Armando/0000-0001-7391-6974
CR BULMER MG, 1971, AM NAT, V105, P201, DOI 10.1086/282718
   CABALLERO A, 1994, HEREDITY, V73, P657, DOI 10.1038/hdy.1994.174
   Dempfle L., 1990, Advances in statistical methods for genetic improvement of livestock.., P98
   Dempfle L., 1975, Genetical Research, V24, P127
   FALCONER DS, 1973, GENET RES, V22, P291
   Falconer D. S. M., 1996, INTRO QUANTITATIVE G
   HILL WG, 1976, BIOMETRICS, V32, P889, DOI 10.2307/2529272
   HILL WG, 1985, GENET SEL EVOL, V17, P351, DOI 10.1186/1297-9686-17-3-351
   LUSH JL, 1947, AM NAT, V81, P241, DOI 10.1086/281520
   LUSH JL, 1947, AM NAT, V81, P293
   RAWLINGS JO, 1976, BIOMETRICS, V32, P875, DOI 10.2307/2529271
   TORO M, 1990, GENET SEL EVOL, V22, P93, DOI 10.1051/gse:19900107
NR 12
TC 13
Z9 13
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0999-193X
J9 GENET SEL EVOL
JI Genet. Sel. Evol.
PY 1996
VL 28
IS 4
BP 379
EP 383
DI 10.1051/gse:19960405
PG 5
WC Agriculture, Dairy & Animal Science; Genetics & Heredity
SC Agriculture; Genetics & Heredity
GA VT869
UT WOS:A1996VT86900005
OA gold
DA 2017-08-15
ER

PT J
AU Ariyoshi, K
   Berry, N
   Wilkins, A
   Ricard, D
   Aaby, P
   Naucler, A
   Ngom, PT
   Jobe, O
   Jaffar, S
   Dias, F
   Tedder, RS
   Whittle, H
AF Ariyoshi, K
   Berry, N
   Wilkins, A
   Ricard, D
   Aaby, P
   Naucler, A
   Ngom, PT
   Jobe, O
   Jaffar, S
   Dias, F
   Tedder, RS
   Whittle, H
TI A community-based study of human immunodeficiency virus type 2 provirus
   load in a rural village in West Africa
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HIV-2; EPIDEMIOLOGY; QUANTITATION; INFECTION; PCR
AB A community-based study of provirus load in human immunodeficiency virus (HIV) type 2-infected subjects was done in a rural village in Guinea-Bissau. HIV-2 provirus load varied considerably, with a geometric mean of 124.3 (95% confidence interval, 86.0-179.6) copies/10(5) CD4 cells, which is a level similar to that found in HIV-1 infection. Neither malaria parasitemia, active syphilis, or human T cell leukemia virus coinfection significantly influenced provirus load, nor did age, Eleven of 104 HIV-2-infected subjects had died after 3 years of follow-up; 9 of those who died had a high provirus load of greater than or equal to 100 copies/10(5) CD4 cells and a relatively low CD4 cell percentage of < 29%.
C1 UCL, SCH MED, DIV VIROL, LONDON W1N 8AA, ENGLAND.
   STATE SERUM INST, DANISH EPIDEMIOL SCI CTR, COPENHAGEN, DENMARK.
   NATL BACTERIOL LAB, S-10521 STOCKHOLM, SWEDEN.
   LAB NACL SAUDE PUBL, BISSAU, GUINEA BISSAU.
RP Ariyoshi, K (reprint author), MRC LABS, POB 273, BANJUL, GAMBIA.
CR ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BIENIASZ PD, 1993, AIDS, V7, P803, DOI 10.1097/00002030-199306000-00007
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   CHEVRET S, 1994, J INFECT DIS, V169, P882
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   FERRE F, 1992, AIDS RES HUM RETROV, V8, P269, DOI 10.1089/aid.1992.8.269
   HARTUNG S, 1992, J VIROL, V66, P2143
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 15
TC 57
Z9 59
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN
PY 1996
VL 173
IS 1
BP 245
EP 248
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA TM343
UT WOS:A1996TM34300036
PM 8537668
OA No
DA 2017-08-15
ER

PT B
AU Poskitt, EME
AF Poskitt, EME
BE Boulton, J
   Laron, Z
   Rey, J
TI Early feeding and obesity
SO LONG-TERM CONSEQUENCES OF EARLY FEEDING
SE NESTLE NUTRITION WORKSHOP SERIES
LA English
DT Proceedings Paper
CT 36th Nestle Nutrition Workshop - Long-Term Consequences of Early Feeding
CY OCT 23-27, 1994
CL CEBU, PHILIPPINES
RP Poskitt, EME (reprint author), MCR LABS,DUNN NUTR GRP,POB 273,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA E WASHINGTON SQ, PHILADELPHIA, PA 19105
BN 0-397-51728-9
J9 NESTLE NUTR WORKS SE
PY 1996
VL 36
BP 179
EP 191
PG 13
WC Endocrinology & Metabolism; Engineering, Electrical & Electronic;
   Nutrition & Dietetics; Pediatrics
SC Endocrinology & Metabolism; Engineering; Nutrition & Dietetics;
   Pediatrics
GA BG68R
UT WOS:A1996BG68R00013
OA No
DA 2017-08-15
ER

PT B
AU Kunjo, EM
AF Kunjo, EM
BE Brown, H
   Cussans, GW
   Devine, MD
   Duke, SO
   FernandezQuintanilla, C
   Helweg, A
   Labrada, RE
   Landes, M
   Kudsk, P
   Streibig, JC
TI Practical results of Striga research in the Gambia
SO SECOND INTERNATIONAL WEED CONTROL CONGRESS - PROCEEDINGS, VOLS 1-4
LA English
DT Proceedings Paper
CT 2nd International Weed Control Congress
CY JUN 25-28, 1996
CL COPENHAGEN, DENMARK
SP AgrEvo, BASF, Bayer, CFPI, CIBA, DowElanco, DuPont Agr Prod, Griffin Corp, Hardi Int, Herbicide Resistance Action Comm, Ishihara Sangyo Kaisha Ltd, ISK Biosci Corp, LG Chem Ltd, Monsanto Europe Africa, Rhone Poulenc, Ricerca Inc, Sandoz Agro Inc, Stewart Agr Res, Zeneca Agrochem, Danida, Danish Environm Protect Agcy, Danish Inst Plant & Soil Sci, Danish Vet & Agr Res Council, Commiss European Communities, FAO, Federat Danish Farmers Unions, Royal Vet & Agr Univ, Thomas B Thrige Fund
C1 Natl Agr Res Inst, Western Div, Yundum, Gambia.
RP Kunjo, EM (reprint author), Natl Agr Res Inst, Western Div, Yundum, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU DANMARKS JORDBRUGSFORSKNING
PI SLAGELSE
PA AFD PLANTEBESKYTTELSE FORSKNINGSCENTER FLAKKEBJERG, DK 4200 SLAGELSE,
   DENMARK
BN 87-984996-1-0
PY 1996
BP 685
EP 686
PG 2
WC Agronomy; Plant Sciences
SC Agriculture; Plant Sciences
GA BL70T
UT WOS:000076408300102
OA No
DA 2017-08-15
ER

PT J
AU McGuire, W
   DAlessandro, U
   Olaleye, BO
   Thomson, MC
   Langerock, P
   Greenwood, BM
   Kwiatkowski, D
AF McGuire, W
   DAlessandro, U
   Olaleye, BO
   Thomson, MC
   Langerock, P
   Greenwood, BM
   Kwiatkowski, D
TI C-reactive protein and haptoglobin in the evaluation of a
   community-based malaria control programme
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; C-reactive protein; haptoglobin;
   children; The Gambia
ID TUMOR-NECROSIS-FACTOR; NETS MOSQUITO NETS; TREATED BED NETS;
   FALCIPARUM-MALARIA; WEST-AFRICA; GAMBIAN CHILDREN; RURAL AREA;
   INDICATOR; MORTALITY; MORBIDITY
AB When cross-sectional surveys are used to evaluate malaria intervention programmes in the community, the prevalence of morbidity is difficult to assess because of the fluctuating nature of malarial fever. We have therefore investigated the impact of bed net usage on 2 surrogate markers of malarial morbidity: ii) elevated C-reactive protein (CRP) (>8 mg/L) plus detectable parasitaemia, as an indicator of malaria-induced acute-phase response; and (ii) reduced haptoglobin levels (<180 mg/L), which in this population indicates malaria-induced intravascular haemolysis. Among 1505 Gambian children 1-5 years old, examined on a single occasion at the end of the malarial transmission season, 5% had parasitaemia plus fever, while 24%. had parasitaemia plus elevated CRP, and 35% had low haptoglobin. The proportion of children who had parasitaemia plus elevated CRP was significantly lower among those who had slept under insecticide-treated bed nets than among those who did not use a bed net (16% vs. 34%, P<0.003), and the proportion with low haptoglobin differed similarly (24% vs. 49%, P<0.003). Use of an untreated bed net had a weaker effect on both indices (22% had parasitaemia plus elevated CRP, 34% had low haptoglobin). CRP and haptoglobin are simple and inexpensive to measure in large numbers of people, and these results suggest that they could be useful for the assessment of malaria intervention programmes.
C1 MRC,FAJARA,GAMBIA.
RP McGuire, W (reprint author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD OX3 9DU,ENGLAND.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Wellcome Trust
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ALONSO PL, 1993, T ROYAL SOC TROPI S2, V87, P537
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   DAlessandro U, 1995, T ROY SOC TROP MED H, V89, P596, DOI 10.1016/0035-9203(95)90401-8
   GILLESPIE SH, 1991, J CLIN PATHOL, V44, P228, DOI 10.1136/jcp.44.3.228
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HURT N, 1994, T ROY SOC TROP MED H, V88, P182, DOI 10.1016/0035-9203(94)90287-9
   KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   NAIK P, 1984, T ROY SOC TROP MED H, V78, P812, DOI 10.1016/0035-9203(84)90027-0
   REE GH, 1971, T ROY SOC TROP MED H, V65, P574, DOI 10.1016/0035-9203(71)90038-1
   ROUGEMONT A, 1988, LANCET, V2, P709
   SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1
   SISAY F, 1992, T ROY SOC TROP MED H, V86, P14, DOI 10.1016/0035-9203(92)90418-C
   SMITH T, 1994, PARASITOLOGY, V109, P539
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   SNOW RW, 1989, ANN TROP MED PARASIT, V83, P321
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   STADNYK AW, 1991, IMMUNOPARASITOL TOD, pA7
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7
   TRAPE JF, 1988, AM J EPIDEMIOL, V127, P1282
   Voller A., 1980, MANUAL CLIN IMMUNOLO, P359
   YERLY S, 1990, ACTA TROP, V47, P237, DOI 10.1016/0001-706X(90)90015-R
   YOUNG B, 1991, PATHOLOGY, V23, P118
NR 26
TC 29
Z9 29
U1 0
U2 2
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JAN-FEB
PY 1996
VL 90
IS 1
BP 10
EP 14
DI 10.1016/S0035-9203(96)90461-7
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA TZ676
UT WOS:A1996TZ67600003
PM 8730300
OA No
DA 2017-08-15
ER

PT J
AU FAIRWEATHERTAIT, S
   PRENTICE, A
   HEUMANN, KG
   JARJOU, LMA
   STIRLING, DM
   WHARF, SG
   TURNLUND, JR
AF FAIRWEATHERTAIT, S
   PRENTICE, A
   HEUMANN, KG
   JARJOU, LMA
   STIRLING, DM
   WHARF, SG
   TURNLUND, JR
TI EFFECT OF CALCIUM SUPPLEMENTS AND STAGE OF LACTATION ON THE
   CALCIUM-ABSORPTION EFFICIENCY OF LACTATING WOMEN ACCUSTOMED TO
   LOW-CALCIUM INTAKES
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE CALCIUM; ABSORPTION; LACTATION; CALCIUM SUPPLEMENTS; STABLE ISOTOPES
ID PREGNANCY; MAGNESIUM; HUMANS; MILK
AB The effect of calcium intake on the calcium absorption efficiency from 100 mL cow milk was measured in lactating Gambian mothers habituated to a low-calcium diet [mean intake 7.08 mmol (283 mg)ld], and compared with UK lactating mothers consuming high-calcium diets [mean intake 29.2 mmol (1168 mg)/d] by using a double stable-isotope technique (oral Ca-44 and intravenous Ca-42). In a double-blind trial starting 9 d postpartum, Gambian mothers were given a calcium supplement [17.85 mmol (714 mg)/d] or placebo for 12 mo. At 3 and 12 mo postpartum, mean (I SEM) calcium absorption from isotopically enriched milk was 52.3 +/- 3.1% (n = 25) and 47.2 +/- 4.8% (n = 24) in the unsupplemented Gambian mothers and 48.8 +/- 2.8% (n = 28) and 42.9 +/- 3.7% (n = 24) in the supplemented mothers, respectively. There was no effect of supplementation or stage of lactation on the efficiency of calcium absorption. At 3 mo postpartum the UK mothers absorbed 32.2 +/- 3.8% of the isotopically enriched calcium added to milk, which was significantly less than that of the Gambian mothers (P < 0.01).
C1 MRC,DUNN NUTR UNIT,CAMBRIDGE,ENGLAND.
   MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
   UNIV REGENSBURG,INST INORGAN CHEM,W-8400 REGENSBURG,GERMANY.
   HUMAN NUTR RES CTR,USDA,SAN FRANCISCO,CA.
RP FAIRWEATHERTAIT, S (reprint author), INST FOOD RES,NORWICH LAB,NORWICH RES PK,NORWICH NR4 7UA,NORFOLK,ENGLAND.
RI Fairweather-Tait, Susan/K-4251-2012
CR AUBERT JP, 1963, J CLIN INVEST, V42, P885, DOI 10.1172/JCI104781
   FAIRWEATHERTAIT SJ, 1989, BRIT J NUTR, V62, P379, DOI 10.1079/BJN19890038
   HEANEY RP, 1975, J LAB CLIN MED, V85, P881
   HEANEY RP, 1988, AM J CLIN NUTR, V47, P262
   HEANEY RP, 1989, AM J CLIN NUTR, V49, P372
   HEUMANN KG, 1979, FRESEN Z ANAL CHEM, V297, P35, DOI 10.1007/BF00487746
   KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384
   MALM OLE J., 1958, SCAND JOUR CLIN AND LAB INVERT, V10, P1
   MOSER-VEILLON P B, 1989, FASEB Journal, V3, pA645
   NORMAN DA, 1981, J CLIN INVEST, V67, P1599, DOI 10.1172/JCI110194
   Paul AA, 1978, MCCANCE WIDDOWSONS C
   Payne R. W., 1987, GENSTAT 5 REFERENCE
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   Prentice A., 1994, AM J CLIN NUTR S, V59, p477S
   Prentice Andrew, 1986, HUMAN LACTATION, P13
   RECKER RR, 1988, AM J CLIN NUTR, V47, P93
   SHEIKH MS, 1990, MINER ELECTROL METAB, V16, P130
   SPECKER BL, 1994, AM J CLIN NUTR, V59, P593
   TURNLUND JR, 1990, J MICRONUTR ANAL, V7, P117
   YERGEY AL, 1987, BIOMED ENVIRON MASS, V14, P603, DOI 10.1002/bms.1200141105
   YERGEY AL, 1994, J NUTR, V124, P674
NR 22
TC 43
Z9 44
U1 0
U2 1
PU AMER SOC CLIN NUTRITION INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE SUBSCRIPTIONS, RM L-2310, BETHESDA, MD 20814-3998
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC
PY 1995
VL 62
IS 6
BP 1188
EP 1192
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA TJ284
UT WOS:A1995TJ28400002
PM 7491878
OA No
DA 2017-08-15
ER

PT J
AU Jallow, BP
AF Jallow, BP
TI Emissions of greenhouse gases from agriculture, land-use change, and
   forestry in the Gambia
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Proceedings Paper
CT Workshop on African Greenhouse Gas Emission Inventories and Mitigation
   Options - Forestry, Land-Use Change, and Agriculture
CY MAY 29-JUN 02, 1995
CL JOHANNESBURG, SOUTH AFRICA
SP US Country Studies Program, UNEP
AB The Gambia has successfully completed a national greenhouse gas emissions inventory based on the results of a study funded by the United Nations Environment Programme (UNEP)/Global Environment Facility (GEF) Country Case Study Program. The concepts of multisectoral, multidisciplinary, and interdisciplinary collaboration were most useful in the preparation of this inventory. New data were gathered during the study period, some through regional collaboration with institutions such as Environment and Development in the Third World (ENDA-TM) Energy Program and the Ecological Monitoring Center in Dakar, Senegal, and some through national surveys and the use of remote sensing techniques, as in the Bushfires Survey. Most of the data collected are used in this paper. The Intergovernmental Panel on Climate Change/Organisation for Economic Go-operation and Development/International Energy Agency (IPCC/OECD/IEA) methodology is used to calculate greenhouse gas emissions. Many of the default data in the IPCC/OECD/IEA methodology have also been used. Overall results indicate that in the biomass sectors (agriculture, forestry, and land-use change) carbon dioxide (CO2) is emitted most, with a total of 1.7 Tg. This is followed by methane (CH4), 22.3 Gg; carbon monoxide (CO), 18.7 Gg; nitrogen oxides (NOx), 0.3 Gg; and nitrous oxide (N2O), 0.014 Gg. The Global Warming Potential (GWP) was used as an index to describe the relative effects of the various gases reported here. Based on the emissions in The Gambia in 1993, it was found that CO2 will contribute 75%, CH4 about 24.5%, and N2O 0.2% of the warming expected in the 100-year period beginning in 1993. The results in this analysis are limited by the shortcomings of the IPCC/OECD/IEA methodology and scarce national data Because the methodology was developed outside of the developing world, most of its emissions factors and coefficients were developed and tested in environments that are very different from The Gambia. This is likely to introduce some uncertainties into the results of the calculations. Factors and coefficients that are country- or region-specific are likely to provide more accurate results and should be developed. The surveys were conducted either during the wet season or just at the end of the wet season. This seasonal factor should contribute to variations in the results, particularly in the livestock numbers and composition survey. Use of one-time survey data is also likely to introduce uncertainty into the results.
RP Jallow, BP (reprint author), DEPT WATER RESOURCES,7 MARINA PARADE,BANJUL,GAMBIA.
CR HOUGHTON JT, 1992, SUPPLEMENTAL REPORT
   JABARA CL, 1990, EC REFORM POVERTY GA
   Prince SD, 1990, REMOTE SENSING SAHEL
   1994, IPCC DRAFT GUIDELINE
   1993, 1993 STATISTICAL YB
   1991, SECTORAL CONTRIBUTIO
   1992, GAMBIA ENV ACTION PL
   1994, 1991 GREENHOUSE GAS
   GAMBIA 1992 SECTORAL
   1995, IPCC GUIDELINES NATI
NR 10
TC 2
Z9 2
U1 3
U2 13
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0167-6369
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD NOV-DEC
PY 1995
VL 38
IS 2-3
BP 301
EP 312
DI 10.1007/BF00546771
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA TP551
UT WOS:A1995TP55100017
PM 24197953
OA No
DA 2017-08-15
ER

PT J
AU MULHOLLAND, EK
   FALADE, AG
   CORRAH, PT
   OMOSIGHO, C
   NJAI, P
   GIADOM, B
   ADEGBOLA, RA
   TSCHAPPELER, H
   TODD, J
   GREENWOOD, BM
AF MULHOLLAND, EK
   FALADE, AG
   CORRAH, PT
   OMOSIGHO, C
   NJAI, P
   GIADOM, B
   ADEGBOLA, RA
   TSCHAPPELER, H
   TODD, J
   GREENWOOD, BM
TI A RANDOMIZED TRIAL OF CHLORAMPHENICOL VS TRIMETHOPRIM-SULFAMETHOXAZOLE
   FOR THE TREATMENT OF MALNOURISHED CHILDREN WITH COMMUNITY-ACQUIRED
   PNEUMONIA
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE MALNUTRITION; CHLORAMPHENICOL; TRIMETHOPRIM-SULFAMETHOXAZOLE; PNEUMONIA;
   TREATMENT TRIAL; STREPTOCOCCUS PNEUMONIAE; ANTIMICROBIAL SUSCEPTIBILITY
ID MALNUTRITION; PHARMACOKINETICS; METABOLISM
AB Children in developing countries who present with malnutrition often have infections, particularly pneumonia, at the time of presentation. We evaluated the initial antibiotic management of 144 Gambian children who presented for the first time with malnutrition and who had clinical or radiologic evidence of pneumonia. They were enrolled in a double blind trial of trimethoprim-sulfamethoxazole vs. chloramphenicol. Most children in the study underwent detailed investigations of bacterial and viral etiology as part of another study. The study drug was administered for a week along with oral metronidazole, vitamins and standardized nutritional therapy. Treatment failure was defined as the need for change to parenteral antibiotics during treatment, failure to respond to a week of treatment with the study drug or relapse during the following 2 weeks. There were no differences between the treatment groups in the clinical indicators of severity, etiology or radiologic findings. Thirty-three children were excluded from the analysis because of tuberculosis, inappropriate enrollment or inadequate follow up. Of the 111 children remaining, 32 (16 in each arm of the study) failed treatment. Clinical failure was not related to in vitro antimicrobial resistance in the 20 cases in which invasive bacterial isolates were obtained. Those who failed treatment were more likely to have had lower chest wall indrawing and positive bacterial cultures than those who were successfully treated. In an area with infrequent antimicrobial resistance of common respiratory pathogens, oral chloramphenicol and trimethoprim-sulfamethoxazole were equally effective in the initial management of malnourished children with community-acquired pneumonia.
C1 MRC LABS,BANJUL,GAMBIA.
RP MULHOLLAND, EK (reprint author), WHO,ARI PROGRAMME,CH-1211 GENEVA 27,SWITZERLAND.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   ARDATI KO, 1979, J PEDIATR-US, V95, P801, DOI 10.1016/S0022-3476(79)80740-4
   ASMAR BI, 1981, AM J DIS CHILD, V135, P1100
   DOHERTY JF, 1991, LANCET, V338, P1454
   FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299
   GUTMAN LT, 1984, PEDIATR INFECT DIS J, V3, P349, DOI 10.1097/00006454-198407000-00018
   HOPPU K, 1989, ARCH DIS CHILD, V64, P343
   KHANUM S, 1994, LANCET, V344, P1728
   KRISHNASWAMY K, 1978, CLIN PHARMACOKINET, V3, P216, DOI 10.2165/00003088-197803030-00003
   MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5
   MEHTA S, 1975, AM J CLIN NUTR, V28, P977
   MEHTA S, 1983, J PEDIATR GASTR NUTR, V2, P407
   RISTUCCIA AM, 1985, THER DRUG MONIT, V7, P159, DOI 10.1097/00007691-198506000-00004
   SALTER AJ, 1982, REV INFECT DIS, V4, P196
   SAMOTRA K, 1986, ACTA PHARMACOL SIN, V7, P162
   SMITH AL, 1983, PEDIATR CLIN N AM, P209
   YUNIS AA, 1970, ARCH INTERN MED, V126, P272, DOI 10.1001/archinte.126.2.272
NR 17
TC 15
Z9 15
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 1995
VL 14
IS 11
BP 959
EP 965
DI 10.1097/00006454-199511000-00007
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA TE790
UT WOS:A1995TE79000008
PM 8584362
OA No
DA 2017-08-15
ER

PT J
AU Greenwood, BM
   David, PH
   OtooForbes, LN
   Allen, SJ
   Alonso, PL
   Schellenberg, JRA
   Byass, P
   Hurwitz, M
   Menon, A
   Snow, RW
AF Greenwood, BM
   David, PH
   OtooForbes, LN
   Allen, SJ
   Alonso, PL
   Schellenberg, JRA
   Byass, P
   Hurwitz, M
   Menon, A
   Snow, RW
TI Mortality and morbidity from malaria after stopping malaria
   chemoprophylaxis
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; prophylaxis; morbidity; mortality; pyrimethamine plus dapsone;
   children; The Gambia
ID GAMBIAN CHILDREN; RURAL AREA; PERIOD
AB Gambian children who had received malaria chemoprophylaxis for a variable period of time during their first 5 years of life were followed to determine whether they experienced a rebound in mortality or in morbidity from malaria during the period after chemoprophylaxis was stopped. The risk of dying between the ages of 5 years, when chemoprophylaxis was stopped, and 10 years was no higher among children who had received chemoprophylaxis with Maloprim(R) (pyrimethamine plus dapsone) for some period during their first 5 years of life than among children who had received placebo (21 vs. 24 deaths) and the beneficial effect of chemoprophylaxis on mortality observed during the first 5 years of life was sustained. The incidence of clinical attacks of malaria during the year after medication was stopped was significantly higher among children who had previously received Maloprim(R) for several years than among children who had previously received placebo. However, at the end of this year, there was no significant difference in spleen rate, parasite rate or packed cell volume between the 2 groups of children. Thus, stopping chemoprophylaxis after a period of several years increased the risk of clinical malaria but did not result in a rebound in mortality in Gambian children. However, the number of deaths recorded was small, so a modest effect on mortality cannot be excluded.
C1 MRC,BANJUL,GAMBIA.
RP Greenwood, BM (reprint author), LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
OI Byass, Peter/0000-0001-5474-4361
CR ALLEN SJ, 1990, J TROP MED HYG, V93, P313
   ALONSO PL, 1993, T ROYAL SOC TROPI S2, V8
   ARCHIBALD H. MUNRO, 1956, BULL WORLD HEALTH ORGAN, V15, P775
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P549
   COLBOURNE M. J., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P356, DOI 10.1016/0035-9203(55)90058-4
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   Molineaux L, 1980, GARKI PROJECT
   OTOO LN, 1988, T ROY SOC TROP MED H, V82, P59, DOI 10.1016/0035-9203(88)90263-5
   OTOO LN, 1989, T ROY SOC TROP MED H, V83, P778, DOI 10.1016/0035-9203(89)90324-6
   PRINGLE G, 1966, B WORLD HEALTH ORGAN, V34, P269
NR 12
TC 64
Z9 64
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1995
VL 89
IS 6
BP 629
EP 633
DI 10.1016/0035-9203(95)90419-0
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA TP678
UT WOS:A1995TP67800015
PM 8594677
OA No
DA 2017-08-15
ER

PT J
AU vanHensbroek, MB
   MorrisJones, S
   Meisner, S
   Jaffar, S
   Bayo, L
   Dackour, R
   Phillips, C
   Greenwood, BM
AF vanHensbroek, MB
   MorrisJones, S
   Meisner, S
   Jaffar, S
   Bayo, L
   Dackour, R
   Phillips, C
   Greenwood, BM
TI Iron, but not folic acid, combined with effective antimalarial therapy
   promotes haematological recovery in African children after acute
   falciparum malaria
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE malaria; Plasmodium falciparum; chloroquine; pyrimethamine-sulfadoxine;
   iron; folic acid; children; The Gambia
ID GAMBIAN CHILDREN; PLASMODIUM-FALCIPARUM; ANEMIA; CHLOROQUINE;
   SULFADOXINE
AB Whether children with malarial anaemia should receive supplementation with iron or folic acid is uncertain. Therefore, the effects of supplementary treatment with iron or folic acid, given together with chloroquine or pyrimethamine-sulfadoxine (Fansidar(R)), has been assessed in 600 Gambian children with uncomplicated falciparum malaria. After one month, haematological recovery was significantly better in the group treated with Fansidar(R) than in the chloroquine-treated group (difference in mean haemoglobin level=0.54 g/dL, P=0.01). Children who received iron had a significantly better response than those given placebo (differences in mean haemoglobin level after one month and at dry season follow-up=0.70 g/dL, P=0.006, and 0.81 g/dL, P=0.001, respectively). Iron supplementation was not associated with increased prevalence of malaria. Supplementation with folic acid did not improve the haematological response but, among children who received Fansidar(R), the treatment failure rate was significantly higher among those given folic acid than among those given placebo. Thus, supplementation with iron, but not folic acid, improves haematological recovery without increasing susceptibility to malaria.
C1 ACAD MED CTR,INFECT DIS & TROP MED UNIT,AMSTERDAM,NETHERLANDS.
   MED RES COUNCIL LABS,BANJUL,GAMBIA.
OI Phillips, Christine/0000-0001-5602-3664
CR ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   ABDALLA SH, 1984, T ROY SOC TROP MED H, V78, P60, DOI 10.1016/0035-9203(84)90173-1
   ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265
   BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6
   BLOLAND PB, 1993, J INFECT DIS, V167, P932
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P585
   Eggelte TA, 1990, INT MONOGRAPH SERIES, V3, P35
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12
   KEUTER M, 1992, TROP GEOGR MED, V44, P1
   MEAD R, 1986, DESIGN EXPT
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P169, DOI 10.1016/0035-9203(86)90232-4
   PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17
   SNOW RW, 1991, T ROY SOC TROP MED H, V85, P584, DOI 10.1016/0035-9203(91)90351-X
   Strickland G T, 1970, Am J Trop Med Hyg, V19, P910
   WATKINS WM, 1985, MOL BIOCHEM PARASIT, V14, P55, DOI 10.1016/0166-6851(85)90105-7
   WEATHERALL DJ, 1983, CIBA F S 94, P74
   WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, P1570
   1968, WHO TECHNICAL REPORT, V405
   [Anonymous], 1988, SAS STAT USERS GUIDE
NR 24
TC 97
Z9 97
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1995
VL 89
IS 6
BP 672
EP 676
DI 10.1016/0035-9203(95)90438-7
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA TP678
UT WOS:A1995TP67800031
PM 8594693
OA No
DA 2017-08-15
ER

PT J
AU NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
AF NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
TI HELMINTH-PARASITES AND HYPOBIOSIS OF NEMATODES IN NDAMA CATTLE DURING
   THE DRY SEASON IN THE GAMBIA
SO VETERINARY PARASITOLOGY
LA English
DT Note
DE CATTLE; HELMINTHS; HYPOBIOSIS
AB Three series of necropsies of cattle were performed, corresponding to early dry season, approximately 1 month after the last rains (November, n = 6), mid dry season (February, n = 6) and end dry season (April, n = 3), Eggs per gram of faeces (epg) were determined just before necropsy; Three trematodes (Fasciola gigantica, Schistosoma spp. and Paramphistomatids) and 11 nematodes were identified from cattle, with the prevalence rate varying from 6.7% to 100%. Haemonchus contortus was the most abundant nematode species, constituting from 81% (February) to 34.8% (April) of the total nematode burden. The proportion of L(4) (indicating hypobiosis) of H. contortus was 85-99%, During the dry season, 44-67% of Oesophagostomum radiatum and 8-34% of Cooperia spp, population occurred as L(4). There was no correlation between the number of worms found at necropsy and the epg. H. contortus survives almost exclusively as larvae in the abomasal mucosae, whereas Cooperia spp. and O. radiatum survive partly as larvae in the lumen, and also in nodules in the case of O. radiatum, and partly as hypometabolic adults with highly reduced fecundity. Trichostrongylus axei, T. colubriformis, Bunostomum phlebotomum, Strongyloides papillosus, Nematodirus spp. and Setaria labiatopapillosa occurred in small numbers.
C1 INST TROP MED,B-2000 ANTWERP,BELGIUM.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   LAB PFISTER,CH-3018 BERN,SWITZERLAND.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR DUNN AM, 1978, VET HELMINTHOLOGY, P43
   Eysker M., 1991, P SO C AVIAN DISEASE, P40
   GIBBS HC, 1982, VET PARASITOL, V11, P25, DOI 10.1016/0304-4017(82)90119-4
   HART JA, 1964, BRIT VET J, V120, P87
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   Mattioli R. C., 1992, Parassitologia (Rome), V34, P109
   MURRAY M, 1981, VET REC, V109, P503
   NDAO M, 1992, 7TH P INT C TROP VET, V2, P485
   NDAO M, 1995, IN PRESS VET RES COM
   PANDEY VS, 1990, VET PARASITOL, V36, P347, DOI 10.1016/0304-4017(90)90048-G
   Soulsby EJL, 1965, TXB VET CLIN PARASIT, V1
   1992, STATISTICS VERSION 5
   [Anonymous], 1986, MANUAL VET PARASITOL
NR 13
TC 12
Z9 14
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 1995
VL 60
IS 1-2
BP 161
EP 166
DI 10.1016/0304-4017(94)00771-4
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA TE730
UT WOS:A1995TE73000016
PM 8644452
OA No
DA 2017-08-15
ER

PT J
AU WEAVER, LT
   DIBBA, B
   SONKO, B
   BOHANE, TD
   HOARE, S
AF WEAVER, LT
   DIBBA, B
   SONKO, B
   BOHANE, TD
   HOARE, S
TI MEASUREMENT OF STARCH DIGESTION OF NATURALLY C-13-ENRICHED WEANING
   FOODS, BEFORE AND AFTER PARTIAL DIGESTION WITH AMYLASE-RICH FLOUR, USING
   A C-13 BREATH TEST
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE AMYLASE; CEREAL; DIGESTION; WEANING FOODS
ID CHILDREN
AB Malnutrition in infancy is a global problem which leads to retardation of childhood growth and development. There is a pressing need to improve weaning strategies for infants of the developing world. Traditional Gambian weaning foods are watery and of low energy density, but addition of energy in the form of fat and carbohydrate leads to thick, viscous gruels which are difficult to ingest. Partial digestion with amylase (EC 3.2.1.1)-rich flour reduces their viscosity while retaining their energy density. The aim of the present study was to measure the digestibility of a maize-based weaning food, before and after amylase digestion, in malnourished children using a C-13 breath test. Ten children (aged 7-16 months; mean weight-for-age Z score -0.8) received isovolumetric and isoenergetic quantities of a maize-based weaning food naturally abundant with C-13. Breath samples were collected at intervals of 30 min for 5 h thereafter and (CO2)-C-13 enrichment was measured by isotope-ratio mass spectrometry. Percentage dose of C-13 recovered increased from a mean 13.7 (SD 3.7)% before, to 18.3 (SD 5.6)% after ingestion of amylase-treated weaning foods (P < 0.1). There was a significant inverse relation between age and weight, and percentage dose of C-13 recovered in children receiving amylase-treated feeds. There were no differences in concentrations of amylase in saliva of infants or breast milk of their mothers. Partial digestion of supplementary foods may improve the nutrition of undernourished weaning children, not only by reducing their viscosity, thereby increasing ingestion, but also by improving their digestion and thereby their absorption.
C1 MRC,DUNN NUTR UNIT,CAMBRIDGE CB4 1XJ,ENGLAND.
   KENEBA,W KIANG,GAMBIA.
CR BLACKBUR.WR, 1969, LAB INVEST, V20, P305
   DEWIT O, 1992, PEDIATR RES, V32, P45, DOI 10.1203/00006450-199207000-00009
   DEWIT O, 1990, PEDIATR RES, V28, P502, DOI 10.1203/00006450-199011000-00017
   DEWIT O, 1990, P NUTR SOC, V49, pA5
   HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607
   HARDING M, 1994, ISOTOPENPRAXIS, V30, P1, DOI 10.1080/00211919408046707
   HELLSTROM A, 1981, J TROP PEDIATRICS, V27, P127
   HUDSON GJ, 1980, ECOL FOOD NUTR, V10, P9
   MCCLEAN P, 1993, ARCH DIS CHILD, V68, P62
   Nout M. J. R., 1993, International Journal of Food Sciences and Nutrition, V43, P213, DOI 10.3109/09637489309027545
   ROWLAND M G M, 1978, Lancet, V1, P136
   ROWLAND MGM, 1980, ACTA PEDIATRICA SCAN, V232, P33
   SAUNIERE JF, 1986, DIGEST DIS SCI, V31, P481, DOI 10.1007/BF01320311
   SAUNIERE JP, 1988, AM J CLIN NUTR, V44, P1233
   Weaver L. T., 1994, International Journal of Food Sciences and Nutrition, V45, P127, DOI 10.3109/09637489409166151
   WEAVER LT, 1993, PROGR UNDERSTANDING, P155
   1991, LANCET, V338, P604
NR 17
TC 18
Z9 18
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT
PY 1995
VL 74
IS 4
BP 531
EP 537
DI 10.1079/BJN19950156
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA TD152
UT WOS:A1995TD15200008
PM 7577891
OA No
DA 2017-08-15
ER

PT J
AU ADEGBOLA, RA
   MULHOLLAND, EK
   GREENWOOD, BM
AF ADEGBOLA, RA
   MULHOLLAND, EK
   GREENWOOD, BM
TI DETERMINING ETIOLOGY OF PNEUMONIA - REPLY
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
DE PNEUMONIA; ANTIBIOTICS
ID ANTIBIOTICS
RP ADEGBOLA, RA (reprint author), MRC LABS,BANJUL,GAMBIA.
CR CUNNINGHAM DG, 1983, J PEDIATR-US, V103, P747, DOI 10.1016/S0022-3476(83)80473-9
   OBASEIKIEBOR EE, 1987, J ANTIMICROB CHEMOTH, V20, P759, DOI 10.1093/jac/20.5.759
   YANG YH, 1993, PEDIATR INFECT DIS J, V12, P986, DOI 10.1097/00006454-199312000-00004
NR 3
TC 3
Z9 3
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1995
VL 14
IS 10
BP 920
EP 921
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA RZ912
UT WOS:A1995RZ91200030
OA No
DA 2017-08-15
ER

PT J
AU ASPRAY, TJ
   PRENTICE, A
   COLE, TJ
AF ASPRAY, TJ
   PRENTICE, A
   COLE, TJ
TI THE BONE-MINERAL CONTENT OF WEIGHT-BEARING BONES IS INFLUENCED BY THE
   RATIO OF SITTING TO STANDING HEIGHT IN ELDERLY GAMBIAN WOMEN
SO BONE
LA English
DT Article
DE BONE MINERAL CONTENT; SITTING HEIGHT; OSTEOPOROSIS; WOMEN; AFRICA
ID DENSITY; BRITISH; HIP
AB Body size is an important predictor of bone mineral content (BMC) at various anatomical sites but the influence of relative body proportions on BMC has previously been little studied. Using single- and dual-photon absorptiometry, we measured BMC at the distal and midshaft of the radius, the neck of femur, and the lumbar spine in 190 rural West African women aged 45-84 years. After regression adjustment for age, bone width and weight, sitting height and standing height were not separate significant determinants of BMC, except at the lumbar spine (standing height, p < 0.05). However, the ratio of sitting:standing height was a significant determinant of BMC at the neck of femur and lumbar spine, but not the midshaft or distal radius. The fact that sitting:standing height ratio is a positive predictor for BMC at hip and lumbar spine may reflect a higher peak bone mass or selective conservation of mineral in weight-bearing bones in subjects with a proportionately longer torso. We do not know whether the relationship is racially determined but we recommend that this simple combination of measurements be used in further studies in subjects of all races.
C1 MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
   MRC,DUNN NUTR UNIT,CAMBRIDGE,ENGLAND.
OI Cole, Tim/0000-0001-5711-8200
CR ADEBAJO AO, 1991, AGE AGEING, V20, P435, DOI 10.1093/ageing/20.6.435
   BEVIER WC, 1989, J BONE MINER RES, V4, P421
   EVELETH PB, 1976, WORLDWIDE VARIATION, P222
   LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247
   MAY H, 1994, AGE AGEING, V23, P235, DOI 10.1093/ageing/23.3.235
   OOMS ME, 1993, J BONE MINER RES, V8, P669
   PRENTICE A, 1990, BONE MINER, V10, P211, DOI 10.1016/0169-6009(90)90263-F
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
NR 9
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE PUBL CO INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 8756-3282
J9 BONE
JI Bone
PD SEP
PY 1995
VL 17
IS 3
BP 261
EP 263
DI 10.1016/8756-3282(95)00216-Z
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA RT429
UT WOS:A1995RT42900010
PM 8541139
OA No
DA 2017-08-15
ER

PT J
AU WALLER, D
   KRISHNA, S
   CRAWLEY, J
   MILLER, K
   NOSTEN, F
   CHAPMAN, D
   TERKUILE, FO
   CRADDOCK, C
   BERRY, C
   HOLLOWAY, PAH
   BREWSTER, D
   GREENWOOD, BM
   WHITE, NJ
AF WALLER, D
   KRISHNA, S
   CRAWLEY, J
   MILLER, K
   NOSTEN, F
   CHAPMAN, D
   TERKUILE, FO
   CRADDOCK, C
   BERRY, C
   HOLLOWAY, PAH
   BREWSTER, D
   GREENWOOD, BM
   WHITE, NJ
TI CLINICAL-FEATURES AND OUTCOME OF SEVERE MALARIA IN GAMBIAN CHILDREN
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; CHILDHOOD CEREBRAL MALARIA; AFRICAN CHILDREN;
   MALAWIAN CHILDREN; INTRAMUSCULAR CHLOROQUINE; INTRACRANIAL-PRESSURE;
   WEST-AFRICA; QUININE; MORTALITY; SEQUELAE
AB The clinical and laboratory features of severe falciparum malaria in 180 Gambian children were studied between 1985 and 1989. Of the 180 children, 118 (66%) presented with seizures, 77 (43%) had cerebral malaria, 35 (20%) had witnessed seizures after admission, 29 (16%) were hypoglycemic, and 27 (15%) died. Respiratory distress was a common harbinger of a fatal outcome. The differences in admission parasite counts in the blood, hematocrit, and opening cerebrospinal pressures for patients who died and survivors were not significant. A multiple logistic regression model identified neurological status (coma, particularly if associated with extensor posturing), stage of parasite development on the peripheral blood film, pulse rate of >150 or respiratory rate of >50, hypoglycemia, and hyperlactatemia (plasma lactate level, >5 mmol/L) as independent indicators of a fatal outcome, Biochemical evidence of hepatic and renal dysfunction was an additional marker of a poor prognosis, but, in contrast to severe malaria in adults, none of these children with severe malaria had acute renal failure.
C1 MAHIDOL UNIV,FAC TROP MED,BANGKOK 10400,THAILAND.
   JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,HEADINGTON,OXON,ENGLAND.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341.
   UNIV WASHINGTON,DIV INFECT DIS,SEATTLE,WA 98195.
   UNIV AMSTERDAM,ACAD MED CTR,INFECT DIS & TROP MED UNIT,1105 AZ AMSTERDAM,NETHERLANDS.
   MRC,FAJARA,SENEGAL.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
RI White, Nicholas/I-4629-2012
OI Krishna, Sanjeev/0000-0003-0066-0634; Nosten,
   Francois/0000-0002-7951-0745
FU Wellcome Trust
CR AHMAD S H, 1986, Indian Journal of Pediatrics, V53, P409, DOI 10.1007/BF02760427
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ARMENGAUD M, 1962, B SOC MED AFR NOIRE, V7, P167
   BERNER H, 1975, KLIN PADIATR, V187, P401
   BERNHEIMER LP, 1986, ADV SPECIAL ED, V5, P61
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   BONDI FS, 1992, T ROY SOC TROP MED H, V86, P17, DOI 10.1016/0035-9203(92)90420-H
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   CARME B, 1993, AM J TROP MED HYG, V48, P216
   Commey J. O. O., 1980, Ghana Medical Journal, V19, P68
   FIELD JW, 1949, T ROY SOC TROP MED H, V43, P33, DOI 10.1016/0035-9203(49)90022-X
   GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   GUIGNARD J, 1963, ANN PEDIATR, V43, P646
   IKPATT NW, 1990, E AFR MED J, V67, P341
   KAWO NG, 1990, LANCET, V336, P454, DOI 10.1016/0140-6736(90)92009-7
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   KWIATKOWSKI D, 1991, LANCET, V337, P1281
   KWIATKOWSKI D, 1993, Q J MED, V86, P91
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   LEMERCIER G, 1969, PATHOL BIOL, V17, P459
   LOOAREESUWAN S, 1983, LANCET, V1, P434
   LOOAREESUWAN S, 1995, CLIN INFECT DIS, V21, P300
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Musoke L. K., 1966, East African Medical Journal, V43, P561
   NEEQUAYE J, 1991, T ROY SOC TROP MED H, V85, P718, DOI 10.1016/0035-9203(91)90425-X
   NEWTON CRJ, 1992, 13TH P INT C TROP ME
   NEWTON CRJC, 1994, ARCH DIS CHILD, V70, P281
   NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B
   OMANGA U, 1983, ANN PEDIATR-PARIS, V30, P294
   PASVOL G, 1991, AM J TROP MED HYG, V45, P702
   REY M, 1966, Bulletin de la Societe de Pathologie Exotique, V59, P683
   ROTHE H, 1956, East Afr Med J, V33, P405
   SANOHKO A, 1968, Bulletin de la Societe Medicale d'Afrique Noire de Langue Francaise, V13, P662
   SCHMUTZHARD E, 1984, T ROY SOC TROP MED H, V78, P351, DOI 10.1016/0035-9203(84)90118-4
   SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   SOLOMON T, 1994, LANCET, V343, P149, DOI 10.1016/S0140-6736(94)90937-7
   STACE J, 1982, PAPUA NEW GUINEA MED, V25, P230
   TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E
   TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602
   THAPA B R, 1988, Indian Pediatrics, V25, P61
   TRANG TTM, 1992, CLIN INFECT DIS, V15, P874
   TRAPE JF, 1987, T ROY SOC TROP MED H, V81, P34
   WALKER O, 1992, T ROY SOC TROP MED H, V86, P491, DOI 10.1016/0035-9203(92)90082-N
   WALLER D, 1990, T ROY SOC TROP MED H, V84, P488, DOI 10.1016/0035-9203(90)90009-4
   WALLER D, 1991, T ROY SOC TROP MED H, V85, P362, DOI 10.1016/0035-9203(91)90291-6
   WATTANAGOON Y, 1994, T ROY SOC TROP MED H, V88, P426, DOI 10.1016/0035-9203(94)90415-4
   WHITE NJ, 1989, LANCET, V1, P435
   WHITE NJ, 1988, NEW ENGL J MED, V319, P1493, DOI 10.1056/NEJM198812083192301
   WHITE NJ, 1989, LANCET, V2, P1313
   WHITE NJ, 1992, LANCET, V339, P317, DOI 10.1016/0140-6736(92)91644-N
   WHITE NJ, 1987, LANCET, V1, P708
   WHITE NJ, 1991, LANCET, V338, P640, DOI 10.1016/0140-6736(91)90654-8
   WHITE NJ, 1992, ADV PARASIT, V31, P84
   WOLFGOULD C, 1991, J TROP PEDIATRICS, V38, P290
   WRIGHT PW, 1993, PEDIATR INFECT DIS J, V12, P37, DOI 10.1097/00006454-199301000-00009
   [Anonymous], 1990, T R SOC TROP MED S2, V84, P1
NR 64
TC 134
Z9 136
U1 1
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP
PY 1995
VL 21
IS 3
BP 577
EP 587
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA RU940
UT WOS:A1995RU94000017
PM 8527547
OA No
DA 2017-08-15
ER

PT J
AU WEBER, MW
   PALMER, A
   OPARAUGO, A
   MULHOLLAND, EK
AF WEBER, MW
   PALMER, A
   OPARAUGO, A
   MULHOLLAND, EK
TI COMPARISON OF NASAL PRONGS AND NASOPHARYNGEAL CATHETER FOR THE DELIVERY
   OF OXYGEN IN CHILDREN WITH HYPOXEMIA BECAUSE OF A LOWER
   RESPIRATORY-TRACT INFECTION
SO JOURNAL OF PEDIATRICS
LA English
DT Article
AB Objective To determine the best method of oxygen delivery for children in developing countries who have hypoxemia caused by acute lower respiratory tract infection,
   Methods: One hundred eighteen children between 7 days and 5 years of age with a lower respiratory tract infection and arterial hemoglobin oxygen saturation (Sao(2)) less than 90% were randomly selected to receive oxygen by nasopharyngeal (NP) catheter (n = 56) or nasal prongs (n = 62), A crossover study to determine the flow rate necessary to achieve an Sao(2) of 95% was performed in 60 children,
   Results: One hundred twelve children could be oxygenated by the allocated method; in six oxygenation was poor with either method. The mean duration of therapy was 87.5 hours for the prongs and 94.9 hours for the NP catheter (not significant), The median oxygen consumption was 2142 L for prongs and 1692 L for the NP catheter (not significant), In the crossover study the prongs needed, on average, 26% higher oxygen flow rates than the NP catheter to obtain an Sao(2) of 95% (p = 0.003), Complete nasal obstruction was observed in 24 of the children (44%) in the NP catheter group and in 8 (13%) in the prongs group (p < 0.001). Eighteen children died, 11 with NP catheter and 7 with prongs (not significant),
   Conclusions: Because nasal prongs are less prone to complications, and oxygenation in children is equally effective, they are a more appropriate method than the NP catheter for oxygen delivery to children in developing countries with acute lower respiratory tract infections.
C1 HANNOVER MED SCH, CHILDRENS HOSP, W-3000 HANNOVER, GERMANY.
   ROYAL VICTORIA HOSP, BANJUL, GAMBIA.
RP WEBER, MW (reprint author), MRC LABS, POB 273, FAJARA, GAMBIA.
CR DYKE T, 1994, BRIT MED J, V308, P119
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   Guilfoile T, 1981, RESPIRATORY CARE, V26, P35
   KLEIN M, 1989, LANCET, V1, P493
   ONYANGO FE, 1993, BRIT MED J, V306, P612
   SHANN F, 1988, LANCET, V2, P1238
   Who Programme for the Control of Acute Respiratory Infections, 1993, WHOARI9328
   1993, 1993 WORLD BANK WORL
   1990, WHOARI905
NR 9
TC 38
Z9 40
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD SEP
PY 1995
VL 127
IS 3
BP 378
EP 383
DI 10.1016/S0022-3476(95)70067-6
PG 6
WC Pediatrics
SC Pediatrics
GA RT738
UT WOS:A1995RT73800007
PM 7658266
OA No
DA 2017-08-15
ER

PT J
AU ASPRAY, TJ
   WEAVER, LT
   KENNY, RA
   JAMES, OFW
AF ASPRAY, TJ
   WEAVER, LT
   KENNY, RA
   JAMES, OFW
TI ORTHOSTATIC HYPOTENSION IS COMMON IN ELDERLY RURAL GAMBIAN WOMEN
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
C1 MRC,DUNN NUTR UNIT,LONDON W1N 4AL,ENGLAND.
   UNIV NEWCASTLE UPON TYNE,DEPT GERIATR MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.
   MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
CR RUTAN GH, 1992, HYPERTENSION, V19, P508
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD SEP
PY 1995
VL 43
IS 9
BP SA71
EP SA71
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA RT908
UT WOS:A1995RT90800314
OA No
DA 2017-08-15
ER

PT J
AU ASPRAY, TJ
   WEAVER, LT
   PRENTICE, A
   JAMES, OFW
AF ASPRAY, TJ
   WEAVER, LT
   PRENTICE, A
   JAMES, OFW
TI HEALTH SCREENING OF THE ELDERLY - A RURAL AFRICAN EXPERIENCE
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Meeting Abstract
C1 MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
   MRC,DUNN NUTR UNIT,CAMBRIDGE CB4 1XJ,ENGLAND.
   UNIV NEWCASTLE UPON TYNE,DEPT GERIATR MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD SEP
PY 1995
VL 43
IS 9
BP SA72
EP SA72
PG 1
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA RT908
UT WOS:A1995RT90800315
OA No
DA 2017-08-15
ER

PT J
AU WEBER, M
   MUHE, L
AF WEBER, M
   MUHE, L
TI VITAMIN-D DEFICIENCY AND TETANUS
SO MONATSSCHRIFT KINDERHEILKUNDE
LA German
DT Note
RP WEBER, M (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0026-9298
J9 MONATSSCHR KINDERH
JI Mon.schr. Kinderheilkd.
PD SEP
PY 1995
VL 143
IS 9
BP 877
EP 877
PG 1
WC Pediatrics
SC Pediatrics
GA RY329
UT WOS:A1995RY32900013
OA No
DA 2017-08-15
ER

PT J
AU AABY, P
   SAMB, B
   SIMONDON, F
   SECK, AMC
   KNUDSEN, K
   WHITTLE, H
AF AABY, P
   SAMB, B
   SIMONDON, F
   SECK, AMC
   KNUDSEN, K
   WHITTLE, H
TI NONSPECIFIC BENEFICIAL EFFECT OF MEASLES IMMUNIZATION - ANALYSIS OF
   MORTALITY STUDIES FROM DEVELOPING-COUNTRIES
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID CHILDHOOD MORTALITY; GUINEA-BISSAU; RURAL BANGLADESH; VACCINATION;
   COMMUNITY; SURVIVAL; SENEGAL; TITER; AGE
AB Objective-To examine whether the reduction in mortality after standard titre measles immunisation in developing countries can be explained simply by the prevention of acute measles and its long term consequences.
   Design-An analysis of all studies comparing mortality of unimmunised children and children immunised with standard titre measles vaccine in developing countries.
   Studies-10 cohort and two case-control studies from Bangladesh, Benin, Burundi, Guinea-Bissau, Haiti, Senegal, and Zaire.
   Main outcome measures-Protective efficacy of standard titre measles immunisation against all cause mortality. Extent to which difference in mortality between immunised and unimmunised children could be explained by prevention of measles disease.
   Results-Protective efficacy against death after measles immunisation ranged from 30% to 86%. Efficacy was highest in the studies with short follow up and when children were immunised in infancy (range 44-100%). Vaccine efficacy against death was much greater than the proportion of deaths attributed to acute measles disease. In four studies from Guinea-Bissau, Senegal, and Burundi vaccine efficacy against death remained almost unchanged when cases of measles were excluded from the analysis. Diphtheria-tetanus-pertussis and polio vaccinations were not associated with reduction in mortality.
   Conclusion-These observations suggest that standard titre measles vaccine may confer a beneficial effect which is unrelated to the specific protection against measles disease.
C1 ORSTOM,DAKAR,SENEGAL.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
RP AABY, P (reprint author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.
CR AABY P, 1993, BRIT MED J, V307, P1308
   AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1984, J TROP PEDIATRICS, V30, P164
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   DULOU A, IN PRESS AM J EPIDEM
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   Garenne M, 1986, ESTIMATION MORTALITE, P515
   HARRIS MF, 1979, S AFR MED J, P38
   HOLT EA, 1990, PEDIATRICS, V85, P188
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   [Anonymous], 1981, LANCET, V1, P764
NR 20
TC 184
Z9 185
U1 1
U2 5
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD AUG 19
PY 1995
VL 311
IS 7003
BP 481
EP 485
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA RQ670
UT WOS:A1995RQ67000014
PM 7647643
OA No
DA 2017-08-15
ER

PT J
AU DALESSANDRO, U
   LEACH, A
   DRAKELEY, CJ
   BENNETT, S
   OLALEYE, BO
   FEGAN, GW
   JAWARA, M
   LANGEROCK, P
   GEORGE, MO
   TARGETT, GAT
   GREENWOOD, BM
AF DALESSANDRO, U
   LEACH, A
   DRAKELEY, CJ
   BENNETT, S
   OLALEYE, BO
   FEGAN, GW
   JAWARA, M
   LANGEROCK, P
   GEORGE, MO
   TARGETT, GAT
   GREENWOOD, BM
TI EFFICACY TRIAL OF MALARIA VACCINE SPF66 IN GAMBIAN INFANTS
SO LANCET
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; SYNTHETIC VACCINE; IMMUNE-RESPONSE;
   WEST-AFRICA; RURAL AREA; IMMUNOGENICITY; CHILDREN; SAFETY; MOSQUITOS;
   CULICIDAE
AB SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-erythrocytic and asexual brood-stage proteins of Plasmodium falciparum, SPf66 was found to have a 31% protective efficacy in an area of intensive malaria transmission in Tanzanian chiIdren, 1-5 years old. We report a randomised, double-blind, placebo-controlled trial of SPf66 against clinical P falciparum malaria in Gambian infants. 630 children, aged 6-11 months at time of the first dose, received three doses of SPf66 or injected polio Vaccine (IPV). Morbidity was monitored during the following rainy season by means of active and passive case detection. Cross-sectional surveys were carried out at the beginning and at the end of the rainy season. An episode of clinical malaria was defined as fever (greater than or equal to 37.5 degrees C) and a parasite density of 6000/mu L or more. Analysis of efficacy was done on 547 children (316 SPf66/231 IPV). No differences in mortality or in health centre admissions were found between the two groups of children. 347 clinical episodes of malaria were detected during the three acid a half months of surveillance. SPf66 vaccine was associated with a protective efficacy against the first or only clinical episode of 8% (95% CI -18 to 29, p=0.50) and against the overall incidence of clinical episodes of malaria of 3% (95% CI -24 to 24, p=0.81). No significant differences in parasite rates or in any other index of malaria were found between the two groups of children.
   The findings of this study differ from previous reports on SPf66 efficacy from South America and from Tanzania. In The Gambia, protection against clinical attacks of malaria during the rainy season after immunisation in children 6-11 months old at time of the first dose was not achieved.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.
   MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA.
RP DALESSANDRO, U (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Fegan,
   Greg/0000-0002-2663-2765
CR ALONSO PL, 1994, LANCET, V344, P1175
   AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9
   AMADOR R, 1992, J INFECT DIS, V166, P139
   ARMSTRONGSCHELL.JR, 1994, PARASITOL TODAY, V10, P439
   BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336
   COOPER JA, 1993, PARASITOL TODAY, V9, P50, DOI 10.1016/0169-4758(93)90031-A
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P595, DOI 10.1016/0035-9203(89)90364-7
   LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x
   LOPEZ MC, 1994, VACCINE, V12, P585, DOI 10.1016/0264-410X(94)90261-5
   MURILLO LA, 1992, PARASITE IMMUNOL, V14, P87, DOI 10.1111/j.1365-3024.1992.tb00008.x
   NOYA O, 1994, J INFECT DIS, V170, P396
   PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8
   PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x
   PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z
   SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
   WIRTZ RA, 1987, J MED ENTOMOL, V24, P433
NR 26
TC 139
Z9 139
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0099-5355
J9 LANCET
JI Lancet
PD AUG 19
PY 1995
VL 346
IS 8973
BP 462
EP 467
DI 10.1016/S0140-6736(95)91321-1
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA RP857
UT WOS:A1995RP85700009
PM 7637479
OA No
DA 2017-08-15
ER

PT J
AU BENN, CS
   WHITTLE, H
   AABY, P
   BALE, C
   MICHAELSEN, KF
   OLSEN, J
AF BENN, CS
   WHITTLE, H
   AABY, P
   BALE, C
   MICHAELSEN, KF
   OLSEN, J
TI VITAMIN-A AND MEASLES VACCINATION
SO LANCET
LA English
DT Letter
C1 RES DEPT HUMAN NUTR,COPENHAGEN,DENMARK.
   AARHUS UNIV,INST EPIDEMIOL & SOCIAL MED,AARHUS,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   PROJECTO SAUDE BANDIM,BISSAU,GUINEA BISSAU.
RP BENN, CS (reprint author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN S,DENMARK.
CR JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9
   WHITTLE HC, 1988, LANCET, V1, P963
   1988, VITAMIN A SUPPLEMENT
NR 3
TC 10
Z9 10
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0099-5355
J9 LANCET
JI Lancet
PD AUG 19
PY 1995
VL 346
IS 8973
BP 503
EP 504
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA RP857
UT WOS:A1995RP85700042
PM 7637497
OA No
DA 2017-08-15
ER

PT J
AU HAWKES, S
   WEST, B
   WILSON, S
   WHITTLE, H
   MABEY, D
AF HAWKES, S
   WEST, B
   WILSON, S
   WHITTLE, H
   MABEY, D
TI ASYMPTOMATIC CARRIAGE OF HAEMOPHILUS-DUCREYI CONFIRMED BY THE POLYMERASE
   CHAIN-REACTION
SO GENITOURINARY MEDICINE
LA English
DT Article
DE HAEMOPHILUS DUCREYI; ASYMPTOMATIC CARRIAGE; PCR
ID GENITAL ULCER DISEASES; HEMOPHILUS-DUCREYI; HIV-2 INFECTION; DIAGNOSIS;
   GAMBIA; EPIDEMIOLOGY; ASSOCIATION
AB Objective-To investigate asymptomatic carriage of Haemophilus ducreyi by using polymerase chain reaction (PCR) on samples from women at high risk of infection.
   Subjects-213 commercial sex workers (CSWs) recruited in The Gambia, West Africa.
   Methods-Genital samples (cervical, vaginal and ulcer) were tested for the presence of H ducreyi by PCR with the technique of ''one tube nested primer''.
   Results-12 CSWs were PCR positive for H ducreyi; 8 of these women had genital ulcers on examination.
   Conclusion-Using a simplified PCR technique for detecting H ducreyi we have shown that 2% of CSWs were carrying the organism without clinical symptoms or signs. This has important implications for sexually transmitted disease control programmes in areas with a high prevalence of chancroid.
C1 MRC LABS,BANJUL,GAMBIA.
RP HAWKES, S (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
CR BLACKMORE CA, 1985, J INFECT DIS, V151, P840
   BOGAERTS J, 1989, SEXUALLY TRANSMITTED, V3, P123
   CAMERON DW, 1989, LANCET, V2, P403
   CHUI L, 1993, J CLIN MICROBIOL, V31, P659
   DANGOR Y, 1990, SEX TRANSM DIS, V17, P184
   DANGOR Y, 1987, S AF MED J, V76, P339
   JOHNSON SR, 1994, SEX TRANSM DIS, V21, P13, DOI 10.1097/00007435-199401000-00004
   JONES CC, 1991, ARCH DERMATOL, V127, P1823, DOI 10.1001/archderm.127.12.1823
   MABEY DCW, 1987, GENITOURIN MED, V63, P312
   MARTIN DH, 1994, SEX TRANSM DIS, V21, pS76
   MCNICOL PJ, 1984, J ANTIMICROB CHEMOTH, V14, P561
   MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137
   MOSES S, 1991, AIDS, V5, P407, DOI 10.1097/00002030-199104000-00008
   PEPIN J, 1992, AIDS, V6, P489
   PEPIN J, 1991, AIDS, V5, P69
   PLUMMER FA, 1983, LANCET, V2, P1293
   RONALD AR, 1990, SEXUALLY TRANSMITTED
   ROSSAU R, 1991, J GEN MICROBIOL, V137, P277
   SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265
   Stamm WE, 1990, CHLAMYDIA TRACHOMATI
   WALL RA, 1985, J ANTIMICROB CHEMOTH, V16, P165, DOI 10.1093/jac/16.2.165
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61
   WEST B, 1995, J CLIN MICROBIOL, V33, P787
   WILSON SM, 1993, J CLIN MICROBIOL, V31, P776
   1991, WHO810 TECHN REP SER
   [Anonymous], 1993, WORLD DEV REPORT 199
NR 26
TC 26
Z9 27
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0266-4348
J9 GENITOURIN MED
JI Genitourin. Med.
PD AUG
PY 1995
VL 71
IS 4
BP 224
EP 227
PG 4
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Urology & Nephrology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Urology & Nephrology
GA RN263
UT WOS:A1995RN26300004
PM 7590712
OA No
DA 2017-08-15
ER

PT J
AU LEACH, A
   DRAKELEY, CJ
   DALESSANDRO, U
   FEGAN, GW
   BENNETT, S
   BALLOU, WR
   TARGETT, GAT
   GREENWOOD, BM
AF LEACH, A
   DRAKELEY, CJ
   DALESSANDRO, U
   FEGAN, GW
   BENNETT, S
   BALLOU, WR
   TARGETT, GAT
   GREENWOOD, BM
TI A PILOT SAFETY AND IMMUNOGENICITY STUDY OF THE MALARIA VACCINE SPF66 IN
   GAMBIAN INFANTS
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE MALARIA; PLASMODIUM FALCIPARUM; SPF66; VACCINE; SAFETY; IMMUNOGENICITY
AB A pilot safety and immunogenicity trial of the malar ia vaccine SPf66 has been undertaken in 150 Gambian infants. No significant systemic side effects were recorded but modest local reactions were seen after the administration of a third 1.0 mg dose. SPf66 produced in Colombia was more immunogenic than SPf66 produced in the USA and a 1.0 mg dose of each vaccine gave higher antibody levels than a 0.5 mg dose. However, antibody levels fell rapidly after administration of the third dose of vaccine and showed little change over the following malaria transmission season. The incidence of clinical malaria was higher among children who received SPf66 than among children who received inactivated polio vaccine, the effect being most marked among children who received 1.0 mg Colombian SPf66. As the trial was not designed to measure the effect of SPf66 on morbidity from malaria, the significance of this finding is uncertain.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.
   WALTER REED ARMY INST RES,DCD & I,DEPT IMMUNOL,WASHINGTON,DC.
RP LEACH, A (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Wellcome Trust
CR ALONSO PL, 1994, LANCET, V344, P1175
   ARMSTRONGSCHELL.JR, 1994, PARASITOL TODAY, V10, P439
   DALESSANDRO U, 1995, IN PRESS LANCET, V346
   FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075
   GRAYSTON JT, 1962, ANN NY ACAD SCI, V98, P352, DOI 10.1111/j.1749-6632.1962.tb30558.x
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422
   ROCHA CL, 1992, PARASITE IMMUNOL, V14, P95, DOI 10.1111/j.1365-3024.1992.tb00009.x
   TANNER M, 1994, PARASITOL TODAY, V11, P10
NR 8
TC 22
Z9 22
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD AUG
PY 1995
VL 17
IS 8
BP 441
EP 444
DI 10.1111/j.1365-3024.1995.tb00912.x
PG 4
WC Immunology; Parasitology
SC Immunology; Parasitology
GA RV521
UT WOS:A1995RV52100007
PM 7501425
OA No
DA 2017-08-15
ER

PT J
AU SAMB, B
   SIMONDON, F
   AABY, P
   WHITTLE, H
   SECK, MC
AF SAMB, B
   SIMONDON, F
   AABY, P
   WHITTLE, H
   SECK, MC
TI PROPHYLACTIC USE OF ANTIBIOTICS AND REDUCED CASE-FATALITY IN MEASLES
   INFECTION
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE ANTIBIOTICS; CASE FATALITY; MEASLES; PROPHYLACTIC USE
ID SENEGAL
C1 DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN S,DENMARK.
   ORSTOM,UR MALADIES INFECT & PARASITAIRES,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
CR DOVER AS, 1975, JAMA-J AM MED ASSOC, V234, P612, DOI 10.1001/jama.234.6.612
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   WEINSTEIN L, 1955, NEW ENGL J MED, V253, P679, DOI 10.1056/NEJM195510202531602
   1993, MEASLES UPDATE
NR 5
TC 11
Z9 11
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 1995
VL 14
IS 8
BP 695
EP 696
DI 10.1097/00006454-199508000-00009
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA RN780
UT WOS:A1995RN78000009
PM 8532428
OA No
DA 2017-08-15
ER

PT J
AU MATTIOLI, RC
   CASSAMA, M
AF MATTIOLI, RC
   CASSAMA, M
TI COMPARISON OF CHARACTERISTICS OF LIFE-CYCLE IN FEMALE TICKS COLLECTED ON
   NDAMA AND ZEBU CATTLE
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID RESISTANCE; IMMUNITY; FIELD
AB Characteristics of the life cycle of female ticks (Amblyomma variegatum, Hyalomma truncatum and Boophilus geigyi) fed on N'Dama and zebu cattle were studied in the laboratory from pre-oviposition period to larval development. Percentage of A. variegatum eggs hatched and engorgement weight of H. truncatum were lower in ticks collected on N'Dama than on zebu cattle. Laboratory results confirmed field observations of species specific tick resistance in the N'Dama breed.
RP MATTIOLI, RC (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR AESCHLIMANN A, 1967, Acta Tropica, V24, P281
   BARRE N, 1990, 1990 P SEM HELD ST J, P63
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DECASTRO JJ, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P244
   ELBL A, 1966, MUSEE ROYAL AFRIQU 8, V4, P275
   Gueye A, 1990, Rev Elev Med Vet Pays Trop, V42, P517
   JONGEJAN F, 1989, EXP APPL ACAROL, V7, P181, DOI 10.1007/BF01194059
   LATIF AA, 1991, J MED ENTOMOL, V28, P127
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   RECHAV Y, 1991, ONDERSTEPOORT J VET, V58, P181
   RHODAIN F, 1985, PRECIS ENTOMOLOGIE M
   Uilenberg G, 1975, Rev Elev Med Vet Pays Trop, V28, P405
   WAGLAND BM, 1979, 56TH P S HELD ANN C, P55
   Willadsen P, 1980, Adv Parasitol, V18, P293, DOI 10.1016/S0065-308X(08)60402-9
NR 14
TC 9
Z9 9
U1 0
U2 1
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD AUG
PY 1995
VL 27
IS 3
BP 150
EP 154
DI 10.1007/BF02248959
PG 5
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA RW459
UT WOS:A1995RW45900003
PM 7502345
OA No
DA 2017-08-15
ER

PT J
AU SANYANG, FB
   WAGNER, HGR
   CLIFFORD, DJ
AF SANYANG, FB
   WAGNER, HGR
   CLIFFORD, DJ
TI INFLUENCE OF SUCKLING ON CALVING INTERVAL OF NDAMA COWS IN THE GAMBIA
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Note
RP SANYANG, FB (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR AGYEMANG K, 1993, ANIM PROD, V56, P165
   AGYEMANG K, 1990, J DAIRY SCI, V74, P1599
   OXENREID SL, 1968, AM J VET RES, V29, P2099
   SHORT RE, 1972, J ANIM SCI, V34, P70
NR 4
TC 1
Z9 1
U1 0
U2 0
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD AUG
PY 1995
VL 27
IS 3
BP 191
EP 192
DI 10.1007/BF02248970
PG 2
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA RW459
UT WOS:A1995RW45900011
PM 7502353
OA No
DA 2017-08-15
ER

PT J
AU RUWENDE, C
   KHOO, SC
   SNOW, AW
   YATES, SNR
   KWIATKOWSKI, D
   GUPTA, S
   WARN, P
   ALLSOPP, CEM
   GILBERT, SC
   PESCHU, N
   NEWBOLD, CI
   GREENWOOD, BM
   MARSH, K
   HILL, AVS
AF RUWENDE, C
   KHOO, SC
   SNOW, AW
   YATES, SNR
   KWIATKOWSKI, D
   GUPTA, S
   WARN, P
   ALLSOPP, CEM
   GILBERT, SC
   PESCHU, N
   NEWBOLD, CI
   GREENWOOD, BM
   MARSH, K
   HILL, AVS
TI NATURAL-SELECTION OF HEMIZYGOTES AND HETEROZYGOTES FOR G6PD DEFICIENCY
   IN AFRICA BY RESISTANCE TO SEVERE MALARIA
SO NATURE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY;
   VARIANT; DEHYDROGENASE; SEQUENCE; CHILDREN; ENZYME
AB GLUCOSE-6-PHOSPHATE dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people(1). The geographical correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria(2.3). However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results(4-8). Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females(1,5-11). Furthermore, how much protection may be afforded is unknown. Here we report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is associated with a 46-58% reduction in risk of severe malaria for both female heterozygotes and male hemizygotes. A mathematical model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, associated with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions. Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.
C1 UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.
   UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.
   KEMRI,CLIN RES CTR,KILIFI UNIT,KILIFI,KENYA.
   MRC LABS,BANJUL,GAMBIA.
   UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND.
RI HILL, Adrian/C-1306-2008
OI Newbold, Chris/0000-0002-9274-3789; Gilbert, Sarah/0000-0002-6823-9750
FU Wellcome Trust
CR ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0
   BEUTLER E, 1990, SEMIN HEMATOL, V27, P137
   BEUTLER E, 1989, BLOOD, V7, P2550
   BIENZLE U, 1972, LANCET, V1, P107
   Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1
   GILLES HM, 1967, LANCET, V1, P138
   GREENBERG DR, 1993, SOLID STATE ELECTRON, V36, P53, DOI 10.1016/0038-1101(93)90068-2
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HELLER P, 1979, NEW ENGL J MED, V300, P1001, DOI 10.1056/NEJM197905033001801
   HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951
   KURDIHAIDAR B, 1990, MOL BIOCHEM PARASIT, V41, P83, DOI 10.1016/0166-6851(90)90099-8
   LING IT, 1988, MOL BIOCHEM PARASIT, V31, P47, DOI 10.1016/0166-6851(88)90144-2
   Livingstone F. B., 1985, FREQUENCIES HEMOGLOB
   LUZZATTO L, 1979, LANCET, V1, P1183
   LUZZATTO L, 1985, ADV HUM GENET, V14, P217
   Luzzato L, 1989, METABOLIC BASIS INHE, P2237
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   MARTIN SK, 1979, LANCET, V1, P524
   MARTIN SK, 1994, PARASIT TODAY, V7, P251
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   MILLER LH, 1988, MALARIA PRINCIPLES P, P493
   MOTULSKY AG, 1961, LANCET, V1, P1168
   MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28
   ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298
   USANGA EA, 1985, NATURE, V313, P793, DOI 10.1038/313793a0
   VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568
NR 29
TC 332
Z9 347
U1 3
U2 32
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA 4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF
SN 0028-0836
J9 NATURE
JI Nature
PD JUL 20
PY 1995
VL 376
IS 6537
BP 246
EP 249
DI 10.1038/376246a0
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA RK331
UT WOS:A1995RK33100044
PM 7617034
OA No
DA 2017-08-15
ER

PT J
AU JEPSON, AP
   BANYA, WAS
   SISAYJOOF, F
   HASSANKING, M
   BENNETT, S
   WHITTLE, HC
AF JEPSON, AP
   BANYA, WAS
   SISAYJOOF, F
   HASSANKING, M
   BENNETT, S
   WHITTLE, HC
TI GENETIC-REGULATION OF FEVER IN PLASMODIUM-FALCIPARUM MALARIA IN GAMBIAN
   TWIN CHILDREN
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Note
ID RESISTANCE; VARIANCE
AB The role of genetic factors in determining the clinical response of children to Plasmodium falci-parum infection is not fully understood. A longitudinal survey of malaria morbidity in a cohort of 258 pairs of twin children was conducted in a rural area of Gambia to assess the extend to which genetic factors determine the host's susceptibility and clinical response to infection. The marginal correlation (which measures the excess probability of both twins being affected above that expected assuming independence) for malaria was higher in dizygous (DZ) than in monozygous (MZ) twin pairs, indicating that infection per se is largely determined by environmental factors. Once infected however, both members of an MZ pair were more likely to develop fever than were twins of a DZ pair, suggesting that genetic factors influence the presentation of clinical disease.
C1 MRC LABS,BANJUL,GAMBIA.
   LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON,ENGLAND.
CR BATE CAW, 1994, INFECT IMMUN, V62, P3086
   CHRISTIAN JC, 1979, ACTA GENET MED GEMEL, V28, P35
   CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M
   DALFONSO S, 1994, IMMUNOGENETICS, V39, P150
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HANNAH MC, 1983, ACTA GENET MED GEMEL, V32, P127
   HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367
   HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H
   KWIATKOWSKI D, 1989, J EXP MED, V169, P357, DOI 10.1084/jem.169.1.357
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   ROBERTS DJ, 1993, PARASITOL TODAY, V9, P281, DOI 10.1016/0169-4758(93)90121-U
   STEVENSON MM, 1982, INFECT IMMUN, V38, P80
   WILLIAMS CJ, 1992, COMPUT METH PROG BIO, V38, P167, DOI 10.1016/0169-2607(92)90084-K
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x
NR 16
TC 53
Z9 55
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL
PY 1995
VL 172
IS 1
BP 316
EP 319
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA RF041
UT WOS:A1995RF04100056
PM 7797941
OA No
DA 2017-08-15
ER

PT J
AU ABLETHOMAS, U
   HILL, R
   OKEEFE, P
   PEARSALL, NM
AF ABLETHOMAS, U
   HILL, R
   OKEEFE, P
   PEARSALL, NM
TI DISSEMINATION OF PHOTOVOLTAICS IN THE GAMBIA
SO RENEWABLE ENERGY
LA English
DT Article; Proceedings Paper
CT International Conference on Solar Electricity - Photovoltaics and Wind
CY OCT 02-07, 1994
CL CAIRO, EGYPT
SP NREL, Natl Renewable Energy Lab, Golden, Colorado, US, WREN
AB The Gambia has abundant solar energy but a significant shortfall in electrical generation and distribution capacity, along with a growing demand for electricity. This paper will outline areas in the application of photovoltaics (PV) in The Gambia which are both technically and economically viable. Photovoltaics is beginning to contribute to developmental efforts, but this contribution is rarely quantified. The paper will discuss the socio-economic benefits that The Gambia has derived from this appropriate technology. The application of PV on a scale much wider than the present will require strengthening of the infrastructure in PV systems, construction and maintenance and financing. The infrastructural needs of the country and its manufacturing capabilities will be assessed along with the organizational aspects for successful PV dissemination.
C1 NORTHUMBRIA UNIV,DEPT ENVIRONM,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.
   GAMBIA CIVIL AVIAT AUTHOR,BANJUL INT AIRPORT,YUNDUM,GAMBIA.
RP ABLETHOMAS, U (reprint author), NORTHUMBRIA UNIV,NEWCASTLE PHOTOVOLTAICS APPLICAT CTR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.
CR ABELTHOMAS U, 1994, 3 WORLD REN EN C REA, P247
   ABLETHOMAS U, 1993, 11TH P EC PHOT SOL E, P1526
   ABLETHOMAS U, 1993, PHOTOVOLTIACS GAMBIA
   ABLETHOMAS U, 1994, 12TH P EUR PHOT SOL, P2041
   AUBREE M, 1988, 8TH P EC PHOT SOL EN
   DERRICK A, 1989, SOLAR PHOTOVOLTAICS
   JONES GJ, 1987, 19TH P IEEE PHOT SPE
   MCNELIS B, 1985, 6TH P PHOT SOL EN C
   1986, EVALUATION PHOTOVOLT
   1983, SMALL SCALE SOLAR PO
   1985, NTIS SAND8570182 US
NR 11
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD JUL-SEP
PY 1995
VL 6
IS 5-6
BP 507
EP 513
DI 10.1016/0960-1481(95)00048-O
PG 7
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA RW955
UT WOS:A1995RW95500009
OA No
DA 2017-08-15
ER

PT J
AU ARIYOSHI, K
   CHAM, F
   BERRY, N
   JAFFAR, S
   SABALLY, S
   CORRAH, T
   WHITTLE, H
AF ARIYOSHI, K
   CHAM, F
   BERRY, N
   JAFFAR, S
   SABALLY, S
   CORRAH, T
   WHITTLE, H
TI HIV-2-SPECIFIC CYTOTOXIC T-LYMPHOCYTE ACTIVITY IS INVERSELY RELATED TO
   PROVIRAL LOAD
SO AIDS
LA English
DT Article
DE HIV-2; CYTOTOXIC T LYMPHOCYTES; VIRAL LOAD
ID QUANTITATIVE-ANALYSIS; VIRUS; HIV-1; INDIVIDUALS; RESPONSES
AB Objectives: To characterize HIV-specific cytotoxic T-lymphocyte (CTL) activiti
   Methods: Peripheral blood mononuclear cells were collected from 16 HIV-2-seropositive and four HIV-1/-2 dually seropositive subjects. CTL were restimulated with autologous phytohaemagglutinin-stimulated blasts and CTL activities in 'bulk' cultures were evaluated 7 and 14 days later by a standard Cr-51-release assay using autologous B-cell lines infected with recombinant vaccinia expressing HIV-2 Gag, Pol or Nef protein. Proviral load was quantified by polymerase chain reaction (PCR) which used HIV-2 long terminal repeat primers and an external standard control made by an HIV-2(CBL-22) chronically infected C8166 cell line. A biotinylated primer was used to capture the S-35 dATP-incorporated secondary PCR product in a quantitative radiometric assay.
   Results: After 14 days of culture CTL responses against Gag or Pol protein were seen in 18 (90.0%) and 14 (70.0%) out of 20 subjects, respectively, whereas a CTL response was noted against Nef protein in five (25.0%) out of 20 subjects. In 14 (70.0%) out of 20 subjects multiple HIV proteins were simultaneously recognized. The sum of specific lysis (%) against HIV-2 Gag, Pol and Nef at 30:1 effector-to-target ratio, or specific lysis of the dominant CTL response, correlated strongly with HIV-2 proviral load expressed as copies per 10(5) CD4+ cells (r=-0.625, P=0.003 and r=-0.674, P=0.001, respectively).
   Conclusion: HIV-2-specific CTL to multiple gene products was demonstrated in most HIV-2-infected individuals. An inverse correlation between the level of CTL activity and proviral load was found, which supports the hypothesis that CTL are important in the control of HIV-2 replication.
C1 UCL, SCH MED, DIV VIROL, LONDON W1N 8AA, ENGLAND.
RP ARIYOSHI, K (reprint author), MRC LABS, POB 273, BANJUL, GAMBIA.
CR BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   BORROW P, 1994, J VIROL, V68, P6103
   CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   KOUP RA, 1994, J VIROL, V68, P4650
   KUNDU SK, 1994, IMMUNOLOGY, V83, P81
   LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MCMICHAEL AJ, 1994, AIDS S1, V8, pS155
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   SCHULZ TF, 1990, J VIROL, V64, P5177
   WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1
NR 20
TC 37
Z9 37
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN
PY 1995
VL 9
IS 6
BP 555
EP 559
DI 10.1097/00002030-199506000-00004
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA RA007
UT WOS:A1995RA00700004
PM 7662192
OA No
DA 2017-08-15
ER

PT J
AU NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
   VANMEIRVENNE, N
AF NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
   VANMEIRVENNE, N
TI EVALUATION OF SODIUM DODECYL-SULFATE (SDS) AS A HEMOLYTIC AGENT FOR THE
   DETECTION OF MICROFILARIAE AND TRYPANOSOMES IN THE BLOOD OF CATTLE
SO ANNALES DE LA SOCIETE BELGE DE MEDECINE TROPICALE
LA English
DT Article
ID AFRICAN TRYPANOSOMIASIS; DIAGNOSIS
C1 INST TROP MED,B-2000 ANTWERP 1,BELGIUM.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   LAB PFISTER,CH-3018 BERN,SWITZERLAND.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR BOQUENTIN R, 1989, 20E REUN CSIRTC MOMB, P142
   HARRIS JS, 1945, AM J TROP MED, V25, P497
   ISHARAZA WK, 1989, 20TH ISCTRC M MOMB K
   KNOTT J., 1939, TRANS ROY SOC TROP MED AND HYG, V33, P191, DOI 10.1016/S0035-9203(39)90101-X
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PARIS J, 1982, ACTA TROP, V39, P307
   SHOHO C, 1960, CEYLON VET J, V8, P745
   Sokal R.R., PRINCIPLES PRACTICE
   VANMEIRVENNE N, 1989, 25TH TRYP SEM BRIT S
   VANMEIRVENNE N, 1988, 9TH M INT WORK GROUP
NR 10
TC 1
Z9 1
U1 0
U2 0
PU N V CEUTERICK
PI LOUVAIN
PA BRUSSELSESTRAAT 153, B-3000 LOUVAIN, BELGIUM
SN 0365-6527
J9 ANN SOC BELG MED TR
JI Ann. Soc. Belg. Med. Trop.
PD JUN
PY 1995
VL 75
IS 2
BP 145
EP 148
PG 4
WC Tropical Medicine
SC Tropical Medicine
GA RX707
UT WOS:A1995RX70700008
PM 7487203
OA No
DA 2017-08-15
ER

PT J
AU THOMSON, MC
   ADIAMAH, JH
   CONNOR, SJ
   JAWARA, M
   BENNETT, S
   DALESSANDRO, U
   QUINONES, M
   LANGEROCK, P
   GREENWOOD, BM
AF THOMSON, MC
   ADIAMAH, JH
   CONNOR, SJ
   JAWARA, M
   BENNETT, S
   DALESSANDRO, U
   QUINONES, M
   LANGEROCK, P
   GREENWOOD, BM
TI ENTOMOLOGICAL EVALUATION OF THE GAMBIAS NATIONAL IMPREGNATED BEDNET
   PROGRAM
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Article
ID MALARIA; TRIAL; AREA; MOSQUITOS; CULICIDAE; COMPLEX; DIPTERA
AB Entomological studies mere conducted in paired study villages in three of the five study areas used for the epidemiological assessment of the Gambia's National Impregnated Bednet Programme. Baseline data collected in 1991 were compared with post-intervention data from 1992, when one of each village pair (from areas II, III and V) was included in the treatment programme in which villagers' nets were dipped in permethrin. In a longitudinal study, indoor-resting densities of Anopheles gambine s.l. in the treated villages were significantly reduced, when compared with their paired untreated village, in areas II (t=3.32, 13 degrees of freedom, P=0.006) and III (t=3 71, 13 degrees of freedom, P=0.003). However, this was not associated with higher outdoor-biting rates in the evenings in the treated villages than in the controls. The reduction in vector population was most evident in area II, where the treated village was relatively isolated and 74% of the population slept under a treated net.
   Anopheles gambine s.l. were also collected during two fortnightly periods in area V, where the sporozoite rates in 1991 had been relatively high (7.65% and 6.07%). There was no significant decrease in the sporozoite rate in the treated village in area V in 1992, despite the fact that this village was over 5 km from its nearest neighbouring village. However, the proportion of villagers sleeping under a treated net in this village was <50%.
   No clear evidence for an epidemiologically significant 'mass killing effect', resulting from the village-wide use of treated nets, emerges in this or any other study undertaken in The Gambia. However, such an effect is indicated by results from Salikene, where the village mosquito population was relatively isolated and where the majority of the population slept under a treated net. This situation is unlikely to be repeated in most Gambian villages in the primary-health-care scheme, since treated and untreated villages are generally interspersed and the mosquito populations move freely between them. We must therefore conclude that, on a national scale, the nets provide an exceptionally high level of personal rather than community protection. The mechanisms underlying the personal protection are, however, still unclear.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR BIRLEY MH, 1987, PARASITOL TODAY, V3, P231, DOI 10.1016/0169-4758(87)90145-1
   BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336
   COLUZZI M, 1964, ESTRATTO RIV MALARIO, V43, P4
   Curtis C. F., 1990, Appropriate technology in vector control., P5
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   GOKOOL S, 1992, PARASITOL TODAY, V8, P347, DOI 10.1016/0169-4758(92)90072-A
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   HIRSH AT, 1994, THESIS U LONDON
   KARCH S, 1993, ANN SOC BELG MED TR, V73, P37
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   MSUYA FHM, 1991, ACTA TROP, V49, P165, DOI 10.1016/0001-706X(91)90035-I
   NJUNWA KJ, 1991, ACTA TROP, V49, P87, DOI 10.1016/0001-706X(91)90056-P
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   THOMSON MC, 1995, IN PRESS MED VET ENT, V9
   THOMSON MC, 1995, IN PRESS SOCIAL SCI
   WIRTZ RA, 1987, J MED ENTOMOL, V24, P433
NR 19
TC 28
Z9 28
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD JUN
PY 1995
VL 89
IS 3
BP 229
EP 241
PG 13
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA RE361
UT WOS:A1995RE36100002
PM 7668914
OA No
DA 2017-08-15
ER

PT J
AU HEMINGWAY, J
   LINDSAY, SW
   SMALL, GJ
   JAWARA, M
   COLLINS, FH
AF HEMINGWAY, J
   LINDSAY, SW
   SMALL, GJ
   JAWARA, M
   COLLINS, FH
TI INSECTICIDE SUSCEPTIBILITY STATUS IN INDIVIDUAL-SPECIES OF THE
   ANOPHELES-GAMBIAE COMPLEX (DIPTERA, CULICIDAE) IN AN AREA OF THE GAMBIA
   WHERE PYRETHROID IMPREGNATED BEDNETS ARE USED EXTENSIVELY FOR MALARIA
   CONTROL
SO BULLETIN OF ENTOMOLOGICAL RESEARCH
LA English
DT Article
ID TREATED BED NETS; TARGETED CHEMOPROPHYLAXIS; CROSS-RESISTANCE; DDT
   RESISTANCE; WEST-AFRICA; RURAL AREA; SRI-LANKA; MECHANISMS; CHILDREN;
   STRAINS
AB Pyrethroid-impregnated bednets are being used nationwide in The Gambia. The future success of this malaria control programme depends partly on the vectors remaining susceptible to those insecticides used for treating the nets. The present study was carried out on the south bank of the river Gambia, during the first large scale trial of nets in this country. Thus this area represents a sentinel site for detecting insecticide resistance in local vectors. This study gives an example of how a system of early detection for resistance problems can be set up in a relatively complex situation where multiple vectors and non-vectors are present. Samples of the Anopheles gambiae complex were caught indoors using light traps in twelve villages used in the bednet study. In all villages A. gambiae sensu stricto Giles was the predominant member of the complex as determined using the rDNA-PCR diagnostic assay. Limited bioassays with DDT and permethrin, and biochemical assays for a range of insecticide resistance mechanisms suggest that the A. gambiae complex remains completely susceptible to all major classes of commonly used insecticides including pyrethroids. Biochemical assays suggest that a low frequency of: DDT resistance may occur in A. melas Theobald. This is based on elevated glutathione S-transferase levels coupled with increased levels of DDT metabolism and does not involve cross-resistance to pyrethroids. Therefore we do not envisage a decline in the efficacy of treated nets against malaria vectors in the study area in the immediate future, although monitoring should be continued whilst wide-scale use of impregnated bednets is operational.
C1 MRC, BANJUL, GAMBIA.
   CTR DIS CONTROL, ATLANTA, GA 30333 USA.
RP HEMINGWAY, J (reprint author), UNIV WALES COLL CARDIFF, DEPT PURE & APPL BIOL, POB 915, CARDIFF CF1 3TL, S GLAM, WALES.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   DAVIDSON G, 1956, NATURE, V178, P863, DOI 10.1038/178863a0
   FARNHAM AW, 1976, PESTIC SCI, V7, P278, DOI 10.1002/ps.2780070312
   FFRENCHCONSTANT RH, 1989, MED VET ENTOMOL, V3, P9, DOI 10.1111/j.1365-2915.1989.tb00468.x
   GREENWOOD BM, 1993, T ROYAL SOC TROPIC S, V87, P60
   HARIDI AM, 1972, B WORLD HEALTH ORGAN, V47, P619
   HEMINGWAY J, 1985, PESTIC BIOCHEM PHYS, V24, P68, DOI 10.1016/0048-3575(85)90115-4
   HEMINGWAY J, 1989, B ENTOMOL RES, V79, P123
   HERATH PRJ, 1988, B ENTOMOL RES, V78, P717
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   LINES JD, 1991, MED VET ENTOMOL, V5, P261, DOI 10.1111/j.1365-2915.1991.tb00550.x
   PASKEWITZ SM, 1989, MED ENTOMOL, V4, P367
   PEIRIS HTR, 1990, B ENTOMOL RES, V80, P453
   PRAPANTHADARA L, 1995, B ENTOMOL RES, V85, P267
   PRASITTISUK C, 1977, PESTIC SCI, V8, P527, DOI 10.1002/ps.2780080516
   RONGSRIYAM Y, 1975, B ENTOMOL RES, V65, P459
   SAWICKI RM, 1975, WHOVBCEC7510 REP
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   VULULE JM, 1994, MED VET ENTOMOL, V8, P71, DOI 10.1111/j.1365-2915.1994.tb00389.x
NR 20
TC 10
Z9 10
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-4853
J9 B ENTOMOL RES
JI Bull. Entomol. Res.
PD JUN
PY 1995
VL 85
IS 2
BP 229
EP 234
PG 6
WC Entomology
SC Entomology
GA TD339
UT WOS:A1995TD33900008
OA No
DA 2017-08-15
ER

PT J
AU SNIADACK, DH
   SCHWARTZ, B
   LIPMAN, H
   BOGAERTS, J
   BUTLER, JC
   DAGAN, R
   ECHANIZAVILES, G
   LLOYDEVANS, N
   FENOLL, A
   GIRGIS, NI
   HENRICHSEN, J
   KLUGMAN, K
   LEHMANN, D
   TAKALA, AK
   VANDEPITTE, J
   GOVE, S
   BREIMAN, RF
AF SNIADACK, DH
   SCHWARTZ, B
   LIPMAN, H
   BOGAERTS, J
   BUTLER, JC
   DAGAN, R
   ECHANIZAVILES, G
   LLOYDEVANS, N
   FENOLL, A
   GIRGIS, NI
   HENRICHSEN, J
   KLUGMAN, K
   LEHMANN, D
   TAKALA, AK
   VANDEPITTE, J
   GOVE, S
   BREIMAN, RF
TI POTENTIAL INTERVENTIONS FOR THE PREVENTION OF CHILDHOOD PNEUMONIA -
   GEOGRAPHIC AND TEMPORAL DIFFERENCES IN SEROTYPE AND SEROGROUP
   DISTRIBUTION OF STERILE SITE PNEUMOCOCCAL ISOLATES FROM CHILDREN -
   IMPLICATIONS FOR VACCINE STRATEGIES
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE PNEUMOCOCCUS; SEROTYPE; SEROGROUP; CONJUGATE VACCINE
ID PAPUA-NEW-GUINEA; RESPIRATORY-TRACT INFECTIONS;
   STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; GAMBIAN CHILDREN;
   ETIOLOGY; POLYSACCHARIDE; IMMUNOGENICITY; MENINGITIS; PAKISTAN
AB Streptococcus pneumoniae is a leading cause of fatal bacterial pneumonia in young children. Pneumococcal polysaccharide vaccines have not been promoted for use in young children because many constituent serotypes are not immunogenic in children < 2 years old. Conjugating pneumococcal polysaccharide epitopes to a protein carrier would likely increase vaccine immunogenicity in children, We reviewed published and unpublished pneumococcal serotype and serogroup data from 16 countries on 6 continents to determine geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates among children and to estimate coverage of proposed and potential pneumococcal conjugate vaccine formulas, The most common pneumococcal serotypes or groups from developed countries were, in descending order, 14, 6, 19, 18, 9, 23, 7, 4, 1 and 15. In developing countries the order was 6, 14, 8, 5, 1, 19, 9, 23, 18, 15 and 7. Development of customized heptavalent vaccine formulas, one for use in all developed countries and one for use in all developing countries, would not provide substantially better coverage against invasive pneumococcal disease than two currently proposed heptavalent formulas, An optimal nanovalent vaccine for global use would include serotypes 1, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Geographic and temporal variation in pneumococcal serotypes demonstrates the need for a species-wide pneumococcal vaccine.
C1 CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333.
   CTR HOSP KIGALI,KIGALI,RWANDA.
   BEN GURION UNIV NEGEV,BEER SHEVA,ISRAEL.
   INST NACL SALUD PUBL,CUERNAVACA,MORELOS,MEXICO.
   MRC,BANJUL,GAMBIA.
   CTR NACL MICROBIOL VIROL & INMUNOL SANITARIAS MAJADAHONDA,MADRID,SPAIN.
   BIOMED RES CTR INFECT DIS,CAIRO,EGYPT.
   STATEN SERUMINST,COPENHAGEN,DENMARK.
   S AFRICAN INST MED RES,JOHANNESBURG 2000,SOUTH AFRICA.
   PAPUA NEW GUINEA INST MED RES,GOROKA,PAPUA N GUINEA.
   NATL PUBL HLTH INST,HELSINKI,FINLAND.
   KATHOLIEKE UNIV LEUVEN,B-3001 LOUVAIN,BELGIUM.
   WHO,PROGRAM CONTROL ACUTE RESP INFECT,GENEVA,SWITZERLAND.
CR APPLEBAUM P C, 1987, European Journal of Clinical Microbiology, V6, P367
   BARKER J, 1989, J INFECT DIS, V159, P348
   BOGAERTS J, 1993, J INFECTION, V27, P157, DOI 10.1016/0163-4453(93)94728-T
   DOUGLAS RM, 1983, J INFECT DIS, V148, P131
   ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323
   FENOLL A, 1991, REV INFECT DIS, V13, P56
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   GARENNE M, 1992, WORLD HLTH STAT Q, V46, P180
   GRATTEN M, 1985, PAPUA NEW GUINEA MED, V28, P233
   GRATTEN M, 1991, PAPUA NEW GUINEA MED, V34, P185
   Guirguis N I, 1990, J Egypt Public Health Assoc, V65, P291
   HANSMAN D, 1983, AUST NZ J MED, V13, P359, DOI 10.1111/j.1445-5994.1983.tb04481.x
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171
   Leowski J, 1986, World Health Stat Q, V39, P138
   MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006
   MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5
   MCDANIEL LS, 1991, INFECT IMMUN, V59, P222
   MOGDASY MC, 1992, PEDIATR INFECT DIS J, V11, P648
   NIEMINEN T, 1992, 32ND INT C ANT AG CH
   PATON JC, 1991, INFECT IMMUN, V59, P2297
   RIJKERS GT, 1987, SCAND J IMMUNOL, V25, P447
   ROBBINS JB, 1983, J INFECT DIS, V148, P1136
   SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278
   STEINHOFF MC, 1992, 32ND INT C ANT AG CH
   TALKINGTON DF, 1992, 92ND GEN M AM SOC MI
   TAUNAY AE, 1990, REV I MED TROP, V32, P11, DOI 10.1590/S0036-46651990000100003
   TIMENS W, 1989, J IMMUNOL, V143, P3200
   VELLA PP, 1992, INFECT IMMUN, V60, P4977
   WEISSENBACHER M, 1990, REV INFECT DIS, V12, pS889
   WITT CS, 1991, CLIN EXP IMMUNOL, V83, P219
NR 33
TC 167
Z9 174
U1 1
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 1995
VL 14
IS 6
BP 503
EP 510
DI 10.1097/00006454-199506000-00007
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA RC781
UT WOS:A1995RC78100007
PM 7667055
OA No
DA 2017-08-15
ER

PT J
AU NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
AF NDAO, M
   PANDEY, VS
   ZINSSTAG, J
   PFISTER, K
TI EFFECT OF A SINGLE DRY SEASON ANTHELMINTIC TREATMENT OF NDAMA CATTLE ON
   COMMUNAL PASTURES IN THE GAMBIA
SO VETERINARY RESEARCH COMMUNICATIONS
LA English
DT Article
DE ANTHELMINTIC; CATTLE; CLIMATE; GAMBIA; MANAGEMENT; NDAMA; NEMATODE
AB The effect of a single anthelmintic treatment of cattle during the early dry season was studied. One hundred and sixty-six N'Dama cattle, 1-3 years old, were selected from five herds. There were 65 males and 101 females divided into two groups of 83 animals each. One group was treated with fenbendazole at 7.5 mg/kg body weight by mouth in November 1992; the other group remained as the untreated control. At monthly intervals from November 1992 to April 1993, each animal was weighed and the number of eggs/g of faeces (epg) was determined. The infective larvae (L3) were examined following culture of pooled samples from each group of animals. In April 1993, 6 animals (3 treated and 3 controls) from the herds under study were necropsied. The difference in the weight gains (4.6 kg) of the two groups was highly significant (p<0.0001). The difference in the weight gains and the epg between the treated and control groups was influenced by the age of the animals. Of the treated animals, one contained no nematodes, one contained only 25 Oesophagostomum radiatum: and the third contained 25 Cooperia LA. The three untreated animals were all infected. It was concluded that the treatment in early dry season, with an anthelmintic effective against both adults and larvae, led to a significant reduction in egg counts, to elimination of adults and hypobiotic larvae and, consequently, to an increase in the body weight gain by the treated animals.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   LABOR PFISTER,CH-3018 BERN,SWITZERLAND.
RP NDAO, M (reprint author), INST TROP MED,NATL STR 155,B-2000 ANTWERP,BELGIUM.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR ANKERS P, 1992, 7TH P INT C I TROP V, V2, P411
   ASHTONTATE, 1984, DBASE 3 USERS MANUAL, P546
   Boch J., 1983, VETERINARMEDIZINISCH
   Chiejina S. N., 1986, Helminthological Abstracts, V55, P413
   CHIEJINA SN, 1986, TROP ANIM HEALTH PRO, V18, P55, DOI 10.1007/BF02359663
   CHIEJINA SN, 1984, RES VET SCI, V37, P148
   EYSKER M, 1991, SO C AVIAN DISEASES, P40
   HART JA, 1964, BRIT VET J, V120, P87
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   LEE R. P., 1960, BRIT VET JOUR, V116, P34
   Leperre P., 1992, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V45, P55
   NDAO M, 1995, IN PRESS VET PARASIT
   PANDEY VS, 1993, VET PARASITOL, V51, P99, DOI 10.1016/0304-4017(93)90200-7
   ZINSSTAG J, 1992, 7TH P INT C I TROP V, V2, P575
   1985, SAS USERS GUIDES STA
   [Anonymous], 1986, MANUAL VET PARASITOL
NR 16
TC 6
Z9 7
U1 1
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0165-7380
J9 VET RES COMMUN
JI Vet. Res. Commun.
PD JUN
PY 1995
VL 19
IS 3
BP 205
EP 213
DI 10.1007/BF01839299
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA RC932
UT WOS:A1995RC93200005
PM 7571394
OA No
DA 2017-08-15
ER

PT J
AU CIRNE, MD
   DUARTE, MNDR
   NOBREGA, DD
   DESOUZA, EMD
   MONTEIRO, D
   OLIVEIRA, MJC
   DANTAS, MCD
   CAVALCANTE, AMS
   BUENO, H
   FRANZOSI, I
   MENEZES, M
   RISI, JB
   BIELLIK, RJ
   GREENWOOD, BM
   HALL, AJ
   ROWE, M
   WELLS, J
   WHITTLE, H
   MBOGE, M
   GALAZKA, A
   ROBERTSON, SE
   SCOTT, RM
   WRIGHT, PF
   LINKINS, RW
   ORENSTEIN, WA
   PATRIARCA, PA
   ZELL, ER
   KEW, O
   MAHER, K
   PALLANSCH, M
   VANNOY, T
AF CIRNE, MD
   DUARTE, MNDR
   NOBREGA, DD
   DESOUZA, EMD
   MONTEIRO, D
   OLIVEIRA, MJC
   DANTAS, MCD
   CAVALCANTE, AMS
   BUENO, H
   FRANZOSI, I
   MENEZES, M
   RISI, JB
   BIELLIK, RJ
   GREENWOOD, BM
   HALL, AJ
   ROWE, M
   WELLS, J
   WHITTLE, H
   MBOGE, M
   GALAZKA, A
   ROBERTSON, SE
   SCOTT, RM
   WRIGHT, PF
   LINKINS, RW
   ORENSTEIN, WA
   PATRIARCA, PA
   ZELL, ER
   KEW, O
   MAHER, K
   PALLANSCH, M
   VANNOY, T
TI FACTORS AFFECTING THE IMMUNOGENICITY OF ORAL POLIOVIRUS VACCINE - A
   PROSPECTIVE EVALUATION IN BRAZIL AND THE GAMBIA
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID POLIOMYELITIS; ERADICATION; IMMUNIZATION; EPIDEMIOLOGY; PROGRESS;
   CHILDREN; DISEASES
AB To assess factors that may influence the immunogenicity of oral poliovirus vaccine (OPV), neutralizing antibody responses were measured in 1409 infants in Brazil and the Gambia who were randomized to receive one of four different formulations of OPV at similar to birth and at 6, 10, and 14 weeks. Overall seroconversion rates at the end of the trial were 85% for poliovirus type 1 (P1), 94% for type 2 (P2), and 68% for type 3 (P3). Factors associated with vaccine failure included high levels of maternal antibody (P1, P2, and P3), vaccination during the rainy season (P1, P2, and P3), diarrhea at the time of vaccination (P2 and P3), household exposure to other OPV recipients (P1), and breast-feeding (P3) (P < .05 for each factor, logistic regression analysis). OPV containing twice the standard potency of Sabin type 1 virus increased seroconversion rates to P1 by 8% in Brazil(P < .05) and 15% in the Gambia (P < .001). Suboptimal responses to OPV in developing countries are determined by a complex array of factors related to the vaccine, host, and environment.
C1 DEPT HLTH,NATAL,RN,BRAZIL.
   FDN SAUDE AMAURY MEDEIROS,CENT LAB,RECIFE,PE,BRAZIL.
   PAN AMER HLTH ORG,BRASILIA,DF,BRAZIL.
   MRC LABS,FAJARA,SENEGAL.
   MINIST HLTH,BANJUL,GAMBIA.
   WHO,EXPANDED PROGRAMME IMMUNIZAT,CH-1211 GENEVA,SWITZERLAND.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA.
CR ARMITAGE P, 1987, STATISTICAL METHODS, P318
   BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057
   BENYESHMELNICK M, 1976, AMJ EPIDEMIOL, V86, P112
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   COHENABBO A, IN PRESS PEDIATR INF
   Cutts F. T., 1988, Health Policy and Planning, V3, P291, DOI 10.1093/heapol/3.4.291
   DEFOREST A, 1973, J PEDIATR, V83, P94
   DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239
   De-Xiang D, 1986, B WORLD HEALTH ORGAN, V64, P853
   DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736
   EHRENGUT W, 1984, MONATSSCHR KINDERH, V132, P29
   Finney DJ, 1964, STAT METHODS BIOL AS, P524
   GELFAND HM, 1960, J IMMUNOL, V85, P46
   GELFAND HM, 1961, 5TH INT POL C COP, P285
   GELFAND HM, 1959, SCI PUBLICATION PAN, V44
   GONZAGA AJ, 1963, PEDIATRICS, V32, P1039
   HENDERSON RH, 1988, B WORLD HEALTH ORGAN, V66, P535
   HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4
   JOHN TJ, 1976, PEDIATRICS, V57, P47
   KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P447
   KRUGMAN S, 1961, AM J DIS CHILD, V101, P23
   LAGO PM, 1994, B WORLD HEALTH ORGAN, V72, P221
   LEBARON C, 1994, 34 INT C ANT AG CHEM, P229
   LEMON SM, 1991, PROG MED VIROL, V38, P42
   MAHMOUD AMM, 1978, GAZZETTE EGYPT PAEDI, V6, P81
   MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615
   MODLIN JF, 1993, 33RD INT C ANT AG CH, P346
   MONTEFIORE DG, 1971, SCI PUB, V226, P182
   MURPHY W, 1967, PEDIATRICS, V40, P980
   PANGI NS, 1977, INDIAN PEDIATR, V14, P523
   PATRIARCA PA, 1988, LANCET, V1, P429
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   Patriarca PA, 1993, MEASLES POLIOMYELITI, P303
   PLOTKIN STANLEY A., 1966, AMER J DIS CHILDREN, V111, P27
   PREM KA, 1959, SCI PUBLICATION PAN, V44, P254
   REICHLER MR, 1992, 32ND INT C ANT AG CH, P398
   RICHARDSON G, 1993, 33RD INT C ANT AG CH, P346
   RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8
   ROBERTSON H. E., 1962, CANADIAN JOUR PUBL HEALTH, V53, P179
   SABIN AB, 1963, PEDIATRICS, V31, P623
   Sangkawibha N, 1974, Southeast Asian J Trop Med Public Health, V5, P171
   SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P247
   STREBEL PM, 1992, CLIN INFECT DIS, V14, P568
   SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W
   SWARTZ TA, 1972, J HYG-CAMBRIDGE, V70, P719
   WECKX LY, 1992, B WORLD HEALTH ORGAN, V70, P85
   WOOD DJ, 1992, BIOLOGICALS, V30, P203
   WRIGHT PF, 1991, NEW ENGL J MED, V325, P1174
   YORKE JA, 1979, AM J EPIDEMIOL, V109, P103
   1985, WKLY EPIDEMIOL REC, V60, P13
   [Anonymous], 1989, SAS STAT USERS GUIDE, V1
   1993, WHOUNICEFEPIRS931 TE
   1988, PROCEDURAL GUIDE POL, P22
   1993, 33RD INT C ANT AG CH, P346
   1990, WKLY EPIDEMIOL REC, V65, P15
NR 55
TC 72
Z9 74
U1 1
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY
PY 1995
VL 171
IS 5
BP 1097
EP 1106
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA QU640
UT WOS:A1995QU64000004
OA No
DA 2017-08-15
ER

PT J
AU MENENDEZ, C
   TODD, J
   ALONSO, PL
   FRANCIS, N
   LULAT, S
   CEESAY, S
   ASCASO, C
   SMITH, T
   MBOGE, B
   GREENWOOD, BM
AF MENENDEZ, C
   TODD, J
   ALONSO, PL
   FRANCIS, N
   LULAT, S
   CEESAY, S
   ASCASO, C
   SMITH, T
   MBOGE, B
   GREENWOOD, BM
TI THE RESPONSE TO IRON SUPPLEMENTATION OF PREGNANT-WOMEN WITH THE
   HEMOGLOBIN GENOTYPE AA OR AS
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE IRON SUPPLEMENTATION; PREGNANT WOMEN; HEMOGLOBIN AA AND AS; THE GAMBIA
ID SICKLE-CELL TRAIT; MALARIA; AFRICA; ANEMIA; INFUSION; CHILDREN; SAVANNA;
   NIGERIA; GUINEA
AB The influence of haemoglobin genotype on the response to iron supplementation was studied in a randomized, double blind, placebo-controlled trial involving 497 multigravid pregnant women from a rural area of The Gambia. Women were randomly allocated to receive either oral iron (60mg elemental iron per day) or placebo. At 36 weeks of pregnancy, women who had received oral iron during pregnancy had higher mean haemoglobin, packed cell volume, plasma iron and ferritin levels than did women who received placebo. Iron supplementation of pregnant women with the AA haemoglobin genotype also resulted in increases in the packed cell volume (PCV) and haemoglobin level measured after delivery, and in the birth weight of the infant. However, in AS women PCV and haemoglobin level at delivery were lower in the supplemented group and supplementation was also associated with reduced birth weights. In malaria endemic areas, pregnant women with the haemoglobin genotype AS may not benefit from iron supplementation during pregnancy.
C1 MRC,BANJUL,GAMBIA.
   CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND.
   SWISS TROP INST,DEPT EPIDEMIOL & PUBL HLTH,CH-4002 BASEL,SWITZERLAND.
   MINIST HLTH,BANJUL,GAMBIA.
RP MENENDEZ, C (reprint author), UNIV BARCELONA,HOSP CLIN & PROV,FDN RECERCA BIOMED,UNIDAD EPIDEMIOL & BIOESTADIST,VILLARROEL 170,BARCELONA,SPAIN.
RI Smith, Thomas/B-5569-2015
OI Smith, Thomas/0000-0002-3650-9381
CR ADAMS JQ, 1953, OBSTET GYNECOL, V2, P335
   ALLISON A. C., 1957, EXPTL PARASITOL, V6, P418, DOI 10.1016/0014-4894(57)90032-2
   BLANK A M, 1969, Clinical Obstetrics and Gynecology, V12, P123, DOI 10.1097/00003081-196903000-00006
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   BRABIN BJ, 1985, T ROY SOC TROP MED H, V79, P733, DOI 10.1016/0035-9203(85)90207-X
   BYLES AB, 1970, BRIT MED J, V3, P625
   CORNILLEBROGGER R, 1979, ANN TROP MED PARASIT, V73, P173
   FLEMING AF, 1968, LANCET, V2, P574
   FLEMING AF, 1979, ANN TROP MED PARASIT, V73, P161
   FLEMING AF, 1989, T ROY SOC TROP MED H, V83, P441, DOI 10.1016/0035-9203(89)90241-1
   FLEMING AF, 1984, ANN TROP MED PARASIT, V78, P395
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HARRISON C, 1987, LAB PRACT, V36, P95
   HEBBEL RP, 1990, SEMIN HEMATOL, V27, P51
   MCCURDY PR, 1964, AM J OBSTET GYNECOL, V90, P891
   MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7
   MENENDEZ C, 1993, J TROP MED HYG, V96, P175
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P818, DOI 10.1016/0035-9203(86)90393-7
   RICEEVANS C, 1987, ACTA HAEMATOL-BASEL, V78, P105
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P6
   van Dongen P W, 1982, Med J Zambia, V16, P58
   WHALLEY PJ, 1963, JAMA-J AM MED ASSOC, V186, P1132
NR 22
TC 26
Z9 26
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1995
VL 89
IS 3
BP 289
EP 292
DI 10.1016/0035-9203(95)90546-4
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RF454
UT WOS:A1995RF45400019
PM 7660438
OA No
DA 2017-08-15
ER

PT J
AU FORTUIN, M
   MAINE, N
   MENDY, M
   HALL, A
   GEORGE, M
   WHITTLE, H
AF FORTUIN, M
   MAINE, N
   MENDY, M
   HALL, A
   GEORGE, M
   WHITTLE, H
TI MEASLES, POLIO AND TETANUS TOXOID ANTIBODY-LEVELS IN GAMBIAN CHILDREN
   AGED 3 TO 4 YEARS FOLLOWING ROUTINE VACCINATION
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE VACCINATION; MEASLES; POLIO; TETANUS TOROID; ANTIBODY PERSISTENCE
ID EPIDEMIC POLIOMYELITIS; ENDEMIC DISEASE; IMMUNIZATION; EFFICACY
AB A nation-wide cross-sectional survey of 816 children 3-4 years old was carried out in The Gambia between September 1990 and July 1991 to assess the seroprevalence of antibodies against 3 diseases included in the expanded programme on immunization: measles, poliomyelitis and tetanus. Among 689 children whose records were available, 94.5% were fully immunized. Measles vaccine was administered to 97% of the children and 91% of these had detectable antibodies at the time of the survey. Antibodies against type 1 and type 3 polioviruses, after up to 6 doses of oral polio vaccine, were present in 88.1% and 89.3% of the children respectively. Ninety-seven percent of the children who had received 4 doses of diphtheria-pertussis-tetanus vaccine (DPT) and 91% of those who received 3 doses had detectable tetanus toroid antibodies at the age of 3-4 years. This study shows that serological responses to EPI vaccines given in infancy persist at very satisfactory levels throughout early childhood.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,COMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
   GOVT GAMBIA,DEPT MED & HLTH,BANJUL,GAMBIA.
   MRC LABS,BANJUL,GAMBIA.
RP FORTUIN, M (reprint author), INT AGCY RES CANC,GAMBIA HEPATITIS INTERVENT STUDY,BANJUL,GAMBIA.
CR BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2
   BROWN GC, 1964, PUBLIC HEALTH REP, V79, P585, DOI 10.2307/4592199
   DEMING MS, 1992, AM J EPIDEMIOL, V135, P393
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   Galazka A.M., 1993, IMMUNOLOGICAL BASIS
   Halsey NA, 1983, SCI PUBLICATION, V451, P4
   NOKES DJ, 1988, LANCET, V2, P1374
   OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381
   SEDGWICK AK, 1983, J CLIN MICROBIOL, V18, P104
   WHITTLE HC, 1984, LANCET, V2, P834
   1990, MANUAL VIROLOGICAL I
   1992, WHO EPIGAG92WP10 MIM
   1992, INTERSCIENCE C ANTIM
NR 14
TC 8
Z9 8
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1995
VL 89
IS 3
BP 326
EP 329
DI 10.1016/0035-9203(95)90564-2
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RF454
UT WOS:A1995RF45400032
PM 7660451
OA No
DA 2017-08-15
ER

PT J
AU KAUFMANN, J
   KOMMA, A
   PFISTER, K
AF KAUFMANN, J
   KOMMA, A
   PFISTER, K
TI EFFECT OF HERD MANAGEMENT ON THE CONTAMINATION OF NIGHT HOLDING AREAS
   (CORREOS) AND INFECTIONS WITH GASTROINTESTINAL NEMATODES OF NDAMA CATTLE
   IN THE GAMBIA
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID SEASONAL EPIDEMIOLOGY
AB The densities of infective nematode larvae (L3/m2) in the night holding places (locally called ''correos'') of 2 traditionally kept N'Dama herds were estimated at weekly intervals throughout an entire rainy season.  Herd 1 moved correos every 3 weeks whereas herd 2 remained in the same area for most of the rainy season.  Removal to a new correo was invariably accompanied by a drastic drop of L3/m2.  Conversely, L3/m2 increased rapidly up to values of more than 1,000 when the herds used the same night holding place for more than 3 weeks.  Calves kept in herds with frequent changes of the correo showed significantly lower nematode egg counts and higher growth rates during the rainy season, combined with a reduced weight loss during the following dry season.  The results of this study indicate that a regular frequent change of the correo is an effective method of reducing nematode infection risk and increasing calf growth and that this might be a sustainable part of an integrated strategic programme to control gastrointestinal nematode infections wherever correos are used.
C1 LABOR PFISTER,CH-3018 BERN,SWITZERLAND.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
RP KAUFMANN, J (reprint author), UNIV BERN,FAC VET MED,DEPT VET PARASITOL,POSTFACH 3001,CH-3000 BERN,SWITZERLAND.
CR BAIRDEN K, 1981, EPIDEMIOLOGY CONTROL, P31
   DWINGER RH, 1989, 6TH P INT C I TROP V, P170
   FRITSCHE T, 1993, VET PARASITOL, V49, P271, DOI 10.1016/0304-4017(93)90126-8
   Gordon H. McL., 1939, Journal of the Council for Scientific and Industrial Research Australia, V12, P50
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   KAUFMANN J, 1989, 6TH P INT C I TROP V, P341
   KAUFMANN J, 1989, 6TH INT C I TROP VET, P95
NR 8
TC 2
Z9 2
U1 0
U2 1
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD MAY
PY 1995
VL 27
IS 2
BP 76
EP 82
DI 10.1007/BF02236314
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA RE115
UT WOS:A1995RE11500003
PM 7652942
OA No
DA 2017-08-15
ER

PT J
AU MATTIOLI, RC
   BAH, M
   KORA, S
   CASSAMA, M
   CLIFFORD, DJ
AF MATTIOLI, RC
   BAH, M
   KORA, S
   CASSAMA, M
   CLIFFORD, DJ
TI SUSCEPTIBILITY TO DIFFERENT TICK GENERA IN GAMBIAN NDAMA AND GOBRA ZEBU
   CATTLE EXPOSED TO NATURALLY-OCCURRING TICK INFESTATIONS
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID AMBLYOMMA-VARIEGATUM; BOOPHILUS-MICROPLUS; CROSSBRED CATTLE; RESISTANCE;
   FIELD; TRYPANOSOMES; BREEDS
AB Tick collection on one side of the body and whole tail was performed weekly over one year on 11 Gambian N'Dama (Bos taurus) and 11 Gobra zebu (Bos indicus) cattle to assess breed susceptibility to naturally occurring ticks.  Enzyme-linked immunosorbant assay was also performed to assess the serological prevalence of Anaplasma marginale antigen and Babesia bigemina antibody.  Packed red cell volume was measured and liveweight gain was recorded.
   Significantly higher numbers of Amblyomma variegatum (P < 0.002) and Hyalomma spp. (P < 0.001) were found on Gobra zebu than on N'Dama cattle.  The serological prevalence of A. marginale antigen was significantly (P < 0.001) lower in N'Dama breed, whilst no difference in the serological prevalence of B. bigemina antibody was found between N'Dama and Gobra cattle.  Packed red cell volume was negatively affected by A. marginale infection in both breeds, but to a lesser extent in N'Dama cattle.  Liveweight gain was significantly (P < 0.003) higher in N'Dama in comparison with Gobra cattle during the period of abundance of A. variegatum and Hyalomma spp. adults.  The significantly lower burdens of A. variegatum and Hyalomma spp. ticks in Gambian N'Dama in comparison with Gobra zebu cattle confirms previous findings.  It also shows a more deleterious effect of ticks and tick-borne diseases on animal production and health in Gobra zebu than in N'Dama cattle.  The presence of a tick resistant trait in N'Dama cattle is suggested.
RP MATTIOLI, RC (reprint author), INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR Abdala A A, 1990, Rev Elev Med Vet Pays Trop, V43, P155
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   ANZIANI OS, 1987, TROP ANIM HEALTH PRO, V19, P83, DOI 10.1007/BF02297324
   CLAXTON J, 1991, VET PARASITOL, V40, P293, DOI 10.1016/0304-4017(91)90109-9
   DALGIESH RJ, 1990, TROP ANIM HEALTH PRO, V22, P44, DOI 10.1007/BF02243499
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   ELBL A, 1966, MUSEE ROYAL AFRI 145, V1, P275
   ELBL A, 1966, MUSEE ROYAL AFRI 148, V4, P412
   FIVAZ BH, 1992, TROP ANIM HEALTH PRO, V24, P81, DOI 10.1007/BF02356949
   Gueye A, 1990, Rev Elev Med Vet Pays Trop, V42, P517
   JONGEJAN F, 1989, EXP APPL ACAROL, V7, P181, DOI 10.1007/BF01194059
   KAISER MN, 1982, TROP ANIM HEALTH PRO, V14, P63, DOI 10.1007/BF02282583
   KEMP DK, 1980, 56TH P S ANN C AUSTR, P64
   KUTTLER KL, 1988, TROP ANIM HEALTH PRO, V20, P85, DOI 10.1007/BF02242231
   KUTTLER KL, 1988, TROP ANIM HEALTH PRO, V20, P37, DOI 10.1007/BF02239643
   Macadam I., 1976, Dermatophilus infection in animals and man,, P33
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   MUSOKE AJ, 1984, IMMUNOLOGY, V52, P231
   MUSOKE AJ, 1981, PARASITE IMMUNOL, V3, P97, DOI 10.1111/j.1365-3024.1981.tb00388.x
   Nakamura RM, 1986, HDB EXPT IMMUNOLOGY, V1, P271
   OKELLY JC, 1976, J PARASITOL, V62, P312, DOI 10.2307/3279295
   OKELLY JC, 1969, AUST J BIOL SCI, V22, P1497
   Pegram R. G., 1993, World Animal Review (Multilingual Edition), V74-75, P2
   RECHAV Y, 1991, ONDERSTEPOORT J VET, V58, P181
   RECHAV Y, 1989, MED VETERINARY ENTOM, V3, P34
   SEEBECK RM, 1971, AUST J BIOL SCI, V24, P373
   SEIFERT GW, 1971, AUST J AGR RES, V22, P159, DOI 10.1071/AR9710159
   STACHURSKI F, 1993, VET PARASITOL, V49, P299, DOI 10.1016/0304-4017(93)90128-A
   STARKEY PH, 1984, WORLD ANIM REV, V50, P2
   WALKER AR, 1993, J MED ENTOMOL, V30, P136
   1990, PARASSITOLOGIA, V32, P3
NR 31
TC 18
Z9 18
U1 1
U2 1
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD MAY
PY 1995
VL 27
IS 2
BP 95
EP 105
DI 10.1007/BF02236320
PG 11
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA RE115
UT WOS:A1995RE11500007
PM 7652946
OA No
DA 2017-08-15
ER

PT J
AU TANNER, JC
   LITTLE, DA
   HOLDEN, SJ
   DAMPHA, K
AF TANNER, JC
   LITTLE, DA
   HOLDEN, SJ
   DAMPHA, K
TI REDUCING AGE AT 1ST CALVING IN NDAMA HEIFERS USING GROUNDNUT CAKE AS A
   SUPPLEMENT TO GRAZED NATURAL PASTURE IN THE GAMBIA
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID PRODUCTIVITY
AB N'Dama heifers, initially weighing 129 kg at approximately 30 months of age, were supplemented with 250, 500 or 1000 g/head/day groundnut cake for 3 or 6 months during the dry or dry and wet seasons.  Highly significant improvements in rates of liveweight gain and reproductive performance were obtained.  Supplementation during the dry season only, approximately trebled the proportion of animals calving within 2 years of the beginning of the trial (6 vs 20%, P < 0.05), while this increase was around eight-fold in the animals that continued to receive supplement during the wet season (6 vs 50%, P < 0.05).  Conceptions occurred at an overall mean liveweight of 185 kg, and a ''target'' liveweight of 200 kg for the first conception of N'Dama heifers is proposed as the basis for husbandry recommendations concerning these animals.  It is concluded that such intervention can reduce the usually observed age at first calving of village based N'Dama heifers by 12 months, in a fashion that is both practicable and financially advantageous.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR AGYEMANG K, 1991, ANIM REPROD SCI, V26, P51, DOI 10.1016/0378-4320(91)90065-8
   AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   Bayer W, 1991, ANIMAL RES DEV, V34, P57
   Dunsmore J.R., 1976, LAND RESOURCES STUDY, V22
   DWINGER RH, 1990, 6TH P INT C I TROP V, P169
   DWINGER RH, 1995, IN PRESS VETERINARY
   ITTY P, 1991, THESIS SWISS FEDERAL
   Lamond D. R., 1970, ANIM BREED ABSTR, V38, P359
   LITTLE DA, 1991, TROP AGR, V68, P259
   LITTLE DA, 1991, TROP ANIM HEALTH PRO, V23, P126, DOI 10.1007/BF02361198
   LITTLE DA, 1993, BRIT SOC ANIMAL PROD, V16, P156
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PULLAN NB, 1980, TROP ANIM HEALTH PRO, V12, P17, DOI 10.1007/BF02242626
   Snedecor G.W., 1967, STATISTICAL METHODS
   TANNER JC, 1993, BRIT SOC ANIMAL PROD, V16, P190
   TILLEY J. M. A., 1963, JOUR BRIT GRASSLAND SOC, V18, P104
   1989, ANN REPORT, P26
   1980, NUTRIENT REQUIREMENT
NR 18
TC 1
Z9 1
U1 0
U2 1
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD MAY
PY 1995
VL 27
IS 2
BP 113
EP 120
DI 10.1007/BF02236323
PG 8
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA RE115
UT WOS:A1995RE11500009
PM 7652937
OA No
DA 2017-08-15
ER

PT J
AU WHITTLE, HC
   MAINE, N
   PILKINGTON, J
   MENDY, M
   FORTUIN, M
   BUNN, J
   ALLISON, L
   HOWARD, C
   HALL, A
AF WHITTLE, HC
   MAINE, N
   PILKINGTON, J
   MENDY, M
   FORTUIN, M
   BUNN, J
   ALLISON, L
   HOWARD, C
   HALL, A
TI LONG-TERM EFFICACY OF CONTINUING HEPATITIS-B VACCINATION IN INFANCY IN 2
   GAMBIAN VILLAGES
SO LANCET
LA English
DT Article
ID TRANSMISSION; CHILDREN; VIRUS
AB In 1984, all non-immune children under the age of 5 years in the Gambian villages of Keneba and Manduar were vaccinated against hepatitis B virus (HBV). All children born in these villages since 1984 have been vaccinated in infancy.
   Despite a rapid fall in antibody concentrations, vaccine efficacy against HBV infection and chronic carriage of HBsAg has increased with time. Overall, vaccine efficacies in 1993 against HBV infection and chronic HBsAg carriage were 94.7% (95% CI 93.0-96.0) and 95.3% (91.0-97.5), respectively. Breakthrough infections in vaccinated children largely originate from chronic HBsAg carriers. Thus, we tested 261 chronic carriers for HBV DNA and e antigen. The prevalence of these markers of infectivity, and the amount of HBV DNA, decreased greatly with age. Detailed studies of breakthrough infections over two 4-year periods revealed that in the second period there were fewer than half the expected numbers of infections.
   Our findings suggest that in Keneba acid Manduar longterm vaccination is progressively decreasing HBV transmission by chronic carriers, since their infectivity diminishes with time.
C1 DUNN NUTR UNIT, KENEBA, GAMBIA.
   GAMBIA HEPATITIS INTERVENT STUDY, BANJUL, GAMBIA.
   UNIV LONDON ROYAL VET COLL, DEPT PATHOL, LONDON SW1, ENGLAND.
RP WHITTLE, HC (reprint author), MRC LABS, POB 273, BANJUL, GAMBIA.
CR BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Barin F, 1981, Prog Med Virol, V27, P148
   COURSAGET P, 1990, COLLOQ INSE, V194, P287
   COURSAGET P, 1986, LANCET, V2, P1143
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1994, J INFECT DIS, V169, P1374
   HALL AJ, 1989, LANCET, V1, P1057
   KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443
   MAYANS MV, 1990, LANCET, V336, P1107
   MCGREGOR IA, 1976, OIKOS, V27, P186
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   WELLER IVD, 1982, J MED VIROL, V9, P273, DOI 10.1002/jmv.1890090405
   WHITTLE HC, 1987, ANN TROP PAEDIATR, V7, P6
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHITTLE HC, 1990, J INFECT DIS, V161, P112
NR 17
TC 107
Z9 107
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 29
PY 1995
VL 345
IS 8957
BP 1089
EP 1092
DI 10.1016/S0140-6736(95)90822-6
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA QV411
UT WOS:A1995QV41100014
PM 7715343
OA No
DA 2017-08-15
ER

PT J
AU NJIE, M
   REED, JD
AF NJIE, M
   REED, JD
TI POTENTIAL OF CROP RESIDUES AND AGRICULTURAL BY-PRODUCTS FOR FEEDING
   SHEEP IN A GAMBIAN VILLAGE
SO ANIMAL FEED SCIENCE AND TECHNOLOGY
LA English
DT Article
DE BY-PRODUCTS, AGRICULTURAL; CROP RESIDUES; SHEEP, ADULT
AB The quantity and potential use of crop residues and agricultural by-products for feeding sheep were determined in a Gambian village. The crop residues present were millet and maize stover, rice straw and groundnut hay, The yield of crop residues was estimated by sampling quadrats which were randomly placed along transects in ten fields per crop. Agricultural by-products included millet bran, maize bran, rice bran, sesame cake and groundnut cake, Yields of agricultural by-products were determined by estimating the amount of crop which was processed in the village and directly measuring extraction rate. The nutritive value of crop residues and by-products was determined by the detergent systems of forage analysis, Most of the cereal crop residues were grazed in the field. Groundnut crop residue was harvested and stored for feeding livestock but only 47% of this hay was collected, Groundnut leaves contained high concentrations of crude protein and metabolizable energy, and the groundnut stems were higher in crude protein than all fractions of the cereal crop residues. Stored groundnut hay was of lower nutritive value than immediately after harvest, since substantial loss of nutrients occurred during harvest and storage, Millet bran was the most abundant by-product available in the village, and was higher in crude protein and metabolizable energy and lower in neutral-detergent fibre than either maize and rice bran, Rice bran had a low nutritive value because of contamination with hulls that contain high amounts of lignin and biogenic silica and are not removed before milling, The high content of ether extract in groundnut and sesame cakes indicated that the oil press used in the village was inefficient. Only 10% of the groundnut cake was available in the village because most of the groundnuts were sold to the government marketing board, The results indicated that the village has adequate quantities of crop residues and by-products to meet the feed requirements of improved sheep production systems. However, many production constraints exist and research and extension programmmes for improved sheep production are needed. Simple diets for sheep based on available feed resources are presented.
C1 DEPT LIVESTOCK SERV,ABUKO,GAMBIA.
RP NJIE, M (reprint author), UNIV WISCONSIN,DEPT MEAT & ANIM SCI,1675 OBSERV DR,256,MADISON,WI 53706, USA.
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   Czerkawski J. W, 1986, INTRO RUMEN STUDIES
   Goering HK, 1970, USDA AGR HDB, V379
   GREENWOOD AC, 1989, UNPUB SMALL RUMINANT
   NJAI O, 1988, UNPUB FEED MANAGEMEN
   NJIE M, 1990, UNPUB FINAL REPORT T
   NJIE M, 1986, THESIS SWEDISH U AGR
   OWEN E, 1988, PLANT BREEDING NUTR, P133
   POWELL JM, 1985, TROP AGR, V62, P77
   RUSSO S, 1986, 11 MIN GOVT GAMB MIN
   TORRENCE E, 1990, UNPUB EC APPRAISAL T
   van Soest P. J., 1982, NUTRITIONAL ECOLOGY
   1990, TECHNICAL B DEP PLAN, V13
   1980, NUTRIENT REQUIREMENT
NR 14
TC 9
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0377-8401
J9 ANIM FEED SCI TECH
JI Anim. Feed Sci. Technol.
PD APR
PY 1995
VL 52
IS 3-4
BP 313
EP 323
DI 10.1016/0377-8401(94)00710-Q
PG 11
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA QU241
UT WOS:A1995QU24100012
OA No
DA 2017-08-15
ER

PT J
AU HUDSON, GJ
AF HUDSON, GJ
TI FOOD-INTAKE IN A WEST-AFRICAN VILLAGE - ESTIMATION OF FOOD-INTAKE FROM A
   SHARED BOWL
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE WEST AFRICA; FOOD INTAKE; SHARED BOWLS; ENERGY INTAKE; ENERGY
   EXPENDITURE
ID DIETARY-INTAKE; WATER
AB Novel methodology is described for the estimation of food intake in the particularly difficult circumstance where groups of people eat directly from a shared bowl of cooked food. Detailed observation and measurement of meal preparation is combined with food table values for composition to calculate the nutrient content of each meal. The distribution of food between individuals is estimated by a suitable algorithm. The ability of the algorithm to identify seasonal changes in energy intakes is demonstrated by comparison of the calculated energy intakes with values for the total energy expenditure of free-living adult male subjects, as measured by the stable isotope, doubly-labelled water technique. This comparison suggests that the energy intake calculated from detailed observation of two cooked meals per day is equivalent to approximately 80% of the total energy expenditure and, by inference, total dietary energy intake. The remaining energy intake may well be derived from uncooked 'snack foods', such as raw fruit and vegetables, or from cooked food obtained, by purchase or as a gift, away from the home. This is the first description of a successful method for the estimation of food intake when people eat directly from shared bowls of food.
C1 MRC COMPOUND,W KIANG,GAMBIA.
RP HUDSON, GJ (reprint author), MRC,DUNN CLIN NUTR CTR,HILLS RD,CAMBRIDGE CB2 2DH,ENGLAND.
CR Anderson T. L., 1977, CURRENT CONCEPTS PAR, P111
   Bingham S. A., 1987, Nutrition Abstracts and Reviews, A (Human and Experimental), V57, P705
   BINGHAM SA, 1991, ANN NUTR METAB, V35, P117, DOI 10.1159/000177635
   BORRELLI R, 1990, BRIT J NUTR, V63, P411, DOI 10.1079/BJN19900129
   COWARD WA, 1988, P NUTR SOC, V47, P209, DOI 10.1079/PNS19880037
   COWARD WA, 1991, NEW TECHNIQUES NUTRI, P137
   DIAZ E, 1990, P NUTR SOC, V49, pA44
   HUDSON GJ, 1989, NUTR REP INT, V40, P335
   HUDSON GJ, 1992, THESIS CNAA LONDON
   KRETSCH MJ, 1990, AM J CLIN NUTR, V51, P477
   LIFSON N, 1966, J THEOR BIOL, V12, P46, DOI 10.1016/0022-5193(66)90185-8
   Paul AA, 1978, MCCANCE WIDDOWSONS C
   PLATT BS, 1962, MRC SPECIAL REPORT S, V302
   Prentice A, 1990, DOUBLY LABELLED WATE
   SINGH J, 1988, P NUTR SOC, V47, pA41
NR 15
TC 22
Z9 22
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR
PY 1995
VL 73
IS 4
BP 551
EP 569
DI 10.1079/BJN19950058
PG 19
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA QV988
UT WOS:A1995QV98800006
PM 7794871
OA No
DA 2017-08-15
ER

PT J
AU MULHOLLAND, K
AF MULHOLLAND, K
TI MEASLES AND PERTUSSIS - THE TIMING OF VACCINATION - REPLY
SO LANCET
LA English
DT Letter
RP MULHOLLAND, K (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR CARSON MM, 1995, PEDIATR INFECT DIS J, V14, P17, DOI 10.1097/00006454-199501000-00003
   MURPHY MD, 1984, PEDIATRICS, V74, P90
   NELSON JD, 1978, AM J DIS CHILD, V132, P371
   STETLER HC, 1986, PEDIATRICS, V77, P471
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0099-5355
J9 LANCET
JI Lancet
PD APR 1
PY 1995
VL 345
IS 8953
BP 858
EP 859
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA QQ195
UT WOS:A1995QQ19500042
OA No
DA 2017-08-15
ER

PT J
AU THURSZ, MR
   KWIATKOWSKI, D
   TOROK, ME
   ALLSOPP, CEM
   GREENWOOD, BM
   WHITTLE, HC
   THOMAS, HC
   HILL, AVS
AF THURSZ, MR
   KWIATKOWSKI, D
   TOROK, ME
   ALLSOPP, CEM
   GREENWOOD, BM
   WHITTLE, HC
   THOMAS, HC
   HILL, AVS
TI ASSOCIATION OF HEPATITIS-B SURFACE-ANTIGEN CARRIAGE WITH SEVERE MALARIA
   IN GAMBIAN CHILDREN
SO NATURE MEDICINE
LA English
DT Article
ID VIRUS
AB Severe malaria is a major cause of childhood mortality in sub-Saharan Africa but the factors predisposing children to Severe forms of malaria have not been fully elucidated. In a case-control study of over 1,200 Cambian children hepatitis B virus carriage was significantly increased amongst cases of severe malaria compared to matched controls. We suggest,that this association may relate to impaired clearance of liver stage parasites in the presence of the reduced level of HLA class l antigen expression on hepatocytes Infected by hepatitis B virus. If this association is causal and viral carriage predisposes to severe malaria, widespread vaccination against hepatitis B virus may reduce mortality from severe malaria.
C1 ST MARYS HOSP,SCH MED,ACAD DEPT MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND.
   UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
RP THURSZ, MR (reprint author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND.
RI HILL, Adrian/C-1306-2008; Thomas, Howard/A-3152-2009
FU Wellcome Trust
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   DECKER R, 1983, VIRAL HEPATITIS SCI
   FOSTER GR, 1993, HEPATOLOGY, V17, P757, DOI 10.1016/0270-9139(93)90148-G
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   IKEDA T, 1986, HEPATOLOGY, V6, P963
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   RYDER RW, 1984, LANCET, V2, P449
   THURSZ MR, IN PRESS NEW ENGL J
NR 11
TC 37
Z9 40
U1 0
U2 0
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD APR
PY 1995
VL 1
IS 4
BP 374
EP 375
DI 10.1038/nm0495-374
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA RN098
UT WOS:A1995RN09800036
PM 7585070
OA No
DA 2017-08-15
ER

PT J
AU IMBODEN, M
   MULLER, N
   HEMPHILL, A
   MATTIOLI, R
   SEEBECK, T
AF IMBODEN, M
   MULLER, N
   HEMPHILL, A
   MATTIOLI, R
   SEEBECK, T
TI REPETITIVE PROTEINS FROM THE FLAGELLAR CYTOSKELETON OF AFRICAN
   TRYPANOSOMES ARE DIAGNOSTICALLY USEFUL ANTIGENS
SO PARASITOLOGY
LA English
DT Article
DE TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CONGOLENSE; TRYPANOSOMA VIVAX;
   CYTOSKELETON; REPETITIVE PROTEIN; ANTIGEN; DIAGNOSIS
ID MICROTUBULE-ASSOCIATED PROTEIN; BINDING MOTIF; CRUZI; BRUCEI; ANTIBODY;
   GENES; EXPRESSION; SEQUENCE; MICE
AB Trypanosome infection of mammalian hosts leads, within days, to a strong early response against a small, distinct number of parasite proteins. One of these proteins is the variable surface glycoprotein (VSG). Most of the others are apparently non-variable, intracellular trypanosome proteins. Two of these antigens I-2 and I-17 are now characterized at the molecular level. Both exhibit a highly repetitive amino acid sequence organization, but they show no sequence similarity either to each other or to any other proteins known to date. Preliminary serological analyses indicate that both allow the early, sensitive and specific detection of infections with different species of trypanosomatids, making them interesting candidates for the development of diagnostic tools for trypanosomiasis detection.
C1 UNIV BERN,INST PARASITOL,CH-3012 BERN,SWITZERLAND.
   INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
RP IMBODEN, M (reprint author), UNIV BERN,INST GEN MICROBIOL,BALTZERSTR 4,CH-3012 BERN,SWITZERLAND.
CR ALCINA A, 1988, CELL BIOL INT REP, V12, P979, DOI 10.1016/0309-1651(88)90166-X
   BARNES DA, 1989, MOL BIOCHEM PARASIT, V34, P135, DOI 10.1016/0166-6851(89)90005-4
   BRUN R, 1979, ACTA TROP, V36, P289
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.immunol.8.1.83
   DEGEE ALW, 1988, J IMMUNOL, V140, P283
   DOSSANTOS CND, 1992, BIO-TECHNOL, V10, P1474, DOI 10.1038/nbt1192-1474
   DUNCAN LR, 1991, MOL BIOCHEM PARASIT, V48, P11, DOI 10.1016/0166-6851(91)90159-4
   HEMPHILL A, 1992, J CELL BIOL, V117, P95, DOI 10.1083/jcb.117.1.95
   HEMPHILL A, 1991, J STRUCTURAL BIOL, V107, P222
   HOFT DF, 1989, INFECT IMMUN, V57, P1959
   HYUNH TV, 1985, DNA CLONING TECHNIQU, V1, P49
   IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAFAILLE JJ, 1989, MOL BIOCHEM PARASIT, V35, P127, DOI 10.1016/0166-6851(89)90115-1
   LAWSON D, 1983, J CELL BIOL, V97, P1891, DOI 10.1083/jcb.97.6.1891
   LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041
   MULLER N, 1992, PARASITOLOGY, V104, P111
   MULLER N, 1993, PARASITOLOGY, V107, P411
   POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9
   RINDISBACHER L, 1993, MOL BIOCHEM PARASIT, V58, P83, DOI 10.1016/0166-6851(93)90093-D
   RUIZ AM, 1990, MOL BIOCHEM PARASIT, V39, P117, DOI 10.1016/0166-6851(90)90014-D
   SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695
   SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912
   SEED JR, 1987, J PARASITOL, V73, P840, DOI 10.2307/3282427
   VOGEL M, 1988, MOL BIOCHEM PARASIT, V31, P117, DOI 10.1016/0166-6851(88)90162-4
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
NR 27
TC 27
Z9 27
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD APR
PY 1995
VL 110
BP 249
EP 258
PN 3
PG 10
WC Parasitology
SC Parasitology
GA QR322
UT WOS:A1995QR32200002
PM 7724233
OA No
DA 2017-08-15
ER

PT J
AU ADEGBOLA, RA
   MULHOLLAND, EK
   BAILEY, R
   SECKA, O
   SADIQ, T
   GLASGOW, K
   MABEY, D
AF ADEGBOLA, RA
   MULHOLLAND, EK
   BAILEY, R
   SECKA, O
   SADIQ, T
   GLASGOW, K
   MABEY, D
TI EFFECT OF AZITHROMYCIN ON PHARYNGEAL, MICROFLORA
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
DE AZITHROMYCIN; PHARYNGEAL FLORA
C1 LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.
RP ADEGBOLA, RA (reprint author), MRC LABS,BANJUL,GAMBIA.
CR KUSCHNER RA, 1994, LANCET, V343, P1396
   LODE H, 1991, EUR J CLIN MICROBIOL, V10, P807, DOI 10.1007/BF01975832
   WILLIAMS JD, 1991, EUR J CLIN MICROBIOL, V10, P813, DOI 10.1007/BF01975833
NR 3
TC 13
Z9 13
U1 3
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 1995
VL 14
IS 4
BP 335
EP 336
DI 10.1097/00006454-199504000-00024
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA QT556
UT WOS:A1995QT55600024
PM 7603826
OA No
DA 2017-08-15
ER

PT J
AU TWUMASI, PA
   KUMAH, S
   LEACH, A
   ODEMPSEY, TJD
   CEESAY, SJ
   TODD, J
   BROOME, CV
   CARLONE, GM
   PAIS, LB
   HOLDER, PK
   PLIKAYTIS, BD
   GREENWOOD, BM
AF TWUMASI, PA
   KUMAH, S
   LEACH, A
   ODEMPSEY, TJD
   CEESAY, SJ
   TODD, J
   BROOME, CV
   CARLONE, GM
   PAIS, LB
   HOLDER, PK
   PLIKAYTIS, BD
   GREENWOOD, BM
TI A TRIAL OF A GROUP-A PLUS GROUP-C MENINGOCOCCAL POLYSACCHARIDE-PROTEIN
   CONJUGATE VACCINE IN AFRICAN INFANTS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID NEISSERIA-MENINGITIDIS GROUP; GROUP-A; EPIDEMIC; ANTIBODY; PERSISTENCE;
   AGE
AB The safety and immunogenicity of a group A plus group C meningococcal polysaccharide-CRM(197) conjugate vaccine was evaluated in 304 8- to 10-week-old Gambian infants. Infants were immunized with one, two, or three doses of conjugate vaccine or with two doses of a meningococcal A plus C polysaccharide vaccine. The conjugate vaccine produced few systemic side effects, and local reactions were similar to those produced by the polysaccharide vaccine. Postvaccination group A meningococcal polysaccharide antibody levels, measured by ELISA, increased progressively after one, two, or three doses of conjugate vaccine. However, one dose of conjugate vaccine given at the age of 6 months induced a higher group C meningococcal antibody response than did two doses of conjugate vaccine given at 2 and 6 months. Two doses of conjugate vaccine induced higher levels of antibody than did two doses of polysaccharide vaccine. Thus, this new meningococcal conjugate vaccine proved to be safe and immunogenic.
C1 MRC LABS,BANJUL,GAMBIA.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA.
CR BINKIN N, 1982, LANCET, V2, P315
   BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297
   BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   CEESAY SJ, 1993, J INFECT DIS, V167, P1212
   CLAESSON BA, 1991, PEDIATR INFECT DIS J, V10, P560, DOI 10.1097/00006454-199108000-00002
   CONSTANTINO P, 1992, VACCINE, V10, P691
   ERWA HH, 1973, B WORLD HEALTH ORGAN, V49, P301
   Ettori D, 1977, MEDECINE TROPICALE, V37, P225
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475
   GOLD R, 1977, J INFECT DIS, V136, pS31
   GRANOFF DM, 1993, J INFECT DIS, V168, P663
   GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P756, DOI 10.1016/0035-9203(80)90195-9
   GREENWOOD BM, 1980, LANCET, V1, P729
   GREENWOOD BM, 1987, J INFECTION, V14, P167, DOI 10.1016/S0163-4453(87)92052-4
   GREENWOOD BM, 1986, T R SOC TROP MED HYG, V80, P106
   Greenwood BM, 1987, BACTERIAL MENINGITIS, P61
   Lapeyssonnie L., 1963, B WHO              S, V28, P3
   MOHAMMED I, 1981, LANCET, V2, P80
   MOORE PS, 1992, INT J EPIDEMIOL, V21, P155, DOI 10.1093/ije/21.1.155
   MULHOLLAND EK, 1993, ANN TROP PAEDIATR, V13, P153
   REINGOLD AL, 1985, LANCET, V2, P114
   WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667
   WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645
NR 24
TC 122
Z9 127
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1995
VL 171
IS 3
BP 632
EP 638
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA QJ455
UT WOS:A1995QJ45500017
PM 7876610
OA No
DA 2017-08-15
ER

PT J
AU SAMB, B
   AABY, P
   WHITTLE, HC
   SECK, AMC
   RAHMAN, S
   BENNETT, J
   MARKOWITZ, L
   SIMONDON, F
AF SAMB, B
   AABY, P
   WHITTLE, HC
   SECK, AMC
   RAHMAN, S
   BENNETT, J
   MARKOWITZ, L
   SIMONDON, F
TI SEROLOGIC STATUS AND MEASLES ATTACK RATES AMONG VACCINATED AND
   UNVACCINATED CHILDREN IN RURAL SENEGAL
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HEMAGGLUTININ-INHIBITING ANTIBODIES; MEASLES; MEASLES VACCINE;
   PLAQUE-NEUTRALIZING ANTIBODIES; SECONDARY ATTACK RATES; SEROLOGY;
   VACCINE EFFICACY
ID MORTALITY; EFFICACY; STRAIN
AB During a measles vaccine trial in a rural area of Senegal, antibody status was examined within 10 days of exposure for 228 previously vaccinated and 313 unvaccinated children more than 12 months old who were exposed to measles at home. Thirty-six percent of the children developed clinical measles, the clinical diagnosis being confirmed for 135 of the 137 children from whom 2 blood samples were collected. Vaccine efficacy was 90% (95% confidence interval, 83 to 94%). The hemagglutinin inhibiting antibodies (HI) or plaque neutralizing antibodies (PN) assays were equally efficient in predicting susceptibility and protection against measles. Vaccinated children who had no detectable HI or PN antibodies at exposure had significant protection against measles compared with seronegative unvaccinated children (HI vaccine efficacy, 49% (95% confidence interval, 21 to 68%); PN vaccine efficacy, 43% (95% confidence interval, 12 to 62%)). The attack rate was high for children with a titer of 40 to 125 mIU) 67% (4 of 6) of those with a positive hemagglutinin-inhibiting antibody test and 36% (13 of 36) of those with a positive PN test developed measles. Attack rates among children with HI or PN titers above 125 mIU were 2% (6 of 295) and 3% (7 of 258), respectively. Because titers of less than or equal to 120 mIU have been found to offer little protection in another study, this antibody level may be the best screening value for assessing susceptibility and protection against measles. However, it should be noted that many seronegative vaccinated children are protected against measles infection.
C1 STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN S,DENMARK.
   ORSTOM,UNITE RECH MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341.
CR AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   ALBRECHT P, 1981, J VIROL METHODS, V3, P251, DOI 10.1016/0166-0934(81)90062-8
   AMMARI LK, 1993, INFECT CONT HOSP EP, V14, P81
   BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   BURNET FM, 1968, LANCET, V2, P610
   CHAHNAZARIAN A, 1992, POPULATION SANTE NIA
   CHEN RT, 1990, J INFECT DIS, V162, P1036
   CHRISTENSEN PE, 1953, ACTAMED SCAND, V4, P30
   CHRISTENSEN PE, 1951, ACTAMED SCAND, V144, P3133
   Expanded Programme on Immunization, 1982, WKLY EPIDEMIOL REC, V57, P89
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M, 1987, RISQUES DECES ASS DI
   Garenne ML, 1982, THESIS U PENNSYLVANI
   GOOD RA, 1956, PEDIATRICS, V18, P109
   KRUGMAN S, 1983, REV INFECT DIS, V5, P477
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   STOKES J, 1961, AM J HYG, V74, P293
   WHITTLE HC, 1988, LANCET, V1, P963
   1990, WKLY EPIDEMIOL REC, V65, P6
NR 23
TC 100
Z9 102
U1 0
U2 5
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 1995
VL 14
IS 3
BP 203
EP 209
DI 10.1097/00006454-199503000-00007
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA QL716
UT WOS:A1995QL71600007
PM 7761185
OA No
DA 2017-08-15
ER

PT J
AU KORAM, KA
   BENNETT, S
   ADIAMAH, JH
   GREENWOOD, BM
AF KORAM, KA
   BENNETT, S
   ADIAMAH, JH
   GREENWOOD, BM
TI SOCIOECONOMIC RISK-FACTORS FOR MALARIA IN A PERIURBAN AREA OF THE GAMBIA
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE MALARIA; SOCIOECONOMIC RISK FACTORS; THE GAMBIA
ID TREATED BED NETS; EPIDEMIOLOGY; INFECTIONS; CHILDREN
AB Successful control of malaria depends upon a detailed knowledge of its epidemiology, including knowledge of the social and economic factors that influence its prevalence. Little is known about the socio-economic factors that influence the prevalence of malaria in tropical Africa. Therefore, we undertook such a study in over 350 Gambian children with malaria resident in a peri-urban area with seasonal transmission, using the case-control approach. Malaria was associated with poor quality housing and crowding and with travel to rural areas, where the level of malaria transmission is higher than in urban centres. No association was found between the risk of malaria and the overall education level of parents or guardians of study children. However, the knowledge of malaria possessed by mothers of cases of malaria was less than that of controls, suggesting that further education of the study community on the causation of malaria and on ways of preventing it could be of value.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   BANGUERO H, 1984, SOC SCI MED, V19, P1099, DOI 10.1016/0277-9536(84)90313-7
   Bruce-Chwatt LJ, 1985, ESSENTIAL MALARIOLOG
   BUTRAPORN P, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P386
   CASTRO E, 1988, EC HLTH TROPICAL DIS
   CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   ELSAMANI FZ, 1987, J TROP MED HYG, V90, P69
   FERNANDEZ R, 1988, EC HLTH TROPICAL DIS
   FUNGLADDA W, 1987, J TROP MED HYG, V90, P233
   GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P77
   GARENNE M, 1991, HLTH TRANSITION SERI, V1
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   HARVERSON G, 1968, West African Medical Journal and Nigerian Practitioner, V17, P63
   Kaona F A, 1990, Afr J Med Med Sci, V19, P219
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   LINES J, 1992, PARASITOL TODAY, V8, P381, DOI 10.1016/0169-4758(92)90176-3
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   ROSEN G, 1979, HDB MED SOCIOLOGY
   SHUTE GT, 1988, MALARIA PRINCIPLES P
   WARRELL DA, 1990, T ROYAL SOC TROPI S2, V84
   1986, WHO TECHNICAL REPORT, V735
NR 24
TC 73
Z9 74
U1 0
U2 6
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1995
VL 89
IS 2
BP 146
EP 150
DI 10.1016/0035-9203(95)90471-9
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RW847
UT WOS:A1995RW84700005
PM 7778137
OA No
DA 2017-08-15
ER

PT J
AU KORAM, KA
   BENNETT, S
   ADIAMAH, JH
   GREENWOOD, BM
AF KORAM, KA
   BENNETT, S
   ADIAMAH, JH
   GREENWOOD, BM
TI SOCIOECONOMIC DETERMINANTS ARE NOT MAJOR RISK-FACTORS FOR SEVERE MALARIA
   IN GAMBIAN CHILDREN
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE MALARIA; PLASMODIUM FALCIPARUM; RISK FACTORS; THE GAMBIA
ID PENICILLIN
AB Only a small proportion of subjects infected with Plasmodium falciparum develop severe disease. Why this should be is not fully understood. To investigate the possible importance of socio-economic variables on the severity of malaria in Gambian children we undertook a case-control study of 384 children with severe or mild malaria. Few differences were found between the 2 groups. Children with severe malaria had a longer duration of symptoms when recruited than mild cases but this difference was largely accounted for by the fact that most children with severe disease were recruited at a referral hospital, whilst mild cases were recruited at a primary health care facility nearer their home. There was no difference between groups in the time before mothers sought some form of health care. Mothers of children with severe disease were less ready to take their child to hospital than mothers of mild cases, suggesting that education on the importance of taking a child with features of malaria to a health centre as soon as possible might have some effect on the development of severe disease. However, overall, the results of this study suggested that socio-economic and behavioural factors are not the major determinants for severe malaria in African children.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   BANGUERO H, 1984, SOC SCI MED, V19, P1099, DOI 10.1016/0277-9536(84)90313-7
   BUTTRAPORN P, 1986, SE ASIAN J TROPICAL, V17, P386
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   CARME B, 1994, AM J TROP MED HYG, V50, P131
   CARTWRIGHT K, 1992, BRIT MED J, V305, P143
   FUNGLADDA W, 1987, J TROP MED HYG, V90, P233
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   HAYES RJ, 1992, J TROP MED HYG, V95, P157
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   STRANG JR, 1992, BRIT MED J, V305, P141
NR 13
TC 42
Z9 45
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1995
VL 89
IS 2
BP 151
EP 154
DI 10.1016/0035-9203(95)90472-7
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RW847
UT WOS:A1995RW84700006
PM 7778138
OA No
DA 2017-08-15
ER

PT J
AU DALESSANDRO, U
   OLALEYE, BO
   MCGUIRE, W
   LANGEROCK, P
   BENNETT, S
   AIKINS, MK
   THOMSON, MC
   CHAM, MK
   CHAM, BA
   GREENWOOD, BM
AF DALESSANDRO, U
   OLALEYE, BO
   MCGUIRE, W
   LANGEROCK, P
   BENNETT, S
   AIKINS, MK
   THOMSON, MC
   CHAM, MK
   CHAM, BA
   GREENWOOD, BM
TI MORTALITY AND MORBIDITY FROM MALARIA IN GAMBIAN CHILDREN AFTER
   INTRODUCTION OF AN IMPREGNATED BEDNET PROGRAM
SO LANCET
LA English
DT Article
ID AFRICA; NETS; STRATEGY; TRIAL
AB After the success of a controlled trial of insecticide-treated bednets in lowering child mortality, The Gambia initiated a National Insecticide Impregnated Bednet Programme (NlBP) in 1992 with the objective of introducing this form of malaria control into all large villages in The Gambia.
   Five areas (population 115 895) were chosen as sentinel sites for evaluation of the NlBP. During the first year of intervention a 25% reduction was achieved in ail-cause mortality in children 1-9 years old living in treated villages (rate ratio 0.75 [95% CI 0.57-0.98], p=0.04). If one area where the programme was ineffective was excluded, the was 38% (0.62 [0.46-0.83), p=0.001). A in rates of parasitaemia and high-density parasitaemia, an increase in mean packed-cell volume (rate ratio 0.75 [95% Cl 0.59-0.98], p=0.04) and an improvement in the nutritional status of children living in treated villages were also detected.
   In a country such as The Gambia, where nets were widely used and which has a good primary health care system, it is possible to achieve insecticide-treatment of bednets at a national level with a significant reduction in child mortality; but at a cost which the country cannot afford.
C1 MRC LABS,BANJUL,GAMBIA.
   JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD,ENGLAND.
   LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON,ENGLAND.
   MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90173-N
   ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391
   EWBANK DC, 1993, INT J EPIDEMIOL, V22, pS8
   GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1983, T R SOC TROP MED S2, V87, P3
   Mauritsen R. H., 1984, THESIS U WASHINGTON
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   THOMPSON BH, 1993, CIRCULATION, V88, P638
   WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 17
TC 293
Z9 295
U1 1
U2 13
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0099-5355
J9 LANCET
JI Lancet
PD FEB 25
PY 1995
VL 345
IS 8948
BP 479
EP 483
DI 10.1016/S0140-6736(95)90582-0
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA QH929
UT WOS:A1995QH92900009
PM 7861874
OA No
DA 2017-08-15
ER

PT J
AU MULHOLLAND, K
AF MULHOLLAND, K
TI MEASLES AND PERTUSSIS IN DEVELOPING-COUNTRIES WITH GOOD VACCINE COVERAGE
SO LANCET
LA English
DT Editorial Material
ID EPIDEMIC; IMMUNITY; CHILDREN; IMMUNIZATION; POLICY; AGE
RP MULHOLLAND, K (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ADCOCK LM, 1992, INFECT DIS CLIN N AM, V6, P133
   BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802
   BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002
   BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315
   BLACK FL, 1986, AM J EPIDEMIOL, V124, P442
   BOTTIGER M, 1993, SCAND J INFECT DIS, V25, P239, DOI 10.3109/00365549309008490
   CARTER H, 1992, BRIT MED J, V304, P637
   Clements C. John, 1992, World Health Statistics Quarterly, V45, P285
   COHEN P, 1946, J PEDIATR, V29, P609, DOI 10.1016/S0022-3476(46)80128-8
   ENGLUND JA, IN PRESS J INFECT DI
   KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213
   LAMB WH, 1988, REV INFECT DIS, V10, P457
   LINNEMANN CC, 1982, PEDIATRICS, V69, P332
   MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4
   PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004
   PRESTON NW, 1994, LANCET, V344, P491, DOI 10.1016/S0140-6736(94)91894-5
   PROVENZANO RW, 1965, NEW ENGL J MED, V273, P959, DOI 10.1056/NEJM196510282731804
   REYNOLDS DW, 1972, AM J DIS CHILD, V124, P848
   SCHOUB BD, 1993, S AFR MED J, V83, P82
   TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93
   1994, CVI FORUM, V7, P2
   1992, LANCET, V340, P232
NR 22
TC 34
Z9 35
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0099-5355
J9 LANCET
JI Lancet
PD FEB 4
PY 1995
VL 345
IS 8945
BP 305
EP 307
DI 10.1016/S0140-6736(95)90282-1
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA QE731
UT WOS:A1995QE73100016
PM 7837867
OA No
DA 2017-08-15
ER

PT J
AU BAILEY, RL
   HOLLAND, MJ
   WHITTLE, HC
   MABEY, DCW
AF BAILEY, RL
   HOLLAND, MJ
   WHITTLE, HC
   MABEY, DCW
TI SUBJECTS RECOVERING FROM HUMAN OCULAR CHLAMYDIAL INFECTION HAVE ENHANCED
   LYMPHOPROLIFERATIVE RESPONSES TO CHLAMYDIAL ANTIGENS COMPARED WITH THOSE
   OF PERSISTENTLY DISEASED CONTROLS
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MEDIATED IMMUNE-RESPONSES; OUTER-MEMBRANE PROTEIN; GENITAL-INFECTION;
   GAMMA-INTERFERON; TRACHOMATIS; RESOLUTION; IDENTIFICATION; MECHANISM;
   EPITOPES; LINES
AB Cell-mediated immune responses to chlamydial and common recall antigens were measured in 26 subjects whose clinical signs of trachoma persisted over 6 months of follow-up and in 21 subjects whose clinical signs resolved spontaneously over the same period. Seven-day lymphocyte proliferative responses to chlamydial but not common recall antigens were significantly greater in subjects whose disease resolved spontaneously. There was, however, no detectable difference between the two groups in gamma interferon levels in supernatants from lymphocyte cultures stimulated with these antigens. These results are consistent with the hypothesis that cell-mediated immune responses play an important role in the clearance of ocular chlamydial infection in humans.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.
   MRC,BANJUL,GAMBIA.
CR ANDERSON RM, 1992, INFECT DIS, P32
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   BYRNE GI, 1988, INFECT IMMUN, V56, P2023
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   GERMAIN A, 1992, REPRODUCTIVE TRACT I
   HANNA L, 1968, J IMMUNOL, V101, P43
   HAYES LJ, 1992, J INFECT DIS, V166, P1173
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   ISHIZAKI M, 1992, INFECT IMMUN, V60, P3714
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MABEY DCW, 1991, CLIN EXP IMMUNOL, V86, P37
   MABEY DCW, 1987, LANCET, V2, P1491
   PAL S, 1991, REG IMMUNOL, V3, P171
   RAMSEY KH, 1991, INFECT IMMUN, V59, P925
   RAMSEY KH, 1988, INFECT IMMUN, V56, P1320
   RANK RG, 1992, INFECT IMMUN, V60, P4427
   RANK RG, 1983, INFECT IMMUN, V48, P847
   SACKS DL, 1978, CLIN EXP IMMUNOL, V33, P57
   SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115
   SU H, 1990, J EXP MED, V172, P203, DOI 10.1084/jem.172.1.203
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   TAYLOR HR, 1985, REV INFECT DIS, V7, P737
   WATKINS NG, 1986, P NATL ACAD SCI USA, V83, P7480, DOI 10.1073/pnas.83.19.7480
   WILLIAMS DM, 1988, INFECT IMMUN, V56, P3004
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
   YOUNG E, 1984, J INFECT DIS, V150, P745
   YUAN Y, 1992, INFECT IMMUN, V60, P2288
NR 27
TC 65
Z9 66
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 1995
VL 63
IS 2
BP 389
EP 392
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA QC603
UT WOS:A1995QC60300003
PM 7822001
OA No
DA 2017-08-15
ER

PT J
AU SAMB, B
   WHITTLE, H
   AABY, P
   SECK, AMC
   BENNETT, J
   MARKOWITZ, L
   NGOM, PT
   ZELLER, H
   MICHAELSEN, KF
   SIMONDON, F
AF SAMB, B
   WHITTLE, H
   AABY, P
   SECK, AMC
   BENNETT, J
   MARKOWITZ, L
   NGOM, PT
   ZELLER, H
   MICHAELSEN, KF
   SIMONDON, F
TI NO EVIDENCE OF LONG-TERM IMMUNOSUPPRESSION AFTER HIGH-TITER
   EDMONSTRON-ZAGREB MEASLES VACCINATION IN SENEGAL
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID RURAL SENEGAL; MORTALITY; VACCINES; CHILDREN
C1 STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN S,DENMARK.
   UNIV CHEIKH ANTA DIOP,ORSTOM,DAKAR,SENEGAL.
   INST PASTEUR,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
   ROYAL VET & AGR UNIV,HUMAN NUTR RES DEPT,COPENHAGEN,DENMARK.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341.
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, 1994, IN PRESS B WHO
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   LEON ME, 1993, J INFECT DIS, V168, P1097
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
NR 10
TC 12
Z9 12
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB
PY 1995
VL 171
IS 2
BP 506
EP 508
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA QF229
UT WOS:A1995QF22900048
PM 7844403
OA No
DA 2017-08-15
ER

PT J
AU NDAO, M
   BELOT, J
   ZINSSTAG, J
   PFISTER, K
AF NDAO, M
   BELOT, J
   ZINSSTAG, J
   PFISTER, K
TI EPIDEMIOLOGY OF GASTROINTESTINAL NEMATODES OF CATTLE IN THE
   TREE-CROPPING PASTURE SYSTEM OF SENEGAL
SO REVUE DE MEDECINE VETERINAIRE
LA French
DT Article
DE EPIDEMIOLOGY; GASTROINTESTINAL NEMATODES; HAEMONCHUS; BUNOSTOMUM;
   COOPEIA; OESOPHAGOSTOMUM; TREE-CROPPING PASTURE SYSTEM; SENEGAL; CATTLE
AB From october 1990 until september 1991, 52 bovines in a tree-cropping pasture system were examined, all animals appeared to be infected with at least one of the following species of nematodes:  Haemonchus contortus was found in 92 %, Cooperia punctata in 88%, Oesophagostomum radiatum in 75% and Bunostomum phlebotomum in 54% of the bovines.  In the abomasum, the mean charge of adult Haemonchus contortus was 63 and 14 respectively in january and february; while larvval stages reach 1635 and 1203 respectively.  During these two months, 96% to 99% of Haemonchus were hypobiotic.  Adult Cooperia sp., Oesophagostomum sp. and Bunostomum sp. were found during the whole year.  The results showed massive infestations of the animals during the rainy season with losses during the dry season as a result from the combination of malnutrion and parasitisms.  Haemonchus, constraint to bovine health and production.
C1 ROYAL BELGIUM EMBASSY,VET DEPT ZAMBIA,DEV COOPERAT SECT,LUSAKA,ZAMBIA.
   LAB PFISTER,CH-3018 BERN,SWITZERLAND.
   INT TRYPANOTOLERENCE CTR,BANJUL,GAMBIA.
RP NDAO, M (reprint author), INST TROP MED PRINCE LEOPOLD,NATL 155,B-2000 ANTWERP,BELGIUM.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR ANKERS P, 7TH C INT I MED VET, P411
   EUZEBY J, 1981, TRAVAUX PRATIQUES HE, V1
   GORDON HM, 1993, J COUNC SCI IND RES, V13, P50
   GRETILLAT S, 1969, PRINCIPALES HELMINTH
   HELRICH H, 1956, P HELMINTHOL SOC WAS, V23, P102
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PANDEY VS, 1994, VET PARASITOL, V54, P241
   PARENT R, 1984, REV ELEV MED VET PAY, V37, P341
   RONCY PM, 1981, PRECIS PARASITOLOGIE
   VERCRUYSSE J, 1984, VET PARASITOL, V17, P159
   ZINSSTAG J, 1993, 14TH INT C WORLD ASS
   1990, MINISTERE RESSOURCES
NR 13
TC 6
Z9 7
U1 0
U2 0
PU ECOLE NATIONAL VET TOULOUSE
PI TOULOUSE
PA 23 CHEMIN DES CAPELLES, 31076 TOULOUSE, FRANCE
SN 0035-1555
J9 REV MED VET-TOULOUSE
JI Rev. Med. Vet.
PD FEB
PY 1995
VL 146
IS 2
BP 129
EP 134
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA QL135
UT WOS:A1995QL13500007
OA No
DA 2017-08-15
ER

PT J
AU FALADE, AG
   TSCHAPPELER, H
   GREENWOOD, BM
   MULHOLLAND, EK
AF FALADE, AG
   TSCHAPPELER, H
   GREENWOOD, BM
   MULHOLLAND, EK
TI USE OF SIMPLE CLINICAL SIGNS TO PREDICT PNEUMONIA IN YOUNG GAMBIAN
   CHILDREN - THE INFLUENCE OF MALNUTRITION
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID DIAGNOSIS
AB The current WHO recommendations for the case management of acute respiratory infections (ARI) in children aged 2 months to 5 years in developing countries use fast breathing (respiratory rate of greater than or equal to 50 per minute in children under 12 months and greater than or equal to 40 in children aged 12 months to 5 years) and lower chest wall indrawing to determine which child is likely to have pneumonia and should therefore receive antibiotics. We have evaluated these and other physical signs in 487 malnourished children and 255 well nourished children who presented with a cough or breathing difficulty. Pneumonia, defined as definite radiological pneumonia or probable radiological pneumonia associated with crackles on auscultation, was present in 145 (30%) of the malnourished children and 68 (26%) of the well nourished children. The respiratory rate predicted pneumonia equally well in the two groups, but to achieve an appropriate sensitivity and specificity the respiratory rate cut-off required in malnourished children was approximately 5 breaths per minute less than that in well nourished children. Intercostal indrawing was more common and lower chest wall indrawing was less common in the malnourished children, with or without pneumonia. These results suggest that fast breathing, as defined at present by WHO, and lower chest wall indrawing are not sufficiently sensitive as predictors of pneumonia in malnourished children. As the latter are a high-risk group, we should like to recommend that children with malnutrition who present with a cough, fast breathing or difficult breathing should be treated with antibiotics.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV BERN,INSELSPITAL,CHILDRENS HOSP,DEPT RADIOL,CH-3010 BERN,SWITZERLAND.
CR CHERIAN T, 1988, LANCET, V2, P125
   DOHERTY JF, 1991, LANCET, V338, P1454
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295
   TUPASI TE, 1990, REV INFECT DIS, V12, pS1047
NR 8
TC 42
Z9 44
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1995
VL 73
IS 3
BP 299
EP 304
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA RH593
UT WOS:A1995RH59300003
PM 7614661
OA No
DA 2017-08-15
ER

PT J
AU POOLMAN, JT
   KRIZKUZEMENSKA, P
   ASHTON, F
   BIBB, W
   DANKERT, J
   DEMINA, A
   FROHOLM, LO
   HASSANKING, M
   JONES, DM
   LIND, I
   PRAKASH, K
   XUJING, H
AF POOLMAN, JT
   KRIZKUZEMENSKA, P
   ASHTON, F
   BIBB, W
   DANKERT, J
   DEMINA, A
   FROHOLM, LO
   HASSANKING, M
   JONES, DM
   LIND, I
   PRAKASH, K
   XUJING, H
TI SEROTYPES AND SUBTYPES OF NEISSERIA-MENINGITIDIS - RESULTS OF AN
   INTERNATIONAL STUDY COMPARING SENSITIVITIES AND SPECIFICITIES OF
   MONOCLONAL-ANTIBODIES
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID GROUP-B; MENINGOCOCCAL DISEASE; VACCINE; FRANCE
AB An international study supported by the World Health Organization comparing monoclonal antibodies for serotyping and serosubtyping of Neisseria meningitidis strains was performed and the results were assessed in 1992. A collection of 6 serotype-specific (1, 2a, 2b, 4, 14, and 15) and 12 serosubtype-specific (P1.1, P1.2, P1.4, P1.5, P1.6, P1.7, P1.9, P1.10, P1.12, P1.14, P1.15, and P1.16) monoclonal antibodies was provided to 11 participating laboratories throughout the world. Monoclonal antibodies were tested on 85 Neisseria meningitidis strains,vith known reference results, Whole-cell enzyme-linked immunosorbent assay was used for analysis in 10 of 11 laboratories. The sensitivities and specificities of individual serotype- and subtype-specific monoclonal antibodies were evaluated. Differences in individual laboratories and with individual monoclonal antibodies were assessed. Relatively large differences in sensitivities were achieved in individual laboratories. On the contrary, the specificities remained at high levels in all laboratories. The sensitivities of serotype-specific monoclonal antibodies ranged from 72.0 to 100%. Individual serosubtype-specific monoclonal antibodies showed sensitivities ranging from 64.1 to 98.1%. The most frequent reason for the incorrect results obtained with the monoclonal antibodies were false-negative results. The collaborative study demonstrated that some monoclonal antibodies are not very sensitive, Another study to define the most suitable monoclonal antibodies is planned.
C1 UNIV AMSTERDAM,AMSTERDAM,NETHERLANDS.
   NATL INST PUBL HLTH,CR-10042 PRAGUE,CZECH REPUBLIC.
   LAB CTR DIS CONTROL,OTTAWA,ON K1A 0L2,CANADA.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341.
   MOSCOW CENT EPIDEMIOL INST,MOSCOW,RUSSIA.
   NATL INST PUBL HLTH,OSLO,NORWAY.
   MRC,BANJUL,GAMBIA.
   PUBL HLTH LAB,MANCHESTER,LANCS,ENGLAND.
   STATENS SERUM INST,DK-2300 COPENHAGEN,DENMARK.
   LADY HARDING MED COLL,NEW DELHI,INDIA.
   INST EPIDEMIOL & MICROBIOL,BEIJING,PEOPLES R CHINA.
RP POOLMAN, JT (reprint author), NATL INST PUBL HLTH & ENVIRONM PROTECT,VACCINE DEV & IMMUNE MECHANISMS LAB,POB 1,3720 BA BILTHOVEN,NETHERLANDS.
RI Krizova, Pavla/M-6120-2015
CR ABDILLAHI H, 1988, MICROB PATHOGENESIS, V4, P27, DOI 10.1016/0882-4010(88)90045-9
   ASHTON FE, 1991, CAN J MICROBIOL, V37, P613
   BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S
   CALAIN P, 1988, EUR J CLIN MICROBIOL, V7, P788, DOI 10.1007/BF01975051
   DEMORAES JC, 1992, LANCET, V340, P1074
   FRASCH CE, 1985, REV INFECT DIS, V7, P504
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   HOIBY E A, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P147
   KAYHTY H, 1989, SCAND J INFECT DIS, V21, P527, DOI 10.3109/00365548909037881
   KUZEMENSKA P, 1990, Ceskoslovenska Epidemiologie Mikrobiologie Imunologie, V39, P78
   KUZEMENSKA P, 1992, WHO WORKSHOP
   LAST JM, 1983, DICT EPIDEMIOLOGY, P96
   POOLMAN JT, 1988, EUR J CLIN MICROBIOL, V7, P291, DOI 10.1007/BF01963104
   POOLMAN JT, 1986, LANCET, V2, P555
   RIOU JY, 1990, ANN BIOL CLIN-PARIS, V48, P227
   SCHOLTEN RJPM, 1993, CLIN INFECT DIS, V16, P237
NR 16
TC 26
Z9 26
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD JAN
PY 1995
VL 2
IS 1
BP 69
EP 72
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA QA649
UT WOS:A1995QA64900013
PM 7719916
OA No
DA 2017-08-15
ER

PT J
AU LEE, SP
   MORGAN, S
   SKINNER, J
   THOMAS, WA
   JONES, SR
   SUTTON, J
   KHANNA, R
   WHITTLE, HC
   RICKINSON, AB
AF LEE, SP
   MORGAN, S
   SKINNER, J
   THOMAS, WA
   JONES, SR
   SUTTON, J
   KHANNA, R
   WHITTLE, HC
   RICKINSON, AB
TI EPSTEIN-BARR-VIRUS ISOLATES WITH THE MAJOR HLA B35.01-RESTRICTED
   CYTOTOXIC T-LYMPHOCYTE EPITOPE ARE PREVALENT IN A HIGHLY B35.01-POSITIVE
   AFRICAN POPULATION
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE EPSTEIN-BARR VIRUS; CYTOTOXIC T LYMPHOCYTE; HLA B35; EPITOPE
ID INFECTED B-CELLS; DOWN-REGULATION; RECOGNITION; PEPTIDE; SPECIFICITY;
   ANTIGENS; PROTEIN; ASSOCIATION; HLA-A11; ESCAPE
AB An influence of cytotoxic T lymphocyte (CTL) response over Epstein-Barr virus (EBV) evolution was first suggested by the finding that virus isolates from highly HLA-All-positive Oriental populations were specifically mutated in two immunodominant All-restricted CTL epitopes. Here we turn to a second HLA allele, B35.01 and show that B35.01-restricted CTL responses in Caucasian donors reproducibly map to a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 EBV nuclear antigen 3A protein (B95.8 strain). In this case, however, most EBV isolates from a highly B35.01-positive population (in The Gambia) either retained the CTL epitope sequence or carried a mutation (P --> S at position 2) which conserved antigenicity; changes leading to reduced antigenicity (Y --> N at position 1) were found in only a minority of cases. Furthermore, CTL recognizing the YPLHEQHGM epitope could be reactivated from the blood of some B35.01-positive Gambian donors by in vitro stimulation with the synthetic peptide, indicating that epitope-specific immunity does exist in this population. Possible differences between the All-based and B35.01-based studies are discussed.
C1 UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.
   UNIV OXFORD,INST MOLEC MED,OXFORD,ENGLAND.
   QUEENSLAND INST MED RES,BANCROFT CTR,BRISBANE,QLD 4006,AUSTRALIA.
   MRC LABS,BANJUL,GAMBIA.
RI Khanna, Rajiv/A-7691-2008
OI Khanna, Rajiv/0000-0003-2241-0353
CR ABDULHAMID M, 1992, VIROLOGY, V190, P168
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0
   BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879
   BURROWS SR, 1994, J GEN VIROL, V75, P2489, DOI 10.1099/0022-1317-75-9-2489
   BURROWS SR, 1992, EUR J IMMUNOL, V22, P191, DOI 10.1002/eji.1830220128
   BURROWS SR, 1992, IMMUNOLOGY, V76, P174
   CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0
   DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013
   DECAMPOSLIMA PO, 1994, J EXP MED, V179, P1297, DOI 10.1084/jem.179.4.1297
   DOUMAS BT, 1975, CLIN CHEM, V21, P1159
   FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906
   GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862
   GAVIOLI R, 1993, J VIROL, V67, P1572
   GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   IMANISHI T, 1992, HLA 1991, P1066
   KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169
   KIEFF E, 1990, VIROLOGY, P1889
   LEE SP, 1993, J VIROL, V67, P7428
   LUNG ML, 1991, VIROLOGY, V185, P67, DOI 10.1016/0042-6822(91)90754-Y
   MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190
   Moss D J, 1992, Semin Immunol, V4, P97
   MOSS DJ, 1981, EUR J IMMUNOL, V11, P686, DOI 10.1002/eji.1830110904
   MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157
   PEMBERTON RM, 1990, IMMUNOLOGY, V70, P223
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0
   RICKINSON AB, 1992, CANCER SURV, V13, P53
   RICKINSON AB, 1987, J VIROL, V61, P1310
   SAMPLE J, 1990, J VIROL, V64, P4084
   VANBLEEK GM, 1990, NATURE, V348, P213
   WALLACE LE, 1982, EUR J IMMUNOL, V12, P1012, DOI 10.1002/eji.1830121206
   YOUNG LS, 1987, J GEN VIROL, V68, P2853, DOI 10.1099/0022-1317-68-11-2853
NR 34
TC 28
Z9 28
U1 0
U2 0
PU VCH PUBLISHERS INC
PI DEERFIELD BEACH
PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JAN
PY 1995
VL 25
IS 1
BP 102
EP 110
DI 10.1002/eji.1830250119
PG 9
WC Immunology
SC Immunology
GA QQ478
UT WOS:A1995QQ47800018
PM 7531142
OA No
DA 2017-08-15
ER

PT J
AU MILLER, JE
   LINDSAY, SW
   SCHELLENBERG, JRMA
   ADIAMAH, J
   JAWARA, M
   CURTIS, CF
AF MILLER, JE
   LINDSAY, SW
   SCHELLENBERG, JRMA
   ADIAMAH, J
   JAWARA, M
   CURTIS, CF
TI VILLAGE TRIAL OF BEDNETS IMPREGNATED WITH WASH-RESISTANT PERMETHRIN
   COMPARED WITH OTHER PYRETHROID FORMULATIONS
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE ANOPHELES-GAMBIAE; PYRETHROID-IMPREGNATED MOSQUITO NETS; BEDNETS;
   PERMETHRIN; WASH-RESISTANT PERMETHRIN; LAMBDA-CYHALOTHRIN; MALARIA;
   MOSQUITO CONTROL; THE GAMBIA
ID TREATED BED NETS; INSECTICIDE; GAMBIA
AB A village-scale field trial of pyrethroid-impregnated mosquito nets was undertaken in The Gambia, West Africa, in the Mandinka village of Saruja (13-degrees-13'N, 14-degrees-15'W) during July-November 1989.  Nearly all the villagers possessed and used their own bednets.  Anopheles gambiae is the main vector of human malaria in the area.
   An experimental wash-resistant formulation of permethrin was compared with standard emulsifiable concentrate (EC) formulations of permethrin and lambda-cyhalothrin, versus placebo-treated bednets.  Target concentrations of pyrethroids on bednets were permethrin 500 mg/m2 and lambda-cyhalothrin 25 mg/m2.  The experimental design involved random allocation of a treatment to one net per family.  Whereas 68% of people questioned said they washed their nets fortnightly, observations during the 16-week trial period showed that only 4/130 (3%) of nets involved in the trial had been washed as frequently as once per month.
   Early morning searches for mosquitoes under bednets (1 day/week for 16 weeks) found significantly more mosquitoes (60% An.gambiae) in placebo-treated nets than in pyrethroid-treated nets.  The numbers found with each of the three pyrethroid treatments did not differ significantly from each other.  Insecticidal efficacy of the treatments was tested by bioassays using wild-caught unfed mosquitoes exposed to netting for 3 min.  Linear regression analysis of bioassay mortality against number of times that a net had been washed by villagers showed that nets impregnated with the wash-resistant permethrin retained their insecticidal properties better than nets impregnated with lambda-cyhalothrin or with the standard permethrin formulation.
C1 MRC,FAJARA,GAMBIA.
RP MILLER, JE (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,GOWER ST,LONDON WC1E 7HT,ENGLAND.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   CURTIS CF, 1992, MEM I OSWALDO CRUZ, V87, P363
   GREENWOOD BM, 1993, T ROYAL SOC TROPI S2, V77, pS1
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1991, PESTIC SCI, V32, P397, DOI 10.1002/ps.2780320402
   LINDSAY SW, 1993, T ROYAL SOC TROPIC S, V87, pS45
   MACCORMACK CP, 1986, J TROP MED HYG, V89, P295
   MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x
   MILLER JE, 1990, THESIS U LONDON
   NJAU RJA, 1991, UNPUB FIELD TRIAL IN
   NJUNWA KJ, 1991, ACTA TROP, V49, P87, DOI 10.1016/0001-706X(91)90056-P
   PLEASS RJ, 1993, B ENTOMOL RES, V83, P133
   ROZENDAAL JA, 1989, MED VET ENTOMOL, V3, P353, DOI 10.1111/j.1365-2915.1989.tb00242.x
   SNOW RW, 1987, B ENTOMOL RES, V77, P279
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P647, DOI 10.1016/0035-9203(88)90547-0
NR 15
TC 23
Z9 23
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD JAN
PY 1995
VL 9
IS 1
BP 43
EP 49
DI 10.1111/j.1365-2915.1995.tb00115.x
PG 7
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA PZ470
UT WOS:A1995PZ47000006
PM 7696687
OA No
DA 2017-08-15
ER

PT J
AU LINDSAY, SW
   ARMSTRONG, JRM
   SCHELLENBERG, JRMA
   ZEILER, HA
   DALY, RJ
   SALUM, FM
   WILKINS, HA
AF LINDSAY, SW
   ARMSTRONG, JRM
   SCHELLENBERG, JRMA
   ZEILER, HA
   DALY, RJ
   SALUM, FM
   WILKINS, HA
TI EXPOSURE TO GAMBIAN CHILDREN TO ANOPHELES-GAMBIAE MALARIA VECTORS IN AN
   IRRIGATED RICE PRODUCTION AREA
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE ANOPHELES-ARABIENSIS; ANOPHELES-GAMBIAE; BEDNETS; BITING BEHAVIOR;
   MALARIA TRANSMISSION; MALARIA VECTORS; RICE; THE GAMBIA
ID MOSQUITOS; CULICIDAE; DISEASE; DIPTERA
AB Variation in exposure of children to malaria vectors of the Anopheles gambiae complex was recorded in a Gambian village situated near an irrigated area of rice cultivation.  Observations were made in 1987 and 1988 during two dry seasons, when pumped water was used to grow rice, and two rainy seasons, when rice was produced using a combination of irrigated and rainfed paddies.  Routine collections of mosquitoes were made from under bednets.  Most of these specimens were assumed to have fed on the occupants of the net and thus represented a crude measure of exposure to malaria.  Most nets in the village were in good condition, but even these were a poor defence against blood-seeking mosquitoes.
   Two annual peaks in the numbers of An.gambiae s.l. corresponded with the irrigation of rice paddies in the dry and wet seasons.  When there were few vectors in the village the frequency distribution of mosquitoes caught under nets was described best by a Poisson process.  When high numbers were present the daily distributions were over-dispersed and fitted a negative binomial model.  The spatial distribution of mosquitoes varied between dry and wet seasons and was related to the predominant wind direction at night, suggesting that wind assisted the dispersal of mosquitoes from their breeding sites.
   For individual children in the rainy season, increased exposure to malaria vectors was associated with living adjacent to a mosquito breeding site, being resident in larger compounds, having open eaves in the house, a store-room adjacent to the bedroom, the absence of a ceiling in the bedroom, the absence of wood smoke indoors and leaving the bednet untucked at night.  In the dry season a high level of exposure was associated with living close to a mosquito breeding site, having an unfenced compound, sleeping in a room without a ceiling and using insecticide aerosols.  These observations demonstrate that within a village there are systematic and persistent differences in the level of exposure to malaria parasites experienced by individual children.
C1 MRC,FAJARA,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   ANDERSON RM, 1978, PARASITOLOGY, V76, P119
   ANSCOMBE FJ, 1950, BIOMETRIKA, V37, P358
   BERTRAM D. S., 1956, Bulletin of Entomological Research, V47, P669
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   CURTIS CF, 1987, MED VET ENTOMOL, V1, P109, DOI 10.1111/j.1365-2915.1987.tb00331.x
   DYE C, 1986, T ROY SOC TROP MED H, V80, P69, DOI 10.1016/0035-9203(86)90199-9
   DYE C, 1988, PARASITOL TODAY, V4, P160
   Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241
   GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0
   GILLIES MT, 1978, B ENTOMOL RES, V68, P401
   GILLIES MT, 1974, NATURE, V252, P388, DOI 10.1038/252388b0
   GILLIES MT, 1978, B ENTOMOL RES, V68, P145
   GILLIES MT, 1970, B ENTOMOL RES, V60, P225
   HAMON J, 1959, CAHIERS ORSTROM, V2, P37
   HANNEY P. W., 1960, BULL ENT RES, V51, P145
   HOLSTEIN M, 1952, WORLD HLTH MONOGRAPH, V9
   KERR J. A., 1933, BULL ENT RES [LONDON], V24, P493
   KINGSOLVER JG, 1987, AM NAT, V130, P811, DOI 10.1086/284749
   LINDSAY SW, 1993, J MED ENTOMOL, V30, P368
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P97, DOI 10.1111/j.1365-2915.1989.tb00481.x
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P465
   Macdonald G., 1957, EPIDEMIOLOGY CONTROL
   Molineaux L, 1980, GARKI PROJECT
   PORT GR, 1980, B ENTOMOL RES, V70, P133
   Ross R, 1911, PREVENTION MALARIA
   SNOW RW, 1987, ANN TROP MED PARASIT, V81, P449
   SNOW WF, 1976, B ENTOMOL RES, V65, P555
   SNOW WF, 1987, MED VET ENTOMOL, V1, P9, DOI 10.1111/j.1365-2915.1987.tb00318.x
   SOUTHWOOD TRE, 1987, ECOLOGICAL METHODS
   Waters W. E., 1959, Forest Science Washington, V5, P397
NR 34
TC 52
Z9 53
U1 2
U2 5
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD JAN
PY 1995
VL 9
IS 1
BP 50
EP 58
DI 10.1111/j.1365-2915.1995.tb00116.x
PG 9
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA PZ470
UT WOS:A1995PZ47000007
PM 7696688
OA No
DA 2017-08-15
ER

PT J
AU RASHEED, FN
   BULMER, JN
   DEFRANCISCO, A
   JAWLA, MFB
   JAKOBSEN, PH
   JEPSON, A
   GREENWOOD, BM
AF RASHEED, FN
   BULMER, JN
   DEFRANCISCO, A
   JAWLA, MFB
   JAKOBSEN, PH
   JEPSON, A
   GREENWOOD, BM
TI RELATIONSHIPS BETWEEN MATERNAL MALARIA AND MALARIAL IMMUNE-RESPONSES IN
   MOTHERS AND NEONATES
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE IMMUNOLOGY; FETUS; PREGNANCY; MALARIA; PLACENTA
ID PLACENTAL MALARIA; GAMBIAN CHILDREN; T-CELLS; PREGNANCY; ANTIGENS;
   BIRTH; PRECURSORS; ANTIBODIES; CORTISOL; HUMANS
AB Immune responses of 97 Gambian women and their neonates were studied. New methods distinguished between active and previous placental malaria, were used to examine relationships between maternal malaria and neonatal immune responses. Many placentas (61%) had active or previous malarial infection. Maternal and cord malarial IgG levels correlated (P < 0.001). Malarial IgG was raised in cord blood in active placental malaria; IgM was not detected. Mean lymphoproliferation and the proportion of responders to soluble P. falciparum antigens (F32) and conserved regions of p190 expressed on trophozoites and schizonts (190L and 190N) were higher in neonates than mothers. There was no clear relationship between maternal malaria and neonatal mean lymphoproliferation to malarial antigens, although fewer neonates responded when mothers were actively infected. Matched maternal and neonatal lymphoproliferation responses did not correlate. However, first born neonatal lymphoproliferation to PPD and malarial antigens appeared lower than other neonates, in agreement with lower lymphoproliferation in primigravidae compared with multigravidae. Also in common with mothers, autologous plasma suppressed neonatal lymphoproliferation to PPD and malarial antigens, suggesting common immunoregulation. Higher cortisol or other circulating factors in first pregnancies may be implicated The relevance of cell-mediated malarial immune responses detected at birth remains to be established.
C1 UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DIV PATHOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
   MED & HLTH DEPT,BANJUL,GAMBIA.
   STATE UNIV HOSP,DEPT INFECT DIS,MALARIA RES GRP,COPENHAGEN,DENMARK.
   UNIV COPENHAGEN,INST MED MICROBIOL,DK-1168 COPENHAGEN,DENMARK.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ANDERSSON U, 1981, IMMUNOL REV, V57, P5, DOI 10.1111/j.1600-065X.1981.tb00440.x
   BRABIN BJ, 1991, APPLIED FIELD RES MA
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x
   CRAMER DV, 1974, AM J OBSTET GYNECOL, V120, P431
   DESOWITZ RS, 1988, ANN TROP MED PARASIT, V82, P121
   DRUILHE P, 1976, NOUV PRESSE MED, V5, P1430
   FIELD EJ, 1971, LANCET, V2, P337
   GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071
   GILL TJ, 1975, J IMMUNOGENET, V6, P197
   HART CA, 1988, BAILLIERE CLIN IMMUN, V2, P735
   HASSAN J, 1993, RES IMMUNOL, V144, P87, DOI 10.1016/0923-2494(93)80064-6
   HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061
   HEDGE VC, 1991, MED HYPOTHESES, V35, P159
   HO M, 1989, PARASITE IMMUNOL, V11, P105, DOI 10.1111/j.1365-3024.1989.tb00652.x
   HOWARD LM, 1992, 8TH INT C IMM BUD, P45
   HUTTER NH, 1987, THESIS U LONDON LOND
   JAKOBSEN PH, 1988, PARASITE IMMUNOL, V10, P593, DOI 10.1111/j.1365-3024.1988.tb00247.x
   JANOSSY G, 1989, T LYMPHOCYTE DIFFERE, P39
   JONES KR, 1990, EUR J IMMUNOL, V20, P307
   KLEIN J, 1990, IMMUNOLOGICAL TOLERA, P329
   KORTMANN HF, 1972, THESIS U AMSTERDAM U
   LOMBARD H, 1932, TROPICAL DISEASE B, V29, P350
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MCLAUGHLIN GL, 1987, AM J TROP MED HYG, V37, P258
   MOHR JA, 1972, LANCET, V1, P688
   OTOO LN, 1988, T ROY SOC TROP MED H, V82, P59, DOI 10.1016/0035-9203(88)90263-5
   POPE RM, 1990, BAILLIERE CLIN RHEUM, V4, P33, DOI 10.1016/S0950-3579(05)80242-0
   RASHEED FN, 1993, LANCET, V341, P828, DOI 10.1016/0140-6736(93)90602-D
   RASHEED FN, 1993, AM J TROP MED HYG, V48, P154
   RASHEED FN, 1992, J IMMUNOL METHODS, V146, P185, DOI 10.1016/0022-1759(92)90227-K
   RASHEED FN, 1994, MED HYPOTHESES, V42, P76, DOI 10.1016/0306-9877(94)90079-5
   REINHARDT MC, 1980, CIBA F S, V77, P149
   RILEY EM, 1989, AM J TROP MED HYG, V40, P141
   SANJEEVI CB, 1991, ACTA PAEDIATR SCAND, V80, P1134, DOI 10.1111/j.1651-2227.1991.tb11800.x
   Schwetz J, 1934, T ROY SOC TROP MED H, V28, P167, DOI 10.1016/S0035-9203(34)90139-5
   SINIGAGLIA F, 1988, J IMMUNOL, V140, P3568
   THOMAS V, 1980, T ROY SOC TROP MED H, V74, P73, DOI 10.1016/0035-9203(80)90014-0
   VLEUGELS MP, 1986, AM J OBSTET GYNECOL, V155, P118
   VLEUGELS MPH, 1988, T ROY SOC TROP MED H, V83, P173
   WEINBERG ED, 1984, REV INFECT DIS, V6, P814
   Wilson C.B., 1990, INFECT DIS FETUS NEW, P17
NR 43
TC 52
Z9 53
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JAN
PY 1995
VL 17
IS 1
BP 1
EP 10
DI 10.1111/j.1365-3024.1995.tb00960.x
PG 10
WC Immunology; Parasitology
SC Immunology; Parasitology
GA QG755
UT WOS:A1995QG75500001
PM 7731730
OA No
DA 2017-08-15
ER

PT J
AU RILEY, EM
   WILLIAMSON, KC
   GREENWOOD, BM
   KASLOW, DC
AF RILEY, EM
   WILLIAMSON, KC
   GREENWOOD, BM
   KASLOW, DC
TI HUMAN IMMUNE RECOGNITION OF RECOMBINANT PROTEINS REPRESENTING DISCRETE
   DOMAINS OF THE PLASMODIUM-FALCIPARUM GAMETE SURFACE PROTEIN, PFS230
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE MALARIA; TRANSMISSION BLOCKING IMMUNITY; PFS230; PLASMODIUM-FALCIPARUM;
   GAMETES
ID TRANSMISSION-BLOCKING ANTIBODIES; SEXUAL STAGES; MALARIA TRANSMISSION;
   TARGET ANTIGEN; T-CELL; GALLINACEUM; RESPONSES; EXPRESSION; INFECTION;
   PARASITES
AB The 230 kD gametocyte/gamete-specific surface protein of Plasmodium falciparum, Pfs230, is a target of antibodies which inhibit the development of the parasite inside the mosquito vector. A transmission blocking vaccine based on Pfs230 may be a powerful tool for malaria control. As a first step, Pfs230 has been expressed in E. coli as a series of recombinant proteins,fused to maltose binding protein. We have used the fusion proteins to assess cellular and humoral immune responses to Pfs230 in malaria-immune adult Gambian blood donors; responses to the fusion proteins have been compared with responses to native Pfs230. The tetrapeptide repeat region of the molecule appears to be immunodominant for both antibody-producing cells and peripheral blood T cells. We postulate that this may represent a mechanism for immune evasion since the N-terminal repeat region of the molecule is cleaved from the mature protein and shed into the plasma. Responses to fusion proteins representing the seven-cysteine motifs were correlated within individual donors, suggesting that cross-reactive epitopes occur within the motifs. Antibody responses to recombinant proteins were poorly correlated with responses to native Pfs230 suggesting that dominant epitopes of the native protein are not adequately represented in the recombinant proteins. Although prokaryotic expression products may be suitable for induction of cellular immune responses to Pfs230, alternative expression systems may be needed for creation of appropriate B cell epitopes.
C1 NIAID,MALARIA RES LAB,MOLEC VACCINE SECT,BETHESDA,MD 20892.
   MRC LABS,FAJARA,GAMBIA.
RP RILEY, EM (reprint author), UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,DIV BIOL SCI,W MAINS RD,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND.
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU Wellcome Trust
CR ANDERSSON G, 1989, J IMMUNOL METHODS, V125, P89, DOI 10.1016/0022-1759(89)90081-1
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   CARTER R, 1989, J EXP MED, V169, P135, DOI 10.1084/jem.169.1.135
   CARTER R, 1988, PROG ALLERGY, V41, P193
   CARTER R, 1979, EXP PARASITOL, V47, P194, DOI 10.1016/0014-4894(79)90073-0
   CHAPPEL JA, 1993, MOL BIOCHEM PARASIT, V60, P303, DOI 10.1016/0166-6851(93)90141-J
   DALY TM, 1993, INFECT IMMUN, V61, P2462
   GRAVES PM, 1988, PARASITE IMMUNOL, V10, P209, DOI 10.1111/j.1365-3024.1988.tb00215.x
   GWADZ RW, 1976, SCIENCE, V193, P1150, DOI 10.1126/science.959832
   HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x
   KARUNAWEERA ND, 1992, CLIN EXP IMMUNOL, V88, P499
   MATTEI D, 1989, PARASITE IMMUNOL, V11, P15, DOI 10.1111/j.1365-3024.1989.tb00645.x
   NAOTUNNE TD, 1993, IMMUNOLOGY, V78, P555
   NAOTUNNE TD, 1991, J EXP MED, V173, P523, DOI 10.1084/jem.173.3.523
   NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0
   PICOT S, 1993, CLIN EXP IMMUNOL, V93, P184
   QUAKYI IA, 1987, J IMMUNOL, V139, P4213
   READ D, 1994, PARASITE IMMUNOL, V16, P511, DOI 10.1111/j.1365-3024.1994.tb00305.x
   RENER J, 1983, J EXP MED, V158, P976, DOI 10.1084/jem.158.3.976
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   RILEY EM, 1993, PARASITE IMMUNOL, V16, P55
   STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831
   TROYEBLOMBERG M, 1989, J IMMUNOL, V143, P3043
   VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460
   WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V58, P355, DOI 10.1016/0166-6851(93)90058-6
   WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V62, P125, DOI 10.1016/0166-6851(93)90186-2
NR 26
TC 20
Z9 22
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JAN
PY 1995
VL 17
IS 1
BP 11
EP 19
DI 10.1111/j.1365-3024.1995.tb00961.x
PG 9
WC Immunology; Parasitology
SC Immunology; Parasitology
GA QG755
UT WOS:A1995QG75500002
PM 7731731
OA No
DA 2017-08-15
ER

PT J
AU MULLER, O
   QUINONES, M
   CHAM, K
   AIKINS, M
   GREENWOOD, B
AF MULLER, O
   QUINONES, M
   CHAM, K
   AIKINS, M
   GREENWOOD, B
TI DETECTING PERMETHRIN ON TREATED BED NETS
SO LANCET
LA English
DT Letter
ID CHILDREN
RP MULLER, O (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   FALBE J, 1989, ROMPO CHEM LEXIKON, V1, P368
   GRAVES PM, 1987, B WORLD HEALTH ORGAN, V65, P869
   Rozendaal J. A., 1989, Tropical Diseases Bulletin, V86, pR1
   1993, B WORLD HEALTH ORGAN, V71, P281
NR 5
TC 14
Z9 14
U1 1
U2 1
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 17
PY 1994
VL 344
IS 8938
BP 1699
EP 1700
DI 10.1016/S0140-6736(94)90481-2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA PX302
UT WOS:A1994PX30200030
PM 7996972
OA No
DA 2017-08-15
ER

PT J
AU MILLS, A
   FOXRUSHBY, J
   AIKINS, M
   DALESSANDRO, U
   CHAM, K
   GREENWOOD, B
AF MILLS, A
   FOXRUSHBY, J
   AIKINS, M
   DALESSANDRO, U
   CHAM, K
   GREENWOOD, B
TI FINANCING MECHANISMS FOR VILLAGE ACTIVITIES IN THE GAMBIA AND THEIR
   IMPLICATIONS FOR FINANCING INSECTICIDE FOR BEDNET IMPREGNATION
SO JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE FINANCING; BEDNETS; MALARIA
ID MORTALITY; CHILDREN; NETS
AB The recent enthusiasm for impregnated bednets as a malaria control measure leaves unresolved the question of how to finance them. The National Impregnated Bednet Programme in The Gambia faced the question of how to obtain funds from villages to finance the cost of insecticide, but knew very little about current village fundraising for development purposes. A survey was conducted of such fundraising, and questions also asked about willingness to pay for insecticide and preferred means of paying. All 53 villages surveyed paid taxes/rates, but 34% of villages reported no voluntary fundraising. The most common reason for collecting money was for the maintenance of wells (40% of villages). Collective farming was used as a means of raising money in 32% of villages. There was some variation in the type and extent of fundraising by region and also by the predominant ethnic groups of the village. Villages with voluntary fundraising activities seemed to have well established collective mechanisms for agreeing on sums to be collected and their use, and for collecting and recording income and expenditure. Non-payment was rare, and misuse of funds was not reported. Respondents were asked how much compounds might be willing to pay for insecticide impregnation: the most frequently cited maximum amounts were D5 and 10, and minimum D1 and 5 (D15=pound 1). The paper discusses payment options for insecticide, such as whether the village should be allowed to decide itself how to raise funds, and whether the payment should be made only by households with nets or by a village-wide mechanism such as collective farming. The paper concludes with details of the actual mechanism selected for implementation by the National Impregnated Bednet Programme.
C1 MRC LABS,BANJUL,GAMBIA.
RP MILLS, A (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Mills,
   Anne/0000-0001-9863-9950
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q
NR 2
TC 24
Z9 24
U1 0
U2 5
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0022-5304
J9 J TROP MED HYG
JI J. Trop. Med. Hyg.
PD DEC
PY 1994
VL 97
IS 6
BP 325
EP 332
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA PV230
UT WOS:A1994PV23000001
PM 7966533
OA No
DA 2017-08-15
ER

PT J
AU ZINSSTAG, J
   NJIE, M
   KAUFMANN, J
   PFISTER, K
AF ZINSSTAG, J
   NJIE, M
   KAUFMANN, J
   PFISTER, K
TI PROLONGED SUPPRESSION OF TRICHOSTRONGYLE EGG OUTPUT OF NDAMA CATTLE BY A
   SINGLE LARVICIDAL TREATMENT
SO ACTA TROPICA
LA English
DT Article
DE GASTROINTESTINAL STRONGYLES; NDAMA CATTLE; DRY SEASON EPIDEMIOLOGY;
   IVERMECTIN; THE GAMBIA
ID GASTROINTESTINAL NEMATODES; SURVIVAL; PASTURE
AB Gambian village cattle herds were treated with a single dose of ivermectine (Ivomec(R), MSD-AGVET Inc. 1 m1/50 kg body weight) during the dry season. This treatment suppressed the trichostrongyle egg rise prior to the rains and led to delayed egg production for at least 6 months after the onset of the rainy season, compared to untreated animals from neighbouring villages. However, the results clearly indicate that a single treatment with ivermectine during the dry season does not lead to complete suppression of the gastrointestinal strongyle infections, since a worm population still gradually built up. During the second year the ranked level of the egg excretion was significantly lower than that of the control group throughout the year until December, except in August. The results further support the hypothesis that trichostrongyle reinfection is unimportant during the dry season in this climatic zone.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   UNIV BERN,INST PARASITOL,CH-3012 BERN,SWITZERLAND.
   LAB PFISTER,CH-3018 BERN,SWITZERLAND.
RP ZINSSTAG, J (reprint author), CTR SUISSE RECH SCI,BP 1303,ABIDJAN 01,COTE IVOIRE.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR ANKERS P, 1992, 7TH INT C I TROP VET
   BOCH J, 1983, VETERINARMEDIZINISCH, P44
   CHIEJINA SN, 1989, VET RES COMMUN, V13, P103, DOI 10.1007/BF00346720
   CHIEJINA SN, 1984, RES VET SCI, V37, P148
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   LEANING WHD, 1987, P MSD AGVET S EC IMP, P89
   NDAO M, 1994, THESIS LEOPOLD I TRO, P12
   ZINSSTAG J, 1992, 7TH INT C I TROP VET
NR 8
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD NOV
PY 1994
VL 58
IS 2
BP 99
EP 103
DI 10.1016/0001-706X(94)90049-3
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA PW852
UT WOS:A1994PW85200002
PM 7887345
OA No
DA 2017-08-15
ER

PT J
AU WHITTLE, H
   MORRIS, J
   TODD, J
   CORRAH, T
   SABALLY, S
   BANGALI, J
   NGOM, PT
   ROLFE, M
   WILKINS, A
AF WHITTLE, H
   MORRIS, J
   TODD, J
   CORRAH, T
   SABALLY, S
   BANGALI, J
   NGOM, PT
   ROLFE, M
   WILKINS, A
TI HIV-2-INFECTED PATIENTS SURVIVE LONGER THAN HIV-1-INFECTED PATIENTS
SO AIDS
LA English
DT Article
DE HIV-1; HIV-2; SURVIVAL; MYCOBACTERIUM TUBERCULOSIS; CD4+ LYMPHOCYTE;
   BETA(2)-MICROGLOBULIN
ID HIV-2 INFECTION; WEST-AFRICA; GUINEA-BISSAU; COTE-DIVOIRE; TRANSMISSION;
   AIDS; PROSTITUTES; PREDICTORS; MORTALITY; ABIDJAN
AB Objective: To compare survival of patients infected with HIV-1 and HIV-2.
   Design: Longitudinal follow-up of 175 HIV-1- and 294 HIV-2-infected patients identified in, or referred to a hospital in The Gambia.
   Methods: Survival analysis methods were used and the death rate ratios for HIV-2 relative to HIV-1 patients were estimated using proportional hazard regression models that allowed for age, sex and clinical or immunological features.
   Results: The overall death rate ratio for HIV-2 relative to HIV-1 was 0.67 [95% confidence interval (CI), 0.49-0.91] when adjusted for age, sex and World Health Organization Bangui clinical classification. When allowing for age, sex and three strata of CD4+ count, the rate ratio was 0.64 (95% CI, 0.43-0.94), and for three strata of beta(2)-microglobulin levels 0.60 (95% CI, 0.42-0.84).
   Conclusion: Mortality rate in HIV-2-infected patients is approximately two-thirds of that for HIV-1-infected patients.
C1 UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.
   ROYAL VICTORIA HOSP,DEPT MED,BANJUL,GAMBIA.
RP WHITTLE, H (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ANCELLE R, 1987, LANCET, V1, P688
   ANDREASSON PA, 1993, AIDS, V7, P989
   COX DR, 1972, J R STAT SOC B, V34, P187
   DECOCK KM, 1991, AIDS, V5, pS21
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   DUFOORT G, 1988, LANCET, V2, P510
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421
   LINDAN CP, 1992, ANN INTERN MED, V116, P320
   MBAGA JM, 1990, E AFR MED J, V67, P95
   MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013
   NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   POULSEN AG, 1989, LANCET, V1, P827
   ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   1985, WKLY EPIDEMIOL REC, V60, P342
   1992, MMWR-MORBID MORTAL W, V41, P1
NR 22
TC 92
Z9 93
U1 0
U2 3
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD NOV
PY 1994
VL 8
IS 11
BP 1617
EP 1620
DI 10.1097/00002030-199411000-00015
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA PN949
UT WOS:A1994PN94900015
PM 7848600
OA No
DA 2017-08-15
ER

PT J
AU SUARA, RO
   ADEGBOLA, RA
   BAKER, CJ
   SECKA, O
   MULHOLLAND, EK
   GREENWOOD, BM
AF SUARA, RO
   ADEGBOLA, RA
   BAKER, CJ
   SECKA, O
   MULHOLLAND, EK
   GREENWOOD, BM
TI CARRIAGE OF GROUP-B STREPTOCOCCI IN PREGNANT GAMBIAN MOTHERS AND THEIR
   INFANTS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Note
ID WOMEN; TRANSMISSION; EPIDEMIOLOGY
AB The prevalence of group B streptococcal (GBS) colonization was studied in 136 pregnant women and their newborn infants by collecting vaginal and rectal swabs from the mothers and throat, rectal, and umbilical swabs from their infants. Maternal and infant colonization rates were 22% and 23%, respectively. One-third of infants born to colonized mothers and 15% of infants born to noncolonized mothers had GBS isolated. Of GBS-colonized infants, 50% remained colonized at the mean age of 2 months. Type V was the commonest serotype among GBS isolates from mothers and infants; type III strains were uncommon. The rarity of GBS disease in Gambian infants may be due to low rates of maternal carriage with the more virulent GBS serotypes.
C1 MRC LABS,BANJUL,GAMBIA.
   BAYLOR COLL MED,DEPT PEDIAT,INFECT DIS SECT,HOUSTON,TX 77030.
   BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,INFECT DIS SECT,HOUSTON,TX 77030.
FU NIAID NIH HHS [AI-15126]
CR ABER RC, 1976, PEDIATRICS, V58, P346
   ANTHONY BF, 1978, J INFECT DIS, V137, P524
   BADRI MS, 1977, J INFECT DIS, V135, P308
   BAKER CJ, 1973, J PEDIATR-US, V83, P919, DOI 10.1016/S0022-3476(73)80524-4
   BAKER CJ, 1994, IN PRESS INFECTIOUS
   Faye-Kette AH, 1991, B SOC PATHOL EXOT, V84, P532
   FERRIERI P, 1977, J MED MICROBIOL, V10, P103
   FRANCIOSI RA, 1973, J PEDIATR-US, V82, P707, DOI 10.1016/S0022-3476(73)80604-3
   HOGKAMPKOISTANJ.JA, 1982, J INFECT DIS, V145, P800
   Mani V, 1984, Indian Pediatr, V21, P357
   ONILE BA, 1980, T ROY SOC TROP MED H, V74, P367, DOI 10.1016/0035-9203(80)90102-9
   SUNNA E, 1991, TROP GEOGR MED, V43, P161
NR 12
TC 52
Z9 54
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 1994
VL 170
IS 5
BP 1316
EP 1319
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA PN668
UT WOS:A1994PN66800044
PM 7963736
OA No
DA 2017-08-15
ER

PT J
AU SCHELLENBERG, JRMA
   SMITH, T
   ALONSO, PL
   HAYES, RJ
AF SCHELLENBERG, JRMA
   SMITH, T
   ALONSO, PL
   HAYES, RJ
TI WHAT IS CLINICAL MALARIA - FINDING CASE DEFINITIONS FOR FIELD-RESEARCH
   IN HIGHLY ENDEMIC AREAS
SO PARASITOLOGY TODAY
LA English
DT Article
ID NETS PREVENT MALARIA; TREATED BED NETS; WEST-AFRICA; GAMBIAN CHILDREN;
   MORTALITY; TRANSMISSION; MORBIDITY; INTENSE
AB In non-endemic areas, the diagnosis of clinical malaria may be made on the basis of fever and a positive blood film. However, in areas of high endemicity, asymptomatic parasitaemia is very common: to assume that a child who presents with fever and parasitaemia is ill from malaria will result in overdiagnosis. In this article, Jo Schelienberg, Tom Smith, Pedro Alonso and Richard Hayes discuss the relationship between fever and parasite density in such areas, and show how the proportion of fevers due to malaria (the attributable fraction) can be estimated and used to evaluate case definitions for use in field trials.
C1 SWISS TROP INST,CH-4002 BASEL,SWITZERLAND.
   IFAKARA CTR,IFAKARA,TANZANIA.
   HOSP CLIN BARCELONA,EPIDEMIOL RES UNIT,E-08036 BARCELONA,SPAIN.
   MRC LABS,BANJUL,GAMBIA.
RP SCHELLENBERG, JRMA (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI Smith, Thomas/B-5569-2015
OI Smith, Thomas/0000-0002-3650-9381; Hayes, Richard/0000-0002-1729-9892
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90173-N
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HURT N, 1994, T ROY SOC TROP MED H, V88, P182, DOI 10.1016/0035-9203(94)90287-9
   Last JM, 1988, DICT EPIDEMIOLOGY
   LYIMO E, 1991, ACTA TROP, V49, P109
   ROOTH IB, 1992, AM J TROP MED HYG, V47, P675
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P
   Schlesselman JJ, 1982, CASE CONTROL STUDIES
   SEXTON JD, 1990, AM J TROP MED HYG, V43, P11
   SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M
   SMITH T, IN PRESS STATISTICS
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   TARGETT GAT, 1991, MALARIA WAITING VACC
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9
   VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W
   VELEMA JP, 1991, T ROY SOC TROP MED H, V85, P430, DOI 10.1016/0035-9203(91)90206-E
NR 20
TC 49
Z9 49
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0169-4758
J9 PARASITOL TODAY
JI Parasitol. Today
PD NOV
PY 1994
VL 10
IS 11
BP 439
EP 442
DI 10.1016/0169-4758(94)90179-1
PG 4
WC Parasitology
SC Parasitology
GA PN030
UT WOS:A1994PN03000012
PM 15275531
OA No
DA 2017-08-15
ER

PT J
AU ADEGBOLA, RA
   FALADE, AG
   SAM, BE
   AIDOO, M
   BALDEH, I
   HAZLETT, D
   WHITTLE, H
   GREENWOOD, BM
   MULHOLLAND, EK
AF ADEGBOLA, RA
   FALADE, AG
   SAM, BE
   AIDOO, M
   BALDEH, I
   HAZLETT, D
   WHITTLE, H
   GREENWOOD, BM
   MULHOLLAND, EK
TI THE ETIOLOGY OF PNEUMONIA IN MALNOURISHED AND WELL-NOURISHED GAMBIAN
   CHILDREN
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE PNEUMONIA; MALNUTRITION; LUNG; ETIOLOGY
ID RESPIRATORY-TRACT INFECTIONS; DEVELOPING-COUNTRIES; MALNUTRITION;
   INFANTS; FIBRONECTIN; DIAGNOSIS; IMMUNITY; WORLD
AB During a a-year period 159 malnourished children ages 3 months to 5 years with radiologic evidence of pneumonia were investigated to determine the cause of their pneumonia. In addition 119 malnourished children without pneumonia, 119 well-nourished children with pneumonia and 52 well-nourished children without pneumonia were studied as controls. Percutaneous lung aspiration was performed on 35 malnourished and 59 well-nourished children with pneumonia. Bacteria were isolated from the blood, lung or pleural fluid of 28 (18%) malnourished children with pneumonia, 42 (35%) well-nourished children with pneumonia and from the blood of 5 (4%) malnourished children without pneumonia. Streptococcus pneumoniae and Haemophilus influenzae, which were the two organisms isolated most frequently in both groups of children with pneumonia, were found in 17 (11%) malnourished and 39 (33%) well-nourished children with pneumonia. Mycobacterium tuberculosis was detected in 5 malnourished children with pneumonia. A potentially pathogenic virus was identified in 35% of malnourished children with pneumonia and 40% of well-nourished children with pneumonia, and from 25% of children without pneumonia. The viruses identified most frequently were adenovirus and respiratory syncytial virus. There were 26 viral isolates from lung aspirate specimens. Respiratory syncytial virus was more frequently isolated from well-nourished children, while herpes simplex was more often found in malnourished children. Both bacterial and viral agents were identified in 25 children. In situations where measles and kwashiorkor are uncommon, the likely bacterial causes of community-acquired pneumonia in both well-nourished and malnourished children are S. pneumoniae and H. influenzae but, in malnourished children, particularly those with edema, the possibility of other causes, particularly M. tuberculosis, must always be kept in mind.
RP ADEGBOLA, RA (reprint author), MRC,POB 273,BANJUL,GAMBIA.
CR ABRAHAM SN, 1983, INFECT IMMUN, V41, P1261
   BERKOWITZ FE, 1984, AM J DIS CHILD, V138, P551
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   BERMAN S, 1985, REV INFECT DIS, V7, P674
   BERMAN S, 1983, PEDIATRICS, V71, P210
   BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515
   Brown K. H., 1981, Nutrition Research, V1, P33, DOI 10.1016/S0271-5317(81)80006-1
   CARR DT, 1967, MAYO CLIN PROC, V42, P23
   CHANDRA RK, 1983, LANCET, V1, P688
   DIALLO AA, 1979, NIGERIAN MED J, V9, P421
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   GREENWOOD BM, 1992, W AFRICA J INFECT S1, V165, pS26
   GREENWOOD DM, 1981, IMMUNOLOGY MED TROPI, P188
   GWATKIN DR, 1980, AM J PUBLIC HEALTH, V70, P1286, DOI 10.2105/AJPH.70.12.1286
   JAMES JW, 1972, AM J CLIN NUTR, V25, P690
   JONES FL, 1966, DIS CHEST, V50, P403
   KIPPS A, 1976, S AFR MED J, V50, P1083
   KLOENE W, 1970, AM J EPIDEMIOL, V92, P307
   Leowski J, 1986, World Health Stat Q, V39, P138
   MCFARLANE H, 1973, CLIN EXP IMMUNOL, V13, P153
   MIMICA I, 1971, AM J DIS CHILD, V122, P278
   NICHOL KP, 1967, NEW ENGL J MED, V277, P667, DOI 10.1056/NEJM196709282771301
   ONEILL KP, 1989, BRIT MED J, V298, P1061
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SMYTHE PM, 1971, LANCET, V2, P939
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295
   TUPASI TE, 1990, REV INFECT DIS, V12, pS1047
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   WATSON RR, 1979, CRC CR REV FOOD SCI, V12, P113
   WESLEY A G, 1971, South African Medical Journal, V45, P1402
   YODER MC, 1987, J PEDIATR GASTR NUTR, V6, P84, DOI 10.1097/00005176-198701000-00015
NR 32
TC 124
Z9 133
U1 0
U2 5
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 1994
VL 13
IS 11
BP 975
EP 982
DI 10.1097/00006454-199411000-00008
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA PT216
UT WOS:A1994PT21600009
PM 7845751
OA No
DA 2017-08-15
ER

PT J
AU GREENWOOD, AM
   MENENDEZ, C
   ALONSO, PL
   JAFFAR, S
   LANGEROCK, P
   LULAT, S
   TODD, J
   MBOGE, B
   FRANCIS, N
   GREENWOOD, BM
AF GREENWOOD, AM
   MENENDEZ, C
   ALONSO, PL
   JAFFAR, S
   LANGEROCK, P
   LULAT, S
   TODD, J
   MBOGE, B
   FRANCIS, N
   GREENWOOD, BM
TI CAN MALARIA CHEMOPROPHYLAXIS BE RESTRICTED TO FIRST PREGNANCIES
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID RESPONSES
AB The harmful effects of malaria are most pronounced during first pregnancies and chemoprophylaxis is most effective when given at this time. However, restriction of chemoprophylaxis to first pregnancies might lead to enhanced susceptibility to malaria during second pregnancies. We have investigated this possibility by studying the outcome of second pregnancies in 165 Gambian women who had received either malaria chemoprophylaxis with Maloprim(R) or placebo during their first pregnancy. Many of these primigravidae did not present until the third trimester of pregnancy so that some are likely to have experienced a malaria infection before they started medication. The prevalence of malaria infection of the blood and of the placenta during second pregnancies was similar in women who had received chemoprophylaxis during their first pregnancy and in those who had not, and the mean birth weights of babies born to women in each group were almost identical. Thus, in areas where the epidemiology of malaria is similar to that of The Gambia and where most women present relatively late in pregnancy, it may be possible to restrict malaria chemoprophylaxis to first pregnancies with consequent savings in cost and a reduction in drug pressure on Plasmodium falciparum.
C1 MINIST HLTH,BANJUL,GAMBIA.
   CHARING CROSS HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND.
RP GREENWOOD, AM (reprint author), MRC LABS,BANJUL,GAMBIA.
CR BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   McGregor I A, 1987, Parassitologia, V29, P153
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MENENDEZ C, IN PRESS J TROPICAL
   MORLEY D, 1964, BRIT MED J, V1, P667
   RASHEED FN, 1993, AM J TROP MED HYG, V48, P154
   RILEY EM, 1989, AM J TROP MED HYG, V40, P141
   SHEARMEN RP, 1974, CIBA F S, V27, P27
   VLEUGELS MPH, 1987, BRIT J OBSTET GYNAEC, V94, P758, DOI 10.1111/j.1471-0528.1987.tb03722.x
NR 11
TC 29
Z9 29
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1994
VL 88
IS 6
BP 681
EP 682
DI 10.1016/0035-9203(94)90228-3
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA QA846
UT WOS:A1994QA84600026
PM 7886770
OA No
DA 2017-08-15
ER

PT J
AU LISSE, IM
   AABY, P
   WHITTLE, H
   KNUDSEN, K
AF LISSE, IM
   AABY, P
   WHITTLE, H
   KNUDSEN, K
TI A COMMUNITY STUDY OF T-LYMPHOCYTE SUBSETS AND MALARIA PARASITEMIA
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FALCIPARUM-MALARIA; CELL SUBSETS; MORTALITY; CHILDREN
AB In a community survey of 312 children aged 3-6 years in urban Guinea-Bissau, we examined Plasmodium falciparum parasitaemia and T cell subsets. 183 children (59%) had parasites in their blood, 13 had fever greater than or equal to 37.5 degrees C, and 9 (3%) had fever and a parasite density >5000/mu L (clinical malaria). Compared with children with no parasitaemia or asymptomatic parasitaemia, children with acute malaria had lymphopenia and significantly lower total CD4 and CD8 cell counts, but there was no significant difference in white blood cell count percentages of CD4 and CD8 cells, or the CD4/CD8 ratio. Children with parasitaemia but without fever had a significantly lower percentage of CD4 cells than children without parasites (P=0.031), but did not differ in any other haematological index. Controlling for other factors, the CD4 cell percentage was inversely correlated with the density of malaria parasites (P=0.024), whereas there was no association with CD8 cell percentage or the CD4/CD8 ratio. Asymptomatic parasitaemia may be an important confounder in general community studies of T cell subsets in the tropics.
C1 STATENS SERUM INST,CTR DANISH EPIDEMIOL SCI,EPIDEMIOL RES UNIT,COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
RP LISSE, IM (reprint author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT PATHOL,DK-2650 HVIDOVRE,DENMARK.
CR AABY P, 1993, J PEDIATR-US, V122, P904
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HO M, 1990, IMMUNOL LETT, V25, P135, DOI 10.1016/0165-2478(90)90104-X
   LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   STACH JL, 1986, CLIN IMMUNOL IMMUNOP, V38, P129, DOI 10.1016/0090-1229(86)90130-3
   TONGTAWE P, 1988, ASIAN PAC J ALLERGY, V6, P11
   TROYEBLOMBERG M, 1984, CLIN EXP IMMUNOL, V58, P380
   1992, GLOBAL PROGRAMME AID
NR 9
TC 42
Z9 42
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV-DEC
PY 1994
VL 88
IS 6
BP 709
EP 710
DI 10.1016/0035-9203(94)90242-9
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA QA846
UT WOS:A1994QA84600038
PM 7886782
OA No
DA 2017-08-15
ER

PT J
AU AABY, P
   KNUDSEN, K
   SIMONDON, F
   SAMB, B
   WHITTLE, H
   SECK, AMC
   BENNETT, J
AF AABY, P
   KNUDSEN, K
   SIMONDON, F
   SAMB, B
   WHITTLE, H
   SECK, AMC
   BENNETT, J
TI HIGH-TITER MEASLES-VACCINES FOR BOYS
SO LANCET
LA English
DT Letter
ID CHILD-MORTALITY; TITER; SENEGAL
C1 ORSTOM,UR MALAD INFECT & PARASITARIES,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
RP AABY, P (reprint author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK.
CR AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, IN PRESS B WHO
   GARENNE, 1994, LANCET, V344, P261
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   HOLT EA, 1993, J INFECT DIS, V168, P1087
NR 6
TC 3
Z9 3
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 29
PY 1994
VL 344
IS 8931
BP 1226
EP 1227
DI 10.1016/S0140-6736(94)90539-8
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA PN803
UT WOS:A1994PN80300042
PM 7802829
OA No
DA 2017-08-15
ER

PT J
AU PINDER, M
   EVERAERE, S
   ROELANTS, GE
AF PINDER, M
   EVERAERE, S
   ROELANTS, GE
TI LOA LOA - IMMUNOLOGICAL RESPONSES DURING EXPERIMENTAL INFECTIONS IN
   MANDRILLS (MANDRILLUS SPHINX)
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE LOA LOA; FILARIASIS; PRIMATE MODEL; MICROFILAREMIA; HUMORAL IMMUNITY;
   IMMUNOSUPPRESSION
ID REACTIVE SURFACE-ANTIGENS; BRUGIA-MALAYI; ANTIBODY-RESPONSES;
   IMMUNE-REACTIONS; RHESUS-MONKEYS; MICROFILARIAE; FILARIASIS; IVERMECTIN;
   PAHANGI; LOIASIS
AB Six intact, adult mandrills (Mandrillus sphinx) were infected with human-derived, diurnal Loa loa infective larvae. Microfilaremia, hematological, and immunological parameters were followed for 2-4 years. A major aim was to investigate the relationship between specific humoral immunity to microfilariae and microfilaremia acid also to assess whether infection led to generalized immune dysfunction. Microfilaremia was similar to previous studies for 4 mandrills, with a prepatent period of 153.5 +/- 10.1 days, a peak of 34-1,798 mf/ml around Day 200, followed by a decline to low, persistent microfilaremia. One mandrill (No. 20) had a longer prepatent period and very low, but persistant, levels of microfilaremia, and one (No. 19) had gradually increasing levels which remained > 10,000 mf/ml for 3 years. To assess generalized immune perturbations several parameters were studied. There was neither generalized leukocytosis nor relative or absolute eosinophila. Serum Ig concentrations were measured from 0-600 days postinfection by radial immunodiffusion using a rabbit anti-mandrill Ig serum, and these were remarkably stable. Proliferative responses of peripheral blood mononuclear cells from these infected mandrills and noninfected controls showed no significant differences in the magnitude of proliferation after stimulation with a range of doses of PHA, PWM, or Concanavalin A. Thus, no evidence of generalized immune dysfunction was found in the peripheral blood. Serum IgG levels to soluble mf antigens were estimated by an indirect ELISA and all animals had maximal levels around Week 22 postinfection, at the time of maximum microfilaremia, and these decreased over the next 2-3 years in all mandrills except No, 19, in which levels remained fairly constant. Serum IgG levels to adult worm antigens showed a similar pattern but were not, or were only slightly, diminished late in infection. Antibody to mf sheath antigens were detected by indirect immunofluorescence and agglutination of live mf. Antibody to sheath antigens were never detected in mandrill 19 but were present from Week 8 postinfection to 2-4 weeks before patency in all the others. Antisheath antibodies were not detected in serum at later time points, i.e., postpatency, in any mandrill, even at time points when microfilaremia was <1 mf/ml. The anti-sheath antibody was IgM and no anti-sheath IgG was detected. Ig was detected on the surface of circulating mf in 1 mandrill (No. 20). The appearance of these antibodies prior to maturation of the adults indicates that certain L4 or immature adult antigens cross-react with the surface of mf. These results indicate that in the absence of antibody to the sheath there was no suppression of peripheral microfilaremia, whereas the 5 animals in which such antibody was detected in the prepatent period later showed pronounced suppression. (C) 1994 Academic Press, Inc.
RP PINDER, M (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR AU ACS, 1982, Z PARASITENKD, V68, P313, DOI 10.1007/BF00927409
   BENJAMIN DB, 1976, AM J TROP MED HYG, V25, P266
   CARME B, 1991, AM J TROP MED HYG, V44, P684
   CARTEL JL, 1990, TROP MED PARASITOL, V41, P241
   CATTY D, 1988, ANTIBODIES PRACTICAL, V1, P146
   CRANDELL RB, 1983, ACTA TROP, V40, P53
   Duke B. O. L., 1960, Annals of Tropical Medicine and Parasitology, V54, P141
   DUKE B. O. L., 1960, ANN TROP MED AND PARASITOL, V54, P15
   DUKE BO, 1961, ANN TROP MED PARASIT, V55, P263
   DUPONT A, 1988, T ROY SOC TROP MED H, V82, P730, DOI 10.1016/0035-9203(88)90218-0
   EBERHARD ML, 1981, J PARASITOL, V67, P556, DOI 10.2307/3280490
   FAIN A, 1978, B WORLD HEALTH ORGAN, V56, P155
   GREENE BM, 1981, J IMMUNOL, V127, P1611
   GRIEVE RB, 1985, TROP MED PARASITOL, V36, P225
   GROVE DI, 1978, AM J TROP MED HYG, V27, P508
   KERSHAW WE, 1950, ANN TROP MED PARASIT, V44, P361
   MACKENZIE CD, 1982, T ROY SOC TROP MED H, V76, P778, DOI 10.1016/0035-9203(82)90106-7
   MAIZELS RM, 1991, PARASITOL TODAY, V7, P271, DOI 10.1016/0169-4758(91)90093-4
   MAIZELS RM, 1983, PARASITOLOGY, V87, P249
   MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186
   MCGREEVY PB, 1980, AM J TROP MED HYG, V29, P553
   NOIREAU F, 1989, T ROY SOC TROP MED H, V83, P529, DOI 10.1016/0035-9203(89)90280-0
   NUTMAN TB, 1986, J INFECT DIS, V154, P10
   ORIHEL TC, 1975, AM J TROP MED HYG, V24, P606
   ORIHEL TC, 1985, TROP MED PARASITOL, V36, P215
   PHILIPP M, 1984, CONTEMP TOP IMMUNOBI, V12, P275
   PHILIPP M, 1986, T ROY SOC TROP MED H, V80, P385, DOI 10.1016/0035-9203(86)90322-6
   PIESSENS WF, 1980, AM J TROP MED HYG, V29, P563
   PINDER M, 1992, PARASITE IMMUNOL, V14, P541, DOI 10.1111/j.1365-3024.1992.tb00027.x
   PINDER M, 1988, PARASITOL TODAY, V4, P279, DOI 10.1016/0169-4758(88)90019-1
   PINDER M, 1988, J IMMUNOL, V141, P2480
   PINDER M, 1991, ACTA TROP, V49, P305, DOI 10.1016/0001-706X(91)90081-T
   PINDER M, 1990, J PARASITOL, V76, P373, DOI 10.2307/3282669
   RICHARDLENOBLE D, 1988, AM J TROP MED HYG, V39, P480
   SASA M, 1976, HUMAN FILARIASIS, P122
   SIMONSEN PE, 1983, T ROY SOC TROP MED H, V77, P829, DOI 10.1016/0035-9203(83)90299-7
   VANHOEGAERDEN M, 1986, AM J TROP MED HYG, V35, P148
   WEISS N, 1978, ACTA TROP, V35, P137
   WONG MM, 1979, AM J VET RES, V40, P414
   WONG MM, 1963, AM J TROP MED HYG, V13, P57
NR 40
TC 22
Z9 22
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0014-4894
J9 EXP PARASITOL
JI Exp. Parasitol.
PD SEP
PY 1994
VL 79
IS 2
BP 126
EP 136
DI 10.1006/expr.1994.1072
PG 11
WC Parasitology
SC Parasitology
GA PE012
UT WOS:A1994PE01200004
PM 8056077
OA No
DA 2017-08-15
ER

PT J
AU SOYANNWO, OA
AF SOYANNWO, OA
TI ECTOPIC PREGNANCY AND ANESTHESIA IN GAMBIA
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Letter
DE ECTOPIC PREGNANCY; ANESTHESIA
C1 ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
CR Ectopic pregnancy, 1992, INT J GYNECOL OBSTET, V37, P213
   MAKINDE OO, 1990, INT J GYNECOL OBSTET, V33, P239, DOI 10.1016/0020-7292(90)90008-9
   Soyannwo O A, 1992, World Health Forum, V13, P208
NR 3
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD SEP
PY 1994
VL 46
IS 3
BP 331
EP 332
DI 10.1016/0020-7292(94)90417-0
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA PH614
UT WOS:A1994PH61400015
PM 7806007
OA No
DA 2017-08-15
ER

PT J
AU MENENDEZ, C
   TODD, J
   ALONSO, PL
   FRANCIS, N
   LULAT, S
   CEESAY, S
   MBOGE, B
   GREENWOOD, BM
AF MENENDEZ, C
   TODD, J
   ALONSO, PL
   FRANCIS, N
   LULAT, S
   CEESAY, S
   MBOGE, B
   GREENWOOD, BM
TI THE EFFECTS OF IRON SUPPLEMENTATION DURING PREGNANCY, GIVEN BY
   TRADITIONAL BIRTH ATTENDANTS, ON THE PREVALENCE OF ANEMIA AND MALARIA
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PAPUA-NEW-GUINEA; INFUSION; CHILDREN; ANEMIA
AB A randomized, double-blind, placebo-controlled community-based trial of oral iron supplementation (200 mg ferrous sulphate daily) administered to multigravid pregnant women by traditional birth attendants (TBAs) was carried out in a rural area of The Gambia. Iron supplementation led to a significant reduction in the prevalence of anaemia and of iron deficiency. Iron supplementation was not accompanied by increased susceptibility to malaria infection; there was no difference in the prevalence and seventy of peripheral blood or placental malaria infection between the 2 groups of women. The birth weight of children born to women who received iron prophylaxis was increased by an average of 56 g. It is concluded that oral iron prophylaxis can be successfully delivered through TBAs integrated into a primary health care programme. This simple intervention can produce significant beneficial effects on the health of the mother without inducing increased susceptibility to malaria and has the potential for reducing perinatal mortality by increasing birth weight.
C1 MRC LABS,BANJUL,GAMBIA.
   CHARING CROSS & WESTMINSTER HOSP MED SCH,DEPT HISTOPATHOL,LONDON SW1P 2AR,ENGLAND.
   MINIST HLTH,BANJUL,GAMBIA.
RP MENENDEZ, C (reprint author), HOSP CLIN BARCELONA,SECC MED TROP,UNIDAD EPIEMIOL,VILLARROEL 170,E-08036 BARCELONA,SPAIN.
CR BONNAR J, 1969, LANCET, V1, P457
   BYLES AB, 1970, BRIT MED J, V3, P625
   DeMayer EM, 1989, PREVENTING CONTROLLI
   FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211
   FLEMING AF, 1974, MED J AUSTRALIA, V11, P429
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HARRISON C, 1987, LAB PRACT, V36, P95
   HARRISON KA, 1973, J OBSTET GYN BR COMM, V80, P798
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   KUIZON MD, 1983, NUTR RES, V3, P257, DOI 10.1016/S0271-5317(83)80072-4
   MACGREGOR MARGARET W., 1963, SCOTTISH MED JOUR, V8, P134
   MENENDEZ C, 1993, J TROP MED HYG, V96, P175
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P818, DOI 10.1016/0035-9203(86)90393-7
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17
   WATKINSON M, 1983, BRIT MED J, V1, P251
NR 17
TC 93
Z9 96
U1 0
U2 4
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD SEP-OCT
PY 1994
VL 88
IS 5
BP 590
EP 593
DI 10.1016/0035-9203(94)90176-7
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA PQ487
UT WOS:A1994PQ48700031
PM 7992349
OA No
DA 2017-08-15
ER

PT J
AU DWINGER, RH
   AGYEMANG, K
   KAUFMANN, J
   GRIEVE, AS
   BAH, ML
AF DWINGER, RH
   AGYEMANG, K
   KAUFMANN, J
   GRIEVE, AS
   BAH, ML
TI EFFECTS OF TRYPANOSOME AND HELMINTH INFECTIONS ON HEALTH AND PRODUCTION
   PARAMETERS OF VILLAGE-NDAMA CATTLE IN THE GAMBIA
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE TRYPANOSOMA CONGOLENSE; TRYPANOSOMA VIVAX; STRONGYLIDAE, GENERAL; CATTLE
   PROTOZOA; CATTLE NEMATODA
ID AFRICAN TRYPANOSOMIASIS; GASTROINTESTINAL NEMATODES; BOVINE
   TRYPANOSOMIASIS; IMMUNOSUPPRESSION; CONGOLENSE; DIAGNOSIS
AB The effects of trypanosome and helminth infections on health and production parameters in 2000 village N'Dama cattle were assessed periodically. Blood examination showed Trypanosoma congolense and Trypanosoma vivax to be prevalent, while strongylid-type eggs were those most frequently encountered in faecal samples. A distinct seasonal fluctuation was detected for both blood levels of trypanosomes and helminth egg output. Strongylid burden and trypanosome infection had significant negative effects on packed red cell volume levels and body weights mainly in animals of 2-3 years old. Clear indications of an increased susceptibility to trypanosomosis were found in animals affected by helminths. Similarly, animals infected with trypanosomes were more frequently infested with strongyles and egg counts were higher than in cattle in which no trypanosomes were detected.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   INT LIVESTOCK CTR AFRICA,SUBHUMID RES SITE,KADUNA,NIGERIA.
   UNIV BERN,DEPT VET PARASITOL,CH-3001 BERN,SWITZERLAND.
RP DWINGER, RH (reprint author), UNIV NACL HEREDIA,ESC MED VET,PROYECTO UNA RUU,APDO 86-3000,HEREDIA,COSTA RICA.
CR AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   CONNOR RJ, 1985, LIVESTOCK PRODUCTION, V9, P13
   DWINGER RH, 1994, IN PRESS VET Q
   FIENNES RNTW, 1950, ANN TROP MED PARASIT, V44, P42
   GOODWIN LG, 1972, BRIT J EXP PATHOL, V53, P40
   GRIFFIN L, 1981, J COMP PATHOL, V91, P85, DOI 10.1016/0021-9975(81)90048-7
   GRIFFIN L, 1980, VET PARASITOL, V7, P11, DOI 10.1016/0304-4017(80)90004-7
   HOLMES PH, 1974, VET REC, V95, P86
   ILEMOBADE AA, 1982, PARASITE IMMUNOL, V4, P273, DOI 10.1111/j.1365-3024.1982.tb00438.x
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   MACKENZIE PKI, 1975, VET REC, V97, P452
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   PARIS J, 1982, ACTA TROP, V39, P307
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   RURANGIRWA FR, 1983, PARASITE IMMUNOL, V5, P267, DOI 10.1111/j.1365-3024.1983.tb00743.x
   SCOTT J M, 1977, Tropical Animal Health and Production, V9, P159, DOI 10.1007/BF02236590
   SHARPE RT, 1982, RES VET SCI, V32, P289
   SKERMAN KD, 1966, HDB FOOD AGR ORG UN, V2
   SPECHT EJK, 1982, VET PARASITOL, V11, P329, DOI 10.1016/0304-4017(82)90101-7
   Stewart J.L., 1937, VET REC, V49, P1289
   URQUHART GM, 1972, T ROY SOC TROP MED H, V66, P342, DOI 10.1016/0035-9203(72)90225-8
   1988, BETAIL TRYPANOTOLERA, V3, P61
   1979, MONOGRAPH INT LIVEST, V2, P303
   1977, TECHNICAL B MINISTRY, V18, P8
   [Anonymous], 1988, SAS STAT USERS GUIDE
NR 27
TC 14
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 1994
VL 54
IS 4
BP 353
EP 365
DI 10.1016/0304-4017(94)90002-7
PG 13
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA PP211
UT WOS:A1994PP21100002
PM 7839560
OA No
DA 2017-08-15
ER

PT J
AU BENNETT, J
   AABY, P
   SIMONDON, F
   SAMB, B
   WHITTLE, H
   SECK, AMC
   MARKOWITZ, L
AF BENNETT, J
   AABY, P
   SIMONDON, F
   SAMB, B
   WHITTLE, H
   SECK, AMC
   MARKOWITZ, L
TI SEX-DIFFERENCES IN MEASLES FATALITY AND EDMONSTON-ZAGREB MEASLES-VACCINE
SO LANCET
LA English
DT Letter
C1 STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN,DENMARK.
   ORSTOM,UR MALAD INFECT & PARASITAIRES,DAKAR,SENEGAL.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   MRC LABS,BANJUL,GAMBIA.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341.
RP BENNETT, J (reprint author), TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA 30307, USA.
CR AABY P, 1991, ANN TROP PAEDIATR, V11, P397
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, IN PRESS B WHO
   DILRAJ, 1994, LANCET, V343, P1366
   KARIM SSA, 1991, S AFR MED J, V80, P579
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 20
PY 1994
VL 344
IS 8921
BP 545
EP 545
DI 10.1016/S0140-6736(94)91936-4
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC535
UT WOS:A1994PC53500051
PM 7914637
OA No
DA 2017-08-15
ER

PT J
AU BERRY, N
   ARIYOSHI, K
   JOBE, O
   NGUM, PT
   CORRAH, T
   WILKINS, A
   WHITTLE, H
   TEDDER, R
AF BERRY, N
   ARIYOSHI, K
   JOBE, O
   NGUM, PT
   CORRAH, T
   WILKINS, A
   WHITTLE, H
   TEDDER, R
TI HIV TYPE-2 PROVIRAL LOAD MEASURED BY QUANTITATIVE POLYMERASE
   CHAIN-REACTION CORRELATES WITH CD4+ LYMPHOPENIA IN HIV TYPE 2-INFECTED
   INDIVIDUALS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-2; BLOOD MONONUCLEAR-CELLS; INFECTED
   INDIVIDUALS; WEST-AFRICA; DNA LOAD; EPIDEMIOLOGY; PATIENT; ISOLATE;
   DISEASE; BISSAU
AB The efficiency of detection of 2 sets of primer pairs from putatively conserved regions of the human immunodeficiency virus type 2 (HIV-2) genome were assessed in 86 seropositive individuals from The Gambia by nested polymerase chain reaction (PCR). HIV-2 long terminal repeat (LTR) target sequences were detected in DNA extracted from peripheral blood mononuclear cells (PBMCs) in 84 of 86 (97%) individuals whereas HIV-2 integrase (pol) gene sequences were detected in 39 of 41 (95%) individuals. The use of LTR target sequences and recombinant Pfu DNA polymerase, rather than Tag polymerase, in a modified secondary amplification reaction mediated the incorporation of S-35-labeled nucleotides in a quantitative radiometric assay. This sensitive assay was used to quantify HIV-2 proviral DNA in clinical samples and compared well with estimations by limiting end-point dilution of target molecules. A linear response between counts and the number of copies amplified from serial dilutions of pROD10 plasmid DNA (3-2000 copies) yielded a standard curve to allow extrapolation to clinical data. Increased levels of HIV-2 proviral DNA, expressed as copies per 10(5) CD4-positive lymphocytes, were associated with declining CD4 count in 63 adult patients (Spearman rank correlation, r = -0.71, n = 63, p < 0.001) and with the occurrence of HIV-related clinical disease. Kruskall-Wallis analysis of variance analysis showed the mean proviral copy number (log(10)) to be significantly different between groups (p < 0.001) where CD4 counts were grouped as <200/mm(3) (3.4 +/- 1.05 copies), 200-500/mm(3) (2.84 +/- 0.93 copies), and >500/mm(3) (1.88 +/- 0.43 copies). HIV-2 proviral loads were therefore 33 times higher in patients with low CD4 counts (<200/mm(3)) compared to individuals where CD4 counts exceeded 500/mm(3).
C1 MRC LABS, BANJUL, GAMBIA.
RP BERRY, N (reprint author), UCL, SCH MED, DIV VIROL, WINDEYER BLDG, 46 CLEVELAND ST, LONDON W1P 6DB, ENGLAND.
CR BIENIASZ PD, 1993, AIDS, V7, P803, DOI 10.1097/00002030-199306000-00007
   BOERI E, 1992, J VIROL, V66, P4546
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501
   DECOCK K, 1990, AIDS, V5, P859
   DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013
   DIETRICH U, 1989, NATURE, V342, P948, DOI 10.1038/342948a0
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   FERRE F, 1992, AIDS RES HUM RETROV, V8, P269, DOI 10.1089/aid.1992.8.269
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   GRANKVIST O, 1992, J ACQ IMMUN DEF SYND, V5, P286
   Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31
   JURRIAANS S, 1992, AIDS, V6, P635, DOI 10.1097/00002030-199207000-00004
   Kanki P J, 1991, AIDS Clin Rev, P17
   KERSTENS L, 1992, AIDS, V6, P803
   KIRCHHOFF F, 1990, AIDS, V4, P847, DOI 10.1097/00002030-199009000-00003
   KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457
   O'BRIEN T R, 1992, Journal of the American Medical Association, V267, P2775, DOI 10.1001/jama.267.20.2775
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   POULSEN AG, 1989, LANCET, V1, P827
   RAYFIELD M, 1988, J INFECT DIS, V158, P1170
   RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P
   SCHECHTER MT, 1991, AIDS, V5, P373, DOI 10.1097/00002030-199104000-00003
   SHULTZ T, 1990, J VIROL, V64, P5177
   SIMMONDS P, 1990, J VIROL, V64, P864
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   SMALLMANRAYNOR M, 1992, 8TH INT C AIDS
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WOOD R, 1993, J ACQ IMMUN DEF SYND, V6, P237
   YERLY S, 1992, J INFECT DIS, V166, P269
   1992, MMWR-MORBID MORTAL W, V41, pRR17
NR 34
TC 69
Z9 70
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 1994
VL 10
IS 8
BP 1031
EP 1037
DI 10.1089/aid.1994.10.1031
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA PE522
UT WOS:A1994PE52200023
PM 7811534
OA No
DA 2017-08-15
ER

PT J
AU BYASS, P
   HANLON, PW
AF BYASS, P
   HANLON, PW
TI DAILY MORBIDITY RECORDS - RECALL AND RELIABILITY
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
ID DIARRHEA; HEALTH; CHILDREN
AB Methodological issues concerning the collection and analysis of daily morbidity data in community studies in developing countries are discussed. The effects of recall period and inter-observer variation on symptom prevalence are considered in the context of a longitudinal study in The Gambia, in which prevalence fell by about half over 1-week's recall. In the same study, many infant-days were recorded separately on two occasions, allowing an assessment of reliability in this type of morbidity diary data. The implications of these findings both in terms of data quality and cost-effectiveness are discussed, with the conclusion that weekly interviews examining the previous week's morbidity on a day-by-day basis are operationally optimal.
C1 MRC,BANJUL,GAMBIA.
OI Byass, Peter/0000-0001-5474-4361
CR ALAM N, 1989, INT J EPIDEMIOL, V18, P697, DOI 10.1093/ije/18.3.697
   BOERMA JT, 1991, INT J EPIDEMIOL, V20, P1073, DOI 10.1093/ije/20.4.1073
   CARRABIS JD, 1987, DBASE 3 PLUS COMPLET
   DONKER DK, 1992, MEDINFO 92
   GOH SGJ, 1985, J DIARRHOEAL DISEASE, V3, P7
   HALABI S, 1992, INT J EPIDEMIOL, V21, P607, DOI 10.1093/ije/21.3.607
   HANLON P, 1987, LANCET, V1, P1342
   HANLON P, 1987, THESIS U GLASGOW
   HANLON P, 1987, ANN TROP PAEDIATR, V7, P6
   KROEGER A, 1983, INT J EPIDEMIOL, V12, P465, DOI 10.1093/ije/12.4.465
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   PICKERING H, 1985, SOC SCI MED, V21, P121, DOI 10.1016/0277-9536(85)90080-2
   ROWLAND MGM, 1986, DIARRHOEA MALNUTRITI, P7
   ROWLAND MGM, 1982, DIARRHEA MALNUTRITIO, P87
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   SNOW RW, 1989, ANN TROP MED PARASIT, V83, P321
   1990, M METHODOLOGICAL ISS
NR 17
TC 24
Z9 24
U1 1
U2 3
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 1994
VL 23
IS 4
BP 757
EP 763
DI 10.1093/ije/23.4.757
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PG751
UT WOS:A1994PG75100014
PM 8002190
OA No
DA 2017-08-15
ER

PT J
AU MENENDEZ, C
   TODD, J
   ALONSO, PL
   LULAT, S
   FRANCIS, N
   GREENWOOD, BM
AF MENENDEZ, C
   TODD, J
   ALONSO, PL
   LULAT, S
   FRANCIS, N
   GREENWOOD, BM
TI MALARIA CHEMOPROPHYLAXIS, INFECTION OF THE PLACENTA AND BIRTH-WEIGHT IN
   GAMBIAN PRIMIGRAVIDAE
SO JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE MALARIA; CHEMOPROPHYLAXIS; BIRTH-WEIGHT
ID PREGNANCY; ATTENDANTS; AFRICA
AB A randomized, double blind, placebo-controlled community based trial of Maloprim (pyrimethamine 12.5 mg+dapsone 100 mg) administered to primigravid pregnant women by Traditional Birth Attendants was carried out in a rural area of The Gambia, West Africa. Placental histology showed less malaria infection in women who received chemoprophylaxis than in those who received placebo. The birth weight of children born to women who received chemoprophylaxis was increased by an average of 153 g. Within the treatment groups, there were no significant differences in the birthweights of babies born to women who had histological evidence of malaria infection of the placenta compared to those who had no malaria infection. This study confirms the beneficial effect of malaria prophylaxis for primigravid pregnant women but questions the mechanism by which malaria affects foetal development.
C1 MRC LABS,BANJUL,GAMBIA.
   CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RP,ENGLAND.
RP MENENDEZ, C (reprint author), HOSP CLIN BARCELONA,SERV ENFERMEDADAS INFECCIOSAS,TROP MED SECT,VILLARROEL 170,E-08036 BARCELONA,SPAIN.
CR ARCHIBALD H. MUNRO, 1956, BULL WORLD HEALTH ORGAN, V15, P842
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   BRAY RS, 1979, T ROY SOC TROP MED H, V73, P427, DOI 10.1016/0035-9203(79)90170-6
   BRUCECHWATT LJ, 1952, ANN TROP MED PARASIT, V46, P173
   COT M, 1992, AM J TROP MED HYG, V46, P21
   FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211
   GILLES HM, 1969, ANN TROP MED PARASIT, V63, P245
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   HAMILTON PJ, 1972, T ROY SOC TROP MED H, V66, P594, DOI 10.1016/0035-9203(72)90305-7
   HARRISON KA, 1973, J OBSTET GYN BR COMM, V80, P798
   JELIFFE EFP, 1968, B WORLD HEALTH ORGAN, V33, P69
   MACGREGOR MARGARET W., 1963, SCOTTISH MED JOUR, V8, P134
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517
   MCGREGOR IA, 1987, PARASSITOLOGIA, V219, P153
   MENENDEZ C, 1993, J TROP MED HYG, V96, P175
   MENENDEZ C, 1994, IN PRESS T ROYAL SOC, V88
   MORLEY D, 1964, BRIT MED J, V1, P667
   NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D
   RASHEED FN, 1993, IN PRESS AM J TROPIC
   Reinhardt M. C., 1978, Helvetica Paediatrica Acta, V33, P65
   RILEY EM, 1989, AM J TROP MED HYG, V40, P141
   VLEUGELS MPH, 1984, THESIS NIJMEGEN HELM
   WATKINSON M, 1983, BRIT MED J, V1, P251
   1986, WHO TECHNICAL REPORT, V735
NR 25
TC 54
Z9 55
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0022-5304
J9 J TROP MED HYG
JI J. Trop. Med. Hyg.
PD AUG
PY 1994
VL 97
IS 4
BP 244
EP 248
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA PA748
UT WOS:A1994PA74800011
PM 8064949
OA No
DA 2017-08-15
ER

PT J
AU WACHER, TJ
   MILLIGAN, PJM
   RAWLINGS, P
   SNOW, WF
AF WACHER, TJ
   MILLIGAN, PJM
   RAWLINGS, P
   SNOW, WF
TI TSETSE-TRYPANOSOMIASIS CHALLENGE TO VILLAGE-NDAMA CATTLE IN THE GAMBIA -
   FIELD ASSESSMENTS OF SPATIAL AND TEMPORAL PATTERNS OF TSETSE-CATTLE
   CONTACT AND THE RISK OF TRYPANOSOMIASIS INFECTION
SO PARASITOLOGY
LA English
DT Article
DE ANIMAL TRYPANOSOMIASIS; CHALLENGE; SPATIAL HETEROGENEITY;
   TRYPANOTOLERANT CATTLE
ID GLOSSINA-PALLIDIPES; POPULATION-DYNAMICS; MILK-PRODUCTION;
   TRYPANOTOLERANT; PERFORMANCE; PREVALENCE; DIPTERA; FLIES; KEPT; TRAP
AB The severity of the trypanosomiasis problem in a particular location is traditionally assessed in terms of a challenge index - the product of some measure of tsetse abundance and infection rate - which is assumed to be proportional to the force of infection. However, this index masks variation in the force of infection between herds and among individuals within herds. It is also not comparable between sites since the relative abundance of tsetse to hosts map vary. We have studied spatial distribution of herds of cattle in relation to tsetse in The Gambia and calculated an index of challenge based on the ratio of vectors to hosts over the livestock ranging area. This index is strongly correlated with estimates of the force of infection calculated from the incidence of infection in susceptible zebu; and it provides information on heterogeneity in exposure of different herds to tsetse.
C1 UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,ENGLAND.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
FU Wellcome Trust
CR Agyemang K., 1991, Bulletin of Animal Health and Production in Africa, V39, P129
   AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1991, ANIM REPROD SCI, V26, P51, DOI 10.1016/0378-4320(91)90065-8
   AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   BAYLIS M, 1990, 1990 OV DEV ADM U BR
   CAWDERY MJH, 1959, EATRO1958 E AFR HIGH, P61
   CLAXTON JR, 1992, ACTA TROP, V50, P219, DOI 10.1016/0001-706X(92)90078-C
   COE MJ, 1976, OECOLOGIA, V22, P341, DOI 10.1007/BF00345312
   Dietz K., 1980, Lecture Notes in Biomathematics, V39, P264
   DRANSFIELD RD, 1984, INSECT SCI APPL, V5, P363
   DWINGER RH, 1990, TROP ANIM HEALTH PRO, V22, P37, DOI 10.1007/BF02243497
   DWINGER RH, 1992, PARASITE IMMUNOL, V14, P351, DOI 10.1111/j.1365-3024.1992.tb00473.x
   DWINGER RH, 1989, 6TH P INT C I TROP V, P169
   DYE C, 1986, T ROY SOC TROP MED H, V80, P69, DOI 10.1016/0035-9203(86)90199-9
   DYE C, 1986, Parasitology Today, V2, P203, DOI 10.1016/0169-4758(86)90082-7
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   LEAK SGA, 1990, INSECT SCI APPL, V11, P293
   LEAK SGA, 1988, 1987 LIV PROD TSETS
   MCNAMARA JJ, 1991, ACTA TROP, V48, P127
   MILLIGAN PJM, 1991, THESIS U SALFORD
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   PILSON RD, 1967, B ENTOMOL RES, V57, P227
   RANDOLPH SE, 1992, MED VET ENTOMOL, V6, P231, DOI 10.1111/j.1365-2915.1992.tb00611.x
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   ROGERS D, 1979, J ANIM ECOL, V48, P825, DOI 10.2307/4197
   ROGERS DJ, 1984, INSECT SCI APPL, V5, P369
   ROGERS DJ, 1985, ACTA TROP, V42, P5
   ROGERS DJ, 1980, AGA801 FAO EXP CONS, P61
   RURANGIRWA FR, 1986, ACTA TROP, V43, P379
   SHAW APM, 1987, FAO671 FOOD AGR AN H
   SMITH IM, 1958, 7TH P M INT SCI COMM, P63
   SNOW WF, 1983, ACTA TROP, V40, P331
   SNOW WF, 1989, 20TH P M INT SCI COU, P187
   STAAK C, 1981, TROPENMED PARASITOL, V32, P97
   WACHER TJ, 1993, IN PRESS ANN TROPICA
   WACHER TJ, 1988, AFRICAN TRYPANOTOLER, P70
   WILLIAMS B, 1992, J APPL ECOL, V29, P163, DOI 10.2307/2404359
   WOOLHOUSE MEJ, 1991, P ROY SOC B-BIOL SCI, V245, P109, DOI 10.1098/rspb.1991.0095
NR 38
TC 11
Z9 11
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD AUG
PY 1994
VL 109
BP 149
EP 162
PN 2
PG 14
WC Parasitology
SC Parasitology
GA PC741
UT WOS:A1994PC74100003
PM 8084661
OA No
DA 2017-08-15
ER

PT J
AU ABLETHOMAS, U
   HILL, R
   OKEEFE, P
   PEARSALL, NM
AF ABLETHOMAS, U
   HILL, R
   OKEEFE, P
   PEARSALL, NM
TI COST-EFFECTIVENESS AND BENEFITS OF PHOTOVOLTAICS IN THE GAMBIA
SO RENEWABLE ENERGY
LA English
DT Article; Proceedings Paper
CT World Renewable Energy Congress - Climate Change, Energy and the
   Environment
CY SEP 11-16, 1994
CL READING, ENGLAND
DE PHOTOVOLTAICS; THE GAMBIA; COST-BENEFITS; RELIABILITY
AB This paper will discuss the socio-economic benefits that the Gambia has derived from photovoltaics (PV) and its future potential. Technical performance, reliability and cost estimates are assessed for some PV applications.
C1 GAMBIA CIVIL AVIAT AUTHOR,BANJUL INT AIRPORT,YUNDUM,GAMBIA.
   NORTHUMBRIA UNIV,DEPT ENVIRONM,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.
RP ABLETHOMAS, U (reprint author), NORTHUMBRIA UNIV,NEWCASTLE PHOTOVOLTAICS APPLICAT CTR,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND.
CR ABLETHOMAS U, 1993, PHOTOVOLTAICS GAMBIA
   ABLETHOMAS U, 1992, 11TH P EUR PHOT SOL
   ABLETHOMAS U, 1994, 12TH P EUR PHOT SOL
   DERRICK A, 1991, SOLAR PHOTOVOLTAIC P
   1992, BP SOLAR PRODUCT CAT
NR 5
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD AUG
PY 1994
VL 5
IS 1-4
BP 247
EP 249
DI 10.1016/0960-1481(94)90379-4
PG 3
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA PU945
UT WOS:A1994PU94500033
OA No
DA 2017-08-15
ER

PT J
AU ROLFE, M
AF ROLFE, M
TI HIV-2 AND ITS NEUROLOGICAL MANIFESTATIONS
SO SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; WEST-AFRICA; PRIMARY
   INFECTION; HUMAN RETROVIRUS; HTLV-III; TYPE-2; GAMBIA; PREVALENCE;
   ANTIBODIES
AB The human immunodeficiency virus type 2 (HIV-2) produces a similar spectrum of illness as HIV-1, including AIDS, and is clinically indistinguishable. There is evidence that it is less pathogenic, with a longer natural history. HIV-2 infection is endemic in West Africa, especially in the former Portuguese and French colonies. Trade, migration, war and tourism have been important factors in the spread of the virus through the subregion and beyond. Diagnostic facilities necessary for the accurate diagnosis of neurological disease are not available in most of Africa and autopsy reports have been few. These constraints have restricted the information available on the pattern of neuropathology induced by HIV-2. However, it possesses neurotropic properties similar to those of HIV-1 and produces disease by means of direct action of the virus on the nervous system, and immunosuppression which allows opportunistic infections and tumours to occur.
RP ROLFE, M (reprint author), ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
CR ANCELLE R, 1987, LANCET, V1, P688
   BESNIER JM, 1990, LANCET, V335, P798, DOI 10.1016/0140-6736(90)90920-Z
   BREW BJ, 1988, JR COLL PHYSICIANS L, V3, P140
   BRUNVEZINET F, 1987, LANCET, V1, P128
   BRUNVEZINET F, 1988, 5TH INT C AIDS STOCK
   Bryceson A, 1988, Lancet, V2, P221
   CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   COLEBUNDERS R, 1988, J INFECT DIS, V157, P314
   COOPER DA, 1985, LANCET, V1, P537
   DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089
   DECOCK KM, 1991, AIDS, V5, pS21
   DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013
   DECOCK KM, 1991, BRIT MED J, V302, P496
   DELACRUZ F, 1989, 5 INT C AIDS MONTR
   DENNING DW, 1987, BRIT MED J, V294, P143
   EVANS LA, 1988, SCIENCE, V240, P1522, DOI 10.1126/science.2836951
   GOUDSMIT J, 1986, BRIT MED J, V292, P1231
   HUGHES A, 1990, BLOOD REV, V4, P158, DOI 10.1016/0268-960X(90)90043-R
   HUGON J, 1988, LANCET, V1, P189
   JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503
   KANKI P, 1990, LTH INT C AIDS SAN F
   KAWAMURA M, 1989, LANCET, V1, P385
   KLEMM E, 1988, J NEUROL, V235, P304, DOI 10.1007/BF00314179
   KLOSER PC, 1989, ARCH INTERN MED, V149, P1875, DOI 10.1001/archinte.149.8.1875
   KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832
   KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383
   LEVY JA, 1985, LANCET, V2, P586
   LUCAS S, 1991, 6TH INT C AIDS AFR
   LUCAS SB, 1991, AIDS, V5, pS143
   LYONS SF, 1988, AIDS, V2, P406
   MABEY DCW, 1988, BRIT MED J, V296, P83
   MATOSALMEIDA MJM, 1989, 5 INT C AIDS MONTR
   NATH A, 1987, NEUROLOGY, V37, P37
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   PINCHING AJ, 1988, JR COLL PHYSICIANS L, V3, P136
   POULSEN AG, 1989, LANCET, V1, P827
   POULSEN AG, 1990, 5TH INT C AIDS AFR
   SAIMOT AG, 1987, LANCET, V1, P688
   SCHULZ TF, 1990, J VIROL, V64, P5177
   VERONESI R, 1987, LANCET, V2, P402
   WILKINS A, 1991, AIDS, V5, P1127, DOI 10.1097/00002030-199109000-00012
NR 42
TC 6
Z9 6
U1 0
U2 0
PU MED ASSOC S AFRICA
PI JOHANNESBURG
PA MED HOUSE CENTRAL SQ 7430 PINELANDS JOHANNESBURG, SOUTH AFRICA
SN 0038-2469
J9 S AFR MED J
JI S. Afr. Med. J.
PD AUG
PY 1994
VL 84
IS 8
BP 503
EP 505
PN 1
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC529
UT WOS:A1994PC52900016
PM 7825087
OA No
DA 2017-08-15
ER

PT J
AU LEPERRE, P
   CLAXTON, JR
AF LEPERRE, P
   CLAXTON, JR
TI COMPARATIVE-STUDY OF TRYPANOSOMOSIS IN ZEBU AND NDAMA CATTLE IN THE
   GAMBIA
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID GLOSSINIDAE; DIAGNOSIS; DIPTERA
AB An experiment was conducted in The Gambia to compare trypanosomosis incidence between zebu and N'Dama cattle. It was considered important to compare the 2 breeds under identical management conditions and the animals were maintained together at 3 locations, traditionally managed and under a range of tsetse challenges. The results show that trypanosomosis incidence was significantly higher in zebu than in N'Dama. Titre of antibody against Trypanosoma vivax measur ed by an IFAT showed a significant differ ence between zebu and N'Dama. Val lations in packed cell volume wer e greater in zebu than in N'Dama.
C1 ITC,BANJUL,GAMBIA.
CR CLAXTON JR, 1992, ACTA TROP, V50, P219, DOI 10.1016/0001-706X(92)90078-C
   DWINGER RH, 1988, LIVESTOCK PRODUCTION, P100
   DWINGER RH, 1989, LIVESTOCK PRODUCTION, P168
   FLINT S, 1985, B ENTOMOL RES, V75, P529
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   MURRAY M, 1983, LIVESTOCK PRODUCTION, P5
   PARIS J, 1982, ACTA TROP, V39, P307
   QUEVAL R, 1989, 20TH P M INT SCI COU
   RAWLINGS P, 1987, 19TH P M ISCTRC LOM, P360
   SNOW WF, 1989, 20TH P M ISCTRC MOMB
   WACHER TJ, 1988, AFRICAN TRYPANOTOLER, P70
   1979, MONOGRAPH INT LIVE 2, V1
NR 13
TC 7
Z9 7
U1 0
U2 0
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD AUG
PY 1994
VL 26
IS 3
BP 139
EP 145
DI 10.1007/BF02241070
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA QK064
UT WOS:A1994QK06400002
PM 7809985
OA No
DA 2017-08-15
ER

PT J
AU ZINSSTAG, J
   PFISTER, K
AF ZINSSTAG, J
   PFISTER, K
TI WORKSHOP SUMMARY - STRATEGIES AND ECONOMICS OF PARASITE CONTROL IN
   AFRICA
SO VETERINARY PARASITOLOGY
LA English
DT Article; Proceedings Paper
CT 14th International Conference of the
   World-Association-for-the-Advancement-of-Veterinary-Parasitology on
   Understanding and Control of Parasitic Disease of Animals
CY AUG 08-13, 1993
CL CAMBRIDGE, ENGLAND
SP WORLD ASSOC ADV VET PARASITOL
C1 LABOR PFISTER,MORGENSTR 83B,CH-3018 BERN,SWITZERLAND.
   INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
NR 0
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 1994
VL 54
IS 1-3
BP 309
EP 311
DI 10.1016/0304-4017(94)90103-1
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA PH115
UT WOS:A1994PH11500026
PM 7846865
OA No
DA 2017-08-15
ER

PT J
AU RICARD, D
   WILKINS, A
   NGUM, PT
   HAYES, R
   MORGAN, G
   DASILVA, AP
   WHITTLE, H
AF RICARD, D
   WILKINS, A
   NGUM, PT
   HAYES, R
   MORGAN, G
   DASILVA, AP
   WHITTLE, H
TI THE EFFECTS OF HIV-2 INFECTION IN A RURAL AREA OF GUINEA-BISSAU
SO AIDS
LA English
DT Article
DE HIV-2; GUINEA-BISSAU; EPIDEMIOLOGY; MORTALITY; CD4 LYMPHOCYTE;
   BETA(2)-MICROGLOBULIN; NEOPTERIN
ID IMMUNODEFICIENCY VIRUS TYPE-2; WEST-AFRICA; COTE-DIVOIRE; AIDS;
   MORTALITY; HEMOPHILIA; COMMUNITY; ABIDJAN; GAMBIA; WOMEN
AB Objective: To investigate the clinical and immunologic effects, and pattern of mortality associated with HIV-2 infection.
   Setting: A rural community in Guinea-Bissau.
   Methods: Serologic screening of 2774 subjects aged > 14 years followed by studies of the prevalence of clinical and immunologic abnormalities among 133 subjects with HIV-2 infection and 160 seronegative controls, and surveillance of mortality among all subjects who were screened during a mean of 2 years of follow-up.
   Results: Generalized lymphadenopathy was the only clinical abnormality significantly associated with HIV-2 infection. Infection was associated with lower CD4 counts and higher beta(2)-microglobulin and neopterin levels. During follow-up, 5.5% of infected subjects died compared with 1.8% of the seronegatives (rate ratio adjusted for age and sex, 3.5; 95% confidence interval ((CI), 1.8-6.7). Proportional hazard regression analysis showed that the rate ratio varied with age (P=0.003) and there was some evidence that the excess of mortality in infected subjects was, in absolute terms, least in the oldest subjects (trend test; P=0.08).
   Conclusions: The findings support previous suggestions that HIV-2 is less pathogenic than HIV-1; the data also suggest that mortality associated with infection may be lower in older subjects.
C1 MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   INST CHILD HLTH,LONDON,ENGLAND.
   MINIST HLTH,BISSAU,GUINEA BISSAU.
OI Hayes, Richard/0000-0002-1729-9892
CR ALEDORT LM, 1992, BRIT MED J, V304, P212
   DARBY SC, 1989, BRIT MED J, V298, P1064
   DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z
   GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   LEGUENNO B, 1992, J MED VIROL, V38, P67, DOI 10.1002/jmv.1890380114
   LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421
   LINDAN CP, 1992, ANN INTERN MED, V116, P320
   LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013
   MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137
   MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3
   NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457
   NAUCLER A, 1991, AIDS, V5, P301, DOI 10.1097/00002030-199103000-00009
   NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   PEPIN J, 1992, AIDS, V6, P489
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   POLLACK S, 1993, LANCET, V342, P50, DOI 10.1016/0140-6736(93)91912-6
   POULSEN AG, 1989, LANCET, V1, P827
   ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   1985, WKLY EPIDEMIOL REC, V60, P342
NR 25
TC 47
Z9 47
U1 0
U2 2
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD JUL
PY 1994
VL 8
IS 7
BP 977
EP 982
DI 10.1097/00002030-199407000-00016
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA NU947
UT WOS:A1994NU94700016
PM 7946109
OA No
DA 2017-08-15
ER

PT J
AU LAM, KMC
   WHITTLE, H
   GRZYWACZ, M
   CRAWFORD, DH
AF LAM, KMC
   WHITTLE, H
   GRZYWACZ, M
   CRAWFORD, DH
TI EPSTEIN-BARR VIRUS-CARRYING B-CELLS ARE LARGE, SURFACE IGM, IGD-BEARING
   CELLS IN NORMAL INDIVIDUALS AND ACUTE MALARIA PATIENTS
SO IMMUNOLOGY
LA English
DT Article
ID INFECTIOUS-MONONUCLEOSIS; PERIPHERAL-BLOOD; SPONTANEOUS OUTGROWTH;
   MEDIATED IMMUNITY; BURKITTS-LYMPHOMA; VIRAL LATENCY; EBV;
   TRANSFORMATION; LEUKOCYTES; ANTIGENS
AB In this study the presence of Epstein-Barr virus (EBV) carrying B lymphocytes in different B-cell subpopulations from peripheral blood was determined by spontaneous outgrowth which gives rise to lymphoblastoid cell lines. In healthy seropositive adults, the EBV-carrying B cell was predominantly within the IgM- and IgD-positive but not the IgG-positive subpopulations. Furthermore, these B lymphocytes were in the low-density (large cell) Percoll fraction. The IgM- and IgD-positive B cell phenotype suggests the EBV-carrying B cells to be circulating virgin B cells recently released from the bone marrow. These B cells have an estimated life span of only 6-8 weeks suggesting that long-term EBV persistence in the body may be the result of infection of a more primitive B-cell type. Similar experiments were carried out in children with acute malaria from the Gambia, West Africa, where Burkitt lymphoma (BL) is endemic in order to determine whether a population of EBV-carrying B cells could be identified which had a similar phenotype to the BL cell. The EBV-carrying B cells in this patient group were also found in the IgM-positive, IgG-negative B-cell subpopulation. The majority of these cells were found in the low-density (large cell) Percoll fraction although in some patients a proportion was derived from the high-density (small cell) fraction. This cellular phenotype is not representative of a BL cell.
C1 MRC LABS,BANJUL,GAMBIA.
RP LAM, KMC (reprint author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
FU Wellcome Trust
CR CRAWFORD DH, 1981, LANCET, V1, P10
   DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824
   EVANS AS, 1968, NEW ENGL J MED, V279, P1121, DOI 10.1056/NEJM196811212792101
   Geser A., 1983, EUR J CANCER CLIN ON, V19, P1394
   GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693
   GREGORY CD, 1987, J IMMUNOL, V139, P313
   HENLE G, 1966, J BACTERIOL, V91, P1248
   HENLE W, 1970, SCIENCE, V169, P188, DOI 10.1126/science.169.3941.188
   KIEFF E, 1990, VIROLOGY, P1889
   KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2
   KLEIN G, 1976, INT J CANCER, V17, P21, DOI 10.1002/ijc.2910170105
   LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2
   LENOIR G, 1987, ADV VIRAL ONCOL, V6, P173
   LEWIN N, 1987, INT J CANCER, V39, P472, DOI 10.1002/ijc.2910390411
   LEWIN N, 1988, IMMUNOBIOLOGY, V7, P221
   LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H
   MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383
   MOSS DJ, 1978, INT J CANCER, V22, P662, DOI 10.1002/ijc.2910220604
   MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157
   NIEDERMAN JC, 1970, NEW ENGL J MED, V282, P361, DOI 10.1056/NEJM197002122820704
   NILSSON K, 1971, INT J CANCER, V8, P443
   OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C
   POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619
   QU LR, 1992, J VIROL, V66, P3715
   RICKINSON AB, 1974, INT J CANCER, V14, P704, DOI 10.1002/ijc.2910140603
   RICKINSON AB, 1977, INT J CANCER, V19, P775, DOI 10.1002/ijc.2910190606
   ROCCHI G, 1977, NEW ENGL J MED, V296, P132, DOI 10.1056/NEJM197701202960302
   ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404
   SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0
   TOSATO G, 1984, J CLIN INVEST, V73, P1789, DOI 10.1172/JCI111388
   YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115
   YAO QY, 1991, INT J CANCER, V48, P253, DOI 10.1002/ijc.2910480217
NR 32
TC 5
Z9 5
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD JUL
PY 1994
VL 82
IS 3
BP 383
EP 388
PG 6
WC Immunology
SC Immunology
GA NV457
UT WOS:A1994NV45700009
PM 7959872
OA No
DA 2017-08-15
ER

PT J
AU HASSANKING, M
   BALDEH, I
   SECKA, O
   FALADE, A
   GREENWOOD, B
AF HASSANKING, M
   BALDEH, I
   SECKA, O
   FALADE, A
   GREENWOOD, B
TI DETECTION OF STREPTOCOCCUS-PNEUMONIAE DNA IN BLOOD CULTURES BY PCR
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PNEUMOCOCCAL PNEUMONIA; CHAIN-REACTION; DIAGNOSIS; IDENTIFICATION;
   PROBE; ACID; INVITRO
AB We have developed a PCR assay, with primers derived from the autolysin (lyt) gene, for the detection of Streptococcus pneumoniae DNA in blood cultures. The predicted fragment of 247 bp was detected in all strains of pneumococci, embracing 12 different serotypes that were tested. Although DNA extracted from four viridans streptococci spp. Streptococcus oralis, Streptococcus mitis, Streptococcus sanguis, and Streptococcus parasanguis) gave amplification products, these were quite different from the predicted fragment for S. pneumoniae. Application of the assay for diagnosis of septicemia caused by S. pneumoniae showed concordance between PCR and culture results. However, on four occasions PCR was positive in supernatants from both paired culture bottles while pneumococci were cultured from only one. Performing PCR on negative cultures in controlled studies such as vaccine trials may provide a sensitive tool for increasing case detection.
RP HASSANKING, M (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR DAVIS TE, 1991, J CLIN MICROBIOL, V29, P2193
   DENYS GA, 1992, J CLIN MICROBIOL, V30, P2725
   GARCIA P, 1986, GENE, V43, P265, DOI 10.1016/0378-1119(86)90215-5
   GUATELLI JC, 1989, CLIN MICROBIOL REV, V2, P217
   Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31
   HOLTJE JV, 1975, J BIOL CHEM, V250, P6072
   KALIN M, 1983, SCAND J INFECT DIS, V15, P247
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   PERLINO CA, 1984, J INFECT DIS, V150, P139
   POZZI G, 1989, J CLIN MICROBIOL, V27, P370
   RUDOLPH KM, 1993, J CLIN MICROBIOL, V31, P2661
   SCHLEIFER KH, 1987, SYST APPL MICROBIOL, V10, P1
   TENOVER F C, 1988, Clinical Microbiology Reviews, V1, P82
   TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694
   WOLCOTT MJ, 1992, CLIN MICROBIOL REV, V5, P370
NR 15
TC 34
Z9 34
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 1994
VL 32
IS 7
BP 1721
EP 1724
PG 4
WC Microbiology
SC Microbiology
GA NR924
UT WOS:A1994NR92400019
PM 7929764
OA No
DA 2017-08-15
ER

PT J
AU LITTLE, DA
   WASSINK, GJ
   RILEY, JA
   AGYEMANG, K
   BADJIE, B
   DWINGER, RH
AF LITTLE, DA
   WASSINK, GJ
   RILEY, JA
   AGYEMANG, K
   BADJIE, B
   DWINGER, RH
TI FEED SUPPLEMENTATION OF VILLAGE-BASED NDAMA CALVES
SO TROPICAL AGRICULTURE
LA English
DT Article
DE PROTEIN SUPPLEMENTS; NDAMA CALVES; CALF PERFORMANCE
ID GAMBIA
AB Four experiments were carried out in which supplements of locally available proteinaceous by-products were given to young, mainly pre-weaned calves that ranged in initial weight from 30 to 90 kg.  The experiments were part of a programme designed to establish practical and economical nutrition interventions for the improved productivity of N'Dama cattle under traditional village husbandry in a sub-humid agro-ecological environment in West Africa.  The supplements included groundnut cake, sesame cake, and cotton seed, supplied during both the dry and wet seasons.  While significant increases in growth rate were obtained to both dry and wet season supplementation, the responses were both inconsistent and much smaller than those obtained in other studies with older weaned N'Dama cattle.  It is concluded that feed supplementation of young cattle should probably be restricted to animals whose liveweight exceeds 100 kg.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR AGYEMANG K, 1991, ANIM PROD, V53, P11
   AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   DUNSMORE JR, 1976, LAND RESOURCE STUDY, V22
   DWINGER RH, 1990, 6TH P INT C I TROP V, P169
   JEANNIN P, 1987, 19TH P M INT SCI COU, P222
   LITTLE DA, 1989, TROP AGR, V66, P33
   LITTLE DA, 1991, TROP ANIM HEALTH PRO, V23, P126, DOI 10.1007/BF02361198
   LITTLE DA, 1991, TROP AGR TRINIDAD, V66, P259
   Snedecor G.W., 1967, STATISTICAL METHODS
   TILLEY J. M. A., 1963, JOUR BRIT GRASSLAND SOC, V18, P104
NR 10
TC 0
Z9 0
U1 0
U2 0
PU TROPICAL AGRICULTURE
PI TRINIDAD
PA UNIV WEST INDIES FAC OF AGRICULTURE ST AUGUSTINE, TRINIDAD, WEST INDIES
SN 0041-3216
J9 TROP AGR
JI Trop. Agric.
PD JUL
PY 1994
VL 71
IS 3
BP 219
EP 222
PG 4
WC Agriculture, Multidisciplinary; Agronomy
SC Agriculture
GA QT278
UT WOS:A1994QT27800011
OA No
DA 2017-08-15
ER

PT J
AU LITTLE, DA
   WASSINK, GJ
   AGYEMANG, K
   LEPERRE, P
   JANNEH, L
   BADJIE, B
AF LITTLE, DA
   WASSINK, GJ
   AGYEMANG, K
   LEPERRE, P
   JANNEH, L
   BADJIE, B
TI FEED SUPPLEMENTATION OF LACTATING NDAMA COWS UNDER VILLAGE HUSBANDRY
SO TROPICAL AGRICULTURE
LA English
DT Article
DE NDAMA CATTLE; LACTATION; SUPPLEMENTATION; PRODUCTIVITY; THE GAMBIA
ID MILK-PRODUCTION; GAMBIA; CALVES; CAKE
AB Groups of lactating N'Dama cows maintained under traditional husbandry conditions were given dry-season supplements of locally available oil seed residues to establish nutritional recommendations for improving livestock productivity in the sub-humid zone of West Africa.  In one experiment cows were given 0 or 1 kg cotton seed head-1 day-1 for the last five months of the dry season in three Gambian villages.  In a second experiment cows were given a total of 90 kg sesame cake over the last six months of the dry season, at rates of 1 kg day-1 for the first or last three months, or 0.5 kg day-1 throughout.  During this period the provision of supplements produced significant overall average increases exceeding 60% in both milk offtake for human consumption and calf growth.  Maternal liveweight losses were reduced by a mean of 30%.  Concomitant significant increases in postpartum resumption of reproductive activity (two- to three-fold) and reduced calf mortality also occurred, while evidence was obtained that the improved diet better enabled the animals to withstand the effects of trypanosome infections.  It was demonstrated that the dry-season provision of oil seed residues to lactating N'Dama cows in this environment can be expected to produce an extra litre of milk offtake, 260 g calf growth, and 380 g maternal liveweight gain kg-1 crude protein supplied, in addition to the improvement in other productivity characteristics.  The second experiment showed much greater efficiency of resource use when fed more slowly for the longer period, and the economic benefits of such interventions appear to be substantial.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1993, ANIM PROD, V56, P165
   AGYEMANG K, 1991, J DAIRY SCI, V74, P1599
   AGYEMANG K, 1987, LIVESTOCK PRODUCTION, P231
   DWINGER RH, 1990, LIVESTOCK PRODUCTION, P169
   Jahnke HE, 1982, LIVESTOCK PRODUCTION
   JEANNIN P, 1987, 19TH P M INT SCI COU, P222
   JEANNIN P, 1987, LIVESTOCK PRODUCTION, P174
   Little D. A., 1990, Proceedings of the Nutrition Society, V49, p209A
   LITTLE DA, 1991, TROP AGR, V68, P259
   LITTLE DA, 1991, TROP ANIM HEALTH PRO, V23, P126, DOI 10.1007/BF02361198
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1981, VET REC, V19, P503
   PARIS J, 1982, ACTA TROP, V37, P307
   Snedecor G.W., 1967, STATISTICAL METHODS
   STARKEY PH, 1984, WORLD ANIM REV, V50, P2
   TILLEY J. M. A., 1963, JOUR BRIT GRASSLAND SOC, V18, P104
   1980, NUTRIENT REQUIREMENT
   1979, ILCA MONOGR, V2
NR 19
TC 6
Z9 6
U1 0
U2 1
PU TROPICAL AGRICULTURE
PI TRINIDAD
PA UNIV WEST INDIES FAC OF AGRICULTURE ST AUGUSTINE, TRINIDAD, WEST INDIES
SN 0041-3216
J9 TROP AGR
JI Trop. Agric.
PD JUL
PY 1994
VL 71
IS 3
BP 223
EP 228
PG 6
WC Agriculture, Multidisciplinary; Agronomy
SC Agriculture
GA QT278
UT WOS:A1994QT27800012
OA No
DA 2017-08-15
ER

PT J
AU DWINGER, RH
   AGYEMANG, K
   SNOW, WF
   RAWLINGS, P
   LEPERRE, P
   BAH, ML
AF DWINGER, RH
   AGYEMANG, K
   SNOW, WF
   RAWLINGS, P
   LEPERRE, P
   BAH, ML
TI PRODUCTIVITY OF TRYPANOTOLERANT CATTLE KEPT UNDER TRADITIONAL MANAGEMENT
   CONDITIONS IN THE GAMBIA
SO VETERINARY QUARTERLY
LA English
DT Article
ID AFRICAN TRYPANOSOMIASIS; NDAMA CATTLE; GLOSSINIDAE; DIAGNOSIS; DIPTERA
AB The productivity of trypanotolerant N'Dama cattle, kept under traditional management conditions in The Gambia, West Africa, was assessed by the regular, monthly collection of health and production parameters in two study areas. The study areas Were selected because of differences in tsetse challenge. Performance traits were used to build up an index to estimate the productivity of village N'Dama cattle. The productivity index per 100 kg cow maintained per year varied from 37.2 kg in the study area of Keneba village (with a low tsetse challenge) to 21.4 kg for cattle kept near the villages of Tuba and Sambelkunda, an area which had a high tsetse challenge. Average age at first calving was 4.5 or 5.0 years depending on the study area, calving intervals were 623 or 703 days and there was an average 12% loss of body weight in adult females during the dry season. The productivity indices of village N'Dama cattle in The Gambia compare favourably with similar indices for trypanotolerant and trypanosusceptible breeds elsewhere in Africa, and show that even under harsh conditions and with high tsetse challenge, they are able to effectively produce milk and meat for the rural population.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
   INT LIVESTOCK CTR AFRICA,ADDIS ABABA,ETHIOPIA.
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   DWINGER RH, 1992, PARASITE IMMUNOL, V14, P351, DOI 10.1111/j.1365-3024.1992.tb00473.x
   FLINT S, 1985, B ENTOMOL RES, V75, P529
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   HARVEY WR, 1977, USERS GUIDE LEAST SQ
   Herbert I. V., 1964, Vet Bull, V34, P563
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   MCNAMARA JJ, 1991, ACTA TROP, V48, P127
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   PARIS J, 1982, ACTA TROP, V39, P307
   RENNIE T, 1977, TROP ANIM HEALTH PRO, V9, P1, DOI 10.1007/BF02297380
   WATERSBAYER A, 1988, DAIRYING FULANI AGRO, P96
   WILSON RT, 1985, ANIM REPROD SCI, V9, P1, DOI 10.1016/0378-4320(85)90036-3
   WILSON RT, 1986, ILCA14 RES REP, P43
   1988, BETAIL TRYPANOTOLERA, V3
   1975, STATISTICAL PACKAGE
   1977, MIN AGR FISH FOOD TE, V18, P8
   1979, TRYPANOTOLERANT LIVE, V2
NR 19
TC 13
Z9 13
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0165-2176
J9 VET QUART
JI Vet. Q.
PD JUL
PY 1994
VL 16
IS 2
BP 81
EP 86
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA PC705
UT WOS:A1994PC70500005
PM 7985361
OA No
DA 2017-08-15
ER

PT J
AU BOCKARIE, MJ
   SERVICE, MW
   BARNISH, G
   MAUDE, GH
   GREENWOOD, BM
AF BOCKARIE, MJ
   SERVICE, MW
   BARNISH, G
   MAUDE, GH
   GREENWOOD, BM
TI MALARIA IN A RURAL AREA OF SIERRA-LEONE .3. VECTOR ECOLOGY AND DISEASE
   TRANSMISSION
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Article
ID IDENTIFICATION; MOSQUITOS
C1 MED RES COUNCIL LAB,BO,SIERRA LEONE.
   UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.
   UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.
   MRC,BANJUL,GAMBIA.
CR BARNISH G, 1993, ANN TROP MED PARASIT, V87, P137
   BARNISH G, 1993, ANN TROP MED PARASIT, V87, P125
   BLACKLOCK B., 1921, Ann. Trop. Med. Parasit., V15, P463
   Blacklock D. B., 1942, ANN TROP MED AND PARASITOL, V36, P182
   BLACKLOCK D. B., 1941, ANN TROP MED AND PARASITOL, V35, P37
   BLACKLOCK DB, 1925, ANN MED SANITARY REP, P61
   BOREHAM PFL, 1982, B ENTOMOL RES, V72, P489
   BRENGUES J, 1973, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V11, P107
   BRUN LO, 1973, THESIS U RENNES FRAN
   CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11
   Coluzzi M., 1968, Parassitologia, V10, P179
   Detinova TS, 1962, MONOGRAPH SERIES WHO, V47
   GARRETTJONES C, 1969, B WORLD HEALTH ORGAN, V40, P531
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   GITHEKO AK, 1992, THESIS U LIVERPOOL
   GORDON R. M., 1932, ANN TROY MED AND PARASITOL, V26, P273
   GORDON RM, 1929, ANN MED SANITARY REP
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   HILL SM, 1992, T ROY SOC TROP MED H, V86, P213, DOI 10.1016/0035-9203(92)90578-Z
   HUNT R H, 1973, Parassitologia (Rome), V15, P137
   KUHLOW F, 1978, TROPENMED PARASITOL, V29, P371
   Lewis D. J., 1956, Annals of Tropical Medicine and Parasitology, V50, P299
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   Muirhead-Thomson RC, 1945, B ENTOMOL RES, V36, P185
   PETRARCA V, 1991, J MED ENTOMOL, V28, P307
   Ribbands CR, 1944, B ENTOMOL RES, V35, P271
   RIBBANDS CR, 1946, B ENTOMOL RES, V36, P395
   ROSS R, 1900, LIVERPOOL SCH TROPIC, V2
   SERVICE MW, 1977, B ENTOMOL RES, V67, P343
   SERVICE MW, 1986, B ENTOMOL RES, V76, P321
   TREDRE FR, 1946, ANN TROP MED PARASIT, V24, P380
   WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P69
NR 32
TC 25
Z9 27
U1 0
U2 4
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD JUN
PY 1994
VL 88
IS 3
BP 251
EP 262
PG 12
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA NX129
UT WOS:A1994NX12900002
PM 7944670
OA No
DA 2017-08-15
ER

PT J
AU FORTUIN, M
   KARTHIGESU, V
   ALLISON, L
   HOWARD, C
   HOARE, S
   MENDY, M
   WHITTLE, HC
AF FORTUIN, M
   KARTHIGESU, V
   ALLISON, L
   HOWARD, C
   HOARE, S
   MENDY, M
   WHITTLE, HC
TI BREAKTHROUGH INFECTIONS AND IDENTIFICATION OF A VIRAL VARIANT IN GAMBIAN
   CHILDREN IMMUNIZED WITH HEPATITIS-B VACCINE
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Note
ID SURFACE-ANTIGEN; VIRUS; EFFICACY
AB Hepatitis B (HB) breakthrough infections, identified by the presence of HB core (c) antibody, were found in 32 of 358 Gambian children vaccinated with plasma-derived HB vaccine. Over 2 years, 15 of these children lost their HBc antibodies. These children had significantly higher HB surface antibody levels before infection than those who retained HBc antibodies. One child, who responded well to the vaccine, had HB viral DNA detected in the presence of HBs antibodies. The S gene sequence of this DNA showed nucleotide changes that resulted in an amino acid substitution at residue 141 (lysine to glutamic acid) of the surface antigen. This finding suggests the child was infected with a variant virus that was not neutralized by antibodies resulting from HB vaccination.
C1 MRC LABS,BANJUL,GAMBIA.
   INT AGCY RES CANC,GAMBIA HEPATITIS INTERVENT STUDY,BANJUL,GAMBIA.
   UNIV LONDON ROYAL VET COLL,DEPT PATHOL & INFECT DIS,LONDON,ENGLAND.
   MRC,DUNN NUTR LABS,CAMBRIDGE,ENGLAND.
CR BROWN J L, 1992, Hepatology, V15, P144, DOI 10.1002/hep.1840150124
   CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A
   COURSAGET P, 1986, LANCET, V2, P1143
   COURSAGET P, 1987, LANCET, V2, P1354
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   Harrison TJ, 1991, J HEPATOL, V13, P105
   IMAI M, 1974, IMMUNOLOGY, V27, P871
   KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443
   NEURATH A R, 1990, Peptide Research, V3, P116
   NORDER H, 1992, J GEN VIROL, V73, P1201, DOI 10.1099/0022-1317-73-5-1201
   STEWARD MW, 1993, VACCINE, V11, P1405, DOI 10.1016/0264-410X(93)90169-X
   VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
NR 13
TC 68
Z9 68
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN
PY 1994
VL 169
IS 6
BP 1374
EP 1376
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NX991
UT WOS:A1994NX99100031
PM 8195620
OA No
DA 2017-08-15
ER

PT J
AU MORLEY, CJ
   RASHIQ, H
   THOMAS, IRJ
   WEAVER, LT
AF MORLEY, CJ
   RASHIQ, H
   THOMAS, IRJ
   WEAVER, LT
TI USE OF BABY-CHECK TO ASSESS THE SEVERITY OF ILLNESS IN BABIES ATTENDING
   A CLINIC IN THE GAMBIA
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID SCORING SYSTEM; VILLAGE
AB Baby Check is a systematic way of grading the severity of illness in infants. We studied its usefulness for assessing 53 infants presenting to a clinic in a West African village. Their ages ranged from 2 weeks to 7 months. The Baby Check scores ranged from 0 to 30. Forty-four infants were considered by the doctors to be well or mildly ill, 41 of these had scores below 9. The three infants with higher scores had symptoms and signs suggesting they were more than mildly ill. Nine infants were considered to be moderately ill. Their scores ranged from 4 to 30. The babies with the low scores had fen symptoms and diagnoses suggesting they were only mildly ill. The babies with the highest scores all had diagnoses requiring medical attention. This pilot study of Baby Check in a developing country suggests that its use by health workers could increase the accuracy with which babies are referred for a medical opinion, and be a valuable tool for the identification of such infants in a busy clinic.
C1 MRC,DUNN NUTR UNIT,KENEBA,GAMBIA.
   MRC,DUNN NUTR UNIT,CAMBRIDGE,ENGLAND.
RP MORLEY, CJ (reprint author), ADDENBROOKES HOSP,DEPT PAEDIAT,BOX 116,CAMBRIDGE CB2 2QQ,ENGLAND.
CR COLE TJ, 1991, J ROY STAT SOC A STA, V154, P287, DOI 10.2307/2983042
   DOWNES B, 1991, J TROP PEDIATRICS, V37, P106
   LAMB WH, 1984, LANCET, V2, P912
   MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100
   MORLEY CJ, 1991, ARCH DIS CHILD, V66, P115
   THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106
   THORNTON AJ, 1991, ARCH DIS CHILD, V66, P111
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
NR 8
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD JUN
PY 1994
VL 40
IS 3
BP 144
EP 148
PG 5
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA NY333
UT WOS:A1994NY33300005
PM 8078112
OA No
DA 2017-08-15
ER

PT J
AU DELMISTRO, A
   CHOTARD, J
   HALL, AJ
   FORTUIN, M
   WHITTLE, H
   DEROSSI, A
   CHIECOBIANCHI, L
AF DELMISTRO, A
   CHOTARD, J
   HALL, AJ
   FORTUIN, M
   WHITTLE, H
   DEROSSI, A
   CHIECOBIANCHI, L
TI HTLV-I/II SEROPREVALENCE IN THE GAMBIA - A STUDY OF MOTHER-CHILD PAIRS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Note
ID VIRUS TYPE-I; INFECTION; TRANSMISSION; POPULATION; PEPTIDES; ANTIBODY;
   AFRICA
C1 IARC,BANJUL,GAMBIA.
   MRC,FAJARA,SENEGAL.
RP DELMISTRO, A (reprint author), UNIV PADUA,INST ONCOL,VIA GATTAMELATA 64,I-35128 PADUA,ITALY.
RI del mistro, annarosa/E-9352-2014; De Rossi, Anita/L-3128-2015
OI del mistro, annarosa/0000-0001-7201-9374; De Rossi,
   Anita/0000-0001-6435-7509
CR DELAPORTE E, 1991, AIDS, V5, P771
   DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19
   DEROSSI A, 1991, EUR J CANCER, V27, P835, DOI 10.1016/0277-5379(91)90128-Z
   DONEGAN E, 1992, TRANSFUSION, V32, P68, DOI 10.1046/j.1537-2995.1992.32192116436.x
   GOUBAU P, 1993, J MED VIROL, V39, P28, DOI 10.1002/jmv.1890390107
   HALL A J, 1987, Cancer Research, V47, P5782
   HAYES CG, 1991, J INFECT DIS, V163, P257
   HENEINE W, 1991, NEW ENGL J MED, V324, P565
   HJELLE B, 1991, J INFECT DIS, V163, P435
   MANNS A, 1991, BLOOD, V77, P896
   MURPHY EL, 1990, HUMAN RETROVIROLOGY : HTLV, P295
   ROBERTS CR, 1992, J MED VIROL, V36, P298, DOI 10.1002/jmv.1890360412
   TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508
   WIKTOR SZ, 1992, 5TH P INT C HUM RETR
   1990, WHO WKLY EPIDEM REC, V37, P281
NR 15
TC 10
Z9 10
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 1994
VL 10
IS 5
BP 617
EP 620
DI 10.1089/aid.1994.10.617
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA NR146
UT WOS:A1994NR14600015
PM 7917523
OA No
DA 2017-08-15
ER

PT J
AU GREENWOOD, AM
   MENENDEZ, C
   TODD, J
   GREENWOOD, BM
AF GREENWOOD, AM
   MENENDEZ, C
   TODD, J
   GREENWOOD, BM
TI THE DISTRIBUTION OF BIRTH WEIGHTS IN GAMBIAN WOMEN WHO RECEIVED MALARIA
   CHEMOPROPHYLAXIS DURING THEIR FIRST PREGNANCY AND IN CONTROL WOMEN
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB The distribution of birth weights among the infants of 172 Gambian primigravidae who had received chemoprophylaxis with Maloprim(R) (pyrimethamine+dapsone) during pregnancy was compared with that of the infants of 149 primigravidae who had received placebo. Administration of chemoprophylaxis led to a reduction in the prevalence of low birth weight babies and to an increase in the median birth weight. However, these changes were not accompanied by a comparable increase in the prevalence of high birth weight babies. The perinatal mortality rate was lower, although not significantly so, among the babies of women who had received chemoprophylaxis. Thus, no evidence was found to support the view that administration of chemoprophylaxis might increase the risks of delivery by causing cephalo/pelvic disproportion.
RP GREENWOOD, AM (reprint author), MRC LABS,BANJUL,GAMBIA.
CR GARNER P, 1992, LANCET, V340, P1021, DOI 10.1016/0140-6736(92)93022-F
   GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   MENENDEZ C, IN PRESS J TROPICAL
   MORLEY D, 1964, BRIT MED J, V1, P667
   PRENTICE AM, 1988, EUR J CLIN NUTR, V42, P87
   VICTORA CG, 1987, INT J EPIDEMIOL, V16, P239, DOI 10.1093/ije/16.2.239
NR 7
TC 28
Z9 29
U1 0
U2 1
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1994
VL 88
IS 3
BP 311
EP 312
DI 10.1016/0035-9203(94)90094-9
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NX711
UT WOS:A1994NX71100020
PM 7974672
OA No
DA 2017-08-15
ER

PT J
AU MATTILI, RC
   ZINSSTAG, J
   PEISTER, K
AF MATTILI, RC
   ZINSSTAG, J
   PEISTER, K
TI FREQUENCY OF TRYPANOSOMOSIS AND GASTROINTESTINAL PARASITES IN DRAFT
   DONKEYS IN THE GAMBIA IN RELATION TO ANIMAL HUSBANDRY
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
ID NDAMA CATTLE
AB Prevalence of trypanosomosis, gastrointestinal strongyles and level of strongyle egg outputs were studied in relation to husbandry practices in the draught donkey population in The Gambia. Feeding regime, number of working hours per day and overnight penning practices of donkeys affected significantly (P < 0.05) the level of gastrointestinal strongyle egg output, but not (P > 0.05) trypanosomosis prevalence. Dual trypanosome and gastrointestinal strongyle infection significantly reduced the PCV (P < 0.001). Animals positive for gastrointestinal strongyles alone did not show a significantly (P > 0.05) lower PCV than those found negative. Husbandry practices to improve the situation are recommended.
RP MATTILI, RC (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
RI Zinsstag, Jakob/A-8317-2008
OI Zinsstag, Jakob/0000-0002-8899-6097
CR BIANCHIN I, 1987, TROP ANIM HEALTH PRO, V19, P39, DOI 10.1007/BF02250844
   Cabaret J., 1976, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V29, P221
   CHAM PA, 1990, 3RD P WORKSH W AFR A, P306
   DUNN AM, 1978, VET HELMINTHOLOGY, P323
   FITSCHE T, 1992, THESIS VETERINARY FA
   FUJIOKA K, 1987, REV MONDIALE ZOOTECH, V63, P40
   GIBSON TE, 1963, P NUTR SOC, V22, P15, DOI 10.1079/PNS19630006
   Graber M, 1972, Rev Elev Med Vet Pays Trop, V25, P53
   ITARD J, 1981, MANUELS PRECIS ELEVA, P304
   Jacobs D.E., 1986, COLOUR ATLAS EQUINE
   KAGGWA EK, 1989, REV ELEVAGE MED VETE, V24, P205
   KAGGWA EK, 1988, REV ELEVAGE MED VETE, V41, P265
   KAUFMANN J, 1992, VET PARASITOL, V43, P157, DOI 10.1016/0304-4017(92)90157-5
   KAUFMANN J, 1990, VET PARASITOL, V37, P45, DOI 10.1016/0304-4017(90)90024-6
   LOUM B, 1989, UNPUB 5TH COUNC M BA, P40
   MCCLENNAN KJR, 1970, AFRICAN TRYPANOSOMIA, P751
   Mohamed F. H. A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P535
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1983, LIVESTOCK PRODUCTIVI, P198
   ROUILLE D, 1988, FICHES TECHNIQUES PA, P44
   SMITH AJ, 1990, 3RD P WORKSH W AFR A, P156
   SOWE J, 1990, 3RD P WORKSH W AFR A, P315
   STARKEY P, 1990, 3RD P WORKSH W AFR A, P90
   Stephen L. E., 1970, P774
   VERY P, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P325
   WHITLOCK J. H., 1949, CORNELL VET, V39, P146
   1991, STATISTICAL YB GAMBI, P38
NR 27
TC 16
Z9 16
U1 0
U2 4
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT, 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD MAY
PY 1994
VL 26
IS 2
BP 102
EP 108
DI 10.1007/BF02239909
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA NY751
UT WOS:A1994NY75100009
PM 7941024
OA No
DA 2017-08-15
ER

PT J
AU GUPTA, S
   HILL, AVS
   KWIATKOWSKI, D
   GREENWOOD, AM
   GREENWOOD, BM
   DAY, KP
AF GUPTA, S
   HILL, AVS
   KWIATKOWSKI, D
   GREENWOOD, AM
   GREENWOOD, BM
   DAY, KP
TI PARASITE VIRULENCE AND DISEASE PATTERNS IN PLASMODIUM-FALCIPARUM MALARIA
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID TREATED BED NETS; GAMBIAN CHILDREN; INFECTED ERYTHROCYTES;
   SEQUESTRATION; COEVOLUTION; POPULATION; PROTECTION; ANTIGENS; INVITRO;
   CELLS
AB Heterogeneity in parasite virulence is one of several factors that have been proposed to contribute to the wide spectrum of disease severity in Plasmodium falciparum malaria. We use observed age-structured patterns of disease to define a population structure of P. falciparum, where the latter contains several independently transmitted antigenic types or ''strains'' that each induce some degree of strain-specific antidisease immunity upon infection. Patterns of incidence of severe and mild disease may be explained by assuming that a majority of these strains are associated with mild disease and that although severe malarial anemia is a complication occurring in a certain proportion of early infections with ''mild'' parasites, cerebral malaria is caused by a few distinct highly virulent strains. Considerable variation in parasite virulence, as a major factor of disease severity in malaria, is made possible by the absence of competition between the various parasite strains, arising from weak shared immune responses. The theoretical framework Presented in this paper can explain other epidemiological observations, such as the results of interventions with insecticide-impregnated bednets.
C1 UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
   UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,LONDON SW7 2BB,ENGLAND.
RP GUPTA, S (reprint author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.
RI HILL, Adrian/C-1306-2008; Day, Karen/F-3697-2015
OI Day, Karen/0000-0002-6115-6135
FU Wellcome Trust
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ANDERSON RM, 1982, PARASITOLOGY, V85, P411
   Anderson RM, 1991, INFECTIOUS DISEASES
   Aron J.L., 1982, P139
   BERENDT AR, 1990, PARASITOL TODAY, V6, P247, DOI 10.1016/0169-4758(90)90184-6
   BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   Carter R, 1979, Bull World Health Organ, V57 Suppl 1, P37
   Carter R., 1988, MALARIA PRINCIPLES P, P253
   CATTANI JA, 1986, AM J TROP MED HYG, V35, P3
   COVELL G, 1951, BRIT MED BULL, V8, P51
   Cox F.E.G., 1988, P1503
   DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292
   DAY KP, 1990, PARASITOL TODAY, V6, P68
   ERUNKULU OA, 1992, CLIN EXP IMMUNOL, V89, P296
   GAMAGEMENDIS AC, 1992, PARASITE IMMUNOL, V14, P385, DOI 10.1111/j.1365-3024.1992.tb00013.x
   Garnham PCC, 1966, MALARIA PARASITES OT
   GREENWOOD BM, 1991, PARASITOL TODAY, V8, P239
   GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293
   GUPTA S, 1992, THESIS U LONDON
   GUPTA S, 1994, MODELS INFECTIOUS HU
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HOWARD RJ, 1988, PROG ALLERGY, V41, P98
   James S P, 1932, Proc R Soc Med, V25, P1153
   KWIATKOWSKI D, 1989, J EXP MED, V169, P357, DOI 10.1084/jem.169.1.357
   LEVIN SA, 1981, AM NAT, V117, P300
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   MARSH K, 1988, EXP PARASITOL, V65, P202, DOI 10.1016/0014-4894(88)90123-3
   MASAKE RA, 1987, PARASITOLOGY, V94, P349
   MAY RM, 1990, PARASITOLOGY, V100, pS89
   MCGREGOR IA, 1965, T ROY SOC TROP MED H, V59, P145, DOI 10.1016/0035-9203(65)90075-1
   NAOTUNNE TD, 1993, IMMUNOLOGY, V78, P555
   NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T
   OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163
   ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0
   ROOTH I, 1992, T ROY SOC TROP MED H, V86, P479, DOI 10.1016/0035-9203(92)90076-O
   SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
NR 39
TC 118
Z9 120
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 26
PY 1994
VL 91
IS 9
BP 3715
EP 3719
DI 10.1073/pnas.91.9.3715
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NJ034
UT WOS:A1994NJ03400051
PM 8170975
OA No
DA 2017-08-15
ER

PT J
AU JAKOBSEN, PH
   MORRISJONES, S
   THEANDER, TG
   HVIID, L
   HANSEN, MB
   BENDTZEN, K
   RIDLEY, RG
   GREENWOOD, BM
AF JAKOBSEN, PH
   MORRISJONES, S
   THEANDER, TG
   HVIID, L
   HANSEN, MB
   BENDTZEN, K
   RIDLEY, RG
   GREENWOOD, BM
TI INCREASED PLASMA-LEVELS OF SOLUBLE IL-2R ARE ASSOCIATED WITH SEVERE
   PLASMODIUM-FALCIPARUM MALARIA
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE MALARIA; SOLUBLE IL-2 RECEPTOR; CYTOKINES
ID TUMOR-NECROSIS-FACTOR; PURIFIED HUMAN INTERLEUKIN-2; MURINE CEREBRAL
   MALARIA; T-CELL CLONES; MEROZOITE PROTEINS; INTERFERON-GAMMA;
   IMMUNE-RESPONSE; LYMPHOCYTES-T; PROTECTION; ANTIGENS
AB Plasma samples from children with mild and severe Plasmodium falciparum malaria and from children with unrelated diseases were collected to investigate whether the clinical outcome of infection was associated with plasma factors which reflected the activity of different cells of the immune system. Children with severe P. falciparum malaria had significantly higher plasma levels of soluble IL-2R than children with mild malaria. Plasma levels of IL-2R and levels of parasitaemia were significantly correlated. Neither parasitaemia nor plasma levels of tumour necrosis factor-alpha (TNF-alpha), IL-6, lymphotoxin (LT), interferon-gamma (IFN-gamma), IL-4, soluble IL-4R or soluble CD8 differed significantly between the two groups of children with malaria. High plasma levels of soluble CD8 were associated with failure of lymphocytes to produce IFN-2R in vitro following stimulation with P. falciparum antigen. We conclude that soluble IL-2R is a useful marker of disease severity independently of the association with levels of parasitaemia, and that functional regulation of different lymphocyte subsets occurs during acute malaria episodes.
C1 UNIV COPENHAGEN,RIGSHOSP,DEPT INFECT DIS,CTR MED PARASITOL,DK-2200 COPENHAGEN,DENMARK.
   UNIV COPENHAGEN,INST MED MICROBIOL & IMMUNOL,DK-1168 COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   UNIV COPENHAGEN,RIGSHOSP,MED IMMUNOL LAB,DK-2200 COPENHAGEN,DENMARK.
   UNIV EDINBURGH,INST CELL & MOLEC BIOL,DIV BIOL SCI,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.
RI Theander, Thor/F-6714-2015
OI Theander, Thor/0000-0002-3509-7514; Hviid, Lars/0000-0002-1698-4927
CR ABUZEID YA, 1992, CLIN EXP IMMUNOL, V88, P112
   BLOOM BR, 1992, IMMUNOL TODAY, V13, P131, DOI 10.1016/0167-5699(92)90110-S
   BRAKE DA, 1988, J IMMUNOL, V140, P1989
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   CHIZZOLINI C, 1990, CLIN EXP IMMUNOL, V79, P95
   CLARK IA, 1992, T ROY SOC TROP MED H, V86, P602, DOI 10.1016/0035-9203(92)90144-2
   DELORON P, 1989, J CLIN MICROBIOL, V27, P1887
   FERRANTE A, 1990, INFECT IMMUN, V58, P3996
   GRAU GE, 1986, J IMMUNOL, V137, P2348
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572
   GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918
   HANSEN MB, 1991, IMMUNOL LETT, V30, P133, DOI 10.1016/0165-2478(91)90102-G
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HVIID L, 1991, FEMS MICROBIOL IMMUN, V76, P219, DOI 10.1111/j.1574-6968.1991.tb04218.x
   JAKOBSEN PH, 1993, INFECT IMMUN, V61, P268
   JAKOBSEN PH, 1991, T ROY SOC TROP MED H, V85, P26, DOI 10.1016/0035-9203(91)90141-K
   JAKOBSEN PH, 1993, PARASITE IMMUNOL, V15, P229, DOI 10.1111/j.1365-3024.1993.tb00605.x
   KEMP M, 1992, INFECT IMMUN, V60, P2246
   KREMSNER PG, 1989, J INFECT DIS, V160, P357
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   LELCHUK R, 1985, IMMUNOLOGY, V56, P113
   LOTZE MT, 1987, CANCER RES, V47, P2188
   LOTZE MT, 1985, J IMMUNOL, V134, P157
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   MSHANA RN, 1990, INT IMMUNOL, V2, P1121, DOI 10.1093/intimm/2.12.1121
   NGUYENDINH P, 1988, J INFECT DIS, V158, P1403
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1989, INFECT IMMUN, V57, P1281
   RILEY EM, 1991, EUR J IMMUNOL, V21, P1019, DOI 10.1002/eji.1830210424
   RILEY EM, 1993, CLIN EXP IMMUNOL, V91, P495
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P122
   TAYLORROBINSON AW, 1992, IMMUNOLOGY, V77, P99
   TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366
   Theander Thor G., 1993, Immunology and Infectious Diseases (Oxford), V3, P97
   Warrell DA, 1990, T R SOC TROP MED S2, V84, P1
NR 38
TC 32
Z9 32
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 1994
VL 96
IS 1
BP 98
EP 103
PG 6
WC Immunology
SC Immunology
GA ND728
UT WOS:A1994ND72800018
PM 8149674
OA No
DA 2017-08-15
ER

PT J
AU DEFRANCISCO, A
   SCHELLENBERG, JA
   HALL, AJ
   GREENWOOD, AM
   CHAM, K
   GREENWOOD, BM
AF DEFRANCISCO, A
   SCHELLENBERG, JA
   HALL, AJ
   GREENWOOD, AM
   CHAM, K
   GREENWOOD, BM
TI COMPARISON OF MORTALITY BETWEEN VILLAGES WITH AND WITHOUT PRIMARY
   HEALTH-CARE WORKERS IN UPPER RIVER DIVISION, THE GAMBIA
SO JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE PHC; HEALTH SERVICES; HEALTH SERVICES UTILIZATION; TRADITIONAL HEALERS;
   VILLAGE HEALTH WORKERS; MORTALITY
ID CARE PROGRAM; COMMUNITY; CHILDREN; WORKERS; IMPACT
AB Health services utilization was analysed in a rural area of The Gambia. In general, health workers were consulted frequently. However, verbal autopsies showed that children who died had rarely consulted health workers, particularly if they came from villages where such workers were not posted. Traditional healers were consulted frequently, independently of the presence of a village health worker. The relationship between cause specific mortality and the utilization of health services is discussed. Childhood mortality was similar in villages with or without a primary health care worker at the time of the study.
C1 MRC,BANJUL,GAMBIA.
   UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON,ENGLAND.
   UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON,ENGLAND.
   MED & HLTH DEPT,BANJUL,GAMBIA.
RI Sandall, Jane/D-4146-2009
OI Sandall, Jane/0000-0003-2000-743X
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345
   DEFRANCISCO A, 1991, METHODS FIELD TRIALS, P169
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   MACCORMACK CP, 1983, TROP DOCT, V13, P51
   MAHLER W, 1975, WHO CHRON, V29, P457
   MENON A, 1991, J TROP MED HYG, V94, P268
   RIFKIN SB, 1978, LANCET, V1, P34
   ROXEROBIXBY L, 1986, STUD FAMILY PLANN, V17, P57
   SANDIFORD P, 1991, AM J PUBLIC HEALTH, V81, P30, DOI 10.2105/AJPH.81.1.30
   VANNORREN B, 1989, SOC SCI MED, V28, P1091, DOI 10.1016/0277-9536(89)90393-6
   VAUGHAN JP, 1980, J TROP MED HYG, V83, P3
   VAUGHAN JP, 1983, TROP DOCT, V13, P105
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   WALKER G, 1982, TROP DOCT, V12, P194
   WALT G, 1982, TROP DOCT, V12, P145
   1978, PRIMARY HLTH CARE JO
   1981, PHC INTRACOUNTRY WOR
   1989, E REGION DIVISIONAL
   1983, POPULATION HOUSING C
NR 21
TC 16
Z9 18
U1 1
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0022-5304
J9 J TROP MED HYG
JI J. Trop. Med. Hyg.
PD APR
PY 1994
VL 97
IS 2
BP 69
EP 74
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NF895
UT WOS:A1994NF89500002
PM 8170005
OA No
DA 2017-08-15
ER

PT J
AU AIKINS, MK
   PICKERING, H
   GREENWOOD, BM
AF AIKINS, MK
   PICKERING, H
   GREENWOOD, BM
TI ATTITUDES TO MALARIA, TRADITIONAL PRACTICES AND BEDNETS (MOSQUITO NETS)
   AS VECTOR CONTROL MEASURES - A COMPARATIVE-STUDY IN 5 WEST-AFRICAN
   COUNTRIES
SO JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE MALARIA; BEDNETS; WEST AFRICA
ID BED-NETS; RURAL AREA; MORTALITY; MORBIDITY; CHILDREN; GAMBIA
AB Five West African communities were visited to assess the knowledge of the cause of malaria and to document traditional ways of treating and preventing the infection. Knowledge of the cause of malaria was low in the five communities visited. People were more concerned about mosquitoes being a nuisance than a cause of the infection. Various herbs were used as mosquito repellents, Malaria was treated by a number of traditional practices, including herbal remedies. Bednets were used to a varying extent, from 44% Ghana to 86% Gambia, in each community to protect against mosquito bites but also for other purposes such as privacy, decoration and protection from roof debris dropping on the bed.
C1 MRC,BANJUL,GAMBIA.
CR AIKINS MK, 1991, T ROYAL SOC TROPI S2, V87, P25
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   BARNISH G, 1992, MED PLANT RECIPES ME
   BRADLEY AK, 1986, LANCET, V2, P204
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   HUDGENS J, 1990, W AFRICA ROUGH GUIDE
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   1991, 1991 LOND SCH HYG TR, P9
   [Anonymous], 1992, DEV ENV
NR 9
TC 58
Z9 62
U1 1
U2 9
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0022-5304
J9 J TROP MED HYG
JI J. Trop. Med. Hyg.
PD APR
PY 1994
VL 97
IS 2
BP 81
EP 86
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NF895
UT WOS:A1994NF89500004
PM 8170007
OA No
DA 2017-08-15
ER

PT J
AU ADEGBOLA, RA
   DEMBA, E
   DEVEER, G
   TODD, J
AF ADEGBOLA, RA
   DEMBA, E
   DEVEER, G
   TODD, J
TI CRYPTOSPORIDIUM INFECTION IN GAMBIAN CHILDREN LESS-THAN 5 YEARS OF AGE
SO JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE CRYPTOSPORIDIUM; INFECTION; GAMBIAN CHILDREN
ID GUINEA-BISSAU; PROTOZOAN
AB Cryptosporidium infection was studied in Gambian children less than 5 years of age over a 12-month period. Children who presented with diarrhoea at the Medical Research Council (MRC) clinic were selected randomly for detection of Cryptosporidium. They were compared with control children who presented with reasons other than diarrhoea. Cross-sectional surveys were conducted also to assess the community prevalence of Cryptosporidium. Cryptosporidium was found in 53 (9%) of 600 children with diarrhoea. In contrast Cryptosporidium was found in only 17 (3%) of 600 control children (X(2)=18.6, 1 df, P<0.001). All 53 children with Cryptosporidium and diarrhoea were less than 2 years of age. In the community surveys, 11 (4%) of 250 children were Cryptosporidium positive. Cryptosporidium infection showed a well defined seasonal peak in association with the rains and a high relative humidity.
RP ADEGBOLA, RA (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR ADDY PAK, 1986, LANCET, V1, P734
   CANNING EU, 1990, T ROY SOC TROP MED H, V84, P19, DOI 10.1016/0035-9203(90)90451-J
   CARSTENSEN H, 1987, T ROY SOC TROP MED H, V81, P860, DOI 10.1016/0035-9203(87)90054-X
   CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325
   FAYER R, 1986, MICROBIOL REV, V50, P458
   GOH SGJ, 1985, J DIARRHOEAL DISEASE, V3, P7
   HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109
   JANOFF EN, 1987, J CLIN MICROBIOL, V25, P967
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   MATA L, 1984, AM J TROP MED HYG, V33, P24
   MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566
   PICKERING H, 1987, T ROY SOC TROP MED H, V81, P853, DOI 10.1016/0035-9203(87)90052-6
   REINTHALER FF, 1987, TROP MED PARASITOL, V38, P51
   ROWLAND M G M, 1985, Annals of Tropical Paediatrics, V5, P23
   ROWLAND MGM, 1977, T ROY SOC TROP MED H, V71, P199, DOI 10.1016/0035-9203(77)90006-2
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
NR 16
TC 26
Z9 28
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0022-5304
J9 J TROP MED HYG
JI J. Trop. Med. Hyg.
PD APR
PY 1994
VL 97
IS 2
BP 103
EP 107
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NF895
UT WOS:A1994NF89500008
PM 8169999
OA No
DA 2017-08-15
ER

PT J
AU SUARA, RO
   MULHOLLAND, KE
   GLEZEN, WP
   NJIE, J
   SIBER, GR
   ANWARUDDIN, R
   THOMPSON, C
   DIANAN, L
   ROBERTON, D
   GREENWOOD, BM
AF SUARA, RO
   MULHOLLAND, KE
   GLEZEN, WP
   NJIE, J
   SIBER, GR
   ANWARUDDIN, R
   THOMPSON, C
   DIANAN, L
   ROBERTON, D
   GREENWOOD, BM
TI MATERNAL IMMUNIZATION WITH HAEMOPHILUS-INFLUENZAE TYPE-B PRP-T CONJUGATE
   VACCINE IN THE GAMBIA, WEST-AFRICA
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 BAYLOR COLL MED,HOUSTON,TX 77030.
   HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115.
   ADELAIDE CHILDRENS HOSP INC,ADELAIDE,SA 5006,AUSTRALIA.
   MRC LABS,BANTUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 1994
VL 35
IS 4
BP A122
EP A122
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA NG779
UT WOS:A1994NG77900718
OA No
DA 2017-08-15
ER

PT J
AU MAYANS, MV
   HALL, AJ
   INSKIP, HM
   LINDSAY, SW
   CHOTARD, J
   MENDY, M
   WHITTLE, HC
AF MAYANS, MV
   HALL, AJ
   INSKIP, HM
   LINDSAY, SW
   CHOTARD, J
   MENDY, M
   WHITTLE, HC
TI DO BEDBUGS TRANSMIT HEPATITIS-B
SO LANCET
LA English
DT Article
ID ANTIGEN
AB An intervention study was done over two years in seven Gambian villages to determine the contribution of bedbugs to hepatitis B transmission. In addition, fortnightly questionnaires were completed for each child to assess other possible routes of transmission. The intervention, insecticide spraying of the child's dwelling, was highly effective in reducing exposure to bedbugs but there was no effect on hepatitis B infection. No other risk factor for transmission was identified despite a consistent village-to-village variation in the rate of childhood infection. The major mode of transmission of hepatitis B in childhood remains unknown.
C1 LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
   WHO,INT AGCY RES CANC,BANJUL,GAMBIA.
OI Inskip, Hazel/0000-0001-8897-1749
CR Barin F, 1981, Prog Med Virol, V27, P148
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   JUPP PG, 1979, S AFR MED J, V56, P54
   MAYANS MV, 1990, LANCET, V336, P1107
   NEWKIRK MM, 1975, GASTROENTEROLOGY, V69, P982
   OGSTON CW, 1979, J INFECT DIS, V40, P411
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
NR 7
TC 26
Z9 26
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR 26
PY 1994
VL 343
IS 8900
BP 761
EP 763
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC351
UT WOS:A1994NC35100010
OA No
DA 2017-08-15
ER

PT J
AU MULHOLLAND, EK
   HOESTERMANN, A
   SUARA, RO
   ADEGBOLA, RA
   SIBER, G
   THOMPSON, C
   GREENWOOD, BM
AF MULHOLLAND, EK
   HOESTERMANN, A
   SUARA, RO
   ADEGBOLA, RA
   SIBER, G
   THOMPSON, C
   GREENWOOD, BM
TI HAEMOPHILUS-INFLUENZAE TYPE-B MENINGITIS AFTER 3 DOSES OF VACCINE
SO LANCET
LA English
DT Letter
ID HEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE; ANTIBODY-RESPONSE; INFANTS
RP MULHOLLAND, EK (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0
   DAUM RS, 1991, J INFECT DIS, V164, P1154
   FRITZELL B, 1992, J PEDIATR-US, V121, P355, DOI 10.1016/S0022-3476(05)81786-X
   OREILLY RJ, 1975, J CLIN INVEST, V56, P1012, DOI 10.1172/JCI108148
NR 4
TC 3
Z9 3
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR 26
PY 1994
VL 343
IS 8900
BP 794
EP 794
DI 10.1016/S0140-6736(94)91870-8
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC351
UT WOS:A1994NC35100044
PM 7907751
OA No
DA 2017-08-15
ER

PT J
AU GREENWOOD, AM
   DALESSANDRO, U
   SISAY, F
   GREENWOOD, BM
AF GREENWOOD, AM
   DALESSANDRO, U
   SISAY, F
   GREENWOOD, BM
TI TREPONEMAL INFECTION AND PREGNANCY OUTCOME IN WEST-AFRICA - REPLY
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
RP GREENWOOD, AM (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
CR MEHEUS A, 1994, J INFECT DIS, V169, P701
NR 1
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1994
VL 169
IS 3
BP 702
EP 702
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NP109
UT WOS:A1994NP10900047
OA No
DA 2017-08-15
ER

PT J
AU DEMING, M
   JAITEH, KO
   OTTEN, MW
AF DEMING, M
   JAITEH, KO
   OTTEN, MW
TI EPIDEMIC POLIOMYELITIS IN THE GAMBIA FOLLOWING THE CONTROL OF
   POLIOMYELITIS AS AN ENDEMIC DISEASE .2. CLINICAL EFFICACY OF TRIVALENT
   POLIO VACCINE - REPLY
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Letter
C1 MINIST HLTH & SOCIAL WELFARE,DEPT MED & HLTH SERV,EPIDEMIOL & STAT UNIT,BANJUL,GAMBIA.
   CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,ATLANTA,GA.
RP DEMING, M (reprint author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,ATLANTA,GA 30333, USA.
CR ARYA SC, 1994, AM J EPIDEMIOL, V139, P449
   DEMING MS, 1992, AM J EPIDEMIOL, V135, P393
   MAGRATH DI, 1976, P S STABILITY EFFECT, P35
   Mauler R, 1978, Dev Biol Stand, V41, P267
   Mirchamsy H, 1978, Dev Biol Stand, V41, P255
   PEETERMANS J, 1976, P S STABILITY EFFECT, P61
   WALLIS C, 1961, TEX REP BIOL MED, V19, P683
   1989, WHO EPIGEN898 PUBL, P29
NR 8
TC 0
Z9 0
U1 0
U2 0
PU JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH
PI BALTIMORE
PA 111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD FEB 15
PY 1994
VL 139
IS 4
BP 450
EP 451
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MY894
UT WOS:A1994MY89400017
OA No
DA 2017-08-15
ER

PT J
AU RILEY, EM
   BENNETT, S
   JEPSON, A
   HASSANKING, M
   WHITTLE, H
   OLERUP, O
   CARTER, R
AF RILEY, EM
   BENNETT, S
   JEPSON, A
   HASSANKING, M
   WHITTLE, H
   OLERUP, O
   CARTER, R
TI HUMAN-ANTIBODY RESPONSES TO PFS-230, A SEXUAL STAGE-SPECIFIC
   SURFACE-ANTIGEN OF PLASMODIUM-FALCIPARUM - NONRESPONSIVENESS IS A STABLE
   PHENOTYPE BUT DOES NOT APPEAR TO BE GENETICALLY REGULATED
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE MALARIA; GAMETES; ANTIBODIES; TRANSMISSION BLOCKING; PLASMODIUM
   FALCIPARUM
ID TRANSMISSION-BLOCKING ANTIBODIES; IMMUNE-RESPONSES; TARGET ANTIGENS;
   HLA-DR; MALARIA; RESTRICTION; GALLINACEUM; MOSQUITO; PROTEIN; MHC
AB The 230 kD gamete surface protein of the malaria parasite Plasmodium falciparum (Pfs 230) is a target of transmission blocking antibodies. Anti-Pfs 230 antibodies are induced following natural infection with malaria but are plot found in all P. falciparum-exposed individuals. In this study we have shown that approximately 40% of malaria-exposed Gambians do not make antibodies to the native Pfs 230 molecule. This phenotype is remarkably stable over time and does not appear to be related to age, malaria exposure or major histocompatibility complex genotype. Comparison of antibody responses in twins indicates that the anti-Pfs 230 response is not strictly genetically controlled, but a high degree of concordance within both dizygous and monozygous twin pairs suggests that factors associated with exposure to malaria in childhood may be important in determining the subsequent immune response.
C1 MRC LABS,FAJARA,GAMBIA.
   LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.
   NOVUM,KAROLINSKA INST,CTR BIOTECHNOL,S-14152 HUDDINGE,SWEDEN.
RP RILEY, EM (reprint author), UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,DIV BIOL SCI,ASHWORTH LABS,W MAINS RD,EDINBURGH EH9 3JT,SCOTLAND.
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU Wellcome Trust
CR CARLSSON B, 1987, HUM IMMUNOL, V20, P95, DOI 10.1016/0198-8859(87)90025-5
   CARTER R, 1989, EXP PARASITOL, V69, P140, DOI 10.1016/0014-4894(89)90182-3
   CARTER R, 1989, J EXP MED, V169, P135, DOI 10.1084/jem.169.1.135
   FOO A, 1991, AM J TROP MED HYG, V44, P623
   GRAVES PM, 1988, PARASITE IMMUNOL, V10, P209, DOI 10.1111/j.1365-3024.1988.tb00215.x
   GRAVES PM, 1985, INFECT IMMUN, V48, P611
   HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x
   NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0
   OLERUP O, 1991, P NATL ACAD SCI USA, V88, P8480, DOI 10.1073/pnas.88.19.8480
   PREMAWANSA S, 1993, PARASITE IMMUNOL, V16, P35
   QUAKYI IA, 1987, J IMMUNOL, V139, P4213
   RENER J, 1983, J EXP MED, V158, P976, DOI 10.1084/jem.158.3.976
   RILEY EM, 1992, INT IMMUNOL, V4, P1055, DOI 10.1093/intimm/4.9.1055
   RILEY EM, 1990, J IMMUNOL, V144, P4810
   VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460
   WANG Z, 1987, ANN HUM GENET, V51, P269
   WIZEL B, 1991, P NATL ACAD SCI USA, V88, P9533, DOI 10.1073/pnas.88.21.9533
NR 17
TC 27
Z9 27
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD FEB
PY 1994
VL 16
IS 2
BP 55
EP 62
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA MX316
UT WOS:A1994MX31600001
PM 8015855
OA No
DA 2017-08-15
ER

PT J
AU LISSE, IM
   AABY, P
   KNUDSEN, K
   WHITTLE, H
   ANDERSEN, H
AF LISSE, IM
   AABY, P
   KNUDSEN, K
   WHITTLE, H
   ANDERSEN, H
TI LONG-TERM IMPACT OF HIGH-TITER EDMONSTON-ZAGREB MEASLES-VACCINE ON
   T-LYMPHOCYTE SUBSETS
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE EDMONSTON-ZAGREB; HIGH-TITER MEASLES VACCINE; MEASLES; MEASLES VACCINE;
   T CELL SUBSETS
ID MORTALITY
AB Several trials of high titer measles vaccine (>10(4.7) plaque-forming unit) have found female recipients of Edmonston-Zagreb (EZ) vaccine to have lower survival than female recipients of standard measles vaccine. Two trials with medium and high titer EZ vaccine from the age of 4 months were conducted in Guinea-Bissau. To test for possible long term impact on the immune system, an investigation of T cell subsets was conducted among all children still residing in the community at 3 to 5 years of age. No differences were found between recipients of medium titer vaccine and controls. In the second trial, however, recipients of high titer had lower CD4:CD8 ratios than controls and had significantly higher CD8 percentages and lower CD4:CD8 ratios than recipients of medium titer EZ. When analyzed by sex, differences were found only among the girls. However, these differences were small and seemed unlikely to explain the reduced survival which has been associated with high titer EZ measles vaccination. In the 2 years after the investigation of T cell subsets, there was no increased mortality for recipients of EZ vaccine. Hence it is unlikely that high titer vaccine has an persistent adverse effect on survival after 3 years of age.
C1 STATENS SERUMINST,EPIDEMIOL RES UNIT,COPENHAGEN,DENMARK.
   MRC LABS,FAJARA,GAMBIA.
   DANCHURCHAID,BISSAU,GUINEA BISSAU.
RP LISSE, IM (reprint author), HVIDOVRE UNIV HOSP,DEPT PATHOL,DK-2650 HVIDOVRE,DENMARK.
CR AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1988, LANCET, V2, P809
   AABY P, 1991, MED VIROL, V10, P83
   AABY P, 1993, J PEDIATR-US, V122, P904
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   GRIFFIN DE, 1991, REV INFECT DIS S1, V13, P29
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   LEON ME, 1993, J INFECT DIS, V168, P1097
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   1992, WEEKLY EPIDEMIOL REC, V67, P357
NR 14
TC 21
Z9 21
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 1994
VL 13
IS 2
BP 109
EP 112
DI 10.1097/00006454-199402000-00006
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA MW838
UT WOS:A1994MW83800006
PM 8190534
OA No
DA 2017-08-15
ER

PT J
AU ODEMPSEY, TJD
   MCARDLE, TF
   LLOYDEVANS, N
   BALDEH, I
   LAURENCE, BE
   SECKA, O
   GREENWOOD, BM
AF ODEMPSEY, TJD
   MCARDLE, TF
   LLOYDEVANS, N
   BALDEH, I
   LAURENCE, BE
   SECKA, O
   GREENWOOD, BM
TI IMPORTANCE OF ENTERIC BACTERIA AS A CAUSE OF PNEUMONIA, MENINGITIS AND
   SEPTICEMIA AMONG CHILDREN IN A RURAL-COMMUNITY IN THE GAMBIA,
   WEST-AFRICA
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE PNEUMONIA; MENINGITIS; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE;
   PNEUMOCOCCUS; SALMONELLA; HAEMOPHILUS INFLUENZA TYPE B
ID MALARIA; COTRIMOXAZOLE; ETIOLOGY
AB Two thousand eight hundred ninety-eight children younger than 5 years old were investigated during a 2-year period in a rural area of The Gambia for possible pneumonia, meningitis or septicemia. After clinical examination and appropriate investigations, 1014 children were diagnosed as having pneumonia, 31 as having meningitis and 100 as having septicemia. Nine hundred seven children had a final diagnosis of malaria including 702 who satisfied the World Health Organization criteria for a diagnosis of pneumonia. A bacterial etiology was established in 115 (11%) patients with a final diagnosis of pneumonia, in 25 (81%) with meningitis and in 29 (29%) with suspected septicemia. Overall the pneumococcus was the leading pathogen identified among children with pneumonia and meningitis and ranked third among those with septicemia. However, during the wet season, when malaria transmission was highest, 50% of blood culture isolates obtained from children satisfying the World Health Organization criteria for a diagnosis of pneumonia were Salmonella or coliform species, and the pneumococcus and Haemophilus influenzae type b accounted for only 43% of isolates. Thus enteric bacteria may be as important as those bacteria more usually associated with respiratory disease among children presenting with a clinical picture of pneumonia during the wet season. This finding has important implications for case management and surveillance for antibiotic resistance.
C1 MRC LABS,BANJUL,GAMBIA.
   GAMBIA GOVT,MRC UNIT,BANJUL,GAMBIA.
CR BERKOWITZ FE, 1984, AM J DIS CHILD, V138, P551
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   BISNO A L, 1968, West Indian Medical Journal, V17, P215
   BLASER MJ, 1982, AM J EPIDEMIOL, V116, P266
   BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A
   BOCKEMUHL J, 1976, TROPENMED PARASITOL, V27, P112
   BROWN KM, 1982, INFECT IMMUN, V37, P1227
   DARAMOLA OO, 1991, T ROY SOC TROP MED H, V85, P345, DOI 10.1016/0035-9203(91)90285-7
   DUGGAN MB, 1975, ARCH DIS CHILD, V50, P67
   FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009
   GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45
   GREENWOOD BM, 1984, REV INFECT DIS, V6, P374
   GREENWOOD BM, 1974, CLIN EXP IMMUNOL, V18, P267
   GREENWOOD BM, 1978, T ROY SOC TROP MED H, V72, P378, DOI 10.1016/0035-9203(78)90131-1
   Haddock R L, 1986, J Diarrhoeal Dis Res, V4, P229
   HAND WL, 1977, CLIN EXP IMMUNOL, V30, P262
   KAYE D, 1963, J IMMUNOL, V91, P65
   MABEY D, 1987, J INFECT DIS, V6, P1319
   NESBITT A, 1989, J TROP PEDIATRICS, V35, P35
   ODEMPSEY TJD, IN PRESS T R SOC TRO
   REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O
   SHEAR HL, 1984, INFECT IMMUN, V44, P130
   SRICHAIKUL T, 1969, ARCH INTERN MED, V124, P623, DOI 10.1001/archinte.124.5.623
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   1992, WHOARI9223
   1990, WHOARI905
   1991, WHOARI9120
NR 27
TC 75
Z9 75
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 1994
VL 13
IS 2
BP 122
EP 128
DI 10.1097/00006454-199402000-00009
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA MW838
UT WOS:A1994MW83800009
PM 8190537
OA No
DA 2017-08-15
ER

PT J
AU BARTHOLOMEW, PW
   KHIBE, T
   LITTLE, DA
AF BARTHOLOMEW, PW
   KHIBE, T
   LITTLE, DA
TI EFFECT OF LIVEWEIGHT AND BODY CONDITION ON WORK OUTPUT FROM DRAFT OXEN
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
AB A trial was carried out to assess the effect of liveweight and body condition on working capacity of zebu oxen. Over a working period of 9 days, animals which started work with a mean liveweight of 360 kg and body condition score of M+ produced the highest daily work output (3.43 MJ). At an initial liveweight of 360 kg, body condition had relatively little effect on work output, and animals of condition score M- produced a daily work output of 3.19 MJ. In contrast, at a mean live-weight of 310 kg al the start of work, mean daily work output of animals of condition score M+ was significantly lower than that of animals in poorer condition (M-), at 0.81 compared with 2.50 MJ work output per day.
   It was concluded that body weight as indicated by body size is probably a more useful indicator of likely capacity for work than body condition under the short-season working conditions typical for oxen in the semi-arid zone of central Mali.
C1 INT LIVESTOCK CTR AFRICA,BAMAKO,MALI.
   INST NATL RECH ZOOTECH FORESTIERE & HYDROBIOL,BAMAKO,MALI.
   INT LIVESTOCK CTR AFRICA,BANJUL,GAMBIA.
CR BARTHOLOMEW PW, 1993, TROP ANIM HEALTH PRO, V25, P50, DOI 10.1007/BF02236886
   BARWELL I, 1982, HARNESSING DRAUGHT A
   DELGADO CL, 1982, AM J AGR ECON, V64, P188, DOI 10.2307/1241122
   GOE MR, 1983, WORLD ANIM REV, V45, P2
   KHIBE T, 1990, 1990 W AFR AN TRACT
   LITTLE DA, 1981, J AGR SCI, V96, P213
   Nicholson MJ, 1986, GUIDE CONDITION SCOR
   SMITH AJ, 1981, WORLD ANIM REV, V40, P43
   WILSON RT, 1986, ILCA14 RES REP
NR 9
TC 8
Z9 9
U1 0
U2 0
PU EDINBURGH UNIV PRESS
PI EDINBURGH
PA TRADE DEPT, 22 GEORGE SQUARE, EDINBURGH, MIDLOTHIAN, SCOTLAND EH8 9LF
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD FEB
PY 1994
VL 26
IS 1
BP 58
EP 64
DI 10.1007/BF02241135
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA NG661
UT WOS:A1994NG66100009
PM 8009651
OA No
DA 2017-08-15
ER

PT J
AU OSAER, S
   GOOSSENS, B
   CLIFFORD, DJ
   KORA, S
   KASSAMA, M
AF OSAER, S
   GOOSSENS, B
   CLIFFORD, DJ
   KORA, S
   KASSAMA, M
TI A COMPARISON OF THE SUSCEPTIBILITY OF DJALLONKE SHEEP AND WEST-AFRICAN
   DWARF GOATS TO EXPERIMENTAL-INFECTION WITH 2 DIFFERENT STRAINS
   OFTRYPANOSOMA-CONGOLENSE
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE TRYPANOSOMA-CONGOLENSE; SHEEP-PROTOZOA; GOAT; PATHOGENICITY-PROTOZOA
ID TRYPANOSOMA-CONGOLENSE; TRYPANOTOLERANCE; DIAGNOSIS; CATTLE; BREEDS
AB Two cloned strains of Trypanosoma congolense, of West and East African origin, were used to infect by intradermal inoculation two groups of young adult female Djallonke sheep and West African Dwarf goats. For a 3 month period post-infection, packed red cell volume (PCV), parasitaemia, body weight and clinical parameters were followed to evaluate their trypanotolerant nature and to control the pathogenicity of the two strains of T. congolense. Although the West African strain of T congolense was more pathogenic than the East African strain, it seemed that the Djallonke sheep and the West African Dwarf goats, despite high levels of parasitaemia and a concomitant drop in PCV, showed a high degree of trypanotolerance, as reflected by zero mortality and an increase in body weight during 12 weeks of observation.
RP OSAER, S (reprint author), INT TRYPANOTOLERANCE CTR,PMB 14,BANJUL,GAMBIA.
CR AGYEMANG R, 1990, B ANIM HLTH PROD AFR, V39, P129
   BUNGENER W, 1976, TROPENMED PARASITOL, V27, P405
   DWINGER RH, 1992, RES VET SCI, V52, P292, DOI 10.1016/0034-5288(92)90027-Y
   DWINGER RH, 1990, ACTA TROP, V47, P23, DOI 10.1016/0001-706X(90)90004-J
   GREENWOOD AC, 1989, REPORT SMALL RUMINAN
   GRIFFIN L, 1979, J COMP PATHOL, V89, P457, DOI 10.1016/0021-9975(79)90037-9
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   HUISMAN THJ, 1963, ADV CLIN CHEM, V6, P231, DOI 10.1016/S0065-2423(08)60240-1
   KAAYA G P, 1977, Bulletin of Animal Health and Production in Africa, V25, P397
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATENDE JM, 1987, TROP MED PARASITOL, V38, P41
   LOSOS GJ, 1972, VET PATHOL S, V9, P10
   MACKENZIE PK, 1973, RES VET SCI, V15, P256
   Mawuena K, 1987, Rev Elev Med Vet Pays Trop, V40, P55
   Mawuena K, 1986, Rev Elev Med Vet Pays Trop, V39, P307
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   MUTAYOBA BM, 1989, VET PARASITOL, V31, P95, DOI 10.1016/0304-4017(89)90024-1
   MWANGI DM, 1990, TROP ANIM HEALTH PRO, V22, P95, DOI 10.1007/BF02239832
   PARIS J, 1982, ACTA TROP, V39, P307
   RYAN B.F., 1985, MINITAB HDB
   SNOW WF, 1979, ACTA TROP, V36, P47
   THIENPONT D, 1979, DIAGNOSE VERMINOSE D
   TOURE SM, 1981, TRYPANOTOLERANCE STU
   WEITZ B, 1963, B WORLD HEALTH ORGAN, V28, P711
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
NR 26
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 1994
VL 51
IS 3-4
BP 191
EP 204
DI 10.1016/0304-4017(94)90156-2
PG 14
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA MX547
UT WOS:A1994MX54700002
PM 8171821
OA No
DA 2017-08-15
ER

PT S
AU BUSIA, NKA
AF BUSIA, NKA
BE McCarthyArnolds, E
   Penna, DR
   Sobrepena, DJC
TI THE STATUS OF HUMAN-RIGHTS IN PRECOLONIAL AFRICA - IMPLICATIONS FOR
   CONTEMPORARY PRACTICES
SO AFRICA, HUMAN RIGHTS, AND THE GLOBAL SYSTEM: THE POLITICAL ECONOMY OF
   HUMAN RIGHTS IN A CHANGING WORLD
SE STUDIES IN HUMAN RIGHTS
LA English
DT Proceedings Paper
CT Conference on Africa and Global Human Rights
CY MAY 07-08, 1992
CL UNIV DENVER, GRAD SCH INT STUDIES, DENVER, CO
SP UNIV DENVER, GRAD SCH INT STUDIES
HO UNIV DENVER, GRAD SCH INT STUDIES
C1 AFRICAN CTR DEMOCRACY & HUMAN RIGHTS STUDIES,BANJUL,GAMBIA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU GREENWOOD PRESS
PI WESTPORT
PA 88 POST RD WEST, P O BOX 5007, WESTPORT, CT 06881
SN 0146-3586
BN 0-313-29007-5
J9 STUD HUM RIGHTS
PY 1994
IS 15
BP 225
EP 250
PG 26
WC Political Science; Social Issues
SC Government & Law; Social Issues
GA BA46L
UT WOS:A1994BA46L00012
OA No
DA 2017-08-15
ER

PT J
AU TODD, JE
   DEFRANCISCO, A
   ODEMPSEY, TJD
   GREENWOOD, BM
AF TODD, JE
   DEFRANCISCO, A
   ODEMPSEY, TJD
   GREENWOOD, BM
TI THE LIMITATIONS OF VERBAL AUTOPSY IN A MALARIA-ENDEMIC REGION
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
AB Verbal autopsies are being used widely to describe the causes of mortality and to assess the effect of interventions against specific diseases in developing countries where many deaths occur at home. A verbal autopsy has been in use in the Upper River Division of The Gambia since 1988. In this paper we present the results of a validation study of this technique. One hundred and forty-one verbal autopsies were reviewed on two occasions by the same three physicians. In 38 (27%) of the cases, the first and subsequent diagnoses differed. In 94 children admitted to Basse Health Centre, the results of verbal autopsies were compared with the diagnoses made by a paediatrician-only 44 (47%) matched. The poor sensitivity and specificity of the verbal autopsy in this study may have been due to the confounding effect of malaria, which can be difficult to distinguish from other causes of death in this community.
C1 MRC LABS,BOX 273,BANJUL,GAMBIA.
NR 0
TC 75
Z9 75
U1 0
U2 2
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PY 1994
VL 14
IS 1
BP 31
EP 36
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA NC301
UT WOS:A1994NC30100006
PM 7516132
OA No
DA 2017-08-15
ER

PT J
AU MULHOLLAND, EK
   BYASS, P
   CAMPBELL, H
   FRITZELL, B
   GREENWOOD, AM
   TODD, J
   GREENWOOD, BM
AF MULHOLLAND, EK
   BYASS, P
   CAMPBELL, H
   FRITZELL, B
   GREENWOOD, AM
   TODD, J
   GREENWOOD, BM
TI THE IMMUNOGENICITY AND SAFETY OF HAEMOPHILUS-INFLUENZAE TYPE-B TETANUS
   TOXOID CONJUGATE VACCINE IN GAMBIAN INFANTS
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
AB In developing countries, Haemophilus influenzae type b is a major cause of meningitis and pneumonia in the lst year of life. The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) were evaluated in two studies of Gambian infants. In the first study, 131 infants were recruited and randomized into three groups to receive PRP-T at 1 and 3 months (group A), PRP-T at 2 and 4 months (group B) or no PRP-T (group C). The liquid form of PRP-T was used. The geometric mean titre (GMT) of anti-PRP antibody 1 month after the second dose was 0.26 mug/ml in group A and 0.41 mug/ml in group B. In the second study, 66 infants were given PRP-T in the lyophilized form at 2, 3 and 4 months of age. The GMT 1 month after the first dose was 0.09 mug/ml, after the second 0.74 mug/ml and after the third 2.32 mug/ml. After the third dose, 72% of children had antibody levels greater than 1.0 mug/ml and 93% greater than 0. 15 mug/ml. No serious side-effects were observed and the rate of adverse reactions was consistent with the concurrent administration of diphtheriatetanus-pertussis (DPT) vaccine.
RP MULHOLLAND, EK (reprint author), MRC LABS,POB 273,BANJUL,GAMBIA.
OI Byass, Peter/0000-0001-5474-4361
NR 0
TC 11
Z9 12
U1 0
U2 0
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0272-4936
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PY 1994
VL 14
IS 3
BP 183
EP 188
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA PH408
UT WOS:A1994PH40800002
PM 7825990
OA No
DA 2017-08-15
ER

PT J
AU AABY, P
   SAMB, B
   SIMONDON, F
   KNUDSEN, K
   SECK, AMC
   BENNETT, J
   MARKOWITZ, L
   RHODES, P
   WHITTLE, H
AF AABY, P
   SAMB, B
   SIMONDON, F
   KNUDSEN, K
   SECK, AMC
   BENNETT, J
   MARKOWITZ, L
   RHODES, P
   WHITTLE, H
TI SEX-SPECIFIC DIFFERENCES IN MORTALITY AFTER HIGH-TITER MEASLES
   IMMUNIZATION IN RURAL SENEGAL
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID EDMONSTON-ZAGREB; CHILD-MORTALITY; VACCINES; TITER; VACCINATION;
   EXPOSURE; URBAN; LIFE; EFFICACY; SCHWARZ
AB Administration of high-titre measles vaccine (Edmonston-Zagreb (EZ) at >10(5) plaque-forming units (PFU) per dose) before the age of 9 months has been recommended in areas with high measles mortality before the routine age of immunization after 9 months. The study compares the long-term survival after high-titre measles immunization at 5 months of age with that following routine immunization with standard-titre vaccine at 10 months of age. At 5 months of age the high-titre group received Edmonston-Zagreb (EZ-HT, 5 months) or Schwarz (SW-HT, 5 months) at titres >10(5) PFU per dose, while the standard-titre group received placebo at 5 months of age and <10(4) PFU per dose of Schwarz vaccine at 10 months (SW-std, 10 months). AN the children were followed up to at least 36 months of age. The mortality ratio (MR) for infants in the EZ-HT, 5 months and SW-HT, 5 months groups was 1.32 (P = 0.089) and 1.45 (P = 0.092), respectively, which did not differ significantly from that of recipients of the SW-std, 10 months. The higher MR among recipients of the high-titre vaccines was due to the significantly lower survival among females compared with the females who received SW-std vaccine (EZ-HT, 5 months MR = 1.76, P = 0.013; SW-HT, 5 months MR = 2.14, P = 0.017). For children aged 5-10 months the high-titre measles vaccine did not increase mortality relative to unvaccinated children who had received placebo.
C1 ORSTOM,DAKAR,SENEGAL.
   STATENS SERUM INST,EPIDEMIOL RES UNIT,COPENHAGEN,DENMARK.
   UNIV COPENHAGEN,STAT RES UNIT,COPENHAGEN,DENMARK.
   UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL.
   TASK FORCE CHILD SURVIVAL & DEV,ATLANTA,GA.
   CTR DIS CONTROL,ATLANTA,GA 30333.
   MRC LABS,BANJUL,GAMBIA.
CR AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8
   AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1990, AM J EPIDEMIOL, V132, P211
   AABY P, 1988, LANCET, V2, P809
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1993, J PEDIATR-US, V122, P904
   AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443
   BECKER C, 1992, POPULATION SANTE NIA
   COX DR, 1972, J R STAT SOC B, V34, P187
   DABIS F, 1988, AM J EPIDEMIOL, V127, P171
   DIAZORTEGA JL, 1992, LANCET, V340, P924, DOI 10.1016/0140-6736(92)93345-N
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GARENNE M, 1990, J INFECT DIS, V161, P1088
   GARENNE M, 1991, LANCET, V338, P1518
   GARENNE M, 1987, RISQUES DECES ASS DI
   GARENNE M, 1991, MEASUREMENTS ANAL MO
   LOENING WEK, 1983, LANCET, V2, P324
   MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788
   TIDJANI O, 1989, LANCET, V2, P1357
   WHITTLE H, 1988, LANCET, V2, P811
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   1991, WEEKLY EPIDEMIOLOGIC, V66, P249
   1990, WEEKLY EPIDEMIOLOGIC, V65, P6
   1992, WEEKLY EPIDEMIOLOGIC, V67, P357
NR 28
TC 54
Z9 54
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1994
VL 72
IS 5
BP 761
EP 770
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PR381
UT WOS:A1994PR38100010
PM 7955026
OA No
DA 2017-08-15
ER

PT B
AU KEITA, S
AF KEITA, S
GP INTEGRATED PEST MANAGEMENT WORKING GRP
TI Integrated pest management in The Gambia
SO IPM IMPLEMENTATION WORKSHOP FOR WEST AFRICA, WORKSHOP PROCEEDINGS
LA English
DT Proceedings Paper
CT Workshop on the IPM Implementation Workshop for West-Africa
CY APR 27-MAY 01, 1992
CL ACCRA, GHANA
SP Integrated Pest Management Working Grp
C1 DEPT AGR RES YUNDUM,YUNDUM,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURAL RESOURCES INSTITUTE
PI KENT
PA PUBLICATIONS & PUBLICITY SECT CENTRAL AVE, CHATHAM MARITIME, KENT,
   ENGLAND ME4 4TB
BN 0-85954-378-1
PY 1994
BP 94
EP 95
PG 2
WC Agricultural Economics & Policy; Agronomy; Entomology
SC Agriculture; Entomology
GA BE10A
UT WOS:A1994BE10A00031
OA No
DA 2017-08-15
ER

PT J
AU RAWLINGS, P
   WACHER, TJ
   SNOW, WF
AF RAWLINGS, P
   WACHER, TJ
   SNOW, WF
TI CATTLE-TSETSE CONTACT IN RELATION TO THE DAILY ACTIVITY PATTERNS OF
   GLOSSINA-MORSITANS SUBMORSITANS IN THE GAMBIA
SO MEDICAL AND VETERINARY ENTOMOLOGY
LA English
DT Article
DE TSETSE; CATTLE; FLIGHT ACTIVITY; GLOSSINA MORSITANS SUBMORSITANS;
   DIPTERA; GLOSSINIDAE; CHALLENGE; TRAPS; ANIMAL BAITS; HUNGER STATUS; THE
   GAMBIA
ID DIPTERA
AB The daily flight activity patterns of one of the main vectors of animal trypanosomiasis in West Africa, Glossina morsitans submorsitans, were assessed using four different methods. Results from all the methods showed that there was some flight activity nearly every hour in all seasons but they differed in the level of contact between grazing cattle herds and G. m. submorsitans. In the late dry season, trap data indicated that there was negligible activity from midday to late afternoon, whereas observations of tsetse contact with cattle herds or hand-net collections on herd followings showed no fall in attack rates on the cattle by G. m. submorsitans.
   Differences between trap and animal-baited collection data may be attributable to the type of G. m. submorsitans sampled by each method. Male G. m. submorsitans captured by traps were more fat depleted than those caught on ox-baited flyrounds or by hand-net collections on herd followings. All methods showed that male G. m. submorsitans were most fat depleted in the late dry season and least in the early dry season. It was concluded that the traps were mainly sampling the spontaneous flights of G. m. submorsitans. Hunger and endogenous rhythms increase the likelihood of spontaneous flights towards dusk, particularly in conditions such as those at midday in the very hot, late dry season. However, the presence of cattle herds in infested habitats probably activated nearby G. m. submorsitans and the continual movement through the grazing areas ensured contact with tsetse throughout grazing.
   The data indicated that strategic management of herd grazing times cannot eliminate the risk of trypanosomiasis transmission occurring, irrespective of the harshness of the dry season climate. An assessment of the level of this risk could only be measured suitably by collecting tsetse using animal-baited methods, not from trap data.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR BRADY J, 1978, PHYSIOL ENTOMOL, V3, P177, DOI 10.1111/j.1365-3032.1978.tb00147.x
   BRADY J, 1972, B ENTOMOL RES, V62, P257
   BRADY J, 1974, B ENTOMOL RES, V63, P441
   BURSELL E., 1961, Proceedings of the Royal Entomological Society of London, V36, P9
   BURSELL E, 1970, AFRICAN TRYPANOSOMIA, P382
   CRUMP AJ, 1979, PHYSIOL ENTOMOL, V4, P311, DOI 10.1111/j.1365-3032.1979.tb00622.x
   DEAN GJW, 1969, J APPL ECOL, V6, P13, DOI 10.2307/2401298
   FLINT S, 1985, B ENTOMOL RES, V75, P529
   FORD J, 1970, AFRICAN TRYPANOSOMIA, P298
   GLASGOW JP, 1970, AFRICAN TRYPANOSOMIA, P395
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   Gruvel J., 1975, Revue Elev Med vet Pays trop, V28, P173
   HARVEY WR, 1977, USERS GUIDE LEAST SQ
   HUYTON PM, 1975, J ENTOMOL SER A, V50, P23
   MILLIGAN PJM, 1988, PARASITOLOGY, V99, P121
   PAGE W. A., 1959, BULL ENT RES, V50, P617
   PILSON RD, 1967, B ENTOMOL RES, V57, P227
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   RAWLINGS P, 1994, IN PRESS B ENTOMOLOG
   SHERENI W, 1984, Transactions of the Zimbabwe Scientific Association, V62, P22
   SNOW WF, 1979, ACTA TROP, V36, P7
   VALE GA, 1974, B ENTOMOL RES, V64, P554
   WACHER TJ, 1988, AFRICAN TRYPANOTOLER, P70
NR 23
TC 5
Z9 5
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0269-283X
J9 MED VET ENTOMOL
JI Med. Vet. Entomol.
PD JAN
PY 1994
VL 8
IS 1
BP 57
EP 62
DI 10.1111/j.1365-2915.1994.tb00386.x
PG 6
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA MT584
UT WOS:A1994MT58400011
PM 8161846
OA No
DA 2017-08-15
ER

PT J
AU MARBIAH, NT
   MAGBITI, E
   LINES, JD
   MAUDE, GH
   GREENWOOD, BM
   BRADLEY, D
   PETERSEN, E
AF MARBIAH, NT
   MAGBITI, E
   LINES, JD
   MAUDE, GH
   GREENWOOD, BM
   BRADLEY, D
   PETERSEN, E
TI A DOUBLE COMPARATIVE-STUDY OF THE ACCEPTABILITY OF UNTREATED BED NETS
   VERSUS PERMETHRIN, LAMBDA-CYHALOTHRIN AND DELTAMETHRIN IMPREGNATED BED
   NETS
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT CEC/Latin-American Malaria Conference/IV CEC Makarua Contract Holders
   Meeting
CY SEP 09-12, 1993
CL CALI, COLOMBIA
SP COMMISS EUROPEAN COMMUNITIES, UNIV VALLE
DE MALARIA; BED NETS; INSECTICIDES; PYRETHROIDS
ID GAMBIAN CHILDREN; MOSQUITO-NETS; MALARIA; TRIAL
C1 MINIST HLTH,FREETOWN,SIERRA LEONE.
   LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1,ENGLAND.
   UK MRC LABS,BANJUL,GAMBIA.
   STATENS SERUM INST,PARASITOL LAB,DK-2300 COPENHAGEN S,DENMARK.
RP MARBIAH, NT (reprint author), LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Barnish G, 1993, Parassitologia, V35 Suppl, P1
   BLAGOVESHCHENSK.D, 1945, T R SOC TROP MED HYG, V39, P134
   Bockarie M.J., 1993, Parassitologia (Rome), V35, P5
   BRADLEY AK, 1986, LANCET, V2, P204
   Curtis C. F., 1992, Review of Medical and Veterinary Entomology, V80, P543
   Curtis C.F., 1990, APPROPRIATE TECHNOLO
   GOUCK HK, 1971, MOSQ NEWS, V31, P95
   GOUCK HK, 1967, J ECON ENTOMOL, V60, P1451
   HARPER PA, 1947, AM J TROP MED, V27, P49
   MACCORMACK CP, 1986, J TROP MED HYG, V89, P295
   NJUNWA KJ, 1991, ACTA TROP, V49, P87, DOI 10.1016/0001-706X(91)90056-P
   Petersen E, 1993, Parassitologia, V35 Suppl, P81
   RANQUE P, 1984, 11 INT C TROP MED MA, P124
   Ross R., 1910, PREVENTION MALARIA
   Rozendaal J. A., 1989, Tropical Diseases Bulletin, V86, pR1
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   SNOW RW, 1986, T R SOC TROP MED HYG, V82, P212
NR 19
TC 4
Z9 4
U1 0
U2 0
PU MEM INST OSWALDO CRUZ
PI RIO DE JANEIRO
PA SECRETARY CAIXA POSTAL 926, 20001 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 1994
VL 89
SU 2
BP 3
EP 7
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA QQ813
UT WOS:A1994QQ81300004
PM 7565126
OA gold
DA 2017-08-15
ER

PT B
AU CLIFFORD, OJ
AF CLIFFORD, OJ
BE Rowlands, GJ
   Teale, AJ
TI Multiplication of improved trypanotolerant livestock
SO TOWARDS INCREASED USE OF TRYPANOTOLERANCE: CURRENT RESEARCH AND FUTURE
   DIRECTIONS
LA English
DT Proceedings Paper
CT Towards Increased Use of Trypanotolerance - Current Research and Future
   Directions Workshop
CY APR 26-29, 1993
CL INT LAB RES ANIM DIS, NAIROBI, KENYA
SP Int Lab Res Anim Dis, Int Livestock Ctr Africa
HO INT LAB RES ANIM DIS
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT LABORATORY RESEARCH ANIMAL DISEASES
PI NAIROBI
PA BOX 30709, NAIROBI, KENYA
BN 92-9055-298-0
PY 1994
BP 157
EP 163
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA BD14P
UT WOS:A1994BD14P00022
OA No
DA 2017-08-15
ER

PT B
AU WILSON, RT
   HAMMOND, K
AF WILSON, RT
   HAMMOND, K
BE Rowlands, GJ
   Teale, AJ
TI Programme for conservation of domestic animal diversity: A food and
   agriculture organization contribution to conserving animal genetic
   resources
SO TOWARDS INCREASED USE OF TRYPANOTOLERANCE: CURRENT RESEARCH AND FUTURE
   DIRECTIONS
LA English
DT Proceedings Paper
CT Towards Increased Use of Trypanotolerance - Current Research and Future
   Directions Workshop
CY APR 26-29, 1993
CL INT LAB RES ANIM DIS, NAIROBI, KENYA
SP Int Lab Res Anim Dis, Int Livestock Ctr Africa
HO INT LAB RES ANIM DIS
C1 PROJECT PROMOT TRYPANOTOLERANT LIVESTOCK,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT LABORATORY RESEARCH ANIMAL DISEASES
PI NAIROBI
PA BOX 30709, NAIROBI, KENYA
BN 92-9055-298-0
PY 1994
BP 165
EP 173
PG 9
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA BD14P
UT WOS:A1994BD14P00023
OA No
DA 2017-08-15
ER

PT J
AU KRISHNA, S
   WALLER, DW
   TERKUILE, F
   KWIATKOWSKI, D
   CRAWLEY, J
   CRADDOCK, CFC
   NOSTEN, F
   CHAPMAN, D
   BREWSTER, D
   HOLLOWAY, PA
   WHITE, NJ
AF KRISHNA, S
   WALLER, DW
   TERKUILE, F
   KWIATKOWSKI, D
   CRAWLEY, J
   CRADDOCK, CFC
   NOSTEN, F
   CHAPMAN, D
   BREWSTER, D
   HOLLOWAY, PA
   WHITE, NJ
TI LACTIC-ACIDOSIS AND HYPOGLYCEMIA IN CHILDREN WITH SEVERE MALARIA -
   PATHOPHYSIOLOGICAL AND PROGNOSTIC-SIGNIFICANCE
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; SEVERE FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM;
   CEREBRAL MALARIA; INTRAVENOUS QUININE; GLUCOSE-METABOLISM; LACTATE
   PRODUCTION; GAMBIAN CHILDREN; HYPOGLYCEMIA; MODEL
AB Serial clinical and metabolic changes were monitored in 115 Gambian children (1.5-12 years old) with severe malaria. Fifty-three children (46%) had cerebral malaria (coma score less than or equal to 2) and 21 (18%) died. Admission geometric mean venous blood lactate concentrations were almost twice as high in fatal cases as in survivors (7.1 mmol/L vs. 3.6 mmol/L; P<0.001) and were correlated with levels of tumour necrosis factor (r=0.42, n=79; P<0.0001) and interleukin 1-alpha (r=0.6, n=34; P<0.0001). Admission blood venous glucose concentrations were lower in fatal cases than survivors (3.2 mmol/L, vs. 5.8 mmol/L; P<0.0001). Treatment with quinine was associated with significantly more episodes of post-admission hypoglycaemia when compared with artemether or chloroquine. After treatment, lactate concentrations fell rapidly in survivors but fell only slightly, or rose, in fatal cases. Plasma cytokine levels fluctuated widely after admission. Sustained hyperlactataemia (raised lactate concentrations, 4 h after admission) proved to be the best overall prognostic indicator of outcome in this series. Lactic acidosis is an important cause of death in severe malaria.
C1 MAHIDOL UNIV,FAC TROP MED,BANGKOK 10400,THAILAND.
   JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD OX3 9DU,OXON,ENGLAND.
   JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC HAEMATOL GRP,OXFORD OX3 9DU,OXON,ENGLAND.
   JOHN RADCLIFFE HOSP,DEPT CLIN BIOCHEM,OXFORD OX3 9DU,OXON,ENGLAND.
   MRC LABS,FAJARA,SENEGAL.
   UNIV AMSTERDAM,DEPT INTERNAL MED,INFECT DIS UNIT,AMSTERDAM,NETHERLANDS.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
   JOHN HUNTER HOSP,DEPT PAEDIAT,HUNTER REG MAIL CTR,NSW 2310,AUSTRALIA.
RI White, Nicholas/I-4629-2012
OI Krishna, Sanjeev/0000-0003-0066-0634
FU Wellcome Trust
CR ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265
   Cohen RD, 1990, METABOLIC MOL BASIS, P962
   DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776
   DAVIS TME, 1990, CLIN ENDOCRINOL, V33, P739, DOI 10.1111/j.1365-2265.1990.tb03911.x
   DELREY A, 1987, AM J PHYSIOL, V253, pR794
   ENGELBERTS I, 1991, LANCET, V338, P515, DOI 10.1016/0140-6736(91)90591-C
   EVANS DA, 1989, AM J PHYSIOL, V257, pR1182
   FINCH CA, 1979, J CLIN INVEST, V64, P129, DOI 10.1172/JCI109431
   GARDINER M, 1982, J CEREBR BLOOD F MET, V2, P429
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GREENWOOD BM, 1990, PARASITOL TODAY, V6, P188, DOI 10.1016/0169-4758(90)90351-4
   HOLLOWAY PAH, 1991, EXP PARASITOL, V72, P123, DOI 10.1016/0014-4894(91)90130-O
   Hosmer D, 1989, APPLIED LOGISTIC REG
   KREISBERG RA, 1980, ANN INTERN MED, V92, P227
   KWIATKOWSKI D, 1993, Q J MED, V86, P91
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   KWIATKOWSKI D, 1990, IMMUNOL LETT, V25, P213, DOI 10.1016/0165-2478(90)90117-9
   LEE MD, 1987, P NATL ACAD SCI USA, V84, P2590, DOI 10.1073/pnas.84.9.2590
   LUPO M, 1990, METABOLISM, V39, P373
   MARSH K, 1988, EXP PARASITOL, V65, P202, DOI 10.1016/0014-4894(88)90123-3
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   MORDES JP, 1991, INTENS CARE MED, P994
   OKITOLONDA W, 1987, BRIT MED J, V295, P716
   ORRINGER CE, 1977, NEW ENGL J MED, V297, P796, DOI 10.1056/NEJM197710132971502
   PFALLER MA, 1982, EXP PARASITOL, V54, P391, DOI 10.1016/0014-4894(82)90048-0
   PUKRITTAYAMAKAM.S, 1991, CLIN SCI, V82, P63
   PUKTRITTAYAKAME.S, 1991, T ROY SOC TROP MED H, V85, P189
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   TAYLOR TE, 1993, Q J MED, V86, P99
   TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602
   TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010
   VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H
   VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457
   WALLER D, 1991, T ROY SOC TROP MED H, V85, P362, DOI 10.1016/0035-9203(91)90291-6
   WARRELL DA, 1988, LANCET, V1, P534
   WHITE NJ, 1985, LANCET, V1, P776
   WHITE NJ, 1989, T ROY SOC TROP MED H, V83, P767, DOI 10.1016/0035-9203(89)90322-2
   WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201
   WHITE NJ, 1992, LANCET, V339, P317, DOI 10.1016/0140-6736(92)91644-N
   WHITE NJ, 1987, LANCET, V1, P708
   WHITE NJ, 1991, LANCET, V338, P640, DOI 10.1016/0140-6736(91)90654-8
   WHITE NJ, 1992, ADV PARASIT, V31, P84
   WHITE NJ, 1988, LANCET, V2, P1313
   YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784
NR 44
TC 168
Z9 172
U1 0
U2 2
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JAN-FEB
PY 1994
VL 88
IS 1
BP 67
EP 73
DI 10.1016/0035-9203(94)90504-5
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MY063
UT WOS:A1994MY06300024
PM 8154008
OA No
DA 2017-08-15
ER

PT J
AU GOUTEUX, JP
   DAMICO, F
   CUISANCE, D
   BLANC, F
   DEMBA, D
   STAAK, C
   CLAUSEN, PH
   KOTAGUINZA, A
   LEGALL, F
AF GOUTEUX, JP
   DAMICO, F
   CUISANCE, D
   BLANC, F
   DEMBA, D
   STAAK, C
   CLAUSEN, PH
   KOTAGUINZA, A
   LEGALL, F
TI FEEDING-BEHAVIOR OF GLOSSINA FUSCIPES FUSCIPES NEWSTEAD, 1910 (DIPTERA,
   GLOSSINIDAE) IN 2 CATTLE-BREEDING AREAS OF THE CENTRAL-AFRICAN-REPUBLIC
SO VETERINARY RESEARCH
LA French
DT Article
DE GLOSSINA FUSCIPES FUSCIPES; FEEDING BEHAVIOR; LIVESTOCK; CENTRAL AFRICAN
   REPUBLIC
ID FLUMETHRIN POUR; TSETSE-FLIES; CHALLENGE; KENYA
AB From 1987 to 1993, a survey on the feeding behavior of Glossina fuscipes fuscipes was conducted in the Central African Republic. A total of 556 blood-meal samples was analyzed by ELISA. According to the results, the number of blood meals from cattle was rather low (12% on average). During the rainy season, this number increased significantly and varied according to the sampling area. Along the riverine forests, this amounted to 5%, while blood meals from wild ruminants amounted to 87%. In the neighborhood of watering-places, the number of cattle blood meals reached 9-22%. Reptiles were found to be important hosts (17-35%). In all cases, man presented a non-negligible host (4-14%), similar to suidae (2-19%). The authors discuss the relevance of these results to risk of trypanosomes transmission.
C1 UNIV PAU & PAYS ADOUR,ORSTOM,IPRA,MATH APPLIQUEES LAB,F-64000 PAU,FRANCE.
   ORSTOM,CIRAD,EMVT,EPIDEMIOL MALAD VECTEURS LAB,F-34032 MONTPELLIER 1,FRANCE.
   AGCY NATL DEV ELEVAGE,FNEC,BANJUL,GAMBIA.
   BUNDESGESUNDHEITSAMT,INST VET MED,GTZ BGA SERV LAB,W-1000 BERLIN 33,GERMANY.
CR BAUER B, 1992, TROP MED PARASITOL, V43, P41
   BERTUCAT P, 1965, THESIS MASION ALFORT
   BOUDET G, 1977, REV ELEV MED VET PAY, V30, P175
   BOUTRAIS J, 1988, PEUHL SAVANES HUMIDE
   Bruce D, 1910, P R SOC LOND B-CONTA, V82, P490, DOI 10.1098/rspb.1910.0043
   CHALLIER A, 1977, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V15, P283
   Chizyuka H G, 1986, Parasitol Today, V2, P123, DOI 10.1016/0169-4758(86)90046-3
   CUISANCE D, 1992, MEM SOC R BELGE ENTO, V35, P103
   DEFABREGUES BP, 1979, REV ELEV MED VET PAY, V32, P185
   DESROTOUR J, 1967, LACROUTS CHEPTEL BOV, P287
   Finelle P, 1963, REV ELEV MED VET PAY, V16, P337
   FINELLE P., 1962, REV ELEVAGE ET MED VET PAYS TROP, V15, P247
   Fio-Ngaindiro G., 1987, Revue Scientifique et Technique, Office International des Epizooties, V6, P955
   Fiske W. F., 1920, Bulletin of Entomological Research London, V10
   FORD J, 1960, 1ST P FED SCI C SAL, P357
   GATES DB, 1984, ANN TROP MED PARASIT, V78, P301
   GINGRICH J B, 1982, Molecular and Biochemical Parasitology, P273
   Gouteux J. P., 1991, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V44, P295
   Gouteux Jean-Paul, 1991, Bulletin de la Societe Entomologique de France, V96, P443
   GOUTEUX JP, 1993, B SOC PATHOL EXOT, V86
   GOUTEUX JP, 1982, CAH ORSTOM EMP, V2, P109
   JENICEK M, 1987, EPIDEMIOLOGIE PRINCI, P135
   KUTUZA S B, 1981, Bulletin of Animal Health and Production in Africa, V29, P55
   LEAK SGA, 1990, INSECT SCI APPL, V11, P293
   LEGALL F, 1993, IN PRESS REV ELEV ME
   LOHR KF, 1991, TROP MED PARASITOL, V42, P131
   MATTHIESSEN P, 1988, ORYX, V19, P202
   MOLOO SK, 1980, INSECT SCI APPL, V1, P117
   MOLOO SK, 1980, ANN TROP MED PARASIT, V74, P219
   MUNSTERMANN S, 1984, THESIS U BERLIN
   OKOTH JO, 1988, ANN TROP MED PARASIT, V82, P517
   OLOO FP, 1983, THESIS U NAIROBI
   PANTOBE D, 1984, ATLAS REPUBLIQUE CEN, P26
   RIORDAN K, 1972, Entomologist, V105, P118
   ROGERS DJ, 1985, ACTA TROP, V45, P379
   SMITH IM, 1958, 7 P M INT SCI COUNC, V7, P63
   SNOW WF, 1983, ACTA TROP, V40, P331
   SOUTHON HAW, 1964, P E AFR ACAD, V2, P131
   STAAK C, 1986, TROP MED PARASITOL, V37, P59
   STAAK C, 1983, 3RD P INT S VET LAB
   VANVEGTEN JA, 1971, THESIS U AMSTERDAM
   WEITZ B, 1963, B WORLD HEALTH ORGAN, V28, P711
   WEITZ B, 1964, ENDEAVOUR, V23, P38
   WHITESIDE EF, 1962, DRUGS PARASITES HOST, P117
   WINCKEL F, 1991, 21TH P M INT SCI COU, P520
NR 45
TC 4
Z9 4
U1 0
U2 0
PU EDITIONS SCIENTIFIQUES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0928-4249
J9 VET RES
JI Vet. Res.
PY 1994
VL 25
IS 1
BP 16
EP 28
PG 13
WC Veterinary Sciences
SC Veterinary Sciences
GA MW153
UT WOS:A1994MW15300003
PM 8142953
OA No
DA 2017-08-15
ER

PT J
AU RAWLINGS, P
   CEESAY, ML
   WACHER, TJ
   SNOW, WF
AF RAWLINGS, P
   CEESAY, ML
   WACHER, TJ
   SNOW, WF
TI THE DISTRIBUTION OF THE TSETSE-FLIES GLOSSINA-MORSITANS-SUBMORSITANS AND
   G-PALPALIS-GAMBIENSIS (DIPTERA, GLOSSINIDAE) IN THE GAMBIA AND THE
   APPLICATION OF SURVEY RESULTS TO TSETSE AND TRYPANOSOMIASIS CONTROL
SO BULLETIN OF ENTOMOLOGICAL RESEARCH
LA English
DT Article
ID CATTLE; TRAPS
AB A country-wide survey of the distribution of tsetse flies Glossina morsitans submorsitans Newstead and G. palpalis gambiensis Vanderplank was carried out in The Gambia, during 1989-1990, using box traps at 1654 sites over an area of 10,000 km2. The general distribution of tsetse had changed little during the last 45 years. G. m. submorsitans was present in dry, canopied woodland throughout most of the country, but was absent from an area south of the River Gambia stretching from the coast to some 100 km inland. G. p. gambiensis occurred in evergreen forest and woodland near the coast, and in riparian habitats along the length of the River Gambia and its major tributaries. Nowhere in the country was more than 20 km from tsetse-infested areas. Five major foci of G. m. submorsitans infestation were identified. Demographic, climatic and environmental factors affect tsetse populations in The Gambia, but it is expected that these foci of infestation will persist for at least the next 5-10 years. The numbers of tsetse trapped, expressed as relative densities, were used to assess the extent and severity of losses from trypanosomiasis to different categories of livestock. Survey results such as these could be used to assess whether control measures to reduce tsetse challenge are likely to be economically viable by using techniques such as insecticide-impregnated targets, pour-ons or chemotherapy.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR AGYEMANG K, 1990, ANIM PROD, V50, P383
   AGYEMANG K, 1992, ACTA TROP, V50, P91
   Barrett J., 1991, 20 M INT SCI COUNC T, P456
   BAUER B, 1991, 20TH P M INT SCI COU, P448
   Bouet G., 1916, Bulletin de la Societe de Pathologie Exotique Paris, V9
   CAMPBELL RWH, 1950, TRYPANOSOMIASIS TSET
   DIATE A, 1989, ELEVAGE POTENTIALITI
   DRANSFIELD RD, 1990, B ENTOMOL RES, V80, P265
   FLINT S, 1985, B ENTOMOL RES, V75, P529
   FORESTER H, 1986, EVALUATION NATIONAL
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   HUTCHINSON MP, 1953, ANN TROP MED PARASIT, V47, P169
   HUTCHINSONMP, 1953, ANN TROP MED PARASIT, V47, P156
   LAVEISSIERE C, 1987, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V25, P145
   LAVEISSIERE C, 1987, TROPICAL MED PARASIT, V41, P185
   MANN RD, 1975, UNPUB GAMBIA LAND VE
   MULLER A, 1983, GTZ TECHNICAL B, V10
   Nash TAM, 1948, TSETSE FLIES BRIT W
   NORTON GA, 1991, UNPUB REPORT DEV DEC, P7
   RAWLINGS P, 1991, PARASITOLOGY, V102, P371
   RAWLINGS P, IN PRESS AFRICAN LIV, V2
   SHAW APM, 1987, FAO672 AN PROD HLTH, V2
   Simpson J. G., 1911, Bulletin of Entomological Research London, V2
   SNOW WF, 1979, ACTA TROP, V36, P47
   SOWE J, 1988, UNPUB FOALING MORTAL
   SUMBERG J, 1988, UNPUB NOTES CATTLE S
   THOMSON JW, 1991, 20TH P M INT SCI COU, P450
   Toure S M, 1971, Rev Elev Med Vet Pays Trop, V24, P551
   TOURE SM, 1974, 1974 I EL MED VET PA, P353
   VALE GA, 1988, B ENTOMOL RES, V78, P31
   1987, POPULATION HOUSING C, V1
   1990, TECHNICAL B MINISTRY, V12
   1991, 1990 91 NATIONAL AGR
   1990, POPULATION HOUSING C, V4
   1989, TECHNICAL B MIN AG N, V895
NR 35
TC 25
Z9 25
U1 0
U2 3
PU C A B INTERNATIONAL
PI WALLINGFORD
PA  WALLINGFORD, OXON, ENGLAND OX10 8DE
SN 0007-4853
J9 B ENTOMOL RES
JI Bull. Entomol. Res.
PD DEC
PY 1993
VL 83
IS 4
BP 625
EP 632
PG 8
WC Entomology
SC Entomology
GA MW327
UT WOS:A1993MW32700016
OA No
DA 2017-08-15
ER

PT J
AU DEFRANCISCO, A
   MORRIS, J
   HALL, AJ
   SCHELLENBERG, JRMA
   GREENWOOD, BM
AF DEFRANCISCO, A
   MORRIS, J
   HALL, AJ
   SCHELLENBERG, JRMA
   GREENWOOD, BM
TI RISK-FACTORS FOR MORTALITY FROM ACUTE LOWER RESPIRATORY-TRACT INFECTIONS
   IN YOUNG GAMBIAN CHILDREN
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
ID INDOOR AIR-POLLUTION; DEVELOPING-COUNTRIES; INTENSIVE EXPOSURE;
   EPIDEMIOLOGY; MALNUTRITION; DETERMINANTS; COMMUNITY; INFANTS; SMOKING;
   ILLNESS
AB A case-control study has been undertaken in a rural area of The Gambia to evaluate risk factors for death from acute lower respiratory tract infections (ALRI) in young children. On the basis of a post-mortem interview 129 children aged < 2 years were thought to have died from ALRI. These cases were each matched according to age, sex, ethnic group, time and place of death with a child who had died from a cause other than an ALRI and with two live control children. Cases and controls were well matched. Comparison of cases and live controls suggested that exposure to smoke during cooking, parental smoking and exclusive, prolonged breastfeeding were associated with an increased risk of death from ALRI whilst sharing a bed with siblings, use of antenatal and welfare clinics and immunization were associated with a reduced risk of death from ALRI. No associations were found between mortality from ALRI and maternal education and literacy, socioeconomic status or with the age of the mother. Comparison of children who died from causes other than ALRI with the live controls showed a similar pattern of associations and no significant differences were found in any of the risk factors studied between children whose deaths were attributed to ALRI and those whose death was attributed to another cause. Association of death with exposure to smoke during cooking was the strongest risk factor identified. This risk might be altered by reducing smoke exposure during cooking.
C1 MRC LABS,BANJUL,GAMBIA.
   LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON,ENGLAND.
   LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON,ENGLAND.
CR AABY P, 1988, REV INFECT DIS, V10, P478
   AABY P, 1984, AM J EPIDEMIOL, V120, P49
   ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424
   AZIZI BHO, 1991, INT J EPIDEMIOL, V20, P144, DOI 10.1093/ije/20.1.144
   BERMAN S, 1991, REV INFECT DIS, V13, pS454
   BORRERO I, 1990, REV INFECT DIS, V12, pS950
   DEFRANCISCO A, 1990, METHODS FIELD TRIALS
   DEFRANCISCO A, 1993, IN PRESS ANN TROP PA
   ERIKSEN MP, 1988, ANNU REV PUBL HEALTH, V9, P47, DOI 10.1146/annurev.pu.09.050188.000403
   GREENFIE.S, 1967, NEW ENGL J MED, V277, P497, DOI 10.1056/NEJM196709072771001
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   GREENWOOD M, 1988, REV INFECT DIS, V10, P492
   HOPPENBROUWERS T, 1990, LUNG S, V168, pS335
   JAAKKOLA JJK, 1991, AM J PUBLIC HEALTH, V81, P1060, DOI 10.2105/AJPH.81.8.1060
   KENDALL PA, 1985, ARI CHILDHOOD, P72
   KOSSOVE D, 1982, S AFR MED J, V61, P622
   LUTTER C, WHOCCDEDP925
   MORRIS K, 1990, AM J DIS CHILD, V144, P105
   OSTRO BD, 1989, RISK ANAL, V9, P189, DOI 10.1111/j.1539-6924.1989.tb01239.x
   PANDEY MR, 1989, LANCET, V1, P427
   PIO A, 1986, PEDIATR INFECT DIS J, V5, P179, DOI 10.1097/00006454-198603000-00003
   Pio A, 1985, ACUTE RESPIRATORY IN, P3
   ROTHMAN KJ, 1988, INT J EPIDEMIOL, V7, pS955
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   SMITH TA, 1991, AM J CLIN NUTR, V53, P963
   SPAANS WA, 1990, AUST NZ J OBSTET GYN, V30, P327, DOI 10.1111/j.1479-828X.1990.tb02021.x
   TUPASI TE, 1990, REV INFECT DIS, V12, pS940
   TUPASI TE, 1988, J INFECT DIS, V157, P615
   VICTORA CG, 1984, AM J CLIN NUTR, V39, P307
   VICTORA CG, 1989, INT J EPIDEMIOL, V18, P918, DOI 10.1093/ije/18.4.918
   VICTORA CG, 1988, PEDIATRICS, V81, P807
   WAFULA EM, 1990, E AFR MED J, V67, P24
   WOODWARD A, 1990, J EPIDEMIOL COMMUN H, V44, P224, DOI 10.1136/jech.44.3.224
   1988, WHOPEP883
   1986, GROWTH CHART TOOL US
   [Anonymous], 1991, ANN REPORT
NR 36
TC 58
Z9 62
U1 0
U2 4
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD DEC
PY 1993
VL 22
IS 6
BP 1174
EP 1182
DI 10.1093/ije/22.6.1174
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MU551
UT WOS:A1993MU55100027
PM 8144302
OA No
DA 2017-08-15
ER

PT J
AU MCKAY, T
AF MCKAY, T
TI ANTIBIOTIC-RESISTANCE IN PNEUMOCOCCAL MENINGITIS
SO LANCET
LA English
DT Letter
ID BACTERIAL-MENINGITIS
RP MCKAY, T (reprint author), ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA.
CR FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J
   GEORGE RE, 1992, LANCET, V339, P931
   Mathies A W Jr, 1967, Antimicrob Agents Chemother (Bethesda), V7, P218
   MCKAY T, 1989, TROP DOCT, V19, P158
   SHANN F, 1985, LANCET, V2, P681
   WEEKS JL, 1981, ANTIMICROB AGENTS CH, V20, P281
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 15
PY 1992
VL 340
IS 8816
BP 438
EP 438
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA JJ449
UT WOS:A1992JJ44900058
PM 1353601
OA No
DA 2017-08-15
ER

PT J
AU CLAXTON, JR
   LEPERRE, P
   RAWLINGS, P
   SNOW, WF
   DWINGER, RH
AF CLAXTON, JR
   LEPERRE, P
   RAWLINGS, P
   SNOW, WF
   DWINGER, RH
TI TRYPANOSOMIASIS IN CATTLE IN GAMBIA - INCIDENCE, PREVALENCE AND TSETSE
   CHALLENGE
SO ACTA TROPICA
LA English
DT Article
DE TRYPANOSOMIASIS INCIDENCE; TRYPANOSOMA PREVALENCE; TSETSE CHALLENGE;
   BERENIL INDEX; TRYPANOTOLERANCE; CATTLE
ID AFRICAN TRYPANOSOMIASIS; MORSITANS
AB The incidence of trypanosome infections, measured by a Berenil Index in experimental herds of 10 Zebu and 10 N'Dama cattle, was compared with tsetse challenge and with the prevalence of parasitaemia in local N'Dama at three villages in Gambia.  Tsetse challenge was more strongly correlated with the incidence of parasitaemia in the Zebu than in the N'Dama.  There was a strong correlation between prevalence and incidence of infection in the N'Dama.  There was no correlation, however, between prevalence of infection in cattle and tsetse challenge unless the data were offset by 3-5 months.  The Berenil Index in the Zebu increased at about twice the rate as in the N'Dama under corresponding levels of challenge.  It is concluded that whereas incidence of infection in susceptible animals is best measured independently, it can, under stable conditions, be inferred from an assessment of tsetse challenge.
C1 INT TRYPANOTOLERANCE CTR,BANJUL,GAMBIA.
CR CLAXTON JR, 1989, IN PRESS 20TH P M IN
   DUNSMORE JR, 1976, AGR DEV GAMBIA AGR E
   GREEN CH, 1986, B ENTOMOL RES, V76, P409
   LEAK SGA, 1988, LIVESTOCK PRODUCTION
   MURRAY M, 1981, VET REC, V109, P503
   PARIS J, 1982, ACTA TROP, V39, P307
   ROGERS DJ, 1985, ACTA TROP, V42, P5
   VANHOEVE K, 1984, VET REC, V76, P260
NR 8
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD FEB
PY 1992
VL 50
IS 3
BP 219
EP 225
DI 10.1016/0001-706X(92)90078-C
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA HF100
UT WOS:A1992HF10000003
PM 1348598
OA No
DA 2017-08-15
ER

PT J
AU MAYANS, MV
   HALL, AJ
   INSKIP, HM
   CHOTARD, J
   LINDSAY, SW
   COROMINA, E
   MENDY, M
   ALONSO, PL
   WHITTLE, H
AF MAYANS, MV
   HALL, AJ
   INSKIP, HM
   CHOTARD, J
   LINDSAY, SW
   COROMINA, E
   MENDY, M
   ALONSO, PL
   WHITTLE, H
TI RISK-FACTORS FOR TRANSMISSION OF HEPATITIS-B VIRUS TO GAMBIAN CHILDREN
SO LANCET
LA English
DT Article
C1 WHO,INT AGCY RES CANC,BANJUL,GAMBIA.
   MRC LABS,FAJARA,SENEGAMBIA.
OI Inskip, Hazel/0000-0001-8897-1749
CR BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199
   FOSTER O, 1984, LANCET, V1, P576
   FOX E, 1988, T ROY SOC TROP MED H, V82, P750, DOI 10.1016/0035-9203(88)90225-8
   JOUBERT JJ, 1985, S AFR J SCI, V81, P167
   JUPP PG, 1979, S AFR MED J, V56, P54
   OGSTON CW, 1981, J MED ENTOMOL, V18, P107
   OGSTON CW, 1979, J INFECT DIS, V140, P411
   OGSTON CW, 1980, T ROY SOC TROP MED H, V74, P823, DOI 10.1016/0035-9203(80)90216-3
   PRINCE AM, 1972, LANCET, V2, P247
   SMITH PG, 1976, BIOMETRICS, V32, P817, DOI 10.2307/2529267
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   TABOR E, 1985, J MED VIROL, V15, P113, DOI 10.1002/jmv.1890150203
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHITTLE HC, IN PRESS J INFECT DI
   WILLS W, 1977, LANCET, V2, P217
NR 15
TC 45
Z9 47
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 3
PY 1990
VL 336
IS 8723
BP 1107
EP 1109
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA EF992
UT WOS:A1990EF99200013
PM 1977989
OA No
DA 2017-08-15
ER

PT J
AU DEGROOT, AS
   JOHNSON, A
   MALOY, WL
   QUAKYI, IA
   RILEY, EM
   BANKS, SM
   BERZOFSKY, JA
   GOOD, MF
AF DEGROOT, AS
   JOHNSON, A
   MALOY, WL
   QUAKYI, IA
   RILEY, EM
   BANKS, SM
   BERZOFSKY, JA
   GOOD, MF
TI HUMAN IMMUNE-RESPONSE TO POLYMORPHIC T-CELL EPITOPES FROM
   PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE PROTEIN
SO CLINICAL RESEARCH
LA English
DT Meeting Abstract
C1 NCI,BETHESDA,MD 20205.
   NIAID,BETHESDA,MD 20205.
   GEORGETOWN UNIV,WASHINGTON,DC.
   MRC,BANJUL,GAMBIA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086
SN 0009-9279
J9 CLIN RES
JI Clin. Res.
PD APR
PY 1989
VL 37
IS 2
BP A562
EP A562
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA U0044
UT WOS:A1989U004401942
OA No
DA 2017-08-15
ER

PT J
AU BEHRENS, R
   NORTHROP, C
   LUNN, P
   NEALE, G
AF BEHRENS, R
   NORTHROP, C
   LUNN, P
   NEALE, G
TI FACTORS AFFECTING THE INTEGRITY OF INTESTINAL-MUCOSA IN GAMBIAN CHILDREN
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Meeting Abstract
C1 DUNN NUTR UNIT,CAMBRIDGE CB4 1XF,ENGLAND.
   MRC LABS,DUNN NUTR GRP,FAJARA,GAMBIA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU C A B INTERNATIONAL
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, WALLINGFORD, OXON, ENGLAND OX10 8DE
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD JUL
PY 1986
VL 45
IS 2
BP A67
EP A67
PG 1
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA D3006
UT WOS:A1986D300600029
OA No
DA 2017-08-15
ER

PT J
AU SHERWOOD, JA
   ROBERTS, DD
   MARSH, K
   SPITALNIK, SL
   MILLER, LH
   HOWARD, RJ
AF SHERWOOD, JA
   ROBERTS, DD
   MARSH, K
   SPITALNIK, SL
   MILLER, LH
   HOWARD, RJ
TI PARASITIZED ERYTHROCYTE BINDING TO THROMBOSPONDIN IN FALCIPARUM-MALARIA
SO CLINICAL RESEARCH
LA English
DT Meeting Abstract
C1 LAB PARASIT DIS,BETHESDA,MD.
   MRC LABS,FAJARA,GAMBIA.
RI Roberts, David/A-9699-2008
OI Roberts, David/0000-0002-2481-2981
CR 1985, NATURE, V318, P64
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086
SN 0009-9279
J9 CLIN RES
JI Clin. Res.
PD APR
PY 1986
VL 34
IS 2
BP A723
EP A723
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA C5398
UT WOS:A1986C539802672
OA No
DA 2017-08-15
ER

PT J
AU MARSH, K
   HOWARD, RJ
AF MARSH, K
   HOWARD, RJ
TI ANTIGENS INDUCED ON ERYTHROCYTES BY PLASMODIUM-FALCIPARUM - EXPRESSION
   OF DIVERSE AND CONSERVED DETERMINANTS
SO SCIENCE
LA English
DT Article
C1 NIAID,PARASIT DIS LAB,MALARIA SECT,BETHESDA,MD 20205.
RP MARSH, K (reprint author), MED RES COUNCIL LABS,FAJARA,GAMBIA.
CR ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585
   ALEY SB, 1984, J EXP MED, V160, P1584
   ALEY SB, PARASITOLOGY
   BARNWELL JW, 1983, INFECT IMMUN, V40, P985
   BROWN J, 1980, CLIN EXP IMMUNOL, V41, P423
   BROWN KN, 1970, EXP PARASITOL, V28, P318, DOI 10.1016/0014-4894(70)90102-5
   CELADA A, 1983, J IMMUNOL METHODS, V63, P263, DOI 10.1016/0022-1759(83)90430-1
   DAVID PH, 1983, P NATL ACAD SCI-BIOL, V80, P5075, DOI 10.1073/pnas.80.16.5075
   DUNN MJ, 1969, J CLIN INVEST, V48, P674, DOI 10.1172/JCI106025
   ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9
   GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3
   HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137
   HOWARD RJ, 1984, PHILOS T ROY SOC B, V307, P141, DOI 10.1098/rstb.1984.0115
   HOWARD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P4129, DOI 10.1073/pnas.80.13.4129
   HOWARD RJ, UNPUB
   HOWARD RJ, 1983, CONT TOPICS IMMUNOLO, V12, P127
   LANGRETH SG, 1979, EXP PARASITOL, V48, P213, DOI 10.1016/0014-4894(79)90101-2
   LANGRETH SG, 1979, J EXP MED, V150, P1241, DOI 10.1084/jem.150.5.1241
   LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567
   MARSH K, UNPUB
   MERYMAN HT, 1972, TRANSFUSION, V12, P145
   REKVIG OP, 1977, VOX SANG, V33, P280
   SHEAR HL, 1979, J EXP MED, V149, P1288, DOI 10.1084/jem.149.6.1288
   SHERWOOD JA, PARASITE IMMUNOL
   TANABE K, 1982, J CELL BIOL, V93, P680, DOI 10.1083/jcb.93.3.680
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   UDEINYA IJ, 1983, EXP PARASITOL, V56, P207, DOI 10.1016/0014-4894(83)90064-4
   UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935
   UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0
NR 29
TC 280
Z9 280
U1 0
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 10
PY 1986
VL 231
IS 4734
BP 150
EP 153
DI 10.1126/science.2417315
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AWX70
UT WOS:A1986AWX7000028
PM 2417315
OA No
DA 2017-08-15
ER

PT J
AU BROWN, J
   WHITTLE, HC
   BERZINS, K
   HOWARD, RJ
   MARSH, K
   SJOBERG, K
AF BROWN, J
   WHITTLE, HC
   BERZINS, K
   HOWARD, RJ
   MARSH, K
   SJOBERG, K
TI INHIBITION OF PLASMODIUM-FALCIPARUM GROWTH BY IGG ANTIBODY PRODUCED BY
   HUMAN-LYMPHOCYTES TRANSFORMED WITH EPSTEIN-BARR-VIRUS
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
C1 UNIV STOCKHOLM,WENNER GREN INST,DEPT IMMUNOL,S-11345 STOCKHOLM,SWEDEN.
   NIAID,PARASIT DIS LAB,MALARIA SECT,BETHESDA,MD 20205.
RP BROWN, J (reprint author), MED RES COUNCIL LABS,FAJARA,GAMBIA.
CR BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   BOYLE DB, 1982, INFECT IMMUN, V38, P94
   EPSTEIN N, 1981, J IMMUNOL, V127, P212
   HALL R, 1983, MOL BIOCHEM PARASIT, V7, P247, DOI 10.1016/0166-6851(83)90025-7
   Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0
   HOWARD RJ, 1984, MOL BIOCHEM PARASIT, V11, P349, DOI 10.1016/0166-6851(84)90078-1
   HOWARD RJ, 1984, PARASITOLOGY, V88, P27
   JENSEN JB, 1978, AM J TROP MED HYG, V27, P743
   KISHIMOTO T, 1978, NATURE, V271, P756, DOI 10.1038/271756a0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEMSVANKAN P, 1983, J IMMUNOL METHODS, V57, P51, DOI 10.1016/0022-1759(83)90064-9
   LUNDGREN K, 1983, J IMMUNOL, V131, P2000
   NEWBOLD CI, 1982, MOL BIOCHEM PARASIT, V5, P45, DOI 10.1016/0166-6851(82)90005-6
   PERRIN LH, 1981, NATURE, V289, P301, DOI 10.1038/289301a0
   PERRIN LH, 1980, CLIN EXP IMMUNOL, V41, P91
   SAUL A, 1984, PARASITE IMMUNOL, V6, P39, DOI 10.1111/j.1365-3024.1984.tb00780.x
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
NR 17
TC 17
Z9 17
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 1986
VL 63
IS 1
BP 135
EP 140
PG 6
WC Immunology
SC Immunology
GA AXZ33
UT WOS:A1986AXZ3300019
PM 3006952
OA No
DA 2017-08-15
ER

PT J
AU ABDALLA, SH
   MABEY, DCW
   CORRAH, PT
AF ABDALLA, SH
   MABEY, DCW
   CORRAH, PT
TI PRIMARY ACQUIRED SIDEROBLASTIC ANEMIA IN A GAMBIAN PATIENT
SO CLINICAL AND LABORATORY HAEMATOLOGY
LA English
DT Article
C1 MRC LABS,FAJARA,GAMBIA.
RP ABDALLA, SH (reprint author), UNIV LONDON,ST MARYS HOSP,SCH MED,DEPT HAEMATOL,LONDON W2 1PG,ENGLAND.
CR BJORKMAN SE, 1956, BLOOD, V11, P250
   DACIE JV, 1959, BRIT J HAEMATOL, V5, P56, DOI 10.1111/j.1365-2141.1959.tb04013.x
   HARDISTY RM, 1984, BLOOD ITS DISORDERS
   KUSHNER JP, 1971, MEDICINE, V50, P139
   MACGIBBON BH, 1965, BRIT J HAEMATOL, V11, P59, DOI 10.1111/j.1365-2141.1965.tb00085.x
   Wintrobe MM, 1981, CLIN HEMATOLOGY
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0141-9854
J9 CLIN LAB HAEMATOL
JI Clin. Lab. Haematol.
PY 1986
VL 8
IS 3
BP 257
EP 260
PG 4
WC Hematology
SC Hematology
GA D9256
UT WOS:A1986D925600010
PM 3757453
OA No
DA 2017-08-15
ER

PT J
AU PICKERING, H
   HAYES, RJ
   NGANDU, N
   SMITH, PG
AF PICKERING, H
   HAYES, RJ
   NGANDU, N
   SMITH, PG
TI SOCIAL AND ENVIRONMENTAL-FACTORS ASSOCIATED WITH THE RISK OF
   CHILD-MORTALITY IN A PERIURBAN COMMUNITY IN THE GAMBIA
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 UNIV LONDON LONDON SCH HYG & TROP MED,TROP EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
   MRC LABS,FAJARA,GAMBIA.
CR BRASS W, 1982, POPULATION DEV MIDDL, P341
   CALDWELL JC, 1979, POP STUD-J DEMOG, V33, P395, DOI 10.2307/2173888
   DUGDALE AE, 1980, MED J AUSTR      OCT, P380
   HILL AG, 1983, 835 CTR POP STUD LON
   LINDENBAUM S, 1983, ICDDRB1983 REP
   MOTT FL, 1982, 32 WORLD FERT SURV S
   NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614
   PICKERING H, 1984, THESIS U LONDON
   1980, 405 WORLD BANK STAFF
NR 9
TC 19
Z9 19
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PY 1986
VL 80
IS 2
BP 311
EP 316
DI 10.1016/0035-9203(86)90045-3
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA C4730
UT WOS:A1986C473000029
PM 3787693
OA No
DA 2017-08-15
ER

PT J
AU MABEY, DCW
   OGBASELASSIE, G
   ROBERTSON, JN
   HECKELS, JE
   WARD, ME
AF MABEY, DCW
   OGBASELASSIE, G
   ROBERTSON, JN
   HECKELS, JE
   WARD, ME
TI TUBAL INFERTILITY IN THE GAMBIA - CHLAMYDIAL AND GONOCOCCAL SEROLOGY IN
   WOMEN WITH TUBAL OCCLUSION COMPARED WITH PREGNANT CONTROLS
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
C1 MRC LABS,FAJARA,GAMBIA.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
CR BALLARD RC, 1981, S AFRICAN J SEXUALLY, V1, P24
   BELSEY MA, 1976, B WORLD HEALTH ORGAN, V54, P319
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   BROWN IM, 1976, S AFR MED J, V50, P1342
   BRUNHAM RC, 1983, INFECT IMMUN, V39, P1491
   Carty M J, 1972, East Afr Med J, V49, P376
   CATES W, 1985, LANCET, V2, P596
   CEVENINI R, 1984, J CLIN PATHOL, V37, P686, DOI 10.1136/jcp.37.6.686
   DIAZ JL, 1982, J GEN MICROBIOL, V128, P585
   FINN MP, 1983, J CLIN MICROBIOL, V17, P848
   Grech E S, 1973, Trop Doct, V3, P123
   LAMBDEN PR, 1982, J GEN MICROBIOL, V128, P2105
   LEE JD, 1982, STATISTICS COMPUTER, P151
   MABEY DCW, 1982, LANCET, V2, P300
   MABEY DCW, 1984, BRIT J VENER DIS, V60, P331
   MARDH PA, 1981, BRIT J VENER DIS, V57, P125
   MARDH PA, 1978, IMMUNOBIOLOGY NEISSE, P377
   MATI JKG, 1973, E AFRICAN MED J, V50, P95
   MEUWISSEN JH, 1966, TROP GEOGR MED, V18, P147
   MOUTSINGA H, 1973, MED AFRIQUE NOIRE, V20, P103
   MUIR DG, 1980, AM J OBSTET GYNECOL, V138, P913
   Nasah B T, 1980, Int J Gynaecol Obstet, V18, P48
   OJO OA, 1971, ISRAEL J MED SCI, V7, P280
   REIMANN K, 1980, ACTA PATH MICRO IM C, V88, P155
   SAIKKU P, 1983, J CLIN MICROBIOL, V17, P22
   SALARI SH, 1981, J GEN MICROBIOL, V123, P197
   SEDGWICK AK, 1983, J CLIN MICROBIOL, V18, P104
   SVENSSON L, 1980, AM J OBSTET GYNECOL, V138, P1017
   WAGER GP, 1980, AM J OBSTET GYNECOL, V138, P1028
   WESTROM L, 1975, AM J OBSTET GYNECOL, V121, P707
NR 30
TC 34
Z9 34
U1 1
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1985
VL 63
IS 6
BP 1107
EP 1113
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA C2632
UT WOS:A1985C263200013
PM 3938962
OA No
DA 2017-08-15
ER

PT J
AU LAWRENCE, F
   LAMB, WH
   LAMB, C
   LAWRENCE, M
AF LAWRENCE, F
   LAMB, WH
   LAMB, C
   LAWRENCE, M
TI A QUANTIFICATION OF CHILD-CARE AND INFANT CAREGIVER INTERACTION IN A
   WEST-AFRICAN VILLAGE
SO EARLY HUMAN DEVELOPMENT
LA English
DT Article
C1 MRC,DUNN NUTR GRP,KENEBA,GAMBIA.
RP LAWRENCE, F (reprint author), MRC,DUNN NUTR GRP,CAMBRIDGE,ENGLAND.
CR BECKWITH L, 1971, CHILD DEV, V42, P1083, DOI 10.1111/j.1467-8624.1971.tb02004.x
   BRADLEY RH, 1976, DEV PSYCHOL, V12, P93, DOI 10.1037//0012-1649.12.2.93
   ELARDO R, 1975, CHILD DEV, V46, P71
   Griffiths R., 1954, ABILITIES BABIES STU
   LAMB ME, 1977, CHILD DEV, V48, P167, DOI 10.1111/j.1467-8624.1977.tb04257.x
   MACGREGOR IA, 1961, BR MED J, V2, P1661
   THOMPSON BARBARA, 1967, J TROP PEDIAT, V13, P124
   THOMSON B, 1965, THESIS ABERDEEN U AB
   WACHS TD, 1971, MERRILL-PALMER Q BEH, V17, P283
NR 9
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0378-3782
J9 EARLY HUM DEV
JI Early Hum. Dev.
PY 1985
VL 12
IS 1
BP 71
EP 80
DI 10.1016/0378-3782(85)90139-2
PG 10
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA AVD34
UT WOS:A1985AVD3400010
PM 4065000
OA No
DA 2017-08-15
ER

PT J
AU WALL, RA
   MABEY, DCW
   BELLO, CSS
   FELMINGHAM, D
AF WALL, RA
   MABEY, DCW
   BELLO, CSS
   FELMINGHAM, D
TI THE COMPARATIVE INVITRO ACTIVITY OF 12 4-QUINOLONE ANTIMICROBIALS
   AGAINST HEMOPHILUS-DUCREYI
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
C1 UNIV COLL HOSP LONDON,DEPT MICROBIOL,LONDON,ENGLAND.
RP WALL, RA (reprint author), MRC LABS,FAJARA,GAMBIA.
CR BILGERI YR, 1982, ANTIMICROB AGENTS CH, V22, P686
   CHAPEL T, 1978, J INFECT DIS, V137, P50
   FAST MV, 1982, LANCET, V2, P509
   FAST MV, 1983, SEX TRANSM DIS, V10, P1, DOI 10.1097/00007435-198301000-00001
   HAMMOND GW, 1979, J ANTIMICROB CHEMOTH, V5, P261, DOI 10.1093/jac/5.3.261
   HAMMOND GW, 1978, J CLIN MICROBIOL, V7, P39
   HAMMOND GW, 1980, REV INFECT DIS, V2, P867
   LYKKEOLESEN L, 1979, LANCET, V1, P654
   MCNICOL PJ, 1984, J ANTIMICROBIAL CHEM
   NSANZE H, 1981, BRIT J VENER DIS, V57, P378
   REEVES DS, 1984, J ANTIMICROB CHEMOTH, V13, P333, DOI 10.1093/jac/13.4.333
   RUDOLPH AH, 1979, INT J DERMATOL, V18, P797, DOI 10.1111/j.1365-4362.1979.tb04466.x
   SANSONLEPORS MJ, 1983, J ANTIMICROB CHEMOTH, V11, P271
   SNG EH, 1982, BRIT J VENER DIS, V58, P239
   STURM AW, 1984, J CLIN MICROBIOL, V19, P672
   WALL RA, 1983, LANCET, V2, P1303
   WILLCOX R R, 1963, Br J Clin Pract, V17, P455
NR 17
TC 29
Z9 29
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PY 1985
VL 16
IS 2
BP 165
EP 168
DI 10.1093/jac/16.2.165
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA APS78
UT WOS:A1985APS7800005
PM 3877717
OA No
DA 2017-08-15
ER

PT J
AU AJDUKIEWICZ, A
   CROWDEN, A
   HUDSON, E
   PYNE, C
AF AJDUKIEWICZ, A
   CROWDEN, A
   HUDSON, E
   PYNE, C
TI LIVER ASPIRATION IN THE DIAGNOSIS OF HEPATOCELLULAR-CARCINOMA IN THE
   GAMBIA
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
C1 NORTHWICK PK HOSP,DEPT HISTOPATHOL,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.
   CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.
   MRC LABS,BANJUL,GAMBIA.
   ROYAL VICTORIA HOSP,BANJUL,GAMBIA.
CR Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0
   ALPERT E, 1971, GASTROENTEROLOGY, V61, P137
   ANTHONY PP, 1973, J PATHOL, V110, P37, DOI 10.1002/path.1711100105
   ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217
   ANTHONY PP, 1978, RECENT ADV HISTOPATH
   BRITS CJ, 1974, S AFR MED J, V48, P2207
   CHAN CH, 1975, MED CLIN N AM, V59, P989
   CONN HO, 1976, CLIN GASTROENTEROL, V5, P665
   CRAWLEY JCW, 1981, MED RADIONUCLIDE IMA
   DECOCK DM, 1981, E AFR MED J, V58, P636
   DOLL R, 1966, CANCER INCIDENCE 5 C, V1
   EKELUND P, 1971, ACTA MED SCAND, V189, P373
   FERRUCCI JT, 1979, RADIOLOGY, V130, P345
   FOX CH, 1979, LANCET, V1, P1387
   FRABLE WJ, 1983, HUM PATHOL, V14, P9, DOI 10.1016/S0046-8177(83)80042-2
   HADZIYANNIS SJ, 1980, CLIN GASTROENTEROL, V9, P117
   KEW MC, 1983, POSTGRAD MED J, V59, P78
   LEEK AE, 1975, BRIT J OBSTET GYNAEC, V82, P669, DOI 10.1111/j.1471-0528.1975.tb00704.x
   LUNDQUIST A, 1970, Acta Medica Scandinavica, V188, P465
   OKUDA K, 1976, HEPATOCELLULAR CARCI
   PORTER B, 1981, ACTA RADIOL DIAGN, V22, P663
   REYNOLDS TB, 1976, HEPATOCELLULAR CARCI
   RISKA H, 1975, BRIT MED J, V1, P517
   SAKURAI M, 1983, AM J SURG PATHOL, V7, P191, DOI 10.1097/00000478-198303000-00010
   SCHULZ TB, 1976, ACTA MED SCAND, V199, P141
   SCHWERK WB, 1981, CANCER, V48, P1469, DOI 10.1002/1097-0142(19810915)48:6<1469::AID-CNCR2820480632>3.0.CO;2-E
   TAO LC, 1979, ACTA CYTOL, V23, P287
   TAO LC, 1984, CANCER, V53, P547
   VECCHIO TJ, 1966, NEW ENGL J MED, V274, P1171, DOI 10.1056/NEJM196605262742104
   Zajicek J., 1979, ASPIRATION BIOPSY 2
   ZORNOZA J, 1980, AM J ROENTGENOL, V134, P331
   1978, CODE PRACTICE PREVEN
NR 32
TC 8
Z9 8
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0021-9746
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PY 1985
VL 38
IS 2
BP 185
EP 192
DI 10.1136/jcp.38.2.185
PG 8
WC Pathology
SC Pathology
GA ABP91
UT WOS:A1985ABP9100011
PM 2578485
OA No
DA 2017-08-15
ER

PT J
AU WALL, RA
   MABEY, DCW
   CORRAH, PT
AF WALL, RA
   MABEY, DCW
   CORRAH, PT
TI HEMOPHILUS-INFLUENZAE NON TYPE-B
SO LANCET
LA English
DT Letter
RP WALL, RA (reprint author), MRC LABS,FAJARA,GAMBIA.
CR 1985, LANCET, V1, P1343
NR 1
TC 18
Z9 18
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PY 1985
VL 2
IS 8459
BP 845
EP 845
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA ASC84
UT WOS:A1985ASC8400057
PM 2864574
OA No
DA 2017-08-15
ER

PT J
AU LAMB, WH
   LAMB, CMB
   WHITEHEAD, RG
AF LAMB, WH
   LAMB, CMB
   WHITEHEAD, RG
TI RURAL HEALTH-CARE IN THE DEVELOPING WORLD
SO LANCET
LA English
DT Letter
C1 DUNN NUTR UNIT,CAMBRIDGE,ENGLAND.
RP LAMB, WH (reprint author), DUNN NUTR UNIT,KENEBA,GAMBIA.
CR GOWERS, 1984, LANCET, V2, P1396
   1984, LANCET, V2, P1215
   1984, LANCET, V2, P912
NR 3
TC 1
Z9 1
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PY 1985
VL 1
IS 8424
BP 334
EP 334
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA ABJ55
UT WOS:A1985ABJ5500016
PM 2857377
OA No
DA 2017-08-15
ER

EF